Patent Publication Number: US-2004043930-A1

Title: Novel proteins and nucleic acids encoding same

Description:
RELATED APPLICATIONS  
     [0001] This application claims priority to U.S. Ser. No. 60/370349, filed Apr. 5, 2002; U.S. Ser. No. 60/384543, filed May 30, 2002; U.S. Ser. No. 60/370969, filed Apr. 8, 2002; U.S. Ser. No. 60/403748, filed Aug. 15, 2002; U.S. Ser. No. 60/372019, filed Apr. 12, 2002; and U.S. Ser. No. 60/374379, filed Apr. 22, 2002, and this application is a continuation-in-part of U.S. Ser. No. 09/779679, filed Feb. 8, 2001; which claims priority to U.S. Ser. No. 60/181045, filed Feb. 8, 2000; U.S. Ser. No. 10/055877, filed Jan. 22, 2002; which claims priority to U.S. Ser. No. 60/262892, filed Jan. 19, 2001; U.S. Ser. No. 10/038854, filed Dec. 31, 2001; which claims priority to U.S. Ser. No. 60/259785, filed Jan. 4, 2001; and U.S. Ser. No. 60/294080, filed May 29, 2001; U.S. Ser. No. 10/044564, filed Jan. 11, 2002; which claims priority to U.S. Ser. No. 60/261026, filed Jan. 11, 2001; and U.S. Ser. No. 60/313170, filed Aug. 17, 2001; U.S. Ser. No. 10/092900, filed Mar. 7, 2002; which claims priority to U.S. Ser. No. 60/299027, filed Jun. 18, 2001; U.S. Ser. No. 10/115479, filed Apr. 2, 2002; which claims priority to U.S. Ser. No. 60/283657, filed Apr. 13, 2001; U.S. Ser. No. 10/160619, filed Jun. 3, 2002; which claims priority to U.S. Ser. No. 60/295607, filed Jun. 4, 2001; U.S. Ser. No. 10/287226, filed Nov. 4, 2002; which claims priority to U.S. Ser. No. 60/333461, filed Nov. 27, 2001; U.S. Ser. No. 10/307719, filed Dec. 2, 2002; which claims priority to U.S. Ser. No. 60/339286, filed Dec. 11, 2001; U.S. Ser. No. 10/093463, filed Mar. 8, 2002 which claims priority to U.S. Ser. No. 60/274191, filed Mar. 8, 2001; U.S. Ser. No. 60/287424, filed Apr. 30, 2001; and U.S. Ser. No. 10/161493, filed Jun. 3, 2002, which claims priority to U.S. Ser. No. 60/337524, filed Nov. 16, 2001 each of which is incorporated herein by reference in its entirety. 
    
    
     
       FIELD OF THE INVENTION  
       [0002] The present invention relates to novel polypeptides that are targets of small molecule drugs and that have properties related to stimulation of biochemical or physiological responses in a cell, a tissue, an organ or an organism. More particularly, the novel polypeptides are gene products of novel genes, or are specified biologically active fragments or derivatives thereof. Methods of use encompass diagnostic and prognostic assay procedures as well as methods of treating diverse pathological conditions.  
       BACKGROUND  
       [0003] Eukaryotic cells are characterized by biochemical and physiological processes which under normal conditions are exquisitely balanced to achieve the preservation and propagation of the cells. When such cells are components of multicellular organisms such as vertebrates, or more particularly organisms such as mammals, the regulation of the biochemical and physiological processes involves intricate signaling pathways. Frequently, such signaling pathways involve extracellular signaling proteins, cellular receptors that bind the signaling proteins and signal transducing components located within the cells.  
       [0004] Signaling proteins may be classified as endocrine effectors, paracrine effectors or autocrine effectors. Endocrine effectors are signaling molecules secreted by a given organ into the circulatory system, which are then transported to a distant target organ or tissue. The target cells include the receptors for the endocrine effector, and when the endocrine effector binds, a signaling cascade is induced. Paracrine effectors involve secreting cells and receptor cells in close proximity to each other, for example two different classes of cells in the same tissue or organ. One class of cells secretes the paracrine effector, which then reaches the second class of cells, for example by diffusion through the extracellular fluid. The second class of cells contains the receptors for the paracrine effector; binding of the effector results in induction of the signaling cascade that elicits the corresponding biochemical or physiological effect. Autocrine effectors are highly analogous to paracrine effectors, except that the same cell type that secretes the autocrine effector also contains the receptor. Thus the autocrine effector binds to receptors on the same cell, or on identical neighboring cells. The binding process then elicits the characteristic biochemical or physiological effect.  
       [0005] Signaling processes may elicit a variety of effects on cells and tissues including by way of nonlimiting example induction of cell or tissue proliferation, suppression of growth or proliferation, induction of differentiation or maturation of a cell or tissue, and suppression of differentiation or maturation of a cell or tissue.  
       [0006] Many pathological conditions involve dysregulation of expression of important effector proteins. In certain classes of pathologies the dysregulation is manifested as diminished or suppressed level of synthesis and secretion of protein effectors. In other classes of pathologies the dysregulation is manifested as increased or up-regulated level of synthesis and secretion of protein effectors. In a clinical setting a subject may be suspected of suffering from a condition brought on by altered or mis-regulated levels of a protein effector of interest. Therefore there is a need to assay for the level of the protein effector of interest in a biological sample from such a subject, and to compare the level with that characteristic of a nonpathological condition. There also is a need to provide the protein effector as a product of manufacture. Administration of the effector to a subject in need thereof is useful in treatment of the pathological condition. Accordingly, there is a need for a method of treatment of a pathological condition brought on by a diminished or suppressed levels of the protein effector of interest. In addition, there is a need for a method of treatment of a pathological condition brought on by a increased or up-regulated levels of the protein effector of interest.  
       [0007] Small molecule targets have been implicated in various disease states or pathologies. These targets may be proteins, and particularly enzymatic proteins, which are acted upon by small molecule drugs for the purpose of altering target function and achieving a desired result. Cellular, animal and clinical studies can be performed to elucidate the genetic contribution to the etiology and pathogenesis of conditions in which small molecule targets are implicated in a variety of physiologic, pharmacologic or native states. These studies utilize the core technologies at CuraGen Corporation to look at differential gene expression, protein-protein interactions, large-scale sequencing of expressed genes and the association of genetic variations such as, but not limited to, single nucleotide polymorphisms (SNPs) or splice variants in and between biological samples from experimental and control groups. The goal of such studies is to identify potential avenues for therapeutic intervention in order to prevent, treat the consequences or cure the conditions.  
       [0008] In order to treat diseases, pathologies and other abnormal states or conditions in which a mammalian organism has been diagnosed as being, or as being at risk for becoming, other than in a normal state or condition, it is important to identify new therapeutic agents. Such a procedure includes at least the steps of identifying a target component within an affected tissue or organ, and identifying a candidate therapeutic agent that modulates the functional attributes of the target. The target component may be any biological macromolecule implicated in the disease or pathology. Commonly the target is a polypeptide or protein with specific functional attributes. Other classes of macromolecule may be a nucleic acid, a polysaccharide, a lipid such as a complex lipid or a glycolipid; in addition a target may be a sub-cellular structure or extra-cellular structure that is comprised of more than one of these classes of macromolecule. Once such a target has been identified, it may be employed in a screening assay in order to identify favorable candidate therapeutic agents from among a large population of substances or compounds.  
       [0009] In many cases the objective of such screening assays is to identify small molecule candidates; this is commonly approached by the use of combinatorial methodologies to develop the population of substances to be tested. The implementation of high throughput screening methodologies is advantageous when working with large, combinatorial libraries of compounds.  
       SUMMARY OF THE INVENTION  
       [0010] The invention includes nucleic acid sequences and the novel polypeptides they encode. The novel nucleic acids and polypeptides are referred to herein as NOVX, or NOV1, NOV2, NOV3, etc., nucleic acids and polypeptides. These nucleic acids and polypeptides, as well as derivatives, homologs, analogs and fragments thereof, will hereinafter be collectively designated as “NOVX” nucleic acid, which represents the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or polypeptide sequences, which represents the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48.  
       [0011] In one aspect, the invention provides an isolated polypeptide comprising a mature form of a NOVX amino acid. One example is a variant of a mature form of a NOVX amino acid sequence, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. The amino acid can be, for example, a NOVX amino acid sequence or a variant of a NOVX amino acid sequence, wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed. The invention also includes fragments of any of these. In another aspect, the invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof.  
       [0012] Also included in the invention is a NOVX polypeptide that is a naturally occurring allelic variant of a NOVX sequence. In one embodiment, the allelic variant includes an amino acid sequence that is the translation of a nucleic acid sequence differing by a single nucleotide from a NOVX nucleic acid sequence. In another embodiment, the NOVX polypeptide is a variant polypeptide described therein, wherein any amino acid specified in the chosen sequence is changed to provide a conservative substitution. In one embodiment, the invention discloses a method for determining the presence or amount of the NOVX polypeptide in a sample. The method involves the steps of: providing a sample; introducing the sample to an antibody that binds immunospecifically to the polypeptide; and determining the presence or amount of antibody bound to the NOVX polypeptide, thereby determining the presence or amount of the NOVX polypeptide in the sample. In another embodiment, the invention provides a method for determining the presence of or predisposition to a disease associated with altered levels of a NOVX polypeptide in a mammalian subject. This method involves the steps of: measuring the level of expression of the polypeptide in a sample from the first mammalian subject; and comparing the amount of the polypeptide in the sample of the first step to the amount of the polypeptide present in a control sample from a second mammalian subject known not to have, or not to be predisposed to, the disease, wherein an alteration in the expression level of the polypeptide in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.  
       [0013] In a further embodiment, the invention includes a method of identifying an agent that binds to a NOVX polypeptide. This method involves the steps of: introducing the polypeptide to the agent; and determining whether the agent binds to the polypeptide. In various embodiments, the agent is a cellular receptor or a downstream effector.  
       [0014] In another aspect, the invention provides a method for identifying a potential therapeutic agent for use in treatment of a pathology, wherein the pathology is related to aberrant expression or aberrant physiological interactions of a NOVX polypeptide. The method involves the steps of: providing a cell expressing the NOVX polypeptide and having a property or function ascribable to the polypeptide; contacting the cell with a composition comprising a candidate substance; and determining whether the substance alters the property or function ascribable to the polypeptide; whereby, if an alteration observed in the presence of the substance is not observed when the cell is contacted with a composition devoid of the substance, the substance is identified as a potential therapeutic agent. In another aspect, the invention describes a method for screening for a modulator of activity or of latency or predisposition to a pathology associated with the NOVX polypeptide. This method involves the following steps: administering a test compound to a test animal at increased risk for a pathology associated with the NOVX polypeptide, wherein the test animal recombinantly expresses the NOVX polypeptide. This method involves the steps of measuring the activity of the NOVX polypeptide in the test animal after administering the compound of step; and comparing the activity of the protein in the test animal with the activity of the NOVX polypeptide in a control animal not administered the polypeptide, wherein a change in the activity of the NOVX polypeptide in the test animal relative to the control animal indicates the test compound is a modulator of latency of, or predisposition to, a pathology associated with the NOVX polypeptide. In one embodiment, the test animal is a recombinant test animal that expresses a test protein transgene or expresses the transgene under the control of a promoter at an increased level relative to a wild-type test animal, and wherein the promoter is not the native gene promoter of the transgene. In another aspect, the invention includes a method for modulating the activity of the NOVX polypeptide, the method comprising introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide.  
       [0015] The invention also includes an isolated nucleic acid that encodes a NOVX polypeptide, or a fragment, homolog, analog or derivative thereof. In a preferred embodiment, the nucleic acid molecule comprises the nucleotide sequence of a naturally occurring allelic nucleic acid variant. In another embodiment, the nucleic acid encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence. In one embodiment, the NOVX nucleic acid molecule hybridizes under stringent conditions to the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or a complement of the nucleotide sequence. In another aspect, the invention provides a vector or a cell expressing a NOVX nucleotide sequence.  
       [0016] In one embodiment, the invention discloses a method for modulating the activity of a NOVX polypeptide. The method includes the steps of: introducing a cell sample expressing the NOVX polypeptide with a compound that binds to the polypeptide in an amount sufficient to modulate the activity of the polypeptide. In another embodiment, the invention includes an isolated NOVX nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising a NOVX amino acid sequence or a variant of a mature form of the NOVX amino acid sequence, wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed. In another embodiment, the invention includes an amino acid sequence that is a variant of the NOVX amino acid sequence, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed.  
       [0017] In one embodiment, the invention discloses a NOVX nucleic acid fragment encoding at least a portion of a NOVX polypeptide or any variant of the polypeptide, wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed. In another embodiment, the invention includes the complement of any of the NOVX nucleic acid molecules or a naturally occurring allelic nucleic acid variant. In another embodiment, the invention discloses a NOVX nucleic acid molecule that encodes a variant polypeptide, wherein the variant polypeptide has the polypeptide sequence of a naturally occurring polypeptide variant. In another embodiment, the invention discloses a NOVX nucleic acid, wherein the nucleic acid molecule differs by a single nucleotide from a NOVX nucleic acid sequence.  
       [0018] In another aspect, the invention includes a NOVX nucleic acid, wherein one or more nucleotides in the NOVX nucleotide sequence is changed to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In one embodiment, the invention discloses a nucleic acid fragment of the NOVX nucleotide sequence and a nucleic acid fragment wherein one or more nucleotides in the NOVX nucleotide sequence is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed. In another embodiment, the invention includes a nucleic acid molecule wherein the nucleic acid molecule hybridizes under stringent conditions to a NOVX nucleotide sequence or a complement of the NOVX nucleotide sequence. In one embodiment, the invention includes a nucleic acid molecule, wherein the sequence is changed such that no more than 15% of the nucleotides in the coding sequence differ from the NOVX nucleotide sequence or a fragment thereof.  
       [0019] In a further aspect, the invention includes a method for determining the presence or amount of the NOVX nucleic acid in a sample. The method involves the steps of: providing the sample; introducing the sample to a probe that binds to the nucleic acid molecule; and determining the presence or amount of the probe bound to the NOVX nucleic acid molecule, thereby determining the presence or amount of the NOVX nucleic acid molecule in the sample. In one embodiment, the presence or amount of the nucleic acid molecule is used as a marker for cell or tissue type.  
       [0020] In another aspect, the invention discloses a method for determining the presence of or predisposition to a disease associated with altered levels of the NOVX nucleic acid molecule of in a first mammalian subject. The method involves the steps of: measuring the amount of NOVX nucleic acid in a sample from the first mammalian subject; and comparing the amount of the nucleic acid in the sample of step (a) to the amount of NOVX nucleic acid present in a control sample from a second mammalian subject known not to have or not be predisposed to, the disease; wherein an alteration in the level of the nucleic acid in the first subject as compared to the control sample indicates the presence of or predisposition to the disease.  
       [0021] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety. In the case of conflict, the present specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.  
       [0022] Other features and advantages of the invention will be apparent from the following detailed description and claims.  
       DETAILED DESCRIPTION OF THE INVENTION  
       [0023] The present invention provides novel nucleotides and polypeptides encoded thereby. Included in the invention are the novel nucleic acid sequences, their encoded polypeptides, antibodies, and other related compounds. The sequences are collectively referred to herein as “NOVX nucleic acids” or “NOVX polynucleotides” and the corresponding encoded polypeptides are referred to as “NOVX polypeptides” or “NOVX proteins.” Unless indicated otherwise, “NOVX” is meant to refer to any of the novel sequences disclosed herein. Table A provides a summary of the NOVX nucleic acids and their encoded polypeptides.  
               TABLE A                          Requences and Corresponding SEQ ID Numbers                                         SEQ ID   SEQ ID                   NO   NO       NOVX   Internal   (nucleic   (amino       Assignment   Identification   acid)   acid)   Homology                                         NOV1a   CG164221-01   1   2   Sequence 1 from Patent WO02074987 -                         Homo sapiens         NOV1b   CG164221-02   3   4   Sequence 1 from Patent WO02074987 -                         Homo sapiens         NOV2a   CG180777-01   5   6   Cell cycle related kinase -  Homo                           sapiens         NOV2b   CG180777-02   7   8   Cell cycle related kinase -  Homo                           sapiens         NOV3a   CG181825-01   9   10   Aquaporin 6 (Aquaporin-2 like) (hKID) -                         Homo sapiens         NOV4a   CG50183-01   11   12   C—C chemokine receptor type 11 (C—C                       CKR-11) (CC-CKR-11) (CCR-11)                       (Chemokine receptor-like 1) (CCRL1)                       (CCX CKR) -  Homo sapiens         NOV5a   CG50249-01   13   14   Voltage gated potassium channel                       Kv3.2b (Potassium voltage-gated                       potassium channel subfamily C                       member 2) -  Homo sapiens         NOV5b   CG50249-02   15   16   Voltage gated potassium channel                       Kv3.2b (Potassium voltage-gated                       potassium channel subfamily C                       member 2) -  Homo sapiens         NOV5c   CG50249-03   17   18   Voltage gated potassium channel                       Kv3.2b (Potassium voltage-gated                       potassium channel subfamily C                       member 2) -  Homo sapiens         NOV5d   CG50249-04   19   20   Voltage gated potassium channel                       Kv3.2b (Potassium voltage-gated                       potassium channel subfamily C                       member 2) -  Homo sapiens         NOV6a   CG54236-02   21   22   Cysteinyl leukotriene receptor 2                       (CysLTR2) (PSEC0146) (HG57)                       (HPN321) (hGPCR21) -  Homo sapiens         NOV6b   CG54236-01   23   24   Cysteinyl leukotriene receptor 2                       (CysLTR2) (PSEC0146) (HG57)                       (HPN321) (hGPCR21) -  Homo sapiens         NOV7a   CG54566-01   25   26   Sequence 11 from Patent WO0194416 -                         Homo sapiens         NOV8a   CG55912-01   27   28   Voltage-dependent calcium channel                       gamma-8 subunit (Neuronal voltage-                       gated calcium channel gamma-8                       subunit) -  Rattus norvegicus         NOV9a   CG56001-01   29   30   D-beta-hydroxybutyrate                       dehydrogenase, mitochondrial                       precursor (EC 1.1.1.30) (BDH) (3-                       hydroxybutyrate dehydrogenase) -                         Homo sapiens         NOV9b   CG56001-02   31   32   D-beta-hydroxybutyrate                       dehydrogenase, mitochondrial                       precursor (EC 1.1.1.30) (BDH) (3-                       hydroxybutyrate dehydrogenase) -                         Homo sapiens         NOV10a   CG56151-01   33   34   Solute carrier family 2, facilitated                       glucose transporter, member 2 (Glucose                       transporter type 2, liver) -  Homo                           sapiens         NOV10b   246837923   35   36   Solute carrier family 2, facilitated                       glucose transporter, member 2 (Glucose                       transporter type 2, liver) -  Homo                           sapiens         NOV10c   246837941   37   38   Solute carrier family 2, facilitated                       glucose transporter, member 2 (Glucose                       transporter type 2, liver) -  Homo                           sapiens         NOV10d   CG56151-02   39   40   Solute carrier family 2, facilitated                       glucose transporter, member 2 (Glucose                       transporter type 2, liver) -  Homo                           sapiens         NOV10e   CG56151-03   41   42   Solute carrier family 2, facilitated                       glucose transporter, member 2 (Glucose                       transporter type 2, liver) -  Homo                           sapiens         NOV10f   CG56151-04   43   44   Solute carrier family 2, facilitated                       glucose transporter, member 2 (Glucose                       transporter type 2, liver) -  Homo                           sapiens         NOV11a   CG56155-02   45   46   Plasma kallikrein precursor (EC                       3.4.21.34) (Plasma prekallikrein)                       (Kininogenin) (Fletcher factor) -  Homo                           sapiens         NOV11b   227803167   47   48   Plasma kallikrein precursor (EC                       3.4.21.34) (Plasma prekallikrein)                       (Kininogenin) (Fletcher factor) -  Homo                           sapiens         NOV11c   CG56155-01   49   50   Plasma kallikrein precursor (EC                       3.4.21.34) (Plasma prekallikrein)                       (Kininogenin) (Fletcher factor) -  Homo                           sapiens         NOV11d   CG56155-03   51   52   Plasma kallikrein precursor (EC                       3.4.21.34) (Plasma prekallikrein)                       (Kininogenin) (Fletcher factor) -  Homo                           sapiens         NOV12a   CG56262-01   53   54   Putative calcium binding transporter -                         Homo sapiens         NOV13a   CG56829-01   55   56   Testis-specific serine/threonine kinase                       3 (Similar to serine/threonine kinase)                       (TSSK3) -  Homo sapiens         NOV14a   CG57183-01   57   58   Fibroblast growth factor receptor 3                       precursor (EC 2.7.1.112) (FGFR-3) -                         Homo sapiens         NOV14b   CG57183-02   59   60   Fibroblast growth factor receptor 3                       precursor (EC 2.7.1.112) (FGFR-3) -                         Homo sapiens         NOV15a   CG57341-01   61   62   Sequence 2 from Patent WO0144446 -                         Homo sapiens         NOV16a   CG57460-01   63   64   Hypothetical protein FLJ37478 -  Homo                           sapiens         NOV17a   CG57570-01   65   66   Solute carrier family 41 member 1 -                         Homo sapiens         NOV18a   CG57758-02   67   68   Na+ coupled citrate transporter protein -                         Homo sapiens         NOV18b   CG57758-01   69   70   Na+ coupled citrate transporter protein -                         Homo sapiens         NOV18c   CG57758-03   71   72   Na+ coupled citrate transporter protein -                         Homo sapiens         NOV18d   CG57758-04   73   74   Na+ coupled citrate transporter protein -                         Homo sapiens         NOV18e   CG57758-05   75   76   Na+ coupled citrate transporter protein -                         Homo sapiens         NOV19a   CG59693-01   77   78   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19b   CG59693-02   79   80   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19c   CG59693-03   81   82   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19d   CG59693-04   83   84   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19e   CG59693-05   85   86   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19f   CG59693-06   87   88   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19g   CG59693-07   89   90   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19h   CG59693-08   91   92   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV19i   CG59693-09   93   94   Aldo-keto reductase family 1 member                       C1 (EC 1.1.1.-) (Trans-1,2-                       dihydrobenzene-1,2-diol                       dehydrogenase) (EC 1.3.1.20) (High-                       affinity hepatic bile acid-binding                       protein) (HBAB) (Chlordecone                       reductase homolog HAKRC)                       (Dihydrodiol dehydrogenase 2) (DD2)                       (20 alpha-hydroxysteroid                       dehydrogenase) -  Homo sapiens         NOV20a   CG93088-01   95   96   Adult male lung cDNA, RIKEN full-                       length enriched library,                       clone: 1200003C15                       product: hypothetical protein, full insert                       sequence -  Mus musculus                    
 
       [0024] Table A indicates the homology of NOVX polypeptides to known protein families. Thus, the nucleic acids and polypeptides, antibodies and related compounds according to the invention corresponding to a NOVX as identified in column 1 of Table A will be useful in therapeutic and diagnostic applications implicated in, for example, pathologies and disorders associated with the known protein families identified in column 5 of Table A.  
       [0025] Pathologies, diseases, disorders and condition and the like that are associated with NOVX sequences include, but are not limited to, e.g., cardiomyopathy, atherosclerosis, hypertension, congenital heart defects, aortic stenosis, atrial septal defect (ASD), atrioventricular (A-V) canal defect, ductus arteriosus, pulmonary stenosis, subaortic stenosis, ventricular septal defect (VSD), valve diseases, tuberous sclerosis, scleroderma, obesity, metabolic disturbances associated with obesity, transplantation, adrenoleukodystrophy, congenital adrenal hyperplasia, prostate cancer, diabetes, metabolic disorders, neoplasm; adenocarcinoma, lymphoma, uterus cancer, fertility, hemophilia, hypercoagulation, idiopathic thrombocytopenic purpura, immunodeficiencies, graft versus host disease, AIDS, bronchial asthma, Crohn&#39;s disease; multiple sclerosis, treatment of Albright Hereditary Ostoeodystrophy, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, hematopoietic disorders, and the various dyslipidemias, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers, as well as conditions such as transplantation and fertility.  
       [0026] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.  
       [0027] Consistent with other known members of the family of proteins, identified in column 5 of Table A, the NOVX polypeptides of the present invention show homology to, and contain domains that are characteristic of, other members of such protein families. Details of the sequence relatedness and domain analysis for each NOVX are presented in Example A.  
       [0028] The NOVX nucleic acids and polypeptides can also be used to screen for molecules, which inhibit or enhance NOVX activity or function. Specifically, the nucleic acids and polypeptides according to the invention may be used as targets for the identification of small molecules that modulate or inhibit diseases associated with the protein families listed in Table A.  
       [0029] The NOVX nucleic acids and polypeptides are also useful for detecting specific cell types. Details of the expression analysis for each NOVX are presented in Example C. Accordingly, the NOVX nucleic acids, polypeptides, antibodies and related compounds according to the invention will have diagnostic and therapeutic applications in the detection of a variety of diseases with differential expression in normal vs. diseased tissues, e.g., detection of a variety of cancers. SNP analysis for each NOVX, if applicable, is presented in Example D.  
       [0030] Additional utilities for NOVX nucleic acids and polypeptides according to the invention are disclosed herein.  
       [0031] NOVX Clones  
       [0032] NOVX nucleic acids and their encoded polypeptides are useful in a variety of applications and contexts. The various NOVX nucleic acids and polypeptides according to the invention are useful as novel members of the protein families according to the presence of domains and sequence relatedness to previously described proteins. Additionally, NOVX nucleic acids and polypeptides can also be used to identify proteins that are members of the family to which the NOVX polypeptides belong.  
       [0033] The NOVX genes and their corresponding encoded proteins are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the NOVX genes, based on the tissues in which they are most highly expressed. Uses include developing products for the diagnosis or treatment of a variety of diseases and disorders.  
       [0034] The NOVX nucleic acids and proteins of the invention are useful in potential diagnostic and therapeutic applications and as a research tool. These include serving as a specific or selective nucleic acid or protein diagnostic and/or prognostic marker, wherein the presence or amount of the nucleic acid or the protein are to be assessed, as well as potential therapeutic applications such as the following: (i) a protein therapeutic, (ii) a small molecule drug target, (iii) an antibody target (therapeutic, diagnostic, drug targeting/cytotoxic antibody), (iv) a nucleic acid useful in gene therapy (gene delivery/gene ablation), and (v) a composition promoting tissue regeneration in vitro and in vivo (vi) a biological defense weapon.  
       [0035] In one specific embodiment, the invention includes an isolated polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, wherein any amino acid in the mature form is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) an amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48 wherein any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; and (e) a fragment of any of (a) through (d).  
       [0036] In another specific embodiment, the invention includes an isolated nucleic acid molecule comprising a nucleic acid sequence encoding a polypeptide comprising an amino acid sequence selected from the group consisting of: (a) a mature form of the amino acid sequence given SEQ ID NO: 2n, wherein n is an integer between 1 and 48; (b) a variant of a mature form of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48 wherein any amino acid in the mature form of the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence of the mature form are so changed; (c) the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48; (d) a variant of the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, in which any amino acid specified in the chosen sequence is changed to a different amino acid, provided that no more than 15% of the amino acid residues in the sequence are so changed; (e) a nucleic acid fragment encoding at least a portion of a polypeptide comprising the amino acid sequence selected from the group consisting of SEQ ID NO: 2n, wherein n is an integer between 1 and 48 or any variant of said polypeptide wherein any amino acid of the chosen sequence is changed to a different amino acid, provided that no more than 10% of the amino acid residues in the sequence are so changed; and (f) the complement of any of said nucleic acid molecules.  
       [0037] In yet another specific embodiment, the invention includes an isolated nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleotide sequence selected from the group consisting of: (a) the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48; (b) a nucleotide sequence wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed; (c) a nucleic acid fragment of the sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48; and (d) a nucleic acid fragment wherein one or more nucleotides in the nucleotide sequence selected from the group consisting of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48 is changed from that selected from the group consisting of the chosen sequence to a different nucleotide provided that no more than 15% of the nucleotides are so changed.  
       [0038] NOVX Nucleic Acids and Polypeptides  
       [0039] One aspect of the invention pertains to isolated nucleic acid molecules that encode NOVX polypeptides or biologically active portions thereof. Also included in the invention are nucleic acid fragments sufficient for use as hybridization probes to identify NOVX-encoding nucleic acids (e.g., NOVX mRNAs) and fragments for use as PCR primers for the amplification and/or mutation of NOVX nucleic acid molecules. As used herein, the term “nucleic acid molecule” is intended to include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), analogs of the DNA or RNA generated using nucleotide analogs, and derivatives, fragments and homologs thereof. The nucleic acid molecule may be single-stranded or double-stranded, but preferably is comprised double-stranded DNA.  
       [0040] A NOVX nucleic acid can encode a mature NOVX polypeptide. As used herein, a “mature” form of a polypeptide or protein disclosed in the present invention is the product of a naturally occurring polypeptide or precursor form or proprotein. The naturally occurring polypeptide, precursor or proprotein includes, by way of nonlimiting example, the full-length gene product encoded by the corresponding gene. Alternatively, it may be defined as the polypeptide, precursor or proprotein encoded by an ORF described herein. The product “mature” form arises, by way of nonlimiting example, as a result of one or more naturally occurring processing steps that may take place within the cell (e.g., host cell) in which the gene product arises. Examples of such processing steps leading to a “mature” form of a polypeptide or protein include the cleavage of the N-terminal methionine residue encoded by the initiation codon of an ORF, or the proteolytic cleavage of a signal peptide or leader sequence. Thus a mature form arising from a precursor polypeptide or protein that has residues 1 to N, where residue 1 is the N-terminal methionine, would have residues 2 through N remaining after removal of the N-terminal methionine. Alternatively, a mature form arising from a precursor polypeptide or protein having residues 1 to N, in which an N-terminal signal sequence from residue 1 to residue M is cleaved, would have the residues from residue M+1 to residue N remaining. Further as used herein, a “mature” form of a polypeptide or protein may arise from a step of post-translational modification other than a proteolytic cleavage event. Such additional processes include, by way of non-limiting example, glycosylation, myristylation or phosphorylation. In general, a mature polypeptide or protein may result from the operation of only one of these processes, or a combination of any of them.  
       [0041] The term “probe”, as utilized herein, refers to nucleic acid sequences of variable length, preferably between at least about 10 nucleotides (nt), about 100 nt, or as many as approximately, e.g., 6,000 nt, depending upon the specific use. Probes are used in the detection of identical, similar, or complementary nucleic acid sequences. Longer length probes are generally obtained from a natural or recombinant source, are highly specific, and much slower to hybridize than shorter-length oligomer probes. Probes may be single-stranded or double-stranded and designed to have specificity in PCR, membrane-based hybridization technologies, or ELISA-like technologies.  
       [0042] The term “isolated” nucleic acid molecule, as used herein, is a nucleic acid that is separated from other nucleic acid molecules which are present in the natural source of the nucleic acid. Preferably, an “isolated” nucleic acid is free of sequences which naturally flank the nucleic acid (i.e., sequences located at the 5′- and 3′-termini of the nucleic acid) in the genomic DNA of the organism from which the nucleic acid is derived. For example, in various embodiments, the isolated NOVX nucleic acid molecules can contain less than about 5 kb, 4 kb, 3 kb, 2 kb, 1 kb, 0.5 kb or 0.1 kb of nucleotide sequences which naturally flank the nucleic acid molecule in genomic DNA of the cell/tissue from which the nucleic acid is derived (e.g., brain, heart, liver, spleen, etc.). Moreover, an “isolated” nucleic acid molecule, such as a cDNA molecule, can be substantially free of other cellular material, or culture medium, or of chemical precursors or other chemicals.  
       [0043] A nucleic acid molecule of the invention, e.g., a nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or a complement of this nucleotide sequence, can be isolated using standard molecular biology techniques and the sequence information provided herein. Using all or a portion of the nucleic acid sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, as a hybridization probe, NOVX molecules can be isolated using standard hybridization and cloning techniques (e.g., as described in Sambrook, et al., (eds.), M OLECULAR  C LONING : A L ABORATORY  M ANUAL  2 nd  Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989; and Ausubel, et al., (eds.), C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, New York, NY, 1993.)  
       [0044] A nucleic acid of the invention can be amplified using cDNA, mRNA or alternatively, genomic DNA, as a template with appropriate oligonucleotide primers according to standard PCR amplification techniques. The nucleic acid so amplified can be cloned into an appropriate vector and characterized by DNA sequence analysis. Furthermore, oligonucleotides corresponding to NOVX nucleotide sequences can be prepared by standard synthetic techniques, e.g., using an automated DNA synthesizer.  
       [0045] As used herein, the term “oligonucleotide” refers to a series of linked nucleotide residues. A short oligonucleotide sequence may be based on, or designed from, a genomic or cDNA sequence and is used to amplify, confirm, or reveal the presence of an identical, similar or complementary DNA or RNA in a particular cell or tissue. Oligonucleotides comprise a nucleic acid sequence having about 10 nt, 50 nt, or 100 nt in length, preferably about 15 nt to 30 nt in length. In one embodiment of the invention, an oligonucleotide comprising a nucleic acid molecule less than 100 nt in length would further comprise at least 6 contiguous nucleotides of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or a complement thereof. Oligonucleotides may be chemically synthesized and may also be used as probes.  
       [0046] In another embodiment, an isolated nucleic acid molecule of the invention comprises a nucleic acid molecule that is a complement of the nucleotide sequence shown in SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or a portion of this nucleotide sequence (e.g., a fragment that can be used as a probe or primer or a fragment encoding a biologically-active portion of a NOVX polypeptide). A nucleic acid molecule that is complementary to the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, is one that is sufficiently complementary to the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, that it can hydrogen bond with few or no mismatches to the nucleotide sequence shown in SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, thereby forming a stable duplex.  
       [0047] As used herein, the term “complementary” refers to Watson-Crick or Hoogsteen base pairing between nucleotides units of a nucleic acid molecule, and the term “binding” means the physical or chemical interaction between two polypeptides or compounds or associated polypeptides or compounds or combinations thereof. Binding includes ionic, non-ionic, van der Waals, hydrophobic interactions, and the like. A physical interaction can be either direct or indirect. Indirect interactions may be through or due to the effects of another polypeptide or compound. Direct binding refers to interactions that do not take place through, or due to, the effect of another polypeptide or compound, but instead are without other substantial chemical intermediates.  
       [0048] A “fragment” provided herein is defined as a sequence of at least 6 (contiguous) nucleic acids or at least 4 (contiguous) amino acids, a length sufficient to allow for specific hybridization in the case of nucleic acids or for specific recognition of an epitope in the case of amino acids, and is at most some portion less than a full length sequence. Fragments may be derived from any contiguous portion of a nucleic acid or amino acid sequence of choice.  
       [0049] A full-length NOVX clone is identified as containing an ATG translation start codon and an in-frame stop codon. Any disclosed NOVX nucleotide sequence lacking an ATG start codon therefore encodes a truncated C-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 5′ direction of the disclosed sequence. Any disclosed NOVX nucleotide sequence lacking an in-frame stop codon similarly encodes a truncated N-terminal fragment of the respective NOVX polypeptide, and requires that the corresponding full-length cDNA extend in the 3′ direction of the disclosed sequence.  
       [0050] A “derivative” is a nucleic acid sequence or amino acid sequence formed from the native compounds either directly, by modification or partial substitution. An “analog” is a nucleic acid sequence or amino acid sequence that has a structure similar to, but not identical to, the native compound, e.g., they differs from it in respect to certain components or side chains. Analogs may be synthetic or derived from a different evolutionary origin and may have a similar or opposite metabolic activity compared to wild type. A “homolog” is a nucleic acid sequence or amino acid sequence of a particular gene that is derived from different species.  
       [0051] Derivatives and analogs may be full length or other than full length. Derivatives or analogs of the nucleic acids or proteins of the invention include, but are not limited to, molecules comprising regions that are substantially homologous to the nucleic acids or proteins of the invention, in various embodiments, by at least about 70%, 80%, or 95% identity (with a preferred identity of 80-95%) over a nucleic acid or amino acid sequence of identical size or when compared to an aligned sequence in which the alignment is done by a computer homology program known in the art, or whose encoding nucleic acid is capable of hybridizing to the complement of a sequence encoding the proteins under stringent, moderately stringent, or low stringent conditions. See e.g., Ausubel, et al., C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, New York, N.Y., 1993, and below.  
       [0052] A “homologous nucleic acid sequence” or “homologous amino acid sequence,” or variations thereof, refer to sequences characterized by a homology at the nucleotide level or amino acid level as discussed above. Homologous nucleotide sequences include those sequences coding for isoforms of NOVX polypeptides. Isoforms can be expressed in different tissues of the same organism as a result of, for example, alternative splicing of RNA. Alternatively, isoforms can be encoded by different genes. In the invention, homologous nucleotide sequences include nucleotide sequences encoding for a NOVX polypeptide of species other than humans, including, but not limited to: vertebrates, and thus can include, e.g., frog, mouse, rat, rabbit, dog, cat cow, horse, and other organisms. Homologous nucleotide sequences also include, but are not limited to, naturally occurring allelic variations and mutations of the nucleotide sequences set forth herein. A homologous nucleotide sequence does not, however, include the exact nucleotide sequence encoding human NOVX protein. Homologous nucleic acid sequences include those nucleic acid sequences that encode conservative amino acid substitutions (see below) in SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, as well as a polypeptide possessing NOVX biological activity. Various biological activities of the NOVX proteins are described below.  
       [0053] A NOVX polypeptide is encoded by the open reading frame (“ORF”) of a NOVX nucleic acid. An ORF corresponds to a nucleotide sequence that could potentially be translated into a polypeptide. A stretch of nucleic acids comprising an ORF is uninterrupted by a stop codon. An ORF that represents the coding sequence for a full protein begins with an ATG “start” codon and terminates with one of the three “stop” codons, namely, TAA, TAG, or TGA. For the purposes of this invention, an ORF may be any part of a coding sequence, with or without a start codon, a stop codon, or both. For an ORF to be considered as a good candidate for coding for a bona fide cellular protein, a minimum size requirement is often set, e.g., a stretch of DNA that would encode a protein of 50 amino acids or more.  
       [0054] The nucleotide sequences determined from the cloning of the human NOVX genes allows for the generation of probes and primers designed for use in identifying and/or cloning NOVX homologues in other cell types, e.g., from other tissues, as well as NOVX homologues from other vertebrates. The probe/primer typically comprises substantially purified oligonucleotide. The oligonucleotide typically comprises a region of nucleotide sequence that hybridizes under stringent conditions to at least about 12, 25, 50, 100, 150, 200, 250, 300, 350 or 400 consecutive sense strand nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48; or an anti-sense strand nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48; or of a naturally occurring mutant of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48.  
       [0055] Probes based on the human NOVX nucleotide sequences can be used to detect transcripts or genomic sequences encoding the same or homologous proteins. In various embodiments, the probe has a detectable label attached, e.g., the label can be a radioisotope, a fluorescent compound, an enzyme, or an enzyme co-factor. Such probes can be used as a part of a diagnostic test kit for identifying cells or tissues which mis-express a NOVX protein, such as by measuring a level of a NOVX-encoding nucleic acid in a sample of cells from a subject e.g., detecting NOVX mRNA levels or determining whether a genomic NOVX gene has been mutated or deleted.  
       [0056] “A polypeptide having a biologically-active portion of a NOVX polypeptide” refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. A nucleic acid fragment encoding a “biologically-active portion of NOVX” can be prepared by isolating a portion of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, that encodes a polypeptide having a NOVX biological activity (the biological activities of the NOVX proteins are described below), expressing the encoded portion of NOVX protein (e.g., by recombinant expression in vitro) and assessing the activity of the encoded portion of NOVX.  
       [0057] NOVX Nucleic Acid and Polypeptide Variants  
       [0058] The invention further encompasses nucleic acid molecules that differ from the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, due to degeneracy of the genetic code and thus encode the same NOVX proteins as that encoded by the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48. In another embodiment, an isolated nucleic acid molecule of the invention has a nucleotide sequence encoding a protein having an amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 48.  
       [0059] In addition to the human NOVX nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, it will be appreciated by those skilled in the art that DNA sequence polymorphisms that lead to changes in the amino acid sequences of the NOVX polypeptides may exist within a population (e.g., the human population). Such genetic polymorphism in the NOVX genes may exist among individuals within a population due to natural allelic variation. As used herein, the terms “gene” and “recombinant gene” refer to nucleic acid molecules comprising an open reading frame (ORF) encoding a NOVX protein, preferably a vertebrate NOVX protein. Such natural allelic variations can typically result in 1-5% variance in the nucleotide sequence of the NOVX genes. Any and all such nucleotide variations and resulting amino acid polymorphisms in the NOVX polypeptides, which are the result of natural allelic variation and that do not alter the functional activity of the NOVX polypeptides, are intended to be within the scope of the invention.  
       [0060] Moreover, nucleic acid molecules encoding NOVX proteins from other species, and thus that have a nucleotide sequence that differs from a human SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, are intended to be within the scope of the invention. Nucleic acid molecules corresponding to natural allelic variants and homologues of the NOVX cDNAs of the invention can be isolated based on their homology to the human NOVX nucleic acids disclosed herein using the human cDNAs, or a portion thereof, as a hybridization probe according to standard hybridization techniques under stringent hybridization conditions.  
       [0061] Accordingly, in another embodiment, an isolated nucleic acid molecule of the invention is at least 6 nucleotides in length and hybridizes under stringent conditions to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48. In another embodiment, the nucleic acid is at least 10, 25, 50, 100, 250, 500, 750, 1000, 1500, or 2000 or more nucleotides in length. In yet another embodiment, an isolated nucleic acid molecule of the invention hybridizes to the coding region. As used herein, the term “hybridizes under stringent conditions” is intended to describe conditions for hybridization and washing under which nucleotide sequences at least about 65% homologous to each other typically remain hybridized to each other.  
       [0062] Homologs (i.e., nucleic acids encoding NOVX proteins derived from species other than human) or other related sequences (e.g., paralogs) can be obtained by low, moderate or high stringency hybridization with all or a portion of the particular human sequence as a probe using methods well known in the art for nucleic acid hybridization and cloning.  
       [0063] As used herein, the phrase “stringent hybridization conditions” refers to conditions under which a probe, primer or oligonucleotide will hybridize to its target sequence, but to no other sequences. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures than shorter sequences. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. The Tm is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target sequence hybridize to the target sequence at equilibrium. Since the target sequences are generally present at excess, at Tm, 50% of the probes are occupied at equilibrium. Typically, stringent conditions will be those in which the salt concentration is less than about 1.0 M sodium ion, typically about 0.01 to 1.0 M sodium ion (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30° C. for short probes, primers or oligonucleotides (e.g., 10 nt to 50 nt) and at least about 60° C. for longer probes, primers and oligonucleotides. Stringent conditions may also be achieved with the addition of destabilizing agents, such as formamide.  
       [0064] Stringent conditions are known to those skilled in the art and can be found in Ausubel, et al., (eds.), C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, N.Y. (1989), 6.3.1-6.3.6. Preferably, the conditions are such that sequences at least about 65%, 70%, 75%, 85%, 90%, 95%, 98%, or 99% homologous to each other typically remain hybridized to each other. A non-limiting example of stringent hybridization conditions are hybridization in a high salt buffer comprising 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 mg/ml denatured salmon sperm DNA at 65° C., followed by one or more washes in 0.2×SSC, 0.01% BSA at 50° C. An isolated nucleic acid molecule of the invention that hybridizes under stringent conditions to a sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, corresponds to a naturally-occurring nucleic acid molecule. As used herein, a “naturally-occurring” nucleic acid molecule refers to an RNA or DNA molecule having a nucleotide sequence that occurs in nature (e.g., encodes a natural protein).  
       [0065] In a second embodiment, a nucleic acid sequence that is hybridizable to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or fragments, analogs or derivatives thereof, under conditions of moderate stringency is provided. A non-limiting example of moderate stringency hybridization conditions are hybridization in 6×SSC, 5×Reinhardt&#39;s solution, 0.5% SDS and 100 mg/ml denatured salmon sperm DNA at 55° C., followed by one or more washes in 1×SSC, 0.1% SDS at 37° C. Other conditions of moderate stringency that may be used are well-known within the art. See, e.g., Ausubel, et al. (eds.), 1993, C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, NY, and Krieger, 1990; G ENE  T RANSFER AND  E XPRESSION , A L ABORATORY  M ANUAL , Stockton Press, N.Y.  
       [0066] In a third embodiment, a nucleic acid that is hybridizable to the nucleic acid molecule comprising the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or fragments, analogs or derivatives thereof, under conditions of low stringency, is provided. A non-limiting example of low stringency hybridization conditions are hybridization in 35% formamide, 5×SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 mg/ml denatured salmon sperm DNA, 10% (wt/vol) dextran sulfate at 40° C., followed by one or more washes in 2×SSC, 25 mM Tris-HCl (pH 7.4),5 mM EDTA, and 0.1% SDS at 50° C. Other conditions of low stringency that may be used are well known in the art (e.g., as employed for cross-species hybridizations). See, e.g., Ausubel, et al. (eds.), 1993, C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, NY, and Kriegler, 1990, G ENE  T RANSFER AND  E XPRESSION , A L ABORATORY  M ANUAL , Stockton Press, NY; Shilo and Weinberg, 1981 . Proc Natl Acad Sci USA  78: 6789-6792.  
       [0067] Conservative Mutations  
       [0068] In addition to naturally-occurring allelic variants of NOVX sequences that may exist in the population, the skilled artisan will further appreciate that changes can be introduced by mutation into the nucleotide sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, thereby leading to changes in the amino acid sequences of the encoded NOVX protein, without altering the functional ability of that NOVX protein. For example, nucleotide substitutions leading to amino acid substitutions at “non-essential” amino acid residues can be made in the sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 48. A “non-essential” amino acid residue is a residue that can be altered from the wild-type sequences of the NOVX proteins without altering their biological activity, whereas an “essential” amino acid residue is required for such biological activity. For example, amino acid residues that are conserved among the NOVX proteins of the invention are not particularly amenable to alteration. Amino acids for which conservative substitutions can be made are well-known within the art.  
       [0069] Another aspect of the invention pertains to nucleic acid molecules encoding NOVX proteins that contain changes in amino acid residues that are not essential for activity. Such NOVX proteins differ in amino acid sequence from SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, yet retain biological activity. In one embodiment, the isolated nucleic acid molecule comprises a nucleotide sequence encoding a protein, wherein the protein comprises an amino acid sequence at least about 40% homologous to the amino acid sequences of SEQ ID NO: 2n, wherein n is an integer between 1 and 48. Preferably, the protein encoded by the nucleic acid molecule is at least about 60% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 48; more preferably at least about 70% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 48; still more preferably at least about 80% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 48; even more preferably at least about 90% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 48; and most preferably at least about 95% homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 48.  
       [0070] An isolated nucleic acid molecule encoding a NOVX protein homologous to the protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, can be created by introducing one or more nucleotide substitutions, additions or deletions into the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, such that one or more amino acid substitutions, additions or deletions are introduced into the encoded protein.  
       [0071] Mutations can be introduced any one of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, by standard techniques, such as site-directed mutagenesis and PCR-mediated mutagenesis. Preferably, conservative amino acid substitutions are made at one or more non-essential amino acid residues. A “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined within the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, a non-essential amino acid residue in the NOVX protein is replaced with another amino acid residue from the same side chain family. Alternatively, in another embodiment, mutations can be introduced randomly along all or part of a NOVX coding sequence, such as by saturation mutagenesis, and the resultant mutants can be screened for NOVX biological activity to identify mutants that retain activity. Following mutagenesis of a nucleic acid of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, the encoded protein can be expressed by any recombinant technology known in the art and the activity of the protein can be determined.  
       [0072] The relatedness of amino acid families may also be determined based on side chain interactions. Substituted amino acids may be fully conserved “strong” residues or fully conserved “weak” residues. The “strong” group of conserved amino acid residues may be any one of the following groups: STA, NEQK, NHQK, NDEQ, QHRK, MILV, MILF, HY, FYW, wherein the single letter amino acid codes are grouped by those amino acids that may be substituted for each other. Likewise, the “weak” group of conserved residues may be any one of the following: CSA, ATV, SAG, STNK, STPA, SGND, SNDEQK, NDEQHK, NEQHRK, HFY, wherein the letters within each group represent the single letter amino acid code.  
       [0073] In one embodiment, a mutant NOVX protein can be assayed for (i) the ability to form protein:protein interactions with other NOVX proteins, other cell-surface proteins, or biologically-active portions thereof, (ii) complex formation between a mutant NOVX protein and a NOVX ligand; or (iii) the ability of a mutant NOVX protein to bind to an intracellular target protein or biologically-active portion thereof; (e.g., avidin proteins).  
       [0074] In yet another embodiment, a mutant NOVX protein can be assayed for the ability to regulate a specific biological function (e.g., regulation of insulin release).  
       [0075] Interfering RNA  
       [0076] In one aspect of the invention, NOVX gene expression can be attenuated by RNA interference. One approach well-known in the art is short interfering RNA (siRNA) mediated gene silencing where expression products of a NOVX gene are targeted by specific double stranded NOVX derived siRNA nucleotide sequences that are complementary to at least a 19-25 nt long segment of the NOVX gene transcript, including the 5′ untranslated (UT) region, the ORF, or the 3′ UT region. See, e.g., PCT applications WO00/44895, WO99/32619, WO01/75164, WO01/92513, WO 01/29058, WO01/89304, WO02/16620, and WO62/29858, each incorporated by reference herein in their entirety. Targeted genes can be a NOVX gene, or an upstream or downstream modulator of the NOVX gene. Nonlimiting examples of upstream or downstream modulators of a NOVX gene include, e.g., a transcription factor that binds the NOVX gene promoter, a kinase or phosphatase that interacts with a NOVX polypeptide, and polypeptides involved in a NOVX regulatory pathway.  
       [0077] According to the methods of the present invention, NOVX gene expression is silenced using short interfering RNA. A NOVX polynucleotide according to the invention includes a siRNA polynucleotide. Such a NOVX siRNA can be obtained using a NOVX polynucleotide sequence, for example, by processing the NOVX ribopolynucleotide sequence in a cell-free system, such as but not limited to a Drosophila extract, or by transcription of recombinant double stranded NOVX RNA or by chemical synthesis of nucleotide sequences homologous to a NOVX sequence. See, e.g., Tuschl, Zamore, Lehmann, Bartel and Sharp (1999), Genes &amp; Dev. 13: 3191-3197, incorporated herein by reference in its entirety. When synthesized, a typical 0.2 micromolar-scale RNA synthesis provides about 1 milligram of siRNA, which is sufficient for 1000 transfection experiments using a 24-well tissue culture plate format.  
       [0078] The most efficient silencing is generally observed with siRNA duplexes composed of a 21-nt sense strand and a 21-nt antisense strand, paired in a manner to have a 2-nt 3′ overhang. The sequence of the 2-nt 3′ overhang makes an additional small contribution to the specificity of siRNA target recognition. The contribution to specificity is localized to the unpaired nucleotide adjacent to the first paired bases. In one embodiment, the nucleotides in the 3′ overhang are ribonucleotides. In an alternative embodiment, the nucleotides in the 3′ overhang are deoxyribonucleotides. Using 2′-deoxyribonucleotides in the 3′ overhangs is as efficient as using ribonucleotides, but deoxyribonucleotides are often cheaper to synthesize and are most likely more nuclease resistant.  
       [0079] A contemplated recombinant expression vector of the invention comprises a NOVX DNA molecule cloned into an expression vector comprising operatively-linked regulatory sequences flanking the NOVX sequence in a manner that allows for expression (by transcription of the DNA molecule) of both strands. An RNA molecule that is antisense to NOVX mRNA is transcribed by a first promoter (e.g., a promoter sequence 3′ of the cloned DNA) and an RNA molecule that is the sense strand for the NOVX mRNA is transcribed by a second promoter (e.g., a promoter sequence 5′ of the cloned DNA). The sense and antisense strands may hybridize in vivo to generate siRNA constructs for silencing of the NOVX gene. Alternatively, two constructs can be utilized to create the sense and anti-sense strands of a siRNA construct. Finally, cloned DNA can encode a construct having secondary structure, wherein a single transcript has both the sense and complementary antisense sequences from the target gene or genes. In an example of this embodiment, a hairpin RNAi product is homologous to all or a portion of the target gene. In another example, a hairpin RNAi product is a siRNA. The regulatory sequences flanking the NOVX sequence may be identical or may be different, such that their expression may be modulated independently, or in a temporal or spatial manner.  
       [0080] In a specific embodiment, siRNAs are transcribed intracellularly by cloning the NOVX gene templates into a vector containing, e.g., a RNA pol III transcription unit from the smaller nuclear RNA (snRNA) U6 or the human RNase P RNA H1. One example of a vector system is the GeneSuppressor™ RNA Interference kit (commercially available from Imgenex). The U6 and H1 promoters are members of the type III class of Pol III promoters. The +1 nucleotide of the U6-like promoters is always guanosine, whereas the +1 for H1 promoters is adenosine. The termination signal for these promoters is defined by five consecutive thymidines. The transcript is typically cleaved after the second uridine. Cleavage at this position generates a 3′ UU overhang in the expressed siRNA, which is similar to the 3′ overhangs of synthetic siRNAs. Any sequence less than 400 nucleotides in length can be transcribed by these promoter, therefore they are ideally suited for the expression of around 21-nucleotide siRNAs in, e.g., an approximately 50-nucleotide RNA stem-loop transcript.  
       [0081] A siRNA vector appears to have an advantage over synthetic siRNAs where long term knock-down of expression is desired. Cells transfected with a siRNA expression vector would experience steady, long-term mRNA inhibition. In contrast, cells transfected with exogenous synthetic siRNAs typically recover from mRNA suppression within seven days or ten rounds of cell division. The long-term gene silencing ability of siRNA expression vectors may provide for applications in gene therapy.  
       [0082] In general, siRNAs are chopped from longer dsRNA by an ATP-dependent ribonuclease called DICER. DICER is a member of the RNase III family of double-stranded RNA-specific endonucleases. The siRNAs assemble with cellular proteins into an endonuclease complex. In vitro studies in Drosophila suggest that the siRNAs/protein complex (siRNP) is then transferred to a second enzyme complex, called an RNA-induced silencing complex (RISC), which contains an endoribonuclease that is distinct from DICER. RISC uses the sequence encoded by the antisense siRNA strand to find and destroy mRNAs of complementary sequence. The siRNA thus acts as a guide, restricting the ribonuclease to cleave only mRNAs complementary to one of the two siRNA strands.  
       [0083] A NOVX mRNA region to be targeted by siRNA is generally selected from a desired NOVX sequence beginning 50 to 100 nt downstream of the start codon. Alternatively, 5′ or 3′ UTRs and regions nearby the start codon can be used but are generally avoided, as these may be richer in regulatory protein binding sites. UTR-binding proteins and/or translation initiation complexes may interfere with binding of the siRNP or RISC endonuclease complex. An initial BLAST homology search for the selected siRNA sequence is done against an available nucleotide sequence library to ensure that only one gene is targeted. Specificity of target recognition by siRNA duplexes indicate that a single point mutation located in the paired region of an siRNA duplex is sufficient to abolish target mRNA degradation. See, Elbashir et al. 2001 EMBO J. 20(23):6877-88. Hence, consideration should be taken to accommodate SNPs, polymorphisms, allelic variants or species-specific variations when targeting a desired gene.  
       [0084] In one embodiment, a complete NOVX siRNA experiment includes the proper negative control. A negative control siRNA generally has the same nucleotide composition as the NOVX siRNA but lack significant sequence homology to the genome. Typically, one would scramble the nucleotide sequence of the NOVX siRNA and do a homology search to make sure it lacks homology to any other gene.  
       [0085] Two independent NOVX siRNA duplexes can be used to knock-down a target NOVX gene. This helps to control for specificity of the silencing effect. In addition, expression of two independent genes can be simultaneously knocked down by using equal concentrations of different NOVX siRNA duplexes, e.g., a NOVX siRNA and an siRNA for a regulator of a NOVX gene or polypeptide. Availability of siRNA-associating proteins is believed to be more limiting than target mRNA accessibility.  
       [0086] A targeted NOVX region is typically a sequence of two adenines (AA) and two thymidines (TT) divided by a spacer region of nineteen (N19) residues (e.g., AA(N19)TT). A desirable spacer region has a G/C-content of approximately 30% to 70%, and more preferably of about 50%. If the sequence AA(N19)TT is not present in the target sequence, an alternative target region would be AA(N21). The sequence of the NOVX sense siRNA corresponds to (N19)TT or N21, respectively. In the latter case, conversion of the 3′ end of the sense siRNA to TT can be performed if such a sequence does not naturally occur in the NOVX polynucleotide. The rationale for this sequence conversion is to generate a symmetric duplex with respect to the sequence composition of the sense and antisense 3′ overhangs. Symmetric 3′ overhangs may help to ensure that the siRNPs are formed with approximately equal ratios of sense and antisense target RNA-cleaving siRNPs. See, e.g., Elbashir, Lendeckel and Tuschl (2001). Genes &amp; Dev. 15: 188-200, incorporated by reference herein in its entirely. The modification of the overhang of the sense sequence of the siRNA duplex is not expected to affect targeted mRNA recognition, as the antisense siRNA strand guides target recognition.  
       [0087] Alternatively, if the NOVX target mRNA does not contain a suitable AA(N21) sequence, one may search for the sequence NA(N21). Further, the sequence of the sense strand and antisense strand may still be synthesized as 5′ (N19)TT, as it is believed that the sequence of the 3′-most nucleotide of the antisense siRNA does not contribute to specificity. Unlike antisense or ribozyme technology, the secondary structure of the target mRNA does not appear to have a strong effect on silencing. See, Harborth, et al. (2001) J. Cell Science 114: 4557-4565, incorporated by reference in its entirety.  
       [0088] Transfection of NOVX siRNA duplexes can be achieved using standard nucleic acid transfection methods, for example, OLIGOFECTAMINE Reagent (commercially available from Invitrogen). An assay for NOVX gene silencing is generally performed approximately 2 days after transfection. No NOVX gene silencing has been observed in the absence of transfection reagent, allowing for a comparative analysis of the wild-type and silenced NOVX phenotypes. In a specific embodiment, for one well of a 24-well plate, approximately 0.84 μg of the siRNA duplex is generally sufficient. Cells are typically seeded the previous day, and are transfected at about 50% confluence. The choice of cell culture media and conditions are routine to those of skill in the art, and will vary with the choice of cell type. The efficiency of transfection may depend on the cell type, but also on the passage number and the confluency of the cells. The time and the manner of formation of siRNA-liposome complexes (e.g., inversion versus vortexing) are also critical. Low transfection efficiencies are the most frequent cause of unsuccessful NOVX silencing. The efficiency of transfection needs to be carefully examined for each new cell line to be used. Preferred cell are derived from a mammal, more preferably from a rodent such as a rat or mouse, and most preferably from a human. Where used for therapeutic treatment, the cells are preferentially autologous, although non-autologous cell sources are also contemplated as within the scope of the present invention.  
       [0089] For a control experiment, transfection of 0.84 μg single-stranded sense NOVX siRNA will have no effect on NOVX silencing, and 0.84 μg antisense siRNA has a weak silencing effect when compared to 0.84 μg of duplex siRNAs. Control experiments again allow for a comparative analysis of the wild-type and silenced NOVX phenotypes. To control for transfection efficiency, targeting of common proteins is typically performed, for example targeting of lamin A/C or transfection of a CMV-driven EGFP-expression plasmid (e.g., commercially available from Clontech). In the above example, a determination of the fraction of lamin A/C knockdown in cells is determined the next day by such techniques as immunofluorescence, Western blot, Northern blot or other similar assays for protein expression or gene expression. Lamin A/C monoclonal antibodies may be obtained from Santa Cruz Biotechnology.  
       [0090] Depending on the abundance and the half life (or turnover) of the targeted NOVX polynucleotide in a cell, a knock-down phenotype may become apparent after 1 to 3 days, or even later. In cases where no NOVX knock-down phenotype is observed, depletion of the NOVX polynucleotide may be observed by immunofluorescence or Western blotting. If the NOVX polynucleotide is still abundant after 3 days, cells need to be split and transferred to a fresh 24-well plate for re-transfection. If no knock-down of the targeted protein is observed, it may be desirable to analyze whether the target mRNA (NOVX or a NOVX upstream or downstream gene) was effectively destroyed by the transfected siRNA duplex. Two days after transfection, total RNA is prepared, reverse transcribed using a target-specific primer, and PCR-amplified with a primer pair covering at least one exon-exon junction in order to control for amplification of pre-mRNAs. RT/PCR of a non-targeted mRNA is also needed as control. Effective depletion of the mRNA yet undetectable reduction of target protein may indicate that a large reservoir of stable NOVX protein may exist in the cell. Multiple transfection in sufficiently long intervals may be necessary until the target protein is finally depleted to a point where a phenotype may become apparent. If multiple transfection steps are required, cells are split 2 to 3 days after transfection. The cells may be transfected immediately after splitting.  
       [0091] An inventive therapeutic method of the invention contemplates administering a NOVX siRNA construct as therapy to compensate for increased or aberrant NOVX expression or activity. The NOVX ribopolynucleotide is obtained and processed into siRNA fragments, or a NOVX siRNA is synthesized, as described above. The NOVX siRNA is administered to cells or tissues using known nucleic acid transfection techniques, as described above. A NOVX siRNA specific for a NOVX gene will decrease or knockdown NOVX transcription products, which will lead to reduced NOVX polypeptide production, resulting in reduced NOVX polypeptide activity in the cells or tissues.  
       [0092] The present invention also encompasses a method of treating a disease or condition associated with the presence of a NOVX protein in an individual comprising administering to the individual an RNAi construct that targets the mRNA of the protein (the mRNA that encodes the protein) for degradation. A specific RNAi construct includes a siRNA or a double stranded gene transcript that is processed into siRNAs. Upon treatment, the target protein is not produced or is not produced to the extent it would be in the absence of the treatment.  
       [0093] Where the NOVX gene function is not correlated with a known phenotype, a control sample of cells or tissues from healthy individuals provides a reference standard for determining NOVX expression levels. Expression levels are detected using the assays described, e.g., RT-PCR, Northern blotting, Western blotting, ELISA, and the like. A subject sample of cells or tissues is taken from a mammal, preferably a human subject, suffering from a disease state. The NOVX ribopolynucleotide is used to produce siRNA constructs, that are specific for the NOVX gene product. These cells or tissues are treated by administering NOVX siRNA&#39;s to the cells or tissues by methods described for the transfection of nucleic acids into a cell or tissue, and a change in NOVX polypeptide or polynucleotide expression is observed in the subject sample relative to the control sample, using the assays described. This NOVX gene knockdown approach provides a rapid method for determination of a NOVX minus (NOVX − ) phenotype in the treated subject sample. The NOVX −  phenotype observed in the treated subject sample thus serves as a marker for monitoring the course of a disease state during treatment.  
       [0094] In specific embodiments, a NOVX siRNA is used in therapy. Methods for the generation and use of a NOVX siRNA are known to those skilled in the art. Example techniques are provided below.  
       [0095] Production of RNAs  
       [0096] Sense RNA (ssRNA) and antisense RNA (asRNA) of NOVX are produced using known methods such as transcription in RNA expression vectors. In the initial experiments, the sense and antisense RNA are about 500 bases in length each. The produced ssRNA and asRNA (0.5 μM) in 10 mM Tris-HCl (pH 7.5) with 20 mM NaCl were heated to 95° C. for 1 min then cooled and annealed at room temperature for 12 to 16 h. The RNAs are precipitated and resuspended in lysis buffer (below). To monitor annealing, RNAs are electrophoresed in a 2% agarose gel in TBE buffer and stained with ethidium bromide. See, e.g., Sambrook et al., Molecular Cloning. Cold Spring Harbor Laboratory Press, Plainview, N.Y. (1989).  
       [0097] Lysate Preparation  
       [0098] Untreated rabbit reticulocyte lysate (Ambion) are assembled according to the manufacturer&#39;s directions. dsRNA is incubated in the lysate at 30° C. for 10 min prior to the addition of mRNAs. Then NOVX mRNAs are added and the incubation continued for an additional 60 min. The molar ratio of double stranded RNA and mRNA is about 200:1. The NOVX mRNA is radiolabeled (using known techniques) and its stability is monitored by gel electrophoresis.  
       [0099] In a parallel experiment made with the same conditions, the double stranded RNA is internally radiolabeled with a  32 P-ATP. Reactions are stopped by the addition of 2×-proteinase-K buffer and deproteinized as described previously (Tuschl et al., Genes Dev., 13:3191-3197 (1999)). Products are analyzed by electrophoresis in 15% or 18% polyacrylamide sequencing gels using appropriate RNA standards. By monitoring the gels for radioactivity, the natural production of 10 to 25 nt RNAs from the double stranded RNA can be determined.  
       [0100] The band of double stranded RNA, about 21-23 bps, is eluded. The efficacy of these 21-23 mers for suppressing NOVX transcription is assayed in vitro using the same rabbit reticulocyte assay described above using 50 nanomolar of double stranded 21-23 mer for each assay. The sequence of these 21-23 mers is then determined using standard nucleic acid sequencing techniques.  
       [0101] RNA Preparation  
       [0102] 21 nt RNAs, based on the sequence determined above, are chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides are deprotected and gel-purified (Elbashir, Lendeckel, &amp; Tuschl, Genes &amp; Dev. 15, 188-200 (2001)), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, et al., Biochemistry, 32:11658-11668 (1993)).  
       [0103] These RNAs (20 μM) single strands are incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90° C. followed by 1 h at 37° C.  
       [0104] Cell Culture  
       [0105] A cell culture known in the art to regularly express NOVX is propagated using standard conditions. 24 hours before transfection, at approx. 80% confluency, the cells are trypsinized and diluted 1:5 with fresh medium without antibiotics (1-3×105 cells/ml) and transferred to 24-well plates (500 ml/well). Transfection is performed using a commercially available lipofection kit and NOVX expression is monitored using standard techniques with positive and negative control. A positive control is cells that naturally express NOVX while a negative control is cells that do not express NOVX. Base-paired 21 and 22 nt siRNAs with overhanging 3′ ends mediate efficient sequence-specific mRNA degradation in lysates and in cell culture. Different concentrations of siRNAs are used. An efficient concentration for suppression in vitro in mammalian culture is between 25 nM to 100 nM final concentration. This indicates that siRNAs are effective at concentrations that are several orders of magnitude below the concentrations applied in conventional antisense or ribozyme gene targeting experiments.  
       [0106] The above method provides a way both for the deduction of NOVX siRNA sequence and the use of such siRNA for in vitro suppression. In vivo suppression may be performed using the same siRNA using well known in-vivo transfection or gene therapy transfection techniques.  
       [0107] Antisense Nucleic Acids  
       [0108] Another aspect of the invention pertains to isolated antisense nucleic acid molecules that are hybridizable to or complementary to the nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or fragments, analogs or derivatives thereof. An “antisense” nucleic acid comprises a nucleotide sequence that is complementary to a “sense” nucleic acid encoding a protein (e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence). In specific aspects, antisense nucleic acid molecules are provided that comprise a sequence complementary to at least about 10, 25, 50, 100, 250 or 500 nucleotides or an entire NOVX coding strand, or to only a portion thereof. Nucleic acid molecules encoding fragments, homologs, derivatives and analogs of a NOVX protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, or antisense nucleic acids complementary to a NOVX nucleic acid sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, are additionally provided.  
       [0109] In one embodiment, an antisense nucleic acid molecule is antisense to a “coding region” of the coding strand of a nucleotide sequence encoding a NOVX protein. The term “coding region” refers to the region of the nucleotide sequence comprising codons which are translated into amino acid residues. In another embodiment, the antisense nucleic acid molecule is antisense to a “noncoding region” of the coding strand of a nucleotide sequence encoding the NOVX protein. The term “noncoding region” refers to 5′ and 3′ sequences that flank the coding region that are not translated into amino acids (i.e., also referred to as 5′ and 3′ untranslated regions).  
       [0110] Given the coding strand sequences encoding the NOVX protein disclosed herein, antisense nucleic acids of the invention can be designed according to the rules of Watson and Crick or Hoogsteen base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of NOVX mRNA, but more preferably is an oligonucleotide that is antisense to only a portion of the coding or noncoding region of NOVX mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of NOVX mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid of the invention can be constructed using chemical synthesis or enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally-occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids (e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used).  
       [0111] Examples of modified nucleotides that can be used to generate the antisense nucleic acid include: 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-carboxymethylaminomethyl-2-thiouridine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 5-methoxyuracil, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 2-thiouracil, 4-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest, described further in the following subsection).  
       [0112] The antisense nucleic acid molecules of the invention are typically administered to a subject or generated in situ such that they hybridize with or bind to cellular mRNA and/or genomic DNA encoding a NOVX protein to thereby inhibit expression of the protein (e.g., by inhibiting transcription and/or translation). The hybridization can be by conventional nucleotide complementarity to form a stable duplex, or, for example, in the case of an antisense nucleic acid molecule that binds to DNA duplexes, through specific interactions in the major groove of the double helix. An example of a route of administration of antisense nucleic acid molecules of the invention includes direct injection at a tissue site. Alternatively, antisense nucleic acid molecules can be modified to target selected cells and then administered systemically. For example, for systemic administration, antisense molecules can be modified such that they specifically bind to receptors or antigens expressed on a selected cell surface (e.g., by linking the antisense nucleic acid molecules to peptides or antibodies that bind to cell surface receptors or antigens). The antisense nucleic acid molecules can also be delivered to cells using the vectors described herein. To achieve sufficient nucleic acid molecules, vector constructs in which the antisense nucleic acid molecule is placed under the control of a strong pol II or pol III promoter are preferred.  
       [0113] In yet another embodiment, the antisense nucleic acid molecule of the invention is an α-anomeric nucleic acid molecule. An α-anomeric nucleic acid molecule forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other. See, e.g., Gaultier, et al., 1987 . Nucl. Acids Res . 15: 6625-6641. The antisense nucleic acid molecule can also comprise a 2′-o-methylribonucleotide (See, e.g., Inoue, et al. 1987 . Nucl. Acids Res . 15: 6131-6148) or a chimeric RNA-DNA analogue (See, e.g., Inoue, et al., 1987 . FEBS Lett . 215: 327-330.  
       [0114] Ribozymes and PNA Moieties  
       [0115] Nucleic acid modifications include, by way of non-limiting example, modified bases, and nucleic acids whose sugar phosphate backbones are modified or derivatized. These modifications are carried out at least in part to enhance the chemical stability of the modified nucleic acid, such that they may be used, for example, as antisense binding nucleic acids in therapeutic applications in a subject.  
       [0116] In one embodiment, an antisense nucleic acid of the invention is a ribozyme. Ribozymes are catalytic RNA molecules with ribonuclease activity that are capable of cleaving a single-stranded nucleic acid, such as an mRNA, to which they have a complementary region. Thus, ribozymes (e.g., hammerhead ribozymes as described in Haselhoff and Gerlach 1988 . Nature  334: 585-591) can be used to catalytically cleave NOVX mRNA transcripts to thereby inhibit translation of NOVX mRNA. A ribozyme having specificity for a NOVX-encoding nucleic acid can be designed based upon the nucleotide sequence of a NOVX cDNA disclosed herein (i.e., SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48). For example, a derivative of a Tetrahymena L-19 IVS RNA can be constructed in which the nucleotide sequence of the active site is complementary to the nucleotide sequence to be cleaved in a NOVX-encoding mRNA. See, e.g., U.S. Pat. No. 4,987,071 to Cech, et al. and U.S. Pat. No. 5,116,742 to Cech, et al. NOVX mRNA can also be used to select a catalytic RNA having a specific ribonuclease activity from a pool of RNA molecules. See, e.g., Bartel et al., (1993)  Science  261:1411-1418.  
       [0117] Alternatively, NOVX gene expression can be inhibited by targeting nucleotide sequences complementary to the regulatory region of the NOVX nucleic acid (e.g., the NOVX promoter and/or enhancers) to form triple helical structures that prevent transcription of the NOVX gene in target cells. See, e.g., Helene, 1991 . Anticancer Drug Des . 6: 569-84; Helene, et al. 1992 . Ann. N.Y. Acad. Sci . 660: 27-36; Maher, 1992 . Bioassays  14: 807-15.  
       [0118] In various embodiments, the NOVX nucleic acids can be modified at the base moiety, sugar moiety or phosphate backbone to improve, e.g., the stability, hybridization, or solubility of the molecule. For example, the deoxyribose phosphate backbone of the nucleic acids can be modified to generate peptide nucleic acids. See, e.g., Hyrup, et al., 1996 . Bioorg Med Chem  4: 5-23. As used herein, the terms “peptide nucleic acids” or “PNAs” refer to nucleic acid mimics (e.g., DNA mimics) in which the deoxyribose phosphate backbone is replaced by a pseudopeptide backbone and only the four natural nucleotide bases are retained. The neutral backbone of PNAs has been shown to allow for specific hybridization to DNA and RNA under conditions of low ionic strength. The synthesis of PNA oligomer can be performed using standard solid phase peptide synthesis protocols as described in Hyrup, et al., 1996. supra; Perry-O&#39;Keefe, et al., 1996 . Proc. Natl. Acad. Sci. USA  93: 14670-14675.  
       [0119] PNAs of NOVX can be used in therapeutic and diagnostic applications. For example, PNAs can be used as antisense or antigene agents for sequence-specific modulation of gene expression by, e.g., inducing transcription or translation arrest or inhibiting replication. PNAs of NOVX can also be used, for example, in the analysis of single base pair mutations in a gene (e.g., PNA directed PCR clamping; as artificial restriction enzymes when used in combination with other enzymes, e.g., S 1  nucleases (See, Hyrup, et al., 1996.supra); or as probes or primers for DNA sequence and hybridization (See, Hyrup, et al., 1996, supra; Perry-O&#39;Keefe, et al., 1996. supra).  
       [0120] In another embodiment, PNAs of NOVX can be modified, e.g., to enhance their stability or cellular uptake, by attaching lipophilic or other helper groups to PNA, by the formation of PNA-DNA chimeras, or by the use of liposomes or other techniques of drug delivery known in the art. For example, PNA-DNA chimeras of NOVX can be generated that may combine the advantageous properties of PNA and DNA. Such chimeras allow DNA recognition enzymes (e.g., RNase H and DNA polymerases) to interact with the DNA portion while the PNA portion would provide high binding affinity and specificity. PNA-DNA chimeras can be linked using linkers of appropriate lengths selected in terms of base stacking, number of bonds between the nucleotide bases, and orientation (see, Hyrup, et al., 1996. supra). The synthesis of PNA-DNA chimeras can be performed as described in Hyrup, et al., 1996. supra and Finn, et al., 1996 . Nucl Acids Res  24: 3357-3363. For example, a DNA chain can be synthesized on a solid support using standard phosphoramidite coupling chemistry, and modified nucleoside analogs, e.g., 5′-(4-methoxytrityl)-amino-5′-deoxy-thymidine phosphoramidite, can be used between the PNA and the 5′ end of DNA. See, e.g., Mag, et al., 1989 . Nucl Acid Res  17: 5973-5988. PNA monomers are then coupled in a stepwise manner to produce a chimeric molecule with a 5′ PNA segment and a 3′ DNA segment. See, e.g., Finn, et al., 1996. supra. Alternatively, chimeric molecules can be synthesized with a 5′ DNA segment and a 3′ PNA segment. See, e.g., Petersen, et al., 1975 . Bioorg. Med. Chem. Lett . 5: 1119-11124.  
       [0121] In other embodiments, the oligonucleotide may include other appended groups such as peptides (e.g., for targeting host cell receptors in vivo), or agents facilitating transport across the cell membrane (see, e.g., Letsinger, et al., 1989 . Proc. Natl. Acad. Sci. U.S.A . 86: 6553-6556; Lemaitre, et al., 1987 . Proc. Natl. Acad. Sci . 84: 648-652; PCT Publication No. WO88/09810) or the blood-brain barrier (see, e.g., PCT Publication No. WO 89/10134). In addition, oligonucleotides can be modified with hybridization-triggered cleavage agents (see, e.g., Krol, et al., 1988 . BioTechniques  6:958-976) or intercalating agents (see, e.g., Zon, 1988 . Pharm. Res.  5: 539-549). To this end, the oligonucleotide may be conjugated to another molecule, e.g., a peptide, a hybridization triggered cross-linking agent, a transport agent, a hybridization-triggered cleavage agent, and the like.  
       [0122] NOVX Polypeptides  
       [0123] A polypeptide according to the invention includes a polypeptide including the amino acid sequence of NOVX polypeptides whose sequences are provided in any one of SEQ ID NO: 2n, wherein n is an integer between 1 and 48. The invention also includes a mutant or variant protein any of whose residues may be changed from the corresponding residues shown in any one of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, while still encoding a protein that maintains its NOVX activities and physiological functions, or a functional fragment thereof.  
       [0124] In general, a NOVX variant that preserves NOVX-like function includes any variant in which residues at a particular position in the sequence have been substituted by other amino acids, and further include the possibility of inserting an additional residue or residues between two residues of the parent protein as well as the possibility of deleting one or more residues from the parent sequence. Any amino acid substitution, insertion, or deletion is encompassed by the invention. In favorable circumstances, the substitution is a conservative substitution as defined above.  
       [0125] One aspect of the invention pertains to isolated NOVX proteins, and biologically-active portions thereof, or derivatives, fragments, analogs or homologs thereof. Also provided are polypeptide fragments suitable for use as immunogens to raise anti-NOVX antibodies. In one embodiment, native NOVX proteins can be isolated from cells or tissue sources by an appropriate purification scheme using standard protein purification techniques. In another embodiment, NOVX proteins are produced by recombinant DNA techniques. Alternative to recombinant expression, a NOVX protein or polypeptide can be synthesized chemically using standard peptide synthesis techniques.  
       [0126] An “isolated” or “purified” polypeptide or protein or biologically-active portion thereof is substantially free of cellular material or other contaminating proteins from the cell or tissue source from which the NOVX protein is derived, or substantially free from chemical precursors or other chemicals when chemically synthesized. The language “substantially free of cellular material” includes preparations of NOVX proteins in which the protein is separated from cellular components of the cells from which it is isolated or recombinantly-produced. In one embodiment, the language “substantially free of cellular material” includes preparations of NOVX proteins having less than about 30% (by dry weight) of non-NOVX proteins (also referred to herein as a “contaminating protein”), more preferably less than about 20% of non-NOVX proteins, still more preferably less than about 10% of non-NOVX proteins, and most preferably less than about 5% of non-NOVX proteins. When the NOVX protein or biologically-active portion thereof is recombinantly-produced, it is also preferably substantially free of culture medium, i.e., culture medium represents less than about 20%, more preferably less than about 10%, and most preferably less than about 5% of the volume of the NOVX protein preparation.  
       [0127] The language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins in which the protein is separated from chemical precursors or other chemicals that are involved in the synthesis of the protein. In one embodiment, the language “substantially free of chemical precursors or other chemicals” includes preparations of NOVX proteins having less than about 30% (by dry weight) of chemical precursors or non-NOVX chemicals, more preferably less than about 20% chemical precursors or non-NOVX chemicals, still more preferably less than about 10% chemical precursors or non-NOVX chemicals, and most preferably less than about 5% chemical precursors or non-NOVX chemicals.  
       [0128] Biologically-active portions of NOVX proteins include peptides comprising amino acid sequences sufficiently homologous to or derived from the amino acid sequences of the NOVX proteins (e.g., the amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 48) that include fewer amino acids than the full-length NOVX proteins, and exhibit at least one activity of a NOVX protein. Typically, biologically-active portions comprise a domain or motif with at least one activity of the NOVX protein. A biologically-active portion of a NOVX protein can be a polypeptide which is, for example, 10, 25, 50, 100 or more amino acid residues in length.  
       [0129] Moreover, other biologically-active portions, in which other regions of the protein are deleted, can be prepared by recombinant techniques and evaluated for one or more of the functional activities of a native NOVX protein.  
       [0130] In an embodiment, the NOVX protein has an amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 48. In other embodiments, the NOVX protein is substantially homologous to SEQ ID NO: 2n, wherein n is an integer between 1 and 48, and retains the functional activity of the protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, yet differs in amino acid sequence due to natural allelic variation or mutagenesis, as described in detail, below. Accordingly, in another embodiment, the NOVX protein is a protein that comprises an amino acid sequence at least about 45% homologous to the amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, and retains the functional activity of the NOVX proteins of SEQ ID NO: 2n, wherein n is an integer between 1 and 48.  
       [0131] Determining Homology Between Two or More Sequences  
       [0132] To determine the percent homology of two amino acid sequences or of two nucleic acids, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in the sequence of a first amino acid or nucleic acid sequence for optimal alignment with a second amino or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then the molecules are homologous at that position (i.e., as used herein amino acid or nucleic acid “homology” is equivalent to amino acid or nucleic acid “identity”).  
       [0133] The nucleic acid sequence homology may be determined as the degree of identity between two sequences. The homology may be determined using computer programs known in the art, such as GAP software provided in the GCG program package. See, Needleman and Wunsch, 1970 . J Mol Biol  48: 443-453. Using GCG GAP software with the following settings for nucleic acid sequence comparison: GAP creation penalty of 5.0 and GAP extension penalty of 0.3, the coding region of the analogous nucleic acid sequences referred to above exhibits a degree of identity preferably of at least 70%, 75%, 80%, 85%, 90%, 95%, 98%, or 99%, with the CDS (encoding) part of the DNA sequence of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48.  
       [0134] The term “sequence identity” refers to the degree to which two polynucleotide or polypeptide sequences are identical on a residue-by-residue basis over a particular region of comparison. The term “percentage of sequence identity” is calculated by comparing two optimally aligned sequences over that region of comparison, determining the number of positions at which the identical nucleic acid base (e.g., A, T, C, G, U, or I, in the case of nucleic acids) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the region of comparison (i.e., the window size), and multiplying the result by 100 to yield the percentage of sequence identity. The term “substantial identity” as used herein denotes a characteristic of a polynucleotide sequence, wherein the polynucleotide comprises a sequence that has at least 80 percent sequence identity, preferably at least 85 percent identity and often 90 to 95 percent sequence identity, more usually at least 99 percent sequence identity as compared to a reference sequence over a comparison region.  
       [0135] Chimeric and Fusion Proteins  
       [0136] The invention also provides NOVX chimeric or fusion proteins. As used herein, a NOVX “chimeric protein” or “fusion protein” comprises a NOVX polypeptide operatively-linked to a non-NOVX polypeptide. An “NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a NOVX protein of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, whereas a “non-NOVX polypeptide” refers to a polypeptide having an amino acid sequence corresponding to a protein that is not substantially homologous to the NOVX protein, e.g., a protein that is different from the NOVX protein and that is derived from the same or a different organism. Within a NOVX fusion protein the NOVX polypeptide can correspond to all or a portion of a NOVX protein. In one embodiment, a NOVX fusion protein comprises at least one biologically-active portion of a NOVX protein. In another embodiment, a NOVX fusion protein comprises at least two biologically-active portions of a NOVX protein. In yet another embodiment, a NOVX fusion protein comprises at least three biologically-active portions of a NOVX protein. Within the fusion protein, the term “operatively-linked” is intended to indicate that the NOVX polypeptide and the non-NOVX polypeptide are fused in-frame with one another. The non-NOVX polypeptide can be fused to the N-terminus or C-terminus of the NOVX polypeptide.  
       [0137] In one embodiment, the fusion protein is a GST-NOVX fusion protein in which the NOVX sequences are fused to the C-terminus of the GST (glutathione S-transferase) sequences. Such fusion proteins can facilitate the purification of recombinant NOVX polypeptides.  
       [0138] In another embodiment, the fusion protein is a NOVX protein containing a heterologous signal sequence at its N-terminus. In certain host cells (e.g., mammalian host cells), expression and/or secretion of NOVX can be increased through use of a heterologous signal sequence.  
       [0139] In yet another embodiment, the fusion protein is a NOVX-immunoglobulin fusion protein in which the NOVX sequences are fused to sequences derived from a member of the immunoglobulin protein family. The NOVX-immunoglobulin fusion proteins of the invention can be incorporated into pharmaceutical compositions and administered to a subject to inhibit an interaction between a NOVX ligand and a NOVX protein on the surface of a cell, to thereby suppress NOVX-mediated signal transduction in vivo. The NOVX-immunoglobulin fusion proteins can be used to affect the bioavailability of a NOVX cognate ligand. Inhibition of the NOVX ligand/NOVX interaction may be useful therapeutically for both the treatment of proliferative and differentiative disorders, as well as modulating (e.g., promoting or inhibiting) cell survival. Moreover, the NOVX-immunoglobulin fusion proteins of the invention can be used as immunogens to produce anti-NOVX antibodies in a subject, to purify NOVX ligands, and in screening assays to identify molecules that inhibit the interaction of NOVX with a NOVX ligand.  
       [0140] A NOVX chimeric or fusion protein of the invention can be produced by standard recombinant DNA techniques. For example, DNA fragments coding for the different polypeptide sequences are ligated together in-frame in accordance with conventional techniques, e.g., by employing blunt-ended or stagger-ended termini for ligation, restriction enzyme digestion to provide for appropriate termini, filling-in of cohesive ends as appropriate, alkaline phosphatase treatment to avoid undesirable joining, and enzymatic ligation. In another embodiment, the fusion gene can be synthesized by conventional techniques including automated DNA synthesizers. Alternatively, PCR amplification of gene fragments can be carried out using anchor primers that give rise to complementary overhangs between two consecutive gene fragments that can subsequently be annealed and reamplified to generate a chimeric gene sequence (see, e.g., Ausubel, et al. (eds.) C URRENT  P ROTOCOLS IN  M OLECULAR  B IOLOGY , John Wiley &amp; Sons, 1992). Moreover, many expression vectors are commercially available that already encode a fusion moiety (e.g., a GST polypeptide). A NOVX-encoding nucleic acid can be cloned into such an expression vector such that the fusion moiety is linked in-frame to the NOVX protein.  
       [0141] NOVX Agonists and Antagonists  
       [0142] The invention also pertains to variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists. Variants of the NOVX protein can be generated by mutagenesis (e.g., discrete point mutation or truncation of the NOVX protein). An agonist of the NOVX protein can retain substantially the same, or a subset of, the biological activities of the naturally occurring form of the NOVX protein. An antagonist of the NOVX protein can inhibit one or more of the activities of the naturally occurring form of the NOVX protein by, for example, competitively binding to a downstream or upstream member of a cellular signaling cascade which includes the NOVX protein. Thus, specific biological effects can be elicited by treatment with a variant of limited function. In one embodiment, treatment of a subject with a variant having a subset of the biological activities of the naturally occurring form of the protein has fewer side effects in a subject relative to treatment with the naturally occurring form of the NOVX proteins.  
       [0143] Variants of the NOVX proteins that function as either NOVX agonists (i.e., mimetics) or as NOVX antagonists can be identified by screening combinatorial libraries of mutants (e.g., truncation mutants) of the NOVX proteins for NOVX protein agonist or antagonist activity. In one embodiment, a variegated library of NOVX variants is generated by combinatorial mutagenesis at the nucleic acid level and is encoded by a variegated gene library. A variegated library of NOVX variants can be produced by, for example, enzymatically ligating a mixture of synthetic oligonucleotides into gene sequences such that a degenerate set of potential NOVX sequences is expressible as individual polypeptides, or alternatively, as a set of larger fusion proteins (e.g., for phage display) containing the set of NOVX sequences therein. There are a variety of methods which can be used to produce libraries of potential NOVX variants from a degenerate oligonucleotide sequence. Chemical synthesis of a degenerate gene sequence can be performed in an automatic DNA synthesizer, and the synthetic gene then ligated into an appropriate expression vector. Use of a degenerate set of genes allows for the provision, in one mixture, of all of the sequences encoding the desired set of potential NOVX sequences. Methods for synthesizing degenerate oligonucleotides are well-known within the art. See, e.g., Narang, 1983 . Tetrahedron  39: 3; Itakura, et al., 1984 . Annu. Rev. Biochem . 53: 323; Itakura, et al., 1984 . Science  198: 1056; Ike, et al., 1983 . Nucl. Acids Res . 11: 477.  
       [0144] Polypeptide Libraries  
       [0145] In addition, libraries of fragments of the NOVX protein coding sequences can be used to generate a variegated population of NOVX fragments for screening and subsequent selection of variants of a NOVX protein. In one embodiment, a library of coding sequence fragments can be generated by treating a double stranded PCR fragment of a NOVX coding sequence with a nuclease under conditions wherein nicking occurs only about once per molecule, denaturing the double stranded DNA, renaturing the DNA to form double-stranded DNA that can include sense/antisense pairs from different nicked products, removing single stranded portions from reformed duplexes by treatment with S 1  nuclease, and ligating the resulting fragment library into an expression vector. By this method, expression libraries can be derived which encodes N-terminal and internal fragments of various sizes of the NOVX proteins.  
       [0146] Various techniques are known in the art for screening gene products of combinatorial libraries made by point mutations or truncation, and for screening cDNA libraries for gene products having a selected property. Such techniques are adaptable for rapid screening of the gene libraries generated by the combinatorial mutagenesis of NOVX proteins. The most widely used techniques, which are amenable to high throughput analysis, for screening large gene libraries typically include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the combinatorial genes under conditions in which detection of a desired activity facilitates isolation of the vector encoding the gene whose product was detected. Recursive ensemble mutagenesis (REM), a new technique that enhances the frequency of functional mutants in the libraries, can be used in combination with the screening assays to identify NOVX variants. See, e.g., Arkin and Yourvan, 1992 . Proc. Natl. Acad. Sci. USA  89: 7811-7815; Delgrave, et al., 1993 . Protein Engineering  6:327-331.  
       [0147] Anti-NOVX Antibodies  
       [0148] Included in the invention are antibodies to NOVX proteins, or fragments of NOVX proteins. The term “antibody” as used herein refers to immunoglobulin molecules and immunologically active portions of immunoglobulin (Ig) molecules, i.e., molecules that contain an antigen-binding site that specifically binds (immunoreacts with) an antigen. Such antibodies include, but are not limited to, polyclonal, monoclonal, chimeric, single chain, F ab , F ab , and F (ab′)2  fragments, and an F ab  expression library. In general, antibody molecules obtained from humans relates to any of the classes IgG, IgM, IgA, IgE and IgD, which differ from one another by the nature of the heavy chain present in the molecule. Certain classes have subclasses as well, such as IgG 1 , IgG 2 , and others. Furthermore, in humans, the light chain may be a kappa chain or a lambda chain. Reference herein to antibodies includes a reference to all such classes, subclasses and types of human antibody species.  
       [0149] An isolated protein of the invention intended to serve as an antigen, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that immunospecifically bind the antigen, using standard techniques for polyclonal and monoclonal antibody preparation. The full-length protein can be used or, alternatively, the invention provides antigenic peptide fragments of the antigen for use as immunogens. An antigenic peptide fragment comprises at least 6 amino acid residues of the amino acid sequence of the full length protein, such as an amino acid sequence of SEQ ID NO: 2n, wherein n is an integer between 1 and 48, and encompasses an epitope thereof such that an antibody raised against the peptide forms a specific immune complex with the full length protein or with any fragment that contains the epitope. Preferably, the antigenic peptide comprises at least 10 amino acid residues, or at least 15 amino acid residues, or at least 20 amino acid residues, or at least 30 amino acid residues. Preferred epitopes encompassed by the antigenic peptide are regions of the protein that are located on its surface; commonly these are hydrophilic regions.  
       [0150] In certain embodiments of the invention, at least one epitope encompassed by the antigenic peptide is a region of NOVX that is located on the surface of the protein, e.g., a hydrophilic region. A hydrophobicity analysis of the human NOVX protein sequence will indicate which regions of a NOVX polypeptide are particularly hydrophilic and, therefore, are likely to encode surface residues useful for targeting antibody production. As a means for targeting antibody production, hydropathy plots showing regions of hydrophilicity and hydrophobicity may be generated by any method well known in the art, including, for example, the Kyte Doolittle or the Hopp Woods methods, either with or without Fourier transformation. See, e.g., Hopp and Woods, 1981 , Proc. Nat. Acad. Sci. USA  78: 3824-3828; Kyte and Doolittle 1982 , J. Mol. Biol . 157: 105-142, each incorporated herein by reference in their entirety. Antibodies that are specific for one or more domains within an antigenic protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
       [0151] The term “epitope” includes any protein determinant capable of specific binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. A NOVX polypeptide or a fragment thereof comprises at least one antigenic epitope. An anti-NOVX antibody of the present invention is said to specifically bind to antigen NOVX when the equilibrium binding constant (K D ) is ≦1 μM, preferably ≦100 nM, more preferably ≦10 nM, and most preferably ≦100 pM to about 1 pM, as measured by assays such as radioligand binding assays or similar assays known to those skilled in the art.  
       [0152] A protein of the invention, or a derivative, fragment, analog, homolog or ortholog thereof, may be utilized as an immunogen in the generation of antibodies that immunospecifically bind these protein components.  
       [0153] Various procedures known within the art may be used for the production of polyclonal or monoclonal antibodies directed against a protein of the invention, or against derivatives, fragments, analogs homologs or orthologs thereof (see, for example, Antibodies: A Laboratory Manual, Harlow E, and Lane D, 1988, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., incorporated herein by reference). Some of these antibodies are discussed below.  
       [0154] Polyclonal Antibodies  
       [0155] For the production of polyclonal antibodies, various suitable host animals (e.g., rabbit, goat, mouse or other mammal) may be immunized by one or more injections with the native protein, a synthetic variant thereof, or a derivative of the foregoing. An appropriate immunogenic preparation can contain, for example, the naturally occurring immunogenic protein, a chemically synthesized polypeptide representing the immunogenic protein, or a recombinantly expressed immunogenic protein. Furthermore, the protein may be conjugated to a second protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. The preparation can further include an adjuvant. Various adjuvants used to increase the immunological response include, but are not limited to, Freund&#39;s (complete and incomplete), mineral gels (e.g., aluminum hydroxide), surface active substances (e.g., lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, dinitrophenol, etc.), adjuvants usable in humans such as Bacille Calmette-Guerin and Corynebacterium parvum, or similar immunostimulatory agents. Additional examples of adjuvants which can be employed include MPL-TDM adjuvant (monophosphoryl Lipid A, synthetic trehalose dicorynomycolate).  
       [0156] The polyclonal antibody molecules directed against the immunogenic protein can be isolated from the mammal (e.g., from the blood) and further purified by well known techniques, such as affinity chromatography using protein A or protein G, which provide primarily the IgG fraction of immune serum. Subsequently, or alternatively, the specific antigen that is the target of the immunoglobulin sought, or an epitope thereof, may be immobilized on a column to purify the immune specific antibody by immunoaffinity chromatography. Purification of immunoglobulins is discussed, for example, by D. Wilkinson (The Scientist, published by The Scientist, Inc., Philadelphia Pa., Vol. 14, No. 8 (Apr. 17, 2000), pp. 25-28).  
       [0157] Monoclonal Antibodies  
       [0158] The term “monoclonal antibody” (MAb) or “monoclonal antibody composition”, as used herein, refers to a population of antibody molecules that contain only one molecular species of antibody molecule consisting of a unique light chain gene product and a unique heavy chain gene product. In particular, the complementarity determining regions (CDRs) of the monoclonal antibody are identical in all the molecules of the population. MAbs thus contain an antigen binding site capable of immunoreacting with a particular epitope of the antigen characterized by a unique binding affinity for it.  
       [0159] Monoclonal antibodies can be prepared using hybridoma methods, such as those described by Kohler and Milstein, Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes can be immunized in vitro.  
       [0160] The immunizing agent will typically include the protein antigen, a fragment thereof or a fusion protein thereof. Generally, either peripheral blood lymphocytes are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell (Goding, M ONOCLONAL  A NTIBODIES : P RINCIPLES AND  P RACTICE , Academic Press, (1986) pp. 59-103). Immortalized cell lines are usually transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse mycloma cell lines are employed. The hybridoma cells can be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the hybridomas typically will include hypoxanthine, aminopterin, and thymidine (“HAT medium”), which substances prevent the growth of HGPRT-deficient cells.  
       [0161] Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained, for instance, from the Salk Institute Cell Distribution Center, San Diego, Calif. and the American Type Culture Collection, Manassas, Va. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies (Kozbor, J. Immunol., 133:3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, (1987) pp. 51-63).  
       [0162] The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against the antigen. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an in vitro binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunoabsorbent assay (ELISA). Such techniques and assays are known in the art. The binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson and Pollard, Anal. Biochem., 107:220 (1980). It is an objective, especially important in therapeutic applications of monoclonal antibodies, to identify antibodies having a high degree of specificity and a high binding affinity for the target antigen.  
       [0163] After the desired hybridoma cells are identified, the clones can be subcloned by limiting dilution procedures and grown by standard methods (Goding,1986). Suitable culture media for this purpose include, for example, Dulbecco&#39;s Modified Eagle&#39;s Medium and RPMI-1640 medium. Alternatively, the hybridoma cells can be grown in vivo as ascites in a mammal.  
       [0164] The monoclonal antibodies secreted by the subdlones can be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.  
       [0165] The monoclonal antibodies can also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred source of such DNA. Once isolated, the DNA can be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also can be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of the homologous murine sequences (U.S. Pat. No. 4,816,567; Morrison, Nature 368, 812-13 (1994)) or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.  
       [0166] Humanized Antibodies  
       [0167] The antibodies directed against the protein antigens of the invention can further comprise humanized antibodies or human antibodies. These antibodies are suitable for administration to humans without engendering an immune response by the human against the administered immunoglobulin. Humanized forms of antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab′, F(ab′) 2  or other antigen-binding subsequences of antibodies) that are principally comprised of the sequence of a human immunoglobulin, and contain minimal sequence derived from a non-human immunoglobulin. Humanization can be performed following the method of Winter and co-workers (Jones et al., Nature, 321:522-525 (1986); Riechmann et al., Nature, 332:323-327 (1988); Verhoeyen et al., Science, 239:1534-1536 (1988)), by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. (See also U.S. Pat. No. 5,225,539.) In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies can also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the framework regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin (Jones et al., 1986; Riechmann et al., 1988; and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)).  
       [0168] Human Antibodies  
       [0169] Fully human antibodies essentially relate to antibody molecules in which the entire sequence of both the light chain and the heavy chain, including the CDRs, arise from human genes. Such antibodies are termed “human antibodies”, or “fully human antibodies” herein. Human monoclonal antibodies can be prepared by the trioma technique; the human B-cell hybridoma technique (see Kozbor, et al., 1983 Immunol Today 4: 72) and the EBV hybridoma technique to produce human monoclonal antibodies (see Cole, et al., 1985 In: M ONOCLONAL  A NTIBODIES AND  C ANCER  T HERAPY , Alan R. Liss, Inc., pp. 77-96). Human monoclonal antibodies may be utilized in the practice of the present invention and may be produced by using human hybridomas (see Cote, et al., 1983. Proc Natl Acad Sci USA 80: 2026-2030) or by transforming human B-cells with Epstein Barr Virus in vitro (see Cole, et al., 1985 In: M ONOCLONAL  A NTIBODIES AND  C ANCER  T HERAPY , Alan R. Liss, Inc., pp. 77-96).  
       [0170] In addition, human antibodies can also be produced using additional techniques, including phage display libraries (Hoogenboom and Winter, J. Mol. Biol., 227:381 (1991); Marks et al., J. Mol. Biol., 222:581 (1991)). Similarly, human antibodies can be made by introducing human immunoglobulin loci into transgenic animals. For example, mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Pat. Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in Marks et al. (Bio/Technology 10, 779-783 (1992)); Lonberg et al. (Nature 368 856-859 (1994)); Morrison (Nature 368, 812-13 (1994)); Fishwild et al,(Nature Biotechnology 14, 845-51 (1996)); Neuberger (Nature Biotechnology 14, 826 (1996)); and Lonberg and Huszar (Intern. Rev. Immunol. 13 65-93 (1995)).  
       [0171] Human antibodies may additionally be produced using transgenic nonhuman animals which are modified so as to produce fully human antibodies rather than the animal&#39;s endogenous antibodies in response to challenge by an antigen. (See PCT publication WO94/02602). The endogenous genes encoding the heavy and light immunoglobulin chains in the nonhuman host have been incapacitated, and active loci encoding human heavy and light chain immunoglobulins are inserted into the host&#39;s genome. The human genes are incorporated, for example, using yeast artificial chromosomes containing the requisite human DNA segments. An animal which provides all the desired modifications is then obtained as progeny by crossbreeding intermediate transgenic animals containing fewer than the full complement of the modifications. The preferred embodiment of such a nonhuman animal is a mouse, and is termed the Xenomouse™ as disclosed in PCT publications WO 96/33735 and WO 96/34096. This animal produces B cells which secrete fully human immunoglobulins. The antibodies can be obtained directly from the animal after immunization with an immunogen of interest, as, for example, a preparation of a polyclonal antibody, or alternatively from immortalized B cells derived from the animal, such as hybridomas producing monoclonal antibodies. Additionally, the genes encoding the immunoglobulins with human variable regions can be recovered and expressed to obtain the antibodies directly, or can be further modified to obtain analogs of antibodies such as, for example, single chain Fv molecules.  
       [0172] An example of a method of producing a nonhuman host, exemplified as a mouse, lacking expression of an endogenous immunoglobulin heavy chain is disclosed in U.S. Pat. No. 5,939,598. It can be obtained by a method including deleting the J segment genes from at least one endogenous heavy chain locus in an embryonic stem cell to prevent rearrangement of the locus and to prevent formation of a transcript of a rearranged immunoglobulin heavy chain locus, the deletion being effected by a targeting vector containing a gene encoding a selectable marker; and producing from the embryonic stem cell a transgenic mouse whose somatic and germ cells contain the gene encoding the selectable marker.  
       [0173] A method for producing an antibody of interest, such as a human antibody, is disclosed in U.S. Pat. No. 5,916,771. It includes introducing an expression vector that contains a nucleotide sequence encoding a heavy chain into one mammalian host cell in culture, introducing an expression vector containing a nucleotide sequence encoding a light chain into another mammalian host cell, and fusing the two cells to form a hybrid cell. The hybrid cell expresses an antibody containing the heavy chain and the light chain.  
       [0174] In a further improvement on this procedure, a method for identifying a clinically relevant epitope on an immunogen, and a correlative method for selecting an antibody that binds immunospecifically to the relevant epitope with high affinity, are disclosed in PCT publication WO 99/53049.  
       [0175] F ab  Fragments and Single Chain Antibodies  
       [0176] According to the invention, techniques can be adapted for the production of single-chain antibodies specific to an antigenic protein of the invention (see e.g., U.S. Pat. No. 4,946,778). In addition, methods can be adapted for the construction of F ab  expression libraries (see e.g., Huse, et al., 1989 Science 246: 1275-1281) to allow rapid and effective identification of monoclonal F ab  fragments with the desired specificity for a protein or derivatives, fragments, analogs or homologs thereof. Antibody fragments that contain the idiotypes to a protein antigen may be produced by techniques known in the art including, but not limited to: (i) an F (ab′)2  fragment produced by pepsin digestion of an antibody molecule; (ii) an F ab  fragment generated by reducing the disulfide bridges of an F (ab′)2  fragment; (iii) an F ab  fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) F v  fragments.  
       [0177] Bispecific Antibodies  
       [0178] Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for an antigenic protein of the invention. The second binding target is any other antigen, and advantageously is a cell-surface protein or receptor or receptor subunit.  
       [0179] Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities (Milstein and Cuello, Nature, 305:537-539 (1983)). Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography. Similar procedures are disclosed in WO 93/08829, published May 13, 1993, and in Traunecker et al., EMBO J., 10:3655-3659 (1991).  
       [0180] Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh et al., Methods in Enzymology, 121:210 (1986).  
       [0181] According to another approach described in WO 96/27011, the interface between a pair of antibody molecules can be engineered to maximize the percentage of heterodimers that are recovered from recombinant cell culture. The preferred interface comprises at least a part of the CH3 region of an antibody constant domain. In this method, one or more small amino acid side chains from the interface of the first antibody molecule are replaced with larger side chains (e.g., tyrosine or tryptophan). Compensatory “cavities” of identical or similar size to the large side chain(s) are created on the interface of the second antibody molecule by replacing large amino acid side chains with smaller ones (e.g., alanine or threonine). This provides a mechanism for increasing the yield of the heterodimer over other unwanted end-products such as homodimers.  
       [0182] Bispecific antibodies can be prepared as full length antibodies or antibody fragments (e.g., F(ab′) 2  bispecific antibodies). Techniques for generating bispecific antibodies from antibody fragments have been described in the literature. For example, bispecific antibodies can be prepared using chemical linkage. Brennan et al., Science 229:81 (1985) describe a procedure wherein intact antibodies are proteolytically cleaved to generate F(ab′) 2  fragments. These fragments are reduced in the presence of the dithiol complexing agent sodium arsenite to stabilize vicinal dithiols and prevent intermolecular disulfide formation. The Fab′ fragments generated are then converted to thionitrobenzoate (TNB) derivatives. One of the Fab′-TNB derivatives is then reconverted to the Fab′-thiol by reduction with mercaptoethylamine and is mixed with an equimolar amount of the other Fab′-TNB derivative to form the bispecific antibody. The bispecific antibodies produced can be used as agents for the selective inmmobilization of enzymes.  
       [0183] Additionally, Fab′ fragments can be directly recovered from  E. coli  and chemically coupled to form bispecific antibodies. Shalaby et al., J. Exp. Med. 175:217-225 (1992) describe the production of a fully humanized bispecific antibody F(ab′) 2  molecule. Each Fab′ fragment was separately secreted from  E. coli  and subjected to directed chemical coupling in vitro to form the bispecific antibody. The bispecific antibody thus formed was able to bind to cells overexpressing the ErbB2 receptor and normal human T cells, as well as trigger the lytic activity of human cytotoxic lymphocytes against human breast tumor targets.  
       [0184] Various techniques for making and isolating bispecific antibody fragments directly from recombinant cell culture have also been described. For example, bispecific antibodies have been produced using leucine zippers. Kostelny et al., J. Immunol. 148(5):1547-1553 (1992). The leucine zipper peptides from the Fos and Jun proteins were linked to the Fab′ portions of two different antibodies by gene fusion. The antibody homodimers were reduced at the hinge region to form monomers and then re-oxidized to form the antibody heterodimers. This method can also be utilized for the production of antibody homodimers. The “diabody” technology described by Hollinger et al., Proc. Natl. Acad. Sci. USA 90:6444-6448 (1993) has provided an alternative mechanism for making bispecific antibody fragments. The fragments comprise a heavy-chain variable domain (V H ) connected to a light-chain variable domain (V L ) by a linker that is too short to allow pairing between the two domains on the same chain. Accordingly, the V H  and V L  domains of one fragment are forced to pair with the complementary V L  and V H  domains of another fragment, thereby forming two antigen-binding sites. Another strategy for making bispecific antibody fragments by the use of single-chain Fv (sFv) dimers has also been reported. See, Gruber et al., J. Immunol. 152:5368 (1994).  
       [0185] Antibodies with more than two valencies are contemplated. For example, trispecific antibodies can be prepared. Tutt et al., J. Immunol. 147:60 (1991).  
       [0186] Exemplary bispecific antibodies can bind to two different epitopes, at least one of which originates in the protein antigen of the invention. Alternatively, an anti-antigenic arm of an immunoglobulin molecule can be combined with an arm which binds to a triggering molecule on a leukocyte such as a T-cell receptor molecule (e.g., CD2, CD3, CD28, or B7), or Fe receptors for IgG (FcγR), such as FcγRI (CD64), FcγRII (CD32) and FcγRIII (CD16) so as to focus cellular defense mechanisms to the cell expressing the particular antigen. Bispecific antibodies can also be used to direct cytotoxic agents to cells which express a particular antigen. These antibodies possess an antigen-binding arm and an arm which binds a cytotoxic agent or a radionuclide chelator, such as EOTUBE, DPTA, DOTA, or TETA. Another bispecific antibody of interest binds the protein antigen described herein and further binds tissue factor (TF).  
       [0187] Heteroconjugate Antibodies  
       [0188] Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells (U.S. Pat. No. 4,676,980), and for treatment of HIV infection (WO 91/00360; WO 92/200373; EP 03089). It is contemplated that the antibodies can be prepared in vitro using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins can be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Pat. No. 4,676,980.  
       [0189] Effector Function Engineering  
       [0190] It can be desirable to modify the antibody of the invention with respect to effector function, so as to enhance, e.g., the effectiveness of the antibody in treating cancer. For example, cysteine residue(s) can be introduced into the Fe region, thereby allowing interchain disulfide bond formation in this region. The homodimeric antibody thus generated can have improved internalization capability and/or increased complement-mediated cell killing and antibody-dependent cellular cytotoxicity (ADCC). See Caron et al., J. Exp Med., 176: 1191-1195 (1992) and Shopes, J. Immunol., 148: 2918-2922 (1992). Homodimeric antibodies with enhanced anti-tumor activity can also be prepared using heterobifunctional cross-linkers as described in Wolff et al. Cancer Research, 53: 2560-2565 (1993). Alternatively, an antibody can be engineered that has dual Fe regions and can thereby have enhanced complement lysis and ADCC capabilities. See Stevenson et al., Anti-Cancer Drug Design, 3: 219-230 (1989).  
       [0191] Immunoconjugates  
       [0192] The invention also pertains to immunoconjugates comprising an antibody conjugated to a cytotoxic agent such as a chemotherapeutic agent, toxin (e.g., an enzymatically active toxin of bacterial, fungal, plant, or animal origin, or fragments thereof), or a radioactive isotope (i.e., a radioconjugate).  
       [0193] Chemotherapeutic agents useful in the generation of such immunoconjugates have been described above. Enzymatically active toxins and fragments thereof that can be used include diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, sapaonaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes. A variety of radionuclides are available for the production of radioconjugated antibodies. Examples include  212 Bi,  131 I,  131 In,  90 y, and  186 Re.  
       [0194] Conjugates of the antibody and cytotoxic agent are made using a variety of bifunctional protein-coupling agents such as N-succinimidyl-3-(2-pyridyldithiol) propionate (SPDP), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCL), active esters (such as disuccinimidyl suberate), aldehydes (such as glutareldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as tolyene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in Vitetta et al.,  Science , 238: 1098 (1987). Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triaminepentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO94/11026.  
       [0195] In another embodiment, the antibody can be conjugated to a “receptor” (such streptavidin) for utilization in tumor pretargeting wherein the antibody-receptor conjugate is administered to the patient, followed by removal of unbound conjugate from the circulation using a clearing agent and then administration of a “ligand” (e.g., avidin) that is in turn conjugated to a cytotoxic agent.  
       [0196] Immunoliposomes  
       [0197] The antibodies disclosed herein can also be formulated as immunoliposomes. Liposomes containing the antibody are prepared by methods known in the art, such as described in Epstein et al., Proc. Natl. Acad. Sci. USA, 82: 3688 (1985); Hwang et al., Proc. Natl Acad. Sci. USA, 77: 4030 (1980); and U.S. Pat. Nos. 4,485,045 and 4,544,545. Liposomes with enhanced circulation time are disclosed in U.S. Pat. No. 5,013,556.  
       [0198] Particularly useful liposomes can be generated by the reverse-phase evaporation method with a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derivatized phosphatidylethanolamine (PEG-PE). Liposomes are extruded through filters of defined pore size to yield liposomes with the desired diameter. Fab′ fragments of the antibody of the present invention can be conjugated to the liposomes as described in Martin et al., J. Biol. Chem., 257: 286-288 (1982) via a disulfide-interchange reaction. A chemotherapeutic agent (such as Doxorubicin) is optionally contained within the liposome. See Gabizon et al., J. National Cancer Inst., 81(19): 1484 (1989).  
       [0199] Diagnostic Applications of Antibodies Directed Against the Proteins of the Invention  
       [0200] In one embodiment, methods for the screening of antibodies that possess the desired specificity include, but are not limited to, enzyme linked immunosorbent assay (ELISA) and other immunologically mediated techniques known within the art. In a specific embodiment, selection of antibodies that are specific to a particular domain of an NOVX protein is facilitated by generation of hybridomas that bind to the fragment of an NOVX protein possessing such a domain. Thus, antibodies that are specific for a desired domain within an NOVX protein, or derivatives, fragments, analogs or homologs thereof, are also provided herein.  
       [0201] Antibodies directed against a NOVX protein of the invention may be used in methods known within the art relating to the localization and/or quantitation of a NOVX protein (e.g., for use in measuring levels of the NOVX protein within appropriate physiological samples, for use in diagnostic methods, for use in imaging the protein, and the like). In a given embodiment, antibodies specific to a NOVX protein, or derivative, fragment, analog or homolog thereof, that contain the antibody derived antigen binding domain, are utilized as pharmacologically active compounds (referred to hereinafter as “Therapeutics”).  
       [0202] An antibody specific for a NOVX protein of the invention (e.g., a monoclonal antibody or a polyclonal antibody) can be used to isolate a NOVX polypeptide by standard techniques, such as immunoaffinity, chromatography or immunoprecipitation. An antibody to a NOVX polypeptide can facilitate the purification of a natural NOVX antigen from cells, or of a recombinantly produced NOVX antigen expressed in host cells. Moreover, such an anti-NOVX antibody can be used to detect the antigenic NOVX protein (e.g., in a cellular lysate or cell supernatant) in order to evaluate the abundance and pattern of expression of the antigenic NOVX protein. Antibodies directed against a NOVX protein can be used diagnostically to monitor protein levels in tissue as part of a clinical testing procedure, e.g., to, for example, determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling (i. e., physically linking) the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidinibiotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin, and examples of suitable radioactive material include  125 I,  131 I,  35 S or 3 H.  
       [0203] Antibody Therapeutics  
       [0204] Antibodies of the invention, including polyclonal, monoclonal, humanized and fully human antibodies, may used as therapeutic agents. Such agents will generally be employed to treat or prevent a disease or pathology in a subject. An antibody preparation, preferably one having high specificity and high affinity for its target antigen, is administered to the subject and will generally have an effect due to its binding with the target. Such an effect may be one of two kinds, depending on the specific nature of the interaction between the given antibody molecule and the target antigen in question. In the first instance, administration of the antibody may abrogate or inhibit the binding of the target with an endogenous ligand to which it naturally binds. In this case, the antibody binds to the target and masks a binding site of the naturally occurring ligand, wherein the ligand serves as an effector molecule. Thus the receptor mediates a signal transduction pathway for which ligand is responsible.  
       [0205] Alternatively, the effect may be one in which the antibody elicits a physiological result by virtue of binding to an effector binding site on the target molecule. In this case the target, a receptor having an endogenous ligand that may be absent or defective in the disease or pathology, binds the antibody as a surrogate effector ligand, initiating a receptor-based signal transduction event by the receptor.  
       [0206] A therapeutically effective amount of an antibody of the invention relates generally to the amount needed to achieve a therapeutic objective. As noted above, this may be a binding interaction between the antibody and its target antigen that, in certain cases, interferes with the functioning of the target, and in other cases, promotes a physiological response. The amount required to be administered will furthermore depend on the binding affinity of the antibody for its specific antigen, and will also depend on the rate at which an administered antibody is depleted from the free volume other subject to which it is administered. Common ranges for therapeutically effective dosing of an antibody or antibody fragment of the invention may be, by way of nonlimiting example, from about 0.1 mg/kg body weight to about 50 mg/kg body weight. Common dosing frequencies may range, for example, from twice daily to once a week.  
       [0207] Pharmaceutical Compositions of Antibodies  
       [0208] Antibodies specifically binding a protein of the invention, as well as other molecules identified by the screening assays disclosed herein, can be administered for the treatment of various disorders in the form of pharmaceutical compositions. Principles and considerations involved in preparing such compositions, as well as guidance in the choice of components are provided, for example, in Remington: The Science And Practice Of Pharmacy 19th ed. (Alfonso R. Gennaro, et al., editors) Mack Pub. Co., Easton, Pa.: 1995; Drug Absorption Enhancement: Concepts, Possibilities, Limitations, And Trends, Harwood Academic Publishers, Langhorne, Pa., 1994; and Peptide And Protein Drug Delivery (Advances In Parenteral Sciences, Vol. 4), 1991, M. Dekker, New York.  
       [0209] If the antigenic protein is intracellular and whole antibodies are used as inhibitors, internalizing antibodies are preferred. However, liposomes can also be used to deliver the antibody, or an antibody fragment, into cells. Where antibody fragments are used, the smallest inhibitory fragment that specifically binds to the binding domain of the target protein is preferred. For example, based upon the variable-region sequences of an antibody, peptide molecules can be designed that retain the ability to bind the target protein sequence. Such peptides can be synthesized chemically and/or produced by recombinant DNA technology. See, e.g., Marasco et al., Proc. Natl. Acad. Sci. USA, 90: 7889-7893 (1993). The formulation herein can also contain more than one active compound as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Alternatively, or in addition, the composition can comprise an agent that enhances its function, such as, for example, a cytotoxic agent, cytokine, chemotherapeutic agent, or growth-inhibitory agent. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.  
       [0210] The active ingredients can also be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles, and nanocapsules) or in macroemulsions.  
       [0211] The formulations to be used for in vivo administration must be sterile. This is readily accomplished by filtration through sterile filtration membranes.  
       [0212] Sustained-release preparations can be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (for example, poly(2-hydroxyethyl-methacrylate), or poly(vinylalcohol)), polylactides (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and γ ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as the LUPRON DEPOT™ (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), and poly-D-(−)-3-hydroxybutyric acid. While polymers such as ethylene-vinyl acetate and lactic acid-glycolic acid enable release of molecules for over 100 days, certain hydrogels release proteins for shorter time periods.  
       [0213] ELISA Assay  
       [0214] An agent for detecting an analyte protein is an antibody capable of binding to an analyte protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., F ab  or F (ab)2 ) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. Included within the usage of the term “biological sample”, therefore, is blood and a fraction or component of blood including blood serum, blood plasma, or lymph. That is, the detection method of the invention can be used to detect an analyte mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of an analyte mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of an analyte protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of an analyte genomic DNA include Southern hybridizations. Procedures for conducting immunoassays are described, for example in “ELISA: Theory and Practice: Methods in Molecular Biology”, Vol. 42, J. R. Crowther (Ed.) Human Press, Totowa, NJ, 1995; “Immunoassay”, E. Diamandis and T. Christopoulus, Academic Press, Inc., San Diego, Calif., 1996; and “Practice and Theory of Enzyme Immunoassays”, P. Tijssen, Elsevier Science Publishers, Amsterdam, 1985. Furthermore, in vivo techniques for detection of an analyte protein include introducing into a subject a labeled anti-an analyte protein antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.  
       [0215] NOVX Recombinant Expression Vectors and Host Cells  
       [0216] Another aspect of the invention pertains to vectors, preferably expression vectors, containing a nucleic acid encoding a NOVX protein, or derivatives, fragments, analogs or homologs thereof. As used herein, the term “vector” refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector, wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively-linked. Such vectors are referred to herein as “expression vectors”. In general, useful expression vectors in recombinant DNA techniques are often in the form of plasmids. In the present specification, “plasmid” and “vector” can be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors, such as viral vectors (e.g., replication defective retroviruses, adenoviruses and adeno-associated viruses), which serve equivalent functions.  
       [0217] The recombinant expression vectors of the invention comprise a nucleic acid of the invention in a form suitable for expression of the nucleic acid in a host cell, which means that the recombinant expression vectors include one or more regulatory sequences, selected on the basis of the host cells to be used for expression, that is operatively-linked to the nucleic acid sequence to be expressed. Within a recombinant expression vector, “operably-linked” is intended to mean that the nucleotide sequence of interest is linked to the regulatory sequence(s) in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription/translation system or in a host cell when the vector is introduced into the host cell).  
       [0218] The term “regulatory sequence” is intended to includes promoters, enhancers and other expression control elements (e.g., polyadenylation signals). Such regulatory sequences are described, for example, in Goeddel, G ENE  E XPRESSION  T ECHNOLOGY : M ETHODS IN  E NZYMOLOGY  185, Academic Press, San Diego, Calif. (1990). Regulatory sequences include those that direct constitutive expression of a nucleotide sequence in many types of host cell and those that direct expression of the nucleotide sequence only in certain host cells (e.g., tissue-specific regulatory sequences). It will be appreciated by those skilled in the art that the design of the expression vector can depend on such factors as the choice of the host cell to be transformed, the level of expression of protein desired, etc. The expression vectors of the invention can be introduced into host cells to thereby produce proteins or peptides, including fusion proteins or peptides, encoded by nucleic acids as described herein (e.g., NOVX proteins, mutant forms of NOVX proteins, fusion proteins, etc.).  
       [0219] The recombinant expression vectors of the invention can be designed for expression of NOVX proteins in prokaryotic or eukaryotic cells. For example, NOVX proteins can be expressed in bacterial cells such as  Escherichia coli , insect cells (using baculovirus expression vectors) yeast cells or mammalian cells. Suitable host cells are discussed further in Goeddel, G ENE  E XPRESSION  T ECHNOLOGY : M ETHODS IN  E NZYMOLOGY  185, Academic Press, San Diego, Calif. (1990). Alternatively, the recombinant expression vector can be transcribed and translated in vitro, for example using T7 promoter regulatory sequences and T7 polymerase.  
       [0220] Expression of proteins in prokaryotes is most often carried out in  Escherichia coli  with vectors containing constitutive or inducible promoters directing the expression of either fusion or non-fusion proteins. Fusion vectors add a number of amino acids to a protein encoded therein, usually to the amino terminus of the recombinant protein. Such fusion vectors typically serve three purposes: (i) to increase expression of recombinant protein; (ii) to increase the solubility of the recombinant protein; and (iii) to aid in the purification of the recombinant protein by acting as a ligand in affinity purification. Often, in fusion expression vectors, a proteolytic cleavage site is introduced at the junction of the fusion moiety and the recombinant protein to enable separation of the recombinant protein from the fusion moiety subsequent to purification of the fusion protein. Such enzymes, and their cognate recognition sequences, include Factor Xa, thrombin and enterokinase. Typical fusion expression vectors include pGEX (Pharmacia Biotech Inc; Smith and Johnson, 1988 . Gene  67: 31-40), pMAL (New England Biolabs, Beverly, Mass.) and pRIT5 (Pharnacia, Piscataway, N.J.) that fuse glutathione S-transferase (GST), maltose E binding protein, or protein A, respectively, to the target recombinant protein.  
       [0221] Examples of suitable inducible non-fusion  E. coli  expression vectors include pTrc (Amrann et al., (1988)  Gene  69:301-315) and pET 11d (Studier et al., G ENE E   XPRESSION  T ECHNOLOGY : M ETHODS IN  E NZYMOLOGY  185, Academic Press, San Diego, Calif. (1990) 60-89).  
       [0222] One strategy to maximize recombinant protein expression in  E. coli  is to express the protein in a host bacteria with an impaired capacity to proteolytically cleave the recombinant protein. See, e.g., Gottesman, G ENE  E XPRESSION  T ECHNOLOGY : M ETHODS IN  E NZYMOLOGY  185, Academic Press, San Diego, Calif. (1990) 119-128. Another strategy is to alter the nucleic acid sequence of the nucleic acid to be inserted into an expression vector so that the individual codons for each amino acid are those preferentially utilized in  E. coli  (see, e.g., Wada, et al., 1992 . Nucl. Acids Res . 20: 2111-2118). Such alteration of nucleic acid sequences of the invention can be carried out by standard DNA synthesis techniques.  
       [0223] In another embodiment, the NOVX expression vector is a yeast expression vector. Examples of vectors for expression in yeast  Saccharomyces cerivisae  include pYepSec1 (Baldari, et al., 1987 . EMBO J . 6: 229-234), pMFa (Kudan and Herskowitz, 1982 . Cell  30: 933-943), pJRY88 (Schultz et al., 1987 . Gene  54: 113-123), pYES2 (Invitrogen Corporation, San Diego, Calif.), and picZ (InVitrogen Corp, San Diego, Calif.).  
       [0224] Alternatively, NOVX can be expressed in insect cells using baculovirus expression vectors. Baculovirus vectors available for expression of proteins in cultured insect cells (e.g., SF9 cells) include the pAc series (Smith, et al., 1983 . Mol. Cell. Biol . 3: 2156-2165) and the pVL series (Lucklow and Summers, 1989 . Virology  170: 31-39).  
       [0225] In yet another embodiment, a nucleic acid of the invention is expressed in mammalian cells using a mammalian expression vector. Examples of mammalian expression vectors include pCDM8 (Seed, 1987 . Nature  329: 840) and pMT2PC (Kaufman, et al., 1987 . EMBO J . 6: 187-195). When used in mammalian cells, the expression vector&#39;s control functions are often provided by viral regulatory elements. For example, commonly used promoters are derived from polyoma, adenovirus 2, cytomegalovirus, and simian virus 40. For other suitable expression systems for both prokaryotic and eukaryotic cells see, e.g., Chapters 16 and 17 of Sambrook, et al., M OLECULAR  C LONING : A L ABORATORY  M ANUAL . 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989.  
       [0226] In another embodiment, the recombinant mammalian expression vector is capable of directing expression of the nucleic acid preferentially in a particular cell type (e.g., tissue-specific regulatory elements are used to express the nucleic acid). Tissue-specific regulatory elements are known in the art. Non-limiting examples of suitable tissue-specific promoters include the albumin promoter (liver-specific; Pinkert, et al., 1987 . Genes Dev . 1: 268-277), lymphoid-specific promoters (Calame and Eaton, 1988 . Adv. Immunol . 43: 235-275), in particular promoters of T cell receptors (Winoto and Baltimore, 1989 . EMBO J . 8: 729-733) and immunoglobulins (Baneji, et al., 1983 . Cell  33: 729-740; Queen and Baltimore, 1983 . Cell  33: 741-748), neuron-specific promoters (e.g., the neurofilament promoter; Byrne and Ruddle, 1989  Proc. Natl. Acad. Sci. USA  86: 5473-5477), pancreas-specific promoters (Edlund, et al., 1985 . Science  230: 912-916), and mammary gland-specific promoters (e.g., milk whey promoter; U.S. Pat. No. 4,873,316 and European Application Publication No. 264,166). Developmentally-regulated promoters are also encompassed, e.g., the murine hox promoters (Kessel and Gruss, 1990 . Science  249: 374-379) and the α-fetoprotein promoter (Campes and Tilghman, 1989 . Genes Dev . 3: 537-546).  
       [0227] The invention further provides a recombinant expression vector comprising a DNA molecule of the invention cloned into the expression vector in an antisense orientation. That is, the DNA molecule is operatively-linked to a regulatory sequence in a manner that allows for expression (by transcription of the DNA molecule) of an RNA molecule that is antisense to NOVX mRNA. Regulatory sequences operatively linked to a nucleic acid cloned in the antisense orientation can be chosen that direct the continuous expression of the antisense RNA molecule in a variety of cell types, for instance viral promoters and/or enhancers, or regulatory sequences can be chosen that direct constitutive, tissue specific or cell type specific expression of antisense RNA. The antisense expression vector can be in the form of a recombinant plasmid, phagemid or attenuated virus in which antisense nucleic acids are produced under the control of a high efficiency regulatory region, the activity of which can be determined by the cell type into which the vector is introduced. For a discussion of the regulation of gene expression using antisense genes see, e.g., Weintraub, et al., “Antisense RNA as a molecular tool for genetic analysis,”  Reviews - Trends in Genetics , Vol. 1(1) 1986.  
       [0228] Another aspect of the invention pertains to host cells into which a recombinant expression vector of the invention has been introduced. The terms “host cell” and “recombinant host cell” are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but also to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term as used herein.  
       [0229] A host cell can be any prokaryotic or eukaryotic cell. For example, NOVX protein can be expressed in bacterial cells such as  E. coli , insect cells, yeast or mammalian cells (such as Chinese hamster ovary cells (CHO) or COS cells). Other suitable host cells are known to those skilled in the art.  
       [0230] Vector DNA can be introduced into prokaryotic or eukaryotic cells via conventional transformation or transfection techniques. As used herein, the terms “transformation” and “transfection” are intended to refer to a variety of art-recognized techniques for introducing foreign nucleic acid (e.g., DNA) into a host cell, including calcium phosphate or calcium chloride co-precipitation, DEAE-dextran-mediated transfection, lipofection, or electroporation. Suitable methods for transforming or transfecting host cells can be found in Sambrook, et al. (M OLECULAR  C LONING : A L ABORATORY  M ANUAL . 2nd ed., Cold Spring Harbor Laboratory, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989), and other laboratory manuals.  
       [0231] For stable transfection of mammalian cells, it is known that, depending upon the expression vector and transfection technique used, only a small fraction of cells may integrate the foreign DNA into their genome. In order to identify and select these integrants, a gene that encodes a selectable marker (e.g., resistance to antibiotics) is generally introduced into the host cells along with the gene of interest. Various selectable markers include those that confer resistance to drugs, such as G418, hygromycin and methotrexate. Nucleic acid encoding a selectable marker can be introduced into a host cell on the same vector as that encoding NOVX or can be introduced on a separate vector. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (e.g., cells that have incorporated the selectable marker gene will survive, while the other cells die).  
       [0232] A host cell of the invention, such as a prokaryotic or eukaryotic host cell in culture, can be used to produce (i.e., express) NOVX protein. Accordingly, the invention further provides methods for producing NOVX protein using the host cells of the invention. In one embodiment, the method comprises culturing the host cell of invention (into which a recombinant expression vector encoding NOVX protein has been introduced) in a suitable medium such that NOVX protein is produced. In another embodiment, the method further comprises isolating NOVX protein from the medium or the host cell.  
       [0233] Transgenic NOVX Animals  
       [0234] The host cells of the invention can also be used to produce non-human transgenic animals. For example, in one embodiment, a host cell of the invention is a fertilized oocyte or an embryonic stem cell into which NOVX protein-coding sequences have been introduced. Such host cells can then be used to create non-human transgenic animals in which exogenous NOVX sequences have been introduced into their genome or homologous recombinant animals in which endogenous NOVX sequences have been altered. Such animals are useful for studying the function and/or activity of NOVX protein and for identifying and/or evaluating modulators of NOVX protein activity. As used herein, a “transgenic animal” is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a transgene. Other examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. A transgene is exogenous DNA that is integrated into the genome of a cell from which a transgenic animal develops and that remains in the genome of the mature animal, thereby directing the expression of an encoded gene product in one or more cell types or tissues of the transgenic animal. As used herein, a “homologous recombinant animal” is a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous NOVX gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the animal, e.g., an embryonic cell of the animal, prior to development of the animal.  
       [0235] A transgenic animal of the invention can be created by introducing a NOVX-encoding nucleic acid into the male pronuclei of a fertilized oocyte (e.g., by microinjection, retroviral infection) and allowing the oocyte to develop in a pseudopregnant female foster animal. The human NOVX cDNA sequences, i.e., any one of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, can be introduced as a transgene into the genome of a non-human animal. Alternatively, a non-human homologue of the human NOVX gene, such as a mouse NOVX gene, can be isolated based on hybridization to the human NOVX cDNA (described further supra) and used as a transgene. Intronic sequences and polyadenylation signals can also be included in the transgene to increase the efficiency of expression of the transgene. A tissue-specific regulatory sequence(s) can be operably-linked to the NOVX transgene to direct expression of NOVX protein to particular cells. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Pat. Nos. 4,736,866; 4,870,009; and 4,873,191; and Hogan, 1986. In: M ANIPULATING THE  M OUSE  E MBRYO , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Similar methods are used for production of other transgenic animals. A transgenic founder animal can be identified based upon the presence of the NOVX transgene in its genome and/or expression of NOVX mRNA in tissues or cells of the animals. A transgenic founder animal can then be used to breed additional animals carrying the transgene. Moreover, transgenic animals carrying a transgene-encoding NOVX protein can further be bred to other transgenic animals carrying other transgenes.  
       [0236] To create a homologous recombinant animal, a vector is prepared which contains at least a portion of a NOVX gene into which a deletion, addition or substitution has been introduced to thereby alter, e.g., functionally disrupt, the NOVX gene. The NOVX gene can be a human gene (e.g., the cDNA of any one of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48), but more preferably, is a non-human homologue of a human NOVX gene. For example, a mouse homologue of human NOVX gene of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, can be used to construct a homologous recombination vector suitable for altering an endogenous NOVX gene in the mouse genome. In one embodiment, the vector is designed such that, upon homologous recombination, the endogenous NOVX gene is functionally disrupted (i.e., no longer encodes a functional protein; also referred to as a “knock out” vector).  
       [0237] Alternatively, the vector can be designed such that, upon homologous recombination, the endogenous NOVX gene is mutated or otherwise altered but still encodes functional protein (e.g., the upstream regulatory region can be altered to thereby alter the expression of the endogenous NOVX protein). In the homologous recombination vector, the altered portion of the NOVX gene is flanked at its 5′- and 3′-termini by additional nucleic acid of the NOVX gene to allow for homologous recombination to occur between the exogenous NOVX gene carried by the vector and an endogenous NOVX gene in an embryonic stem cell. The additional flanking NOVX nucleic acid is of sufficient length for successful homologous recombination with the endogenous gene. Typically, several kilobases of flanking DNA (both at the 5′- and 3′-termini) are included in the vector. See, e.g., Thomas, et al., 1987 . Cell  51: 503 for a description of homologous recombination vectors. The vector is ten introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced NOVX gene has homologously-recombined with the endogenous NOVX gene are selected. See, e.g., Li, et al., 1992 . Cell  69: 915.  
       [0238] The selected cells are then injected into a blastocyst of an animal (e.g. a mouse) to form aggregation chimeras. See, e.g., Bradley, 1987. In: T ERATOCARCINOMAS AND  E MBRYONIC  S TEM  C ELLS : A P RACTICAL  A PPROACH , Robertson, ed. IRL, Oxford, pp. 113-152. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term. Progeny harboring the homologously-recombined DNA in their germ cells can be used to breed animals in which all cells of the animal contain the homologously-recombined DNA by germline transmission of the transgene. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Bradley, 1991 . Curr. Opin. Biotechnol . 2: 823-829; PCT International Publication Nos.: WO 90/11354; WO 91/01140; WO 92/0968; and WO 93/04169.  
       [0239] In another embodiment, transgenic non-humans animals can be produced that contain selected systems that allow for regulated expression of the transgene. One example of such a system is the cre/loxP recombinase system of bacteriophage P1. For a description of the cre/loxP recombinase system, see, e.g., Lakso, et al., 1992 . Proc. Natl. Acad. Sci. USA  89: 6232-6236. Another example of a recombinase system is the FLP recombinase system of  Saccharomyces cerevisiae . See, O&#39;Gorman, et al., 1991 . Science  251:1351-1355. If a cre/loxP recombinase system is used to regulate expression of the transgene, animals containing transgenes encoding both the Cre recombinase and a selected protein are required. Such animals can be provided through the construction of “double” transgenic animals, e.g., by mating two transgenic animals, one containing a transgene encoding a selected protein and the other containing a transgene encoding a recombinase.  
       [0240] Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut, et a., 1997 . Nature  385: 810-813. In brief, a cell (e.g., a somatic cell) from the transgenic animal can be isolated and induced to exit the growth cycle and enter G 0  phase. The quiescent cell can then be fused, e.g., through the use of electrical pulses, to an enucleated oocyte from an animal of the same species from which the quiescent cell is isolated. The reconstructed oocyte is then cultured such that it develops to morula or blastocyte and then transferred to pseudopregnant female foster animal. The offspring borne of this female foster animal will be a clone of the animal from which the cell (e.g., the somatic cell) is isolated.  
       [0241] Pharmaceutical Compositions  
       [0242] The NOVX nucleic acid molecules, NOVX proteins, and anti-NOVX antibodies (also referred to herein as “active compounds”) of the invention, and derivatives, fragments, analogs and homologs thereof, can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise the nucleic acid molecule, protein, or antibody and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington&#39;s Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger&#39;s solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.  
       [0243] A pharmaceutical composition of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (i.e., topical), transmucosal, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.  
       [0244] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, aluminum monostearate and gelatin.  
       [0245] Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a NOVX protein or anti-NOVX antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.  
       [0246] Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.  
       [0247] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from pressured container or dispenser that contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.  
       [0248] Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.  
       [0249] The compounds can also be prepared in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.  
       [0250] In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.  
       [0251] It is especially advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of individuals.  
       [0252] The nucleic acid molecules of the invention can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see, e.g., U.S. Pat. No. 5,328,470) or by stereotactic injection (see, e.g., Chen, et al., 1994 . Proc. Natl. Acad. Sci. USA  91: 3054-3057). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g., retroviral vectors, the pharmaceutical preparation can include one or more cells that produce the gene delivery system.  
       [0253] The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.  
       [0254] Screening and Detection Methods  
       [0255] The isolated nucleic acid molecules of the invention can be used to express NOVX protein (e.g., via a recombinant expression vector in a host cell in gene therapy applications), to detect NOVX mRNA (e.g., in a biological sample) or a genetic lesion in a NOVX gene, and to modulate NOVX activity, as described further, below. In addition, the NOVX proteins can be used to screen drugs or compounds that modulate the NOVX protein activity or expression as well as to treat disorders characterized by insufficient or excessive production of NOVX protein or production of NOVX protein forms that have decreased or aberrant activity compared to NOVX wild-type protein (e.g.; diabetes (regulates insulin release); obesity (binds and transport lipids); metabolic disturbances associated with obesity, the metabolic syndrome X as well as anorexia and wasting disorders associated with chronic diseases and various cancers, and infectious disease (possesses anti-microbial activity) and the various dyslipidemias. In addition, the anti-NOVX antibodies of the invention can be used to detect and isolate NOVX proteins and modulate NOVX activity. In yet a further aspect, the invention can be used in methods to influence appetite, absorption of nutrients and the disposition of metabolic substrates in both a positive and negative fashion.  
       [0256] The invention further pertains to novel agents identified by the screening assays described herein and uses thereof for treatments as described, supra.  
       [0257] Screening Assays  
       [0258] The invention provides a method (also referred to herein as a “screening assay”) for identifying modulators, i.e., candidate or test compounds or agents (e.g., peptides, peptidomimetics, small molecules or other drugs) that bind to NOVX proteins or have a stimulatory or inhibitory effect on, e.g., NOVX protein expression or NOVX protein activity. The invention also includes compounds identified in the screening assays described herein.  
       [0259] In one embodiment, the invention provides assays for screening candidate or test compounds that bind to or modulate the activity of the membrane-bound form of a NOVX protein or polypeptide or biologically-active portion thereof. The test compounds of the invention can be obtained using any of the numerous approaches in combinatorial library methods known in the art, including: biological libraries; spatially addressable parallel solid phase or solution phase libraries; synthetic library methods requiring deconvolution; the “one-bead one-compound” library method; and synthetic library methods using affinity chromatography selection. The biological library approach is limited to peptide libraries, while the other four approaches are applicable to peptide, non-peptide oligomer or small molecule libraries of compounds. See, e.g., Lam, 1997 . Anticancer Drug Design  12:145.  
       [0260] A “small molecule” as used herein, is meant to refer to a composition that has a molecular weight of less than about 5 kD and most preferably less than about 4 kD. Small molecules can be, e.g., nucleic acids, peptides, polypeptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. Libraries of chemical and/or biological mixtures, such as fungal, bacterial, or algal extracts, are known in the art and can be screened with any of the assays of the invention.  
       [0261] Examples of methods for the synthesis of molecular libraries can be found in the art, for example in: DeWitt, et al., 1993 . Proc. Natl. Acad. Sci. U.S.A . 90: 6909; Erb, et al., 1994 . Proc. Natl. Acad. Sci. U.S.A . 91: 11422; Zuckermann, et al., 1994 . J. Med. Chem . 37: 2678; Cho, et al., 1993 . Science  261: 1303; Carrell, et al., 1994 . Angew. Chem. Int. Ed. Engl . 33: 2059; Carell, et al., 1994 . Angew. Chem. Int. Ed. Engl . 33: 2061; and Gallop, et al., 1994 . J. Med. Chem . 37: 1233.  
       [0262] Libraries of compounds may be presented in solution (e.g., Houghten, 1992 . Biotechniques  13: 412-421), or on beads (Lam, 1991 . Nature  354: 82-84), on chips (Fodor, 1993 . Nature  364: 555-556), bacteria (Ladner, U.S. Pat. No. 5,223,409), spores (Ladner, U.S. Pat. No. 5,233,409), plasmids (Cull, et al., 1992 . Proc. Natl. Acad. Sci. USA  89: 1865-1869) or on phage (Scott and Smith, 1990 . Science  249: 386-390; Devlin, 1990 . Science  249: 404-406; Cwirla, et al., 1990 . Proc. Natl. Acad. Sci. U.S.A . 87: 6378-6382; Felici, 1991 . J. Mol. Biol . 222: 301-310; Ladner, U.S. Pat. No. 5,233,409.).  
       [0263] In one embodiment, an assay is a cell-based assay in which a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface is contacted with a test compound and the ability of the test compound to bind to a NOVX protein determined. The cell, for example, can of mammalian origin or a yeast cell. Determining the ability of the test compound to bind to the NOVX protein can be accomplished, for example, by coupling the test compound with a radioisotope or enzymatic label such that binding of the test compound to the NOVX protein or biologically-active portion thereof can be determined by detecting the labeled compound in a complex. For example, test compounds can be labeled with  125 I,  35 S,  14 C, or  3 H, either directly or indirectly, and the radioisotope detected by direct counting of radioemission or by scintillation counting. Alternatively, test compounds can be enzymatically-labeled with, for example, horseradish peroxidase, alkaline phosphatase, or luciferase, and the enzymatic label detected by determination of conversion of an appropriate substrate to product. In one embodiment, the assay comprises contacting a cell which expresses a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX protein or a biologically-active portion thereof as compared to the known compound.  
       [0264] In another embodiment, an assay is a cell-based assay comprising contacting a cell expressing a membrane-bound form of NOVX protein, or a biologically-active portion thereof, on the cell surface with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX or a biologically-active portion thereof can be accomplished, for example, by determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule. As used herein, a “target molecule” is a molecule with which a NOVX protein binds or interacts in nature, for example, a molecule on the surface of a cell which expresses a NOVX interacting protein, a molecule on the surface of a second cell, a molecule in the extracellular milieu, a molecule associated with the internal surface of a cell membrane or a cytoplasmic molecule. A NOVX target molecule can be a non-NOVX molecule or a NOVX protein or polypeptide of the invention. In one embodiment, a NOVX target molecule is a component of a signal transduction pathway that facilitates transduction of an extracellular signal (e.g., a signal generated by binding of a compound to a membrane-bound NOVX molecule) through the cell membrane and into the cell. The target, for example, can be a second intercellular protein that has catalytic activity or a protein that facilitates the association of downstream signaling molecules with NOVX.  
       [0265] Determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by one of the methods described above for determining direct binding. In one embodiment, determining the ability of the NOVX protein to bind to or interact with a NOVX target molecule can be accomplished by determining the activity of the target molecule. For example, the activity of the target molecule can be determined by detecting induction of a cellular second messenger of the target (i.e., intracellular Ca 2+ , diacylglycerol, IP 3 , etc.), detecting catalytic/enzymatic activity of the target an appropriate substrate, detecting the induction of a reporter gene (comprising a NOVX-responsive regulatory element operatively linked to a nucleic acid encoding a detectable marker, e.g., luciferase), or detecting a cellular response, for example, cell survival, cellular differentiation, or cell proliferation.  
       [0266] In yet another embodiment, an assay of the invention is a cell-free assay comprising contacting a NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to bind to the NOVX protein or biologically-active portion thereof. Binding of the test compound to the NOVX protein can be determined either directly or indirectly as described above. In one such embodiment, the assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the test compound to preferentially bind to NOVX or biologically-active portion thereof as compared to the known compound.  
       [0267] In still another embodiment, an assay is a cell-free assay comprising contacting NOVX protein or biologically-active portion thereof with a test compound and determining the ability of the test compound to modulate (e.g., stimulate or inhibit) the activity of the NOVX protein or biologically-active portion thereof. Determining the ability of the test compound to modulate the activity of NOVX can be accomplished, for example, by determining the ability of the NOVX protein to bind to a NOVX target molecule by one of the methods described above for determining direct binding. In an alternative embodiment, determining the ability of the test compound to modulate the activity of NOVX protein can be accomplished by determining the ability of the NOVX protein further modulate a NOVX target molecule. For example, the catalytic/enzymatic activity of the target molecule on an appropriate substrate can be determined as described, supra.  
       [0268] In yet another embodiment, the cell-free assay comprises contacting the NOVX protein or biologically-active portion thereof with a known compound which binds NOVX protein to form an assay mixture, contacting the assay mixture with a test compound, and determining the ability of the test compound to interact with a NOVX protein, wherein determining the ability of the test compound to interact with a NOVX protein comprises determining the ability of the NOVX protein to preferentially bind to or modulate the activity of a NOVX target molecule.  
       [0269] The cell-free assays of the invention are amenable to use of both the soluble form or the membrane-bound form of NOVX protein. In the case of cell-free assays comprising the membrane-bound form of NOVX protein, it may be desirable to utilize a solubilizing agent such that the membrane-bound form of NOVX protein is maintained in solution. Examples of such solubilizing agents include non-ionic detergents such as n-octylglucoside, n-dodecylglucoside, n-dodecylmaltoside, octanoyl-N-methylglucamide, decanoyl-N-methylglucamide, Tritono® X-100, Tritono® X-114, Thesit®, Isotridecypoly(ethylene glycol ether) n , N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate, 3-(3-cholamidopropyl) dimethylamminiol-1-propane sulfonate (CHAPS), or 3-(3-cholamidopropyl)dimethylamminiol-2-hydroxy-1-propane sulfonate (CHAPSO).  
       [0270] In more than one embodiment of the above assay methods of the invention, it may be desirable to immobilize either NOVX protein or its target molecule to facilitate separation of complexed from uncomplexed forms of one or both of the proteins, as well as to accommodate automation of the assay. Binding of a test compound to NOVX protein, or interaction of NOVX protein with a target molecule in the presence and absence of a candidate compound, can be accomplished in any vessel suitable for containing the reactants. Examples of such vessels include microtiter plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided that adds a domain that allows one or both of the proteins to be bound to a matrix. For example, GST-NOVX fusion proteins or GST-target fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, Mo.) or glutathione derivatized microtiter plates, that are then combined with the test compound or the test compound and either the non-adsorbed target protein or NOVX protein, and the mixture is incubated under conditions conducive to complex formation (e.g., at physiological conditions for salt and pH). Following incubation, the beads or microtiter plate wells are washed to remove any unbound components, the matrix immobilized in the case of beads, complex determined either directly or indirectly, for example, as described, supra. Alternatively, the complexes can be dissociated from the matrix, and the level of NOVX protein binding or activity determined using standard techniques.  
       [0271] Other techniques for immobilizing proteins on matrices can also be used in the screening assays of the invention. For example, either the NOVX protein or its target molecule can be immobilized utilizing conjugation of biotin and streptavidin. Biotinylated NOVX protein or target molecules can be prepared from biotin-NHS (N-hydroxy-succinimide) using techniques well-known within the art (e.g., biotinylation kit, Pierce Chemicals, Rockford, Ill.), and immobilized in the wells of streptavidin-coated 96 well plates (Pierce Chemical). Alternatively, antibodies reactive with NOVX protein or target molecules, but which do not interfere with binding of the NOVX protein to its target molecule, can be derivatized to the wells of the plate, and unbound target or NOVX protein trapped in the wells by antibody conjugation. Methods for detecting such complexes, in addition to those described above for the GST-immobilized complexes, include immunodetection of complexes using antibodies reactive with the NOVX protein or target molecule, as well as enzyme-linked assays that rely on detecting an enzymatic activity associated with the NOVX protein or target molecule.  
       [0272] In another embodiment, modulators of NOVX protein expression are identified in a method wherein a cell is contacted with a candidate compound and the expression of NOVX mRNA or protein in the cell is determined. The level of expression of NOVX mRNA or protein in the presence of the candidate compound is compared to the level of expression of NOVX mRNA or protein in the absence of the candidate compound. The candidate compound can then be identified as a modulator of NOVX mRNA or protein expression based upon this comparison. For example, when expression of NOVX mRNA or protein is greater (i.e., statistically significantly greater) in the presence of the candidate compound than in its absence, the candidate compound is identified as a stimulator of NOVX mRNA or protein expression. Alternatively, when expression of NOVX mRNA or protein is less (statistically significantly less) in the presence of the candidate compound than in its absence, the candidate compound is identified as an inhibitor of NOVX mRNA or protein expression. The level of NOVX mRNA or protein expression in the cells can be determined by methods described herein for detecting NOVX mRNA or protein.  
       [0273] In yet another aspect of the invention, the NOVX proteins can be used as “bait proteins” in a two-hybrid assay or three hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos, et al., 1993 . Cell  72: 223-232; Madura, et al., 1993 . J. Biol. Chem . 268: 12046-12054; Bartel, et al., 1993 . Biotechniques  14: 920-924; Iwabuchi, et al., 1993 . Oncogene  8: 1693-1696; and Brent WO 94/10300), to identify other proteins that bind to or interact with NOVX (“NOVX-binding proteins” or “NOVX-bp”) and modulate NOVX activity. Such NOVX-binding proteins are also involved in the propagation of signals by the NOVX proteins as, for example, upstream or downstream elements of the NOVX pathway.  
       [0274] The two-hybrid system is based on the modular nature of most transcription factors, which consist of separable DNA-binding and activation domains. Briefly, the assay utilizes two different DNA constructs. In one construct, the gene that codes for NOVX is fused to a gene encoding the DNA binding domain of a known transcription factor (e.g., GAL-4). In the other construct, a DNA sequence, from a library of DNA sequences, that encodes an unidentified protein (“prey” or “sample”) is fused to a gene that codes for the activation domain of the known transcription factor. If the “bait” and the “prey” proteins are able to interact, in vivo, forming a NOVX-dependent complex, the DNA-binding and activation domains of the transcription factor are brought into close proximity. This proximity allows transcription of a reporter gene (e.g., LacZ) that is operably linked to a transcriptional regulatory site responsive to the transcription factor. Expression of the reporter gene can be detected and cell colonies containing the functional transcription factor can be isolated and used to obtain the cloned gene that encodes the protein which interacts with NOVX.  
       [0275] The invention further pertains to novel agents identified by the aforementioned screening assays and uses thereof for treatments as described herein.  
       [0276] Detection Assays  
       [0277] Portions or fragments of the cDNA sequences identified herein (and the corresponding complete gene sequences) can be used in numerous ways as polynucleotide reagents. By way of example, and not of limitation, these sequences can be used to: (i) map their respective genes on a chromosome; and, thus, locate gene regions associated with genetic disease; (ii) identify an individual from a minute biological sample (tissue typing); and (iii) aid in forensic identification of a biological sample. Some of these applications are described in the subsections, below.  
       [0278] Chromosome Mapping  
       [0279] Once the sequence (or a portion of the sequence) of a gene has been isolated, this sequence can be used to map the location of the gene on a chromosome. This process is called chromosome mapping. Accordingly, portions or fragments of the NOVX sequences of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or fragments or derivatives thereof, can be used to map the location of the NOVX genes, respectively, on a chromosome. The mapping of the NOVX sequences to chromosomes is an important first step in correlating these sequences with genes associated with disease.  
       [0280] Briefly, NOVX genes can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp in length) from the NOVX sequences. Computer analysis of the NOVX, sequences can be used to rapidly select primers that do not span more than one exon in the genomic DNA, thus complicating the amplification process. These primers can then be used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids containing the human gene corresponding to the NOVX sequences will yield an amplified fragment.  
       [0281] Somatic cell hybrids are prepared by fusing somatic cells from different mammals (e.g., human and mouse cells). As hybrids of human and mouse cells grow and divide, they gradually lose human chromosomes in random order, but retain the mouse chromosomes. By using media in which mouse cells cannot grow, because they lack a particular enzyme, but in which human cells can, the one human chromosome that contains the gene encoding the needed enzyme will be retained. By using various media, panels of hybrid cell lines can be established. Each cell line in a panel contains either a single human chromosome or a small number of human chromosomes, and a full set of mouse chromosomes, allowing easy mapping of individual genes to specific human chromosomes. See, e.g., D&#39;Eustachio, et al., 1983 . Science  220: 919-924. Somatic cell hybrids containing only fragments of human chromosomes can also be produced by using human chromosomes with translocations and deletions.  
       [0282] PCR mapping of somatic cell hybrids is a rapid procedure for assigning a particular sequence to a particular chromosome. Three or more sequences can be assigned per day using a single thermal cycler. Using the NOVX sequences to design oligonucleotide primers, sub-localization can be achieved with panels of fragments from specific chromosomes.  
       [0283] Fluorescence in situ hybridization (FISH) of a DNA sequence to a metaphase chromosomal spread can further be used to provide a precise chromosomal location in one step. Chromosome spreads can be made using cells whose division has been blocked in metaphase by a chemical like colcemid that disrupts the mitotic spindle. The chromosomes can be treated briefly with trypsin, and then stained with Giemsa. A pattern of light and dark bands develops on each chromosome, so that the chromosomes can be identified individually. The FISH technique can be used with a DNA sequence as short as 500 or 600 bases. However, clones larger than 1,000 bases have a higher likelihood of binding to a unique chromosomal location with sufficient signal intensity for simple detection. Preferably 1,000 bases, and more preferably 2,000 bases, will suffice to get good results at a reasonable amount of time. For a review of this technique, see, Verma, et al., H UMAN  C HROMOSOMES : A M ANUAL OF  B ASIC  T ECHNIQUES (Pergamon Press, New York  1988).  
       [0284] Reagents for chromosome mapping can be used individually to mark a single chromosome or a single site on that chromosome, or panels of reagents can be used for marking multiple sites and/or multiple chromosomes. Reagents corresponding to noncoding regions of the genes actually are preferred for mapping purposes. Coding sequences are more likely to be conserved within gene families, thus increasing the chance of cross hybridizations during chromosomal mapping.  
       [0285] Once a sequence has been mapped to a precise chromosomal location, the physical position of the sequence on the chromosome can be correlated with genetic map data. Such data are found, e.g., in McKusick, M ENDELIAN  I NHERITANCE IN  M AN , available on-line through Johns Hopkins University Welch Medical Library). The relationship between genes and disease, mapped to the same chromosomal region, can then be identified through linkage analysis (co-inheritance of physically adjacent genes), described in, e.g., Egeland, et al., 1987 . Nature,  325: 783-787.  
       [0286] Moreover, differences in the DNA sequences between individuals affected and unaffected with a disease associated with the NOVX gene, can be determined. If a mutation is observed in some or all of the affected individuals but not in any unaffected individuals, then the mutation is likely to be the causative agent of the particular disease. Comparison of affected and unaffected individuals generally involves first looking for structural alterations in the chromosomes, such as deletions or translocations that are visible from chromosome spreads or detectable using PCR based on that DNA sequence. Ultimately, complete sequencing of genes from several individuals can be performed to confirm the presence of a mutation and to distinguish mutations from polymorphisms.  
       [0287] Tissue Typing  
       [0288] The NOVX sequences of the invention can also be used to identify individuals from minute biological samples. In this technique, an individual&#39;s genomic DNA is digested with one or more restriction enzymes, and probed on a Southern blot to yield unique bands for identification. The sequences of the invention are useful as additional DNA markers for RFLP (“restriction fragment length polymorphisms,” described in U.S. Pat. No. 5,272,057).  
       [0289] Furthermore, the sequences of the invention can be used to provide an alternative technique that determines the actual base-by-base DNA sequence of selected portions of an individual&#39;s genome. Thus, the NOVX sequences described herein can be used to prepare two PCR primers from the 5′- and 3′-termini of the sequences. These primers can then be used to amplify an individual&#39;s DNA and subsequently sequence it.  
       [0290] Panels of corresponding DNA sequences from individuals, prepared in this manner, can provide unique individual identifications, as each individual will have a unique set of such DNA sequences due to allelic differences. The sequences of the invention can be used to obtain such identification sequences from individuals and from tissue. The NOVX sequences of the invention uniquely represent portions of the human genome. Allelic variation occurs to some degree in the coding regions of these sequences, and to a greater degree in the noncoding regions. It is estimated that allelic variation between individual humans occurs with a frequency of about once per each 500 bases. Much of the allelic variation is due to single nucleotide polymorphisms (SNPs), which include restriction fragment length polymorphisms (RFLPs).  
       [0291] Each of the sequences described herein can, to some degree, be used as a standard against which DNA from an individual can be compared for identification purposes. Because greater numbers of polymorphisms occur in the noncoding regions, fewer sequences are necessary to differentiate individuals. The noncoding sequences can comfortably provide positive individual identification with a panel of perhaps 10 to 1,000 primers that each yield a noncoding amplified sequence of 100 bases. If coding sequences, such as those of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, are used, a more appropriate number of primers for positive individual identification would be 500-2,000.  
       [0292] Predictive Medicine  
       [0293] The invention also pertains to the field of predictive medicine in which diagnostic assays, prognostic assays, pharmacogenomics, and monitoring clinical trials are used for prognostic (predictive) purposes to thereby treat an individual prophylactically. Accordingly, one aspect of the invention relates to diagnostic assays for determining NOVX protein and/or nucleic acid expression as well as NOVX activity, in the context of a biological sample (e.g., blood, serum, cells, tissue) to thereby determine whether an individual is afflicted with a disease or disorder, or is at risk of developing a disorder, associated with aberrant NOVX expression or activity. The disorders include metabolic disorders, diabetes, obesity, infectious disease, anorexia, cancer-associated cachexia, cancer, neurodegenerative disorders, Alzheimer&#39;s Disease, Parkinson&#39;s Disorder, immune disorders, and hematopoietic disorders, and the various dyslipidemias, metabolic disturbances associated with obesity, the metabolic syndrome X and wasting disorders associated with chronic diseases and various cancers. The invention also provides for prognostic (or predictive) assays for determining whether an individual is at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. For example, mutations in a NOVX gene can be assayed in a biological sample. Such assays can be used for prognostic or predictive purpose to thereby prophylactically treat an individual prior to the onset of a disorder characterized by or associated with NOVX protein, nucleic acid expression, or biological activity.  
       [0294] Another aspect of the invention provides methods for determining NOVX protein, nucleic acid expression or activity in an individual to thereby select appropriate therapeutic or prophylactic agents for that individual (referred to herein as “pharmacogenomics”). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual examined to determine the ability of the individual to respond to a particular agent.)  
       [0295] Yet another aspect of the invention pertains to monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX in clinical trials.  
       [0296] These and other agents are described in further detail in the following sections.  
       [0297] Diagnostic Assays  
       [0298] An exemplary method for detecting the presence or absence of NOVX in a biological sample involves obtaining a biological sample from a test subject and contacting the biological sample with a compound or an agent capable of detecting NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) that encodes NOVX protein such that the presence of NOVX is detected in the biological sample. An agent for detecting NOVX mRNA or genomic DNA is a labeled nucleic acid probe capable of hybridizing to NOVX mRNA or genomic DNA. The nucleic acid probe can be, for example, a full-length NOVX nucleic acid, such as the nucleic acid of SEQ ID NO: 2n-1, wherein n is an integer between 1 and 48, or a portion thereof, such as an oligonucleotide of at least 15, 30, 50, 100, 250 or 500 nucleotides in length and sufficient to specifically hybridize under stringent conditions to NOVX mRNA or genomic DNA. Other suitable probes for use in the diagnostic assays of the invention are described herein.  
       [0299] An agent for detecting NOVX protein is an antibody capable of binding to NOVX protein, preferably an antibody with a detectable label. Antibodies can be polyclonal, or more preferably, monoclonal. An intact antibody, or a fragment thereof (e.g., Fab or F(ab′) 2 ) can be used. The term “labeled”, with regard to the probe or antibody, is intended to encompass direct labeling of the probe or antibody by coupling (i.e., physically linking) a detectable substance to the probe or antibody, as well as indirect labeling of the probe or antibody by reactivity with another reagent that is directly labeled. Examples of indirect labeling include detection of a primary antibody using a fluorescently-labeled secondary antibody and end-labeling of a DNA probe with biotin such that it can be detected with fluorescently-labeled streptavidin. The term “biological sample” is intended to include tissues, cells and biological fluids isolated from a subject, as well as tissues, cells and fluids present within a subject. That is, the detection method of the invention can be used to detect NOVX mRNA, protein, or genomic DNA in a biological sample in vitro as well as in vivo. For example, in vitro techniques for detection of NOVX mRNA include Northern hybridizations and in situ hybridizations. In vitro techniques for detection of NOVX protein include enzyme linked immunosorbent assays (ELISAs), Western blots, immunoprecipitations, and immunofluorescence. In vitro techniques for detection of NOVX genomic DNA include Southern hybridizations. Furthermore, in vivo techniques for detection of NOVX protein include introducing into a subject a labeled anti-NOVX antibody. For example, the antibody can be labeled with a radioactive marker whose presence and location in a subject can be detected by standard imaging techniques.  
       [0300] In one embodiment, the biological sample contains protein molecules from the test subject. Alternatively, the biological sample can contain mRNA molecules from the test subject or genomic DNA molecules from the test subject. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject.  
       [0301] In another embodiment, the methods further involve obtaining a control biological sample from a control subject, contacting the control sample with a compound or agent capable of detecting NOVX protein, mRNA, or genomic DNA, such that the presence of NOVX protein, mRNA or genomic DNA is detected in the biological sample, and comparing the presence of NOVX protein, mRNA or genomic DNA in the control sample with the presence of NOVX protein, mRNA or genomic DNA in the test sample.  
       [0302] The invention also encompasses kits for detecting the presence of NOVX in a biological sample. For example, the kit can comprise: a labeled compound or agent capable of detecting NOVX protein or mRNA in a biological sample; means for determining the amount of NOVX in the sample; and means for comparing the amount of NOVX in the sample with a standard. The compound or agent can be packaged in a suitable container. The kit can further comprise instructions for using the kit to detect NOVX protein or nucleic acid.  
       [0303] Prognostic Assays  
       [0304] The diagnostic methods described herein can furthermore be utilized to identify subjects having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. For example, the assays described herein, such as the preceding diagnostic assays or the following assays, can be utilized to identify a subject having or at risk of developing a disorder associated with NOVX protein, nucleic acid expression or activity. Alternatively, the prognostic assays can be utilized to identify a subject having or at risk for developing a disease or disorder. Thus, the invention provides a method for identifying a disease or disorder associated with aberrant NOVX expression or activity in which a test sample is obtained from a subject and NOVX protein or nucleic acid (e.g., mRNA, genomic DNA) is detected, wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject having or at risk of developing a disease or disorder associated with aberrant NOVX expression or activity. As used herein, a “test sample” refers to a biological sample obtained from a subject of interest. For example, a test sample can be a biological fluid (e.g., serum), cell sample, or tissue.  
       [0305] Furthermore, the prognostic assays described herein can be used to determine whether a subject can be administered an agent (e.g., an agonist, antagonist, peptidomimetic, protein, peptide, nucleic acid, small molecule, or other drug candidate) to treat a disease or disorder associated with aberrant NOVX expression or activity. For example, such methods can be used to determine whether a subject can be effectively treated with an agent for a disorder. Thus, the invention provides methods for determining whether a subject can be effectively treated with an agent for a disorder associated with aberrant NOVX expression or activity in which a test sample is obtained and NOVX protein or nucleic acid is detected (e.g., wherein the presence of NOVX protein or nucleic acid is diagnostic for a subject that can be administered the agent to treat a disorder associated with aberrant NOVX expression or activity).  
       [0306] The methods of the invention can also be used to detect genetic lesions in a NOVX gene, thereby determining if a subject with the lesioned gene is at risk for a disorder characterized by aberrant cell proliferation and/or differentiation. In various embodiments, the methods include detecting, in a sample of cells from the subject, the presence or absence of a genetic lesion characterized by at least one of an alteration affecting the integrity of a gene encoding a NOVX-protein, or the misexpression of the NOVX gene. For example, such genetic lesions can be detected by ascertaining the existence of at least one of: (i) a deletion of one or more nucleotides from a NOVX gene; (ii) an addition of one or more nucleotides to a NOVX gene; (iii) a substitution of one or more nucleotides of a NOVX gene, (iv) a chromosomal rearrangement of a NOVX gene; (v) an alteration in the level of a messenger RNA transcript of a NOVX gene, (vi) aberrant modification of a NOVX gene, such as of the methylation pattern of the genomic DNA, (vii) the presence of a non-wild-type splicing pattern of a messenger RNA transcript of a NOVX gene, (viii) a non-wild-type level of a NOVX protein, (ix) allelic loss of a NOVX gene, and (x) inappropriate post-translational modification of a NOVX protein. As described herein, there are a large number of assay techniques known in the art which can be used for detecting lesions in a NOVX gene. A preferred biological sample is a peripheral blood leukocyte sample isolated by conventional means from a subject. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
       [0307] In certain embodiments, detection of the lesion involves the use of a probe/primer in a polymerase chain reaction (PCR) (see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202), such as anchor PCR or RACE PCR, or, alternatively, in a ligation chain reaction (LCR) (see, e.g., Landegran, et al., 1988 . Science  241: 1077-1080; and Nakazawa, et al., 1994 . Proc. Natl. Acad. Sci. USA  91: 360-364), the latter of which can be particularly useful for detecting point mutations in the NOVX-gene (see, Abravaya, et al., 1995 . Nucl. Acids Res . 23: 675-682). This method can include the steps of collecting a sample of cells from a patient, isolating nucleic acid (e.g., genomic, mRNA or both) from the cells of the sample, contacting the nucleic acid sample with one or more primers that specifically hybridize to a NOVX gene under conditions such that hybridization and amplification of the NOVX gene (if present) occurs, and detecting the presence or absence of an amplification product, or detecting the size of the amplification product and comparing the length to a control sample. It is anticipated that PCR and/or LCR may be desirable to use as a preliminary amplification step in conjunction with any of the techniques used for detecting mutations described herein.  
       [0308] Alternative amplification methods include: self sustained sequence replication (see, Guatelli, et al., 1990 . Proc. Natl. Acad. Sci. USA  87: 1874-1878), transcriptional amplification system (see, Kwoh, et al., 1989 . Proc. Natl. Acad. Sci. USA  86: 1173-1177); Qβ Replicase (see, Lizardi, et al, 1988 . BioTechnology  6: 1197), or any other nucleic acid amplification method, followed by the detection of the amplified molecules using techniques well known to those of skill in the art. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers.  
       [0309] In an alternative embodiment, mutations in a NOVX gene from a sample cell can be identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis and compared. Differences in fragment length sizes between sample and control DNA indicates mutations in the sample DNA. Moreover, the use of sequence specific ribozymes (see, e.g., U.S. Pat. No. 5,493,531) can be used to score for the presence of specific mutations by development or loss of a ribozyme cleavage site.  
       [0310] In other embodiments, genetic mutations in NOVX can be identified by hybridizing a sample and control nucleic acids, e.g., DNA or RNA, to high-density arrays containing hundreds or thousands of oligonucleotides probes. See, e.g., Cronin, et al., 1996 . Human Mutation  7: 244-255; Kozal, et al., 1996 . Nat. Med.  2: 753-759. For example, genetic mutations in NOVX can be identified in two dimensional arrays containing light-generated DNA probes as described in Cronin, et al., supra. Briefly, a first hybridization array of probes can be used to scan through long stretches of DNA in a sample and control to identify base changes between the sequences by making linear arrays of sequential overlapping probes. This step allows the identification of point mutations. This is followed by a second hybridization array that allows the characterization of specific mutations by using smaller, specialized probe arrays complementary to all variants or mutations detected. Each mutation array is composed of parallel probe sets, one complementary to the wild-type gene and the other complementary to the mutant gene.  
       [0311] In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the NOVX gene and detect mutations by comparing the sequence of the sample NOVX with the corresponding wild-type (control) sequence. Examples of sequencing reactions include those based on techniques developed by Maxim and Gilbert, 1977 . Proc. Natl. Acad. Sci. USA  74: 560 or Sanger, 1977 . Proc. Natl. Acad. Sci. USA  74: 5463. It is also contemplated that any of a variety of automated sequencing procedures can be utilized when performing the diagnostic assays (see, e.g., Naeve, et al., 1995 . Biotechniques  19: 448), including sequencing by mass spectrometry (see, e.g., PCT International Publication No. WO 94/16101; Cohen, et al., 1996 . Adv. Chromatography  36: 127-162; and Griffin, et al., 1993 . Appl. Biochem. Biotechnol.  38: 147-159).  
       [0312] Other methods for detecting mutations in the NOVX gene include methods in which protection from cleavage agents is used to detect mismatched bases in RNA/RNA or RNA/DNA heteroduplexes. See, e.g., Myers, et al., 1985 . Science  230: 1242. In general, the art technique of “mismatch cleavage” starts by providing heteroduplexes of formed by hybridizing (labeled) RNA or DNA containing the wild-type NOVX sequence with potentially mutant RNA or DNA obtained from a tissue sample. The double-stranded duplexes are treated with an agent that cleaves single-stranded regions of the duplex such as which will exist due to basepair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with S 1  nuclease to enzymatically digesting the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion of the mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, e.g., Cotton, et al., 1988 . Proc. Natl. Acad. Sci. USA  85: 4397; Saleeba, et al., 1992 . Methods Enzymol . 217: 286-295. In an embodiment, the control DNA or RNA can be labeled for detection.  
       [0313] In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called “DNA mismatch repair” enzymes) in defined systems for detecting and mapping point mutations in NOVX cDNAs obtained from samples of cells. For example, the mutY enzyme of  E. coli  cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches. See, e.g., Hsu, et al., 1994 . Carcinogenesis  15: 1657-1662. According to an exemplary embodiment, a probe based on a NOVX sequence, e.g., a wild-type NOVX sequence, is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, e.g., U.S. Pat. No. 5,459,039.  
       [0314] In other embodiments, alterations in electrophoretic mobility will be used to identify mutations in NOVX genes. For example, single strand conformation polymorphism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids. See, e.g., Orita, et al., 1989 . Proc. Natl. Acad. Sci. USA : 86: 2766; Cotton, 1993 . Mutat. Res . 285: 125-144; Hayashi, 1992 . Genet. Anal. Tech. Appl . 9: 73-79. Single-stranded DNA fragments of sample and control NOVX nucleic acids will be denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity of the assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In one embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility. See, e.g., Keen, et al., 1991 . Trends Genet.  7:5.  
       [0315] In yet another embodiment, the movement of mutant or wild-type fragments in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE). See, e.g., Myers, et al., 1985 . Nature  313: 495. When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing gradient to identify differences in the mobility of control and sample DNA. See, e.g., Rosenbaum and Reissner, 1987 . Biophys. Chem . 265:12753.  
       [0316] Examples of other techniques for detecting point mutations include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation is placed centrally and then hybridized to target DNA under conditions that permit hybridization only if a perfect match is found. See, e.g., Saiki, et al., 1986 . Nature  324: 163; Saiki, et al., 1989 . Proc. Natl. Acad. Sci. USA  86: 6230. Such allele specific oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations when the oligonucleotides are attached to the hybridizing membrane and hybridized with labeled target DNA.  
       [0317] Alternatively, allele specific amplification technology that depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation of interest in the center of the molecule (so that amplification depends on differential hybridization; see, e.g., Gibbs, et al., 1989 . Nucl. Acids Res . 17: 2437-2448) or at the extreme 3′-terminus of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (see, e.g., Prossner, 1993 . Tibtech . 11: 238). In addition it may be desirable to introduce a novel restriction site in the region of the mutation to create cleavage-based detection. See, e.g., Gasparini, et al., 1992 . Mol. Cell Probes  6: 1. It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification. See, e.g., Barany, 1991 . Proc. Natl. Acad. Sci. USA  88: 189. In such cases, ligation will occur only if there is a perfect match at the 3′-terminus of the 5′ sequence, making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification.  
       [0318] The methods described herein may be performed, for example, by utilizing pre-packaged diagnostic kits comprising at least one probe nucleic acid or antibody reagent described herein, which may be conveniently used, e.g., in clinical settings to diagnose patients exhibiting symptoms or family history of a disease or illness involving a NOVX gene.  
       [0319] Furthermore, any cell type or tissue, preferably peripheral blood leukocytes, in which NOVX is expressed may be utilized in the prognostic assays described herein. However, any biological sample containing nucleated cells may be used, including, for example, buccal mucosal cells.  
       [0320] Pharmacogenomics  
       [0321] Agents, or modulators that have a stimulatory or inhibitory effect on NOVX activity (e.g., NOVX gene expression), as identified by a screening assay described herein can be administered to individuals to treat (prophylactically or therapeutically) disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.  
       [0322] In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual&#39;s genotype and that individual&#39;s response to a foreign compound or drug) of the individual may be considered. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual&#39;s genotype. Such pharmacogenomics can further be used to determine appropriate dosages and therapeutic regimens. Accordingly, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.  
       [0323] Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons. See e.g., Eichelbaum, 1996 . Clin. Exp. Pharmacol. Physiol ., 23: 983-985; Linder, 1997 . Clin. Chem ., 43: 254-266. In general, two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare defects or as polymorphisms. For example, glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common inherited enzymopathy in which the main clinical complication is hemolysis after ingestion of oxidant drugs (anti-malarials, sulfonamides, analgesics, nitrofurans) and consumption of fava beans.  
       [0324] As an illustrative embodiment, the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action. The discovery of genetic polymorphisms of drug metabolizing enzymes (e.g., N-acetyltransferase 2 (NAT 2) and cytochrome pregnancy zone protein precursor enzymes CYP2D6 and CYP2C19) has provided an explanation as to why some patients do not obtain the expected drug effects or show exaggerated drug response and serious toxicity after taking the standard and safe dose of a drug. These polymorphisms are expressed in two phenotypes in the population, the extensive metabolizer (EM) and poor metabolizer (PM). The prevalence of PM is different among different populations. For example, the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in PM, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, PM show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. At the other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses. Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.  
       [0325] Thus, the activity of NOVX protein, expression of NOVX nucleic acid, or mutation content of NOVX genes in an individual can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual. In addition, pharmacogenetic studies can be used to apply genotyping of polymorphic alleles encoding drug-metabolizing enzymes to the identification of an individual&#39;s drug responsiveness phenotype. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a NOVX modulator, such as a modulator identified by one of the exemplary screening assays described herein.  
       [0326] Monitoring of Effects During Clinical Trials  
       [0327] Monitoring the influence of agents (e.g., drugs, compounds) on the expression or activity of NOVX (e.g., the ability to modulate aberrant cell proliferation and/or differentiation) can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase NOVX gene expression, protein levels, or upregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting decreased NOVX gene expression, protein levels, or downregulated NOVX activity. Alternatively, the effectiveness of an agent determined by a screening assay to decrease NOVX gene expression, protein levels, or downregulate NOVX activity, can be monitored in clinical trails of subjects exhibiting increased NOVX gene expression, protein levels, or upregulated NOVX activity. In such clinical trials, the expression or activity of NOVX and, preferably, other genes that have been implicated in, for example, a cellular proliferation or immune disorder can be used as a “read out” or markers of the immune responsiveness of a particular cell.  
       [0328] By way of example, and not of limitation, genes, including NOVX, that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates NOVX activity (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cellular proliferation disorders, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of NOVX and other genes implicated in the disorder. The levels of gene expression (i.e., a gene expression pattern) can be quantified by Northern blot analysis or RT-PCR, as described herein, or alternatively by measuring the amount of protein produced, by one of the methods as described herein, or by measuring the levels of activity of NOVX or other genes. In this manner, the gene expression pattern can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this response state may be determined before, and at various points during, treatment of the individual with the agent.  
       [0329] In one embodiment, the invention provides a method for monitoring the effectiveness of treatment of a subject with an agent (e.g., an agonist, antagonist, protein, peptide, peptidomimetic, nucleic acid, small molecule, or other drug candidate identified by the screening assays described herein) comprising the steps of (i) obtaining a pre-administration sample from a subject prior to administration of the agent; (ii) detecting the level of expression of a NOVX protein, mRNA, or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the post-administration samples; (v) comparing the level of expression or activity of the NOVX protein, mRNA, or genomic DNA in the pre-administration sample with the NOVX protein, mRNA, or genomic DNA in the post administration sample or samples; and (vi) altering the administration of the agent to the subject accordingly. For example, increased administration of the agent may be desirable to increase the expression or activity of NOVX to higher levels than detected, i.e., to increase the effectiveness of the agent. Alternatively, decreased administration of the agent may be desirable to decrease expression or activity of NOVX to lower levels than detected, i.e., to decrease the effectiveness of the agent.  
       [0330] Methods of Treatment  
       [0331] The invention provides for both prophylactic and therapeutic methods of treating a subject at risk of (or susceptible to) a disorder or having a disorder associated with aberrant NOVX expression or activity. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.  
       [0332] These methods of treatment will be discussed more fully, below.  
       [0333] Diseases and Disorders  
       [0334] Diseases and disorders that are characterized by increased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that antagonize (i.e., reduce or inhibit) activity. Therapeutics that antagonize activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to: (i) an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof; (ii) antibodies to an aforementioned peptide; (iii) nucleic acids encoding an aforementioned peptide; (iv) administration of antisense nucleic acid and nucleic acids that are “dysfunctional” (i.e., due to a heterologous insertion within the coding sequences of coding sequences to an aforementioned peptide) that are utilized to “knockout” endogenous function of an aforementioned peptide by homologous recombination (see, e.g., Capecchi, 1989 . Science  244: 1288-1292); or (v) modulators (i.e., inhibitors, agonists and antagonists, including additional peptide mimetic of the invention or antibodies specific to a peptide of the invention) that alter the interaction between an aforementioned peptide and its binding partner.  
       [0335] Diseases and disorders that are characterized by decreased (relative to a subject not suffering from the disease or disorder) levels or biological activity may be treated with Therapeutics that increase (i.e., are agonists to) activity. Therapeutics that upregulate activity may be administered in a therapeutic or prophylactic manner. Therapeutics that may be utilized include, but are not limited to, an aforementioned peptide, or analogs, derivatives, fragments or homologs thereof, or an agonist that increases bioavailability.  
       [0336] Increased or decreased levels can be readily detected by quantifying peptide and/or RNA, by obtaining a patient tissue sample (e.g., from biopsy tissue) and assaying it in vitro for RNA or peptide levels, structure and/or activity of the expressed peptides (or mRNAs of an aforementioned peptide). Methods that are well-known within the art include, but are not limited to, immunoassays (e.g., by Western blot analysis, immunoprecipitation followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis, immunocytochemistry, etc.) and/or hybridization assays to detect expression of mRNAs (e.g., Northern assays, dot blots, in situ hybridization, and the like).  
       [0337] Prophylactic Methods  
       [0338] In one aspect, the invention provides a method for preventing, in a subject, a disease or condition associated with an aberrant NOVX expression or activity, by administering to the subject an agent that modulates NOVX expression or at least one NOVX activity. Subjects at risk for a disease that is caused or contributed to by aberrant NOVX expression or activity can be identified by, for example, any or a combination of diagnostic or prognostic assays as described herein. Administration of a prophylactic agent can occur prior to the manifestation of symptoms characteristic of the NOVX aberrancy, such that a disease or disorder is prevented or, alternatively, delayed in its progression. Depending upon the type of NOVX aberrancy, for example, a NOVX agonist or NOVX antagonist agent can be used for treating the subject. The appropriate agent can be determined based on screening assays described herein. The prophylactic methods of the invention are further discussed in the following subsections.  
       [0339] Therapeutic Methods  
       [0340] Another aspect of the invention pertains to methods of modulating NOVX expression or activity for therapeutic purposes. The modulatory method of the invention involves contacting a cell with an agent that modulates one or more of the activities of NOVX protein activity associated with the cell. An agent that modulates NOVX protein activity can be an agent as described herein, such as a nucleic acid or a protein, a naturally-occurring cognate ligand of a NOVX protein, a peptide, a NOVX peptidomimetic, or other small molecule. In one embodiment, the agent stimulates one or more NOVX protein activity. Examples of such stimulatory agents include active NOVX protein and a nucleic acid molecule encoding NOVX that has been introduced into the cell. In another embodiment, the agent inhibits one or more NOVX protein activity. Examples of such inhibitory agents include antisense NOVX nucleic acid molecules and anti-NOVX antibodies. These modulatory methods can be performed in vitro (e.g., by culturing the cell with the agent) or, alternatively, in vivo (e.g., by administering the agent to a subject). As such, the invention provides methods of treating an individual afflicted with a disease or disorder characterized by aberrant expression or activity of a NOVX protein or nucleic acid molecule. In one embodiment, the method involves administering an agent (e.g., an agent identified by a screening assay described herein), or combination of agents that modulates (e.g., up-regulates or down-regulates) NOVX expression or activity. In another embodiment, the method involves administering a NOVX protein or nucleic acid molecule as therapy to compensate for reduced or aberrant NOVX expression or activity.  
       [0341] Stimulation of NOVX activity is desirable in situations in which NOVX is abnormally downregulated and/or in which increased NOVX activity is likely to have a beneficial effect. One example of such a situation is where a subject has a disorder characterized by aberrant cell proliferation and/or differentiation (e.g., cancer or immune associated disorders). Another example of such a situation is where the subject has a gestational disease (e.g., preclampsia).  
       [0342] Determination of the Biological Effect of the Therapeutic  
       [0343] In various embodiments of the invention, suitable in vitro or in vivo assays are performed to determine the effect of a specific Therapeutic and whether its administration is indicated for treatment of the affected tissue.  
       [0344] In various specific embodiments, in vitro assays may be performed with representative cells of the type(s) involved in the patient&#39;s disorder, to determine if a given Therapeutic exerts the desired effect upon the cell type(s). Compounds for use in therapy may be tested in suitable animal model systems including, but not limited to rats, mice, chicken, cows, monkeys, rabbits, and the like, prior to testing in human subjects. Similarly, for in vivo testing, any of the animal model system known in the art may be used prior to administration to human subjects.  
       [0345] Prophylactic and Therapeutic Uses of the Compositions of the Invention  
       [0346] The NOVX nucleic acids and proteins of the invention are useful in potential prophylactic and therapeutic applications implicated in a variety of disorders. The disorders include but are not limited to, e.g., those diseases, disorders and conditions listed above, and more particularly include those diseases, disorders, or conditions associated with homologs of a NOVX protein, such as those summarized in Table A.  
       [0347] As an example, a cDNA encoding the NOVX protein of the invention may be useful in gene therapy, and the protein may be useful when administered to a subject in need thereof. By way of non-limiting example, the compositions of the invention will have efficacy for treatment of patients suffering from diseases, disorders, conditions and the like, including but not limited to those listed herein.  
       [0348] Both the novel nucleic acid encoding the NOVX protein, and the NOVX protein of the invention, or fragments thereof, may also be useful in diagnostic applications, wherein the presence or amount of the nucleic acid or the protein are to be assessed. A further use could be as an anti-bacterial molecule (i.e., some peptides have been found to possess anti-bacterial properties). These materials are further useful in the generation of antibodies, which immunospecifically-bind to the novel substances of the invention for use in therapeutic or diagnostic methods.  
       [0349] The invention will be further described in the following examples, which do not limit the scope of the invention described in the claims.  
     
    
    
     EXAMPLES  
     Example A  
     Polynucleotide and Polypeptide Sequences, and Homology Data  
     Example 1  
     [0350] The NOV1 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 1A.  
               TABLE 1A                       NOV1 Sequence Analysis                                            NOV1a, CG164221-01   SEQ ID NO: 1   2343 bp       DNA Sequence   ORF Start: ATG at 36   ORF Stop: end of sequence                       GAGCGCTAACGTCTTTCTGTCTCCCCGCGGTGGTG   ATG ACGGTGAAAACTGAGGCTGCTAAGGGCACC                   CTCACTTACTCCAGGATCAGGGGCATGGTGGCAATTCTCATCGCTTTCATGAAGCAGAGGAGGATGGG               TCTGAACGACTTTATTCAGAAGATTGCCAATAACTCCTATGCATGCAAACACCCTGAAGTTCAGTCCA               TCTTGAAGATCTCCCAACCTCAGGAGCCTGAGCTTATGAATGCCAACCCTTCTCCTCCACCAAGTCCT               TCTCAGCAAATCAACCTTGGCCCGTCGTCCAATCCTCATGCTAAACCATCTGACTTTCACTTCTTGAA               AGTGATCGGAAAGGGCAGTTTTGGAAAGGTTCTTCTAGCAAGACACAAGGCAGAAGAAGTGTTCTATG               CAGTCAAAGTTTTACAGAAGAAAGCAATCCTGAAAAAGAAAGAGGAGAAGCATATTATGTCGGAGCGG               AATGTTCTGTTGAAGAATGTGAAGCACCCTTTCCTGGTGGGCCTTCACTTCTCTTTCCAGACTGCTGA               CAAATTGTACTTTGTCCTAGACTACATTAATGGTGGAGAGTTGTTCTACCATCTCCAGAGGGAACGCT               GCTTCCTGGAACCACGGGCTCGTTTCTATGCTGCTGAAATAGCCAGTGCCTTGGGCTACCTGCATTCA               CTGAACATCGTTTATAGAGACTTAAAACCAGAGAATATTTTGCTAGATTCACAGGGACACATTGTCCT               TACTGACTTCGGACTCTGCAAGGAGAACATTGAACACAACAGCACAACATCCACCTTCTGTGGCACGC               CGGAGTATCTCGCACCTGAGGTGCTTCATAAGCAGCCTTATGACAGGACTGTGGACTGGTGGTGCCTG               GGAGCTGTCTTGTATGAGATGCTGTATGGCCTGCCGCCTTTTTATAGCCGAAACACAGCTGAAATGTA               CGACAACATTCTGAACAAGCCTCTCCAGCTGAAACCAAATATTACAAATTCCGCAAGACACCTCCTGG               AGGGCCTCCTGCAGAAGGACAGGACAAAGCGGCTCGGGGCCAAGGATGACTTCATGGAGATTAAGAGT               CATGTCTTCTTCTCCTTAATTAACTGGGATGATCTCATTAATAAGAAGATTACTCCCCCTTTTAACCC               AAATGTGAGTGGGCCCAACGACCTACGGCACTTTGACCCCGAGTTTACCGAAGAGCCTGTCCCCAACT               CCATTGGCAAGTCCCCTGACAGCGTCCTCGTCACAGCCAGCGTCAAGGAAGCTGCCGAGGCTTTCCTA               GGCTTTTCCTATGCGCCTCCCACGGACTCTTTCCTC TGA   ACCCTGTTAGGGCTTGGTTTTAAAGGATT                   TTATGTGTGTTTCCGAATGTTTTAGTTAGCCTTTTGGTGGAGCCGCCAGCTGACAGGACATCTTACAA                   GAGAATTTGCACATCTCTGGAAGCTTAGCAATCTTATTGCACACTGTTCGCTGGAAGCTTTTTGAAGA                   GCACATTCTCCTCAGTGAGCTCATGAGGTTTTCATTTTTATTCTTCCTTCCAACGTGGTGCTATCTCT                   GAAACGAGCGTTAGAGTGCCGCCTTAGACGGAGGCAGGAGTTTCGTTAGAAAGCGGACGCTGTTCTAA                   AAAAGGTCTCCTGCAGATCTGTCTGGGCTGTGATGACGAATATTATGAAATGTGCCTTTTCTGAAGAG                   ATTGTGTTAGCTCCAAAGCTTTTCCTATCGCAGTGTTTCAGTTCTTTATTTTCCCTTGTGGATATGCT                   GTGTGAACCGTCGTGTGAGTGTGGTATGCCTGATCACAGATGGATTTTGTTATAAGCATCAATGTGAC                   ACTTGCAGGACACTACAACGTGGGACATTGTTTGTTTCTTCCATATTTGGAAGATAAATTTATGTGTA                   GACTTTTTTGTAAGATACGGTTAATAACTAAAATTTATTGAAATGGTCTTGCAATGACTCGTATTCAG                   ATGCTTAAAGAAAGCATTGCTGCTACAAATATTTCTATTTTTAGAAAGGGTTTTTATGGACCAATGCC                   CCAGTTGTCAGTCAGAGCCGTTGGTGTTTTTCATTGTTTAAAATGTCACCTGTAAAATGGGCATTATT                   TATGTTTTTTTTTTTGCATTCCTGATAATTGTATGTATTGTATAAAGAACGTCTGTACATTGGGTTAT                   AACACTAGTATATTTAAACTTACAGGCTTATTTGTAATGTAAACCACCATTTTAATGTACTGTAATTA                   ACATGGTTATAATACGTACAATCCTTCCCTCATCCCATCACACAACTTTTTTTGTGTGTGATAAACTG                   ATTTTGGTTTGCAATAAAACCTTGAAAAATA                                       NOV1a, CG164221-01                   Protein Sequence   SEQ ID NO: 2   431 aa   MW at 48941.8 kD                 MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPEL               MNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAILK               KKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAA               EIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQ               PYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRL               GAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVT               ASVKEAAEAFLGFSYAPPTDSFL                                 NOV1b, CG164221-02   SEQ ID NO: 3   1315 bp       DNA Sequence   ORF Start: ATG at 14   ORF Stop: end of sequence                   CACCGGATCCACC   ATG ACGGTGAAAACTGAGGCTGCTAAGGGCACCCTCACTTACTCCAGGATGAGGG               GCATGGTGGCAATTCTCATCGCTTTCATGAAGCAGAGGAGGATGGGTCTGAACGACTTTATTCAGAAG               ATTGCCAATAACTCCTATGCATGCAAACACCCTGAAGTTCAGTCCATCTTGAAGATCTCCCAACCTCA               GGAGCCTGAGCTTATGAATGCCAACCCTTCTCCTCCACCAAGTCCTTCTCAGCAAATCAACCTTGGCC               CGTCGTCCAATCCTCATGCTAAACCATCTGACTTTCACTTCTTGAAAGTGATCGGAAAGGGCAGTTTT               GGAAAGGTTCTTCTAGCAAGACACAAGGCAGAAGAAGTGTTCTATGCAGTCAAAGTTTTACAGAAGAA               AGCAATCCTGAAAAAGAAAGAGGAGAAGCATATTATGTCGGAGCGGAATGTTCTGTTGAAGAATGTGA               AGCACCCTTTCCTGGTGGGCCTTCACTTCTCTTTCCAGACTGCTGACAAATTGTACTTTGTCCTAGAC               TACATTAATGGTGGAGAGTTGTTCTACCATCTCCAGAGGGAACGCTGCTTCCTGGAACCACGGGCTCG               TTTCTATGCTGCTGAAATAGCCAGTGCCTTGGGCTACCTGCATTCACTGAACATCGTTTATAGAGACT               TAAAACCAGAGAATATTTTGCTAGATTCACAGGGACACATTGTCCTTACTGACTTCGGACTCTGCAAG               GAGAACATTGAACACAACAGCACAACATCCACCTTCTGTGGCACGCCGGAGTATCTCGCACCTGAGGT               GCTTCATAAGCAGCCTTATGACAGGACTGTGGACTGGTGGTGCCTGGGAGCTGTCTTGTATGAGATGC               TGTATGGCCTGCCGCCTTTTTATAGCCGAAACACAGCTGAAATGTACGACAACATTCTGAACAAGCCT               CTCCAGCTGAAACCAAATATTACAAATTCCGCAAGACACCTCCTGGAGGGCCTCCTGCAGAAGGACAG               GACAAAGCGGCTCGGGGCCAAGGATGACTTCATGGAGATTAAGAGTCATGTCTTCTTCTCCTTAATTA               ACTGGGATGATCTCATTAATAAGAAGATTACTCCCCCTTTTAACCCAAATGTGAGTGGGCCCAACGAC               CTACGGCACTTTGACCCCGAGTTTACCGAAGAGCCTGTCCCCAACTCCATTGGCAAGTCCCCTGACAG               CGTCCTCGTCACAGCCAGCGTCAAGGAAGCTGCCGAGGCTTTCCTAGGCTTTTCCTATGCGCCTCCCA               CGGACTCTTTCCTC CTC   GAGGGC                                       NOV1b, CG164221-02                   Protein Sequence   SEQ ID NO: 4   431 aa   MW at 48941.8 kD                 MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKISQPQEPEL               MNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAEEVFYAVKVLQKKAILK               KKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYINGGELFYHLQRERCFLEPRARFYAA               EIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTDFGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQ               PYDRTVDWWCLGAVLYEMLYGLPPFYSRNTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRL               GAKDDFMEIKSHVFFSLINWDDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVT               ASVKEAAEAFLGFSYAPPTDSFL                  
 
     [0351] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 1B.  
               TABLE 1B                       Comparison of the NOV1 protein sequences.                                        NOV1a   MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKI       NOV1b   MTVKTEAAKGTLTYSRMRGMVAILIAFMKQRRMGLNDFIQKIANNSYACKHPEVQSILKI               NOV1a   SQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAE       NOV1b   SQPQEPELMNANPSPPPSPSQQINLGPSSNPHAKPSDFHFLKVIGKGSFGKVLLARHKAE               NOV1a   EVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYIN       NOV1b   EVFYAVKVLQKKAILKKKEEKHIMSERNVLLKNVKHPFLVGLHFSFQTADKLYFVLDYIN               NOV1a   GGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNIVYRDLKPENILLDSQGHIVLTD       NOV1b   GGELFYHLQRERCFLEPRARFYAAEIASALGYLHSLNTVYRDLKPENILLDSQGHIVLTD               NOV1a   FGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSR       NOV1b   FGLCKENIEHNSTTSTFCGTPEYLAPEVLHKQPYDRTVDWWCLGAVLYEMLYGLPPFYSR               NOV1a   NTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINW       NOV1b   NTAEMYDNILNKPLQLKPNITNSARHLLEGLLQKDRTKRLGAKDDFMEIKSHVFFSLINW               NOV1a   DDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLG       NOV1b   DDLINKKITPPFNPNVSGPNDLRHFDPEFTEEPVPNSIGKSPDSVLVTASVKEAAEAFLG               NOV1a   FSYAPPTDSFL       NOV1b   FSYAPPTDSFL               NOV1a   (SEQ ID NO: 2)       NOV1b   (SEQ ID NO: 4)                  
 
     [0352] Further analysis of the NOV1a protein yielded the following properties shown in Table 1C.  
               TABLE 1C                       Protein Sequence Properties NOVIa                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 9; pos. chg 2; neg. chg 1           H-region: length 6; peak value −1.48           PSG score: −5.88           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −12.80           possible cleavage site: between 34 and 35           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 0           number of TMS(s) . . . fixed                                 PERIPHERAL   Likelihood =   3.29 (at 12)                         ALOM score: 3.29 (number of TMSs: 0)           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   4   Hyd Moment (75):   3.99           Hyd Moment (95):   1.34   G content:   3           D/E content:   2   S/T content:   5                         Score: −4.17           Gavel: prediction of cleavage sites for mitochondrial preseq           R-2 motif at 42 RRM|GL           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 11.8%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 55.5           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           39.1%: cytoplasmic           30.4%: nuclear           21.7%: mitochondrial            4.3%: Golgi            4.3%: endoplasmic reticulum           &gt;&gt; prediction for CG164221-01 is cyt (k = 23)                  
 
     [0353] A search of the NOV1a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 1D.  
               TABLE 1D                          Geneseq Results for NOV1a                                         NOV1a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAW90139   Human sgk protein -  Homo     1 . . . 431    431/431 (100%)   0.0             sapiens , 431 aa. [EP887081-A2,   1 . . . 431    431/431 (100%)           30 DEC. 1998]       AAB65613   Novel protein kinase, SEQ ID   1 . . . 431   430/431 (99%)   0.0           NO: 139 -  Homo sapiens , 431 aa.   1 . . . 431   431/431 (99%)           [WO200073469-A2, 07 DEC.           2000]       AAB24115   Human serum and glucocorticoid   1 . . . 431   430/431 (99%)   0.0           regulated kinase protein (HSGK) -   1 . . . 431   431/431 (99%)             Homo sapiens , 431 aa.           [CN1259573-A, 12 JUL. 2000]       AAW77217   Human cell-volume regulating   1 . . . 431   430/431 (99%)   0.0           kinase h-sgk -  Homo sapiens ,   1 . . . 431   431/431 (99%)           431 aa. [EP861896-A2, 02 SEP.           1998]       AAY95279   Human serum and   1 . . . 431   429/431 (99%)   0.0           glucocorticoid-induced protein   1 . . . 431   430/431 (99%)           kinase -  Homo sapiens , 431 aa.           [WO200035946-A1, 22 JUN.           2000]                  
 
     [0354] In a BLAST search of public sequence databases, the NOV1a protein was found to have homology to the proteins shown in the BLASTP data in Table 1E.  
               TABLE 1E                          Public BLASTP Results for NOV1a                                         NOV1a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               CAD58123   Sequence 1 from Patent   1 . . . 431    431/431 (100%)   0.0           WO02074987 -  Homo sapiens     1 . . . 431    431/431 (100%)           (Human), 431 aa.       O00141   Serine/threonine-protein kinase   1 . . . 431   430/431 (99%)   0.0           Sgk1 (EC 2.7.1.37)   1 . . . 431   431/431 (99%)           (Serum/glucocorticoid-regulated           kinase 1) -  Homo sapiens             (Human), 431 aa.       A48094   serum and glucocorticoid-   1 . . . 431   419/431 (97%)   0.0           regulated kinase - rat, 431 aa.   1 . . . 431   426/431 (98%)       Q9XT18   Serine/threonine-protein kinase   1 . . . 431   418/431 (96%)   0.0           Sgk1 (EC 2.7.1.37)   1 . . . 431   426/431 (97%)           (Serum/glucocorticoid-regulated           kinase 1) -  Oryctolagus cuniculus             (Rabbit), 431 aa.       Q9WVC6   Serine/threonine-protein kinase   1 . . . 431   416/431 (96%)   0.0           Sgk1 (EC 2.7.1.37)   1 . . . 431   425/431 (98%)           (Serum/glucocorticoid-regulated           kinase 1) -  Mus musculus             (Mouse), 431 aa.                  
 
     [0355] PFam analysis predicts that the NOV1a protein contains the domains shown in the Table 1F.  
               TABLE 1F                          Domain Analysis of NOV1a                                             Identities/                       Similarities           Pfam   NOV1a Match   for the   Expect           Domain   Region   Matched Region   Value                       pkinase    98 . . . 355   107/301 (36%)   3.2e−88                   212/301 (70%)           pkinase_C   356 . . . 430    28/77 (36%)   2.2e−13                    54/77 (70%)                      
 
     Example 2  
     [0356] The NOV2 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 2A.  
               TABLE 2A                       NOV2 Sequence Analysis                                        NOV2a, CG180777-01  SEQ ID NO: 5          1140 bp           DNA Sequence        ORF Start: ATG at 55  ORF Stop: end of sequence         ATTGGAGTTTGGAAGTTCAGGAGCACAGGAGCACAGGCCCACGACTGCAGCGGG   ATG GACCAGTACTG               CATCCTGGGCCGCATCGGGGAGGGCGCCCACGGCATCGTCTTCAAGGCCAAGCACGTGGAGCCGAGGG               TGGGCTGGCAGTGTCTGCCTTCTATCCTGCAGACTGGCGAGATAGTTGCCCTCAAGAAGGTGGCCCTA               AGGCGGTTGGAGGACGGCTTCCCTAACCAGGCCCTGCGGGAGATTAAGGCTCTGCAGGAGATGGAGGA               CAATCAGTATGTGGTACAACTGAAGGCTGTGTTCCCACACGGTGGAGGCTTTGTGCTGGCCTTTGAGT               TCATGCTGTCGGATCTGGCCGAGGTGGTGCGCCATGCCCAGAGGCCACTAGCCCAGGCACAGGTCAAG               AGCTACCTGCAGATGCTGCTCAAGGGTGTCGCCTTCTGCCATGCCAACAACATTGTACATCGGGACCT               GAAACCTGCCAACCTGCTCATCAGCGCCTCAGGCCAGCTCAAGATAGCGGACTTTGGCCTGGCTCGAG               TCTTTTCCCCAGACGGCAGCCACCTCTACACACACCAGGTGGCCACCAGGTGGTACCGAGCCCCCGAG               CTCCTGTATGGTGCCCGCCAGTATGACCAGGGCGTCGATCTGTGGTCTGTGGGCTGCATCATGGGGGA               GCTGTTGAATGGGTCCCCCCTTTTCCCGGGCAAGAACGATATTGAACAGCTTTGCTATGTGCTTCGCA               TCTTGGGCACCCCAAACCCTCAAGTCTGGCCGGAGCTCACTGAGCTGCCGGACTACAACAAGATCTCC               TTTAAGGAGCAGGTGCCCATGCCCCTGGAGGAGGTGCTGCCTGACGTCTCTCCCCAGGCATTGGATCT               GCTGGGTCAATTCCTTCTCTACCCTCCTCACCAGCGCATCGCAGCTTCCAAGGCTCTCCTCCATCAGT               ACTTCTTCACAGCTCCCCTGCCTGCCCATCCATCTGAGCTGCCGATTCCTCAGCGTCTAGGGGGACCT               GCCCCCAAGGCCCATCCAGGGCCCCCCCACATCCATGACTTCCACGTGGACCGGCCTCTTGAGGAGTC               GCTGTTGAACCCAGAGCTGATTCGGCCCTTCATCCTGGAGGGG TGA   GAAGTT                 NOV2a, CG180777-01       Protein Sequence    SEQ ID NO: 6  359 aa  MW at 40154.1 kD       MDQYCILGRIGEGAHGIVFKAKHVEPRVGWQCLPSILQTGEIVALKKVALRRLEDGFPNQALREIKAL               QEMEDNQYVVQLKAVFPHGGGFVLAFEFMLSDLAEVVRHAQRPLAQAQVKSYLQMLLKGVAFCHANNI               VHRDLKPANLLISASGQLKIADFGLARVFSPDGSHLYTHQVATRWYRAPELLYGARQYDQGVDLWSVG               CIMGELLNGSPLFPGKNDIEQLCYVLRILGTPNPQVWPELTELPDYNKISFKEQVPMPLEEVLPDVSP               QALDLLGQFLLYPPHQRIAASKALLHQYFFTAPLPAHPSELPIPQRLGGPAPKAHPGPPHIHDFHVDR               PLEESLLNPELIRPFILEG               NOV2b, CG180777-02  SEQ ID NO: 7          2078 bp       DNA Sequence        ORF Start: ATG at 238 ORF Stop: end of sequence         CAGGTGCTGCGTGACAGCGGAGGGCTAGGAAAAGGCGCAGTGGGGCCCGGAGCTGTCACCCCTGACTC                   GACGCAGCTTCCGTTCTCCTGGTGACGTGGCCTACAGGAACCGCCCCGGTGGTCAGCTGCCGCGCTGT                   TGCTAGGCAACAGCGTGCGTGCTCAGATCAGCGTGGGGTGGAGGAGAAGTGGAGTTTGGAAGTTCAGG                   GGCACAGGGGCACAGGCCCACGACTGCAGCGGG   ATG GACCAGTACTGCATCCTGGGCCGCATCGGGGA               GGGCGCCCACGGCATCGTCTTCAAGGCCAAGCACGTGGAGACTGGCGAGATAATTGCCCTCAAGAAGG               TGGCCCTAAGGCGGTTGGAAGACGGCTTCCCTAACCAGGCCCTGCGGGAGATTAAGGCTCTGCAGGAG               ATGGAGGACAATCAGTATGTGGTACAACTGAAGGCTGTGTTCCCACACGGTGGAGGCTTTGTGCTGGC               CTTTGAGTTCATGCTGTCGGATCTGGCCGAGGTGGTGCGCCATGCCCAGAGGCCACTAGCCCAGGCAC               AGGTCAAGAGCTACCTGCAGATGCTGCTCAAGGGTGTCGCCTTCTGCCATGCCAACAACATTGTACAT               CGGGACCTGAAACCTGCCAACCTGCTCATCAGCGCCTCAGGCCAGCTCAAGATAGCGGACTTTGGCCT               GGCTCGAGTCTTTTCCCCAGACGGCAGCCGCCTCTACACACACCAGGTGGCCACCAGGTCTGTGGGCT               GCATCATGGGGGAGCTGTTGAATGGGTCCCCCCTTTTCCCGGGCAAGAACGATATTGAACAGCTTTGC               TATGTGCTTCGCATCTTGGGCACCCCAAACCCTCAAGTCTGGCCGGAGCTCACTGAGCTGCCGGACTA               CAACAAGATCTCCTTTAAGGAGCAGGTGCCCATGCCCCTGGAGGAGGTGCTGCCTGACGTCTCTCCCC               AGGCATTGGATCTGCTGGGTCAATTCCTTCTCTACCCTCCTCACCAGCGCATCGCAGCTTCCAAGGCT               CTCCTCCATCAGTACTTCTTCACAGCTCCCCTGCCTGCCCATCCATCTGAGCTGCCGATTCCTCAGCG               TCTAGGGGGACCTGCCCCCAAGGCCCATCCAGGGCCCCCCCACATCCATGACTTCCACGTGGACCGGC               CTCTTGAGGGAGTCGCTGTTGAACCCAGAGCTGATTCGGCCCTTCATCCTGGAGGGGTGAGAAGTTGG               CCCTGGTCCCGTCTGCCTGCTCCTCAGGACCACTCAGTCCACCTGTTCCTCTGCCACCTGCCTGGCTT               CACCCTCCAAGGCCTCCCCATGGCCACAGTGGGCCCACACCACACCTTGCCCCTTAGCCCTTGCGAGG               GTTGGTCTCGAGGCAGAGGTCATGTTCCCAGCCAAGAGTATGAGAACATCCAGTCGAGCAGAGGAGAT               TCATGGCCTGTGCTCGGTGAGCCTTACCTTCTGTGTGCTACTGACGTACCCATCAGGACAGTGAGCTC               TGCTGCCAGTCAAGGCCTGCATATGCAGAATGACGATGCCTGCCTTGGTGCTGCTTCCCCCGAGTGCT               GCCTCCTGGTCAAGGAGAAGTGCAGAGAG TAA   GGTGTCCTTATGTTGGAAACTCAAGTGGAAGGAAGA                   TTTGGTTTGGTTTTATTCTCAGAGCCATTAAACACTAGTTCAGTATGTGAGATATAGATTCTAAAAAC                   CTCAGGTGGTCTGCTTAGTCTGTCTTCTTCCTTTCTCAAGGGAAATGGCTAAGGTGGCATTGTCTCAT                   GGCTCTCGTTTTTGGGGTCATGGGGAGGGTAGCACCAGCATAGCCACTTTTGCCCTGAGGGACTCCTG                   TGTGCTTCACATCACTGAGCACTCATTTAGAAGTGAGGGAGACAGAAGTCTAGGCCCAGGGATGGCTC                   CAGTTGGGGATCCAGCAGGAGACCCTCTGCACATGAGGCTGGTTTACCAACATCTACTCCCTCAGGAT                   GAGCGTGAGCCAGAAGCAGCTGTGTATTTAAGGAAACAAGCGTTCCTGGAATTAATTTATAAATTTAA                   TAAATCCCAATATAATCCCAAAAAAAAAAAAAAAAAAA                 NOV2b, CG180777-02       Protein Sequence    SEQ ID NO: 8  452 aa  MW at 49710.7 kD       MDQYCILGRIGEGAHGIVFKAKHVETGEIIALKKVALRRLEDGFPNQALREIKALQEMEDNQYVVQLK               AVFPHGGGFVLAFEFMLSDLAEVVRHAQRPLAQAQVKSYLQMLLKGVAFCHANNIVHRDLKPANLLIS               ASGQLKIADFGLARVFSPDGSRLYTHQVATRSVGCIMGELLNGSPLFPGKNDIEQLCYVLRILGTPNP               QVWPELTELPDYNKISFKEQVPMPLEEVLPDVSPQALDLLGQFLLYPPHQRIAASKALLHQYFFTAPL               PAHPSELPIPQRLGGPAPKAHPGPPHIHDFHVDRPLEGVAVEPRADSALHPGGVRSWPWSRLPAPQDH               SVHLFLCHLPGFTLQGLPMATVGPHHTLPLSPCEGWSRGRGHVPSQEYENIQSSRGDSWPVLGEPYLL               CATDVPIRTVSSAASQGLHMQNDDACLGAASPECCLLVKEKCRE                  
 
     [0357] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 2B.  
               TABLE 2B                       Comparison of the NOV2 protein sequences.                                        NOV2a   MDQYCILGRIGEGAHGIVFKAKHVEPRVGWQCLPSILQTGEIVALKKVALRRLEDGFPNQ       NOV2b   MDQYCILGRIGEGAHGIVFKAKHVE-------------TGEIIALKKVALRRLEDGFPNQ               NOV2a   ALREIKALQEMEDNQYVVQLKAVFPHGGGFVLAFEFMLSDLAEVVRHAQRPLAQAQVKSY       NOV2b   ALREIKALQEMEDNQYVVQLKAVFPHGGGFVLAFEFMLSDLAEVVRHAQRPLAQAQVKSY               NOV2a   LQMLLKGVAFCHANNIVHRDLKPANLLISASGQLKIADFGLARVFSPDGSHLYTHQVATR       NOV2b   LQMLLKGVAFCHANNIVHRDLKPANLLISASGQLKIADFGLARVFSPDGSRLYTHQVATR               NOV2a   WYRAPELLYGARQYDQGVDLWSVGCIMGELLNGSPLFPGKNDIEQLCYVLRILGTPNPQV       NOV2b   ---------------------SVGCIMGELLNGSPLFPGKNDIEQLCYVLRILGTPNPQV               NOV2a   WPELTELPDYNKISFKEQVPMPLEEVLPDVSPQALDLLGQFLLYPPHQRIAASKALLHQY       NOV2b   WPELTELPDYNKISFKEQVPMPLEEVLPDVSPQALDLLGQFLLYPPHQRIAASKALLHQY               NOV2a   FFTAPLPAHPSELPIPQRLGGPAPKAHPGPPHIHDFHVDRPLE--------ESLLNPELI       NOV2b   FFTAPLPAHPSELPIPQRLGGPAPKAHPGPPHIHDFHVDRPLEGVAVEPRADSALHPGGV               NOV2a   RPFILEG-----------------------------------------------------       NOV2b   RSWPWSRLPAPQDHSVHLFLCHLPGFTLQGLPMATVGPHHTLPLSPCEGWSRGRGHVPSQ               NOV2a   ------------------------------------------------------------       NOV2b   EYENIQSSRGDSWPVLGEPYLLCATDVPIRTVSSAASQGLHMQNDDACLGAASPECCLLV               NOV2a   ------       NOV2b   KEKCRE               NOV2a   (SEQ ID NO: 6)       NOV2b   (SEQ ID NO: 8)                  
 
     [0358] Further analysis of the NOV2a protein yielded the following properties shown in Table 2C.  
               TABLE 2C                       Protein Sequence Properties NOV2a                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 9; pos. chg 1; neg. chg 1           H-region: length 2; peak value −0.20           PSG score: −4.60           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −8.44           possible cleavage site: between 44 and 45           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 0           number of TMS(s) . . . fixed                                 PERIPHERAL   Likelihood =   4.14 (at 146)                         ALOM score: 0.37 (number of TMSs: 0)           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   1   Hyd Moment (75):   6.08           Hyd Moment (95):   4.92   G content:   2           D/E content:   2   S/T content:   0                         Score: −7.23           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 8.9%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           47.8%: cytoplasmic           26.1%: mitochondrial           26.1%: nuclear           &gt;&gt; prediction for CG180777-01 is cyt (k = 23)                  
 
     [0359] A search of the NOV2a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 2D.  
               TABLE 2D                          Geneseq Results for NOV2a                                         NOV2a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAY90244   Human cyclin dependent kinase,   1 . . . 359   357/359 (99%)   0.0           hPNQALRE, protein sequence #3 -   1 . . . 359   358/359 (99%)           Homo sapiens, 359 aa.           [WO200036118-A2, 22 JUN.           2000]       AAY90245   Human cyclin dependent kinase,   1 . . . 359   344/359 (95%)   0.0           hPNQALRE, protein sequence #4 -   1 . . . 345   344/359 (95%)             Homo sapiens , 345 aa.           [WO200036118-A2, 22 JUN.           2000]       AAE11784   Human kinase (PKIN)-18 protein -   1 . . . 359   345/359 (96%)   0.0             Homo sapiens , 346 aa.   1 . . . 346   345/359 (96%)           [WO200181555-A2, 01 NOV.           2001]       AAY90243   Human cyclin dependent kinase,   1 . . . 358   344/358 (96%)   0.0           hPNQALRE, protein sequence #2 -   1 . . . 345   344/358 (96%)             Homo sapiens , 346 aa.           [WO200036118-A2, 22 JUN.           2000]       AAM93918   Human polypeptide, SEQ ID NO:   1 . . . 359   337/359 (93%)   0.0           4077 -  Homo sapiens , 338 aa.   1 . . . 338   337/359 (93%)           [EP1130094-A2, 05 SEP. 2001]                  
 
     [0360] In a BLAST search of public sequence databases, the NOV2a protein was found to have homology to the proteins shown in the BLASTP data in Table 2E.  
               TABLE 2E                          Public BLASTP Results for NOV2a                                         NOV2a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q8IZL9   Cell cycle related kinase -  Homo     1 . . . 359   345/359 (96%)   0.0             sapiens  (Human), 346 aa.   1 . . . 346   345/359 (96%)       Q9JHU3   CDK-related protein kinase   1 . . . 359   325/359 (90%)   0.0           PNQLARE -  Mus musculus     1 . . . 346   335/359 (92%)           (Mouse), 346 aa.       O95137   Cell cycle related kinase (Cyclin-   1 . . . 349   308/349 (88%)         e−174           dependent protein kinase H) -   1 . . . 315   310/349 (88%)             Homo sapiens  (Human), 452 aa.       Q9BUF4   Similar to cell cycle related   1 . . . 294   259/294 (88%)         e−141           kinase -  Homo sapiens  (Human),   1 . . . 260   259/294 (88%)           275 aa.       P29620   CDC2+/CDC28-related protein   2 . . . 338   150/338 (44%)        2e−73           kinase R2 (EC 2.7.1.-) -  Oryza     17 . . . 330    200/338 (58%)             sativa  (Rice), 424 aa.                  
 
     [0361] PFam analysis predicts that the NOV2a protein contains the domains shown in the Table 2F.  
               TABLE 2F                          Domain Analysis of NOV2a                                             Identities/                       Similarities           Pfam   NOV2a Match   for the   Expect           Domain   Region   Matched Region   Value                       pkinase   4 . . . 301   104/317 (33%)   3.7e−73                   220/317 (69%)                      
 
     Example 3  
     [0362] The NOV3 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 3A.  
               TABLE 3A                       NOV3 Sequence Analysis                                        NOV3a, CG181825-01  SEQ ID NO: 9              958 bp           DNA Sequence        ORF Start: ATG at 99  ORF Stop: end of sequence         AGCCAGAGACAGGACACCAGAAGAGACAGGAGATCAGAGACCAGAGGAACAGAGAAGAGGCCCCAGAG                       CAAGGCAAGGAACGGCCAAGGCACCAGGAC   ATG GATGCAGTGGAGCCAGGAGGACGTGGCTGGGCCAG               CATGTTGGCGTGCAGGCTTTGGAAAGCCATCAGCAGGGCGCTGTTTGCAGAGTTCCTGGCCACGGGGC               TGTATGTGTTCTTTGGCGTGGGCTCAGTCATGCGCTGGCCCACAGCACTTCCCTCCGTGCTACAGATT               GCCATCACCTTCAACCTGGTCACCGCCATGGCTGTGCAGGTCACCTGGAAGGCCAGCGGGGCCCACGC               CAACCCCGCCGTGACGCTGGCCTTCCTCGTAGGCTCCCACATCTCTCTGCCCCGTGCTGTGGCCTATG               TGGCTGCCCAGCTGGTGGGGGCCACGGTGGGGGCTGCTCTGCTTTATGGGGTCATGCCGGGAGACATC               CGAGAGACCCTTGGGATCAACGTGGTCCGGAACAGTGTCTCAACTGGCCAGGCGGTGGCAGTGGAGCT               GCTTCTGACCCTGCAGCTGGTGCTCTGTGTCTTCGCTTCCACCGACAGCCGTCAGACATCAGGCTCCC               CGGCCACCATGATTGGGATCTCTGTGGCACTGGGCCACCTCATTGGGATCCACTTCACTGGCTGCTCC               ATGAATCCAGCCCGCTCCTTCGGCCCTGCCATCATCATTGGGAAGTTCACAGTCCACTGGGTCTTCTG               GGTGGGGCCCCTGATGGGAGCCCTCCTGGCCTCACTGATCTACAACTTCGTCCTGTTCCCCGACACCA               AGAACCTGGCGCAGCGGCTGGCTATCCTCACAGGCACCGTAGAGGTGGGGACAGGGGCAGGGGCAGGG               GCGGAGCCCCTGAAGAAGGAATCCCAGCCGGGTTCGGGAGCCGTGGAGATGGAGAGTGTG TGA   AACAG                   CCTAAC                 NOV3a, CG181825-01       Protein Sequence    SEQ ID NO: 10  282 aa MW at 29383.1 kD       MDAVEPGGRGWASMLACRLWKAISRALFAEFLATGLYVFFGVGSVMRWPTALPSVLQIAITFNLVTAM               AVQVTWKASGAHANPAVTLAFLVGSHISLPRAVAYVAAQLVGATVGAALLYGVMPGDIRETLGINVVR               NSVSTGQAVAVELLLTLQLVLCVFASTDSRQTSGSPATMIGISVALGHLIGIHFTGCSMNPARSFGPA               IIIGKFTVHWVFWVGPLMGALLASLIYNFVLFPDTKNLAQRLAILTGTVEVGTGAGAGAEPLKKESQP               GSGAVEMESV                  
 
     [0363] Further analysis of the NOV3a protein yielded the following properties shown in Table 3B.  
               TABLE 3B                       Protein Sequence Properties NOV3a                                        SignalP analysis:   Cleavage site between residues 36 and 37       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 9; pos. chg 1; neg. chg 2           H-region: length 8; peak value 0.00           PSG score: −4.40           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −5.10           possible cleavage site: between 44 and 45           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 6                                         INTEGRAL   Likelihood =   −1.70   Transmembrane   26-42           INTEGRAL   Likelihood =   −1.70   Transmembrane   54-70           INTEGRAL   Likelihood =   −1.06   Transmembrane   101-117           INTEGRAL   Likelihood =   −7.38   Transmembrane   144-160           INTEGRAL   Likelihood =   −0.48   Transmembrane   172-188           INTEGRAL   Likelihood =   −2.39   Transmembrane   214-230           PERIPHERAL   Likelihood =    2.86 (at 81)                         ALOM score: −7.38 (number of TMSs: 6)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 33           Charge difference: −1.0 C(1.0)-N(2.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   3.62           Hyd Moment (95):   8.06   G content:   0           D/E content:   2   S/T content:   0                         Score: −7.16           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 5.7%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           55.6%: endoplasmic reticulum           33.3%: mitochondrial           11.1%: vesicles of secretory system           &gt;&gt; prediction for CG181825-01 is end (k = 9)                  
 
     [0364] A search of the NOV3a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 3C.  
               TABLE 3C                          Geneseq Results for NOV3a                                         NOV3a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABB97500   Novel human protein SEQ ID NO:   22 . . . 254   138/236 (58%)   1e−77           768 -  Homo sapiens , 265 aa.    9 . . . 244   184/236 (77%)           [WO200222660-A2, 21 MAR.           2002]       ABG96280   Human ovarian cancer marker   22 . . . 254   138/236 (58%)   1e−77           OV3 -  Homo sapiens , 265 aa.    9 . . . 244   184/236 (77%)           [WO200271928-A2, 19 SEP.           2002]       AAR51070   A water channel protein localized   22 . . . 251   138/232 (59%)   2e−76           in the rat kidney collecting tubule -    8 . . . 239   175/232 (74%)           Rattus sp. (Sprague-Dawley),           271 aa. [EP591789-A, 13 APR.           1994]       AAW94319   Rat aquaporin-5 - Rattus sp, 265   22 . . . 254   133/236 (56%)   7e−75           aa. [US5858702-A, 12 JAN. 1999]    9 . . . 244   181/236 (76%)       AAW55787   Rat aquaporin-5 - Rattus sp, 265   22 . . . 254   133/236 (56%)   7e−75           aa. [US5741671-A, 21 APR.    9 . . . 244   181/236 (76%)           1998]                  
 
     [0365] In a BLAST search of public sequence databases, the NOV3a protein was found to have homology to the proteins shown in the BLASTP data in Table 3D.  
               TABLE 3D                          Public BLASTP Results for NOV3a                                         NOV3a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q13520   Aquaporin 6 (Aquaporin-2 like)   1 . . . 282   275/282 (97%)   e−152           (hKID) -  Homo sapiens  (Human),   1 . . . 282   275/282 (97%)           282 aa.       Q9WTY0   Aquaporin-6 -  Rattus norvegicus     4 . . . 279   213/276 (77%)   e−117           (Rat), 276 aa.   1 . . . 274   234/276 (84%)       Q8C4A0   Aquaporin 6 -  Mus musculus     4 . . . 278   211/275 (76%)   e−115           (Mouse), 293 aa.   1 . . . 273   230/275 (82%)       P41181   Aquaporin-CD (AQP-CD) (Water   22 . . . 251    148/232 (63%)   6e−81            channel protein for renal collecting   8 . . . 239   178/232 (75%)           duct) (ADH water channel)           (Aquaporin 2) (Collecting duct           water channel protein) (WCH-CD) -             Homo sapiens  (Human), 271 aa.       I64818   water-channel aquaporin 2 - human,   22 . . . 251    147/232 (63%)   5e−80            271 aa.   8 . . . 239   177/232 (75%)                  
 
     [0366] PFam analysis predicts that the NOV3a protein contains the domains shown in the Table 3E.  
               TABLE 3E                          Domain Analysis of NOV3a                                             Identities/                       Similarities for           Pfam   NOV3a Match   the Matched   Expect           Domain   Region   Region   Value                       MIP   16 . . . 231   109/268 (41%)   4.3e−87                   185/268 (69%)                      
 
     Example 4  
     [0367] The NOV4 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 4A.  
               TABLE 4A                       NOV4 Sequence Analysis                                        NOV4a, CG50183-01   SEQ ID NO: 11         1067 bp           DNA Sequence        ORF Start: at 3       ORF Stop: end of sequence         CT   TTG GAACAGAACCAGTCAACAGATTATTATTATGAGGAAAATGAAATGAATGGCACTTATGACTAC               AGTCAATATGAACTGATCTGTATCAAAGAAGATGTCAGAGAATTTGCAAAAGTTTTCCTCCCTGTATT               CCTCACAATAGTTTTCGTCATTGGACTTGCAGGCAATTCCATGGTAGTGGCAATTTATGCCTATTACA               AGAAACAGAGAACCAAAACAGATGTGTACATCCTGAATTTGGCTGTAGCAGATTTACTCCTTCTATTC               ACTCTGCCTTTTTGGGCTGTTAATGCAGTTCATGGGTGGGTTTTAGGGAAAATAATGTGCAAAATAAC               TTCAGCCTTGTACACACTAAACTTTGTCTCTGGAATGCAGTTTCTGGCTTGTATCAGCATAGACAGAT               ATGTGGCAGTAACTAAAGTCCCCAGCCAATCAGGAGTGGGAAAACCATGCTGGATCATCTGTTTCTGT               GTCTGGATGGCTGCCATCTTGCTGAGCATACCCCAGCTGGTTTTTTATACAGTAAATGACAATGCTAG               GTGCATTCCCATTTTCCCCCGCTACCTAGGAACATCAATGAAAGCATTGATTCAAATGCTAGAGATCT               GCATTGGATTTGTAGTACCCTTTCTTATTATGGGGGTGTGCTACTTTATCACGGCAAGGACACTCATG               AAGATGCCAAACATTAAAATATCTCGACCCCTAAAAGTTCTGCTCACAGTCGTTATAGTTTTCATTGT               CACTCAACTGCCTTATAACATTGTCAAGTTCTGCCGAGCCATAGACATCATCTACTCTCTGATCACCA               GCTGCAACATGAGCAAACGCATGGACATCGCCATCCAAGTCACAGAAAGCATCGCACTCTTTCACAGC               TGCCTCAACCCAATCCTTTATGTTTTTATGGGAGCATCTTTCAAAAACTACGTTATGAAAGTGGCCAA               GAAATATGGGTCCTGGAGAAGACAGAGACAAAGTGTGGAGGAGTTTCCTTTTGATTCTGAGGGTCCTA               CAGAGCCAACCAGTACTTTTAGCATT TAA   AGGTAAAACTGCTCTGCC                 NOV4a, CG50183-01   SEQ ID NO: 12  348 aa MW at 39710.8 kD       Protein Sequence       LEQNQSTDYYYEENEMNGTYDYSQYELICIKEDVREFAKVFLPVFLTIVFVIGLAGNSMVVAIYAYYK               KQRTKTDVYILNLAVADLLLLFTLPFWAVNAVHGWVLGKIMCKITSALYTLNFVSGMQFLACISIDRY               VAVTKVPSQSGVGKPCWIICFCVWMAAILLSIPQLVFYTVNDNARCIPIFPRYLGTSMKALIQMLEIC               IGFVVPFLIMGVCYFITARTLMKMPNIKISRPLKVLLTVVIVFIVTQLPYNIVKFCRAIDIIYSLITS               CNMSKRMDIAIQVTESIALFHSCLNPILYVFMGASFKNYVMKVAKKYGSWRRQRQSVEEFPFDSEGPT               EPTSTFSI                  
 
     [0368] Further analysis of the NOV4a protein yielded the following properties shown in Table 4B.  
               TABLE 4B                       Protein Sequence Properties NOV4a                                        SignalP analysis:   Cleavage site between residues 63 and 64       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 8; pos. chg 0; neg. chg 2           H-region: length 3; peak value 0.00           PSG score: −4.40           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −2.97           possible cleavage site: between 56 and 57           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 5                                         INTEGRAL   Likelihood =   −9.24   Transmembrane   40-56           INTEGRAL   Likelihood =   −5.31   Transmembrane   76-92           INTEGRAL   Likelihood =   −8.55   Transmembrane   152-168           INTEGRAL   Likelihood =   −7.75   Transmembrane   203-219           INTEGRAL   Likelihood =   −5.68   Transmembrane   236-252           PERIPHERAL   Likelihood =    0.69 (at 289)                         ALOM score: −9.24 (number of TMSs: 5)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 47           Charge difference: 4.0 C( 3.0)-N(−1.0)           C &gt; N: C-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3b           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   8.15           Hyd Moment (95):   2.75   G content:   0           D/E content:   2   S/T content:   2                         Score: −6.56           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 8.9%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           44.4%: endoplasmic reticulum           22.2%: vacuolar           22.2%: mitochondrial           11.1%: Golgi           &gt;&gt; prediction for CG50183-01 is end (k = 9)                  
 
     [0369] A search of the NOV4a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 4C.  
               TABLE 4C                          Geneseq Results for NOV4a                                         NOV4a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABP81716   Human C—C chemokine receptor   1 . . . 348   348/348 (100%)   0.0           11 protein SEQ ID NO: 607 -   3 . . . 350   348/348 (100%)             Homo sapiens , 350 aa.           [WO200261087-A2, 08 AUG.           2002]       AAB62389   Human chemokine receptor CCX   1 . . . 348   348/348 (100%)   0.0           CKR polypeptide -  Homo     3 . . . 350   348/348 (100%)             sapiens , 382 aa. [WO200127146-           A2, 19 APR. 2001]       AAG67237   Amino acid sequence of human   1 . . . 348   348/348 (100%)   0.0           chemokine receptor CCR11 -   3 . . . 350   348/348 (100%)             Homo sapiens , 350 aa.           [WO200166598-A2, 13 SEP.           2001]       AAU08994   Human G protein-coupled   1 . . . 348   348/348 (100%)   0.0           receptor, GPCR, 2398 -  Homo     3 . . . 350   348/348 (100%)             sapiens , 350 aa. [WO200164882-           A2, 07 SEP. 2001]       AAG80119   Human CCR11 protein -  Homo     1 . . . 348   348/348 (100%)   0.0             sapiens , 350 aa. [WO200172830-   3 . . . 350   348/348 (100%)           A2, 04 OCT. 2001]                  
 
     [0370] In a BLAST search of public sequence databases, the NOV4a protein was found to have homology to the proteins shown in the BLASTP data in Table 4D.  
               TABLE 4D                          Public BLASTP Results for NOV4a                                         NOV4a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9NPB9   C—C chemokine receptor type 11   1 . . . 348    348/348 (100%)   0.0           (C—C CKR-11) (CC-CKR-11)   3 . . . 350    348/348 (100%)           (CCR-11) (Chemokine receptor-           like 1) (CCRL1) (CCX CKR) -             Homo sapiens  (Human), 350 aa.       CAC17062   Sequence 1 from Patent   1 . . . 348   346/348 (99%)   0.0           WO0064941 -  Homo sapiens     3 . . . 350   347/348 (99%)           (Human), 350 aa.       P35350   C—C chemokine receptor type 11   1 . . . 348   299/348 (85%)   e−180           (C—C CKR-11) (CC—CKR-11)   3 . . . 350   326/348 (92%)           (CCR-11) (Possible gustatory           receptor type B) (PPR1 protein) -             Bos taurus  (Bovine), 350 aa.       Q924I3   Chemokine receptor CCR11 -   1 . . . 348   297/348 (85%)   e−177             Mus musculus  (Mouse), 350 aa.   3 . . . 350   323/348 (92%)       Q8C0M1   Chemokine receptor CCR11   1 . . . 348   297/348 (85%)   e−177           homolog -  Mus musculus     3 . . . 350   323/348 (92%)           (Mouse), 350 aa.                  
 
     [0371] PFam analysis predicts that the NOV4a protein contains the domains shown in the Table 4E.  
               TABLE 4E                          Domain Analysis of NOV4a                                             Identities/                       Similarities for           Pfam   NOV4a Match   the Matched   Expect           Domain   Region   Region   Value                       7tm_1   56 . . . 301   90/276 (33%)   1.7e−76                   197/276 (71%)                       
 
     Example 5  
     [0372] The NOV5 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 5A.  
               TABLE 5A                       NOV5 Sequence Analysis                                        NOV5a, CG50249-01   SEQ ID NO: 13         1953 bp           DNA Sequence        ORF Start: ATG at 16  ORF Stop: end of sequence         GTCTGAGTCACAGAG   ATG GGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCG               GCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCG               AGCCCCCAGGCGACTGCTTGACCACGGCGGGCGACAAGCTGCAGCCGTCGCCGCCTCCACTGTCGCCG               CCGCCGAGAGCGCCCCCGCTGTCCCCCGGGCCAGGCGGCTGCTTCGAGGGCGGCGCGGGCAACTGCAG               TTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGCACCCGG               GCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCCCGCAGACGTGTGCGGG               CCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGAT               GACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCG               GCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGG               GGCCCGGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGAAGACCC               CTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATCCTGGTTTCAATTACAA               CTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGAACCAGTCATCAATGGC               ACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATGTAGAAGGAGTGTGTGT               GGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAACTTGAATTCATCAAAA               ATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGTGGGACTCAGTGGGCTG               TCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTGTGAGGATCCTGAGAAT               TTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTTCGAGCTAGTACTAATG               AATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTACCATGATCTACTATGCC               GAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGTTCAAAAACATTCCCAT               TGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGGGGATATGTACCCCCAAACATGGT               CAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGCCATGCCAGTGCCTGTC               ATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAACTTCCAAGGAAAAGAAA               GAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACAGAATTAAATATGGCCT               GCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGAACATAACAGATCAGTG               TTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAAGGCTCCCCATCAGACG               CTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACGACAGGTGATTACACGT               GTGCTTCTGATGGAGGGATCAGGAAAGGTTATGAAAAATCCCGAAGCTTAAACAACATAGCGGGCTTG               GCAGGCAATGCTCTGAGGCTCTCTCCAGTAACATCACCCTACAACTCTCCTTGTCCTCTGAGGCGCTC               TCGATCTCCCATCCCATCTATCTTG TAA   ACCAAACAACCAAACTGCATC                 NOV5a, CG50249-01   SEQ ID NO: 14  638 aa MW at 70224.7 kD       Protein Sequence       MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPPLSPPPRAP               PLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEE               ELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGK               SGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVL               QYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAA               KDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGA               QPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNF               GMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDD               STGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRSLNNIAGLAGNAL               RLSPVTSPYNSPCPLRRSRSPIPSIL               NOV5b, CG50249-02   SEQ ID NO: 15         607 bp       DNA Sequence        ORF Start: ATG at 13  ORF Stop: at 604         AGATTTCCCACC   ATG GGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCA               CGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGC               CCCCAGGCGACTGCTTGACCACAGCGGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCC               GGTGGCGGCCGCGAGTTCTTCTTCGACCGGCATCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCG               CACCGGCAAGCTGCACTGTCCCGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGG               GCATCGACGAGACCGACGTGGAGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAG               GCGCTGGACATCTTCGAGACCCCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGC               CAAGAGGCTGGGCATCGAGGACGCGGCGGGGCTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGA               GGCTGCAGCCCCGCATGTGGGCCCTCTTCGAAGACCCCTACTCGTCCAGAGCCGCCAGG CTC   G                 NOV5b, CG50249-02   SEQ ID NO: 16  197 aa MW at 21779.0 kD       Protein Sequence       MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGNCSSRGGRASDHPGGGR               EFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDI               FETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAAR               NOV5c, CG50249-03   SEQ ID NO: 17         1815 bp       DNA Sequence        ORF Start: ATG at 13  ORF Stop: end of sequence         AGATCTCCCACC   ATG GGCAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGGCACCCGGCA               CGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCTCCTCCGAGC               CCCCAGGCAACTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTC               TTCGACCGGCACCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCC               CGCAGACGTGTGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGG               AGCCCTGCTGCTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACC               CCCGACCTCATTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGA               CGCGGCGGGGCTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGG               CCCTCTTCGAAGACCCCTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATC               CTGGTTTCAATTACAACTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGA               ACCAGTCATCAATGGCACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATG               TAGAAGGAGTGTGTGTGGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAA               CTTGAATTCATCAAAAATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGT               GGGACTCAGTGGGCTGTCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTG               TGAGGATCCTGAGAATTTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTT               CGAGCTAGTACTAATGAATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTAC               CATGATCTACTATGCCGAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGT               TCAAAAACATTCCCATTGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGAGGATACG               TACCCCCAAACATGGTCAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGC               CATGCCAGTGCCTGTCATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAAC               TTCCAAGGAAAAGAAAGAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACA               GAATTAAATATGGCCTGCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGA               ACATAACAGATCAGTGTTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAA               GGCTCCCCATCAGACGCTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACG               ACAGGTGATTACACGTGTGCTTCTGATGGAGGGATCAGGAAAGGATATGAAAAATCCCGAAGCTTAAA               CAACATAGCGGGCTTGGCAGGCAATGCTCTGAGGCTCTCTCCAGTAACATCACCCTACAACTCTCCTT               GTCCTCTGAGGCGCTCTCGATCTCCCATCCCATCTATCTTG CTC   GAG                 NOV5c, CG50249-03   SEQ ID NO: 18  599 aa MW at 66544.6 kD       Protein Sequence       MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGNCSSRGGRASDHPGGGREFFFDRH               PGVFAYVLNYYRTGKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLI               GGDPGDDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSI               TTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFI               KNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRAST               NEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYEDTYPQT               WSGMLVGALCALAGVLTIAMPVPVIVNNFGMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNM               ACNSTQSDTCLGKDNRLLEHNRSVLSGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDY               TCASDGGIRKGYEKSRSLNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL               NOV5d, CG50249-04   SEQ ID NO: 19         3028 bp       DNA Sequence        ORF Start: ATG at 22  ORF Stop: end of sequence         AGTCATGTCTGAGTCACAGAG   ATG GGCAAGATCGAGAACAACGAGAGGGTGATCCTCAATGTCGGGGG               CACCCGGCACGAAACCTACCGCAGCACCCTCAAGACCCTGCCTGGAACACGCCTGGCCCTTCTTGCCT               CCTCCGAGCCCCCAGGCGACTGCTTGACCACGGCGGGCGACAAGCTGCAGCCGTCGCCGCCTCCACTG               TCGCCGCCGCCGAGAGCGCCCCCGCTGTCCCCCGGGCCAGGCGGCTGCTTCGAGGGCGGCGCGGGCAA               CTGCAGTTCCCGCGGCGGCAGGGCCAGCGACCATCCCGGTGGCGGCCGCGAGTTCTTCTTCGACCGGC               ACCCGGGCGTCTTCGCCTATGTGCTCAATTACTACCGCACCGGCAAGCTGCACTGCCCCGCAGACGTG               TGCGGGCCGCTCTTCGAGGAGGAGCTGGCCTTCTGGGGCATCGACGAGACCGACGTGGAGCCCTGCTG               CTGGATGACCTACCGGCAGCACCGCGACGCCGAGGAGGCGCTGGACATCTTCGAGACCCCCGACCTCA               TTGGCGGCGACCCCGGCGACGACGAGGACCTGGCGGCCAAGAGGCTGGGCATCGAGGACGCGGCGGGG               CTCGGGGGCCCCGACGGCAAATCTGGCCGCTGGAGGAGGCTGCAGCCCCGCATGTGGGCCCTCTTCGA               AGACCCCTACTCGTCCAGAGCCGCCAGGTTTATTGCTTTTGCTTCTTTATTCTTCATCCTGGTTTCAA               TTACAACTTTTTGCCTGGAAACACATGAAGCTTTCAATATTGTTAAAAACAAGACAGAACCAGTCATC               AATGGCACAAGTGTTGTTCTACAGTATGAAATTGAAACGGATCCTGCCTTGACGTATGTAGAAGGAGT               GTGTGTGGTGTGGTTTACTTTTGAATTTTTAGTCCGTATTGTTTTTTCACCCAATAAACTTGAATTCA               TCAAAAATCTCTTGAATATCATTGACTTTGTGGCCATCCTACCTTTCTACTTAGAGGTGGGACTCAGT               GGGCTGTCATCCAAAGCTGCTAAAGATGTGCTTGGCTTCCTCAGGGTGGTAAGGTTTGTGAGGATCCT               GAGAATTTTCAAGCTCACCCGCCATTTTGTAGGTCTGAGGGTGCTTGGACATACTCTTCGAGCTAGTA               CTAATGAATTTTTGCTGCTGATAATTTTCCTGGCTCTAGGAGTTTTGATATTTGCTACCATGATCTAC               TATGCCGAGAGAGTGGGAGCTCAACCTAACGACCCTTCAGCTAGTGAGCACACACAGTTCAAAAACAT               TCCCATTGGGTTCTGGTGGGCTGTAGTGACCATGACTACCCTGGGTTATGGGCATATGTACCCCCAAA               CATGGTCAGGCATGCTGGTGGGAGCCCTGTGTGCTCTGGCTGGAGTGCTGACAATAGCCATGCCAGTG               CCTGTCATTGTCAATAATTTTGGAATGTACTACTCCTTGGCAATGGCAAAGCAGAAACTTCCAAGGAA               AAGAAAGAAGCACATCCCTCCTGCTCCTCAGGCAAGCTCACCTACTTTTTGCAAGACAGAATTAAATA               TGGCCTGCAATAGTACACAGAGTGACACATGTCTGGGCAAAGACAATCGACTTCTGGAACATAACAGA               TCAGTGTTATCAGGTGACGACAGTACAGGAAGTGAGCCGCCACTATCACCCCCAGAAAGGCTCCCCAT               CAGACGCTCTAGTACCAGAGACAAAAACAGAAGAGGGGAAACATGTTTCCTACTGACGACAGGTGATT               ACACGTGTGCTTCTGATGGAGGGATCAGGAAAGATAACTGCAAAGAGGTTGTCATTACTGGTTACACG               CAAGCCGAGGCCAGATCTCTTACT TAA   TGACTTGGGGGAAGGCACAAAACATGAGAGAAAGTGTTGTA                   CAGAATTTATCATGGATTATTGACTGCTGAGAAAGGGACAGTGGAATTTAGCCATACAAAGGACTATA                   CTGGAAACAGACTTCTGCTGCTGAATGTGCCCTGATGTGACCAGGTTGCACTTGGAAGAGATCCTCCG                   CGTCTTCATGAGGCACTTAAAGCTTATAAAAGAACTGCGGCTGGAACTCATCTGGTGCTCCCCATGAG                   AGTGCTCTGCTTGTAGACTGGCCAGTGTCCATGAAACAACTGTAAATACCAACATGTGTGCATGGGTC                   AACAGTCTTGGCCATTTCTCATCAAAAGAAGCCAAATTCATGATCAACATCTCTGAAGTTTCAAGTAA                   GGCCCACACTTCTTTGAATTACTCTTCATGGGCCCACATTAGGTTGTGCTGTGAATTACTTAAGGCAG                   TGATACTGATGTAGTATAGTTTTGTCTTAATTTCCCTTATTTCTACTTCTTTGGTTGAATCTATGAAC                   TTGATTGTATAATTTTCTTATAAATTACTGATGTAATCAGCTTGTCAATTATGTTGTGAAATTGTTAG                   TATTCATTTATCAAAAATGACCTATGTTTAGTCACATATTTGTTTAGTTCTGGGAAATTGTTATAGCT                   TAAATGGAACTCACCAACATTATTCATAGTTTAAGTCTTTTATCATTATTACCTCAATTATAAATATT                   ACAAAAACATAATTCTGGCAATGAGAGTATTTTTTTATTCAATGATCAAGGAGCAATGTCAGTATATA                   GTAGAATATCAATTAAATTATATCCTAAAATGTATATTTTGCATAAAAGAGATATTCTTTAATCAATT                   ACTTTTTTGTGAGTTTTGTGGCGAATGAAGCTTGTACGTGTCTTTAAAACTGTTGTAGATGAAACTGT                   ATAAGATTTTTACATCTTGCTTAATCAATATTTTCAGAGTCTATTAGTTCCCCTGGGATTCTGAATAT                   AACATATAGCCTATTATAAATCCCTGTATCGTGGACCTTTTGTGAACATTTCAAGGCGCATGCACAAC                   CTTGATGATAACCAGTGGAAATGTAACTAACTGAAATGAAGAATAAAAGGCAAATGAGCTGGGGATAA                   ACTTGAATGTTATCTGATTAAATTACTCAAATTATT                 NOV5d, CG50249-04   SEQ ID NO: 20  613 aa MW at 67598.7 kD       Protein Sequence       MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPPLSPPPRAP               PLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRTGKLHCPADVCGPLFEE               ELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPGDDEDLAAKRLGIEDAAGLGGPDGK               SGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFILVSITTFCLETHEAFNIVKNKTEPVINGTSVVL               QYEIETDPALTYVEGVCVVWFTFEFLVRIVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAA               KDVLGFLRVVRFVRILRIFKLTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGA               QPNDPSASEHTQFKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNF               GMYYSLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVLSGDD               STGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKDNCKEVVITGYTQAEARSL               T                  
 
     [0373] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 5B.  
               TABLE 5B                       Comparison of the NOV5 protein sequences.                                        NOV5a   MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPP       NOV5b   MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTA----------       NOV5c   MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPG----------------       NOV5d   MGKIENNERVILNVGGTRHETYRSTLKTLPGTRLALLASSEPPGDCLTTAGDKLQPSPPP               NOV5a   LSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRT       NOV5b   -----------------GN-----CSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRT       NOV5c   -----------------------NCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRT       NOV5d   LSPPPRAPPLSPGPGGCFEGGAGNCSSRGGRASDHPGGGREFFFDRHPGVFAYVLNYYRT               NOV5a   GKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPG       NOV5b   GKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPG       NOV5c   GKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPG       NOV5d   GKLHCPADVCGPLFEEELAFWGIDETDVEPCCWMTYRQHRDAEEALDIFETPDLIGGDPG               NOV5a   DDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFIL       NOV5b   DDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAAR-----------       NOV5c   DDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFIL       NOV5d   DDEDLAAKRLGIEDAAGLGGPDGKSGRWRRLQPRMWALFEDPYSSRAARFIAFASLFFIL               NOV5a   VSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVR       NOV5b   ------------------------------------------------------------       NOV5c   VSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVR       NOV5d   VSITTFCLETHEAFNIVKNKTEPVINGTSVVLQYEIETDPALTYVEGVCVVWFTFEFLVR               NOV5a   IVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFK       NOV5b   ------------------------------------------------------------       NOV5c   IVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFK       NOV5d   IVFSPNKLEFIKNLLNIIDFVAILPFYLEVGLSGLSSKAAKDVLGFLRVVRFVRILRIFK               NOV5a   LTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQ       NOV5b   ------------------------------------------------------------       NOV5c   LTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQ       NOV5d   LTRHFVGLRVLGHTLRASTNEFLLLIIFLALGVLIFATMIYYAERVGAQPNDPSASEHTQ               NOV5a   FKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYY       NOV5b   ------------------------------------------------------------       NOV5c   FKNIPIGFWWAVVTMTTLGYEDTYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYY       NOV5d   FKNIPIGFWWAVVTMTTLGYGDMYPQTWSGMLVGALCALAGVLTIAMPVPVIVNNFGMYY               NOV5a   SLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVL       NOV5b   ------------------------------------------------------------       NOV5c   SLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVL       NOV5d   SLAMAKQKLPRKRKKHIPPAPQASSPTFCKTELNMACNSTQSDTCLGKDNRLLEHNRSVL               NOV5a   SGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRS       NOV5b   ------------------------------------------------------------       NOV5c   SGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKGYEKSRS       NOV5d   SGDDSTGSEPPLSPPERLPIRRSSTRDKNRRGETCFLLTTGDYTCASDGGIRKDNCKEVV               NOV5a   LNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL       NOV5b   --------------------------------------       NOV5c   LNNIAGLAGNALRLSPVTSPYNSPCPLRRSRSPIPSIL       NOV5d   ITGYTQAEARSLT-------------------------               NOV5a   (SEQ ID NO: 14)       NOV5b   (SEQ ID NO: 16)       NOV5c   (SEQ ID NO: 18)       NOV5d   (SEQ ID NO: 20)                  
 
     [0374] Further analysis of the NOV5a protein yielded the following properties shown in Table 5C.  
               TABLE 5C                       Protein Sequence Properties NOVSa                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 9; pos. chg 2; neg. chg 2           H-region: length 8; peak value 4.97           PSG score: 0.57           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −3.54           possible cleavage site: between 46 and 47           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 6                                         INTEGRAL   Likelihood =    −6.90   Transmembrane   230-246           INTEGRAL   Likelihood =    −3.24   Transmembrane   287-303           INTEGRAL   Likelihood =    −2.23   Transmembrane   314-330           INTEGRAL   Likelihood =    −0.16   Transmembrane   343-359           INTEGRAL   Likelihood =   −13.00   Transmembrane   382-398           INTEGRAL   Likelihood =    −7.01   Transmembrane   451-467           PERIPHERAL   Likelihood =    3.61 (at 424)                         ALOM score: −13.00 (number of TMSs: 6)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 237           Charge difference: −0.5 C(−0.5)-N( 0.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   5.56           Hyd Moment (95):   3.52   G content:   1           D/E content:   2   S/T content:   0                         Score: −7.90           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: PRKR (4) at 490           pat4: RKRK (5) at 491           pat4: KRKK (5) at 492           pat4: RKKH (3) at 493           pat7: PRKRKKH (5) at 490           pat7: PLRRSRS (4) at 626           bipartite: none           content of basic residues: 10.7%           NLS Score: 1.37           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 89           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           66.7%: endoplasmic reticulum           22.2%: mitochondrial           11.1%: nuclear           &gt;&gt; prediction for CG50249-01 is end (k = 9)                  
 
     [0375] A search of the NOV5a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 5D.  
               TABLE 5D                          Geneseq Results for NOV5a                                         NOV5a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABB78396   Longer splice variant of a human   1 . . . 638   638/638 (100%)   0.0           voltage-gated potassium channel -   1 . . . 638   638/638 (100%)             Homo sapiens , 638 aa.           [GB2372503-A, 28 AUG. 2002]       AAO14201   Human transporter and ion   1 . . . 638   638/638 (100%)   0.0           channel TRICH-18 -  Homo     1 . . . 638   638/638 (100%)             sapiens , 638 aa. [WO200204520-           A2, 17 JAN. 2002]       ABP52157   Human 53763 transporter protein   1 . . . 638   638/638 (100%)   0.0           SEQ ID NO: 11 -  Homo sapiens ,   1 . . . 638   638/638 (100%)           638 aa. [WO200255701-A2, 18           JUL. 2002]       ABG70285   Human novel polypeptide #1 -   1 . . . 638   638/638 (100%)   0.0             Homo sapiens , 638 aa.   1 . . . 638   638/638 (100%)           [WO200257452-A2, 25 JUL.           2002]       ABB78396   Longer splice variant of a human   1 . . . 638   638/638 (100%)   0.0           voltage-gated potassium channel -   1 . . . 638   638/638 (100%)             Homo sapiens , 638 aa.           [GB2372503-A, 28 AUG. 2002]                  
 
     [0376] In a BLAST search of public sequence databases, the NOV5a protein was found to have homology to the proteins shown in the BLASTP data in Table 5E.  
               TABLE 5E                          Public BLASTP Results for NOV5a                                         NOV5a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q96PR1   Voltage gated potassium channel   1 . . . 638    638/638 (100%)   0.0           Kv3.2b (Potassium voltage-gated   1 . . . 638    638/638 (100%)           potassium channel subfamily C           member 2) -  Homo sapiens             (Human), 638 aa.       P22462   Potassium voltage-gated channel   1 . . . 638   623/638 (97%)   0.0           subfamily C member 2 (Potassium   1 . . . 638   625/638 (97%)           channel Kv3.2) (KSHIIIA) -             Rattus norvegicus  (Rat), 638 aa.       Q96PR0   Voltage gated potassium channel   1 . . . 593    593/593 (100%)   0.0           Kv3.2a -  Homo sapiens  (Human),   1 . . . 593    593/593 (100%)           613 aa.       A39402   potassium channel protein IIIA   1 . . . 593   578/593 (97%)   0.0           form 1, shaker-type - rat, 613 aa.   1 . . . 593   580/593 (97%)       S22703   voltage-gated potassium channel   1 . . . 593   577/593 (97%)   0.0           protein Raw1 - rat, 624 aa.   1 . . . 593   579/593 (97%)                  
 
     [0377] PFam analysis predicts that the NOV5a protein contains the domains shown in the Table 5F.  
               TABLE 5F                          Domain Analysis of NOV5a                                             Identities/                       Similarities           Pfam   NOV5a Match   for the   Expect           Domain   Region   Matched Region   Value                       K_tetra    9 . . . 156   50/161 (31%)   3.2e−42                   121/161 (75%)            ion_trans   281 . . . 472   53/233 (23%)   6.3e−43                   155/233 (67%)                       
 
     Example 6  
     [0378] The NOV6 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 6A.  
               TABLE 6A                       NOV6 Sequence Analysis                                        NOV6a, CG54236-02   SEQ ID NO: 21         1193 bp           DNA Sequence        ORF Start: ATG at 105 ORF Stop: end of sequence         TGCTCCCTGTTTCATTAAAACCTAGAGAGATGTAATCAGTAAGCAAGAAGGAAAAAGGGAAATTCACA                 AAGTAACTTTTTGTGTCTGTTTCTTTTTAACCCAGC ATG GAGAGAAAATTTATGTCCTTGCAACCATC               CATCTCCGTATCAGAAATGGAACCAAATGGCACCTTCAGCAATAACAACAGCAGGAACTGCACAATTG               AAAACTTCAAGAGAGAATTTTTCCCAATTGTATATCTGATAATATTTTTCTGGGGAGTCTTGGGAAAT               GGGTTGTCCATATATGTTTTCCTGCAGCCTTATAAGAAGTCCACATCTGTGAACGTTTTCATGCTAAA               TCTGGCCATTTCAGATCTCCTGTTCATAAGCACGCTTCCCTTCAGGGCTGACTATTATCTTAGAGGCT               CCAATTGGATATTTGGAGACCTGGCCTGCAGGATTATGTCTTATTCCTTGTATGTCAACATGTACAGC               AGTATTTATTTCCTGACCGTGCTGAGTGTTGTGCGTTTCCTGGCAATGGTTCACCCCTTTCGGCTTCT               GCATGTCACCAGCATCAGGAGTGCCTGGATCCTCTGTGGGATCATATGGATCCTTATCATGGCTTCCT               CAATAATGCTCCTGGACAGTGGCTCTGAGCAGAACGGCAGTGTCACATCATGCTTAGAGCTGAATCTC               TATAAAATTGCTAAGCTGCAGACCATGAACTATATTGCCTTGGTGGTGGGCTGCCTGCTGCCATTTTT               CACACTCAGCATCTGTTATCTGCTGATCATTCGGGTTCTGTTAAAAGTGGAGGTCCCAGAATCGGGGC               TGCGGGTTTCTCACAGGAAGGCACTGACCACCATCATCATCACCTTGATCATCTTCTTCTTGTGTTTC               CTGCCCTATCACACACTGAGGACCGTCCACTTGACGACATGGAAAGTGGGTTTATGCAAAGACAGACT               GCATAAAGCTTTGGTTATCACACTGGCCTTGGCAGCAGCCAATGCCTGCTTCAATCCTCTGCTCTATT               ACTTTGCTGGGGAGAATTTTAAGGACAGACTAAAGTCTGCACTCAGAAAAGGCCATCCACAGAAGGCA               AAGACAAAGTGTGTTTTCCCTGTTAGTGTGTGGTTGAGAAAGGAAACAAGAGTA TAA   GGAGCTCTTAG                   ATGAGACCTGTTCTTGTATCCTTGTGTCCATCTTCAT                 NOV6a, CG54236-02   SEQ ID NO: 22  346 aa MW at 39634.7 kD       Protein Sequence       MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYK               KSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVR               FLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYI               ALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLT               TWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWL               RKETRV               NOV6b, CG54236-01   SEQ ID NO: 23         1260 bp       DNA Sequence        ORF Start: ATG at 105 ORF Stop: end of sequence         TGCTCCCTGTTTCATTAAAACCTAGAGAGATGTAATCAGTAAGCAAGAAGGAAAAAGGGAAATTCACA                   AAGTAACTTTTTGTGTCTGTTTCTTTTTAACCCAGC   ATG GAGAGAAAATTTATGTCCTTGCAACCATC               CATCTCCGTATCAGAAATGGAACCAAATGGCACCTTCAGCAATAACAACAGCAGGAACTGCACAATTG               AAAACTTCAAGAGAGAATTTTTCCCAATTGTATATCTGATAATATTTTTCTGGGGAGTCTTGGGAAAT               GGGTTGTCCATATATGTTTTCCTGCAGCCTTATAAGAAGTCCACATCTGTGAACGTTTTCATGCTAAA               TCTGGCCATTTCAGATCTCCTGTTCATAAGCACGCTTCCCTTCAGGGCTGACTATTATCTTAGAGGCT               CCAATTGGATATTTGGAGACCTGGCCTGCAGGATTATGTCTTATTCCTTGTATGTCAACATGTACAGC               AGTATTTATTTCCTGACCGTGCTGAGTGTTGTGCGTTTCCTGGCAATGGTTCACCCCTTTCGGCTTCT               GCATGTCACCAGCATCAGGAGTGCCTGGATCCTCTGTGGGATCATATGGATCCTTATCATGGCTTCCT               CAATAATGCTCCTGGACAGTGGCTCTGAGCAGAACGGCAGTGTCACATCATGCTTAGAGCTGAATCTC               TATAAAATTGCTAAGCTGCAGACCATGAACTATATTGCCTTGGTGGTGGGCTGCCTGCTGCCATTTTT               CACACTCAGCATCTGTTATCTGCTGATCATTCGGGTTCTGTTAAAAGTGGAGGTCCCAGAATCGGGGC               TGCGGGTTTCTCACAGGAAGGCACTGACCACCATCATCATCACCTTGATCATCTTCTTCTTGTGTTTC               CTGCCCTATCACACACTGAGGACCGTCCACTTGACGACATGGAAAGTGGGTTTATGCAAAGACAGACT               GCATAAAGCTTTGGTTATCACACTGGCCTTGGCAGCAGCCAATGCCTGCTTCAATCCTCTGCTCTATT               ACTTTGCTGGGGAGAATTTTAAGGACAGACTAAAGTCTGCACTCAGAAAAGGCCATCCACAGAAGGCA               AAGACAAAGTGTGTTTTCCCTGTTAGTGTGTGGTTGAGAAAGGAAACAAGAGTA TAA   GGAGCTCTTAG                   ATGAGACCTGTTCTTGTATCCTTGTGTCCATCTTCATTCACTCATAGTCTCCAAATGACTTTGTATTT                   ACATCACTCCCAACAAATGTTGATTCTTAATATTTA                 NOV6b, CG54236-01   SEQ ID NO: 24  346 aa MW at 39634.7 kD       Protein Sequence       MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSIYVFLQPYK               KSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYVNMYSSIYFLTVLSVVR               FLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQNGSVTSCLELNLYKIAKLQTMNYI               ALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRVSHRKALTTIIITLIIFFLCFLPYHTLRTVHLT               TWKVGLCKDRLHKALVITLALAAANACFNPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWL               RKETRV                  
 
     [0379] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 6B.  
               TABLE 6B                       Comparison of the NOV6 protein sequences.                                        NOV6a   MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSI       NOV6b   MERKFMSLQPSISVSEMEPNGTFSNNNSRNCTIENFKREFFPIVYLIIFFWGVLGNGLSI               NOV6a   YVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYV       NOV6b   YVFLQPYKKSTSVNVFMLNLAISDLLFISTLPFRADYYLRGSNWIFGDLACRIMSYSLYV               NOV6a   NMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQ       NOV6b   NMYSSIYFLTVLSVVRFLAMVHPFRLLHVTSIRSAWILCGIIWILIMASSIMLLDSGSEQ               NOV6a   NGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRV       NOV6b   NGSVTSCLELNLYKIAKLQTMNYIALVVGCLLPFFTLSICYLLIIRVLLKVEVPESGLRV               NOV6a   SHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACF       NOV6b   SHRKALTTIIITLIIFFLCFLPYHTLRTVHLTTWKVGLCKDRLHKALVITLALAAANACF               NOV6a   NPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRV       NOV6b   NPLLYYFAGENFKDRLKSALRKGHPQKAKTKCVFPVSVWLRKETRV               NOV6a   (SEQ ID NO: 22)       NOV6b   (SEQ ID NO: 24)                  
 
     [0380] Further analysis of the NOV6a protein yielded the following properties shown in Table 6C.  
               TABLE 6C                       Protein Sequence Properties NOV6a                                        SignalP analysis:   Cleavage site between residues 60 and 61       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 4; pos. chg 2; neg. chg 1           H-region: length 11; peak value 5.18           PSG score: 0.78           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −0.37           possible cleavage site: between 55 and 56           &gt;&gt;&gt; Seems to have a cleavable signal peptide (1 to 55)           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 56           Tentative number of TMS(s) for the threshold 0.5: 6                                         INTEGRAL   Likelihood =   −2.81   Transmembrane   75-91           INTEGRAL   Likelihood =   −3.72   Transmembrane   125-141           INTEGRAL   Likelihood =   −8.86   Transmembrane   157-173           INTEGRAL   Likelihood =   −7.75   Transmembrane   204-220           INTEGRAL   Likelihood =   −11.36   Transmembrane   245-261           INTEGRAL   Likelihood =   −1.06   Transmembrane   287-303           PERIPHERAL   Likelihood =    2.38 (at 222)                         ALOM score: −11.36 (number of TMSs: 6)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 27           Charge difference: 2.0 C(1.0)-N(−1.0)           C &gt; N: C-terminal side will be inside           &gt;&gt;&gt;Caution: Inconsistent mtop result with signal peptide           &gt;&gt;&gt; membrane topology: type 3b           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   1   Hyd Moment (75):   11.72           Hyd Moment (95):   9.21   G content:    0           D/E content:   2   S/T content:    4                         Score: −3.79           Gavel: prediction of cleavage sites for mitochondrial preseq           R-2 motif at 13 ERK|FM           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 10.4%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals:           XXRR-like motif in the N-terminus: ERKF           KKXX-like motif in the C-terminus: KETR           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           66.7%: endoplasmic reticulum           11.1%: Golgi           11.1%: vacuolar           11.1%: cytoplasmic           &gt;&gt; prediction for CG54236-02 is end (k = 9)                  
 
     [0381] A search of the NOV6a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 6D.  
               TABLE 6D                          Geneseq Results for NOV6a                                         NOV6a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABP81707   Human cysteinyl leukotriene   1 . . . 346   346/346 (100%)   0.0           CYSLT2 receptor protein SEQ ID   1 . . . 346   346/346 (100%)           NO: 589 -  Homo sapiens , 346 aa.           [WO200261087-A2, 08 AUG.           2002]       ABP95624   Human GPCR polypeptide SEQ   1 . . . 346   346/346 (100%)   0.0           ID NO 58 -  Homo sapiens , 346   1 . . . 346   346/346 (100%)           aa. [WO200216548-A2, 28 FEB.           2002]       ABU11923   Human G-protein coupled   1 . . . 346   346/346 (100%)   0.0           receptor HGPRBMY11v1 -   1 . . . 346   346/346 (100%)             Homo sapiens , 346 aa.           [WO200286123-A2, 31 OCT.           2002]       ABB05229   Human LTD4-like G protein-   1 . . . 346   346/346 (100%)   0.0           coupled receptor protein SEQ ID   1 . . . 346   346/346 (100%)           NO: 2 -  Homo sapiens , 346 aa.           [WO200194580-A1, 13 DEC.           2001]       AAG77965   Human G-protein coupled   1 . . . 346   346/346 (100%)   0.0           receptor PFI-017* -  Homo     1 . . . 346   346/346 (100%)             sapiens , 346 aa. [US2001039037-           A1, 08 NOV. 2001]                  
 
     [0382] In a BLAST search of public sequence databases, the NOV6a protein was found to have homology to the proteins shown in the BLASTP data in Table 6E.  
               TABLE 6E                          Public BLASTP Results for NOV6a                                         NOV6a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q9NS75   Cysteinyl leukotriene receptor 2   1 . . . 346    346/346 (100%)   0.0           (CysLTR2) (PSEC0146) (HG57)   1 . . . 346    346/346 (100%)           (HPN321) (hGPCR21) -  Homo               sapiens  (Human), 346 aa.       CAC69290   Sequence 1 from Patent   1 . . . 346   344/346 (99%)   0.0           WO0159118 -  Homo sapiens     1 . . . 346   345/346 (99%)           (Human), 346 aa.       Q95N03   Cysteinyl leukotriene receptor 2   1 . . . 346   275/347 (79%)   e−158           (CysLTR2) -  Sus scrofa  (Pig),   1 . . . 345   300/347 (86%)           345 aa.       Q8R528   Cysteinyl leukotriene 2 receptor -   17 . . . 324    226/308 (73%)   e−132             Mus musculus  (Mouse), 309 aa.   1 . . . 308   256/308 (82%)       Q920A1   Cysteinyl leukotriene receptor 2   17 . . . 324    224/308 (72%)   e−131           (CysLTR2) -  Mus musculus     1 . . . 308   255/308 (82%)           (Mouse), 309 aa.                  
 
     [0383] PFam analysis predicts that the NOV6a protein contains the domains shown in the Table 6F.  
               TABLE 6F                          Domain Analysis of NOV6a                                             Identities/                       Similarities           Pfam   NOV6a Match   for the   Expect           Domain   Region   Matched Region   Value                       7tm_1   55 . . . 305   89/277 (32%)   6.1e−54                   185/277 (67%)            TAS2R   33 . . . 324   64/314 (20%)   0.019                   173/314 (55%)                       
 
     Example 7  
     [0384] The NOV7 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 7A.  
               TABLE 7A                       NOV7 Sequence Analysis                                                NOV7a, CG54566-01   SEQ ID NO: 25   1358 bp           DNA Sequence   ORF Start: ATG at 5   ORF Stop: end of sequence                   AGTG   ATG GATGTTAACAGCAGCGGCCACCCGGACCTCTACGGGCGCCTCTGCTCTTTCCTCCTGCCGG               AGGTGGGGGGCAGGCTGCCCGACCTGAGCCCCGACGGTGGCGCCGAACCGGTCGCGGTCTCCGGGACG               CCGCATCTGCTGAGCGAGGTGACGGCCAGCCCGGCGCCCACCTGGGACGCAACCCCGGGCAATGCCTC               CGGCCGCGGGGAGCAAATCAATCAAGAAAGGGCCGAGAAAGTTGTGATCGGCTCTGTCCTGACGCTCA               TCTCTCTGTCTGCGATCGCGGGCAACTGCCTGGTGGTAATCTCTGTGTGCTTCGTCAAGAAGCTCCGC               CAGCCCTCCAACTACCTCATCGTGTCCATGGCGCTGGCCAACCTCTCGGTGGCCATGGCGGTCATGCC               CTTCATCAGTGTCACCGACCTCATCGGGGGCAAGTGGATCTTTGGACACTTTTTCTGTAACGTCTTCT               CCGTGAATGTCATGTGCTGCACGGCCTGGATCTTGACCTTGTACGTGATCAGCATCGACAGGGACCTT               GGGATCATGAAGCCTCTCACGTACCCTATGAGGCAGAAGGGGAAATGCATGACGAAGATGATTCTTTC               TGTCTGCCTTCTTTCCGCCTTTGTCACTTTACCTACCATTTTTGGTCGGGCTCAGAATGTAAACGATG               ATAAGGTGTGCTTGGTCAATCAAGACTTTGGCTACACGATTTACTCCCCGCATTTGGCAGCATTTATC               CCCATGTGCGTCATGCTTTTCATGTACTATCAGATTTACAAGGCCGCCAGGAAAAGCGCGGCCAAACA               CAGGTTACCTGGCTTCCCTCGAGTGGAGCCAGACAGCGTAGTCACCCTGAATGGCACAGTGAAGTTCC               AGGAGGTGGAAGAGTGTGCAAACCTTTCGAGACTCCTCAAGCATGAAAGGAAAAATATCTCCATCTTT               AAGCGGAAACAGAAAGCAGCGACTACCTTGGGGATCATCGTCTGGGCCTCCACCATGTGCTGGCCGCC               CTTTTTCCTCCTGACAGCCAGACCCTTCTGTCTATGGCACTGCCCTTCTGTCTATGGCACTGCCTGCA               GCTGCATCCCACTGTGGGTGGAGAGGATATTTCCATGGCTGGGCTATGCAAACTCTCTCATTAACCCT               TTTATTTATGCCTTCTTCAACTGGGACCTGAGGACCACCTATTGCAGCCGGCTCCAGTGCCAGTACCA               GAATATCAACCAGACACTCTCAGCTGCAGGCATGCATGAAGCCCTGAAGCTTGCTGAGAGGCCAGAGA               GACCTGAGTTTGTCCTACAAAACTCTGACTACTGTAGAAAAAAAAGTCATGATTCA TGA   CTGAAAG                                       NOV7a, CG54566-01   SEQ ID NO: 26   448 aa   MW at 49974.9kD       Protein Sequence                 MDVNSSGHPDLYGRLCSFLLPEVGGRLPDLSPDGGAEPVAVSGTPHLLSEVTASPAPTWDATPGNASG               RGEQINQERAEKVVIGSVLTLISLSAIAGNCLVVISVCFVKKLRQPSNYLIVSMALANLSVAMAVMPF               ISVTDLIGGKWIFGHFFCNVFSVNVMCCTAWILTLYVISIDRDLGIMKPLTYPMRQKGKCMTKMILSV               CLLSAFVTLPTIFGRAQNVNDDKVCLVNQDFGYTIYSPHLAAFIPMCVMLFMYYQIYKAARKSAAKHR               LPGFPRVEPDSVVTLNGTVKFQEVEECANLSRLLKHERKNISIFKRKQKAATTLGIIVWASTMCWPPF               FLLTARPFCLWHCPSVYGTACSCIPLWVERIFPWLGYANSLINPFIYAFFNWDLRTTYCSRLQCQYQN               INQTLSAAGMHEALKLAERPERPEFVLQNSDYCRKKSHDS                  
 
     [0385] Further analysis of the NOV7a protein yielded the following properties shown in Table 7B.  
               TABLE 7B                       Protein Sequence Properties NOV7a                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 10; pos. chg 0; neg. chg 2           H-region: length 3; peak value 0.00           PSG score: −4.40           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −3.34           possible cleavage site: between 25 and 26           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 5                                         INTEGRAL   Likelihood =   −6.58   Transmembrane   92-108           INTEGRAL   Likelihood =   −4.99   Transmembrane   118-134           INTEGRAL   Likelihood =   −1.81   Transmembrane   160-176           INTEGRAL   Likelihood =   −5.84   Transmembrane   201-217           INTEGRAL   Likelihood =   −1.91   Transmembrane   244-260           PERIPHERAL   Likelihood =    0.63 (at 326)                         ALOM score: −6.58 (number of TMSs: 5)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 99           Charge difference: 3.0 C(3.0)-N(0.0)           C &gt; N: C-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3b           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   3.84           Hyd Moment (95):   1.55   G content:   1           D/E content:   2   S/T content:   2                         Score: −7.77           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 9.4%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals:           KKXX-like motif in the C-terminus: KSHD           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           44.4%: endoplasmic reticulum           22.2%: vacuolar           11.1%: mitochondrial           11.1%: Golgi           11.1%: cytoplasmic           &gt;&gt; prediction for CG54566-01 is end (k = 9)                  
 
     [0386] A search of the NOV7a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 7C.  
               TABLE 7C                          Geneseq Results for NOV7a                                         NOV7a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE15653   Human 5-hydroxytryptamine-7-   1 . . . 448    448/448 (100%)   0.0           receptor-like protein, NOV4 -   1 . . . 448    448/448 (100%)             Homo sapiens , 448 aa.           [WO200194416-A2, 13 DEC.           2001]       ABP81770   Human 5-HT7 receptor protein   1 . . . 448   368/451 (81%)   0.0           SEQ ID NO: 22 -  Homo sapiens ,   2 . . . 445   396/451 (87%)           445 aa. [WO200261087-A2, 08           AUG. 2002]       AAR54782   Human brain serotonin receptor   1 . . . 448   368/451 (81%)   0.0           5-HT4B protein -  Homo sapiens ,   2 . . . 445   396/451 (87%)           445 aa. [WO9409828-A, 11           MAY 1994]       ABB56329   Non-endogenous human GPCR   1 . . . 448   367/451 (81%)   0.0           protein, SEQ ID NO: 451 -  Homo     2 . . . 445   395/451 (87%)             sapiens , 445 aa. [WO200177172-           A2, 18 OCT. 2001]       AAR57200   Rat 5HT6 receptor -  Rattus rattus ,   1 . . . 448   357/454 (78%)   0.0           448 aa. [FR2699922-A, 01 JUL.   2 . . . 445   389/454 (85%)           1994]                  
 
     [0387] In a BLAST search of public sequence databases, the NOV7a protein was found to have homology to the proteins shown in the BLASTP data in Table 7D.  
               TABLE 7D                          Public BLASTP Results for NOV7a                                         NOV7a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               CAD32672   Sequence 11 from Patent   1 . . . 448    448/448 (100%)   0.0           WO0194416 -  Homo sapiens     1 . . . 448    448/448 (100%)           (Human), 448 aa.       AAH47526   5-hydroxytryptamine (serotonin)   1 . . . 448   368/451 (81%)   0.0           receptor 7 (adenylate cyclase-   2 . . . 445   396/451 (87%)           coupled) -  Homo sapiens             (Human), 445 aa.       P34969   5-hydroxytryptamine 7 receptor   1 . . . 436   357/439 (81%)   0.0           (5-HT-7) (5-HT-X) (Serotonin   2 . . . 433   385/439 (87%)           receptor) (5HT7) -  Homo sapiens             (Human), 479 aa.       P32305   5-hydroxytryptamine 7 receptor   1 . . . 448   357/454 (78%)   0.0           (5-HT-7) (5-HT-X) (Serotonin   2 . . . 448   389/454 (85%)           receptor) (5HT7) (GPRFO) -             Rattus norvegicus  (Rat), 448 aa.       Q8SPH2   Serotonin 5-hydroxytryptamine   1 . . . 448   361/454 (79%)   0.0           7-a receptor -  Sus scrofa  (Pig),   2 . . . 447   387/454 (84%)           447 aa.                  
 
     [0388] PFam analysis predicts that the NOV7a protein contains the domains shown in the Table 7E.  
               TABLE 7E                          Domain Analysis of NOV7a                                             Identities/                       Similarities           Pfam   NOV7a Match   for the   Expect           Domain   Region   Matched Region   Value                       7tm_1   97 . . . 387   76/315 (24%)   3.8e−56                   219/315 (70%)                       
 
     Example 8  
     [0389] The NOV8 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 8A.  
               TABLE 8A                       NOV8 Sequence Analysis                                            NOV8a, CG55912-01   SEQ ID NO: 27   1173 bp       DNA Sequence   ORF Start: ATG at 55   ORF Stop: end of sequence                   AATATAGCCGGTCCTGTCCCCGTGTTAACTGGAGTGCTGAAGCGCTGGAACGAA   ATG CGGGGCCTCTG               GTGCGAGAAGGGGGTGCAGGTGCTGCTGACGACGGTGGGCGCCTTCGCCGCCTTCGGCCTCATGACCA               TCGCCATCAGCACTGACTACTGGCTCTACACGGGGCAACAAGAGCGAAAATCTGTCTCAAAAAATAAA               AGAAGTAAGAAGGACCCCGGCGGCCTCACGCACTCGGGCCTCTGGAGGATCTGCTGCCTGGAAGGGTT               GAAAAGAGGCGTCTGCGTGAAGATCAATCATTTCCCGGAGGACACGGACTACGACCACGACAGCGCGG               AGTATCTACTCCGTACGGTCCGGGCCTCCAGCATCTTCCCCATCCTTAGCGCCATCCTGCTGCTGCTC               GGGGGTGTGTGCGTGGCGGCCTCCCGCGTCTACAAGTCCAAGAGGAACATCATTCTGGGCGCAGGGAT               CCTGTTCGTGGCAGCAGGTCTGAGCAACATCATCGGCGTGATCGTGTACATCTCCGCCAACGCGGGCG               AGCCGGGCCGAAGCAGAGCCAAGAAAAACCACTACTCGTACGGCTGGTCCTTCTACTTCGGCGGGCTG               TCGTTCATCCTGGCCGAGGTGATAGGCGTGCTGGCCGTCAACATCTACATCGAGCCAGCCGAGGCGCA               CTGCCAGTCTCGGAGCGGGACCGCGGGGGGTCGTCCGGCTTCCTCACGCTGCACAACGCCTTCCCCAA               GGAGGCGGGCGGCGGCGTCACGGTCACGTTCACCCGGCCGCCCGCCCCGCCCGCGCCACGCCACCCCG               GCCAACACCAACTCCACGGACATCTCCATGTACACGCTCAGCCGCGACCCCTCCAAGGGCAGCCCCCA               TTCCAATGCCACCACCCCCACCCCCACTAGCCTCAAGGATAGGAAAAACTCATTTGTGTCCATAAAAA               TAAAGGTAAAAAAGAAAAAAAGAAATATATATATATATATATATACGCTCAACAGGAAAACCACGCCT               GTG TAG   GGGCGCGGCGGGGGAGCCGAGGGGCGTGTCCGGGGCGCGTGCGGGCGCGCGTGCATCGAGGC                   TGCCGGGGTCGGGGGCGCCCCCGCTTTCCCCCGTGAGCGCGCTGGAGACTGCTGGGCCCGCCCCACGC                   CCACCCTCCCCGCCCCC                                       NOV8a, CG55912-01   SEQ ID NO: 28   323 aa   MW at 35342.3kD       Protein Sequence                 MRGLWCEKGVQVLLTTVGAFAAFGLMTIAISTDYWLYTGQQERKSVSKNKRSKKDPGGLTHSGLWRIC               CLEGLKRGVCVKINHFPEDTDYDHDSAEYLLRTVRASSIFPILSAILLLLGGVCVAASRVYKSKRNII               LGAGILFVAAGLSNIIGVIVYISANAGEPGRSRAKKNHYSYGWSFYFGGLSFILAEVIGVLAVNIYIE               PAEAHCQSRSGTAGGRPASSRCTTPSPRRRAAASRSRSPGRPPRPRHATPANTNSTDISMYTLSRDPS               KGSPHSNATTPTPTSLKDRKNSFVSIKIKVKKKKRNIYIYIYTLNRKTTPV                  
 
     [0390] Further analysis of the NOV8a protein yielded the following properties shown in Table 8B.  
               TABLE 8B                       Protein Sequence Properties NOV8a                                        SignalP analysis:   Cleavage site between residues 22 and 23       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 8; pos. chg 2; neg. chg 1           H-region: length 24; peak value 10.41           PSG score: 6.01           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −3.71           possible cleavage site: between 24 and 25           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 4                                         INTEGRAL   Likelihood =   −3.93   Transmembrane   12-28           INTEGRAL   Likelihood =   −9.50   Transmembrane   107-123           INTEGRAL   Likelihood =   −6.48   Transmembrane   140-156           INTEGRAL   Likelihood =   −5.20   Transmembrane   183-199           PERIPHERAL   Likelihood =    7.21 (at 63)                         ALOM score: −9.50 (number of TMSs: 4)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 19           Charge difference: −2.0 C(0.0)-N(2.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   1   Hyd Moment (75):   13.83           Hyd Moment (95):   3.82   G content:    4           D/E content:   2   S/T content:    5                         Score: −5.73           Gavel: prediction of cleavage sites for mitochondrial preseq           R-2 motif at 12 MRG|LW           NUCDISC: discrimination of nuclear localization signals           pat4: PRRR (4) at 231           pat4: KKKK (5) at 303           pat4: KKKR (5) at 304           pat7: PSPRRRA (4) at 229           pat7: PRRRAAA (5) at 231           bipartite: RKNSFVSIKIKVKKKKR at 291           content of basic residues: 14.9%           NLS Score: 2.00           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals:           XXRR-like motif in the N-terminus: RGLW           KKXX-like motif in the C-terminus: KTTP           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: nuclear           Reliability: 76.7           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           39.1%: endoplasmic reticulum           30.4%: nuclear           17.4%: mitochondrial            4.3%: vesicles of secretory system            4.3%: cytoplasmic            4.3%: peroxisomal           &gt;&gt; prediction for CG55912-01 is end (k = 23)                  
 
     [0391] A search of the NOV8a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 8C.  
               TABLE 8C                          Geneseq Results for NOV8a                                         NOV8a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAY70462   Human membrane channel   7 . . . 323   183/327 (55%)   6e−93           protein-12 (MECHP-12) -  Homo     5 . . . 323   233/327 (70%)             sapiens , 323 aa. [WO200012711-           A2, 09 MAR. 2000]       ABB11805   Human voltage gated Ca channel   7 . . . 323   183/327 (55%)   1e−92           subunit homologue, SEQ ID   7 . . . 325   233/327 (70%)           NO: 2175 -  Homo sapiens , 325 aa.           [WO200157188-A2, 09 AUG.           2001]       AAY84376   A human voltage-gated calcium   7 . . . 323   183/327 (55%)   1e−92           channel designated   5 . . . 323   233/327 (70%)           CACNGLIKE1 -  Homo sapiens ,           323 aa. [WO200014223-A1, 16           MAR. 2000]       AAU97153   Mouse neuronal voltage-gated   7 . . . 323   183/327 (55%)   2e−92           calcium channel gamma subunit   5 . . . 323   232/327 (69%)           Cacng2 - Murinae gen. sp, 323 aa.           [US6365337-B1, 02 APR. 2002]       AAY84374   A human a neuronal voltage-gated   6 . . . 323   173/324 (53%)   1e−85           calcium chanel polypeptide -   4 . . . 315   217/324 (66%)             Homo sapiens , 315 aa.           [WO200014225-A1, 16 MAR.           2000]                  
 
     [0392] In a BLAST search of public sequence databases, the NOV8a protein was found to have homology to the proteins shown in the BLASTP data in Table 8D.  
               TABLE 8D                          Public BLASTP Results for NOV8a                                         NOV8a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q8VHW5   Voltage-dependent calcium channel    2 . . . 275   226/309 (73%)   e−113           gamma-8 subunit (Neuronal   11 . . . 317   234/309 (75%)           voltage-gated calcium channel           gamma-8 subunit) -  Rattus               norvegicus  (Rat), 421 aa.       Q8WXS5   Voltage-dependent calcium channel    2 . . . 275   229/310 (73%)   e−113           gamma-8 subunit (Neuronal   11 . . . 317   236/310 (75%)           voltage-gated calcium channel           gamma-8 subunit) -  Homo sapiens             (Human), 425 aa.       Q8VHW2   Voltage-dependent calcium channel    2 . . . 275   225/309 (72%)   e−113           gamma-8 subunit (Neuronal   11 . . . 317   234/309 (74%)           voltage-gated calcium channel           gamma-8 subunit) -  Mus musculus             (Mouse), 423 aa.       Q9Y698   Voltage-dependent calcium channel    7 . . . 323   183/327 (55%)   4e−92            gamma-2 subunit (Neuronal    5 . . . 323   233/327 (70%)           voltage-gated calcium channel           gamma-2 subunit) -  Homo sapiens             (Human), 323 aa.       O88602   Voltage-dependent calcium channel    7 . . . 323   183/327 (55%)   5e−92            gamma-2 subunit (Neuronal    5 . . . 323   232/327 (69%)           voltage-gated calcium channel           gamma-2 subunit) (Stargazin) -             Mus musculus  (Mouse), 323 aa.                  
 
     [0393] PFam analysis predicts that the NOV8a protein contains the domains shown in the Table 8E.  
               TABLE 8E                          Domain Analysis of NOV8a                                     Identities/                   Similarities for       Pfam   NOV8a Match   the Matched   Expect       Domain   Region   Region   Value               PMP22_Claudin   8 . . . 198   51/198 (26%)   7.6e−53               161/198 (81%)                   
 
     Example 9  
     [0394] The NOV9 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 9A.  
               TABLE 9A                       NOV9 Sequence Analysis                                            NOV9a, CG56001-01   SEQ ID NO: 29   1192 bp       DNA Sequence   ORF Start: ATG at 69   ORF Stop: end of sequence                   TGCTGAGGGTGCATTTATGTTTCAGAACCACCGGGAGGAACTGGGCCATTCTAACACCCGTTGCTACC                   ATG CTGGCCACCCGCCTCTCCAGACCCCTGTCACGGCTCCCAGGAAAAACCCTAAGTGCCTGTGATAG               AGAAAATGGAGCAAGGCGCCCACTATTGCTTGGTTCTACTTCCTTTATCCCGATTGGCCGTCGGACTT               ATGCCAGTGCGGCGGAGCCGGTGAGTGGAAAAGCTGTCCTGGTCACAGGCTGTGACTCTGGATTTGGG               TTCTCATTGGCCAAGCATCTGCATTCAAAAGGCTTCCTTGTGTTTGCTGGCTGCTTGATGAAGGACAA               AGGCCATGATGGGGTCAAGGAGCTGGACAGCCTAAACAGTGACCGATTGAGAACCGTCCAGCTCAATG               TCTGCAGCAGCGAAGAGGTGGAGAAAGTGGTGGAGATTGTCCGCTCGAGCCTGAAGGACCCTGAGAAA               GGTATGTGGGGCCTCGTTAACAATGCCGGCATCTCAACGTTCGGGGAGGTGGAGTTCACCAGCCTGGA               GACCTACAAGCAGGTGGCAGAAGTGAACCTTTGGGGCACAGTGCGGATGACGAAATCCTTTCTCCCCC               TCATCCGAAGGGCCAAAGGTCGCGTCGTCAATATCAGCAGCATGCTGGGCCGCATGGCCAACCCGGCC               CGCTCCCCGTACTGCATCACCAAGTTCGGGGTAGAGGCTTTCTCGGACTGCCTGCGCTATGAGATGTA               CCCCCTGGGCGTGAAGGTCAGCGTGGTGGAGCCCGGCAACTTCATCGCTGCCACCAGCCTTTACAGCC               CTGAGAGCATTCAGGCCATCGCCAAGAAGATGTGGGAGGAGCTGCCTGAGGTCGTGCGCAAGGACTAC               GGCAAGAAGTACTTTGATGAAAAGATCGCCAAGATGGAGACCTACTGCAGCAGTGGCTCCACAGACAC               GTCCCCTGTCATCGATGCTGTCACACACGCCCTGACCGCCACCACCCCCTACACCCGCTACCACCCCA               TGGACTACTACTGGTGGCTGCGAATGCAGATCATGACCCACTTGCCTGGAGCCATCTCCGACATGATC               TACATCCGC TGA   AGAGTCTCGCTGTGGCCTCTGTCAGGGATCCCTGGTGGAAGGGGAGGGGAGGGAGG                   AACCCATATAGTCAACTCTTGATTATCCACGTGTGG                                       NOV9a, CG56001-01   SEQ ID NO: 30   343 aa   MW at 38156.7kD       Protein Sequence                 MLATRLSRPLSRLPGKTLSACDRENGARRPLLLGSTSFIPIGRRTYASAAEPVSGKAVLVTGCDSGFG               FSLAKHLHSKGFLVFAGCLMKDKGHDGVKELDSLNSDRLRTVQLNVCSSEEVEKVVEIVRSSLKDPEK               GMWGLVNNAGISTFGEVEFTSLETYKQVAEVNLWGTVRMTKSFLPLIRRAKGRVVNISSMLGRMANPA               RSPYCITKFGVEAFSDCLRYEMYPLGVKVSVVEPGNFIAATSLYSPESIQAIAKKMWEELPEVVRKDY               GKKYFDEKIAKMETYCSSGSTDTSPVIDAVTHALTATTPYTRYHPMDYYWWLRMQIMTHLPGAISDMI               YIR                                 NOV9b, CG56001-02   SEQ ID NO: 31   1166 bp       DNA Sequence   ORF Start: ATG at 69   ORF Stop: end of sequence                   TGCTGAGGGTGCATTTATGTTTCAGAACCACCGGGAGGAACTGGGCCATTCTAACACCCGTTGCTACC                   ATG CTGGCCACCCGCCTCTCCAGACCCCTGTCACGGCTCCCAGGAAAAACCCTAAGTGCCTGTGATAG               AGAAAATGGAGCAAGACGCCCACTATTGCTTGGTTCTACTTCCTTTATCCCGATTGGCCGTCGGACTT               ATGCCAGTGCGGCGGAGCCGGTTGGCAGCAAAGCTGTCCTGGTCACAGGCTGTGACTCTGGATTTGGG               TTCTCATTGGCCAAGCATCTGCATTCAAAAGGCTTCCTTGTGTTTGCTGGCTGCTTGATGAAGGACAA               AGGCCATGATGGGGTCAAGGAGCTGGACAGCCTAAACAGTGACCGATTGAGAACCGTCCAGCTCAATG               TCTGCAGCAGCGAAGAGGTGGAGAAAGTGGTGGAGATTGTCCGCTCGAGCCTGAAGGACCCTGAGAAA               GGCATGTGGGGCCTCGTTAACAATGCCGGCATCTCAACGTTCGGGGAGGTGGAGTTCACCAGCCTGGA               GACCTACAAGCAGGTGGCAGAAGTGAACCTTTGGGGCACAGTGCGGATGACGAAATCCTTTCTCCCCC               TCATCCGAAGGGCCAAAGGCCGCGTCGTCAATATCAGCAGCATGCTGGGCCGCATGGCCAACCCGGCC               CGCTCCCCGTACTGCATCACCAAGTTCGGGGTAGAGGCTTTCTCGGACTGCCTGCGCTATGAGATGTA               CCCCCTGGGCGTGAAGGTCAGCGTGGTGGAGCCCGGCAACTTCATCGCTGCCACCAGCCTTTACAGCC               CTGAGAGCATTCAGGCCATCGCCAAGAAGATGTGGGAGGAGCTGCCTGAGGTCGTGCGCAAGGACTAC               GGCAAGAAGTACTTTGATGAAAAGATCGCCAAGATGGAGACCTACTGCAGCAGTGGCTCCACAGACAC               GTCCCCTGTCATCGATGCTGTCACACACGCCCTGACCGCCACCACCCCCTACACCCGCTACCACCCCA               TGGACTACTACTGGTGGCTGCGAATGCAGATCATGACCCACTTGCCTGGAGCCATCTCCGACATGATC               TACATCCGC TGA   AGAGTCTCGCTGTGGCCTCTGTCAGGGATTCCTGGTGGAAGGGGAGGGGAGGGAGG                   AACCCATATA                                       NOV9b, CG56001-02   SEQ ID NO: 32   343 aa   MW at 38156.7kD       Protein Sequence                 MLATRLSRPLSRLPGKTLSACDRENGARRPLLLGSTSFIPIGRRTYASAAEPVGSKAVLVTGCDSGFG               FSLAKHLHSKGFLVFAGCLMKDKGHDGVKELDSLNSDRLRTVQLNVCSSEEVEKVVEIVRSSLKDPEK               GMWGLVNNAGISTFGEVEFTSLETYKQVAEVNLWGTVRMTKSFLPLIRRAKGRVVNISSMLGRMANPA               RSPYCITKFGVEAFSDCLRYEMYPLGVKVSVVEPGNFIAATSLYSPESIQAIAKKMWEELPEVVRKDY               GKKYFDEKIAKMETYCSSGSTDTSPVIDAVTHALTATTPYTRYHPMDYYWWLRMQIMTHLPGAISDMI               YIR                  
 
     [0395] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 9B.  
               TABLE 9B                       Comparison of the NOV9 protein sequences.                                        NOV9a   MLATRLSRPLSRLPGKTLSACDRENGARRPLLLGSTSFIPIGRRTYASAAEPVSGKAVLV       NOV9b   MLATRLSRPLSRLPGKTLSACDRENGARRPLLLGSTSFIPIGRRTYASAAEPVGSKAVLV               NOV9a   TGCDSGFGFSLAKHLHSKGFLVFAGCLMKDKGHDGVKELDSLNSDRLRTVQLNVCSSEEV       NOV9b   TGCDSGFGFSLAKHLHSKGFLVFAGCLMKDKGHDGVKELDSLNSDRLRTVQLNVCSSEEV               NOV9a   EKVVEIVRSSLKDPEKGMWGLVNNAGISTFGEVEFTSLETYKQVAEVNLWGTVRMTKSFL       NOV9b   EKVVEIVRSSLKDPEKGMWGLVNNAGISTFGEVEFTSLETYKQVAEVNLWGTVRMTKSFL               NOV9a   PLIRRAKGRVVNISSMLGRMANPARSPYCITKFGVEAFSDCLRYEMYPLGVKVSVVEPGN       NOV9b   PLIRRAKGRVVNISSMLGRMANPARSPYCITKFGVEAFSDCLRYEMYPLGVKVSVVEPGN               NOV9a   FIAATSLYSPESIQAIAKKMWEELPEVVRKDYGKKYFDEKIAKMETYCSSGSTDTSPVID       NOV9b   FIAATSLYSPESIQAIAKKMWEELPEVVRKDYGKKYFDEKIAKMETYCSSGSTDTSPVID               NOV9a   AVTHALTATTPYTRYHPMDYYWWLRMQIMTHLPGAISDMIYIR       NOV9b   AVTHALTATTPYTRYHPMDYYWWLRMQIMTHLPGAISDMIYIR               NOV9a   (SEQ ID NO: 30)       NOV9b   (SEQ ID NO: 32)                  
 
     [0396] Further analysis of the NOV9a protein yielded the following properties shown in Table 9C.  
               TABLE 9C                       Protein Sequence Properties NOV9a                                        SignalP analysis:   Cleavage site between residues 13 and 14       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 8; pos. chg 2; neg. chg 0           H-region: length 3; peak value −7.47           PSG score: −11.88           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −5.98           possible cleavage site: between 43 and 44           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 0           number of TMS(s) . . . fixed           5.36 (at 56) Likelihood = PERIPHERAL           ALOM score: 5.36 (number of TMSs: 0)           MITDISC: discrimination of mitochondrial targeting seq                                     R content:    3   Hyd Moment (75):   8.06           Hyd Moment (95):   10.84   G content:   1           D/E content:    1   S/T content:   5                         Score: −0.40           Gavel: prediction of cleavage sites for mitochondrial preseq           R-3 motif at 47 RRTY|A           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: PLIRRAK (3) at 181           bipartite: none           content of basic residues: 12.8%           NLS Score: −0.22           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals:           XXRR-like motif in the N-terminus: LATR           none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 76.7           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           78.3%: mitochondrial           13.0%: cytoplasmic            8.7%: nuclear           &gt;&gt; prediction for CG56001-01 is mit (k = 23)                  
 
     [0397] A search of the NOV9a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 9D.  
               TABLE 9D                          Geneseq Results for NOV9a                                         NOV9a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABP53584   Human NOV14a protein SEQ ID   1 . . . 343    343/343 (100%)   0.0           NO: 32 -  Homo sapiens , 343 aa.   1 . . . 343    343/343 (100%)           [WO200262999-A2, 15 AUG.           2002]       ABP53584   Human NOV14a protein SEQ ID   1 . . . 343    343/343 (100%)   0.0           NO: 32 -  Homo sapiens , 343 aa.   1 . . . 343    343/343 (100%)           [WO200262999-A2, 15 AUG.           2002]       ABP53585   Human NOV14b protein SEQ   1 . . . 343   341/343 (99%)   0.0           ID NO: 34 -  Homo sapiens , 343   1 . . . 343   341/343 (99%)           aa. [WO200262999-A2, 15           AUG. 2002]       ABP53585   Human NOV14b protein SEQ   1 . . . 343   341/343 (99%)   0.0           ID NO: 34 -  Homo sapiens , 343   1 . . . 343   341/343 (99%)           aa. [WO200262999-A2, 15           AUG. 2002]       AAM78804   Human protein SEQ ID NO   1 . . . 343   341/343 (99%)   0.0           1466 -  Homo sapiens , 343 aa.   1 . . . 343   341/343 (99%)           [WO200157190-A2, 09 AUG.           2001]                  
 
     [0398] In a BLAST search of public sequence databases, the NOV9a protein was found to have homology to the proteins shown in the BLASTP data in Table 9E.  
               TABLE 9E                          Public BLASTP Results for NOV9a                                         NOV9a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q02338   D-beta-hydroxybutyrate    1 . . . 343   341/343 (99%)   0.0           dehydrogenase, mitochondrial    1 . . . 343   341/343 (99%)           precursor (EC 1.1.1.30) (BDH) (3-           hydroxybutyrate dehydrogenase) -             Homo sapiens  (Human), 343 aa.       A42845   3-hydroxybutyrate dehydrogenase   11 . . . 343   319/333 (95%)   0.0           (EC 1.1.1.30) - human, 343 aa   11 . . . 343   321/333 (95%)           (fragment).       P29147   D-beta-hydroxybutyrate    1 . . . 342   297/342 (86%)   e−174           dehydrogenase, mitochondrial    2 . . . 343   313/342 (90%)           precursor (EC 1.1.1.30) (BDH) (3-           hydroxybutyrate dehydrogenase) -             Rattus norvegicus  (Rat), 344 aa.       AAH43683   Hypothetical protein -  Mus      1 . . . 342   297/342 (86%)   e−174             musculus  (Mouse), 343 aa.    1 . . . 342   313/342 (90%)       Q8BK53   D-beta-hydroxybutyrate    1 . . . 342   295/342 (86%)   e−173           dehydrogenase -  Mus musculus      1 . . . 342   312/342 (90%)           (Mouse), 343 aa.                  
 
     [0399] PFam analysis predicts that the NOV9a protein contains the domains shown in the Table 9F.  
               TABLE 9F                          Domain Analysis of NOV9a                                             Identities/                       Similarities for           Pfam   NOV9a Match   the Matched   Expect           Domain   Region   Region   Value                       adh_short   54 . . . 336   80/291 (27%)   7.9e−79                   235/291 (81%)                       
 
     Example 10  
     [0400] The NOV10 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 10A.  
               TABLE 10A                       NOV10 Sequence Analysis                                            NOV10a, CG56151-01   SEQ ID NO: 33   3168 bp       DNA Sequence   ORF Start: ATG at 39   ORF Stop: end of sequence                   CACAAGACCTGGAATTGACAGGACTCCCAACTAGTACA   ATG ACAGAAGATAAGGTCACTGGGACCCTG               GTTTTCACTGTCATCACTGCTGTGCTGGGTTCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGC               ACCTCAACAGGTAATAATATCTCACTATAGACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTA               TCAACAACTATGTTATCAACAGTACAGATGAACTGCCCACAATCTCATACTCAATGAACCCAAAACCA               ACCCCTTGGGCTGAGGAAGAGACTGTGGCAGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCTGT               ATCCAGCTTTGCAGTTGGTGGAATGACTGCATCATTCTTTGGTGGGTGGCTTGGGGACACACTTGGAA               GAATCAAAGCCATGTTAGTAGCAAACATTCTGTCATTAGTTGGAGCTCTCTTGATGGGGTTTTCAAAA               TTGGGACCATCTCATATACTTATAATTGCTGGAAGAAGCATATCAGGACTATATTGTGGGCTAATTTC               AGGCCTGGTTCCTATGTATATCGGTGAAATTGCTCCAACCGCTCTCAGGGGAGCACTTGGCACTTTTC               ATCAGCTGGCCATCGTCACGGGCATTCTTATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAAT               TATGATCTGTGGCACATCCTGCTTGGCCTGTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTT               TTTCTGTCCAGAAAGCCCCAGATACCTTTACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAAGCT               TGAAAAGACTCAGAGGATATGATGATGTCACCAAAGATATTAATGAAATGAGAAAAGAAAGAGAAGAA               GCATCGAGTGAGCAGAAAGTCTCTATAATTCAGCTCTTCACCAATTCCAGCTACCGACAGCCTATTCT               AGTGGCACTGATGCTGCATGTGGCTCAGCAATTTTCCGGAATCAATGGCATTTTTTACTACTCAACCA               GCATTTTTCAGACGGCTGGTATCAGCAAACCTGTTTATGCAACCATTGGAGTTGGCGCTGTAAACATG               GTTTTCACTGCTGTCTCTGTATTCCTTGTGGAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAAT               GAGTGGGATGTTTGTTTGTGCCATCTTCATGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGA               TGAGTTATGTGAGCATGATAGCCATCTTCCTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATC               CCCTGGTTCATGGTGGCTGAGTTTTTCAGTCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCATT               CAGCAATTGGACCTGCAATTTCATTGTAGCTCTGTGTTTCCAGTACATTGCGGACTTCTGTGGACCTT               ATGTGTTTTTCCTCTTTGCTGGAGTGCTCCTGGCCTTTACCCTGTTCACATTTTTTAAAGTTCCAGAA               ACCAAAGGAAAGTCTTTTGAGGAAATTGCTGCAGAATTCCAAAAGAAGAGTGGCTCAGCCCACAGGCC               AAAAGCTGCTGTAGAAATGAAATTCCTAGGAGCTACAGAGACTGTG TAA   AAAAAAACCCTGCTTTTT                   GACATGAACAGAAACAATAAGGGAACCGTCTGTTTTTAAATGATGATTCCTTGAGCATTTTATATCCA                   CATCTTTAAGTATTGTTTTATTTTTATGTGCTCTCATCAGAAATGTCATCAAATATTACCAAAAAAGT                   ATTTTTTTAAGTTAGAGAATATATTTTTGATGGTAAGACTGTAATTAAGTAAACCAAAAAGGCTAGTT                   TATTTTGTTACACTAAAGGGCAGGTGGTTCTAATATTTTTAGCTCTGTTCTTTATAACAAGGTTCTTC                   TAAAATTGAAGAGATTTCAACATATCATTTTTTTAACACATAACTAGAAACCTGAGGATGCAACAAAT                   ATTTATATATTTGAATATCATTAAATTGGAATTTTCTTACCCATATATCTTATGTTAAAGGAGATATG                   GCTAGTGGCAATAAGTTCCATGTTAAAATAGACAACTCTTCCATTTATTGCACTCAGCTTTTTTCTTG                   AGTACTAGAATTTGTATTTTGCTTAAAATTTTACTTTTGTTCTGTATTTTCATGTGGAATGGATTATA                   GAGTATACTAAAAAATGTCTATAGAGAAAAACTTTCATTTTTGGTAGGCTTATCAAAATCTTTCAGCA                   CTCAGAAAAGAAAACCATTTTAGTTCCTTTATTTAATGGCCAAATGGTTTTTGCAAGATTTAACACTA                   AAAAGGTTTCACCTGATCATATAGCGTGGGTTATCAGTTAACATTAACATCTATTATAAAACCATGTT                   GATTCCCTTCTGGTACAATCCTTTGAGTTATAGTTTGCTTTGCTTTTTAATTGAGGACAGCCTGGTTT                   TCACATACACTCAAACAATCATGAGTCAGACATTTGGTATATTACCTCAAATTCCTAATAAGTTTGAT                   CAAATCTAATGTAAGAAAATTTGAAGTAAAGGATTGATCACTTTGTTAAAAATATTTTCTGAATTATT                   ATGTCTCAAAATAAGTTGAAAAGGTAGGGTTTGAGGATTCCTGAGTGTGGGCTTCTGAAACTTCATAA                   ATGTTCAGCTTCAGACTTTTATCAAAATCCCTATTTAATTTTCCTGGAAAGACTGATTGTTTTATGGT                   GTGTTCCTAACATAAAATAATCGTCTCCTTTGACATTTCCTTCTTTGTCTTAGCTGTATACAGATTCT                   AGCCAAACTATTCTATGGCCATTACTAACACGCATTGTACACTATCTATCTGCCTTTACCTACATAGG                   CAAATTGGAAATACACAGATGATTAAACAGACTTTAGCTTACAGTCAATTTTACAATTATGGAAATAT                   AGTTCTGATGGGTCCCAAAAGCTTAGCAGGGTGCTAACGTATCTCTAGGCTGTTTTCTCCACCAACTG                   GAGCACTGATCAATCCTTCTTATGTTTGCTTTAATGTGTATTGAAGAAAAGCACTTTTTAAAAAGTAC                   TCTTTAAGAGTGAAATAATTAAAAACCACTGAACATTTGCTTTGTTTTCTAAAGTTGTTCACATATAT                   GTAATTTAGCAGTCCAAAGAACAAGAAATTGTTTCTTTTC                                       NOV10a, CG56151-01   SEQ ID NO: 34   524 aa   MW at 57488.8kD       Protein Sequence                 MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYVINSTDELP               TISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGWLGDTLGRIKAMLVANILSL               VGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGILISQ               IIGLEFILGNYDLWHILLGLSGVRAILQSLLLFFCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKD               INEMRKEREEASSEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVY               ATIGVGAVNMVFTAVSVFLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFV               SFFEIGPGPIPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAF               TLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV                                 NOV10b, 246837923   SEQ ID NO: 35   1587 bp       DNA Sequence   ORF Start: at 1   ORF Stop: end of sequence                   GGA TCCACCATGACAGAAGATAAGGTCACTGGGACCCTGGTTTTCACTGTCATCACTGCTGTGCTGGG               TTCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGCACCTCAACAGGTAATAATATCTCACTATA               GACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTATCAACAACTATGTTATCAACAGTACAGAT               GAACTGCCCACAATCTCATACTCAATGAACCCAAAACCAACCCCTTGGGCTGAGGAAGAGACTGTGGC               AGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCTGTATCCAGCTTTGCAGTTGGTGGAATGATTG               CATCATTCTTTGGTGGGTGGCTTGGGGACACACTTGGAAGAATCAAAGCCATGTTAGTAGCAAACATT               CTGTCATTAGTTGGAGCTCTCTTGATGGGGTTTTCAAAATTGGGACCATCTCATATACTTATAATTGC               TGGAAGAAGCATATCAGGACTATATTGTGGGCTAATTTCAGGCCTGGTTCCTATGTATATCGGTGAAA               TTGCTCCAACCGCTCTCAGGGGAGCACTTGGCACTTTTCATCAGCTGGCCATCGTCACGGGCATTCTT               ATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAATTATGATCTGTGGCACATCCTGCTTGGCCT               GTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTTTTTCTGTCCAGAAAGCCCCAGATACCTTT               ACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAATCTTGAAAAGACTCAGAGGATATGATGATGTC               ACCAAAGATATTAATGAAATGAGAAAAGAAAGAGAAGAAGCATCGAGTGAGCAGAAAGTCTCTATAAT               TCAGCTCTTCACCAATTCCAGCTACCGACAGCCTATTCTAGTGGCACTGATGCTGCATGTGGCTCAGC               AATTTTCCGGAATCAATGGCATTTTTTACTACTCAACCAGCATTTTTCAGACGGCTGGTATCAGCAAA               CCTGTTTATGCAACCATTGGAGTTGGCGCTGTAAACATGGTTTTCACTGCTGTCTCTGTATTCCTTGT               GGAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAATGAGTGGGATGTTTGTTTGTGCCATCTTCA               TGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGATGAGTTATGTGAGCATGATAGCCATCTTC               CTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATCCCCTGGTTCATGGTGGCTGAGTTTTTCAG               TCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCATTCAGCAATTGGACCTGCAATTTCATTGTAG               CTCTGTGTTTCCAGTACATTGCGGACTTCTGTGGACCTTATGTGTTTTTCCTCTTTGCTGGAGTGCTC               CTGGCCTTTACCCTGTTTACATTTTTTAAAGTTCCAGAAACCAAAGGAAAGTCTTTTGAGGAAATTGC               TGCAGAATTCCAAAAGAAGAGTGGCTCAGCCCACAGGCCAAAAGCTGCTGTAGAAATGAAATTCCTAG               GAGCTACAGAGACTGTGCTCGAG                                     NOV10b, 246837923   SEQ ID NO: 36   529 aa   MW at 58014.4kD       Protein Sequence                 GSTMTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYVINSTD               ELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMIASFFGGWLGDTLGRIKAMLVANI               LSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGIL               ISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLFFCPESPRYLYIKLDEEVKAKQILKRLRGYDDV               TKDINEMRKEREEASSEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISK               PVYATIGVGAVNMVFTAVSVFLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIF               LFVSFFEIGPGPIPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVL               LAFTLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETVLE                                 NOV10c, 246837941   SEQ ID NO: 37   1587 bp       DNA Sequence   ORF Start: at 1   ORF Stop: end of sequence                   GGA TCCACCATGACAGAAGATAAGGTCACTGGGACCCTGGTTTTCACTGTCATCACTGCTGTGCTGGG               TTCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGCACCTCAACAGGTAATAATATCTCACTATA               GACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTATCAACAACTATGTTATCAACAGTACAGAT               GAACTGCCCACAATCTCATACTCAATGAACCCAAAACCAACCCCTTGGGCTGAGGAAGAGACTGTGGC               AGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCTGTATCCAGCTTTGCAGTTGGTGGAATGATTG               CATCATTCTTTGGTGGGTGGCTTGGGGACACACTTGGAAGAATCAAAGCCATGTTAGTAGCAAACATT               CTGTCATTAGTTGGAGCTCTCTTGATGGGGTTTTCAAAATTGGGACCATCTCATATACTTATAATTGC               TGGAAGAAGCATATCAGGACTATATTGTGGGCTAATTTCAGGCCTGGTTCCTATGTATATCGGTGAAA               TTGCTCCAACCGCTCTCAGGGGAGCACTTGGCACTTTTCATCAGCTGGCCATCGTCACGGGCATTCTT               ATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAATTATGATCTGTGGCACATCCTGCTTGGCCT               GTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTTTTTCTGTCCAGAAAGCCCCAGATACCTTT               ACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAAGCTTGAAAAGACTCAGAGGATATGATGATGTC               ACCAAAGATATTAATGAAATGAGAAAAGAAAGAGAAGAAGCATCGAGTGAGCAGAAAGTCTCTATAAT               TCAGCTCTTCACCAATTCCAGCTACCGACAGCCTATTCTAGTGGCACTGATGCTGCATGTGGCTCAGC               AATTTTCCGGAATCAATGGCATTTTTTACTACTCAACCAGCATTTTTCAGACGGCTGGTATCAGCAAA               CCTGTTTATGCAACCATTGGAGTTGGCGCTGTAAACATCGTTTTCACTGCTGTCTCTGTATTCCTTGT               GGAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAATGAGTGGGATGTTTGTTTGTGCCATCTTCA               TGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGATGAGTTATGTGAGCATGATAGCCATCTTC               CTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATCCCCTGGTTCATGGTGGCTGAGTTTTTCAG               TCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCATTCAGCAATTGGACCTGCAATTTCATTGTAG               CTCTGTGTTTCCAGTACATTGCGGACTTCTGTGGACCTTATGTGTTTTTCCTCTTTGCTGGAGTGCTC               CTGGCCTTTACCCTGTTTACATTTTTTAAAGTTCCAGAAACCAAAGGAAAGTCTTTTGAGGAAATTGC               TGCAGAATTCCAAAAGAAGAGTGGCTCAGCCCACAGGCCAAAAGCTGCTGTAGAAATGAAATTCCTAG               GAGCTACAGAGACTGTGCTCGAG                                     NOV10c, 246837941   SEQ ID NO: 38   529 aa   MW at 57988.4kD       Protein Sequence                 GSTMTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYVINSTD               ELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMIASFFGGWLGDTLGRIKAMLVANI               LSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGIL               ISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLFFCPESPRYLYIKLDEEVKAKQSLKRLRGYDDV               TKDINEMRKEREEASSEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISK               PVYATIGVGAVNMVFTAVSVFLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIF               LFVSFFEIGPGPIPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVL               LAFTLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETVLE                                 NOV10d, CG56151-02   SEQ ID NO: 39   1664 bp       DNA Sequence   ORF Start: ATG at 39   ORF Stop: end of sequence                   CACAAGACCTGGAATTGACAGGACTCCCAACTAGTACA   ATG ACAGAAGATAAGGTCACTGGGACCCTG               GTTTTCACTGTCATCACTGCTGTGCTGGGTTCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGC               ACCTCAACAGGTAATAATATCTCACTATAGACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTA               TCAACAACTATGTTATCAACAGTACAGATGAACTGCCCACAATCTCATACTCAATGAACCCAAAACCA               ACCCCTTGGGCTGAGGAAGAGACTGTGGCAGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCTGT               ATCCAGCTTTGCAGTTGGTGGAATGACTGCATCATTCTTTGGTGGGTGGCTTGGGGACACACTTGGAA               GAATCAAAGCCATGTTAGTAGCAAACATTCTGTCATTAGTTGGAGCTCTCTTGATGGGGTTTTCAAAA               TTGGGACCATCTCATATACTTATAATTGCTGGAAGAAGCATATCAGGACTATATTGTGGGCTAATTTC               AGGCCTGGTTCCTATGTATATCGGTGAAATTGCTCCAACCGCTCTCAGGGGAGCACTTGGCACTTTTC               ATCAGCTGGCCATCGTCACGGGCATTCTTATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAAT               TATGATCTGTGGCACATCCTGCTTGGCCTGTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTT               TTTCTGTCCAGAAAGCCCCAGATACCTTTACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAAGCT               TGAAAAGACTCAGAGGATATGATGATGTCACCAAAGATATTAATGAAATGAGAAAAGAAAGAGAAGAA               GCATCGAGTGAGCAGAAAGTCTCTATAATTCAGCTCTTCACCAATTCCAGCTACCGACAGCCTATTCT               AGTGGCACTGATGCTGCATGTGGCTCAGCAATTTTCCGGAATCAATGGCATTTTTTACTACTCAACCA               GCATTTTTCAGACGGCTGGTATCAGCAAACCTGTTTATGCAACCATTGGAGTTGGCGCTGTAAACATG               GTTTTCACTGCTGTCTCTGTATTCCTTGTGGAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAAT               GAGTGGGATGTTTGTTTGTGCCATCTTCATGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGA               TGAGTTATGTGAGCATGATAGCCATCTTCCTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATC               CCCTGGTTTATGGTGGCTGAGTTTTTCAGTCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCATT               CAGCAATTGGACCTGCAATTTCATTGTAGCTCTGTGTTTCCAGTACATTGCGGACTTCTGTGGACCTT               ATGTGTTTTTCCTCTTTGCTGGAGTGCTCCTGGCCTTTACCCTGTTTACATTTTTTAAAGTTCCAGAA               ACCAAAGGAAAGTCTTTTGAGGAAATTGCTGCAGAATTCCAAAAGAAGAGTGGCTCAGCCCACAGGCC               AAAAGCTGCTGTAGAAATGAAATTCCTAGGAGCTACAGAGACTGTG TAA   AAAAAAAACCCTGCTTTTT                   GGCATGAACAGAAACAATAAGGGAACCGTCTG                                       NOV10d, CG56151-02   SEQ ID NO: 40   524 aa   MW at 57488.8kD       Protein Sequence                 MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYVINSTDELP               TISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGWLGDTLGRIKAMLVANILSL               VGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGILISQ               IIGLEFILGNYDLWHILLGLSGVRAILQSLLLFFCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKD               INEMRKEREEASSEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVY               ATIGVGAVNMVFTAVSVFLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFV               SFFEIGPGPIPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAF               TLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV                                 NOV10e, CG56151-03   SEQ ID NO: 41   1587 bp       DNA Sequence   ORF Start: ATG at 10   ORF Stop: end of sequence                   GGATCCACC   ATG ACAGAAGATAAGGTCACTGGGACCCTGGTTTTCACTGTCATCACTGCTGTGCTGGG               TTCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGCACCTCAACAGGTAATAATATCTCACTATA               GACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTATCAACAACTATGTTATCAACAGTACAGAT               GAACTGCCCACAATCTCATACTCAATGAACCCAAAACCAACCCCTTGGGCTGAGGAAGAGACTGTGGC               AGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCTGTATCCAGCTTTGCAGTTGGTGGAATGACTG               CATCATTCTTTGGTGGGTGGCTTGGGGACACACTTGGAAGAATCAAAGCCATGTTAGTAGCAAACATT               CTGTCATTAGTTGGAGCTCTCTTGATGGGGTTTTCAAAATTGGGACCATCTCATATACTTATAATTGC               TGGAAGAAGCATATCAGGACTATATTGTGGGCTAATTTCAGGCCTGGTTCCTATGTATATCGGTGAAA               TTGCTCCAACCGCTCTCAGGGGAGCACTTGGCACTTTTCATCAGCTGGCCATCGTCACGGGCATTCTT               ATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAATTATGATCTGTGGCACATCCTGCTTGGCCT               GTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTTTTTCTGTCCAGAAAGCCCCAGATACCTTT               ACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAAGCTTGAAAAGACTCAGAGGATATGATGATGTC               ACCAAAGATATTAATGAAATGAGAAAAGAAAGAGAAGAAGCATCGAGTGAGCAGAAAGTCTCTATAAT               TCAGCTCTTCACCAATTCCAGCTACCGACAGCCTATTCTAGTGGCACTGATGCTGCATGTGGCTCAGC               AATTTTCCGGAATCAATGGCATTTTTTACTACTCAACCAGCATTTTTCAGACGGCTGGTATCAGCAAA               CCTGTTTATGCAACCATTGGAGTTGGCGCTGTAAACATGGTTTTCACTGCTGTCTCTGTATTCCTTGT               GGAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAATGAGTGGGATGTTTGTTTGTGCCATCTTCA               TGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGATGAGTTATGTGAGCATGATAGCCATCTTC               CTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATCCCCTGGTTTATGGTGGCTGAGTTTTTCAG               TCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCATTCAGCAATTGGACCTGCAATTTCATTGTAG               CTCTGTGTTTCCAGTACATTGCGGACTTCTGTGGACCTTATGTGTTTTTCCTCTTTGCTGGAGTGCTC               CTGGCCTTTACCCTGTTTACATTTTTTAAAGTTCCAGAAACCAAAGGAAAGTCTTTTGAGGAAATTGC               TGCAGAATTCCAAAAGAAGAGTGGCTCAGCCCACAGGCCAAAAGCTGCTGTAGAAATGAAATTCCTAG               GAGCTACAGAGACTGTG CTC   GAG                                       NOV10e, CG56151-03   SEQ ID NO: 42   524 aa   MW at 57488.8kD       Protein Sequence                 MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYVINSTDELP               TISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGWLGDTLGRIKAMLVANILSL               VGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGILISQ               IIGLEFILGNYDLWHILLGLSGVRAILQSLLLFFCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKD               INEMRKEREEASSEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVY               ATIGVGAVNMVFTAVSVFLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFV               SFFEIGPGPIPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAF               TLFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV                                 NOV10f, CG56151-04   SEQ ID NO: 43   1473 bp       DNA Sequence   ORF Start: at 7   ORF Stop: end of sequence                   GGATCC   ACT GTCATCACTGCTGTGCTGGGTTCCTTCCAGTTTGGATATGACATTGGTGTGATCAATGC               ACCTCAACAGGTAATAATATCTCACTATAGACATGTTTTGGGTGTTCCACTGGATGACCGAAAAGCTA               TCAACAACTATGTTATCAACAGTACAGATGAACTGCCCACAATCTCATACTCAATGAACCCAAAACCA               ACCCCTTGGGCTGAGGAAGAGACTGTGGCAGCTGCTCAACTAATCACCATGCTCTGGTCCCTGTCTGT               ATCCAGCTTTGCAGTTGGTGGAATGACTGCATCATTCTTTGGTGGGTGGCTTGGGGACACACTTGGAA               GAATCAAAGCCATGTTAGTAGCAAACATTCTGTCATTAGTTGGAGCTCTCTTGATGGGGTTTTCAAAA               TTGGGACCATCTCATATACTTATAATTGCTGGAAGAAGCATATCAGGACTATATTGTGGGCTAATTTC               AGGCCTGGTTCCTATGTATATCGGTGAAATTGCTCCAACCGCTCTCAGGGGAGCACTTGGCACTTTTC               ATCAGCTGGCCATCGTCACGGGCATTCTTATTAGTCAGATTATTGGTCTTGAATTTATCTTGGGCAAT               TATGATCTGTGGCACATCCTGCTTGGCCTGTCTGGTGTGCGAGCCATCCTTCAGTCTCTGCTACTCTT               TTTCTGTCCAGAAAGCCCCAGATACCTTTACATCAAGTTAGATGAGGAAGTCAAAGCAAAACAAAGCT               TGAAAAGACTCAGAGGATATGATGATGTCACCAAAGATATTAATGAAATGAGAAAAGAAAGAGAAGAA               GCATCGAGTGAGCAGAAAGTCTCTATAATTCAGCTCTTCACCAATTCCAGCTACCGACAGCCTATTCT               AGTGGCACTGATGCTGCATGTGGCTCAGCAATTTTCCGGAATCAATGGCATTTTTTACTACTCAACCA               GCATTTTTCAGACGGCTGGTATCAGCAAACCTGTTTATGCAACCATTGGAGTTGGCGCTGTAAACATG               GTTTTCACTGCTGTCTCTGTATTCCTTGTGGAGAAGGCAGGGCGACGTTCTCTCTTTCTAATTGGAAT               GAGTGGGATGTTTGTTTGTGCCATCTTCATGTCAGTGGGACTTGTGCTGCTGAATAAGTTCTCTTGGA               TGAGTTATGTGAGCATGATAGCCATCTTCCTCTTTGTCAGCTTCTTTGAAATTGGGCCAGGCCCGATC               CCCTGGTTTATGGTGGCTGAGTTTTTCAGTCAAGGACCACGTCCTGCTGCTTTAGCAATAGCTGCATT               CAGCAATTGGACCTGCAATTTCATTGTAGCTCTGTGTTTCCAGTACATTGCGGACTTCTGTGGACCTT               ATGTGTTTTTCCTCTTTGCTGGAGTGCTCCTGGCCTTTACCCTGTTTACATTTTTTAAAGTTCCAGAA               ACCAAAGGAAAGTCTTTTGAGGAAATTGCTGCAGAATTC CTC   GAG                                       NOV10f, CG56151-04   SEQ ID NO: 44   487 aa   MW at 53512.2kD       Protein Sequence                 TVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAINNYVINSTDELPTISYSMNPKPTP               WAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGWLGDTLGRIKAMLVANILSLVGALLMGFSKLG               PSHILIIAGRSISGLYCGLISGLVPMYIGEIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYD               LWHILLGLSGVRAILQSLLLFFCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEAS               SEQKVSIIQLFTNSSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVF               TAVSVFLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGPIPW               FMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFTLFTFFKVPETK               GKSFEEIAAEF                  
 
     [0401] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 10B.  
               TABLE 10B                       Comparison of the NOV10 protein sequences.                                        NOV10a   ---MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAIN       NOV10b   GSTMTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAIN       NOV10c   GSTMTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAIN       NOV10d   ---MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAIN       NOV10e   ---MTEDKVTGTLVFTVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAIN       NOV10f   ---------------TVITAVLGSFQFGYDIGVINAPQQVIISHYRHVLGVPLDDRKAIN               NOV10a   NYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGW       NOV10b   NYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMIASFFGGW       NOV10c   NYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMIASFFGGW       NOV10d   NYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGW       NOV10e   NYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGW       NOV10f   NYVINSTDELPTISYSMNPKPTPWAEEETVAAAQLITMLWSLSVSSFAVGGMTASFFGGW               NOV10a   LGDTLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIG       NOV10b   LGDTLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIG       NOV10c   LGDTLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIG       NOV10d   LGDTLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIG       NOV10e   LGDTLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIG       NOV10f   LGDTLGRIKAMLVANILSLVGALLMGFSKLGPSHILIIAGRSISGLYCGLISGLVPMYIG               NOV10a   EIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLF       NOV10b   EIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLF       NOV10c   EIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLF       NOV10d   EIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLF       NOV10e   EIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLF       NOV10f   EIAPTALRGALGTFHQLAIVTGILISQIIGLEFILGNYDLWHILLGLSGVRAILQSLLLF               NOV10a   FCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTN       NOV10b   FCPESPRYLYIKLDEEVKAKQILKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTN       NOV10c   FCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTN       NOV10d   FCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTN       NOV10e   FCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTN       NOV10f   FCPESPRYLYIKLDEEVKAKQSLKRLRGYDDVTKDINEMRKEREEASSEQKVSIIQLFTN               NOV10a   SSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSV       NOV10b   SSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSV       NOV10c   SSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSV       NOV10d   SSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSV       NOV10e   SSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSV       NOV10f   SSYRQPILVALMLHVAQQFSGINGIFYYSTSIFQTAGISKPVYATIGVGAVNMVFTAVSV               NOV10a   FLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGP       NOV10b   FLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGP       NOV10c   FLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGP       NOV10d   FLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGP       NOV10e   FLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGP       NOV10f   FLVEKAGRRSLFLIGMSGMFVCAIFMSVGLVLLNKFSWMSYVSMIAIFLFVSFFEIGPGP               NOV10a   IPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFT       NOV10b   IPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFT       NOV10c   IPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFT       NOV10d   IPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFT       NOV10e   IPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFT       NOV10f   IPWFMVAEFFSQGPRPAALAIAAFSNWTCNFIVALCFQYIADFCGPYVFFLFAGVLLAFT               NOV10a   LFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV--       NOV10b   LFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETVLE       NOV10c   LFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETVLE       NOV10d   LFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV--       NOV10e   LFTFFKVPETKGKSFEEIAAEFQKKSGSAHRPKAAVEMKFLGATETV--       NOV10f   LFTFFKVPETKGKSFEEIAAEF---------------------------               NOV10a   (SEQ ID NO: 34)       NOV10b   (SEQ ID NO: 36)       NOV10c   (SEQ ID NO: 38)       NOV10d   (SEQ ID NO: 40)       NOV10e   (SEQ ID NO: 42)       NOV10f   (SEQ ID NO: 44)                  
 
     [0402] Further analysis of the NOV10a protein yielded the following properties shown in Table 10C.  
               TABLE 10C                       Protein Sequence Properties NOV10a                                        SignalP analysis:   Cleavage site between residues 21 and 22       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 5; pos. chg 1; neg. chg 2           H-region: length 21; peak value 0.00           PSG score: −4.40           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −2.99           possible cleavage site: between 20 and 21           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 10                                         INTEGRAL   Likelihood =   −2.66   Transmembrane    6-22           INTEGRAL   Likelihood =   −5.36   Transmembrane   128-144           INTEGRAL   Likelihood =   −1.44   Transmembrane   152-168           INTEGRAL   Likelihood =   −4.88   Transmembrane   196-212           INTEGRAL   Likelihood =   −2.28   Transmembrane   220-236           INTEGRAL   Likelihood =   −4.09   Transmembrane   343-356           INTEGRAL   Likelihood =   −6.85   Transmembrane   374-390           INTEGRAL   Likelihood =   −3.66   Transmembrane   398-414           INTEGRAL   Likelihood =    0.10   Transmembrane   436-452           INTEGRAL   Likelihood =   −8.12   Transmembrane   465-481           PERIPHERAL   Likelihood =    0.90 (at 92)                         ALOM score: −8.12 (number of TMSs: 10)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 13           Charge difference: −0.5 C(−0.5)-N( 0.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                         R content:   0   Hyd Moment (75):   9.24               Hyd Moment (95):   7.63   G content:   0           D/E content:   2   S/T content:   1                         Score: −6.13           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 7.3%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions                                 266   D   0.57           267   D   0.57           268   V   0.57           269   T   0.57           270   K   0.57           271   D   0.57           272   I   0.57           273   N   0.57           274   E   0.57           275   M   0.57           276   R   0.57           277   K   0.57           278   E   0.57           279   R   0.57           280   E   0.57           281   E   0.57           282   A   0.57           283   S   0.57           284   S   0.57           285   E   0.57           286   Q   0.57           287   K   0.57           288   V   0.57           289   S   0.57           290   I   0.57           291   I   0.57           292   Q   0.57           293   L   0.57                         total: 28 residues           Final Results (k = 9/23):           66.7%: endoplasmic reticulum           22.2%: mitochondrial           11.1%: nuclear           &gt;&gt; prediction for CG56151-01 is end (k = 9)                  
 
     [0403] A search of the NOV10a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 10D.  
               TABLE 10D                          Geneseq Results for NOV10a                                         NOV10a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABB05602   Human glucose transporter   1 . . . 524    524/524 (100%)   0.0           protein SEQ ID NO: 12 -  Homo     1 . . . 524    524/524 (100%)             sapiens , 524 aa. [US6323002-B1,           27 NOV. 2001]       ABG76953   Human protein, homologous to   1 . . . 524    524/524 (100%)   0.0           glucose transporter type 2,   1 . . . 524    524/524 (100%)           designated NOV5 -  Homo               sapiens , 524 aa. [WO200255705-           A2, 18 JUL. 2002]       AAW17836   Rat glucose transporter GLUT-2 -   1 . . . 524   427/524 (81%)   0.0           Rattus sp, 522 aa.   1 . . . 522   469/524 (89%)           [WO9715668-A2, 01 MAY           1997]       AAY27288   Glucose transporter protein   3 . . . 502   333/507 (65%)   0.0           GLUT2 -  Homo sapiens , 534 aa.   10 . . . 515    407/507 (79%)           [US5942398-A, 24 AUG. 1999]       AAB30522   Amino acid sequence of a   6 . . . 514   288/509 (56%)   e−162           consensus GLUT polypeptide -   10 . . . 483    372/509 (72%)           Synthetic, 493 aa. [US6136547-           A, 24 OCT. 2000]                  
 
     [0404] In a BLAST search of public sequence databases, the NOV10a protein was found to have homology to the proteins shown in the BLASTP data in Table 10E.  
               TABLE 10E                          Public BLASTP Results for NOV10a                                         NOV10a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               P11168   Solute carrier family 2, facilitated   1 . . . 524    524/524 (100%)   0.0           glucose transporter, member 2   1 . . . 524    524/524 (100%)           (Glucose transporter type 2, liver) -             Homo sapiens  (Human), 524 aa.       P14246   Solute carrier family 2, facilitated   1 . . . 524   429/524 (81%)   0.0           glucose transporter, member 2   1 . . . 523   471/524 (89%)           (Glucose transporter type 2, liver) -             Mus musculus  (Mouse), 523 aa.       P12336   Solute carrier family 2, facilitated   1 . . . 524   427/524 (81%)   0.0           glucose transporter, member 2   1 . . . 522   469/524 (89%)           (Glucose transporter type 2, liver) -             Rattus norvegicus  (Rat), 522 aa.       S06920   glucose transport protein, hepatic -   1 . . . 524   426/524 (81%)   0.0           mouse, 523 aa.   1 . . . 523   468/524 (89%)       Q90592   Solute carrier family 2, facilitated   3 . . . 502   333/506 (65%)   0.0           glucose transporter, member 2   10 . . . 514    407/506 (79%)           (Glucose transporter type 2, liver) -             Gallus gallus  (Chicken), 533 aa.                  
 
     [0405] PFam analysis predicts that the NOV10a protein contains the domains shown in the Table 10F.  
               TABLE 10F                          Domain Analysis of NOV10a                                             Identities/                   NOV10a   Similarities           Pfam   Match   for the   Expect           Domain   Region   Matched Region   Value                       OATP_C   10 . . . 394    70/474 (15%)   0.2                   251/474 (53%)           sugar_tr   13 . . . 499   208/521 (40%)   1.4e−201                   436/521 (84%)                      
 
     Example 11  
     [0406] The NOV11 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 11A.  
               TABLE 11A                       NOV11 Sequence Analysis                                            NOV11a, CG56155-02   SEQ ID NO: 45   2038 bp       DNA Sequence   ORF Start: ATG at 10   ORF Stop: end of sequence                   GTTTTCAGA   ATG ATTTTATTCAAGCAAGCAACTTATTTCATTTCCTTGTTTGCTACAGTTTCCTGTGG               ATGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGGATGTAGCTTCCATGTACACCCCAA               ATGCCCAATACTGCCAGATGAGGTGCACATTCCACCCAAGGTGTTTGCTATTCAGTTTTCTTCCAGCA               AGTTCAATCAATGACATGGAGAAAAGGTTTGGTTGCTTCTTGAAAGATAGTGTTACAGGAACCCTGCC               AAAAGTACATCGAACAGGTGCAGTTTCTGGACATTCCTTGAAGCAATGTGGTCATCAAATAAGTGCTT               GCCATCGAGACATTTATAAAGGAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGGTTAGCAGT               GTTGAAGAATGCCAAAAAAGGTGCACCAATAACATTCGCTGCCAGTTTTTTTCATATGCCACGCAAAC               ATTTCACAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTACAGTCCCGGAGGAACACCTACCGCTA               TAAAGGTGCTGAGTAACGTGGAATCTGGATTCTCACTGAAGCCCTGTGCCCTTTCAGAAATTGGTTGC               CACATGAACATCTTCCAGCATCTTGCGTTCTCAGATGTGGATGTTGCCAGGTTTCTCACTCCAGATGC               TTTTGTGTGTCGGACCATCTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATACAAATGTAT               GGAAAATCGAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAAGTTCCTCT               ACTCCTCAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAGAACTTTACCTGAACCCTG               CCATTCTAAAATTTACCCGGGAGTTGACTTTGGAGGAGAAGAATTGAATGTGACTTTTGTTAAAGGAG               TGAATGTTTGCCAAGAGACTTGCACAAAGATGATTCGCTGTCAGTTTTTCACTTATTCTTTACTCCCA               GAAGACTGTAAGGAAGAGAAGTGTAAGTGTTTCTTAAGATTATCTATGGATGGTTCTCCAACTAGGAT               TGCGTATGGGACACAAGGGAGCTCTGGTTACTCTTTGAGATTGTGTAACACTGGGGACAACGCTGTCT               GCACAACAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTGGCCCTGGCAG               GTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGCACCTGTGTGGAGGGTCACTCATAGGACACCAGTG               GGTCCTCACTGCTGCCCACTGCTTTGATGGGCTTCCCCTGCAGGATGTTTGGCGCATCTATAGTGGCA               TTTTAAATCTGTCAGACATTACAAAAGATACACCTTTCTCACAAATAAAAGAGATTATTATTCACCAA               AACTATAAAGTCTCAGAAGGGAATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTGAATTACAC               TGAATTCCAAAAACCAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAACTGTTGGG               TAACCGGATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAGGTAAATATTCCT               TTGGTAACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAATAACCCAACGGATGGTCTGTGC               TGGCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGGAGATTCAGGTGGTCCCTTAGTTTGCAAACACA               ACGGAATGTGGCGTTTGGTGGGCATCACCAGCTGGGGTGAAGGCTGTGCCCGCAGGGAGCAACCTGGT               GTCTACACCAAAGTCGCTGAGTACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGATGGAAAAGC               TCAGATGCAGTCACCAGCA TGA   GAAGCAGTCCAGAGTCTAGGCAATTTTTACAACCTGAGTTCAAGTC                   AAATTCTGAGCCTGGGGGGTCCTCATCTGCAAAGCATGAAGAGTGGCATCTTCTTTGCATCCTAAG                                       NOV11a, CG56155-02   SEQ ID NO: 46   638 aa   MW at 71401.1kD       Protein Sequence                 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSI               NDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEE               CQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMN               IFQHLAFSDVDVARFLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQ               ENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDC               KEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSL               QVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYK               VSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVT               NEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYT               KVAEYMDWILEKTQSSDGKAQMQSPA                                 NOV11b, 227803167   SEQ ID NO: 47   1869 bp       DNA Sequence   ORF Start: at 1   ORF Stop: end of sequence                   GGA TCCGGATGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGGATGTAGCTTCCATGTA               CACCCCAAATGCCCAATACTGCCAGATGAGGTGCACATTCCACCCAAGGTGTTTGCTATTCAGTTTTC               TTCCAGCAAGTTCAATCAATGACATGGAGAAAAGGTTTGGTTGCTTCTTGAAAGATAGTGTTACAGGA               ACCCTGCCAAAAGTACATCGAACAGGTGCAGTTTCTGGACATTCCTTGAAGCAATGTGGTCATCAAAT               AAGTGCTTGCCATCGAGACATTTATAAAGGAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGG               TTAGCAGTGTTGAAGAATGCCAAAAAAGGTGCACCAGTAACATTCGCTGCCAGTTTTTTTCATATGCC               ACGCAAACATTTCACAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTACAGTCCCGGAGGAACACC               TACCGCTATAAAGGTGCTGAGTAACGTGGAATCTGGATTCTCACTGAAGCCCTGTGCCCTTTCAGAAA               TTGGTTGCCACATGAACATCTTCCAGCATCTTGCGTTCTCAGATGTGGATGTTGCCAGGTTTCTCACT               CCAGATGCTTTTGTGTGTCGGACCATCTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATAC               AAATGTATGGAAAATCGAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAA               GTTCCTCTACTCCTCAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAGAACTTTACCT               GAACCCTGCCATTCTAAAATTTACCCGGGAGTTGACTTTGGAGGAGAAGAATTGAATGTGACTTTTGT               TAAAGGAGTGAATGTTTGCCAAGAGACTTGCACAAAGATGATTCGCTGTCAGTTTTTCACTTATTCTT               TACTCCCAGAAGACTGTAAGGAAGAGAAGTGTAAGTGTTTCTTAAGATTATCTATGGATGGTTCTCCA               ACTAGGATTGCGTATGGGACACAAGGGAGCTCTGGTTACTCTTTGAGATTGTGTAACACTGGGGACAA               CGCTGTCTGCACAACAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTGGC               CCTGGCAGGTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGCATCTGTGTGGAGGGTCACTCATAGGA               CACCAGTGGGTCCTCACTGCTGCCCACTGCTTTGATGGGCTTCCCCTGCAGGATGTTTGGCGCATCTA               TAGTGGCATTTTAAATCTGTCAGACATTACAAAAGATACACCTTTCTCACAAATAAAAGAGATTATTA               TTCACCAAAACTATAAAGTCTCAGAAGGGAATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTG               AATTACACTGAATTCCAAAAACCAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAA               CTGTTGGGTAACCGGATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAGGTAA               ATATTCCTTTGGTAACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAATAACCCAACGGATG               GTCTGTGCTGGCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGGAGATTCAGGTGGTCCCTTAGTTTG               CAAACACAATGGAATGTGGCGTTTGGTGGGCATCACCAGCTGGGGTGAAGGCTGTGCCCGCAGGGAGC               AACCTGGTGTCTACACCAAAGTCGCTGAGTACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGAT               GGAAAAGCTCAGATGCAGTCACCAGCACTCGAG                                     NOV11b, 227803167   SEQ ID NO: 48   623 aa   MW at 69594.8kD       Protein Sequence                 GSGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTG               TLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYA               TQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARFLT               PDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLP               EPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSP               TRIAYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIG               HQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPL               NYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRM               VCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSD               GKAQMQSPALE                                 NOV11c, CG56155-01   SEQ ID NO: 49   2245 bp       DNA Sequence   ORF Start: ATG at 72   ORF Stop: end of sequence                   AGAACAGCTTGAAGACCGTTCATTTTTAAGTGACAAGAGACTCACCTCCAAGAAGCAATTGTGTTTTC                   AGA   ATG ATTTTATTCAAGCAAGCAACTTATTTCATTTCCTTGTTTGCTACAGTTTCCTGTGGATGTCT               GACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGGATGTAGCTTCCATGTACACCCCAAATGCCC               AATACTGCCAGATGAGGTGCACATTCCACCCAAGGTGTTTGCTATTCAGTTTTCTTCCAGCAAGTTCA               ATCAATGACATGGAGAAAAGGTTTGGTTGCTTCTTGAAAGATAGTGTTACAGGAACCCTGCCAAAAGT               ACATCGAACAGGTGCAGTTTCTGGACATTCCTTGAAGCAATGTGGTCATCAAATAAGTGCTTGCCATC               GAGACATTTATAAAGGAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGGTTAGCAGTGTTGAA               GAATGCCAAAAAAGGTGCACCAATAACATTCGCTGCCAGTTTTTTTCATATGCCACGCAAACATTTCA               CAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTACAGTCCCGGAGGAACACCTACCGCTATAAAGG               TGCTGAGTAACGTGGAATCTGGATTCTCACTGAAGCCCTGTGCCCTTTCAGAAATTGGTTGCCACATG               AACATCTTCCAGCATCTTGCGTTCTCAGATGTGGATGTTGCCAGGGTTCTCACTCCAGATGCTTTTGT               GTGTCGGACCATCTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATACAAATGTATGGAAAA               TCGAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAAGTTCCTCTACTCCT               CAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAGAACTTTACCTGAACCCTGCCATTC               TAAAATTTACCCGGGAGTTGACTTTGGAGGAGAAGAATTGAATGTGACTTTTGTTAAAGGAGTGAATG               TTTGCCAAGAGACTTGCACAAAGATGATTCGCTGTCAGTTTTTCACTTATTCTTTACTCCCAGAAGAC               TGTAAGGAAGAGAAGTGTAAGTGTTTCTTAAGATTATCTATGGATGGTTCTCCAACTAGGATTGCGTA               TGGGACACAAGGGAGCTCTGGTTACTCTTTGAGATTGTGTAACACTGGGGACAACTCTGTCTGCACAA               CAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTGGCCCTGGCAGGTGAGC               CTGCAGGTGAAGCTGACAGCTCAGAGGCACCTGTGTGGAGGGTCACTCATAGGACACCAGTGGGTCCT               CACTGCTGCCCACTGCTTTGATGGGCTTCCCCTGCAGGATGTTTGGCGCATCTATAGTGGCATTTTAA               ATCTGTCAGACATTACAAAAGATACACCTTTCTCACAAATAAAAGAGATTATTATTCACCAAAACTAT               AAAGTCTCAGAAGGGAATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTGAATTACACTGAATT               CCAAAAACCAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAACTGTTGGGTAACCG               GATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAGGTAAATATTCCTTTGGTA               ACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAATAACCCAACGGATGGTCTGTGCTGGCTA               TAAAGAAGGGGGAAAAGATGCTTGTAAGGGAGATTCAGGTGGTCCCTTAGTTTGCAAACACAACGGAA               TGTGGCGTTTGGTGGGCATCACAAGCTGGGGTGAAGGCTGTGCCCGCAGGGAGCAACCTGGTGTCTAC               ACCAAAGTCGCTGAGTACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGATGGAAAAGCTCAGAT               GCAGTCACCAGCA TGA   GAAGCAGTCCAGAGTCTAGGCAATTTTTACAACCTGAGTTCAAGTCAAATTC                   TGAGCCTGGGGGGTCCTCATCTGCAAAGCATGGAGAGTGGCATCTTCTTTGCATCCTAAGGACGAAAG                   ACACAGTGCACTCAGAGCTGCTGAGGACAATGTCTGCTGAAGCCCGCTTTCAGCACGCCGTAACCAGG                   GGCTGACAATGCGAGGTCGCAACTGAGATCTCCATGACTGTGTGTTGTGAAATAAAATGGTGAAAGAT                   C                                       NOV11c, CG56155-01   SEQ ID NO: 50   638 aa   MW at 71369.0kD       Protein Sequence                 MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSI               NDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEE               CQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMN               IFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQ               ENTISGYSLLTCKRTLPEPCHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDC               KEEKCKCFLRLSMDGSPTRIAYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSL               QVKLTAQRHLCGGSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYK               VSEGNHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVT               NEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYT               KVAEYMDWILEKTQSSDGKAQMQSPA                                 NOV11d, CG56155-03   SEQ ID NO: 51   1869 bp       DNA Sequence   ORF Start: at 7   ORF Stop: end of sequence                   GGATCC   GGA TGTCTGACTCAACTCTATGAAAACGCCTTCTTCAGAGGTGGGGATGTAGCTTCCATGTA               CACCCCAAATGCCCAATACTGCCAGATGAGGTGCACATTCCACCCAAGGTGTTTGCTATTCAGTTTTC               TTCCAGCAAGTTCAATCAATGACATGGAGAAAAGGTTTGGTTGCTTCTTGAAAGATAGTGTTACAGGA               ACCCTGCCAAAAGTACATCGAACAGGTGCAGTTTCTGGACATTCCTTGAAGCAATGTGGTCATCAAAT               AAGTGCTTGCCATCGAGACATTTATAAAGGAGTTGATATGAGAGGAGTCAATTTTAATGTGTCTAAGG               TTAGCAGTGTTGAAGAATGCCAAAAAAGGTGCACCAGTAACATTCGCTGCCAGTTTTTTTCATATGCC               ACGCAAACATTTCACAAGGCAGAGTACCGGAACAATTGCCTATTAAAGTACAGTCCCGGAGGAACACC               TACCGCTATAAAGGTGCTGAGTAACGTGGAATCTGGATTCTCACTGAAGCCCTGTGCCCTTTCAGAAA               TTGGTTGCCACATGAACATCTTCCAGCATCTTGCGTTCTCAGATGTGGATGTTGCCAGGTTTCTCACT               CCAGATGCTTTTGTGTGTCGGACCATCTGCACCTATCACCCCAACTGCCTCTTCTTTACATTCTATAC               AAATGTATGGAAAATCGAGTCACAAAGAAATGTTTGTCTTCTTAAAACATCTGAAAGTGGCACACCAA               GTTCCTCTACTCCTCAAGAAAACACCATATCTGGATATAGCCTTTTAACCTGCAAAAGAACTTTACCT               GAACCCTGCCATTCTAAAATTTACCCGGGAGTTGACTTTGGAGGAGAAGAATTGAATGTGACTTTTGT               TAAAGGAGTGAATGTTTGCCAAGAGACTTGCACAAAGATGATTCGCTGTCAGTTTTTCACTTATTCTT               TACTCCCAGAAGACTGTAAGGAAGAGAAGTGTAAGTGTTTCTTAAGATTATCTATGGATGGTTCTCCA               ACTAGGATTGCGTATGGGACACAAGGGAGCTCTGGTTACTCTTTGAGATTGTGTAACACTGGGGACAA               CGCTGTCTGCACAACAAAAACAAGCACACGCATTGTTGGAGGAACAAACTCTTCTTGGGGAGAGTGGC               CCTGGCAGGTGAGCCTGCAGGTGAAGCTGACAGCTCAGAGGCACCTGTGTGGAGGGTCACTCATAGGA               CACCAGTGGGTCCTCACTGCTGCCCACTGCTTTGATGGGCTTCCCCTGCAGGATGTTTGGCGCATCTA               TAGTGGCATTTTAAATCTGTCAGACATTACAAAAGATACACCTTTCTCACAAATAAAAGAGATTATTA               TTCACCAAAACTATAAAGTCTCAGAAGGGAATCATGATATCGCCTTGATAAAACTCCAGGCTCCTTTG               AATTACACTGAATTCCAAAAACCAATATGCCTACCTTCCAAAGGTGACACAAGCACAATTTATACCAA               CTGTTGGGTAACCGGATGGGGCTTCTCGAAGGAGAAAGGTGAAATCCAAAATATTCTACAAAAGGTAA               ATATTCCTTTGGTAACAAATGAAGAATGCCAGAAAAGATATCAAGATTATAAAATAACCCAACGGATG               GTCTGTGCTGGCTATAAAGAAGGGGGAAAAGATGCTTGTAAGGGAGATTCAGGTGGTCCCTTAGTTTG               CAAACACAATGGAATGTGGCGTTTGGTGGGCATCACCAGCTGGGGTGAAGGCTGTGCCCGCAGGGAGC               AACCTGGTGTCTACACCAAAGTCGCTGAGTACATGGACTGGATTTTAGAGAAAACACAGAGCAGTGAT               GGAAAAGCTCAGATGCAGTCACCAGCA CTC   GAG                                       NOV11d, CG56155-03   SEQ ID NO: 52   619 aa   MW at 69208.4kD       Protein Sequence                 GCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLFSFLPASSINDMEKRFGCFLKDSVTGTL               PKVHRTGAVSGHSLKQCGHQISACHRDIYKGVDMRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQ               TFHKAEYRNNCLLKYSPGGTPTAIKVLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARFLTPD               AFVCRTICTYHPNCLFFTFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEP               CHSKIYPGVDFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTR               IAYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCGGSLIGHQ               WVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEGNHDIALIKLQAPLNY               TEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNIPLVTNEECQKRYQDYKITQRMVC               AGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGEGCARREQPGVYTKVAEYMDWILEKTQSSDGK               AQMQSPA                  
 
     [0407] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 11B.  
               TABLE 11B                       Comparison of the NOV11 protein sequences.                                            NOV11a   MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLF           NOV11b   -----------------GSGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLF       NOV11c   MILFKQATYFISLFATVSCGCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLF       Nov11d   -------------------GCLTQLYENAFFRGGDVASMYTPNAQYCQMRCTFHPRCLLF               NOV11a   SFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVD       NOV11b   SFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVD       NOV11c   SFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVD       NOV11d   SFLPASSINDMEKRFGCFLKDSVTGTLPKVHRTGAVSGHSLKQCGHQISACHRDIYKGVD               NOV11a   MRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIK       NOV11b   MRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIK       NOV11c   MRGVNFNVSKVSSVEECQKRCTNNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIK       NOV11d   MRGVNFNVSKVSSVEECQKRCTSNIRCQFFSYATQTFHKAEYRNNCLLKYSPGGTPTAIK               NOV11a   VLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARFLTPDAFVCRTICTYHPNCLFF       NOV11b   VLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARFLTPDAFVCRTICTYHPNCLFF       NOV11c   VLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARVLTPDAFVCRTICTYHPNCLFF       NOV11d   VLSNVESGFSLKPCALSEIGCHMNIFQHLAFSDVDVARFLTPDAFVCRTICTYHPNCLFF               NOV11a   TFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV       NOV11b   TFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV       NOV11c   TFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV       NOV11d   TFYTNVWKIESQRNVCLLKTSESGTPSSSTPQENTISGYSLLTCKRTLPEPCHSKIYPGV               NOV11a   DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRI       NOV11b   DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRI       NOV11c   DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRI       NOV11d   DFGGEELNVTFVKGVNVCQETCTKMIRCQFFTYSLLPEDCKEEKCKCFLRLSMDGSPTRI               NOV11a   AYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCG       NOV11b   AYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCG       NOV11c   AYGTQGSSGYSLRLCNTGDNSVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCG       NOV11d   AYGTQGSSGYSLRLCNTGDNAVCTTKTSTRIVGGTNSSWGEWPWQVSLQVKLTAQRHLCG               NOV11a   GSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEG       NOV11b   GSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEG       NOV11c   GSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEG       Nov11d   GSLIGHQWVLTAAHCFDGLPLQDVWRIYSGILNLSDITKDTPFSQIKEIIIHQNYKVSEG               NOV11a   NHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNI       NOV11b   NHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNI       NOV11c   NHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNI       NOV11d   NHDIALIKLQAPLNYTEFQKPICLPSKGDTSTIYTNCWVTGWGFSKEKGEIQNILQKVNI               NOV11a   PLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGE       NOV11b   PLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGE       NOV11c   PLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGE       NOV11d   PLVTNEECQKRYQDYKITQRMVCAGYKEGGKDACKGDSGGPLVCKHNGMWRLVGITSWGE               NOV11a   GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA--       NOV11b   GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPALE       NOV11c   GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA--       NOV11d   GCARREQPGVYTKVAEYMDWILEKTQSSDGKAQMQSPA--               NOV11a   (SEQ ID NO: 46)       NOV11b   (SEQ ID NO: 48)       NOV11c   (SEQ ID NO: 50)       NOV11d   (SEQ ID NO: 52)                  
 
     [0408] Further analysis of the NOV11a protein yielded the following properties shown in Table 11C.  
               TABLE 11C                       Protein Sequence Properties NOV11a                                        SignalP analysis:   Cleavage site between residues 20 and 21       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 5; pos. chg 1; neg. chg 0           H-region: length 21; peak value 10.10           PSG score: 5.70           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −2.14           possible cleavage site: between 23 and 24           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 0           number of TMS(s) . . . fixed           PERIPHERAL Likelihood = 0.95 (at 7)           ALOM score: 0.95 (number of TMSs: 0)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 6           Charge difference: −3.0 C(−1.0)-N(2.0)           N &gt;= C: N-terminal side will be inside           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   7.62           Hyd Moment (95):   5.84   G content:   1           D/E content:   1   S/T content:   5                         Score: −3.79           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 10.5%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: found           TLPK at 86           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 55.5           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           26.1%: cytoplasmic           21.7%: mitochondrial           17.4%: nuclear            8.7%: extracellular, including cell wall            8.7%: vacuolar            8.7%: Golgi            8.7%: endoplasmic reticulum           &gt;&gt; prediction for CG56155-02 is cyt (k = 23)                  
 
     [0409] A search of the NOV11a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 11D.  
               TABLE 11D                          Geneseq Results for NOV11a                                             Identities/                   NOV11a   Similarities               Residues/   for the       Geneseq   Protein/Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABG76951   Human protein, homologous to    1 . . . 638    638/638 (100%)   0.0           Kallikrein, designated NOV3 -    1 . . . 638    638/638 (100%)             Homo sapiens , 638 aa.           [WO200255705-A2, 18 JUL.           2002]       AAU68928   Human protease domian of   427 . . . 584    158/158 (100%)   1e−92           kallikrein I -  Homo sapiens , 158    1 . . . 158    158/158 (100%)           aa. [US6294663-B1, 25 SEP.           2001]       AAU82755   Amino acid sequence of novel   319 . . . 621   115/306 (37%)   1e−56           human protease #54 -  Homo     513 . . . 797   172/306 (55%)             sapiens , 802 aa. [WO200200860-           A2, 03 JAN. 2002]       AAB24052   Human PRO618 protein   319 . . . 621   115/306 (37%)   1e−56           sequence SEQ ID NO: 24 -  Homo     513 . . . 797   172/306 (55%)             sapiens , 802 aa. [WO200053754-           A1, 14 SEP. 2000]       AAB44266   Human PRO618 (UNQ354)   319 . . . 621   115/306 (37%)   1e−56           protein sequence SEQ ID   513 . . . 797   172/306 (55%)           NO: 169 -  Homo sapiens , 802 aa.           [WO200053756-A2, 14 SEP.           2000]                  
 
     [0410] In a BLAST search of public sequence databases, the NOV11a protein was found to have homology to the proteins shown in the BLASTP data in Table 11E.  
               TABLE 11E                          Public BLASTP Results for NOV11a                                             Identities/                       Similarities       Protein           for the       Accession       NOV11a Residues/   Matched   Expect       Number   Protein/Organism/Length   Match Residues   Portion   Value                                         P03952   Plasma kallikrein precursor (EC   1 . . . 638   636/638 (99%)   0.0           3.4.21.34) (Plasma prekallikrein)   1 . . . 638   637/638 (99%)           (Kininogenin) (Fletcher factor) -             Homo sapiens  (Human), 638 aa.       O97506   Kallikrein -  Sus scrofa  (Pig), 643   1 . . . 635   503/635 (79%)   0.0           aa.   9 . . . 643   568/635 (89%)       Q8R0P5   Kallikrein B, plasma 1 -  Mus     1 . . . 638   486/638 (76%)   0.0             musculus  (Mouse), 638 aa.   1 . . . 638   554/638 (86%)       P26262   Plasma kallikrein precursor (EC   1 . . . 638   485/638 (76%)   0.0           3.4.21.34) (Plasma prekallikrein)   1 . . . 638   553/638 (86%)           (Kininogenin) (Fletcher factor) -             Mus musculus  (Mouse), 638 aa.       P14272   Plasma kallikrein precursor (EC   1 . . . 638   476/638 (74%)   0.0           3.4.21.34) (Plasma prekallikrein)   1 . . . 638   549/638 (85%)           (Kininogenin) (Fletcher factor) -             Rattus norvegicus  (Rat), 638 aa.                  
 
     [0411] PFam analysis predicts that the NOV11a protein contains the domains shown in the Table 11F.  
               TABLE 11F                          Domain Analysis of NOV11a                                             Identities/                   NOV11a   Similarities           Pfam   Match   for the   Expect           Domain   Region   Matched Region   Value                       PAN    21 . . . 104   19/112 (17%)   7.9e−14                   64/112 (57%)           PAN   111 . . . 194   23/111 (21%)   4.8e−15                   67/111 (60%)           PAN   201 . . . 284   19/111 (17%)     4e−10                   62/111 (56%)           PAN   292 . . . 375   22/111 (20%)   2.3e−09                   65/111 (59%)           trypsin   391 . . . 621   113/263 (43%)    5.2e−92                   196/263 (75%)                       
 
     Example 12  
     [0412] The NOV12 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 12A.  
               TABLE 12A                       NOV12 Sequence Analysis                                            NOV12a, CG56262-01   SEQ ID NO: 53   1551 bp       DNA Sequence   ORF Start: ATG at 108   ORF Stop: end of sequence                   GCGGCCGCGGGAGCTGACCCTGCGGGGTCCCGGGGGGGGAGGGGGAGCCGCGAAGCCCCCACTGAGGC                   CGCCGCTGCCGGGCCTCCCCTCCCCCCCGGGCGGGCGCC   ATG CGGGGGAGCCCGGGCGACGCGGAGCG               GCGGCAGCGCTGGGGTCGCCTGTTCGAGGAGCTGGACAGTAACAAGGATGGCCGCGTGGACGTGCACG               AGTTGCGCCAGGGGCTGGCCAGGCTGGGCGGGGGCAACCCAGACCCCGGCGCCCAACAGGGTATCTCC               TCTGAGGGTGATGCTGACCCAGATGGCGGGCTCGACCTGGAGGAATTTTCCCGCTATCTGCAGGAGCG               GGAACAGCGTCTGCTGCTCATGTTTCACAGTCTTGACCGGAACCAGGATGGTCACATTGATGTCTCTG               AGATCCAACAGAGTTTCCGAGCTCTGGGCATTTCCATCTCGCTGGAGCAGGCTGAGAAAATTTTGCAC               AGCATGGACCGAGACGGCACAATGACCATTGACTGGCAAGAATGGCGCGACCACTTCCTGTTGCATTC               GCTGGAAAATGTGGAGGACGTGCTGTATTTCTGGAAGCATTCCACGGTCCTGGACATTGGCGAGTGCC               TGACAGTGCCGGACGAGTTCTCAAAGCAAGAGAAGCTGACGGGCATGTGGTGGAAACAGCTGGTGGCC               GGCGCAGTGGCAGGTGCCGTGTCACGGACAGGCACGGCCCCTCTGGACCGCCTCAAGGTCTTCATTCA               GGTCCATGCCTCAAAGACCAACCGGCTGAACATCCTTGGGGGGCTTCGAAGCATGGTCCTTGAGGGAG               GCATCCGCTGCCTGTGGCGCGGCAATGGTATTAATGTACTCAAGATTGCCCCCGAGTCAGCTATCAAG               TTCATGGCCTATGAACAGGTGAGGAGGGCCATCCTGGGGCAGCAGGAGACACTGCATGTGCAGGAGCG               CTTCGTGGCTGGCTCCCTGGCTGGTGCCACAGCCCAAACCATCATTTACCCTATGGAGGTGCTGAAGA               CGCGGCTGACCTTGCGCCGGACGGGCCAGTATAAGGGGCTGCTGGACTGCGCCAGGCGTATCCTGGAG               AGGGAGGGGCCCCGTGCCTTCTACCGCGGCTACCTCCCCAACGTGCTGGGCATCATCCCCTATGCGGG               CATCGACCTGGCCGTCTACGAGGTCCTGAAGAACTGGTGGCTTCAGCAGTACAGCCACGACTCGGCAG               ACCCAGGCATCCTCGTGCTCCTGGCCTGCGGTACCATATCCAGCACCTGCGGCCAGATAGCCAGTTAC               CCGCTGGCCCTGGTCCGGACCCGCATGCAGGCACAAGCCTCCATCGAGGGTGGCCCCCAGCTGTCCAT               GCTGGGTCTGCTACGTCACATCCTGTCCCAGGAGGGCATGCGGGGCCTCTACCGGGGGATCGCCCCCA               ACTTCATGAAGGTTATTCCAGCTGTGAGCATCTCCTATGTGGTCTACGAGAACATGAAGCAGGCCTTG               GGGGTCACGTCCAGG TGA   GGGACCCGGAGCCCGTCCCCCCAATCCCTCACCCCCC                                       NOV12a, CG56262-01   SEQ ID NO: 54   468 aa   MW at 52387.5kD       Protein Sequence                 MRGSPGDAERRQRWGRLFEELDSNKDGRVDVHELRQGLARLGGGNPDPGAQQGISSEGDADPDGGLDL               EEFSRYLQEREQRLLLMFHSLDRNQDGHIDVSEIQQSFRALGISISLEQAEKILHSMDRDGTMTIDWQ               EWRDHFLLHSLENVEDVLYFWKHSTVLDIGECLTVPDEFSKQEKLTGMWWKQLVAGAVAGAVSRTGTA               PLDRLKVFIQVHASKTNRLNILGGLRSMVLEGGIRCLWRGNGINVLKIAPESAIKFMAYEQVRRAILG               QQETLHVQERFVAGSLAGATAQTIIYPMEVLKTRLTLRRTGQYKGLLDCARRILEREGPRAFYRGYLP               NVLGIIPYAGIDLAVYEVLKNWWLQQYSHDSADPGILVLLACGTISSTCGQIASYPLALVRTRMQAQA               SIEGGPQLSMLGLLRHILSQEGMRGLYRGIAPNFMKVIPAVSISYVVYENMKQALGVTSR                  
 
     [0413] Further analysis of the NOV12a protein yielded the following properties shown in Table 12B.  
               TABLE 12B                       Protein Sequence Properties NOV12a                                                SignalP analysis:   No Known Signal Sequence Predicted           PSORT II analysis:   PSG: a new signal peptide prediction method               N-region: length 11; pos. chg 3; neg. chg 2               H-region: length 1; peak value −14.40               PSG score: −18.80               GvH: von Heijne&#39;s method for signal seq. recognition               GvH score (threshold: −2.1): −7.60               possible cleavage site: between 46 and 47               &gt;&gt;&gt; Seems to have no N-terminal signal peptide               ALOM: Klein et al&#39;s method for TM region allocation               Init position for calculation: 1               Tentative number of TMS(s) for the threshold 0.5: 1               Number of TMS(s) for threshold 0.5: 0               PERIPHERAL Likelihood = 0.85 (at 342)               ALOM score: −0.90 (number of TMSs: 0)               MITDISC: discrimination of mitochondrial targeting seq                                             R content:   1   Hyd Moment(75):   10.59               Hyd Moment(95):   7.77   G content:   2               D/E content:   2   S/T content:   1                                 Score: −5.97               Gavel: prediction of cleavage sites for mitochondrial preseq               R-2 motif at 12 MRG|SP               NUCDISC: discrimination of nuclear localization signals               pat4: none               pat7: none               bipartite: none               content of basic residues: 11.3%               NLS Score: −0.47               KDEL: ER retention motif in the C-terminus: none               ER Membrane Retention Signals:               XXRR-like motif in the N-terminus: RGSP               none               SKL: peroxisomal targeting signal in the C-terminus: none               PTS2: 2nd peroxisomal targeting signal: none               VAC: possible vacuolar targeting motif: none               RNA-binding motif: none               Actinin-type actin-binding motif:               type 1: none               type 2: none               NMYR: N-myristoylation pattern: none               Prenylation motif: none               memYQRL: transport motif from cell surface to Golgi: none               Tyrosines in the tail: none               Dileucine motif in the tail: none               checking 63 PROSITE DNA binding motifs:               Leucine zipper pattern (PS00029): *** found ***               LEEFSRYLQEREQRLLLMFHSL at 68               none               checking 71 PROSITE ribosomal protein motifs: none               checking 33 PROSITE prokaryotic DNA binding motifs: none               NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination               Prediction: cytoplasmic               Reliability: 94.1               COIL: Lupas&#39;s algorithm to detect coiled-coil regions               total: 0 residues               Final Results (k = 9/23):               52.2%: cytoplasmic               30.4%: nuclear                8.7%: mitochondrial                4.3%: vacuolar                4.3%: vesicles of secretory system               &gt;&gt; prediction for CG56262-01 is cyt (k = 23)                      
 
     [0414] A search of the NOV12a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 12C.  
               TABLE 12C                          Geneseq Results for NOV12a                                             Identities/                   NOV12a   Similarities               Residues/   for the       Geneseq   Protein/Organism/Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value                                         AAE22927   Human transporter and ion   1 . . . 468   463/468 (98%)   0.0           channel (TRICH) 26 -  Homo     1 . . . 468   466/468 (98%)             sapiens , 468 aa. [WO200222684-           A2, 21 MAR. 2002]       AAU27869   Human contig polypeptide   1 . . . 468   463/468 (98%)   0.0           sequence #22 -  Homo sapiens , 509   39 . . . 506    466/468 (98%)           aa. [WO200164834-A2, 07 SEP.           2001]       AAU27697   Human full-length polypeptide   1 . . . 468   463/468 (98%)   0.0           sequence #22 -  Homo sapiens , 471   1 . . . 468   466/468 (98%)           aa. [WO200164834-A2, 07 SEP.           2001]       ABG22637   Novel human diagnostic protein   1 . . . 468   442/470 (94%)   0.0           #22628 -  Homo sapiens , 508 aa.   39 . . . 508    450/470 (95%)           [WO200175067-A2, 11 OCT.           2001]       ABG30434   Human protein sequence #2 used   1 . . . 409   403/409 (98%)   0.0           for determining sequence of   1 . . . 409   406/409 (98%)           unknown gene -  Homo sapiens ,           456 aa. [JP2002176980-A, 25           JUN. 2002]                  
 
     [0415] In a BLAST search of public sequence databases, the NOV12a protein was found to have homology to the proteins shown in the BLASTP data in Table 12D.  
               TABLE 12D                          Public BLASTP Results for NOV12a                                         NOV12a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               CAD55563   Putative calcium binding   1 . . . 407   402/407 (98%)   0.0           transporter -  Homo sapiens     1 . . . 407   405/407 (98%)           (Human), 438 aa.       Q96NQ4   Hypothetical protein FLJ30339 -   85 . . . 468    379/384 (98%)   0.0             Homo sapiens  (Human), 384 aa.   1 . . . 384   382/384 (98%)       CAD20531   Sequence 1 from Patent   1 . . . 407   374/407 (91%)   0.0           WO0174854 -  Homo sapiens     1 . . . 406   388/407 (94%)           (Human), 460 aa (fragment).       AAH43834   Similar to hypothetical protein   6 . . . 468   302/463 (65%)   e−177           MGC36388 -  Xenopus laevis     53 . . . 514    368/463 (79%)           (African clawed frog), 514 aa.       Q8BHG0   Weakly similar to peroxisomal   6 . . . 468   305/463 (65%)   e−176           CA-dependent solute carrier -   41 . . . 502    366/463 (78%)             Mus musculus  (Mouse), 502 aa.                  
 
     [0416] PFam analysis predicts that the NOV12a protein contains the domains shown in the Table 12E.  
               TABLE 12E                          Domain Analysis of NOV12a                                             Identities/                   NOV12a   Similarities           Pfam   Match   for the   Expect           Domain   Region   Matched Region   Value                       efhand   13 . . . 41    8/29 (28%)   0.00022                    26/29 (90%)           efhand    81 . . . 109    8/29 (28%)   0.012                     21/29 (72%)           mito_carr   184 . . . 276   38/124 (31%)   2.1e−24                   78/124 (63%)           mito_carr   278 . . . 369   38/124 (31%)   3.4e−32                   81/124 (65%)           mito_carr   375 . . . 468   31/124 (25%)   2.4e−23                   76/124 (61%)                      
 
     Example 13  
     [0417] The NOV13 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 13A.  
               TABLE 13A                       NOV13 Sequence Analysis                                            NOV13a, CG56829-01   SEQ ID NO: 55   953 bp       DNA Sequence   ORF Start: ATG at 50   ORF Stop: end of sequence                   CAGAGGCAGCATGAGCTGAGAGGGTGATAGGAAGGCGGCGCTAGACAGC   ATG GAGGACTTTCTGCTCT               CCAATGGGTACCAGCTGGGCAAGACCATTGGGGAAGGGACCTACTCAAAAGTCAAAGAAGCATTTTCC               AAAAAACACCAAAGAAAAGTGGCAATTAAAGTTATAGACAAGATGGGAACTTCCTCAGAGTTTATCCA               GAGATTCCTCCCTCGGGAGCTCCAAATCGTCCGTACCCTGGACCACAAGAACATCATCCAGGTGTATG               AGATGCTGGAGTCTGCCGACGGGAAAATCTGCCTGGTGATGGAGCTCGCTGAGGGAGGGGATGTCTTT               GACTGCGTGCTGAATGGGGGGCCACTGCCTGAAAGCCGGGCCAAGGCCCTCTTCCGTCAGATGGTTGA               GGCCATCCGCTACTGCCATGGCTGTGGTGTGGCCCACCGGGACCTCAAATGTGAGAACGCCTTGTTGC               AGGGCTTCAACCTGAAGCTGACTGACTTTGGCTTTGCCAAGGTGTTGCCCAAGTCACACCGGGAGCTG               AGCCAGACCTTCTGCGGCAGTACAGCCTATGCTGCCCCCGAGGTGCTGCAGGGCATTCCCCACGATAG               CAAAAAAGGTGATGTCTGGAGCATGGGTGTGGTCCTGTATGTCATGCTCTGTGCCAGCCTACCTTTTG               ACGACACAGACATCCCCAAGATGCTGTGGCAGCAGCAGAAGGGGGTGTCCTTCCCCACTCATCTGAGC               ATCTCGGCCGATTGCCAGGACCTGCTCAAGAGGCTCCTGGAACCCGATATGATCCTCCGGCCTTCAAT               TGAAGAAGTTAGTTGGCATCCATGGCTAGCAAGCACT TGA   TAAAAGCAATGGCAAGTGCTCTCCAATA                   AAGTAGGGGGAGAAAGCAAACCCAAAAACCCGCTTCTAAAATGGTGATATATATTTTACGCTTTAAGT                   T                                       NOV13a, CG56829-01   SEQ ID NO: 56   268 aa   MW at 30093.6kD       Protein Sequence                 MEDFLLSNGYQLGKTIGEGTYSKVKEAFSKKHQRKVAIKVIDKMGTSSEFIQRFLPRELQIVRTLDHK               NIIQVYEMLESADGKICLVMELAEGGDVFDCVLNGGPLPESRAKALFRQMVEAIRYCHGCGVAHRDLK               CENALLQGFNLKLTDFGFAKVLPKSHRELSQTFCGSTAYAAPEVLQGIPHDSKKGDVWSMGVVLYVML               CASLPFDDTDIPKMLWQQQKGVSFPTHLSISADCQDLLKRLLEPDMILRPSIEEVSWHPWLAST                  
 
     [0418] Further analysis of the NOV13a protein yielded the following properties shown in Table 13B.  
               TABLE 13B                       Protein Sequence Properties NOV13a                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 3; pos.chg 0; neg.chg 2           H-region: length 10; peak value 0.00           PSG score: −4.40           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −9.40           possible cleavage site: between 17 and 18           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 1           Number of TMS(s) for threshold 0.5: 0           PERIPHERAL Likelihood = 2.92 (at 84)           ALOM score: −1.91 (number of TMSs: 0)           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   8.14           Hyd Moment(95):   7.70   G content:   0           D/E content:   2   S/T content:   0                         Score: −6.58           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 11.6%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           52.2%: cytoplasmic           30.4%: mitochondrial           17.4%: nuclear           &gt;&gt; prediction for CG56829-01 is cyt (k = 23)                  
 
     [0419] A search of the NOV13a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 13C.  
               TABLE 13C                          Geneseq Results for NOV13a                                         NOV13a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB65682   Novel protein kinase, SEQ ID   1 . . . 268   266/268 (99%)   e−155           NO: 210 -  Homo sapiens , 268 aa.   1 . . . 268   266/268 (99%)           [WO200073469-A2, 07 DEC.           2000]       AAM47999   Human hTSSK3 SEQ ID NO 2 -   1 . . . 268   265/268 (98%)   e−155             Homo sapiens , 268 aa.   1 . . . 268   265/268 (98%)           [WO200185954-A2, 15 NOV.           2001]       AAE19154   Human kinase polypeptide   1 . . . 268   265/268 (98%)   e−155           (PKIN-12) -  Homo sapiens , 268   1 . . . 268   265/268 (98%)           aa. [WO200208399-A2, 31 JAN.           2002]       ABG30417   Human testis specific kinase   1 . . . 268   265/268 (98%)   e−155           (TSSK) 3 protein -  Homo     1 . . . 268   265/268 (98%)             sapiens , 268 aa. [WO200238732-           A2, 16 MAY 2002]       ABG30419   Mouse testis specific kinase   1 . . . 268   259/268 (96%)   e−151           (TSSK) 3b protein - Mus sp, 268   1 . . . 268   261/268 (96%)           aa. [WO200238732-A2, 16           MAY 2002]                  
 
     [0420] In a BLAST search of public sequence databases, the NOV13a protein was found to have homology to the proteins shown in the BLASTP data in Table 13D.  
               TABLE 13D                          Public BLASTP Results for NOV13a                                         NOV13a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               Q96PN8   Testis-specific serine/threonine   1 . . . 268   265/268 (98%)   e−154           kinase 3 (Similar to serine/   1 . . . 268   265/268 (98%)           threonine kinase) (TSSK3) -             Homo sapiens  (Human), 268 aa.       Q9D2E1   4930594I21Rik protein (Testis-   1 . . . 268   259/268 (96%)   e−151           specific serine/threonine kinase   1 . . . 268   261/268 (96%)           3b) -  Mus musculus  (Mouse), 268           aa.       Q9JL98   Testis specific serine kinase-3 -   1 . . . 268   240/273 (87%)   e−134             Mus musculus  (Mouse), 266 aa.   1 . . . 266   245/273 (88%)       Q8IY55   Hypothetical protein -  Homo     5 . . . 265   125/266 (46%)   1e−69              sapiens  (Human), 358 aa.   7 . . . 272   190/266 (70%)       Q96PF2   Testis specific serine/threonine   5 . . . 265   125/266 (46%)   1e−69            kinase 2 -  Homo sapiens  (Human),   1 . . . 272   190/266 (70%)           358 aa.                  
 
     [0421] PFam analysis predicts that the NOV13a protein contains the domains shown in the Table 13E.  
               TABLE 13E                          Domain Analysis of NOV13a                                             Identities/                   NOV13a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       pkinase   10 . . . 265   99/299 (33%)   1.5e−80                   203/299 (68%)                       
 
     Example 14  
     [0422] The NOV14 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 14A.  
               TABLE 14A                       NOV14 Sequence Analysis                                            NOV14a, CG57183-01   SEQ ID NO: 57   2490 bp       DNA Sequence   ORF Start: ATG at 40   ORF Stop: end of sequence                   CGCGCGCTGCCTGAGGACGCCGCGGCCCCCGCCCCCGCC   ATG GGCGCCCCTGCCTGCGCCCTCGCGCT               CTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGAGTCCTTGGGGACGGAGCAGCGCGTCGTGG               GGCGAGCGGCAGAAGTCCCGGGCCCAGAGCCCGGCCAGCAGGAGCAGTTGGTCTTCGGCAGCGGGGAT               GCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCCATGGGGCCCACTGTCTGGGTCAAGGATGG               CACAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCCCCAGCGGCTGCAGGTGCTGAATGCCTCCC               ACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCACGCAGCGCGTACTGTGCCACTTCAGTGTG               CGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGACGGGGAGGACGAGGCTGAGGACACAGGTGT               GGACACAGGGGCCCCTTACTGGACACGGCCCGAGCGGATGGACAAGAAGCTGCTGGCCGTGCCGGCCG               CCAACACCGTCCGCTTCCGCTGCCCAGCCGCTGGCAACCCCACTCCCTCCATCTCCTGGCTGAAGAAC               GGCAGGGAGTTCCGCGGCGAGCACCGCATTGGAGGCATCAAGCTGCGGCATCAGCAGTGGAGCCTGGT               CATGGAAAGCGTGGTGCCCTCGGACCGCGGCAACTACACCTGCGTCGTGGAGAACAAGTTTGGCAGCA               TCCGGCAGACGTACACGCTGGACGTGCTGGAGCGCTCCCCGCACCGGCCCATCCTGCAGGCGGGGCTG               CCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAGTTCCACTGCAAGGTGTACAGTGACGCACA               GCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAACGGCAGCAAGGTGGGCCCGGACGGCACACCCT               ACGTTACCGTGCTCAAGACGGCGGGCGCTAACACCACCGACAAGGAGCTAGAGGTTCTCTCCTTGCAC               AACGTCACCTTTGAGGACGCCGGGGAGTACACCTGCCTGGCGGGCAATTCTATTGGGTTTTCTCATCA               CTCTGCGTGGCTGGTGGTGCTGCCAGCCGAGGAGGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGT               ATGCAGGCATCCTCAGCTACGGGGTGGGCTTCTTCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTC               TGCCGCCTGCGCAGCCCCCCCAAGAAAGGCCTGGGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCC               GCTCAAGCGACAGGTGTCCCTGGAGTCCAACGCGTCCATGAGCTCCAACACACCACTGGTGCGCATCG               CAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGGCCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCC               AAATGGGAGCTGTCTCGGGCCCGGCTGACCCTGGGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGT               GGTCATGGCGGAGGCCATCGGCATTGACAAGGACCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAAGA               TGCTGAAAGACGATGCCACTGACAAGGACCTGTCGGACCTGGTGTCTGAGATGGAGATGATGAAGATG               ATCGGGAAACACAAAAACATCATCAACCTGCTGGGCGCCTGCACGCAGGGCGGGCCCCTGTACGTGCT               GGTGGAGTACGCGGCCAAGGGTAACCTGCGGGAGTTTCTGCGGGCGCGGCGGCCCCCGGGCCTGGACT               ACTCCTTCGACACCTGCAAGCCGCCCGAGGAGCAGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTAC               CAGGTGGCCCGGGGCATGGAGTACTTGGCCTCCCAGAAGTGCATCCACAGGGACCTGGCTGCCCGCAA               TGTGCTGGTGACCGAGGACAACGTGATGAAGATCGCAGACTTCGGGCTGGCCCGGGACGTGCACAACC               TCGACTACTACAAGAAGACAACCAACGGCCGGCTGCCCGTGAAGTGGATGGCGCCTGAGGCCTTGTTT               GACCGAGTCTACACTCACCAGAGTGACGTCTGGTCCTTTGGGGTCCTGCTCTGGGAGATCTTCACGCT               GGGGGGCTCCCCGTACCCCGGCATCCCTGTGGAGGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCA               TGGACAAGCCCGCCAACTGCACACACGACCTGTACATGATCATGCGGGAGTGCTGGCATGCCGCGCCC               TCCCAGAGGCCCACCTTCAAGCAGCTGGTGGAGGACCTGGACCGTGTCCTTACCGTGACGTCCACCGA               CGAGTACCTGGACCTGTCGGCGCCTTTCGAGCAGTACTCCCCGGGTGGCCAGGACACCCCCAGCTCCA               GCTCCTCAGGGGACGACTCCGTGTTTGCCCACGACCTGCTGCCCCCGGCCCCACCCAGCAGTGGGGGC               TCGCGGACG TGA   AGGGCCACTGGTCCCCAACAATGTGAGGGG                                       NOV14a, CG57183-01   SEQ ID NO: 58   806 aa   MW at 87708.7 kD       Protein Sequence                 MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGP               MGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDED               GEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRIGGI               KLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVE               FHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCL               AGNSIGFSHHSAWLVVLPAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGS               PTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGK               PLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLLGA               CTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLASQK               CIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSF               GVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDL               DRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT                                 NOV14b, CG57183-02   SEQ ID NO: 59   2427 bp       DNA Sequence   ORF Start: ATG at 1   ORF Stop: end of sequence                   ATG GGCGCCCCTGCCTGCGCCCTCGCGCTCTGCGTGGCCGTGGCCATCGTGGCCGGCGCCTCCTCGGA               GTCCTTGGGGACGGAGCAGCGCGTCGTGGGGCGAGCGGCAGAAGTCCCGGGCCCAGAGCCCGGCCAGC               AGGAGCAGTTGGTCTTCGGCAGCGGGGATGCTGTGGAGCTGAGCTGTCCCCCGCCCGGGGGTGGTCCC               ATGGGGCCCACTGTCTGGGTCAAGGATGGCACAGGGCTGGTGCCCTCGGAGCGTGTCCTGGTGGGGCC               CCAGCGGCTGCAGGTGCTGAATGCCTCCCACGAGGACTCCGGGGCCTACAGCTGCCGGCAGCGGCTCA               CGCAGCGCGTACTGTGCCACTTCAGTGTGCGGGTGACAGACGCTCCATCCTCGGGAGATGACGAAGAC               GGGGAGGACGAGGCTGAGGACACAGGTGTGGACACAGGGGCCCCTTACTGGACACGGCCCGAGCGGAT               GGACAAGAAGCTGCTGGCCGTGCCGGCCGCCAACACCGTCCGCTTCCGCTGCCCAGCCGCTGGCAACC               CCACTCCCTCCATCTCCTGGCTGAAGAACGGCAGGGAGTTCCGCGGCGAGCACCGCATTGGAGGCATC               AAGCTGCGGCATCAGCAGTGGAGCCTGGTCATGGAAAGCGTGGTGCCCTCGGACCGCGGCAACTACAC               CTGCGTCGTGGAGAACAAGTTTGGCAGCATCCGGCAGACGTACACGCTGGACGTGCTGGAGCGCTCCC               CGCACCGGCCCATCCTGCAGGCGGGGCTGCCGGCCAACCAGACGGCGGTGCTGGGCAGCGACGTGGAG               TTCCACTGCAAGGTGTACAGTGACGCACAGCCCCACATCCAGTGGCTCAAGCACGTGGAGGTGAACGG               CAGCAAGGTGGGCCCGGACGGCACACCCTACGTTACCGTGCTCAAGTCCTGGATCAGTGAGAGTGTGG               AGGCCGACGTGCGCCTCCGCCTGGCCAATGTGTCGGAGCGGGACGGGGGCGAGTACCTCTGTCGAGCC               ACCAATTTCATAGGCGTGGCCGAGAAGGCCTTTTGGCTGAGCGTTCACGGGCCCCGAGCAGCCGAGGA               GGAGCTGGTGGAGGCTGACGAGGCGGGCAGTGTGTATGCAGGCATCCTCAGCTACGGGGTGGGCTTCT               TCCTGTTCATCCTGGTGGTGGCGGCTGTGACGCTCTGCCGCCTGCGCAGCCCCCCCAAGAAAGGCCTG               GGCTCCCCCACCGTGCACAAGATCTCCCGCTTCCCGCTCAAGCGACAGGTGTCCCTGGAGTCCAACGC               GTCCATGAGCTCCAACACACCACTGGTGCGCATCGCAAGGCTGTCCTCAGGGGAGGGCCCCACGCTGG               CCAATGTCTCCGAGCTCGAGCTGCCTGCCGACCCCAAATGGGAGCTGTCTCGGGCCCGGCTGACCCTG               GGCAAGCCCCTTGGGGAGGGCTGCTTCGGCCAGGTGGTCATGGCGGAGGCCATCGGCATTGACAAGGA               CCGGGCCGCCAAGCCTGTCACCGTAGCCGTGAAGATGCTGAAAGACGATGCCACTGACAAGGACCTGT               CGGACCTGGTGTCTGAGATGGAGATGATGAAGATGATCGGGAAACACAAAAACATCATCAACCTGCTG               GGCGCCTGCACGCAGGGCGGGCCCCTGTACGTGCTGGTGGAGTACGCGGCCAAGGGTAACCTGCGGGA               GTTTCTGCGGGCGCGGCGGCCCCCGGGCCTGGACTACTCCTTCGACACCTGCAAGCCGCCCGAGGAGC               AGCTCACCTTCAAGGACCTGGTGTCCTGTGCCTACCAGGTGGCCCGGGGCATGGAGTACTTGGCCTCC               CAGAAGTGCATCCACAGGGACCTGGCTGCCCGCAATGTGCTGGTGACCGAGGACAACGTGATGAAGAT               CGCAGACTTCGGGCTGGCCCGGGACGTGCACAACCTCGACTACTACAAGAAGACAACCAACGGCCGGC               TGCCCGTGAAGTGGATGGCGCCTGAGGCCTTGTTTGACCGAGTCTACACTCACCAGAGTGACGTCTGG               TCCTTTGGGGTCCTGCTCTGGGAGATCTTCACGCTGGGGGGCTCCCCGTACCCCGGCATCCCTGTGGA               GGAGCTCTTCAAGCTGCTGAAGGAGGGCCACCGCATGGACAAGCCCGCCAACTGCACACACGACCTGT               ACATGATCATGCGGGAGTGCTGGCATGCCGCGCCCTCCCAGAGGCCCACCTTCAAGCAGCTGGTGGAG               GACCTGGACCGTGTCCTTACCGTGACGTCCACCGACGAGTACCTGGACCTGTCGGCGCCTTTCGAGCA               GTACTCCCCGGGTGGCCAGGACACCCCCAGCTCCAGCTCCTCAGGGGACGACTCCGTGTTTGCCCACG               ACCTGCTGCCCCCGGCCCCACCCAGCAGTGGGGGCTCGCGGACG TGA                                       NOV14b, CG57183-02   SEQ ID NO: 60   808 aa   MW at 88156.3 kD       Protein Sequence                 MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELSCPPPGGGP               MGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCHFSVRVTDAPSSGDDED               GEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAGNPTPSISWLKNGREFRGEHRTGGI               KLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQTYTLDVLERSPHRPILQAGLPANQTAVLGSDVE               FHCKVYSDAQPHIQWLKHVEVNGSKVGPDGTPYVTVLKSWISESVEADVRLRLANVSERDGGEYLCRA               TNFIGVAEKAFWLSVHGPRAAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGL               GSPTVHKISRFPLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTL               GKPLGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKNIINLL               GACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSCAYQVARGMEYLAS               QKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVW               SFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVE               DLDRVLTVTSTDEYLDLSAPFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT                  
 
     [0423] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 14B.  
               TABLE 14B                       Comparison of the NOV14 protein sequences.                                        NOV14a   MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS       NOV14b   MGAPACALALCVAVAIVAGASSESLGTEQRVVGRAAEVPGPEPGQQEQLVFGSGDAVELS               NOV14a   CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH       NOV14b   CPPPGGGPMGPTVWVKDGTGLVPSERVLVGPQRLQVLNASHEDSGAYSCRQRLTQRVLCH               NOV14a   FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG       NOV14b   FSVRVTDAPSSGDDEDGEDEAEDTGVDTGAPYWTRPERMDKKLLAVPAANTVRFRCPAAG               NOV14a   NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT       NOV14b   NPTPSISWLKNGREFRGEHRIGGIKLRHQQWSLVMESVVPSDRGNYTCVVENKFGSIRQT               NOV14a   YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP       NOV14b   YTLDVLERSPHRPILQAGLPANQTAVLGSDVEFHCKVYSDAQPHIQWLKHVEVNGSKVGP               NOV14a   DGTPYVTVLKTAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLP--       NOV14b   DGTPYVTVLKSWISESVEADVRLR-LANVSERDGGEYLCRATNFIGVAEKAFWLSVHGPR               NOV14a   -AEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRF       NOV14b   AAEEELVEADEAGSVYAGILSYGVGFFLFILVVAAVTLCRLRSPPKKGLGSPTVHKISRF               NOV14a   PLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKP       NOV14b   PLKRQVSLESNASMSSNTPLVRIARLSSGEGPTLANVSELELPADPKWELSRARLTLGKP               NOV14a   LGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKN       NOV14b   LGEGCFGQVVMAEAIGIDKDRAAKPVTVAVKMLKDDATDKDLSDLVSEMEMMKMIGKHKN               NOV14a   IINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSC       NOV14b   IINLLGACTQGGPLYVLVEYAAKGNLREFLRARRPPGLDYSFDTCKPPEEQLTFKDLVSC               NOV14a   AYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLP       NOV14b   AYQVARGMEYLASQKCIHRDLAARNVLVTEDNVMKIADFGLARDVHNLDYYKKTTNGRLP               NOV14a   VKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPA       NOV14b   VKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFKLLKEGHRMDKPA               NOV14a   NCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDT       NOV14b   NCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLSAPFEQYSPGGQDT               NOV14a   PSSSSSGDDSVFAHDLLPPAPPSSGGSRT       NOV14b   PSSSSSGDDSVFAHDLLPPAPPSSGGSRT               NOV14a   (SEQ ID NO: 58)       NOV14b   (SEQ ID NO: 60)                  
 
     [0424] Further analysis of the NOV14a protein yielded the following properties shown in Table 14C.  
               TABLE 14C                       Protein Sequence Properties NOV14a                                        SignalP analysis:   Cleavage site between residues 23 and 24                 PSORT II analysis:       PSG: a new signal peptide prediction method       N-region: length 0; pos. chg 0; neg. chg 0       H-region: length 22; peak value 9.90       PSG score: 5.50       GvH: von Heijne&#39;s method for signal seq. recognition       GvH score (threshold: −2.1): −0.62       possible cleavage site: between 22 and 23       &gt;&gt;&gt; Seems to have a cleavable signal peptide (1 to 22)       ALOM: Klein et al&#39;s method for TM region allocation       Init position for calculation: 23       Tentative number of TMS(s) for the threshold 0.5: 1       Number of TMS(s) for threshold 0.5: 1                             INTEGRAL   Likelihood =   −9.98   Transmembrane 380-396                         PERIPHERAL   Likelihood =     3.07 (at 677)                 ALOM score: −9.98 (number of TMSs: 1)       MTOP: Prediction of membrane topology (Hartmann et al.)       Center position for calculation: 11       Charge difference: −2.0 C(−1.0)-N( 1.0)       N &gt;= C: N-terminal side will be inside       &gt;&gt;&gt; membrane topology: type 1a (cytoplasmic tail 397 to 806)       MITDISC: discrimination of mitochondrial targeting seq                             R content:   0   Hyd Moment (75):   2.17       Hyd Moment (95):   1.34   G content:   2       D/E content:   1   S/T content:   2                 Score: −6.45       Gavel: prediction of cleavage sites for mitochondrial preseq       cleavage site motif not found       NUCDISC: discrimination of nuclear localization signals       pat4: none       pat7: none       bipartite: none       content of basic residues: 10.0%       NLS Score: −0.47       KDEL: ER retention motif in the C-terminus: none       ER Membrane Retention Signals: none       SKL: peroxisomal targeting signal in the C-terminus: none       PTS2: 2nd peroxisomal targeting signal: none       VAC: possible vacuolar targeting motif: none       RNA-binding motif: none       Actinin-type actin-binding motif:       type 1: none       type 2: none       NMYR: N-myristoylation pattern: MGAPACA       Prenylation motif: none       memYQRL: transport motif from cell surface to Golgi: none       Tyrosines in the tail: too long tail       Dileucine motif in the tail: found       LL at 541       LL at 683       LL at 706       LL at 793       checking 63 PROSITE DNA binding motifs: none       checking 71 PROSITE ribosomal protein motifs: none       checking 33 PROSITE prokaryotic DNA binding motifs: none       NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination       Prediction: cytoplasmic       Reliability: 89       COIL: Lupas&#39;s algorithm to detect coiled-coil regions       total: 0 residues       Final Results (k = 9/23):       44.4%: endoplasmic reticulum       22.2%: Golgi       22.2%: extracellular, including cell wall       11.1%: plasma membrane       &gt;&gt; prediction for CG57183-01 is end (k = 9)                  
 
     [0425] A search of the NOV14a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 14D.  
               TABLE 14D                          Geneseq Results for NOV14a                                         NOV14a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE21976   Human fibroblast growth factor   1 . . . 806   805/806 (99%)   0.0           receptor 3c (FGFR3c) mutant   1 . . . 806   805/806 (99%)           protein -  Homo sapiens , 806 aa.           [US6265632-B1, 24 JUL. 2001]       AAE21977   Mouse fibroblast growth factor   1 . . . 806   745/807 (92%)   0.0           receptor 3 (FGFR3) mutant   1 . . . 801   763/807 (94%)           protein - Mus sp, 801 aa.           [US6265632-B1, 24 JUL. 2001]       AAU02978   Angiotensin converting enzyme   1 . . . 542   541/542 (99%)   0.0           (ACEV) splice variant protein   1 . . . 542   541/542 (99%)           #78 -  Homo sapiens , 561 aa.           [WO200136632-A2, 25 MAY           2001]       AAR21080   flg receptor protein -  Homo     45 . . . 798    535/769 (69%)   0.0             sapiens , 821 aa. [WO9200999-A,   46 . . . 807    615/769 (79%)           23 JAN. 1992]       AAB84383   Amino acid sequence of a   39 . . . 798    508/774 (65%)   0.0           fibroblast growth factor receptor -   33 . . . 803    608/774 (77%)             Homo sapiens , 820 aa.           [US6255454-B1, 03 JUL. 2001]                  
 
     [0426] In a BLAST search of public sequence databases, the NOV14a protein was found to have homology to the proteins shown in the BLASTP data in Table 14E.  
               TABLE 14E                          Public BLASTP Results for NOV14a                                         NOV14a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               P22607   Fibroblast growth factor receptor   1 . . . 806    806/806 (100%)   0.0           3 precursor (EC 2.7.1.112)   1 . . . 806    806/806 (100%)           (FGFR-3) -  Homo sapiens             (Human), 806 aa.       Q8NI15   Fibroblast growth factor receptor   38 . . . 806     769/769 (100%)   0.0           3 -  Homo sapiens  (Human), 769   1 . . . 769    769/769 (100%)           aa (fragment).       A48991   heparin-binding growth factor   1 . . . 806   747/806 (92%)   0.0           receptor - mouse, 800 aa.   1 . . . 800   765/806 (94%)       Q9JHX9   Fibroblast growth factor receptor   1 . . . 806   745/806 (92%)   0.0           3 -  Rattus norvegicus  (Rat), 800   1 . . . 800   764/806 (94%)           aa.       Q99052   Fibroblast growth factor   1 . . . 806   745/806 (92%)   0.0           receptor -  Mus musculus     1 . . . 800   764/806 (94%)           (Mouse), 800 aa.                  
 
     [0427] PFam analysis predicts that the NOV14a protein contains the domains shown in the Table 14F.  
               TABLE 14F                          Domain Analysis of NOV14a                                             Identities/                   NOV14a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       ig    54 . . . 111   18/59 (31%)   8.3e−05                   40/59 (68%)           ig   169 . . . 230   21/65 (32%)   5.6e−07                   50/65 (77%)           ig   268 . . . 341   18/77 (23%)   1.6e−06                   54/77 (70%)           pkinase   472 . . . 750   98/319 (31%)    2.2e−91                   237/319 (74%)                       
 
     Example 15  
     [0428] The NOV15 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 15A.  
               TABLE 15A                       NOV15 Sequence Analysis                                                SEQ ID NO: 61   2077 bp       NOV15a, CG57341-01   SEQ ID NO: 61   2077 bp       DNA Sequence                   ATG GAGCGGTGGCGCGACCGG                 CCGGGCCCTGGTCCAGCAGGGACTGAAGGTGGTGGGCTGCGCCCGCACTGTGGGCAACATCGAGGAGC               TGGCTGCTGAATGTAAGAGTGCAGGCTACCCCGGGACTTTGATCCCCTACAGATGTGACCTATCAAAT               GAAGAGGACATCCTCTCCATGTTCTCAGCTATCCGTTCTCAGCACAGCGGTGTAGACATCTGCATCAA               CAATGCTGGCTTGGCCCGGCCTGACACCCTGCTCTCAGGCAGCACCAGTGGTTGGAAGGACATGTTCA               ATGTGAACGTGCTGGCCCTCAGCATCTGCACACGGGAAGCCTACCAGTCCATGAAGGAGCGGAATGTG               GACGATGGGCACATCATTAACATCAATAGCATGTCTGGCCACCGAGTGTTACCCCTGTCTGTGACCCA               CTTCTATAGTGCCACCAAGTATGCCGTCACTGCGCTGACAGAGGGACTGAGGCAAGAGCTTCGGGAGG               CCCAGACCCACATCCGAGCCACGTGGCAGCTTCGGAGGGAGGAGGCCGCTGCCGGATATCAGGCAGCC               ATCACTGTGAAGCTGGGGTTCTGTGGCCTCCATCCTCTCCCCTCGACCTCCCCAAGACCTGGCAAAGC               TCAGCCCCTGAGAAGGCCCTCTCTGTTGGCCCAGTGCATCTCTCCAGGTGTGGTGGAGACACAATTCG               CCTTCAAACTCCACGACAAGGACCCTGAGAAGGCAGCTGCCACCTATGAGCAAATGAAGTGTCTCAAA               CCCGAGGATGTGGCCGAGGCTGTTATCTACGTCCTCAGCACCCCCGCACACATCCAGATTGGAGACAT               CCAGATGAGGCCCACGGAGCAGAGAGCTCGGCGGAGACGGCTGTCGAGTACCCTTCACCTCGGTGTTG               GGAGCCTGGGAGCGAACTGCGGCGCGGGTTACCGCTCCCGGGGACGCAGCAAGGGGCATCGAGTCCCT               GGCGGGAGCTGCGCCATGGCATTGCTCTCGACCGTCCGGGGCGCGACCTGGGGTCGCCTCGTCACCCG               TCATTTCTCCCATGCAGCGCGGCATGGGGAGCGGCCTGGTGGGGAGGAGCTAAGCCGCTTGCTGCTGG               ATGACCTGGTGCCGACCTCTCGGCTGGAGCTTCTGTTTGGCATGACCCCGTGTCTCCTGGCTCTGCAG               GCCGCCCGCCGCTCTGTGGCCCGGCTCCTGCTCCAGGCGGGTAAAGCTGGGCTGCAGGGGAAGCGGGC               CGAGCTGCTCCGGATGGCCGAGGCGCGGGACATTCCAGTTCTGCGGCCCAGACGGCAGAAACTGGACA               CAATGTGCCGCTACCAGGTCCACCAGGGTGTCTGCATGGAGGTGAGCCCGCTGCGGCCCCGGCCTTGG               AGAGAGGCCGGGGAGGCGAGCCCAGGCGACGACCCCCAGCAGTTGTGGCTCGTCCTCGATGGGATCCA               GGATCCCCGGAATTTTGGGGCTGTGCTGCGTTCCGCACACTTCCTCGGAGTGGATAAGACCAAAGCCC               AGCAGGGCTGGCTCGTGGCCGGCACGGTGGGCTGCCCAAGCACAGAGGATCCCCAGTCCTCCGAGATC               CCCATCATGAGTTGCTTGGAGTTCCTCTGGGAACGGCCTACTCTCCTTGTGCTGGGGAATGAGGGCTC               AGGTCTATCCCAGGAGGTGCAGGCCTCCTGCCAGCTTCTCCTCACCATCCTGCCCCGGCGCCAGCTGC               CTCCTGGACTTGAGTCCTTGAACGTCTCTGTGGCTGCAGGAATTCTTCTTCACTCCATTTGCAGCCAG               AGGAAGGGTTTCCCCACAGAGGGGGAGAGAAGGCAGCTTCTCCAAGACCCCCAAGAACCCTCAGCCAG               GTCTGAAGGGCTCAGCATGGCTCAGCACCCAGGGCTGTCTTCAGGCCCAGAGAAAGAGAGGCAAAATG               AGGGC TGA   CGTGGACTGTCCACAGTGTTCATGTGCTGGAGTCAGGGACGGCCGCACCTGCCTCCGCCG                   GCTCCAGTGTGCGGGGAGCCTCTGCCTGAGTGTGCAC                                       NOV15a, CG57341-01   SEQ ID NO: 62   659 aa   MW at 71854.5 kD       Protein Sequence                 MERWRDRLALVTGASGGIGAAVARALVQQGLKVVGCARTVGNIEELAAECKSAGYPGTLIPYRCDLSN               EEDILSMFSAIRSQHSGVDICINNAGLARPDTLLSGSTSGWKDMFNVNVLALSICTREAYQSMKERNV               DDGHIININSMSGHRVLPLSVTHFYSATKYAVTALTEGLRQELREAQTHIRATWQLRREEAAAGYQAA               ITVKLGFCGLHPLPSTSPRPGKAQPLRRPSLLAQCISPGVVETQFAFKLHDKDPEKAAATYEQMKCLK               PEDVAEAVIYVLSTPAHIQIGDIQMRPTEQRARRRRLSSTLHLGVGSLGANCGAGYRSRGRSKGHRVP               GGSCAMALLSTVRGATWGRLVTRHFSHAARHGERPGGEELSRLLLDDLVPTSRLELLFGMTPCLLALQ               AARRSVARLLLQAGKAGLQGKRAELLRMAEARDIPVLRPRRQKLDTMCRYQVHQGVCMEVSPLRPRPW               REAGEASPGDDPQQLWLVLDGIQDPRNFGAVLRSAHFLGVDKTKAQQGWLVAGTVGCPSTEDPQSSEI               PIMSCLEFLWERPTLLVLGNEGSGLSQEVQASCQLLLTILPRRQLPPGLESLNVSVAAGILLHSICSQ               RKGFPTEGERRQLLQDPQEPSARSEGLSMAQHPGLSSGPEKERQNEG                  
 
     [0429] Further analysis of the NOV15a protein yielded the following properties shown in Table 15B.  
               TABLE 15B                       Protein Sequence Properties NOV15a                                        SignalP analysis:   No Known Signal Sequence Predicted                 PSORT II analysis:       PSG: a new signal peptide prediction method       N-region: length 7; pos. chg 3; neg. chg 2       H-region: length 16; peak value 7.43       PSG score: 3.03       GvH: von Heijne&#39;s method for signal seq. recognition       GvH score (threshold: −2.1): −0.02       possible cleavage site: between 20 and 21       &gt;&gt;&gt; Seems to have a cleavable signal peptide (1 to 20)       ALOM: Klein et al&#39;s method for TM region allocation       Init position for calculation: 21       Tentative number of TMS(s) for the threshold 0.5: 0       number of TMS(s) . . . fixed       PERIPHERAL Likelihood = 0.63 (at 394)       ALOM score: 0.63 (number of TMSs: 0)       MTOP: Prediction of membrane topology (Hartmann et al.)       Center position for calculation: 10       Charge difference: 1.0 C( 3.0)-N( 2.0)       C &gt; N: C-terminal side will be inside       &gt;&gt;&gt;Caution: Inconsistent mtop result with signal peptide       MITDISC: discrimination of mitochondrial targeting seq                             R content:    2   Hyd Moment (75):   4.39       Hyd Moment (95):   11.67   G content:   0       D/E content:    2   S/T content:   0                 Score: −4.81       Gavel: prediction of cleavage sites for mitochondrial preseq       cleavage site motif not found       NUCDISC: discrimination of nuclear localization signals       pat4: RRRR (5) at 305       pat4: RPRR (4) at 446       pat7: PVLRPRR (3) at 443       pat7: PRRQKLD (5) at 447       bipartite: none       content of basic residues: 12.0%       NLS Score: 0.78       KDEL: ER retention motif in the C-terminus: none       ER Membrane Retention Signals:       XXRR-like motif in the N-terminus: ERWR       none       SKL: peroxisomal targeting signal in the C-terminus: none       PTS2: 2nd peroxisomal targeting signal: none       VAC: possible vacuolar targeting motif: none       RNA-binding motif: none       Actinin-type actin-binding motif:       type 1: none       type 2: none       NMYR: N-myristoylation pattern: none       Prenylation motif: none       memYQRL: transport motif from cell surface to Golgi: none       Tyrosines in the tail: none       Dileucine motif in the tail: none       checking 63 PROSITE DNA binding motifs: none       checking 71 PROSITE ribosomal protein motifs: none       checking 33 PROSITE prokaryotic DNA binding motifs: none       NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination       Prediction: nuclear       Reliability: 55.5       COIL: Lupas&#39;s algorithm to detect coiled-coil regions       total: 0 residues       Final Results (k = 9/23):       47.8%: nuclear       39.1%: mitochondrial        4.3%: cytoplasmic        4.3%: vacuolar        4.3%: extracellular, including cell wall       &gt;&gt; prediction for CG57341-01 is nuc (k = 23)                  
 
     [0430] A search of the NOV15a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 15C.  
               TABLE 15C                          Geneseq Results for NOV15a                                         NOV15a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABU10698   Human secreted/transmembrane   1 . . . 302   253/302 (83%)   e−137           protein #189 -  Homo sapiens , 260   6 . . . 258   253/302 (83%)           aa. [US2002127584-A1, 12 SEP.           2002]       AAU76220   Human 21620 alcohol   1 . . . 302   253/302 (83%)   e−137           dehydrogenase (ADH) protein -   6 . . . 258   253/302 (83%)             Homo sapiens , 260 aa.           [US2002010946-A1, 24 JAN.           2002]       ABG95914   Human secreted/transmembrane   1 . . . 302   253/302 (83%)   e−137           protein PRO 1774 -  Homo sapiens ,   6 . . . 258   253/302 (83%)           260 aa. [US2002119130-A1, 29           AUG. 2002.]       AAB87589   Human PRO1774 -  Homo sapiens ,   1 . . . 302   253/302 (83%)   e−137           260 aa. [WO200116318-A2, 08   6 . . . 258   253/302 (83%)           MAR. 2001]       AAB84364   Amino acid sequence of human   1 . . . 302   253/302 (83%)   e−137           alcohol dehydrogenase 21620 -   6 . . . 258   253/302 (83%)             Homo sapiens , 260 aa.           [WO200144446-A2, 21 JUN.           2001]                  
 
     [0431] In a BLAST search of public sequence databases, the NOV15a protein was found to have homology to the proteins shown in the BLASTP data in Table 15D.  
               TABLE 15D                          Public BLASTP Results for NOV15a                                         NOV15a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               CAC43880   Sequence 2 from Patent    1 . . . 302   253/302 (83%)    e−136           WO0144446 -  Homo sapiens      6 . . . 258   253/302 (83%)           (Human), 260 aa.       Q9BUC7   Hypothetical protein -  Homo     75 . . . 302   179/228 (78%)   5e−92             sapiens  (Human), 181 aa.    1 . . . 179   179/228 (78%)       Q96GK2   Hypothetical protein -  Homo     515 . . . 659    142/145 (97%)   1e−76             sapiens  (Human), 158 aa.   14 . . . 158   143/145 (97%)       Q9H664   Hypothetical protein   515 . . . 659    142/145 (97%)   1e−76           FLJ22578 -  Homo sapiens     11 . . . 155   143/145 (97%)           (Human), 155 aa.       Q8BRZ1   Hypothetical protein -  Mus     357 . . . 523    131/167 (78%)   6e−71             musculus  (Mouse), 197 aa.   10 . . . 176   144/167 (85%)                  
 
     [0432] PFam analysis predicts that the NOV15a protein contains the domains shown in the Table 15E.  
               TABLE 15E                          Domain Analysis of NOV15a                                     Identities/                   Similarities           NOV15a   for the   Expect       Pfam Domain   Match Region   Matched Region   Value               adh_short   5 . . . 319   73/337 (22%)   1.9e−33               217/337 (64%)        SpoU_methylase   490 . . . 607    37/156 (24%)     1e−05               91/156 (58%)                  
 
     Example 16  
     [0433] The NOV16 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 16A.  
               TABLE 16A                       NOV16 Sequence Analysis                                            NOV16a, CG57460-01   SEQ ID NO: 63   736 bp       DNA Sequence   ORF Start: ATG at 13   ORF Stop: end of sequence                   AAAGCACCCGAG   ATG ACCCCGGCTCCTCCACCAGGAGCGCGGCCGGGCGCGGCGTCCCTAGCGGGCTT               CGCCGGGGTGGCGTCTCTGGGGCCTGGGGACCCCCGCCGCGCCGCTGACCCGCGCCCTCTGCCCCCAG               CGCTGTGCTTCGCCGTGAGCCGCTCGCTGCTGCTGACGTGCCTGGTGCCGGCCGCGCTGCTGGGCCTG               CGCTACTACTACAGCCGCAAGGTGATCCGCGCCTACCTGGAGTGCGCGCTGCACACGGACATGGCGGA               CATCGAGCAGTACTACATGAAGCCGCCCGGTGTGTCCCTGACCGCCCTATCCCCTGCAGGCTCCTGCT               TCTGGGTGGCCGTGCTGGATGGCAACGTGGTGGGCATTGTGGCTGCACGGGCCCACGAGGAGGACAAC               ACGGTGGAGCTGCTGCGGATGTCTGTGGACTCACGTTTCCGAGGCAAGGGCATCGCCAAGGCGCTGGG               CCGGAAGGTGCTGGAGTTCGCCGTGGTGCACAACTACTCCGCGGTGGTGCTGGGCACGACGGCCGTCA               AGGTGGCCGCCCACAAGCTCTACGAGTCGCTGGGCTTCAGACACATGGGCGCCAGTGACCACTACGTG               CTGCCGGGCATGACCCTCTCGCTGGCTGAGCGCCTCTTCTTCCAGGTCCGCTACCACCGCTACCGCCT               GCAGCTGCGCGAGGAG TGA   CCGCCGCCGCTCGCCCGCCCGCCCCCCCGGCCGCCCT                                       NOV16a, CG57460-01   SEQ ID NO: 64   228 aa   MW at 24767.5 kD       Protein Sequence                 MTPAPPPGARPGAASLAGFAGVASLGPGDPRRAADPRPLPPALCFAVSRSLLLTCLVPAALLGLRYYY               SRKVIRAYLECALHTDMADIEQYYMKPPGVSLTALSPAGSCFWVAVLDGNVVGIVAARAHEEDNTVEL               LRMSVDSRFRGKGIAKALGRKVLEFAVVHNYSAVVLGTTAVKVAAHKLYESLGFRHMGASDHYVLPGM               TLSLAERLFFQVRYHRYRLQLREE                  
 
     [0434] Further analysis of the NOV16a protein yielded the following properties shown in Table 16B.  
               TABLE 16B                       Protein Sequence Properties NOV16a                                        SignalP analysis:   Cleavage site between residues 64 and 65       PSORT II analysis:           PSG: a new signal peptide prediction method           N-region: length 10; pos. chg 1; neg. chg 0           H-region: length 18; peak value 8.32           PSG score: 3.92           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −3.74           possible cleavage site: between 25 and 26           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 2                                         INTEGRAL   Likelihood =   −2.02   Transmembrane   46-62           INTEGRAL   Likelihood =   −2.34   Transmembrane   109-125                                 PERIPHERAL   Likelihood =     2.38 (at 161)                         ALOM score: −2.34 (number of TMSs: 2)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 53           Charge difference: 2.0 C(3.0)-N(1.O)           C &gt; N: C-terminal side will be inside           &gt;&gt;&gt;Caution: Inconsistent mtop result with signal peptide           &gt;&gt;&gt; membrane topology: type 3b           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   1   Hyd Moment(75):   0.78           Hyd Moment (95):   2.47   G content:   6           D/E content:   1   S/T content:   3                         Score: −7.20           Gavel: prediction of cleavage sites for mitochondrial preseq           R-2 motif at 20 ARP|GA           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 11.4%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):                             44.4%:   endoplasmic reticulum           11.1%:   vacuolar           11.1%:   Golgi           11.1%:   mitochondrial           11.1%:   nuclear           11.1%:   cytoplasmic                         &gt;&gt; prediction for CG57460-01 is end (k=9)                  
 
     [0435] A search of the NOV16a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 16C.  
               TABLE 16C                          Geneseq Results for NOV16a                                             Identities/                   NOV16a   Similarities           Protein/Organism/   Residues/   for the       Geneseq   Length   Match   Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAE15442   Human drug metabolising    1 . . . 228   218/228 (95%)    e−121           enzyme (DME)-9 -  Homo      1 . . . 218   218/228 (95%)             sapiens , 218 aa.           [WO200179468-           A2, 25 OCT. 2001]       ABU11545   Human MDDT polypeptide SEQ   42 . . . 228   176/187 (94%)   2e−95           ID 492 -  Homo     20 . . . 196   177/187 (94%)             sapiens , 196 aa.           [WO200279449-A2, 10 OCT.           2002]       AAB19986   Human camello 3 (Hcml13)   42 . . . 195   144/154 (93%)   1e−75           protein (partial) -  Homo      1 . . . 144   144/154 (93%)             sapiens , 144 aa.           [WO200077024-A1, 21           DEC. 2000]       AAB19985   Human camello 2 (Hcml2)   47 . . . 200    63/158 (39%)   2e−21           protein -  Homo     56 . . . 203    92/158 (57%)             sapiens , 227 aa.           [WO200077024-A1, 21 DEC.           2000]       AAB19984   Human camello 1 (Hcml1)   41 . . . 196    60/160 (37%)   1e−19           protein -  Homo     50 . . . 199    88/160 (54%)             sapiens , 227 aa.           [WO200077024-A1, 21 DEC.           2000]                  
 
     [0436] In a BLAST search of public sequence databases, the NOV16a protein was found to have homology to the proteins shown in the BLASTP data in Table 16D.  
               TABLE 16D                          Public BLASTP Results for NOV16a                                             NOV16a   Identities/               Protein       Residues/   Similarities       Accession   Protein/Organism/   Match   for the   Expect       Number   Length   Residues   Matched Portion   Value               Q8N9F0   Hypothetical protein   85 . . . 228   134/144 (93%)    1e−69               FLJ37478 -  Homo      1 . . . 134   134/144 (93%)              sapiens  (Human), 134 aa.       Q8K065   Hypothetical protein -  Mus     176 . . . 228     53/53 (100%)   2e−23             musculus  (Mouse),   1 . . . 53    53/53 (100%)           53 aa (fragment).       Q9UHF3   Putative N-acetyltransferase   47 . . . 200   63/158 (39%)   7e−21           Camello 2 -  Homo     56 . . . 203   92/158 (57%)             sapiens             (Human), 227 aa.       Q9UQ17   GLA protein -  Homo     41 . . . 196   60/160 (37%)   4e−19             sapiens     50 . . . 199   88/160 (54%)           (Human), 227 aa.       Q9UHE5   Putative N-acetyltransferase   41 . . . 196   60/160 (37%)   4e−19           CML1 -  Homo     50 . . . 199   88/160 (54%)             sapiens             (Human), 227 aa.                  
 
     [0437] PFam analysis predicts that the NOV16a protein contains the domains shown in the Table 16E.  
               TABLE 16E                          Domain Analysis of NOV16a                                     Identities/                   Similarities           NOV16a Match   for the       Pfam Domain   Region   Matched Region   Expect Value               Acetyltransf   111 . . . 191   28/82 (34%)   1.8e−17               65/82 (79%)                  
 
     Example 17  
     [0438] The NOV17 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 17A.  
               TABLE 17A                       NOV17 Sequence Analysis                                            NOV17a, CG57570-01   SEQ ID NO: 65   1748 bp       DNA Sequence   ORF Start: ATG at 98   ORF Stop: end of sequence                   GTTCACCCCAAGACTAAGTTCTTTCCCAAGTTAGAGAAGAAGAGAGAAAGCAAAAAGAAGAGAGGAAA                   GTTCTCCCTTCCCCTCCTCCGTGCCTGTC   ATG TCCTCTAAGCCAGAGCCGAAGGACGTCCACCAACTG               AACGGGACTGGCCCTTCTGCCTCTCCCTGCTCTTCAGATGGCCCAGGGAGAGAGCCCTTGGCTGGGAC               CTCAGAGTTCCTGGGGCCTGATGGGGCTGGGGTAGAGGTGGTGATTGAGTCTCGGGCCAACGCCAAGG               GGGTTCGGGAGGAGGACGCCCTGCTGGAGAACGGGAGCCAGAGCAACGAAAGTGACGACGTCAGCACA               GACCGTGGCCCTGCGCCACCTTCCCCGCTCAAGGAGACCTCCTTTTCCATCGGGCTGCAAGTACTGTT               TCCATTCCTCCTGGCAGGCTTTGGGACCGTGGCTGCTGGCATGGTGTTGGACATCGTGCAGCACTGGG               AAGTCTTCCAGAAGGTGACAGAGGTCTTCATCCTAGTGCCTGCGCTGCTGGGGCTCAAAGGGAACCTG               GAAATGACCCTGGCATCAAGGCTTTCCACTGCAGCGAGTATCAACATTGGACACATGGACACACCCAA               GGAGCTCTGGCGGATGATCACTGGGAACATGGCCCTCATCCAGGTGCAGGCCACGGTGGTGGGCTTCC               TGGCGTCCATCGCAGCCGTCGTCTTTGGCTGGATCCCTGATGGCCACTTCAGTATTCCGCACGCCTTC               CTGCTCTGTGCTAGCAGCGTGGCCACAGCCTTCATTGCCTCCCTGGTACTGGGTATGATCATGATTGG               AGTCATCATTGGCTCTCGCAAGATTGGGATCAACCCAGACAATGTGGCCACACCCATTGCTGCCAGCC               TGGGCGACCTCATCACCTTGGCGCTGCTCTCAGGCATCAGCTGGGGACTCCTGACCTCTGCCCTCTCA               GATCACTGGCGATACATCTACCCACTGGTGTGTGCTTTCTTTGTGGCCCTGCTGCCTGTCTGGGTGGT               GCTGGCCCGACGAAGTCCAGCCACAAGGGAGGTGTTGTACTCGGGCTGGGAGCCTGTTATCATTGCCA               TGGCCATCAGCAGTGTGGGAGGCCTCATCTTGGACAAGACTGTCTCAGACCCCAACTTTGCTCGGATG               GCTGTCTTCACGCCTGTGATTAATGGTGTTGGGGGCAATCTGGTGGCAGTGCAGGCCAGCCGCATCTC               CACCTTCCTGCACATGAATGGAATGCCCGGAGAGAACTCTGAGCAAGCTCCTCGCCGCTGTCCCAGTC               CTTGTACCACCTTCTTCAGCCCTGGTGTGAATTCTCGCTCAGCCCGGGTCCTCTTCCTCCTCGTGGTC               CCAGGACACCTGGTGTTCCTCTACACCATCAGCTGTATGCAGGGCGGGCACACCACCCTCACACTCAT               CTTCATCATCTTCTATATGACAGCTGCACTGCTCCAGGTGCTGATTCTCCTGTACATCGCAGACTGGA               TGGTGCACTGGATGTGGGGCCGGGGCCTGGACCCGGACAACTTCTCCATCCCATACTTGACTGCTCTG               GGGGACCTGCTTGGCACTGGGCTCCTAGCACTCAGCTTCCATGTTCTCTGGCTCATAGGGGACCGAGA               CACGGATGTCGGGGAC TAG   CTTGGTCACTCAACATTTTCCCCATCCCTCTGCACTTTCTATTTGAAAT                   TTTTCTTTTGTTCCCCTGTCCCTCCTCCACCCCACACTCCCACCTCTT                                       NOV17a, CG57570-01   SEQ ID NO: 66   517 aa   MW at 55097.3 kD       Protein Sequence                 MSSKPEPKDVHQLNGTGPSASPCSSDGPGREPLAGTSEFLGPDGAGVEVVIESRANAKGVREEDALLE               NGSQSNESDDVSTDRGPAPPSPLKETSFSIGLQVLFPFLLAGFGTVAAGMVLDIVQHWEVFQKVTEVF               ILVPALLGLKGNLEMTLASRLSTAASINIGHMDTPKELWRMITGNMALIQVQATVVGFLASIAAVVFG               WIPDGHFSIPHAFLLCASSVATAFIASLVLGMIMIGVIIGSRKIGINPDNVATPIAASLGDLITLALL               SGISWGLLTSALSDHWRYIYPLVCAFFVALLPVWVVLARRSPATREVLYSGWEPVIIAMAISSVGGLI               LDKTVSDPNFAGMAVFTPVINGVGGNLVAVQASRISTFLHMNGMPGENSEQAPRRCPSPCTTFFSPGV               NSRSARVLFLLVVPGHLVFLYTISCMQGGHTTLTLIFIIFYMTAALLQVLILLYIADWMVHWMWGRGL               DPDNFSIPYLTALGDLLGTGLLALSFHVLWLIGDRDTDVCD                  
 
     [0439] Further analysis of the NOV17a protein yielded the following properties shown in Table 17B.  
               TABLE 17B                       Protein Sequence Properties NOV17a                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:           PSG: a new signal peptide prediction method           N-region: length 9; pos. chg 2; neg. chg 2           H-region: length 16; peak value 3.46           PSG score: −0.94           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −8.12           possible cleavage site: between 25 and 26           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 10                                         INTEGRAL   Likelihood =   −3.35   Transmembrane   107-123           INTEGRAL   Likelihood =     0.21   Transmembrane   128-144           INTEGRAL   Likelihood =   −5.57   Transmembrane   190-206           INTEGRAL   Likelihood =   −10.72    Transmembrane   227-243           INTEGRAL   Likelihood =   −2.34   Transmembrane   259-275           INTEGRAL   Likelihood =   −10.77    Transmembrane   294-310           INTEGRAL   Likelihood =   −2.71   Transmembrane   326-342           INTEGRAL   Likelihood =   −6.26   Transmembrane   415-431           INTEGRAL   Likelihood =   −8.55   Transmembrane   443-459           INTEGRAL   Likelihood =   −3.50   Transmembrane   492-508                                     PERIPHERAL   Likelihood =     0.90   (at 354)                         ALOM score: −10.77 (number of TMSs: 10)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 114           Charge difference: −1.5 C(−1.5)-N(0.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0             Hyd Moment (75):   5.28           Hyd Moment (95):   4.64        G content:   0           D/E content:   2           S/T content:   2                         Score: −6.73           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 5.2%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs:           Leucine zipper pattern (PS00029): *** found ***           LTALGDLLGTGLLALSFHVLWL at 486           none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):                             66.7%:   endoplasmic reticulum           22.2%:   mitochondrial           11.1%:   vesicles of secretory system                         &gt;&gt; prediction for CG57570-01 is end (k=9)                  
 
     [0440] A search of the NOV17a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 17C.  
               TABLE 17C                          Geneseq Results for NOV17a                                         NOV17a   Identities/               Protein/Organism/   Residues/   Similarities       Geneseq   Length   Match   for the   Expect       Identifier   [Patent #, Date]   Residues   Matched Region   Value               ABB08638   Human transporter protein SEQ    1 . . . 517   506/517 (97%)   0.0           ID NO 2 -  Homo      1 . . . 513   507/517 (97%)             sapiens , 513 aa.           [WO200190360-A2, 29 NOV.           2001]       ABP74113   Human TRICH SEQ ID NO 18 -   62 . . . 517   307/457 (67%)   e−173             Homo     125 . . . 573    373/457 (81%)             sapiens , 573 aa.           [WO200246415-A2, 13 JUN.           2002]       AAB95482   Human protein sequence SEQ ID   62 . . . 517   307/457 (67%)   e−173           NO: 18007 -  Homo     42 . . . 490   373/457 (81%)             sapiens , 490           aa. [EP1074617-A2, 07 FEB.           2001]       AAY94882   Human protein clone   60 . . . 508   246/451 (54%)   e−129           HP10031 - Homo      33 . . . 470   315/451 (69%)             sapiens , 487 aa.           [WO200005367-A2,           03 FEB. 2000]       AAM47910   Human initiation   107 . . . 508    227/404 (56%)   e−121           factor 46 - Homo      1 . . . 397   290/404 (71%)             sapiens , 414 aa.           [CN1307045-A, 08 AUG. 2001]                  
 
     [0441] In a BLAST search of public sequence databases, the NOV17a protein was found to have homology to the proteins shown in the BLASTP data in Table 17D.  
               TABLE 17D                          Public BLASTP Results for NOV17a                                         NOV17a   Identities/           Protein       Residues/   Similarities       Accession   Protein/Organism/   Match   for the   Expect       Number   Length   Residues   Matched Portion   Value               Q8IVJ1   Solute carrier family 41 member    1 . . . 517   502/517 (97%)   0.0           1 -  Homo      1 . . . 513   504/517 (97%)             sapiens  (Human), 513           aa.       Q8BJA2   Hypothetical divalent cation    1 . . . 517   496/517 (95%)   0.0           transporter containing protein-    1 . . . 512   499/517 (95%)             Mus musculus  (Mouse), 512 aa.       Q8BYR8   Hypothetical divalent cation   62 . . . 517   306/456 (67%)   e−175           transporter containing protein-   126 . . . 573    373/456 (81%)             Mus musculus  (Mouse), 573 aa.       Q9H0E5   Hypothetical protein   62 . . . 517   307/457 (67%)   e−173           DKFZp434K0427 -  Homo     42 . . . 490   373/457 (81%)             sapiens  (Human), 490 aa.       Q96JW4   Hypothetical protein FLJ14932-   62 . . . 517   307/457 (67%)   e−173             Homo     42 . . . 490   373/457 (81%)             sapiens  (Human), 490 aa.                  
 
     [0442] PFam analysis predicts that the NOV17a protein contains the domains shown in the Table 17E.  
               TABLE 17E                          Domain Analysis of NOV17a                                         Identities/                       Similarities       Pfam   NOV17a   for the       Domain   Match Region   Matched Region   Expect Value               MgtE   138 . . . 276   39/140 (28%)   2.8e−26                   117/140 (84%)       MgtE   356 . . . 503   33/153 (22%)   1.1e−06               103/153 (67%)                  
 
     Example 18  
     [0443] The NOV18 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 18A.  
               TABLE 18A                       NOV18 Sequence Analysis                                            NOV18a, CG57758-02   SEQ ID NO: 67   1899 bp       DNA Sequence   ORF Start: ATG at 31   ORF Stop: end of sequence                   CGTCTCGCCCGCCAGTCTCCCTCCCGCGCG   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTC               CTTCGTGATCTTGTTCGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGGTCA               GTTGCTGTGCCTACGTCATCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTC               ACCTCTCTCATGCCTGTCTTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCA               GTACATGAAGGACACCAACATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGA               ACCTGCACAAGAGGATCGCCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTG               GGCTTCATGGGCGTCACAGCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGT               GCCCATCGTGGAGGCCATATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGG               GACAAGGTACCACAATAAACAACCTGAATGCACTGGAGGATGATACAGTGAAAGCAGTACTAGGAGGA               AAGTGTGTAGCTATAATAAGCACTTACGTCAAAAAAGTAGAAAAACTTCAAATAAACAATCTAATGAC               ACCTCTTAAAAAACTAGAAAAGCAAGAGCAACAGGACCTAGGGCCTGGCATCAGGCCTCAGGACTCTG               CCCAGTGCCAGGAAGACCAAGAGCGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCG               GCCAGCATCGGGGGCACCGCCACCCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAA               CGAGTTGTTTCCTGACAGCAAGGACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACA               TGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCTCCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAG               TCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTA               CCGGAAGCTGGGGCCCTTGTCCTTCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCC               TGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACA               AAGTCAGTCTCCGATGCCACTGTGGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAA               GCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAAGGTAAGTCTCCTGTTCTGATCGCCCCCCCTCCCC               TGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTT               GCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCGTGTGGATGGGCAAGCAGATGGAGCCCTTGCA               CGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAA               GCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCGGCCTCAAT               CCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCC               TCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCTGACATGGTAAAAACAGGAGTCATAA               TGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTG               GATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACT TAG   GAAGAGCCACAAGACCAC                                       NOV18a, CG57758-02   SEQ ID NO: 68   616 aa   MW at 67816.9 kD       Protein Sequence                 MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCCAYVIILMAIYWCTEVIPLAVTSLMPVLLFP               LFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLS               MWISNTATTAMMVPIVEAILQQMEATSAATEAGLEGQGTTINNLNALEDDTVKAVLGGKCVAIISTYV               KKVEKLQINNLMTPLKKLEKQEQQDLGPGIRPQDSAQCQEDQERKRLCKAMTLCICYAASIGGTATLT               GTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKK               NEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKSVSDATVAI               FVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASG               LSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSRSIGLNPLYIMLPCTL               SASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVT               HIET                                 NOV18b, CG57758-01   SEQ ID NO: 69   1790 bp       DNA Sequence   ORF Start: ATG at 16   ORF Stop: end of sequence                   TCTCCCTCCCGCGCG   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTT               CGTCACCCCGCTCCTGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGGTCAGTTGTGCCTACGTCA               TCATCCTCATGGCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTC               TTGCTTTTCCCACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAA               CATGCTGTTCCTGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCG               CCCTGCGCACGCTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACA               GCCCTCCTGTCCATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCAT               ATTGCAGCAGATGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGG               CCAAGGAGCTGCCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAG               CGGAAGAGGTTGTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCAC               CCTGACCGGGACGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGG               ACCTCGTGAACTTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCC               TGGCTGTGGCTCCAGTTTGTTTACATGTTCTCCAGTTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAG               CAAGAAAAACGAGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGCTGGGGCCCTTGTCCT               TCGCGGAGATCAACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGC               TTCATGCCCGGCTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGT               GGCCATCTTTGTGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCC               AGACTGAGGAAGGTAAGTCTCCTGTTCTGATCGCCCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAG               GAGAAAGTGCCCTGGGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGC               CTCGGGGCTGTCCGTGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCA               CCTTGATCTTGTCCTTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTG               TTCCTGCCCATCTTTGCCTCCATGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTG               TACCCTGAGTGCCTCCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCT               ATGGGCACCTCAAGGTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGT               GTGTTTTTGGCTGTCAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAA               TGTGACACATATTGAGACT TAG   GAAGAGCCACAAGACCACACACACAGCCCTTACCCTCCTCAGGACT                   ACCGAACCTTCTGGCACACCTT                                       NOV18b, CG57758-01   SEQ ID NO: 70   568 aa   MW at 62592.9 kD       Protein Sequence                 MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCAYVIILMAIYWCTEVIPLAVTSLMPVLLFPL               FQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLSM               WISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRLC               KAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWLQ               FVYMFSSFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPGW               LTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPW               GIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIF               ASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAV               NTWGRAIFDLDHFPDWANVTHIET                                 NOV18c, CG57758-03   SEQ ID NO: 71   3147 bp       DNA Sequence   ORF Start: ATG at 2   ORF Stop: end of sequence                   G   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCC               TGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATG               GCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCC               ACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCC               TGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACG               CTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTC               CATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGA               TGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTG               CCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTT               GTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGA               CGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAAC               TTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCT               CCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACG               AGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATC               AACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGG               CTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTG               TGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAA               GAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTG               GGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCG               TGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCC               TTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTT               TGCCTCCATGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCCTGAGTGCCT               CCTTTGCCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAG               GTTGCTGACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGT               CAACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTG               AGACT TAG   GAAGAGCCACAAGACCACACACACAGCCCTTACCCTCCTCAGGACTACCGAACCTTCTGG                   CACACCTTGTACAGAGTTTTGGGGTTCACACCCCAAAATGACCCAACGATGTCCACACACCACCAAAA                   CCCAGCCAATGGGCCACCTCTTCCTCCAAGCCCAGATGCAGAGATGGTCATGGGCAGCTGGAGGGTAG                   GCTCAGAAATGAAGGGAACCCCTCAGTGGGCTGCTGGACCCATCTTTCCCAAGCCTTGCCATTATCTC                   TGTGAGGGAGGCCAGGTAGCCGAGGGATCAGGATGCAGGCTGCTGTACCCGCTCTGCCTCAAGCATCC                   CCCACACAGGGCTCTGGTTTTCACTCGCTTCGTCCTAGATAGTTTAAATGGGAATCGGATCCCCTGGT                   TGAGAGCTAAGACAACCACCTACCAGTGCCCATGTCCCTTCCAGCTCACCTTGAGCAGCCTCAGATCA                   TCTCTGTCACTCTGGAAGGGACACCCCAGCCAGGGACGGAATGCCTGGTCTTGAGCAACCTCCCACTG                   CTGGAGTGCGAGTGGGAATCAGAGCCTCCTGAAGCCTCTGGGAACTCCTCCTGTGGCCACCACCAAAG                   GATGAGGAATCTGAGTTGCCAACTTCAGGACGACACCTGGCTTGCCACCCACAGTGCACCACAGGCCA                   ACCTACGCCCTTCATCACTTGGTTCTGTTTTAATCGACTGGCCCCCTGTCCCACCTCTCCAGTGAGCC                   TCCTTCAACTCCTTGGTCCCCTGTTGTCTGGGTCAACATTTGCCGAGACGCCTTGGCTGGCACCCTCT                   GGGGTCCCCCTTTTCTCCCAGGCAGGTCATCTTTTCTGGCAGATGCTTCCCCTGCCATCCCCAAATAG                   CTAGGATCACACTCCAAGTATGGGCAGTGATGGCGCTCTGGGGGCCACAGTGGGCTATCTAGGCCCTC                   CCTCACCTGAGGCCCAGAGTGGACACAGCTGTTAATTTCCACTGGCTATGCCACTTCAGAGTCTTTCA                   TGCCAGCGTTTGAGCTCCTCTGGGTAAAATCTTCCCTTTGTTGACTGGCCTTCACAGCCATGGCTGGT                   GACAACAGAGGATCGTTGAGATTGAGCAGCGCTTGGTGATCTCTCAGCAAACAACCCCTCCCCGTGGG                   CCAATCTACTTGAAGTTACTCGGACAAAGACCCCAAAGTGGGGCAACAACTCCAGAGAGGCTGTGGGA                   ATCTTCAGAAGCCCCCCTGTAAGAGACAGACATGAGAGACAAGCATCTTCTTTCCCCCGCAAGTCCAT                   TTTATTTCCTTCTTGTGCTGCTCTGGAAGAGAGGCAGTAGCAAAGAGATGAGCTCCTGGATGGCATTT                   TCCAGGGCAGGAGAAAGTATGAGAGCCTCAGGAAACCCCATCAAGGACCGAGTATGTGTCTGGTTCCT                   TTGGTGGTTGGCTTCTGGC                                       NOV18c, CG57758-03   SEQ ID NO: 72   568 aa   MW at 63061.4 kD       Protein Sequence                 MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFP               LFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLS               MWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRL               CKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWL               QFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPG               WLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPW               GIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIF               ASMSRSIGLNPLYIMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAV               NTWGRAIFDLDHFPDWANVTHIET                                 NOV18d, CG57758-04   SEQ ID NO: 73   1606 bp       DNA Sequence   ORF Start: ATG at 2   ORF Stop: end of sequence                   G   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCC               TGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATG               GCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCC               ACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCC               TGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACG               CTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTC               CATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGA               TGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTG               CCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTT               GTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGA               CGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAAC               TTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCT               CCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACG               AGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATC               AACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGG               CTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTG               TGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAA               GAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTG               GGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCG               TGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCC               TTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTT               TGCCTCCATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCA               ACACCTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAG               ACT TAG   GAAGAGCCACAAGACCACACACATAGCCCTTACCCT                                       NOV18d, CG57758-04   SEQ ID NO: 74   522 aa   MW at 58109.6 kD       Protein Sequence                 MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFP               LFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLS               MWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRL               CKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWL               QFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPG               WLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPW               GIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIF               ASMVKTGVIMNIIGVFCVFLAVNTWGRAIFDLDHFPDWANVTHIET                                 NOV18e, CG57758-05   SEQ ID NO: 75   1781 bp       DNA Sequence   ORF Start: ATG at 2   ORF Stop: end of sequence                   G   ATG GCCTCGGCGCTGAGCTATGTCTCCAAGTTCAAGTCCTTCGTGATCTTGTTCGTCACCCCGCTCC               TGCTGCTGCCACTCGTCATTCTGATGCCCGCCAAGTTTGTCAGGTGTGCCTACGTCATCATCCTCATG               GCCATTTACTGGTGCACAGAAGTCATCCCTCTGGCTGTCACCTCTCTCATGCCTGTCTTGCTTTTCCC               ACTCTTCCAGATTCTGGACTCCAGGCAGGTGTGTGTCCAGTACATGAAGGACACCAACATGCTGTTCC               TGGGCGGCCTCATCGTGGCCGTGGCTGTGGAGCGCTGGAACCTGCACAAGAGGATCGCCCTGCGCACG               CTCCTCTGGGTGGGGGCCAAGCCTGCACGGCTGATGCTGGGCTTCATGGGCGTCACAGCCCTCCTGTC               CATGTGGATCAGTAACACGGCAACCACGGCCATGATGGTGCCCATCGTGGAGGCCATATTGCAGCAGA               TGGAAGCCACAAGCGCAGCCACCGAGGCCGGCCTGGAGCTGGTGGACAAGGGCAAGGCCAAGGAGCTG               CCAGGGAGTCAAGTGATTTTTGAAGGCCCCACTCTGGGGCAGCAGGAAGACCAAGAGCGGAAGAGGTT               GTGTAAGGCCATGACCCTGTGCATCTGCTACGCGGCCAGCATCGGGGGCACCGCCACCCTGACCGGGA               CGGGACCCAACGTGGTGCTCCTGGGCCAGATGAACGAGTTGTTTCCTGACAGCAAGGACCTCGTGAAC               TTTGCTTCCTGGTTTGCATTTGCCTTTCCCAACATGCTGGTGATGCTGCTGTTCGCCTGGCTGTGGCT               CCAGTTTGTTTACATGAGATTCAATTTTAAAAAGTCCTGGGGCTGCGGGCTAGAGAGCAAGAAAAACG               AGAAGGCTGCCCTCAAGGTGCTGCAGGAGGAGTACCGGAAGTTGGGGCCCTTGTCCTTCGCGGAGATC               AACGTGCTGATCTGCTTCTTCCTGCTGGTCATCCTGTGGTTCTCCCGAGACCCCGGCTTCATGCCCGG               CTGGCTGACTGTTGCCTGGGTGGAGGGTGAGACAAAGTATGTCTCCGATGCCACTGTGGCCATCTTTG               TGGCCACCCTGCTATTCATTGTGCCTTCACAGAAGCCCAAGTTTAACTTCCGCAGCCAGACTGAGGAA               GAAAGGAAAACTCCATTTTATCCCCCTCCCCTGCTGGATTGGAAGGTAACCCAGGAGAAAGTGCCCTG               GGGCATCGTGCTGCTACTAGGGGGCGGATTTGCTCTGGCTAAAGGATCCGAGGCCTCGGGGCTGTCCG               TGTGGATGGGGAAGCAGATGGAGCCCTTGCACGCAGTGCCCCCGGCAGCCATCACCTTGATCTTGTCC               TTGCTCGTTGCCGTGTTCACTGAGTGCACAAGCAACGTGGCCACCACCACCTTGTTCCTGCCCATCTT               TGCCTCCATGAATCACGTCCCCAAGAGCTTCTGTGTTCTGTACGGTGATGTTGCAGTGCTGTCTTTCC               GCAGTCTCGCTCCATCGGCCTCAATCCGCTGTACATCATGCTGCCCTGTACCC TGA   GTGCCTCCTTTG                   CCTTCATGTTGCCTGTGGCCACCCCTCCAAATGCCATCGTGTTCACCTATGGGCACCTCAAGGTTGCT                   GACATGGTGAAAACAGGAGTCATAATGAACATAATTGGAGTCTTCTGTGTGTTTTTGGCTGTCAACAC                   CTGGGGACGGGCCATATTTGACTTGGATCATTTCCCTGACTGGGCTAATGTGACACATATTGAGACTT                   AGGAAGAGCCACA                                       NOV18e, CG57758-05   SEQ ID NO: 76   516 aa   MW at 57173.5 kD       Protein Sequence                 MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTSLMPVLLFP               LFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAKPARLMLGFMGVTALLS               MWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDKGKAKELPGSQVIFEGPTLGQQEDQERKRL               CKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASWFAFAFPNMLVMLLFAWLWL               QFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLSFAEINVLICFFLLVILWFSRDPGFMPG               WLTVAWVEGETKYVSDATVAIFVATLLFIVPSQKPKFNFRSQTEEERKTPFYPPPLLDWKVTQEKVPW               GIVLLLGGGFALAKGSEASGLSVWMGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIF               ASMNHVPKSFCVLYGDVAVLSFRSLAPSASIRCTSCCPVP                  
 
     [0444] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 18B.  
               TABLE 18B                       Comparison of the NOV18 protein sequences.                                        NOV18a   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVSCCAYVIILMAIYWCTEVIPLAVTS       NOV18b   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKVS-CAYVIILMAIYWCTEVIPLAVTS       NOV18c   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTS       NOV18d   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTS       NOV18e   MASALSYVSKFKSFVILFVTPLLLLPLVILMPAKFVRCAYVIILMAIYWCTEVIPLAVTS               NOV18a   LMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAK       NOV18b   LMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAK       NOV18c   LMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAK       NOV18d   LMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAK       NOV18e   LMPVLLFPLFQILDSRQVCVQYMKDTNMLFLGGLIVAVAVERWNLHKRIALRTLLWVGAK               NOV18a   PARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLEGQGTTINNL       NOV18b   PARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLEL----VD--       NOV18c   PARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDK-----       NOV18d   PARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDK-----       NOV18e   PARLMLGFMGVTALLSMWISNTATTAMMVPIVEAILQQMEATSAATEAGLELVDK-----               NOV18a   NALEDDTVKAVLGGKCVAIISTYVKKVEKLQINNLMTPLKKLEKQEQQDLGPGIRPQDSA       NOV18b   --------KGK---------------------------AKELPGSQVIFEGPTLG---Q-       NOV18c   -------------GK-----------------------AKELPGSQVIFEGPTLG-Q---       NOV18d   -------------GK-----------------------AKELPGSQVIFEGPTLG-Q---       NOV18e   -------------GK-----------------------AKELPGSQVIFEGPTLG-Q---               NOV18a   QCQEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASW       NOV18b   -Q-EDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASW       NOV18c   --QEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASW       NOV18d   --QEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASW       NOV18e   --QEDQERKRLCKAMTLCICYAASIGGTATLTGTGPNVVLLGQMNELFPDSKDLVNFASW               NOV18a   FAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLS       NOV18b   FAFAFPNMLVMLLFAWLWLQFVYMFSSFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLS       NOV18c   FAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLS       NOV18d   FAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLS       NOV18e   FAFAFPNMLVMLLFAWLWLQFVYMRFNFKKSWGCGLESKKNEKAALKVLQEEYRKLGPLS               NOV18a   FAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKSVSDATVAIFVATLLFIVPSQ       NOV18b   FAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQ       NOV18c   FAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQ       NOV18d   FAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQ       NOV18e   FAEINVLICFFLLVILWFSRDPGFMPGWLTVAWVEGETKYVSDATVAIFVATLLFIVPSQ               NOV18a   KPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVW       NOV18b   KPKFNFRSQTEEGKSPVLIAPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVW       NOV18c   KPKFNFRSQTEEERK-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVW       NOV18d   KPKFNFRSQTEEERK-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVW       NOV18e   KPKFNFRSQTEEERK-TPFYPPPLLDWKVTQEKVPWGIVLLLGGGFALAKGSEASGLSVW               NOV18a   MGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGLNPLY       NOV18b   MGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGLNPLY       NOV18c   MGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMSR---SIGLNPLY       NOV18d   MGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMVKTGVIMNIIGVF       NOV18e   MGKQMEPLHAVPPAAITLILSLLVAVFTECTSNVATTTLFLPIFASMN------HVPKSF               NOV18a   IMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGR       NOV18b   IMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGR       NOV18c   IMLPCTLSASFAFMLPVATPPNAIVFTYGHLKVADMVKTGVIMNIIGVFCVFLAVNTWGR       NOV18d   CVFLAVNTWGRAIFDLDHFPDWANVTHIET------------------------------       NOV18e   CVLYGD----VAVLSFRSLAPSASIRCTSCCPVP--------------------------               NOV18a   AIFDLDHFPDWANVTHIET       NOV18b   AIFDLDHFPDWANVTHIET       NOV18c   AIFDLDHFPDWANVTHIET       NOV18d   -------------------       NOV18e   -------------------               NOV18a   (SEQ ID NO: 68)       NOV18b   (SEQ ID NO: 70)       NOV18c   (SEQ ID NO: 72)       NOV18d   (SEQ ID NO: 74)       NOV18e   (SEQ ID NO: 76)                  
 
     [0445] Further analysis of the NOV18a protein yielded the following properties shown in Table 18C.  
               TABLE 18C                       Protein Sequence Properties NOV18a                                        SignalP analysis:   Cleavage site between residues 39 and 40       PSORT II analysis:           PSG: a new signal peptide prediction method           N-region: length 10; pos. chg 1; neg. chg 0           H-region: length 1; peak value 5.97           PSG score: 1.57           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1): −2.36           possible cleavage site: between 30 and 31           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 11                                         INTEGRAL   Likelihood =   −12.21    Transmembrane   14-30           INTEGRAL   Likelihood =   −3.61   Transmembrane   35-51           INTEGRAL   Likelihood =   −4.99   Transmembrane   53-69           INTEGRAL   Likelihood =   −1.75   Transmembrane   124-140           INTEGRAL   Likelihood =   −4.19   Transmembrane   309-325           INTEGRAL   Likelihood =   −8.01   Transmembrane   359-375           INTEGRAL   Likelihood =   −6.26   Transmembrane   401-417           INTEGRAL   Likelihood =     0.21   Transmembrane   453-469           INTEGRAL   Likelihood =   −7.11   Transmembrane   491-507           INTEGRAL   Likelihood =   −1.70   Transmembrane   538-554           INTEGRAL   Likelihood =   −7.43   Transmembrane   576-592                                 PERIPHERAL   Likelihood =       0.74 (at 89)                         ALOM score: −12.21 (number of TMSs: 11)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 21           Charge difference: −2.0 C(1.0)-N(3.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0             Hyd Moment(75):   1.18           Hyd Moment (95):   3.95        G content:   0           D/E content:   1           S/T content:   7                         Score: −3.82           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: none           bipartite: none           content of basic residues: 7.6%           NLS Score: −0.47           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):                             66.7%:   endoplasmic reticulum           22.2%:   mitochondrial           11.1%:   nuclear                         &gt;&gt; prediction for CG57758-02 is end (k=9)                  
 
     [0446] A search of the NOV18a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 18D.  
               TABLE 18D                          Geneseq Results for NOV18a                                         NOV18a   Identities/                   Residues/   Similarities       Geneseq   Protein/Organism/Length   Match   for the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAU79946   Human transporter protein   1 . . . 616   535/617 (86%)   0.0           sequence -  Homo sapiens , 568 aa.   1 . . . 568   542/617 (87%)           [US2002019028-A1, 14 FEB.           2002]       AAB23625   Human secreted protein SEQ ID   10 . . . 614    253/623 (40%)   e−141           NO: 50 -  Homo sapiens , 627 aa.   9 . . . 623   395/623 (62%)           [WO200049134-A1, 24 AUG.           2000]       AAB36158   Novel human transporter protein   10 . . . 614    253/623 (40%)   e−141           SEQ ID NO: 2 -  Homo sapiens ,   9 . . . 623   395/623 (62%)           627 aa. [WO200065055-A2, 02           NOV. 2000]       ABB97450   Novel human protein SEQ ID NO:   10 . . . 614    253/623 (40%)   e−141           718 -  Homo sapiens , 627 aa.   9 . . . 623   395/623 (62%)           [WO200222660-A2, 21 MAR.           2002]       AAB42213   Human ORFX ORF1977   10 . . . 614    253/623 (40%)   e−141           polypeptide sequence SEQ ID   9 . . . 623   395/623 (62%)           NO: 3954 -  Homo sapiens , 627 aa.           [WO200058473-A2, 05 OCT.           2000]                  
 
     [0447] In a BLAST search of public sequence databases, the NOV18a protein was found to have homology to the proteins shown in the BLASTP data in Table 18E.  
               TABLE 18E                          Public BLASTP Results for NOV18a                                         NOV18a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         AAN86530   Na+-coupled citrate transporter   1 . . . 616   537/617 (87%)   0.0           protein -  Homo sapiens  (Human),   1 . . . 568   544/617 (88%)           568 aa.       Q8CJ44   Sodium-coupled citrate transporter   1 . . . 616   422/620 (68%)   0.0           -  Rattus norvegicus  (Rat), 572 aa.   1 . . . 572   484/620 (78%)       O57661   Intestinal sodium/LITHIUM-   1 . . . 612   355/619 (57%)   0.0           dependent dicarboxylate   1 . . . 619   472/619 (75%)           transporter (NA(+)/dicarboxylate           cotransporter) -  Xenopus laevis             (African clawed frog), 622 aa.       AAH44437   Similar to solute carrier family 13,   5 . . . 612   330/635 (51%)   0.0           member 2 -  Brachydanio rerio     10 . . . 605    443/635 (68%)           (Zebrafish) ( Danio rerio ), 613 aa.       AAO27449   Sodium dicarboxylate Co-   11 . . . 611    324/602 (53%)   0.0           transporter -  Didelphis marsupialis     11 . . . 587    439/602 (72%)             virginiana  (North American           opossum), 605 aa.                  
 
     [0448] PFam analysis predicts that the NOV18a protein contains the domains shown in the Table 18F.  
               TABLE 18F                          Domain Analysis of NOV18a                                     Identities/                   Similarities           NOV18a   for the Matched   Expect       Pfam Domain   Match Region   Region   Value               Na_sulph_symp   6 . . . 602   163/647 (25%)   3.5e−134               447/647 (69%)                  
 
     Example 19  
     [0449] The NOV19 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 19A.  
               TABLE 19A                       NOV19 Sequence Analysis                                            NOV19a, CG59693-01   SEQ ID NO: 77   972 bp       DNA Sequence   ORF Start: ATG at 1   ORF Stop: end of sequence                   ATG GATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGGATTTGGCAC               CTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCT               TCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAG               ATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCG               ACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCT               ACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAA               ATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATT               GGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGC               TCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGAT               TTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATG               GGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGC               GAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTAC               AATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGC               CATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATC               CATTTTCTGATGAATAT TAA                                       NOV19a, CG59693-01   SEQ ID NO: 78   323 aa   MW at 36787.9 kD       Protein Sequence                 MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSK               IADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGK               ILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLD               FCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSY               NEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY                                 NOV19b, CG59693-02   SEQ ID NO: 79   983 bp       DNA Sequence   ORF Start: ATG at 30   ORF Stop: end of sequence                   ATGGATTCGATATCAGTGTGTGAAGCTGA   ATG ATGGTCACTTCGTGCCTGTCCTGGGATTTGGCACCT               ATGCGCCTGCAGAGGTTACTCCCCCAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAAT               TGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCA               TCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGC               AATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTA               TGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATG               AAAGTGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAA               GATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAA               CAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAA               AACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGA               GAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAA               AAAGCACAAGCGAACCCCAGCCCTGGTTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGG               CCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAG               GAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCC               CCCTAATTATCCATTTTCTGATGAATAT TAA                                       NOV19b, CG59693-02   SEQ ID NO: 80   317 aa   MW at 36217.5 kD       Protein Sequence                 MMVTSCLSWDLAPMRLQRLLPQVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSV               KREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDESGKILFDTV               DLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKD               IVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALVALRYQLQRGVVVLAKSYNEQRIR               QNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY                                 NOV19c, CG59693-03   SEQ ID NO: 81   972 bp       DNA Sequence   ORF Start: ATG at 1   ORF Stop: end of sequence                   ATG GATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGTCCTGGCATTTGGCAC               CTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGGCAATTGAAGCTGGCT               TCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTGGCCATCCGAAGCAAG               ATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTGGTGCAATTCCCATCG               ACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGGATTATGTTGACCTCT               ACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAAGATGAAAATGGAAAA               ATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTGTAAAGATGCAGGATT               GGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCCTCAACAAGCCAGGGC               TCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAGAGAAAACTGCTGGAT               TTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCACCGAGAAGAACCATG               GGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGC               GAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTCCTGGCCAAGAGATAC               AATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTCAGAGGAGATGAAAGC               CATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTGGCCCCCCTAATTATC               CATTTTCTGATGAATAT TAA                                       NOV19c, CG59693-03   SEQ ID NO: 82   323 aa   MW at 36857.0 kD       Protein Sequence                 MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSK               IADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGK               ILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLD               FCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKRY               NEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY                                 NOV19d, CG59693-04   SEQ ID NO: 83   994 bp       DNA Sequence   ORF Start: ATG at 16   ORF Stop: end of sequence                   GCCAGATCTCCCACC   ATG GATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGT               CCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGG               CAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGGACTG               GCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTG               GTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGG               ATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAA               GATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTG               TAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCC               TCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAG               AGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCA               CCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGG               CAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTC               CTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTC               AGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTG               GCCCCCCTAATTATCCATTTTCTGAT GAA   TATCTCGAGGGTG                                       NOV19d, CG59693-04   SEQ ID NO: 84   321 aa   MW at 36495.6 kD       Protein Sequence                 MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSK               IADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGK               ILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLD               FCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSY               NEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSD                                 NOV19e, CG59693-05   SEQ ID NO: 85   1219 bp       DNA Sequence   ORF Start: ATG at 24   ORF Stop: end of sequence                   TGCTAACCAGGCCAGTGACAGAA   ATG GATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTC               ATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGT               CAAATTGGCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAGG               TTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCA               AAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCT               TCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGA               TCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCATG               GAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGA               GATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACT               TCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTG               GGATCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTG               TGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTGCAGCGTGGGG               TTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAG               TTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATAT               TTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATAT TAA CATGGAGGGCATTGCATGAGGTCTG                 CCAGAAGGCCCTGCGTGTGGATGGTGACACAGAGGATGGCTCTATGCTGGTGACTGGACACATCGCCT                   CTGGTTAAATCTCTCCTGCTTGGCGACTTCAGTAAGCTACAGCTAAGCCCATCGGCCGGAAAAGAAAG                   ACAATAATTTTGTTTTTTCATTTTGAAAAAATTAAATGCTCTCTCCTAAAGATTCTTCACCTA                                       NOV19e, CG59693-05   SEQ ID NO: 86   323 aa   MW at 36734.9 kD       Protein Sequence                 MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQVGLAIRSK               IADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGK               ILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLD               FCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSY               NEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY                                 NOV19f, CG59693-06   SEQ ID NO: 87   1001 bp       DNA Sequence   ORF Start: at 11   ORF Stop: end of sequence                   CATCTAGGCC   ACC ATGGCCATGGATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGC               CTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAA               TTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTGG               ACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGC               TTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAA               TTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCC               AAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGA               AGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATG               ATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAA               CCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGAT               CCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCC               TTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGT               GGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGA               CTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTT               GCTGGCCCCCCTAATTATCCATTTTCTGAT GAA   TATTAAACGCGTGATC                                       NOV19f, CG59693-06   SEQ ID NO: 88   324 aa   MW at 36799.0 kD       Protein Sequence                 TMAMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAI               RSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDE               NGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRK               LLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLA               KSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSD                                 NOV19g, CG59693-07   SEQ ID NO: 89   1012 bp       DNA Sequence   ORF Start: at 1   ORF Stop: end of sequence                   GCC GGTACCACCATGGGCCACCATCACCACCATCACGATTCGAAATATCAGTGTGTGAAGCTGAATGA               TGGTCACTTCATGCCTGTCCTGCGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTT               TAGAGGCCACCAAATTGGCAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAAT               GAGGAGCAGGTTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATT               CTACACTTCAAAGCTTTGGTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCAC               TGAAAAATCTTCAATTGGATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGT               GAGGAAGTGATCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTG               GGAGGCCGTGGAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCA               GGCAGCTGGAGATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGT               CATCCTTACTTCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTA               TAGTGCTCTGGGATCCCACCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACC               CAGTCCTTTGTGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTA               CAGCGTGGGGTTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTT               TGAATTCCAGTTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGA               CCCTTGATATTTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATATCTCGAGGGT G                                       NOV19g, CG59693-07   SEQ ID NO: 90   337 aa   MW at 38297.5 kD       Protein Sequence                 AGTTMGHHHHHHDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNN               EEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPG               EEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVEC               HPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQL               QRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYLEG                                 NOV19h, CG59693-08   SEQ ID NO: 91   1225 bp       DNA Sequence   ORF Start: ATG at 24   ORF Stop: end of sequence                   TGCTAACCAGGCCAGTGACAGAA   ATG GATTCGAAATACCAGTGTGTGAAGCTGAATGATGGTCACTTC               ATGCCTGTCCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTCTAGAGGCCGT               CAAATTGGCAATAGAAGCCGGGTTCCACCATATTGATTCTGCACATGTTTACAATAATGAGGAGCAGG               TTGGACTGGCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCA               AAGCTTTGGAGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCT               TCAATTGGACTATGTTGACCTCTATCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGA               TCCCAAAAGATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCATG               GAGAAGTGTAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCACAGGCTGCTGGA               GATGATCCTCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACT               TCAACCAGAGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTG               GGATCCCATCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTG               TGCCTTGGCAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTGCAGCGTGGGG               TTGTGGTCCTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAG               TTGACTTCAGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATAT               TTTTGCTGGCCCCCCTAATTATCCATTTTCTGATGAATAT TAA   CATGGAGGGCATTGCATGAGGTCTG                   CCAGAAGGCCCTGCGTGTGGATGGTGACACAGAGGATGGCTCTATGCTGGTGACTGGACACATCGCCT                   CTGGTTAAATCTCTCCTGCTTGGCGACTTCAGTAAGCTACAGCTAAGCCCATCGGCCGGAAAAGAAAG                   ACAATAATTTTGTTTTTTCATTTTGAAAAAATTAAATGCTCTCTCCTAAAGATTCTTCACCTAAAAAA                   A                                       NOV19h, CG59693-08   SEQ ID NO: 92   323 aa   MW at 36734.9 kD       Protein Sequence                 MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHIDSAHVYNNEEQVGLAIRSK               IADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGK               ILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFNHRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLD               FCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSY               NEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY                                 NOV19i, CG59693-09   SEQ ID NO: 93   996 bp       DNA Sequence   ORF Start: ATG at 16   ORF Stop: end of sequence                   CACCGCGGCCGCACC   ATG GATTCGAAATATCAGTGTGTGAAGCTGAATGATGGTCACTTCATGCCTGT               CCTGGGATTTGGCACCTATGCGCCTGCAGAGGTTCCTAAAAGTAAAGCTTTAGAGGCCACCAAATTGG               CAATTGAAGCTGGCTTCCGCCATATTGATTCTGCTCATTTATACAATAATGAGGAGCAGGTTCGACTG               GCCATCCGAAGCAAGATTGCAGATGGCAGTGTGAAGAGAGAAGACATATTCTACACTTCAAAGCTTTG               GTGCAATTCCCATCGACCAGAGTTGGTCCGACCAGCCTTGGAAAGGTCACTGAAAAATCTTCAATTGG               ATTATGTTGACCTCTACCTTATTCATTTTCCAGTGTCTGTAAAGCCAGGTGAGGAAGTGATCCCAAAA               GATGAAAATGGAAAAATACTATTTGACACAGTGGATCTCTGTGCCACGTGGGAGGCCGTGGAGAAGTG               TAAAGATGCAGGATTGGCCAAGTCCATCGGGGTGTCCAACTTCAACCGCAGGCAGCTGGAGATGATCC               TCAACAAGCCAGGGCTCAAGTACAAGCCTGTCTGCAACCAGGTGGAATGTCATCCTTACTTCAACCAG               AGAAAACTGCTGGATTTCTGCAAGTCAAAAGACATTGTTCTGGTTGCCTATAGTGCTCTGGGATCCCA               CCGAGAAGAACCATGGGTGGACCCGAACTCCCCGGTGCTCTTGGAGGACCCAGTCCTTTGTGCCTTGG               CAAAAAAGCACAAGCGAACCCCAGCCCTGATTGCCCTGCGCTACCAGCTACAGCGTGGGGTTGTGGTC               CTGGCCAAGAGCTACAATGAGCAGCGCATCAGACAGAACGTGCAGGTGTTTGAATTCCAGTTGACTTC               AGAGGAGATGAAAGCCATAGATGGCCTAAACAGAAATGTGCGATATTTGACCCTTGATATTTTTGCTG               GCCCCCCTAATTATCCATTTTCTGATGAATAT TAG   GTCGACGGC                                       NOV19i, CG59693-09   SEQ ID NO: 94   323 aa   MW at 36787.9 kD       Protein Sequence                 MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSK               IADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGK               ILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLD               FCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSY               NEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY                  
 
     [0450] A ClustalW comparison of the above protein sequences yields the following sequence alignment shown in Table 19B.  
               TABLE 19B                       Comparison of the NOV19 protein sequences.                                        NOV19a   -----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHI       NOV19b   ----------------MMVTSCLSWDLAPMRLQRLLP-QVPKSKALEATKLAIEAGFRHI       NOV19c   -----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHI       NOV19d   -----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHI       NOV19e   -----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHI       NOV19f   --------TMAMDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHI       NOV19g   AGTTMGHHHHHHDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHI       NOV19h   -----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEAVKLAIEAGFHHI       NOV19i   -----------MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHI               NOV19a   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD       NOV19b   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD       NOV19c   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD       NOV19d   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD       NOV19e   DSAHVYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLD       NOV19f   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD       NOV19g   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD       NOV19h   DSAHVYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSNSHRPELVRPALERSLKNLQLD       NOV19i   DSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLD               NOV19a   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN       NOV19b   YVDLYLIHFPVSVKPGEEVIPKDESGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN       NOV19c   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN       NOV19d   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN       NOV19e   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFN       NOV19f   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN       NOV19g   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN       NOV19h   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAMEKCKDAGLAKSIGVSNFN       NOV19i   YVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFN               NOV19a   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19b   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19c   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19d   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19e   HRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19f   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19g   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19h   HRLLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD       NOV19i   RRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVD               NOV19a   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19b   PNSPVLLEDPVLCALAKKHKRTPALVALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19c   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKRYNEQRIRQNVQVFEFQLT       NOV19d   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19e   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19f   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19g   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19h   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT       NOV19i   PNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLT               NOV19a   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---       NOV19b   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---       NOV19c   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---       NOV19d   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSD-----       NOV19e   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---       NOV19f   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSD-----       NOV19g   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEYLEG       NOV19h   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---       NOV19i   SEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY---       NOV19a   (SEQ ID NO: 78)       NOV19b   (SEQ ID NO: 80)       NOV19c   (SEQ ID NO: 82)       NOV19d   (SEQ ID NO: 84)       NOV19e   (SEQ ID NO: 86)       NOV19f   (SEQ ID NO: 88)       NOV19g   (SEQ ID NO: 90)       NOV19h   (SEQ ID NO: 92)       NOV19i   (SEQ ID NO: 94)                  
 
     [0451] Further analysis of the NOV19a protein yielded the following properties shown in Table 19C.  
               TABLE 19C                       Protein Sequence Properties NOV19a                                        SignalP analysis:   No Known Signal Sequence Predicted       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 9; pos. chg 2; neg. chg 1           H-region: length 2; peak value −3.30           PSG score: −7.70           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1) : −5.32           possible cleavage site: between 27 and 28           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 0           number of TMS(s) . . . fixed                                     PERIPHERAL   Likelihood =   3.66 (at 253)                             ALOM score: 3.66 (number of TMSs: 0)           MITDISC: discrimination of mitochondrial targeting seq                                     R content:   0   Hyd Moment (75):   0.10           Hyd Moment   4.27   G content:   0           (95):           D/E content:   2   S/T content:   1                         Score: −7.79           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclearlocalization signals           pat4: KKHK (3) at 246           pat4: KHKR (3) at 247           pat7: none           bipartite: none           content of basic residues: 13.3%           NLS Score: −0.10           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern : none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 76.7           COIL: Lupas&#39;s algorithm to detect coiled-coil regions           total: 0 residues           Final Results (k = 9/23):           34.8%: cytoplasmic           30.4%: mitochondrial           30.4%: nuclear           4.3%: vacuolar           &gt;&gt; prediction for CG59693-01 is cyt (k = 23)                  
 
     [0452] A search of the NOV19a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 19D.  
               TABLE 19D                          Geneseq Results for NOV19a                                         NOV19a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               AAB43444   Human cancer associated protein    1 . . . 323   318/323 (98%)   0.0           sequence SEQ ID NO: 889 -  Homo     14 . . . 336   318/323 (98%)             sapiens , 336 aa. [WO200055350-           A1, 21 SEP. 2000]       AAU85559   Clone #59314 (L1426P) of lung    1 . . . 323   311/323 (96%)   0.0           tumour protein -  Homo sapiens ,    1 . . . 323   316/323 (97%)           323 aa. [WO200204514-A2, 17           JAN. 2002]       ABB75050   Human lung tumour L773P   29 . . . 323   288/295 (97%)   e−168           recombinant protein sequence   77 . . . 371   290/295 (97%)           SEQ ID NO: 433 -  Homo sapiens ,           371 aa. [WO200200174-A2, 03           JAN. 2002]       ABB74958   Human lung tumour L773P   29 . . . 323   288/295 (97%)   e−168           protein sequence SEQ ID NO: 172 -   70 . . . 364   290/295 (97%)             Homo sapiens , 364 aa.           [WO200200174-A2, 03 JAN.           2002]       AAU85520   L773P lung tumour protein -   29 . . . 323   288/295 (97%)   e−168             Homo sapiens , 364 aa.   70 . . . 364   290/295 (97%)           [WO200204514-A2, 17 JAN.           2002]                  
 
     [0453] In a BLAST search of public sequence databases, the NOV19a protein was found to have homology to the proteins shown in the BLASTP data in Table 19E.  
               TABLE 19E                          Public BLASTP Results for NOV19a                                         NOV19a   Identities/           Protein       Residues/   Similarities       Accession       Match   for the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value                                         Q04828   Aldo-keto reductase family 1   1 . . . 323   323/323 (100%)   0.0           member C1 (EC 1.1.1.-) (Trans-1,2-   1 . . . 323   323/323 (100%)           dihydrobenzene-1,2-diol           dehydrogenase) (EC 1.3.1.20) (High-           affinity hepatic bile acid-binding           protein) (HBAB) (Chlordecone           reductase homolog HAKRC)           (Dihydrodiol dehydrogenase 2)           (DD2) (20 alpha- hydroxysteroid           dehydrogenase) -  Homo sapiens             (Human), 323 aa.       P52895   Aldo-keto reductase family 1   1 . . . 323   316/323 (97%)   0.0           member C2 (EC 1.1.1.-) (Trans-1,2-   1 . . . 323   318/323 (97%)           dihydrobenzene-1,2-diol           dehydrogenase) (EC 1.3.1.20)           (Chlordecone reductase homolog           HAKRD) (Dihydrodiol           dehydrogenase/bile acid-binding           protein) (DD/BABP) (Dihydrodiol           dehydrogenase 2) (DD2) -  Homo               sapiens  (Human), 323 aa.       I73676   chlordecone reductase homolog   1 . . . 323   313/323 (96%)   0.0           (clone HAKRd) - human, 323 aa.   1 . . . 323   317/323 (97%)       I73675   chlordecone reductase homolog   4 . . . 323   312/320 (97%)   0.0           (clone HAKRc) - human, 320 aa   1 . . . 320   313/320 (97%)           (fragment).       Q95JH6   3(20)alpha-   1 . . . 323   304/323 (94%)   0.0           hydroxysteroid/dihydrodiol/indanol   1 . . . 323   319/323 (98%)           dehydrogenase (EC 1.1.1.112) -             Macaca fuscata  (Japanese macaque),           323 aa.                  
 
     [0454] PFam analysis predicts that the NOV19a protein contains the domains shown in the Table 19F.  
               TABLE 19F                          Domain Analysis of NOV19a                                     Identities/                   Similarities           NOV19a   for the Matched   Expect       Pfam Domain   Match Region   Region   Value               aldo_ket_red   10 . . . 303   164/369 (44%)   3.4e−156               274/369 (74%)                  
 
     Example 20  
     [0455] The NOV20 clone was analyzed, and the nucleotide and encoded polypeptide sequences are shown in Table 20A.  
               TABLE 20A                       NOV20 Sequence Analysis                                            NOV20a, CG93088-01   SEQ ID NO: 95   3815 bp       DNA Sequence   ORF Start: ATG at 263   ORF Stop: end of sequence                           CGGCCGCGATCCCCACCACACCACCAGCCCGGCCGCACGGGGCACTGAGCCGGGTGCTGAGCACCGGA                   GGCCCCGCCGAGGCCGGGACTCAGATGTTGAAAGTTAATTTGTGTAAAGACTTATGCACGTGGTGACA                   TGAGTTCTGCCCAGTGCTCTGAAATCAAAGTGAAGAAATAAATCCATGGAAGCCCAGGCAAATGATGG                   GTGTAGCTATGACTCTCTGAAGGACCTGCAGAGAAACGCCTCCTGATTTTGTCTTACA   ATG GAACTTA               AAAAGTCGCCTGACGGTGGATGGGGCTGGGTGATTGTGTTTGTCTCCTTCCTTACTCAGTTTTTGTGT               TACGGATCCCCACTAGCTGTTGGAGTCCTGTACATAGAATGGCTGGATGCCTTTGGTGAAGGAAAAGG               AAAAACAGCCTGGGTTGGATCCCTGGCAAGTGGAGTTGGCTTGCTTGCAAGTCCTGTCTGCAGTCTCT               GTGTCTCATCTTTTGGAGCAAGACCTGTCACAATCTTCAGTGGCTTCATGGTGGCTGGAGGCCTGATG               TTGAGCAGTTTTGCTCCCAATATCTACTTTCTGTTTTTTTCCTATGGCATTGTTGTAGGTCTTGGATG               TGGTTTATTATACACTGCAACAGTGACCATTACGTGCCAGTATTTTGACGATCGCCGAGGCCTAGCGC               TTGGCCTGATTTCAACAGGTTCAAGCGTTGGCCTTTTCATATATGCTGCTCTGCAGAGGATGCTGGTT               GAGTTCTATGGACTGGATGGATGCTTGCTGATTGTGGGTGCTTTAGCTTTAAATATATTAGCCTGTGG               CAGTCTGATGAGACCCCTCCAATCTTCTGATTGTCCTTTGCCTAAAAAAATAGCTCCAGAAGATCTAC               CAGATAAATACTCCATTTACAATGAAAAAGGAAAGAATCTGGAAGAAAACATAAACATTCTTGACAAG               AGCTACAGTAGTGAGGAAAAATGCAGGATCACGTTAGCCAATGGTGACTGGAAACAAGACAGCCTACT               TCATAAAAACCCCACAGTGACACACACAAAAGAGCCTGAAACGTACAAAAAGAAAGTTGCAGAACAGA               CATATTTTTGCAAACAGCTTGCCAAGAGGAAGTGGCAGTTATATAAAAACTACTGTGGTGAAACTGTG               GCTCTTTTTAAAAACAAAGTATTTTCAGCCCTTTTCATTGCTATCTTACTCTTTGACATCGGAGGGTT               TCCACCTTCATTACTTATGGAAGATGTAGCAAGAAGTTCAAACGTGAAAGAAGAAGAGTTTATTATGC               CACTTATTTCCATTATAGGCATTATGACAGCAGTTGGTAAACTGCTTTTAGGGATACTGGCTGACTTC               AAGTGGATTAATACCTTGTATCTTTATGTTGCTACCTTAATCATCATGGGCCTAGCCTTGTGTGCAAT               TCCATTTGCCAAAAGCTATGTCACATTGGCGTTGCTTTCTGGGATCCTAGGGTTTCTTACTGGTAATT               GGTCCATCTTTCCATATGTGACCACGAAGACTGTGGGAATTGAAAAATTAGCCCATGCCTATGGGATA               TTAATGTTCTTTGCTGGACTTGGAAATAGCCTAGGACCACCATCGTTGGGTTGGTTTTATGACTGGAC               CCAGACCTATGATATTGCATTTTATTTTAGTGGCTTCTGCGTCCTGCTGGGAGGTTTTATTCTGCTGC               TGGCAGCCTTGCCCTCTTGGGATACATGCAACAAGCAACTCCCCAAGCCAGCTCCAACAACTTTCTTG               TACAAAGTTGCCTCTAATGTT TAG   AAGAATATTGGAAGACACTATTTTTGCTATTTTATACCATATAG                   CAACGATATTTTAACAGATTCTCAAGCAAATTTTCTAGAGTCAAGACTATTTTCTCATAGCAAAATTT                   CACAATGACTGACTCTGAATGAATTATTTTTTTTTATATATCCTATTTTTTATGTAGTGTATGCGTAG                   CCTCTATCTCGTATTTTTTTCTATTTCTCCTCCCCACACCATCAATGGGACTATTCTGTTTTGCTGTT                   ATTCACTAGTTCTTAACATTGTAAAAAGTTTGACCAGCCTCAGAAGGCTTTCTCTGTGTAAAGAAGTA                   TAATTTCTCTGCTGACTCCATTTAATCCACTGCAAGGCACCTAGAGAGACTGCTCCTATTTTAAAAGT                   GATGCAAGCATCATGATAAGATATGTGTGAAGCCCACTAGGAAATAAATCATTCTCTTCTCTATGTTT                   GACTTGCTAGTAAACAGAAGACTTCAAGCCAGCCAGGAAATTAAAGTGGCGACTAAAACAGCCTTAAG                   AATTGCAGTGGAGCAAATTGGTCATTTTTTAAAAAAATATATTTTAACCTACAGTCACCAGTTTTCAT                   TATTCTATTTACCTCACTGAAGTACTCGCATGTTGTTTGGTACCCACTGAGCAACTGTTTCAGTTCCT                 AAGGTATTTGCTGAGATGTGGGTGAACTCCAAATGGAGAAGTAGTCACTGTAGACTTTCTTCATGGTT                 GACCACTCCAACCTTGCTCACTTTTGCTTCTTGGCCATCCACTCAGCTGATGTTTCCTGGAAGTGCTA                   ATTTTACCTGTTTCCAAATTGGAAACACATTTCTCAATCATTCCGTTCTGGCAAATGGGAAACATCCA                   TTTGCTTTGGGCACAGTGGGGATGGGCTGCAAGTTCTTGCATATCCTCCCAGTGAAGCATTTATTTGC                   TACTATCAGATTTTACCACTATCAAATATAATTCAAGGGCAGAATTAAACGTGAGTGTGTGTGTGTGT                   GTGTGTGTGTGTGCTATGCATGCTCTAAGTCTGCATGGGATATGGGAATGGAAAAGGGCAATAAGAAA                   TTAATACCCTTATGCAGTTGCATTTAACCTTAAGAAAAATGTCCTTGGGATAAACTCCAATGTTTAAT                   ACATTGATTTTTTTTCTAAAGAAATGGGTTTTAAACTTTGGTATGCATCAGAATTCCCTATAGATCTT                   TTTGAAAATATAGGTACCTGGGTATCACACATAGAACTTTTAATTCTGCTGGTGTAGGCTGTTGCCCA                   AACATCTATAATTTTACTGAGCTCTTCAAGTGATTCTGATAACACAGCCTGGATTGAGAATTTTTATA                   AGATTGGCAATGGAAAAACATTTATTCTTTTAAATAATAATTTTTTTAAAACCCAAGAGGTCAGGGGA                   TTTTATAAACCAATAGCCAAGTGTTCTTTAAATAGGAGGCACCCTTCCCATTGTGCCAAAATCATCTT                   TTCATTTATTTTGAAATTTGTATGATTATTTTATACTTGTATGTTGCCTTTCTTCGAAGGCGCCTGAA                   GCACTTTATAAACACAAATCCTCACAATACCTCTGTGAGGTAGGTAAATAGTACTTTTCTATGTAGTA                   AACCTGGAATATGGAGAATTTCATAACAGTTCATTCTACTTAATAATGCAATAATGGAGCTCCAAGTT                   GTCTTGGACTTCTACACCACACTCAGACTTCTGGAAAGTTTTCTGTACCTCATTCTTTAGTCCCTGTC                   AAGGTTAGTAAATAAAATAAGTGACATAAAAAAAAAAAAAAAACTAAACTACTTGTTGTGTTGAAAGT                   TCCTTTTTGCCAGTTATGTTCAGGAAACCCAATAACCTGAAAAAGTTTGACTTTGATGTGACATCTTC                   ATATTCATCAATGCTGATAATTGTCCAAAGGCATCTTCACTATGTCTGCTAAATAACATCCAATGTGG                   GCGTTATCTGTTGTCTAGGGGATGAATTTTAAGTTACAATAAAATATTTTTCTTTGTTTTGCATCAAA                   AAAAAAA                                       NOV20a, CG93088-01   SEQ ID NO: 96   509 aa   MW at 55780.8 kD       Protein Sequence                 MELKKSPDGGWGWVIVFVSFLTQFLCYGSPLAVGVLYIEWLDAFGEGKGKTAWVGSLASGVGLLASPV               CSLCVSSFGARPVTIFSGFMVAGGLMLSSFAPNIYFLFFSYGIVVGLGCGLLYTATVTITCQYFDDRR               GLALGLISTGSSVGLFIYAALQRMLVEFYGLDGCLLIVGALALNILACGSLMRPLQSSDCPLPKKIAP               EDLPDKYSIYNEKGKNLEENINILDKSYSSEEKCRITLANGDWKQDSLLHKNPTVTHTKEPETYKKKV               AEQTYFCKQLAKRKWQLYKNYCGETVALFKNKVFSALFIAILLFDIGGFPPSLLMEDVARSSNVKEEE               FIMPLISIIGIMTAVGKLLLGILADFKWINTLYLYVATLIIMGLALCAIPFAKSYVTLALLSGILGFL               TGNWSIFPYVTTKTVGIEKLAHAYGILMFFAGLGNSLGPPSLGWFYDWTQTYDIAFYFSGFCVLLGGF               ILLLAALPSWDTCNKQLPKPAPTTFLYKVASNV                  
 
     [0456] Further analysis of the NOV20a protein yielded the following properties shown in Table 20B.  
               TABLE 20B                       Protein Sequence Properties NOV20a                                        SignalP analysis:   Cleavage site between residues 29 and 30       PSORT II analysis:   PSG: a new signal peptide prediction method           N-region: length 8; pos. chg 2; neg. chg 2           H-region: length 30; peak value 11.36           PSG score: 6.96           GvH: von Heijne&#39;s method for signal seq. recognition           GvH score (threshold: −2.1) : −3.41           possible cleavage site: between 28 and 29           &gt;&gt;&gt; Seems to have no N-terminal signal peptide           ALOM: Klein et al&#39;s method for TM region allocation           Init position for calculation: 1           Tentative number of TMS(s) for the threshold 0.5: 11                                         INTEGRAL   Likelihood =   −0.59   Transmembrane   10-26           INTEGRAL   Likelihood =   −2.50   Transmembrane   57-73           INTEGRAL   Likelihood =   −0.85   Transmembrane   83-99           INTEGRAL   Likelihood =   −4.46   Transmembrane   104-120           INTEGRAL   Likelihood =   −0.75   Transmembrane   137-153           INTEGRAL   Likelihood =   −6.32   Transmembrane   171-187           INTEGRAL   Likelihood =   −6.32   Transmembrane   305-321           INTEGRAL   Likelihood =   −5.41   Transmembrane   348-364           INTEGRAL   Likelihood =   −7.38   Transmembrane   376-392           INTEGRAL   Likelihood =    0.05   Transmembrane   394-410           INTEGRAL   Likelihood =   −7.59   Transmembrane   467-483           PERIPHERAL   Likelihood =    3.13 (at 423)                         ALOM score: −7.59 (number of TMSs: 11)           MTOP: Prediction of membrane topology (Hartmann et al.)           Center position for calculation: 17           Charge difference: −2.0 C(−1.0) - N( 1.0)           N &gt;= C: N-terminal side will be inside           &gt;&gt;&gt; membrane topology: type 3a           MITDISC: discrimination of mitochondrial targeting seq                                         R content:   0   Hyd Moment (75):   5.89               Hyd Moment (95):   8.05   G content:   0           D/E content:   2   S/T content:   1                         Score: −6.55           Gavel: prediction of cleavage sites for mitochondrial preseq           cleavage site motif not found           NUCDISC: discrimination of nuclear localization signals           pat4: none           pat7: PETYKKK (3) at 265           bipartite: KKVAEQTYFCKQLAKRK at 270           content of basic residues: 7.9%           NLS Score: 0.28           KDEL: ER retention motif in the C-terminus: none           ER Membrane Retention Signals: none           SKL: peroxisomal targeting signal in the C-terminus: none           PTS2: 2nd peroxisomal targeting signal: none           VAC: possible vacuolar targeting motif: none           RNA-binding motif: none           Actinin-type actin-binding motif:           type 1: none           type 2: none           NMYR: N-myristoylation pattern: none           Prenylation motif: none           memYQRL: transport motif from cell surface to Golgi: none           Tyrosines in the tail: none           Dileucine motif in the tail: none           checking 63 PROSITE DNA binding motifs: none           checking 71 PROSITE ribosomal protein motifs: none           checking 33 PROSITE prokaryotic DNA binding motifs: none           NNCN: Reinhardt&#39;s method for Cytoplasmic/Nuclear discrimination           Prediction: cytoplasmic           Reliability: 94.1           COIL: Lupas&#39;s algorithm to detect coiled-coil regions                                         208 D   0.71                       209 K   0.75           210 Y   0.75           211 S   0.75           212 I   0.75           213 Y   0.75           214 N   0.75           215 E   0.75           216 K   0.75           217 G   0.75           218 K   0.75           219 N   0.75           220 L   0.75           221 E   0.75           222 E   0.75           223 N   0.75           224 I   0.75           225 N   0.75           226 I   0.75           227 L   0.75           228 D   0.75           229 K   0.75           230 S   0.75           231 Y   0.75           232 S   0.75           233 S   0.75           234 E   0.75           235 E   0.75           236 K   0.75                         total: 29 residues           Final Results (k = 9/23) :           66.7%: endoplasmic reticulum           22.2%: mitochondrial           11.1%: vesicles of secretory system           &gt;&gt; prediction for CG93088-01 is end (k = 9)                  
 
     [0457] A search of the NOV20a protein against the Geneseq database, a proprietary database that contains sequences published in patents and patent publication, yielded several homologous proteins shown in Table 20C.  
               TABLE 20C                          Geneseq Results for NOV20a                                         NOV20a   Identities/                   Residues/   Similarities for       Geneseq   Protein/Organism/Length   Match   the Matched   Expect       Identifier   [Patent #, Date]   Residues   Region   Value               ABU12075   Human NOV19a CG93088-01   1 . . . 509   509/509 (100%)   0.0           protein SEQ ID 70 -  Homo     1 . . . 509   509/509 (100%)             sapiens , 509 aa. [WO200281625-           A2, 17 OCT. 2002]       ABG61543   Human transporter and ion   1 . . . 509   507/509 (99%)   0.0           channel, TRICH13, Incyte ID   1 . . . 509   508/509 (99%)           4027693CD1 -  Homo sapiens ,           509 aa. [WO200240541-A2, 23           MAY 2002]       ABB83901   Human transporter protein SEQ   1 . . . 509   507/509 (99%)   0.0           ID NO 2 -  Homo sapiens , 509 aa.   1 . . . 509   508/509 (99%)           [WO200257310-A2, 25 JUL.           2002]       ABP51421   Human MDDT SEQ ID NO 443 -   3 . . . 507   168/509(33%)        3e−74             Homo sapiens , 529 aa.   38 . . . 527    265/509 (52%)           [WO200240715-A2, 23 MAY           2002]       ABG33043   Human 25466 transporter   3 . . . 480   164/482 (34%)        3e−74           protein -  Homo sapiens , 510 aa.   22 . . . 490    256/482 (53%)           [EP1233024-A2, 21 AUG. 2002]                  
 
     [0458] In a BLAST search of public sequence databases, the NOV20a protein was found to have homology to the proteins shown in the BLASTP data in Table 20D.  
               TABLE 20D                          Public BLASTP Results for NOV20a                                         NOV20a   Identities/           Protein       Residues/   Similarities for       Accession       Match   the Matched   Expect       Number   Protein/Organism/Length   Residues   Portion   Value               BAB23369   Adult male lung cDNA, RIKEN   1 . . . 509   445/511 (87%)   0.0           full-length enriched library,   1 . . . 508   471/511 (92%)           clone:1200003C15           product:hypothetical protein, full           insert sequence -  Mus musculus             (Mouse), 508 aa.       Q9UFH8   Hypothetical protein -  Homo     353 . . . 509    155/157 (98%)   3e−87             sapiens  (Human), 157 aa   1 . . . 157   156/157 (98%)           (fragment).       Q9CPZ7   4930425B13Rik protein   352 . . . 509    148/159 (93%)   2e−82           (1200003C15Rik protein) -  Mus     1 . . . 159   152/159 (95%)             musculus  (Mouse), 159 aa.       CAD52855   Sequence 1 from Patent   3 . . . 480   164/482 (34%)   1e−73           EP1233024 -  Homo sapiens     22 . . . 490    256/482 (53%)           (Human), 510aa.       AAH47967   Similar to solute carrier family 16   5 . . . 509   140/509 (27%)   4e−50           (monocarboxylic acid   22 . . . 499    234/509 (45%)           transporters), member 6 -  Xenopus               laevis  (African clawed frog), 533           aa.                  
 
     [0459] PFam analysis predicts that the NOV20a protein contains the domains shown in the Table 20E.  
               TABLE 20E                          Domain Analysis of NOV20a                                             Identities/                   NOV20a   Similarities for           Pfam   Match   the Matched   Expect           Domain   Region   Region   Value                       sugar_tr   11 . . . 456   72/548 (13%)   0.17                   278/548 (51%)                       
 
     Example B  
     Sequencing Methodology and Identification of NOVX Clones  
     [0460] 1. GeneCalling™ Technology: This is a proprietary method of performing differential gene expression profiling between two or more samples developed at CuraGen and described by Shimkets, et al., “Gene expression analysis by transcript profiling coupled to a gene database query” Nature Biotechnology 17:198-803 (1999). cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then digested with up to as many as 120 pairs of restriction enzymes and pairs of linker-adaptors specific for each pair of restriction enzymes were ligated to the appropriate end. The restriction digestion generates a mixture of unique cDNA gene fragments. Limited PCR amplification is performed with primers homologous to the linker adapter sequence where one primer is biotinylated and the other is fluorescently labeled. The doubly labeled material is isolated and the fluorescently labeled single strand is resolved by capillary gel electrophoresis. A computer algorithm compares the electropherograms from an experimental and control group for each of the restriction digestions. This and additional sequence-derived information is used to predict the identity of each differentially expressed gene fragment using a variety of genetic databases. The identity of the gene fragment is confirmed by additional, gene-specific competitive PCR or by isolation and sequencing of the gene fragment.  
     [0461] 2. SeqCalling™ Technology: cDNA was derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth, factors, chemokines or steroids. The cDNA thus derived was then sequenced using CuraGen&#39;s proprietary SeqCalling technology. Sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
     [0462] 3. PathCalling™ Technology: The NOVX nucleic acid sequences are derived by laboratory screening of cDNA library by the two-hybrid approach. cDNA fragments covering either the full length of the DNA sequence, or part of the sequence, or both, are sequenced. In silico prediction was based on sequences available in CuraGen Corporation&#39;s proprietary sequence databases or in the public human sequence databases, and provided either the full length DNA sequence, or some portion thereof.  
     [0463] The laboratory screening was performed using the methods summarized below:  
     [0464] cDNA libraries were derived from various human samples representing multiple tissue types, normal and diseased states, physiological states, and developmental states from different donors. Samples were obtained as whole tissue, primary cells or tissue cultured primary cells or cell lines. Cells and cell lines may have been treated with biological or chemical agents that regulate gene expression, for example, growth factors, chemokines or steroids. The cDNA thus derived was then directionally cloned into the appropriate two-hybrid vector (Ga14-activation domain (Ga14-AD) fusion). Such cDNA libraries as well as commercially available cDNA libraries from Clontech (Palo Alto, Calif.) were then transferred from  E.coli  into a CuraGen Corporation proprietary yeast strain (disclosed in U.S. Pat. Nos. 6,057,101 and 6,083,693, incorporated herein by reference in their entireties).  
     [0465] Ga14-binding domain (Ga14-BD) fusions of a CuraGen Corportion proprietary library of human sequences was used to screen multiple Ga14-AD fusion cDNA libraries resulting in the selection of yeast hybrid diploids in each of which the Ga14-AD fusion contains an individual cDNA. Each sample was amplified using the polymerase chain reaction (PCR) using non-specific primers at the cDNA insert boundaries. Such PCR product was sequenced; sequence traces were evaluated manually and edited for corrections if appropriate. cDNA sequences from all samples were assembled together, sometimes including public human sequences, using bioinformatic programs to produce a consensus sequence for each assembly. Each assembly is included in CuraGen Corporation&#39;s database. Sequences were included as components for assembly when the extent of identity with another component was at least 95% over 50 bp. Each assembly represents a gene or portion thereof and includes information on variants, such as splice forms single nucleotide polymorphisms (SNPs), insertions, deletions and other sequence variations.  
     [0466] Physical clone: the cDNA fragment derived by the screening procedure, covering the entire open reading frame is, as a recombinant DNA, cloned into pACT2 plasmid (Clontech) used to make the cDNA library. The recombinant plasmid is inserted into the host and selected by the yeast hybrid diploid generated during the screening procedure by the mating of both CuraGen Corporation proprietary yeast strains N106′ and YULH (U.S. Pat. Nos. 6,057,101 and 6,083,693).  
     [0467] 4. RACE: Techniques based on the polymerase chain reaction such as rapid amplification of cDNA ends (RACE), were used to isolate or complete the sequence of the cDNA of the invention. Usually multiple clones were sequenced from one or more human samples to derive the sequences for fragments. Various human tissue samples from different donors were used for the RACE reaction. The sequences derived from these procedures were included in the SeqCalling Assembly process described in preceding paragraphs.  
     [0468] 5. Exon Linking: The NOVX target sequences identified in the present invention were subjected to the exon linking process to confirm the sequence. PCR primers were designed by starting at the most upstream sequence available, for the forward primer, and at the most downstream sequence available for the reverse primer. In each case, the sequence was examined, walking inward from the respective termini toward the coding sequence, until a suitable sequence that is either unique or highly selective was encountered, or, in the case of the reverse primer, until the stop codon was reached. Such primers were designed based on in silico predictions for the full length cDNA, part (one or more exons) of the DNA or protein sequence of the target sequence, or by translated homology of the exons to closely related human sequences from other species. These primers were then employed in PCR amplification based on the following pool of human cDNAs: adrenal gland, bone marrow, brain—amygdala, brain—cerebellum, brain—hippocampus, brain—substantia nigra, brain—thalamus, brain—whole, fetal brain, fetal kidney, fetal liver, fetal lung, heart, kidney, lymphoma-Raji, mammary gland, pancreas, pituitary gland, placenta, prostate, salivary gland, skeletal muscle, small intestine, spinal cord, spleen, stomach, testis, thyroid, trachea, uterus. Usually the resulting amplicons were gel purified, cloned and sequenced to high redundancy. The PCR product derived from exon linking was cloned into the pCR2.1 vector from Invitrogen. The resulting bacterial clone has an insert covering the entire open reading frame cloned into the pCR2.1 vector. The resulting sequences from all clones were assembled with themselves, with other fragments in CuraGen Corporation&#39;s database and with public ESTs. Fragments and ESTs were included as components for an assembly when the extent of their identity with another component of the assembly was at least 95% over 50 bp. In addition, sequence traces were evaluated manually and edited for corrections if appropriate. These procedures provide the sequence reported herein.  
     [0469] 6. Physical Clone: Exons were predicted by homology and the intron/exon boundaries were determined using standard genetic rules. Exons were further selected and refined by means of similarity determination using multiple BLAST (for example, tBlastN, BlastX, and BlastN) searches, and, in some instances, GeneScan and Grail. Expressed sequences from both public and proprietary databases were also added when available to further define and complete the gene sequence. The DNA sequence was then manually corrected for apparent inconsistencies thereby obtaining the sequences encoding the full-length protein.  
     [0470] The PCR product derived by exon linking, covering the entire open reading frame, was cloned into the pCR2.1 vector from Invitrogen to provide clones used for expression and screening purposes.  
     Example C  
     Quantitative Expression Analysis of Clones in Various Cells and Tissues  
     [0471] The quantitative expression of various clones was assessed using microtiter plates containing RNA samples from a variety of normal and pathology-derived cells, cell lines and tissues using real time quantitative PCR (RTQ PCR). RTQ PCR was performed on an Applied Biosystems ABI PRISM® 7700 or an ABI PRISM® 7900 HT Sequence Detection System. Various collections of samples are assembled on the plates, and referred to as Panel 1 (containing normal tissues and cancer cell lines), Panel 2 (containing samples derived from tissues from normal and cancer sources), Panel 3 (containing cancer cell lines), Panel 4 (containing cells and cell lines from normal tissues and cells related to inflammatory conditions), Panel 5D/SI (containing human tissues and cell lines with an emphasis on metabolic diseases), AI_comprehensive_panel (containing normal tissue and samples from autoinflammatory diseases), Panel CNSD.01 (containing samples from normal and diseased brains) and CNS_neurodegeneration_panel (containing samples from normal and Alzheimer&#39;s diseased brains).  
     [0472] RNA integrity from all samples is controlled for quality by visual assessment of agarose gel electropherograms using 28S and 18S ribosomal RNA staining intensity ratio as a guide (2:1 to 2.5:1 28s:18s) and the absence of low molecular weight RNAs that would be indicative of degradation products. Samples are controlled against genomic DNA contamination by RTQ PCR reactions run in the absence of reverse transcriptase using probe and primer sets designed to amplify across the span of a single exon.  
     [0473] First, the RNA samples were normalized to reference nucleic acids such as constitutively expressed genes (for example, β-actin and GAPDH). Normalized RNA (5 ul) was converted to cDNA and analyzed by RTQ-PCR using One Step RT-PCR Master Mix Reagents (Applied Biosystems; Catalog No. 4309169) and gene-specific primers according to the manufacturer&#39;s instructions.  
     [0474] In other cases, non-normalized RNA samples were converted to single strand cDNA (sscDNA) using Superscript II (Invitrogen Corporation; Catalog No. 18064-147) and random hexamers according to the manufacturer&#39;s instructions. Reactions containing up to 10 μg of total RNA were performed in a volume of 20 μl and incubated for 60 minutes at 42° C. This reaction can be scaled up to 50 μg of total RNA in a final volume of 100 μl. sscDNA samples are then normalized to reference nucleic acids as described previously, using 1×TaqMan® Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer&#39;s instructions.  
     [0475] Probes and primers were designed for each assay according to Applied Biosystems Primer Express Software package (version I for Apple Computer&#39;s Macintosh Power PC) or a similar algorithm using the target sequence as input. Default settings were used for reaction conditions and the following parameters were set before selecting primers: primer concentration=250 nM, primer melting temperature (Tm) range=58°-60° C., primer optimal Tm=59° C., maximum primer difference=2° C., probe does not have 5′G, probe Tm must be 10° C. greater than primer Tm, amplicon size 75 bp to 100 bp. The probes and primers selected (see below) were synthesized by Synthegen (Houston, Tex., USA). Probes were double purified by HPLC to remove uncoupled dye and evaluated by mass spectroscopy to verify coupling of reporter and quencher dyes to the 5′ and 3′ ends of the probe, respectively. Their final concentrations were: forward and reverse primers, 900 nM each, and probe, 200 nM.  
     [0476] PCR conditions: When working with RNA samples, normalized RNA from each tissue and each cell line was spotted in each well of either a 96 well or a 384-well PCR plate (Applied Biosystems). PCR cocktails included either a single gene specific probe and primers set, or two multiplexed probe and primers sets (a set specific for the target clone and another gene-specific set multiplexed with the target probe). PCR reactions were set up using TaqMan® One-Step RT-PCR Master Mix (Applied Biosystems, Catalog No. 4313803) following manufacturer&#39;s instructions. Reverse transcription was performed at 48° C. for 30 minutes followed by amplification/PCR cycles as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were recorded as CT values (cycle at which a given sample crosses a threshold level of fluorescence) using a log scale, with the difference in RNA concentration between a given sample and the sample with the lowest CT value being represented as 2 to the power of delta CT. The percent relative expression is then obtained by taking the reciprocal of this RNA difference and multiplying by 100. Expression with CT values below 28 is considered as high expression, CT values between 28 and 32 is considered moderate and CT value between 32 to 35 is considered as low expression. All the relative expression with CT values above 35 is not considered as significant expression.  
     [0477] When working with sscDNA samples, normalized sscDNA was used as described previously for RNA samples. PCR reactions containing one or two sets of probe and primers were set up as described previously, using 1×TaqMang. Universal Master mix (Applied Biosystems; catalog No. 4324020), following the manufacturer&#39;s instructions. PCR amplification was performed as follows: 95° C. 10 min, then 40 cycles of 95° C. for 15 seconds, 60° C. for 1 minute. Results were analyzed and processed as described previously.  
     [0478] Panels 1, 1.1, 1.2, and 1.3D  
     [0479] The plates for Panels 1, 1.1, 1.2 and 1.3D include 2 control wells (genomic DNA control and chemistry control) and 94 wells containing cDNA from various samples. The samples in these panels are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in these panels are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on these panels are comprised of samples derived from all major organ systems from single adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose.  
     [0480] In the results for Panels 1, 1.1, 1.2 and 1.3D, the following abbreviations are used:  
     [0481] ca.=carcinoma,  
     [0482] *=established from metastasis,  
     [0483] met=metastasis,  
     [0484] s cell var=small cell variant,  
     [0485] non-s=non-sm=non-small,  
     [0486] squam=squamous,  
     [0487] pl. eff p1 effusion=pleural effusion,  
     [0488] glio=glioma,  
     [0489] astro=astrocytoma, and  
     [0490] neuro=neuroblastoma.  
     [0491] General_screening_panel_v1.4, v1.5, v1.6 and 1.7  
     [0492] The plates for Panels 1.4, 1.5, 1.6 and 1.7 include 2 control wells (genomic DNA control and chemistry control) and 88 to 94 wells containing cDNA from various samples. The samples in Panels 1.4, 1.5, 1.6 and 1.7 are broken into 2 classes: samples derived from cultured cell lines and samples derived from primary normal tissues. The cell lines are derived from cancers of the following types: lung cancer, breast cancer, melanoma, colon cancer, prostate cancer, CNS cancer, squamous cell carcinoma, ovarian cancer, liver cancer, renal cancer, gastric cancer and pancreatic cancer. Cell lines used in Panels 1.4, 1.5, 1.6 and 1.7 are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured using the conditions recommended by the ATCC. The normal tissues found on Panels 1.4, 1.5, 1.6 and 1.7 are comprised of pools of samples derived from all major organ systems from 2 to 5 different adult individuals or fetuses. These samples are derived from the following organs: adult skeletal muscle, fetal skeletal muscle, adult heart, fetal heart, adult kidney, fetal kidney, adult liver, fetal liver, adult lung, fetal lung, various regions of the brain, the spleen, bone marrow, lymph node, pancreas, salivary gland, pituitary gland, adrenal gland, spinal cord, thymus, stomach, small intestine, colon, bladder, trachea, breast, ovary, uterus, placenta, prostate, testis and adipose. Abbreviations are as described for Panels 1, 1.1, 1.2, and 1.3D.  
     [0493] Panels 2D, 2.2, 2.3 and 2.4  
     [0494] The plates for Panels 2D, 2.2, 2.3 and 2.4 generally include 2 control wells and 94 test samples composed of RNA or cDNA isolated from human tissue procured by surgeons working in close cooperation with the National Cancer Institute&#39;s Cooperative Human Tissue Network (CHTN) or the National Disease Research Initiative (NDRI) or from Ardais or Clinomics). The tissues are derived from human malignancies and in cases where indicated many malignant tissues have “matched margins” obtained from noncancerous tissue just adjacent to the tumor. These are termed normal adjacent tissues and are denoted “NAT” in the results below. The tumor tissue and the “matched margins” are evaluated by two independent pathologists (the surgical pathologists and again by a pathologist at NDRI/CHTN/Ardais/Clinomics). Unmatched RNA samples from tissues without malignancy (normal tissues) were also obtained from Ardais or Clinomics. This analysis provides a gross histopathological assessment of tumor differentiation grade. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical stage of the patient. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue, in Table RR). In addition, RNA and cDNA samples were obtained from various human tissues derived from autopsies performed on elderly people or sudden death victims (accidents, etc.). These tissues were ascertained to be free of disease and were purchased from various commercial sources such as Clontech (Palo Alto, Calif.), Research Genetics, and Invitrogen.  
     [0495] HASS Panel v 1.0  
     [0496] The HASS panel v 1.0 plates are comprised of 93 cDNA samples and two controls. Specifically, 81 of these samples are derived from cultured human cancer cell lines that had been subjected to serum starvation, acidosis and anoxia for different time periods as well as controls for these treatments, 3 samples of human primary cells, 9 samples of malignant brain cancer (4 medulloblastomas and 5 glioblastomas) and 2 controls. The human cancer cell lines are obtained from ATCC (American Type Culture Collection) and fall into the following tissue groups: breast cancer, prostate cancer, bladder carcinomas, pancreatic cancers and CNS cancer cell lines. These cancer cells are all cultured under standard recommended conditions. The treatments used (serum starvation, acidosis and anoxia) have been previously published in the scientific literature. The primary human cells were obtained from Clonetics (Walkersville, Md.) and were grown in the media and conditions recommended by Clonetics. The malignant brain cancer samples are obtained as part of a collaboration (Henry Ford Cancer Center) and are evaluated by a pathologist prior to CuraGen receiving the samples. RNA was prepared from these samples using the standard procedures. The genomic and chemistry control wells have been described previously.  
     [0497] ARDAIS Panel v 1.0  
     [0498] The plates for ARDAIS panel v 1.0 generally include 2 control wells and 22 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human lung malignancies (lung adenocarcinoma or lung squamous cell carcinoma) and in cases where indicated many malignant samples have “matched margins” obtained from noncancerous lung tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). Unmatched malignant and non-malignant RNA samples from lungs were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.  
     [0499] ARDAIS Prostate v 1.0  
     [0500] The plates for ARDAIS prostate 1.0 generally include 2 control wells and 68 test samples composed of RNA isolated from human tissue procured by surgeons working in close cooperation with Ardais Corporation. The tissues are derived from human prostate malignancies and in cases where indicated malignant samples have “matched margins” obtained from noncancerous prostate tissue just adjacent to the tumor. These matched margins are taken from the tissue surrounding (i.e. immediately proximal) to the zone of surgery (designated “NAT”, for normal adjacent tissue) in the results below. The tumor tissue and the “matched margins” are evaluated by independent pathologists (the surgical pathologists and again by a pathologist at Ardais). RNA from unmatched malignant and non-malignant prostate samples were also obtained from Ardais. Additional information from Ardais provides a gross histopathological assessment of tumor differentiation grade and stage. Moreover, most samples include the original surgical pathology report that provides information regarding the clinical state of the patient.  
     [0501] Panel 3D, 3.1 and 3.2  
     [0502] The plates of Panel 3D, 3.1, and 3.2 are comprised of 94 cDNA samples and two control samples. Specifically, 92 of these samples are derived from cultured human cancer cell lines, 2 samples of human primary cerebellar tissue and 2 controls. The human cell lines are generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: Squamous cell carcinoma of the tongue, breast cancer, prostate cancer, melanoma, epidermoid carcinoma, sarcomas, bladder carcinomas, pancreatic cancers, kidney cancers, leukemias/lymphomas, ovarian/uterine/cervical, gastric, colon, lung and CNS cancer cell lines. In addition, there are two independent samples of cerebellum. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. The cell lines in panel 3D, 3.1, 3.2, 1, 1.1., 1.2, 1.3D, 1.4, 1.5, and 1.6 are of the most common cell lines used in the scientific literature.  
     [0503] Panels 4D, 4R, and 4.1D  
     [0504] Panel 4 includes samples on a 96 well plate (2 control wells, 94 test samples) composed of RNA (Panel 4R) or cDNA (Panels 4D/4.1D) isolated from various human cell lines or tissues related to inflammatory conditions. Total RNA from control normal tissues such as colon and lung (Stratagene, La Jolla, Calif.) and thymus and kidney (Clontech) was employed. Total RNA from liver tissue from cirrhosis patients and kidney from lupus patients was obtained from BioChain (Biochain Institute, Inc., Hayward, Calif.). Intestinal tissue for RNA preparation from patients diagnosed as having Crohn&#39;s disease and ulcerative colitis was obtained from the National Disease Research Interchange (NDRI) (Philadelphia, Pa.).  
     [0505] Astrocytes, lung fibroblasts, dermal fibroblasts, coronary artery smooth muscle cells, small airway epithelium, bronchial epithelium, microvascular dermal endothelial cells, microvascular lung endothelial cells, human pulmonary aortic endothelial cells, human umbilical vein endothelial cells were all purchased from Clonetics (Walkersville, Md.) and grown in the media supplied for these cell types by Clonetics. These primary cell types were activated with various cytokines or combinations of cytokines for 6 and/or 12-14 hours, as indicated. The following cytokines were used; IL-1 beta at approximately 1-5 ng/ml, TNF alpha at approximately 5-10 ng/ml, IFN gamma at approximately 20-50 ng/ml, IL-4 at approximately 5-10 ng/ml, IL-9 at approximately 5-10 ng/ml, IL-13 at approximately 5-10 ng/ml. Endothelial cells were sometimes starved for various times by culture in the basal media from Clonetics with 0.1% serum.  
     [0506] Mononuclear cells were prepared from blood of employees at CuraGen Corporation, using Ficoll. LAK cells were prepared from these cells by culture in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco/Life Technologies, Rockville, Md.), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco) and Interleukin 2 for 4-6 days. Cells were then either activated with 10-20 ng/ml PMA and 1-2 μg/ml ionomycin, IL-12 at 5-10 ng/ml, IFN gamma at 20-50 ng/ml and IL-18 at 5-10 ng/ml for 6 hours. In some cases, mononuclear cells were cultured for 4-5 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco) with PHA (phytohemagglutinin) or PWM (pokeweed mitogen) at approximately 5 μg/ml. Samples were taken at 24, 48 and 72 hours for RNA preparation. MLR (mixed lymphocyte reaction) samples were obtained by taking blood from two donors, isolating the mononuclear cells using Ficoll and mixing the isolated mononuclear cells 1:1 at a final concentration of approximately 2×10 6  cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol (5.5×10 −5  M) (Gibco), and 10 mM Hepes (Gibco). The MLR was cultured and samples taken at various time points ranging from 1-7 days for RNA preparation.  
     [0507] Monocytes were isolated from mononuclear cells using CD14 Miltenyi Beads, +ve VS selection columns and a Vario Magnet according to the manufacturer&#39;s instructions. Monocytes were differentiated into dendritic cells by culture in DMEM 5% fetal calf serum (FCS) (Hyclone, Logan, Utah), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 1 mM Hepes (Gibco), 50 ng/ml GMCSF and 5 ng/ml IL-4 for 5-7 days. Macrophages were prepared by culture of monocytes for 5-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), 10 mM Hepes (Gibco) and 10% AB Human Serum or MCSF at approximately 50 ng/ml. Monocytes, macrophages and dendritic cells were stimulated for 6 and 12-14 hours with lipopolysaccharide (LPS) at 100 ng/ml. Dendritic cells were also stimulated with anti-CD40 monoclonal antibody (Pharmingen) at 10 μg/ml for 6 and 12-14 hours.  
     [0508] CD4 lymphocytes, CD8 lymphocytes and NK cells were also isolated from mononuclear cells using CD4, CD8 and CD56 Miltenyi beads, positive VS selection columns and a Vario Magnet according to the manufacturer&#39;s instructions. CD45RA and CD45RO CD4 lymphocytes were isolated by depleting mononuclear cells of CD8, CD56, CD14 and CD19 cells using CD8, CD56, CD14 and CD19 Miltenyi beads and positive selection. CD45RO beads were then used to isolate the CD45RO CD4 lymphocytes with the remaining cells being CD45RA CD4 lymphocytes. CD45RA CD4, CD45RO CD4 and CD8 lymphocytes were placed in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco) and plated at 10 6  cells/ml onto Falcon 6 well tissue culture plates that had been coated overnight with 0.5 μg/ml anti-CD28 (Pharmingen) and 3 ug/ml anti-CD3 (OKT3, ATCC) in PBS. After 6 and 24 hours, the cells were harvested for RNA preparation. To prepare chronically activated CD8 lymphocytes, we activated the isolated CD8 lymphocytes for 4 days on anti-CD28 and anti-CD3 coated plates and then harvested the cells and expanded them in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco) and IL-2. The expanded CD8 cells were then activated again with plate bound anti-CD3 and anti-CD28 for 4 days and expanded as before. RNA was isolated 6 and 24 hours after the second activation and after 4 days of the second expansion culture. The isolated NK cells were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco) and IL-2 for 4-6 days before RNA was prepared.  
     [0509] To obtain B cells, tonsils were procured from NDRI. The tonsil was cut up with sterile dissecting scissors and then passed through a sieve. Tonsil cells were then spun down and resupended at 10 6  cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco). To activate the cells, we used PWM at 5 μg/ml or anti-CD40 (Pharmingen) at approximately 10 μg/ml and IL-4 at 5-10 ng/ml. Cells were harvested for RNA preparation at 24,48 and 72 hours.  
     [0510] To prepare the primary and secondary Th1/Th2 and Tr1 cells, six-well Falcon plates were coated overnight with 10 μg/ml anti-CD28 (Pharmingen) and 2 μg/ml OKT3 (ATCC), and then washed twice with PBS. Umbilical cord blood CD4 lymphocytes (Poietic Systems, German Town, Md.) were cultured at 10 5 -10 6  cells/ml in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), 10 mM Hepes (Gibco) and IL-2 (4 ng/ml). IL-12 (5 ng/ml) and anti-IL4 (1 μg/ml) were used to direct to Th1, while IL-4 (5 ng/ml) and anti-IFN gamma (1 μg/ml) were used to direct to Th2 and IL-10 at 5 ng/ml was used to direct to Tr1. After 4-5 days, the activated Th1, Th2 and Tr1 lymphocytes were washed once in DMEM and expanded for 4-7 days in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), 10 mM Hepes (Gibco) and IL-2 (1 ng/ml). Following this, the activated Th1, Th2 and Tr1 lymphocytes were re-stimulated for 5 days with anti-CD28/OKT3 and cytokines as described above, but with the addition of anti-CD95L (1 μg/ml) to prevent apoptosis. After 4-5 days, the Th1, Th2 and Tr1 lymphocytes were washed and then expanded again with IL-2 for 4-7 days. Activated Th1and Th2 lymphocytes were maintained in this way for a maximum of three cycles. RNA was prepared from primary and secondary Th1, Th2 and Tr1 after 6 and 24 hours following the second and third activations with plate bound anti-CD3 and anti-CD28 mAbs and 4 days into the second and third expansion cultures in Interleukin 2.  
     [0511] The following leukocyte cells lines were obtained from the ATCC: Ramos, EOL-1, KU-812. EOL cells were further differentiated by culture in 0.1 mM dbcAMP at 5×10 5  cells/ml for 8 days, changing the media every 3 days and adjusting the cell concentration to 5×10 5  cells/ml. For the culture of these cells, we used DMEM or RPMI (as recommended by the ATCC), with the addition of 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), 10 mM Hepes (Gibco). RNA was either prepared from resting cells or cells activated with PMA at 10 ng/ml and ionomycin at 1 μg/ml for 6 and 14 hours. Keratinocyte line CCD106 and an airway epithelial tumor line NCI-H292 were also obtained from the ATCC. Both were cultured in DMEM 5% FCS (Hyclone), 100 μM non essential amino acids (Gibco), 1 mM sodium pyruvate (Gibco), mercaptoethanol 5.5×10 −5  M (Gibco), and 10 mM Hepes (Gibco). CCD1106 cells were activated for 6 and 14 hours with approximately 5 ng/ml TNF alpha and 1 ng/ml IL-1 beta, while NCI-H292 cells were activated for 6 and 14 hours with the following cytokines: 5 ng/ml IL-4, 5 ng/ml IL-9, 5 ng/ml IL-13 and 25 ng/ml IFN gamma.  
     [0512] For these cell lines and blood cells, RNA was prepared by lysing approximately 10 7  cells/ml using Trizol (Gibco BRL). Briefly, 1/10 volume of bromochloropropane (Molecular Research Corporation) was added to the RNA sample, vortexed and after 10 minutes at room temperature, the tubes were spun at 14,000 rpm in a Sorvall SS34 rotor. The aqueous phase was removed and placed in a 15 ml Falcon Tube. An equal volume of isopropanol was added and left at −20° C. overnight. The precipitated RNA was spun down at 9,000 rpm for 15 min in a Sorvall SS34 rotor and washed in 70% ethanol. The pellet was redissolved in 300 μl of RNAse-free water and 35 μl buffer (Promega) 5 μl DTT, 7 μl RNAsin and 8 μl DNAse were added. The tube was incubated at 37° C. for 30 minutes to remove contaminating genomic DNA, extracted once with phenol chloroform and re-precipitated with 1/10 volume of 3M sodium acetate and 2 volumes of 100% ethanol. The RNA was spun down and placed in RNAse free water. RNA was stored at −80° C.  
     [0513] AI_comprehensive panel_v1.0  
     [0514] The plates for AI_comprehensive panel_v1.0 include two control wells and 89 test samples comprised of cDNA isolated from surgical and postmortem human tissues obtained from the Backus Hospital and Clinomics (Frederick, Md.). Total RNA was extracted from tissue samples from the Backus Hospital in the Facility at CuraGen. Total RNA from other tissues was obtained from Clinomics.  
     [0515] Joint tissues including synovial fluid, synovium, bone and cartilage were obtained from patients undergoing total knee or hip replacement surgery at the Backus Hospital. Tissue samples were immediately snap frozen in liquid nitrogen to ensure that isolated RNA was of optimal quality and not degraded. Additional samples of osteoarthritis and rheumatoid arthritis joint tissues were obtained from Clinomics. Normal control tissues were supplied by Clinomics and were obtained during autopsy of trauma victims.  
     [0516] Surgical specimens of psoriatic tissues and adjacent matched tissues were provided as total RNA by Clinomics. Two male and two female patients were selected between the ages of 25 and 47. None of the patients were taking prescription drugs at the time samples were isolated.  
     [0517] Surgical specimens of diseased colon from patients with ulcerative colitis and Crohns disease and adjacent matched tissues were obtained from Clinomics. Bowel tissue from three female and three male Crohn&#39;s patients between the ages of 41-69 were used. Two patients were not on prescription medication while the others were taking dexamethasone, phenobarbital, or tylenol. Ulcerative colitis tissue was from three male and four female patients. Four of the patients were taking lebvid and two were on phenobarbital.  
     [0518] Total RNA from post mortem lung tissue from trauma victims with no disease or with emphysema, asthma or COPD was purchased from Clinomics. Emphysema patients ranged in age from 40-70 and all were smokers, this age range was chosen to focus on patients with cigarette-linked emphysema and to avoid those patients with alpha-1anti-trypsin deficiencies. Asthma patients ranged in age from 36-75, and excluded smokers to prevent those patients that could also have COPD. COPD patients ranged in age from 35-80 and included both smokers and non-smokers. Most patients were taking corticosteroids, and bronchodilators.  
     [0519] In the labels employed to identify tissues in the AI_comprehensive panel_v1.0 panel, the following abbreviations are used:  
     [0520] AI=Autoimmunity  
     [0521] Syn=Synovial  
     [0522] Normal=No apparent disease  
     [0523] Rep22/Rep20=individual patients  
     [0524] RA=Rheumatoid arthritis  
     [0525] Backus=From Backus Hospital  
     [0526] OA=Osteoarthritis  
     [0527] (SS)(BA)(MF)=Individual patients  
     [0528] Adj=Adjacent tissue  
     [0529] Match control=adjacent tissues  
     [0530] −M=Male  
     [0531] −F=Female  
     [0532] COPD=Chronic obstructive pulmonary disease  
     [0533] AI.05 Chondrosarcoma  
     [0534] The AI.05 chondrosarcoma plates are comprised of SW1353 cells that had been subjected to serum starvation and treatment with cytokines that are known to induce MMP (1, 3 and 13) synthesis (eg. IL1beta). These treatments include: IL-1beta (10 ng/ml), IL-1beta+TNF-alpha (50 ng/ml), IL-1beta+Oncostatin (50 ng/ml) and PMA (100 ng/ml). The SW1353 cells were obtained from the ATCC (American Type Culture Collection) and were all cultured under standard recommended conditions. The SW1353 cells were plated at 3×10 5  cells/ml (in DMEM medium-10% FBS) in 6-well plates. The treatment was done in triplicate, for 6 and 18 h. The supernatants were collected for analysis of MMP 1, 3 and 13 production and for RNA extraction. RNA was prepared from these samples using the standard procedures.  
     [0535] Panels 5D and 5I  
     [0536] The plates for Panel 5D and 5I include two control wells and a variety of cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. Metabolic tissues were obtained from patients enrolled in the Gestational Diabetes study. Cells were obtained during different stages in the differentiation of adipocytes from human mesenchymal stem cells. Human pancreatic islets were also obtained.  
     [0537] In the Gestational Diabetes study subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarean section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (less than 1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted and fast frozen within 5 minutes from the time of removal. The tissue was then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus) and subcutaneous adipose. Patient descriptions are as follows:  
     [0538] Patient 2: Diabetic Hispanic, overweight, not on insulin  
     [0539] Patient 7-9: Nondiabetic Caucasian and obese (BMI&gt;30)  
     [0540] Patient 10: Diabetic Hispanic, overweight, on insulin  
     [0541] Patient 11: Nondiabetic African American and overweight  
     [0542] Patient 12: Diabetic Hispanic on insulin  
     [0543] Adiocyte differentiation was induced in donor progenitor cells obtained from Osirus (a division of Clonetics/BioWhittaker) in triplicate, except for Donor 3U which had only two replicates. Scientists at Clonetics isolated, grew and differentiated human mesenchymal stem cells (HuMSCs) for CuraGen based on the published protocol found in Mark F. Pittenger, et al., Multilineage Potential of Adult Human Mesenchymal Stem Cells Science Apr. 2 1999: 143-147. Clonetics provided Trizol lysates or frozen pellets suitable for mRNA isolation and ds cDNA production. A general description of each donor is as follows:  
     [0544] Donor 2 and 3 U: Mesenchymal Stem cells, Undifferentiated Adipose  
     [0545] Donor 2 and 3 AM: Adipose, AdiposeMidway Differentiated  
     [0546] Donor 2 and 3 AD: Adipose, Adipose Differentiated  
     [0547] Human cell lines were generally obtained from ATCC (American Type Culture Collection), NCI or the German tumor cell bank and fall into the following tissue groups: kidney proximal convoluted tubule, uterine smooth muscle cells, small intestine, liver HepG2 cancer cells, heart primary stromal cells, and adrenal cortical adenoma cells. These cells are all cultured under standard recommended conditions and RNA extracted using the standard procedures. All samples were processed at CuraGen to produce single stranded cDNA.  
     [0548] Panel 5I contains all samples previously described with the addition of pancreatic islets from a 58 year old female patient obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at an outside source and delivered to CuraGen for addition to panel 5I.  
     [0549] In the labels employed to identify tissues in the 5D and 5I panels, the following abbreviations are used:  
     [0550] GO Adipose=Greater Omentum Adipose  
     [0551] SK=Skeletal Muscle  
     [0552] UT Uterus  
     [0553] PL=Placenta  
     [0554] AD=Adipose Differentiated  
     [0555] AM Adipose Midway Differentiated  
     [0556] U=Undifferentiated Stem Cells  
     [0557] Human Metabolic RTQ-PCR Panel  
     [0558] The plates for the Human Metabolic RTQ-PCR Panel include two control wells (genomic DNA control and chemistry control) and 211 cDNAs isolated from human tissues and cell lines with an emphasis on metabolic diseases. This panel is useful for establishing the tissue and cellular expression profiles for genes believed to play a role in the etiology and pathogenesis of obesity and/or diabetes and to confirm differential expression of such genes derived from other methods. Metabolic tissues were obtained from patients enrolled in the CuraGen Gestational Diabetes study and from autopsy tissues from Type II diabetics and age, sex and race-matched control patients. One or more of the following were used to characterize the patients: body mass index [BMI=wt(kg)/ht(m 2 )], serum glucose, HgbA1c. Cell lines used in this panel are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines. RNA from human Pancreatic Islets was also obtained.  
     [0559] In the Gestational Diabetes study, subjects are young (18-40 years), otherwise healthy women with and without gestational diabetes undergoing routine (elective) Caesarian section. After delivery of the infant, when the surgical incisions were being repaired/closed, the obstetrician removed a small sample (less than 1 cc) of the exposed metabolic tissues during the closure of each surgical level. The biopsy material was rinsed in sterile saline, blotted, and then flash frozen in liquid nitrogen and stored, individually, in sterile screw-top tubes and kept on dry ice for shipment to or to be picked up by CuraGen. The metabolic tissues of interest include uterine wall (smooth muscle), visceral adipose, skeletal muscle (rectus), and subcutaneous adipose. Patient descriptions are as follows:  
     [0560] Patient 7—Non-diabetic Caucasian and obese  
     [0561] Patient 8—Non-diabetic Caucasian and obese  
     [0562] Patient 12—Diabetic Caucasian with unknown BMI and on insulin  
     [0563] Patient 13—Diabetic Caucasian, overweight, not on insulin  
     [0564] Patient 15—Diabetic Caucasian, obese, not on insulin  
     [0565] Patient 17—Diabetic Caucasian, normal weight, not on insulin  
     [0566] Patient 18—Diabetic Hispanic, obese, not on insulin  
     [0567] Patient 19—Non-diabetic Caucasian and normal weight  
     [0568] Patient 20—Diabetic Caucasian, overweight, and on insulin  
     [0569] Patient 21—Non-diabetic Caucasian and overweight  
     [0570] Patient 22—Diabetic Caucasian, normal weight, on insulin  
     [0571] Patient 23—Non-diabetic Caucasian and overweight  
     [0572] Patient 25—Diabetic Caucasian, normal weight, not on insulin  
     [0573] Patient 26—Diabetic Caucasian, obese, on insulin  
     [0574] Patient 27—Diabetic Caucasian, obese, on insulin  
     [0575] Total RNA was isolated from metabolic tissues of 12 Type II diabetic patients and 12 matched control patients included hypothalamus, liver, pancreas, small intestine, psoas muscle, diaphragm muscle, visceral adipose, and subcutaneous adipose. The diabetics and non-diabetics were matched for age, sex, ethnicity, and BMI where possible.  
     [0576] The panel also contains pancreatic islets from a 22 year old male patient (with a BMI of 35) obtained from the Diabetes Research Institute at the University of Miami School of Medicine. Islet tissue was processed to total RNA at CuraGen.  
     [0577] Cell lines used in this panel are widely available through the American Type Culture Collection (ATCC), a repository for cultured cell lines, and were cultured at an outside facility. The RNA was extracted at CuraGen according to CuraGen protocols. All samples were then processed at CuraGen to produce single stranded cDNA.  
     [0578] In the labels used to identify tissues in the Human Metabolic panel, the following abbreviations are used:  
     [0579] Pl=placenta  
     [0580] Go=greater omentum  
     [0581] Sk=skeletal muscle  
     [0582] Ut=uterus  
     [0583] CC=Caucasian  
     [0584] HI=Hispanic  
     [0585] A=African American  
     [0586] AS=Asian  
     [0587] Diab=Type II diabetic  
     [0588] Norm=Non-diabetic  
     [0589] Overwt=Overweight; med BMI  
     [0590] Obese=Hi BMI  
     [0591] Low BM=20-25  
     [0592] Med BM=26-30  
     [0593] Hi BMI=Greater than 30  
     [0594] M=Male  
     [0595] #=Patient identifier  
     [0596] Vis.=Visceral  
     [0597] SubQ=Subcutaneous  
     [0598] Panel CNSD.01  
     [0599] The plates for Panel CNSD.01 include two control wells and 94 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center. Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [0600] Disease diagnoses are taken from patient records. The panel contains two brains from each of the following diagnoses: Alzheimer&#39;s disease, Parkinson&#39;s disease, Huntington&#39;s disease, Progressive Supemuclear Palsy, Depression, and “Normal controls”. Within each of these brains, the following regions are represented: cingulate gyrus, temporal pole, globus palladus, substantia nigra, Brodman Area 4 (primary motor strip), Brodman Area 7 (parietal cortex), Brodman Area 9 (prefrontal cortex), and Brodman area 17 (occipital cortex). Not all brain regions are represented in all cases; e.g., Huntington&#39;s disease is characterized in part by neurodegeneration in the globus palladus, thus this region is impossible to obtain from confirmed Huntington&#39;s cases. Likewise Parkinson&#39;s disease is characterized by degeneration of the substantia nigra making this region more difficult to obtain. Normal control brains were examined for neuropathology and found to be free of any pathology consistent with neurodegeneration.  
     [0601] In the labels employed to identify tissues in the CNS panel, the following abbreviations are used:  
     [0602] PSP=Progressive supranuclear palsy  
     [0603] Sub Nigra=Substantia nigra  
     [0604] Glob Palladus=Globus palladus  
     [0605] Temp Pole=Temporal pole  
     [0606] Cing Gyr=Cingulate gyrus  
     [0607] BA 4=Brodman Area 4  
     [0608] Panel CNS_Neurodegeneration_V1.0  
     [0609] The plates for Panel CNS_Neurodegeneration_V1.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [0610] Disease diagnoses are taken from patient records. The panel contains six brains from Alzheimer&#39;s disease (AD) patients, and eight brains from “Normal controls” who showed no evidence of dementia prior to death. The eight normal control brains are divided into two categories: Controls with no dementia and no Alzheimer&#39;s like pathology (Controls) and controls with no dementia but evidence of severe Alzheimeres like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Within each of these brains, the following regions are represented: hippocampus, temporal cortex (Brodman Area 21), parietal cortex (Brodman area 7), and occipital cortex (Brodman area 17). These regions were chosen to encompass all levels of neurodegeneration in AD. The hippocampus is a region of early and severe neuronal loss in AD; the temporal cortex is known to show neurodegeneration in AD after the hippocampus; the parietal cortex shows moderate neuronal death in the late stages of the disease; the occipital cortex is spared in AD and therefore acts as a “control” region within AD patients. Not all brain regions are represented in all cases.  
     [0611] In the labels employed to identify tissues in the CNS_Neurodegeneration_V1.0 panel, the following abbreviations are used:  
     [0612] AD=Alzheimer&#39;s disease brain; patient was demented and showed AD-like pathology upon autopsy  
     [0613] Control=Control brains; patient not demented, showing no neuropathology  
     [0614] Control (Path)=Control brains; pateint not demented but showing sever AD-like pathology  
     [0615] SupTemporal Ctx=Superior Temporal Cortex  
     [0616] Inf Temporal Ctx=Inferior Temporal Cortex  
     [0617] Panel CNS_Neurodegeneration_V2.0  
     [0618] The plates for Panel CNS_Neurodegeneration_V2.0 include two control wells and 47 test samples comprised of cDNA isolated from postmortem human brain tissue obtained from the Harvard Brain Tissue Resource Center (McLean Hospital) and the Human Brain and Spinal Fluid Resource Center (VA Greater Los Angeles Healthcare System). Brains are removed from calvaria of donors between 4 and 24 hours after death, sectioned by neuroanatomists, and frozen at −80° C. in liquid nitrogen vapor. All brains are sectioned and examined by neuropathologists to confirm diagnoses with clear associated neuropathology.  
     [0619] Disease diagnoses are taken from patient records. The panel contains sixteen brains from Alzheimer&#39;s disease (AD) patients, and twenty-nine brains from “Normal controls” who showed no evidence of dementia prior to death. The twenty-nine normal control brains are divided into two categories: Fourteen controls with no dementia and no Alzheimer&#39;s like pathology (Controls) and fifteen controls with no dementia but evidence of severe Alzheimer&#39;s like pathology, (specifically senile plaque load rated as level 3 on a scale of 0-3; 0=no evidence of plaques, 3=severe AD senile plaque load). Tissue from the temporal cotex (Broddmann Area 21) was selected for all samples from the Harvard Brain Tissue Resource Center; from the two sample from the Human Brain and Spinal Fluid Resource Center (samples 1 and 2) tissue from the inferior and superior temporal cortex was used; each sample on the panel represents a pool of inferior and superior temporal cortex from an individual patient. The temporal cortex was chosen as it shows a loss of neurons in the intermediate stages of the disease. Selection of a region which is affected in the early stages of Alzheimer&#39;s disease (e.g., hippocampus or entorhinal cortex) could potentially result in the examination of gene expression after vulnerable neurons are lost, and missing genes involved in the actual neurodegeneration process.  
     [0620] In the labels employed to identify tissues in the CNS_Neurodegeneration_V2.0 panel, the following abbreviations are used:  
     [0621] AD=Alzheimer&#39;s disease brain; patient was demented and showed AD-like pathology upon autopsy  
     [0622] Control=Control brains; patient not demented, showing no neuropathology  
     [0623] AH3=Control brains; pateint not demented but showing sever AD-like pathology  
     [0624] Inf &amp; Sup Temp Ctx Pool=Pool of inferior and superior temporal cortex for a given individual  
     [0625] A. CG164221-01: Protein kinase, Sgk  
     [0626] Expression of gene CG164221-01 was assessed using the primer-probe set Ag6086, described in Table AA. Results of the RTQ-PCR runs are shown in Tables AB, AC and AD.  
     [0627] Table AA. Probe Name Ag6086 
                   TABLE AA                          Probe Name Ag6086                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-aattctcatcgctttcatgaag-3′   22   101   98           Probe   TET-5′-aagtcgttcagacccatcctcctctg-3′-TAMRA   26   123   99       Reverse   5′-ataggagttattggcaatcttctga-3′   25   152   100                  
 
     [0628] Table AB. CNS neurodegeneration_v1.0 
               TABLE AB                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   14.0   13.8           AD 2 Hippo   26.4   17.6           AD 3 Hippo   6.0   5.9           AD 4 Hippo   6.2   5.0           AD 5 Hippo   26.4   25.5           AD 6 Hippo   67.8   58.2           Control 2 Hippo   20.2   19.1           Control 4 Hippo   12.9   12.2           Control (Path) 3 Hippo   3.1   4.5           AD 1 Temporal Ctx   22.4   25.9           AD 2 Temporal Ctx   25.9   22.5           AD 3 Temporal Ctx   3.1   3.3           AD 4 Temporal Ctx   18.3   17.2           AD 5 Inf Temporal Ctx   40.1   72.2           AD 5 Sup Temporal Ctx   47.6   39.8           AD 6 Inf Temporal Ctx   100.0   100.0           AD 6 Sup Temporal Ctx   49.3   52.9           Control 1 Temporal Ctx   2.0   1.9           Control 2 Temporal Ctx   20.9   17.6           Control 3 Temporal Ctx   6.5   6.4           Control 3 Temporal Ctx   6.6   4.2           Control (Path) 1 Temporal Ctx   11.3   8.1           Control (Path) 2 Temporal Ctx   7.0   7.7           Control (Path) 3 Temporal Ctx   0.9   1.5           Control (Path) 4 Temporal Ctx   2.1   3.3           AD 1 Occipital Ctx   10.1   8.5           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   0.3   3.2           AD 4 Occipital Ctx   14.1   11.8           AD 5 Occipital Ctx   20.2   20.7           AD 6 Occipital Ctx   20.2   18.4           Control 1 Occipital Ctx   1.2   1.3           Control 2 Occipital Ctx   27.9   31.6           Control 3 Occipital Ctx   5.6   4.3           Control 4 Occipital Ctx   9.3   6.3           Control (Path) 1 Occipital Ctx   23.5   20.3           Control (Path) 2 Occipital Ctx   2.1   3.1           Control (Path) 3 Occipital Ctx   1.9   2.5           Control (Path) 4 Occipital Ctx   3.1   3.2           Control 1 Parietal Ctx   2.0   2.5           Control 2 Parietal Ctx   33.9   32.3           Control 3 Parietal Ctx   4.6   6.4           Control (Path) 1 Parietal Ctx   12.4   11.7           Control (Path) 2 Parietal Ctx   6.7   7.5           Control (Path) 3 Parietal Ctx   1.4   1.2           Control (Path) 4 Parietal Ctx   6.9   5.2                                              
 
     [0629] Table AC. General —l screening panel v 1.5 
               TABLE AC                          General_screening_panel_v1.5                             Tissue Name   A                                         Adipose   29.9           Melanoma* Hs688(A).T   38.2           Melanoma* Hs688(B).T   17.6           Melanoma* M14   55.5           Melanoma* LOXIMVI   9.1           Melanoma* SK-MEL-5   62.4           Squamous cell carcinoma SCC-4   1.9           Testis Pool   5.9           Prostate ca.* (bone met) PC-3   0.9           Prostate Pool   1.0           Placenta   10.6           Uterus Pool   3.0           Ovarian ca. OVCAR-3   1.4           Ovarian ca. SK-OV-3   4.1           Ovarian ca. OVCAR-4   1.6           Ovarian ca. OVCAR-5   10.7           Ovarian ca. IGROV-1   6.2           Ovarian ca. OVCAR-8   0.5           Ovary   15.1           Breast ca. MCF-7   0.9           Breast ca. MDA-MB-231   4.8           Breast ca. BT 549   24.5           Breast ca. T47D   0.0           Breast ca. MDA-N   11.7           Breast Pool   5.6           Trachea   8.7           Lung   7.4           Fetal Lung   15.8           Lung ca. NCI-N417   0.4           Lung ca. LX-1   1.8           Lung ca. NCI-H146   2.7           Lung ca. SHP-77   9.4           Lung ca. A549   10.1           Lung ca. NCI-H526   0.1           Lung ca. NCI-H23   100.0           Lung ca. NCI-H460   7.1           Lung ca. HOP-62   1.5           Lung ca. NCI-H522   0.1           Liver   1.0           Fetal Liver   4.8           Liver ca. HepG2   1.4           Kidney Pool   4.5           Fetal Kidney   7.7           Renal ca. 786-0   2.5           Renal ca. A498   1.7           Renal ca. ACHN   6.6           Renal ca. UO-31   2.8           Renal ca. TK-10   1.4           Bladder   20.4           Gastric ca. (liver met.) NCI-N87   2.4           Gastric ca. KATO III   3.7           Colon ca. SW-948   0.3           Colon ca. SW480   0.8           Colon ca.* (SW480 met) SW620   0.4           Colon ca. HT29   2.0           Colon ca. HCT-116   0.6           Colon ca. CaCo-2   9.8           Colon cancer tissue   15.9           Colon ca. SW1116   0.5           Colon ca. Colo-205   0.4           Colon ca. SW-48   0.4           Colon Pool   4.2           Small Intestine Pool   1.2           Stomach Pool   3.7           Bone Marrow Pool   3.5           Fetal Heart   5.3           Heart Pool   1.9           Lymph Node Pool   4.0           Fetal Skeletal Muscle   3.4           Skeletal Muscle Pool   6.1           Spleen Pool   7.0           Thymus Pool   6.3           CNS cancer (glio/astro) U87-MG   6.2           CNS cancer (glio/astro) U-118-MG   10.2           CNS cancer (neuro; met) SK-N-AS   4.9           CNS cancer (astro) SF-539   3.4           CNS cancer (astro) SNB-75   13.9           CNS cancer (glio) SNB-19   5.1           CNS cancer (glio) SF-295   6.9           Brain (Amygdala) Pool   6.8           Brain (cerebellum)   8.0           Brain (fetal)   4.4           Brain (Hippocampus) Pool   8.4           Cerebral Cortex Pool   5.5           Brain (Substantia nigra) Pool   4.8           Brain (Thalamus) Pool   8.2           Brain (whole)   7.6           Spinal Cord Pool   7.6           Adrenal Gland   59.9           Pituitary gland Pool   0.5           Salivary Gland   2.6           Thyroid (female)   6.0           Pancreatic ca. CAPAN2   3.1           Pancreas Pool   17.1                                  
 
     [0630] Table AD. Panel 5 Islet  
               TABLE AD                          Panel 5 Islet                             Tissue Name   A                                         97457_Patient-02go_adipose   26.4           97476_Patient-07sk_skeletal muscle   40.6           97477_Patient-07ut_uterus   23.0           97478_Patient-07pl_placenta   28.1           99167_Bayer Patient 1   59.5           97482_Patient-08ut_uterus   24.3           97483_Patient-08pl_placenta   3.9           97486_Patient-09sk_skeletal muscle   5.3           97487_Patient-09ut_uterus   21.0           97488_Patient-09pl_placenta   16.4           97492_Patient-10ut_uterus   29.5           97493_Patient-10pl_placenta   40.9           97495_Patient-11go_adipose   49.3           97496_Patient-11sk_skeletal muscle   17.6           97497_Patient-11ut_uterus   39.0           97498_Patient-11pl_placenta   19.5           97500_Patient-12go_adipose   84.7           97501_Patient-12sk_skeletal muscle   67.8           97502_Patient-12ut_uterus   25.7           97503_Patient-12pl_placenta   37.4           94721_Donor 2 U - A_Mesenchymal Stem Cells   26.2           94722_Donor 2 U - B_Mesenchymal Stem Cells   19.9           94723_Donor 2 U - C Mesenchymal Stem Cells   33.0           94709_Donor 2 AM - A_adipose   4.7           94710_Donor 2 AM - B_adipose   2.7           94711_Donor 2 AM - C_adipose   3.4           94712_Donor 2 AD - A_adipose   12.0           94713_Donor 2 AD - B_adipose   12.6           94714_Donor 2 AD - C_adipose   14.1           94742_Donor 3 U - A_Mesenchymal Stem Cells   4.8           94743_Donor 3 U - B_Mesenchymal Stem Cells   11.0           94730_Donor 3 AM - A_adipose   5.6           94731_Donor 3 AM - B_adipose   4.7           94732_Donor 3 AM - C_adipose   4.0           94733_Donor 3 AD - A_adipose   43.2           94734_Donor 3 AD - B_adipose   15.5           94735_Donor 3 AD - C_adipose   36.9           77138_Liver_HepG2untreated   9.0           73556_Heart_Cardiac stromal cells (primary)   20.0           81735_Small Intestine   31.9           72409_Kidney_Proximal Convoluted Tubule   38.7           82685_Small intestine_Duodenum   4.6           90650_Adrenal_Adrenocortical adenoma   68.3           72410_Kidney_HRCE   79.0           72411_Kidney_HRE   100.0           73139_Uterus_Uterine smooth muscle cells   7.8                                  
 
     [0631] CNS_neurodegeneration_v1.0 Summary: Ag6086 Two experiments with same probe-primer sets are in excellent agreement. This panel confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer&#39;s disease patients. This gene encodes serine/threonine-protein kinase Sgk protein. Blockade of SGK protein encoded by this gene may be of use in the treatment of this disease and decrease neuronal death.  
     [0632] General_screening_panel_v1.5 Summary: Ag6086 This gene shows ubiquitous expression with highest expression in a lung cancer NCI-H23 cell line (CT=25.5). Moderate to high levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0633] Among tissues with metabolic or endocrine function, this gene is expressed at moderate to high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0634] In addition, this gene is expressed at moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0635] Panel 5 Islet Summary: Ag6086 This gene shows wide spread expression in this panel with highest expression in kidney (CT=27.8). The moderate expression of SGK1 in adipose, kidney and skeletal muscle is consistent with literature and the expression pattern seen in panel 1.5. Notably, SGK1 is also expressed in pancreatic islets. SGK is the serine/threonine kinase implicated in development of several diabetic complications, specifically hypertension and diabetic nephropathy (Lang, F.; et al., 2000Proc. Nat. Acad. Sci. 97: 8157-8162. (PMID: 10884438); Lang F, et al. 2001, Sci STKE 108:RE17 (PMID: 11707620). It has been shown that SGK phosphorylates the cytoplasmic domains of several ion channels/transporters modulating their activity, and/or endocytosis rate. SGK gene has been mapped to the region 6q23. Interestingly, duplication of this chromosomal region causes transient neonatal diabetes mellitus characterized by hyperglycemia and predisposition toward type 2 diabetes (Temple, I. K.; et al. 1996, Hum. Molec. Genet. 5: 1117-1124. (PMID: 8842729). Together with the localization of SGK gene in loci for neonatal diabetes, the data suggest that SGK1 might modulate insulin secretion.  
     [0636] B. CG50183-01: Chemokine Receptor  
     [0637] Expression of gene CG50183-01 was assessed using the primer-probe set Gpcr09, described in Table BA. Results of the RTQ-PCR runs are shown in Table BB.  
                   TABLE BA                          Probe Name Gpcr09                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-tgagcaaacgcatggacatc-3′   20   826   101           Probe   TET-5′-ccatccaagtcacagaaagcatcgcact-3′-TAMRA   28   847   102       Reverse   5′-tgggttgaggcagctgtga-3′   19   878   103                  
 
     [0638]               TABLE BB                          Panel 1                             Tissue Name   A                                         Endothelial cells   0.8           Endothelial cells (treated)   0.8           Pancreas   17.4           Pancreatic ca. CAPAN 2   2.5           Adrenal gland   17.2           Thyroid   8.5           Salivary gland   39.2           Pituitary gland   25.3           Brain (fetal)   2.0           Brain (whole)   3.3           Brain (amygdala)   8.2           Brain (cerebellum)   10.8           Brain (hippocampus)   7.3           Brain (substantia nigra)   27.2           Brain (thalamus)   4.0           Brain (hypothalamus)   100.0           Spinal cord   7.8           glio/astro U87-MG   9.9           glio/astro U-118-MG   6.7           astrocytoma SW1783   4.4           neuro*; met SK-N-AS   5.5           astrocytoma SF-539   9.0           astrocytoma SNB-75   4.6           glioma SNB-19   14.9           glioma U251   11.7           glioma SF-295   13.6           Heart   56.3           Skeletal muscle   6.2           Bone marrow   4.8           Thymus   22.1           Spleen   12.6           Lymph node   19.2           Colon (ascending)   37.1           Stomach   24.5           Small intestine   55.1           Colon ca. SW480   3.8           Colon ca.* SW620 (SW480 met)   5.1           Colon ca. HT29   8.4           Colon ca. HCT-116   8.1           Colon ca. CaCo-2   11.2           Colon ca. HCT-15   8.3           Colon ca. HCC-2998   13.5           Gastric ca. * (liver met) NCI-N87   36.3           Bladder   30.6           Trachea   19.6           Kidney   24.1           Kidney (fetal)   14.4           Renal ca. 786-0   5.8           Renal ca. A498   19.2           Renal ca. RXF 393   5.0           Renal ca. ACHN   14.8           Renal ca. UO-31   11.1           Renal ca. TK-10   13.4           Liver   18.4           Liver (fetal)   7.4           Liver ca. (hepatoblast) HepG2   28.3           Lung   0.0           Lung (fetal)   9.1           Lung ca. (small cell) LX-1   7.9           Lung ca. (small cell) NCI-H69   13.2           Lung ca. (s. cell var.) SHP-77   2.2           Lung ca. (large cell) NCI-H460   25.5           Lung ca. (non-sm. cell) A549   20.9           Lung ca. (non-s. cell) NCI-H23   3.6           Lung ca. (non-s. cell) HOP-62   12.5           Lung ca. (non-s. cl) NCI-H522   19.9           Lung ca. (squam.) SW 900   9.5           Lung ca. (squam.) NCI-H596   20.2           Mammary gland   57.8           Breast ca.* (pl. ef) MCF-7   7.6           Breast ca.* (pl. ef) MDA-MB-231   1.2           Breast ca.* (pl. ef) T47D   34.4           Breast ca. BT-549   4.1           Breast ca. MDA-N   51.8           Ovary   6.9           Ovarian ca. OVCAR-3   15.2           Ovarian ca. OVCAR-4   2.6           Ovarian ca. OVCAR-5   22.2           Ovarian ca. OVCAR-8   36.1           Ovarian ca. IGROV-1   12.6           Ovarian ca. (ascites) SK-OV-3   7.5           Uterus   21.8           Placenta   7.5           Prostate   19.5           Prostate ca.* (bone met) PC-3   12.8           Testis   14.8           Melanoma Hs688(A).T   7.5           Melanoma* (met) Hs688(B).T   11.3           Melanoma UACC-62   5.0           Melanoma M14   10.1           Melanoma LOX IMVI   1.6           Melanoma* (met) SK-MEL-5   15.7           Melanoma SK-MEL-28   25.5                                    
     [0639] Panel 1 Summary: Gpcr09 Highest expression is seen in hypothalamus (CT=25). Prominent levels of expression are seen primarily in normal tissues, including mammary gland, heart, colon, stomach, and substantia nigra.  
     [0640] C. CG50249-01: Voltage-Gated Potassium Channel Protein KV3.2 Like  
     [0641] Expression of gene CG50249-01 was assessed using the primer-probe set Ag2503, described in Table CA. Results of the RTQ-PCR runs are shown in Tables CB, CC, CD and CE.  
     [0642] Table CA. Probe Name Ag 2503 
                   TABLE CA                          Probe Name Ag2503                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-gaggctctctccagtaacatca-3′   22   1851   104           Probe   TET-5′-actctccttgtcctctgaggcgctct-3′-TAMRA   26   1880   105       Reverse   5′-gcagtttggttgtttggtttac-3′   22   1929   106                  
 
     [0643] Table CB. CNS_neurodegeneration_v1.0 
               TABLE CB                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   4.1   4.4           AD 2 Hippo   10.5   9.3           AD 3 Hippo   1.3   1.2           AD 4 Hippo   1.6   1.8           AD 5 Hippo   100.0   100.0           AD 6 Hippo   16.8   16.5           Control 2 Hippo   13.4   14.5           Control 4 Hippo   1.1   0.8           Control (Path) 3 Hippo   0.5   0.6           AD 1 Temporal Ctx   3.9   4.1           AD 2 Temporal Ctx   19.3   18.9           AD 3 Temporal Ctx   1.4   1.1           AD 4 Temporal Ctx   9.0   9.4           AD 5 Inf Temporal Ctx   84.1   83.5           AD 5 Sup Temporal Ctx   19.5   17.0           AD 6 Inf Temporal Ctx   18.0   20.2           AD 6 Sup Temporal Ctx   28.7   26.4           Control 1 Temporal Ctx   1.0   0.7           Control 2 Temporal Ctx   31.6   42.6           Control 3 Temporal Ctx   9.0   11.4           Control 3 Temporal Ctx   2.2   1.9           Control (Path) 1 Temporal Ctx   52.5   54.7           Control (Path) 2 Temporal Ctx   32.1   37.9           Control (Path) 3 Temporal Ctx   0.6   1.0           Control (Path) 4 Temporal Ctx   26.8   28.1           AD 1 Occipital Ctx   12.1   12.5           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   1.8   2.1           AD 4 Occipital Ctx   13.8   10.4           AD 5 Occipital Ctx   45.7   48.3           AD 6 Occipital Ctx   15.5   12.6           Control 1 Occipital Ctx   0.2   0.0           Control 2 Occipital Ctx   54.0   56.3           Control 3 Occipital Ctx   11.2   10.7           Control 4 Occipital Ctx   0.5   0.5           Control (Path) 1 Occipital Ctx   76.8   78.5           Control (Path) 2 Occipital Ctx   9.5   8.4           Control (Path) 3 Occipital Ctx   0.2   0.3           Control (Path) 4 Occipital Ctx   13.0   14.1           Control 1 Parietal Ctx   1.0   1.1           Control 2 Parietal Ctx   26.6   26.4           Control 3 Parietal Ctx   18.2   15.4           Control (Path) 1 Parietal Ctx   71.2   73.7           Control (Path) 2 Parietal Ctx   17.7   16.6           Control (Path) 3 Parietal Ctx   0.6   0.5           Control (Path) 4 Parietal Ctx   44.1   43.2                                              
 
     [0644] Table CC. General screening_panel_v1.4 
               TABLE CC                          General_screening_panel_v1.4                                 Tissue Name   A   B                                             Adipose   0.0   0.0           Melanoma* Hs688(A).T   0.0   0.0           Melanoma* Hs688(B).T   0.0   0.0           Melanoma* M14   0.0   0.0           Melanoma* LOXIMVI   0.0   0.1           Melanoma* SK-MEL-5   0.0   0.1           Squamous cell carcinoma SCC-4   0.0   0.0           Testis Pool   0.2   0.3           Prostate ca.* (bone met) PC-3   0.0   0.0           Prostate Pool   6.4   7.8           Placenta   0.0   0.0           Uterus Pool   0.0   0.0           Ovarian ca. OVCAR-3   0.0   0.0           Ovarian ca. SK-OV-3   0.0   0.1           Ovarian ca. OVCAR-4   0.0   0.0           Ovarian ca. OVCAR-5   8.4   7.2           Ovarian ca. IGROV-1   0.0   0.0           Ovarian ca. OVCAR-8   0.0   0.0           Ovary   0.0   0.1           Breast ca. MCF-7   0.0   0.2           Breast ca. MDA-MB-231   0.0   0.0           Breast ca. BT 549   0.0   0.0           Breast ca. T47D   8.1   15.4           Breast ca. MDA-N   0.0   0.0           Breast Pool   0.9   0.5           Trachea   0.2   0.4           Lung   0.0   0.0           Fetal Lung   0.0   0.1           Lung ca. NCI-N417   0.0   0.0           Lung ca. LX-1   0.0   0.0           Lung ca. NCI-H146   1.8   1.8           Lung ca. SHP-77   0.5   0.5           Lung ca. A549   0.0   0.0           Lung ca. NCI-H526   0.0   0.0           Lung ca. NCI-H23   0.0   0.9           Lung ca. NCI-H460   2.0   0.1           Lung ca. HOP-62   0.1   0.0           Lung ca. NCI-H522   0.0   0.0           Liver   0.1   0.0           Fetal Liver   0.0   0.3           Liver ca. HepG2   0.0   0.0           Kidney Pool   0.0   0.1           Fetal Kidney   1.1   2.2           Renal ca. 786-0   0.0   0.0           Renal ca. A498   0.0   0.0           Renal ca. ACHN   0.4   0.0           Renal ca. UO-31   0.0   0.0           Renal ca. TK-10   0.0   0.0           Bladder   0.1   0.1           Gastric ca. (liver met.) NCI-N87   0.1   0.1           Gastric ca. KATO III   0.0   0.0           Colon ca. SW-948   0.0   0.0           Colon ca. SW480   0.0   0.1           Colon ca.* (SW480 met) SW620   0.0   0.0           Colon ca. HT29   0.1   0.1           Colon ca. HCT-116   0.0   0.0           Colon ca. CaCo-2   0.0   0.0           Colon cancer tissue   0.1   0.2           Colon ca. SW1116   0.0   0.0           Colon ca. Colo-205   0.0   0.0           Colon ca. SW-48   0.0   0.0           Colon Pool   0.2   0.1           Small Intestine Pool   0.2   0.4           Stomach Pool   0.2   0.0           Bone Marrow Pool   0.0   0.0           Fetal Heart   0.0   0.0           Heart Pool   0.0   0.1           Lymph Node Pool   0.1   0.1           Fetal Skeletal Muscle   0.1   0.0           Skeletal Muscle Pool   0.0   0.1           Spleen Pool   0.0   0.0           Thymus Pool   0.4   0.7           CNS cancer (glio/astro) U87-MG   0.0   0.0           CNS cancer (glio/astro) U-118-MG   0.1   0.1           CNS cancer (neuro; met) SK-N-AS   0.0   0.0           CNS cancer (astro) SF-539   0.0   0.0           CNS cancer (astro) SNB-75   0.0   0.0           CNS cancer (glio) SNB-19   0.0   0.0           CNS cancer (glio) SF-295   0.0   0.0           Brain (Amygdala) Pool   55.9   49.7           Brain (cerebellum)   1.1   1.1           Brain (fetal)   25.9   38.4           Brain (Hippocampus) Pool   31.0   35.8           Cerebral Cortex Pool   100.0   80.7           Brain (Substantia nigra) Pool   64.2   64.6           Brain (Thalamus) Pool   97.3   100.0           Brain (whole)   66.9   65.5           Spinal Cord Pool   6.4   5.3           Adrenal Gland   0.0   0.0           Pituitary gland Pool   6.6   5.5           Salivary Gland   0.2   0.1           Thyroid (female)   0.0   0.0           Pancreatic ca. CAPAN2   0.0   0.1           Pancreas Pool   0.2   0.7                                              
 
     [0645] Table CD. Panel 1.3D  
               TABLE CD                          Panel 1.3D                                 Tissue Name   A   B                                             Liver adenocarcinoma   0.0   0.0           Pancreas   0.0   0.0           Pancreatic ca. CAPAN 2   0.0   0.0           Adrenal gland   0.4   0.3           Thyroid   0.0   0.0           Salivary gland   0.1   0.1           Pituitary gland   6.0   3.0           Brain (fetal)   9.6   12.1           Brain (whole)   66.9   80.1           Brain (amygdala)   27.0   21.2           Brain (cerebellum)   0.8   2.0           Brain (hippocampus)   100.0   33.2           Brain (substantia nigra)   5.5   5.9           Brain (thalamus)   93.3   100.0           Cerebral Cortex   84.7   23.7           Spinal cord   0.8   0.9           glio/astro U87-MG   0.0   0.0           glio/astro U-118-MG   0.1   0.0           astrocytoma SW1783   0.0   0.0           neuro*; met SK-N-AS   0.0   0.0           astrocytoma SF-539   0.0   0.0           astrocytoma SNB-75   0.0   0.0           glioma SNB-19   0.1   0.0           glioma U251   0.0   0.0           glioma SF-295   0.1   0.0           Heart (fetal)   0.0   0.0           Heart   0.0   0.0           Skeletal muscle (fetal)   0.3   1.3           Skeletal muscle   0.0   0.0           Bone marrow   0.0   0.0           Thymus   0.0   0.0           Spleen   0.0   0.5           Lymph node   0.0   0.0           Colorectal   0.1   0.0           Stomach   0.0   0.0           Small intestine   0.1   0.2           Colon ca. SW480   0.0   0.0           Colon ca.* SW620 (SW480 met)   0.0   0.0           Colon ca. HT29   0.1   0.0           Colon ca. HCT-116   0.0   0.0           Colon ca. CaCo-2   0.0   0.0           Colon ca. tissue (ODO3866)   0.1   0.2           Colon ca. HCC-2998   0.0   0.1           Gastric ca.* (liver met) NCI-N87   0.0   0.1           Bladder   0.0   0.0           Trachea   0.1   0.0           Kidney   0.0   0.0           Kidney (fetal)   0.0   0.2           Renal ca. 786-0   0.0   0.0           Renal ca. A498   0.0   0.0           Renal ca. RXF 393   0.0   0.0           Renal ca. ACHN   0.0   0.0           Renal ca. UO-31   0.0   0.0           Renal ca. TK-10   0.0   0.0           Liver   0.0   0.0           Liver (fetal)   0.0   0.0           Liver ca. (hepatoblast) HepG2   0.0   0.0           Lung   0.0   0.0           Lung (fetal)   0.0   0.0           Lung ca. (small cell) LX-1   0.0   0.1           Lung ca. (small cell) NCI-H69   0.4   0.0           Lung ca. (s. cell var.) SHP-77   0.2   0.1           Lung ca. (large cell) NCI-H460   0.0   0.2           Lung ca. (non-sm. cell) A549   0.0   0.0           Lung ca. (non-s. cell) NCI-H23   0.0   0.1           Lung ca. (non-s. cell) HOP-62   0.1   0.0           Lung ca. (non-s. cl) NCI-H522   0.0   0.0           Lung ca. (squam.) SW 900   0.0   0.0           Lung ca. (squam.) NCI-H596   0.2   0.7           Mammary gland   5.1   1.7           Breast ca.* (pl. ef) MCF-7   0.1   0.0           Breast ca.* (pl. ef) MDA-MB-231   0.0   0.0           Breast ca.* (pl. ef) T47D   0.0   0.0           Breast ca. BT-549   0.0   0.0           Breast ca. MDA-N   0.0   0.0           Ovary   0.0   0.0           Ovarian ca. OVCAR-3   0.0   0.0           Ovarian ca. OVCAR-4   0.0   0.0           Ovarian ca. OVCAR-5   1.5   1.0           Ovarian ca. OVCAR-8   0.0   0.0           Ovarian ca. IGROV-1   0.0   0.0           Ovarian ca.* (ascites) SK-OV-3   0.0   0.3           Uterus   0.2   0.0           Placenta   0.0   0.0           Prostate   3.2   1.7           Prostate ca.* (bone met) PC-3   0.0   0.0           Testis   0.0   0.0           Melanoma Hs688(A).T   0.0   0.0           Melanoma* (met) Hs688(B).T   0.0   0.0           Melanoma UACC-62   0.0   0.0           Melanoma M14   0.0   0.0           Melanoma LOX IMVI   0.0   0.0           Melanoma* (met) SK-MEL-5   0.0   0.0           Adipose   0.0   0.0                                              
 
     [0646]               TABLE CE                          Panel CNS_1                             Tissue Name   A                                         BA4 Control   31.9           BA4 Control2   65.1           BA4 Alzheimer&#39;s2   4.0           BA4 Parkinson&#39;s   70.2           BA4 Parkinson&#39;s2   100.0           BA4 Huntington&#39;s   41.2           BA4 Huntington&#39;s2   2.1           BA4 PSP   5.3           BA4 PSP2   24.7           BA4 Depression   10.8           BA4 Depression2   9.0           BA7 Control   42.3           BA7 Control2   40.9           BA7 Alzheimer&#39;s2   6.4           BA7 Parkinson&#39;s   18.8           BA7 Parkinson&#39;s2   46.3           BA7 Huntington&#39;s   57.8           BA7 Huntington&#39;s2   52.9           BA7 PSP   35.4           BA7 PSP2   25.9           BA7 Depression   5.2           BA9 Control   23.2           BA9 Control2   88.3           BA9 Alzheimer&#39;s   4.9           BA9 Alzheimer&#39;s2   12.8           BA9 Parkinson&#39;s   25.5           BA9 Parkinson&#39;s2   61.6           BA9 Huntington&#39;s   42.3           BA9 Huntington&#39;s2   12.4           BA9 PSP   9.2           BA9 PSP2   4.0           BA9 Depression   3.5           BA9 Depression2   8.4           BA17 Control   58.2           BA17 Control2   62.4           BA17 Alzheimer&#39;s2   7.3           BA17 Parkinson&#39;s   31.9           BA17 Parkinson&#39;s2   57.8           BA17 Huntington&#39;s   32.8           BA17 Huntington&#39;s2   12.8           BA17 Depression   2.6           BA17 Depression2   23.3           BA17 PSP   22.2           BA17 PSP2   10.1           Sub Nigra Control   14.8           Sub Nigra Control2   9.9           Sub Nigra Alzheimer&#39;s2   2.9           Sub Nigra Parkinson&#39;s2   18.9           Sub Nigra Huntington&#39;s   10.5           Sub Nigra Huntington&#39;s2   10.7           Sub Nigra PSP2   0.9           Sub Nigra Depression   0.5           Sub Nigra Depression2   3.1           Glob Palladus Control   0.5           Glob Palladus Control2   1.4           Glob Palladus Alzheimer&#39;s   3.1           Glob Palladus Alzheimer&#39;s2   1.0           Glob Palladus Parkinson&#39;s   39.8           Glob Palladus Parkinson&#39;s2   0.8           Glob Palladus PSP   0.0           Glob Palladus PSP2   0.8           Glob Palladus Depression   0.2           Temp Pole Control   17.3           Temp Pole Control2   50.0           Temp Pole Alzheimer&#39;s   1.7           Temp Pole Alzheimer&#39;s2   3.0           Temp Pole Parkinson&#39;s   19.1           Temp Pole Parkinson&#39;s2   18.4           Temp Pole Huntington&#39;s   34.2           Temp Pole PSP   4.1           Temp Pole PSP2   2.8           Temp Pole Depression2   3.8           Cing Gyr Control   73.2           Cing Gyr Control2   23.8           Cing Gyr Alzheimer&#39;s   19.6           Cing Gyr Alzheimer&#39;s2   3.7           Cing Gyr Parkinson&#39;s   21.0           Cing Gyr Parkinson&#39;s2   26.1           Cing Gyr Huntington&#39;s   49.7           Cing Gyr Huntington&#39;s2   11.3           Cing Gyr PSP   5.6           Cing Gyr PSP2   3.1           Cing Gyr Depression   2.5           Cing Gyr Depression2   7.3                                    
     [0647] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained using Ag2503 exhibits this gene has high brain—preferential expression in the hippocampus, cortex, amygdala, substantia nigra and thalamus. These regions are susceptible to the neurodegeneration associated with Alzheimer&#39;s Disease, Parkinson&#39;s disease, Huntington&#39;s disease and other pathological neurodegenerative conditions. This gene encodes a protein that is homologous to a potassium channel. Potassium channels have been implicated in neurodegenerative diseases, including Alzheimer&#39;s Disease. It has been suggested that modulating these channels to reduce outward K+ current may provide an approach to reducing neuronal degeneration in patients with Alzheimer&#39;s disease. Therefore, agents that modulate the function of this gene product could potentially reduce neuronal degeneration in patients with Alzheimer&#39;s Disease and other neurodegenerative diseases.  
     [0648] In addition, defective potassium channels are known to cause several CNS disorders, including epilepsy and episodic ataxia with myokymia. Therefore, modulation of the expression or function of this gene product may potentially be useful as a treatment for the symptoms produced by ataxia and epilepsy.  
     [0649] References:  
     [0650] Jhamandas J H, et al. J Neurophysiol September 2001;86(3):1312-20  
     [0651] Chi X, et al. Neurosci Lett Aug. 18, 2000 ;290(1):9-12  
     [0652] Piccini A, et al. Neuroreport May 15, 2000;11(7):1375-9  
     [0653] Yu S P, et al. Neurobiol Dis August 1998;5(2):81-8  
     [0654] Colom L V, et al. J Neurochem May 1998;70(5):1925-34  
     [0655] General_screening_panel_v1.4 Summary: Ag2503 Two experiments with the same probe and primer set produce reults that are in excellent agreement, with highest expression in the brain. Please see CNS_neurodegeneration_v1.0 for discussion of potential role in the central nervous system.  
     [0656] There is also moderate to low expression in normal prostate and in cell lines derived from breast, lung, and ovarian cancer. Thus, this expression could be used as a diagnostic marker for the presence of cancers in any of those tissues. Furthermore,inhibition of the activity of the gene product by antibodies or small molecule inhibitors could potentially be used as a treatment of these cancers.  
     [0657] In both experiments, there is also significantly higher levels of expression in the fetal kidney (CTs=30-31) when compared to the adult kidney (CTs=35-36). Thus, expression of this gene could be used to differentiate between adult and fetal sources of this tissue. Furthermore, the higher levels of expression in the fetal kidney suggest that this gene product may be involved in the development of this organ. Thus, therapeutic modulation of the expression or function of the protein encoded by this gene may be useful in the treatment of diseases of the kidney.  
     [0658] Among tissues with metabolic function, the expression of this potassium channel homolog is highest in the pituitary gland and shows very good concordance between the two independent runs. Potassium channels are involved in regulation of secretion in pituitary cells and their modulation by therapeutics such as small molecule inhibitors or antibodies could be used to modulate specific secretory activities in the pituitary.  
     [0659] Panel 1.3D Summary: Ag2503 Two experiments with the same probe and primer set produce results that are in very good agreement, with highest expression in both experiments seen in the brain. Please see CNS_neurodegeneration_v1.0.  
     [0660] Moderate to low expression is also observed in some cancer cell lines (lung and ovary) as well as normal prostate and breast. Thus, this expression could be used as a diagnostic marker for lung and ovarian cancers. Furthermore, inhibition of the activity of this gene product through the application of antibodies or small molecule inhibitors could effective in the treatment of lung or ovarian cancers.  
     [0661] As in panel 1.4, expression of this gene among metabolic tissues is highest in the pituitary. Significantly lower levels of expression are seen in the adrenal gland and in fetal skeletal muscle. Potassium channels are involved in regulation of secretion in pituitary cells and their modulation by therapeutics such as small molecule inhibitors or antibodies could be used to modulate specific secretory activities in the pituitary, as well as in other tissues.  
     [0662] In both experiments, there is also significantly higher levels of expression in the fetal skeletal muscle(CTs=33) when compared to expression in adult skeletal muscle(CTs=40). Thus, expression of this gene could be used to differentiate between adult and fetal sources of this tissue. Furthermore, the higher levels of expression in fetal skeletal muscle suggest that this gene product may be involved in the development of the skeletal muscle in the fetus. Thus, therapeutic modulation of the expression or function of the protein encoded by this gene may be useful in the adult to restore mass or function to weak or dystrophic muscle.  
     [0663] Panel CNS — 1 Summary: Ag2503 Ubiquitous expression in this panel confirms the presence in the brain of this protein product. See NS_neurodegeneration_v1.0 for discussion of potential role in the central nervous system.  
     [0664] D. CG54236-02: Cysteinyl Leukotriene CYSLT2 Receptor  
     [0665] Expression of gene CG54236-02 was assessed using the primer-probe set Ag2695, described in Table DA. Results of the RTQ-PCR runs are shown in Tables DB, DC, DD, DE and DF.  
                   TABLE DA                          Probe Name Ag2695                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-gggaaatgggttgtccatatat-3′   22   266   107           Probe   TET-5′-tcctgcagccttataagaagtccaca-3′-TAMRA   26   292   108       Reverse   5′-atctgaaatggccagatttagc-3′   22   335   109                  
 
     [0666]               TABLE DB                          AI_comprehensive_panel_v1.0                                 Tissue Name   A   B                                             110967 COPD-F   7.1   2.5           110980 COPD-F   6.2   0.0           110968 COPD-M   6.9   7.9           110977 COPD-M   12.3   15.2           110989 Emphysema-F   45.1   28.5           110992 Emphysema-F   15.4   7.6           110993 Emphysema-F   11.9   4.8           110994 Emphysema-F   2.5   0.0           110995 Emphysema-F   12.9   38.4           110996 Emphysema-F   12.2   0.0           110997 Asthma-M   4.2   3.2           111001 Asthma-F   46.3   25.2           111002 Asthma-F   52.5   27.5           111003 Atopic Asthma-F   58.2   46.0           111004 Atopic Asthma-F   42.3   53.2           111005 Atopic Asthma-F   26.4   26.8           111006 Atopic Asthma-F   7.1   13.7           111417 Allergy-M   20.0   18.8           112347 Allergy-M   0.0   0.0           112349 Normal Lung-F   0.0   0.0           112357 Normal Lung-F   34.4   28.9           112354 Normal Lung-M   98.6   55.5           112374 Crohns-F   5.6   7.2           112389 Match Control Crohns-F   11.0   5.2           112375 Crohns-F   7.8   2.5           112732 Match Control Crohns-F   43.5   18.6           112725 Crohns-M   3.2   0.0           112387 Match Control Crohns-M   2.1   8.0           112378 Crohns-M   0.0   0.0           112390 Match Control Crohns-M   28.1   32.5           112726 Crohns-M   23.2   25.3           112731 Match Control Crohns-M   20.0   15.3           112380 Ulcer Col-F   11.3   20.7           112734 Match Control Ulcer Col-F   82.9   43.2           112384 Ulcer Col-F   24.7   25.9           112737 Match Control Ulcer Col-F   8.3   3.7           112386 Ulcer Col-F   2.2   3.6           112738 Match Control Ulcer Col-F   10.5   4.1           112381 Ulcer Col-M   1.5   0.0           112735 Match Control Ulcer Col-M   11.7   4.5           112382 Ulcer Col-M   25.5   16.6           112394 Match Control Ulcer Col-M   1.3   2.9           112383 Ulcer Col-M   12.2   11.7           112736 Match Control Ulcer Col-M   15.7   5.6           112423 Psoriasis-F   21.2   18.2           112427 Match Control Psoriasis-F   54.0   53.2           112418 Psoriasis-M   0.0   6.4           112723 Match Control Psoriasis-M   0.0   0.0           112419 Psoriasis-M   12.5   12.5           112424 Match Control Psoriasis-M   19.5   11.0           112420 Psoriasis-M   85.9   75.3           112425 Match Control Psoriasis-M   48.0   58.2           104689 (MF) OA Bone-Backus   39.0   59.9           104690 (MF) Adj “Normal” Bone-Backus   21.8   27.7           104691 (MF) OA Synovium-Backus   77.4   68.3           104692 (BA) OA Cartilage-Backus   0.0   0.0           104694 (BA) OA Bone-Backus   48.3   47.0           104695 (BA) Adj “Normal” Bone-Backus   24.8   21.5           104696 (BA) OA Synovium-Backus   81.8   49.7           104700 (SS) OA Bone-Backus   26.8   15.2           104701 (SS) Adj “Normal” Bone-Backus   13.5   11.4           104702 (SS) OA Synovium-Backus   62.0   49.0           117093 OA Cartilage Rep7   89.5   59.0           112672 OA Bone5   16.7   38.2           112673 OA Synovium5   15.7   11.3           112674 OA Synovial Fluid cells5   0.0   12.9           117100 OA Cartilage Rep14   7.6   6.1           112756 OA Bone9   22.5   7.9           112757 OA Synovium9   1.7   0.0           112758 OA Synovial Fluid Cells9   6.7   20.4           117125 RA Cartilage Rep2   2.3   4.7           113492 Bone2 RA   42.3   26.8           113493 Synovium2 RA   16.6   3.7           113494 Syn Fluid Cells RA   31.2   23.0           113499 Cartilage4 RA   20.9   20.0           113500 Bone4 RA   22.8   39.5           113501 Synovium4 RA   26.6   24.8           113502 Syn Fluid Cells4 RA   26.2   19.2           113495 Cartilage3 RA   22.4   16.5           113496 Bone3 RA   13.0   18.4           113497 Synovium3 RA   7.0   9.9           113498 Syn Fluid Cells3 RA   25.9   27.4           117106 Normal Cartilage Rep20   6.9   1.9           113663 Bone3 Normal   0.0   0.0           113664 Synovium3 Normal   0.0   0.0           113665 Syn Fluid Cells3 Normal   1.2   0.0           117107 Normal Cartilage Rep22   12.9   0.0           113667 Bone4 Normal   50.7   45.4           113668 Synovium4 Normal   50.0   64.6           113669 Syn Fluid Cells4 Normal   100.0   100.0                                                
     [0667]               TABLE DC                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   20.4   10.6           AD 2 Hippo   51.4   39.0           AD 3 Hippo   16.0   9.4           AD 4 Hippo   17.9   10.7           AD 5 hippo   100.0   88.9           AD 6 Hippo   33.9   25.2           Control 2 Hippo   22.8   21.6           Control 4 Hippo   48.3   22.7           Control (Path) 3 Hippo   24.8   9.9           AD 1 Temporal Ctx   26.6   31.4           AD 2 Temporal Ctx   29.5   40.1           AD 3 Temporal Ctx   7.1   14.2           AD 4 Temporal Ctx   41.5   41.5           AD 5 Inf Temporal Ctx   88.3   100.0           AD 5 Sup Temporal Ctx   62.9   44.1           AD 6 Inf Temporal Ctx   35.1   26.4           AD 6 Sup Temporal Ctx   40.3   33.2           Control 1 Temporal Ctx   49.0   46.0           Control 2 Temporal Ctx   51.4   42.3           Control 3 Temporal Ctx   28.5   31.9           Control 4 Temporal Ctx   22.7   36.3           Control (Path) 1 Temporal Ctx   90.8   70.2           Control (Path) 2 Temporal Ctx   64.2   50.3           Control (Path) 3 Temporal Ctx   49.7   19.6           Control (Path) 4 Temporal Ctx   80.1   71.7           AD 1 Occipital Ctx   19.1   23.5           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   17.4   8.7           AD 4 Occipital Ctx   51.8   33.7           AD 5 Occipital Ctx   14.5   22.5           AD 6 Occipital Ctx   59.0   44.4           Control 1 Occipital Ctx   43.2   34.9           Control 2 Occipital Ctx   80.1   57.0           Control 3 Occipital Ctx   46.3   37.6           Control 4 Occipital Ctx   37.1   11.2           Control (Path) 1 Occipital Ctx   87.7   85.3           Control (Path) 2 Occipital Ctx   50.3   31.0           Control (Path) 3 Occipital Ctx   36.6   22.2           Control (Path) 4 Occipital Ctx   84.7   71.7           Control 1 Parietal Ctx   60.7   48.6           Control 2 Parietal Ctx   55.5   40.9           Control 3 Parietal Ctx   22.8   10.9           Control (Path) 1 Parietal Ctx   97.3   58.2           Control (Path) 2 Parietal Ctx   76.3   46.3           Control (Path) 3 Parietal Ctx   25.0   28.5           Control (Path) 4 Parietal Ctx   84.7   72.2                                                
     [0668]               TABLE DD                          Panel 1.3D                                 Tissue Name   A   B                                             Liver adenocarcinoma   0.0   0.0           Pancreas   2.1   4.2           Pancreatic ca. CAPAN 2   0.0   0.0           Adrenal gland   67.4   100.0           Thyroid   5.1   2.0           Salivary gland   5.1   3.5           Pituitary gland   1.0   4.9           Brain (fetal)   3.5   0.0           Brain (whole)   20.3   16.0           Brain (amygdala)   22.2   12.5           Brain (cerebellum)   2.1   4.5           Brain (hippocampus)   61.1   35.1           Brain (substantia nigra)   9.2   8.8           Brain (thalamus)   8.7   18.6           Cerebral Cortex   45.1   53.2           Spinal cord   11.3   8.0           glio/astro U87-MG   0.0   0.0           glio/astro U-118-MG   4.2   0.0           astrocytoma SW1783   0.0   0.0           neuro*; met SK-N-AS   0.0   0.0           astrocytoma SF-539   9.0   0.0           astrocytoma SNB-75   0.0   0.0           glioma SNB-19   0.0   2.9           glioma U251   0.0   0.0           glioma SF-295   0.0   2.0           Heart (fetal)   17.4   16.5           Heart   41.5   33.0           Skeletal muscle (fetal)   8.6   5.2           Skeletal muscle   0.0   0.0           Bone marrow   3.5   11.7           Thymus   1.4   6.8           Spleen   100.0   59.0           Lymph node   32.3   26.8           Colorectal   17.9   20.2           Stomach   9.5   0.0           Small intestine   13.4   39.0           Colon ca. SW480   0.0   0.0           Colon ca.* SW620 (SW480 met)   0.0   0.0           Colon ca. HT29   0.0   1.9           Colon ca. HCT-116   0.0   0.0           Colon ca. CaCo-2   0.0   0.0           Colon ca. tissue (ODO3866)   11.0   3.4           Colon ca. HCC-2998   0.6   0.0           Gastric ca.* (liver met) NCI-N87   0.0   1.9           Bladder   0.0   2.4           Trachea   4.2   0.0           Kidney   2.4   0.0           Kidney (fetal)   0.0   3.9           Renal ca. 786-0   0.0   0.0           Renal ca. A498   0.0   1.9           Renal ca. RXF 393   0.0   0.0           Renal ca. ACHN   0.0   0.0           Renal ca. UO-31   0.0   0.0           Renal ca. TK-10   0.0   0.0           Liver   1.5   3.9           Liver (fetal)   0.0   2.5           Liver ca. (hepatoblast) HepG2   0.0   0.0           Lung   18.8   16.2           Lung (fetal)   3.7   3.7           Lung ca. (small cell) LX-1   0.0   0.0           Lung ca. (small cell) NCI-H69   0.0   0.0           Lung ca. (s. cell var.) SHP-77   0.0   0.0           Lung ca. (large cell) NCI-H460   0.0   0.0           Lung ca. (non-sm. cell) A549   0.0   0.0           Lung ca. (non-s. cell) NCI-H23   0.0   1.8           Lung ca. (non-s. cell) HOP-62   0.0   0.0           Lung ca. (non-s. cl) NCI-H522   0.0   0.0           Lung ca. (squam.) SW 900   0.0   0.0           Lung ca. (squam.) NCI-H596   2.3   0.0           Mammary gland   5.2   9.0           Breast ca.* (pl. ef) MCF-7   0.0   0.0           Breast ca.* (pl. ef) MDA-MB-231   0.0   0.0           Breast ca.* (pl. ef) T47D   0.0   0.0           Breast ca. BT-549   0.0   0.0           Breast ca. MDA-N   0.0   0.0           Ovary   16.2   9.1           Ovarian ca. OVCAR-3   0.0   0.0           Ovarian ca. OVCAR-4   0.0   0.0           Ovarian ca. OVCAR-5   0.0   0.0           Ovarian ca. OVCAR-8   0.0   0.0           Ovarian ca. IGROV-1   0.0   0.0           Ovarian ca.* (ascites) SK-OV-3   0.0   0.0           Uterus   6.5   4.3           Placenta   49.0   32.5           Prostate   15.0   2.2           Prostate ca.* (bone met) PC-3   0.0   0.0           Testis   2.4   11.0           Melanoma Hs688(A).T   0.0   0.0           Melanoma* (met) Hs688(B).T   0.0   0.0           Melanoma UACC-62   0.0   0.0           Melanoma M14   0.0   0.0           Melanoma LOX IMVI   0.0   0.0           Melanoma* (met) SK-MEL-5   4.0   4.3           Adipose   15.5   16.7                                                
     [0669]               TABLE DE                          Panel 2D                         Tissue Name   A   B                                 Normal Colon   3.8   3.3       CC Well to Mod Diff (ODO3866)   1.5   0.6       CC Margin (ODO3866)   2.7   0.5       CC Gr.2 rectosigmoid (ODO3868)   0.1   0.2       CC Margin (ODO3868)   0.9   0.3       CC Mod Diff (ODO3920)   0.6   0.2       CC Margin (ODO3920)   0.5   0.3       CC Gr.2 ascend colon (ODO3921)   3.2   2.2       CC Margin (ODO3921)   0.8   0.6       CC from Partial Hepatectomy (ODO4309) Mets   1.6   2.0       Liver Margin (ODO4309)   1.3   1.5       Colon mets to lung (OD04451-01)   0.3   1.2       Lung Margin (OD04451-02)   2.9   1.7       Normal Prostate 6546-1   2.0   0.8       Prostate Cancer (OD04410)   1.9   1.7       Prostate Margin (OD04410)   3.5   3.9       Prostate Cancer (OD04720-01)   1.7   0.5       Prostate Margin (OD04720-02)   5.0   4.4       Normal Lung 061010   6.9   7.8       Lung Met to Muscle (ODO4286)   2.2   2.0       Muscle Margin (ODO4286)   0.3   0.5       Lung Malignant Cancer (OD03126)   2.4   3.7       Lung Margin (OD03126)   6.9   6.7       Lung Cancer (OD04404)   5.5   2.1       Lung Margin (OD04404)   1.6   1.9       Lung Cancer (OD04565)   0.6   0.5       Lung Margin (OD04565)   1.0   2.0       Lung Cancer (OD04237-01)   4.5   3.8       Lung Margin (OD04237-02)   3.9   5.2       Ocular Mel Met to Liver (ODO4310)   0.0   0.2       Liver Margin (ODO4310)   1.7   0.7       Melanoma Mets to Lung (OD04321)   100.0   100.0       Lung Margin (OD04321)   7.3   6.5       Normal Kidney   6.4   5.0       Kidney Ca, Nuclear grade 2 (OD04338)   34.2   33.9       Kidney Margin (OD04338)   5.2   5.6       Kidney Ca Nuclear grade 1/2 (OD04339)   1.4   0.8       Kidney Margin (OD04339)   0.9   2.0       Kidney Ca, Clear cell type (OD04340)   8.5   10.3       Kidney Margin (OD04340)   11.3   6.6       Kidney Ca, Nuclear grade 3 (OD04348)   1.4   1.9       Kidney Margin (OD04348)   5.4   7.3       Kidney Cancer (OD04622-01)   49.0   63.7       Kidney Margin (OD04622-03)   0.7   1.2       Kidney Cancer (OD04450-01)   1.4   1.4       Kidney Margin (OD04450-03)   5.7   4.6       Kidney Cancer 8120607   0.2   0.0       Kidney Margin 8120608   1.4   0.5       Kidney Cancer 8120613   0.1   0.1       Kidney Margin 8120614   0.6   0.0       Kidney Cancer 9010320   4.0   2.5       Kidney Margin 9010321   0.4   1.1       Normal Uterus   0.4   0.3       Uterus Cancer 064011   1.2   0.9       Normal Thyroid   0.6   0.8       Thyroid Cancer 064010   7.3   5.7       Thyroid Cancer A302152   7.1   8.9       Thyroid Margin A302153   1.3   1.1       Normal Breast   1.1   1.8       Breast Cancer (OD04566)   0.2   1.3       Breast Cancer (OD04590-01)   2.2   2.0       Breast Cancer Mets (OD04590-03)   6.7   8.5       Breast Cancer Metastasis (OD04655-05)   2.7   2.7       Breast Cancer 064006   0.6   0.6       Breast Cancer 1024   0.7   0.6       Breast Cancer 9100266   0.1   0.3       Breast Margin 9100265   0.2   0.5       Breast Cancer A209073   2.3   1.7       Breast Margin A209073   0.4   0.3       Normal Liver   0.6   0.2       Liver Cancer 064003   0.8   0.0       Liver Cancer 1025   0.2   0.2       Liver Cancer 1026   0.8   0.6       Liver Cancer 6004-T   0.4   0.5       Liver Tissue 6004-N   0.9   0.3       Liver Cancer 6005-T   0.2   0.2       Liver Tissue 6005-N   0.3   0.3       Normal Bladder   0.9   1.5       Bladder Cancer 1023   0.1   0.4       Bladder Cancer A302173   0.5   1.2       Bladder Cancer (OD04718-01)   1.8   1.2       Bladder Normal Adjacent (OD04718-03)   2.2   1.9       Normal Ovary   0.6   0.2       Ovarian Cancer 064008   2.9   1.7       Ovarian Cancer (OD04768-07)   14.4   10.8       Ovary Margin (OD04768-08)   1.4   1.0       Normal Stomach   0.6   1.5       Gastric Cancer 9060358   0.5   0.7       Stomach Margin 9060359   0.6   0.6       Gastric Cancer 9060395   1.1   1.2       Stomach Margin 9060394   1.2   0.4       Gastric Cancer 9060397   0.9   0.9       Stomach Margin 9060396   1.7   1.1       Gastric Cancer 064005   3.0   2.6                                    
     [0670]               TABLE DF                          Panel 4D                         Tissue Name   A   B                                 Secondary Th1 act   1.0   1.6       Secondary Th2 act   21.0   29.5       Secondary Tr1 act   5.0   10.8       Secondary Th1 rest   0.6   3.8       Secondary Th2 rest   13.9   15.4       Secondary Tr1 rest   6.1   5.0       Primary Th1 act   0.0   2.6       Primary Th2 act   39.0   54.3       Primary Tr1 act   10.7   21.6       Primary Th1 rest   21.0   24.7       Primary Th2 rest   26.1   21.2       Primary Tr1 rest   11.7   19.1       CD45RA CD4 lymphocyte act   9.6   7.1       CD45RO CD4 lymphocyte act   15.6   17.3       CD8 lymphocyte act   11.7   9.3       Secondary CD8 lymphocyte rest   8.4   9.0       Secondary CD8 lymphocyte act   22.2   18.3       CD4 lymphocyte none   18.6   9.1       2ry Th1/Th2/Tr1_anti-CD95 CH11   3.8   7.6       LAK cells rest   43.2   32.5       LAK cells IL-2   15.9   18.0       LAK cells IL-2 + IL-12   32.3   30.8       LAK cells IL-2 + IFN gamma   62.9   57.8       LAK cells IL-2 + IL-18   39.2   52.1       LAK cells PMA/ionomycin   43.5   52.9       NK Cells IL-2 rest   37.4   35.6       Two Way MLR 3 day   26.1   23.0       Two Way MLR 5 day   17.0   10.7       Two Way MLR 7 day   2.1   7.4       PBMC rest   19.9   28.3       PBMC PWM   28.3   31.4       PBMC PHA-L   10.9   14.4       Ramos (B cell) none   0.0   0.1       Ramos (B cell) ionomycin   0.0   0.0       B lymphocytes PWM   9.0   9.5       B lymphocytes CD40L and IL-4   9.5   11.1       EOL-1 dbcAMP   1.1   0.0       EOL-1 dbcAMP PMA/ionomycin   3.7   0.6       Dendritic cells none   3.7   10.3       Dendritic cells LPS   6.1   8.1       Dendritic cells anti-CD40   4.9   3.6       Monocytes rest   100.0   100.0       Monocytes LPS   0.0   0.3       Macrophages rest   0.6   3.7       Macrophages LPS   1.0   3.1       HUVEC none   0.0   0.0       HUVEC starved   0.0   0.0       HUVEC IL-1beta   0.0   0.0       HUVEC IFN gamma   0.0   0.0       HUVEC TNF alpha + IFN gamma   0.0   0.0       HUVEC TNF alpha + IL4   0.0   0.0       HUVEC IL-11   0.0   0.0       Lung Microvascular EC none   0.0   0.0       Lung Microvascular EC TNFalpha + IL-1beta   0.0   0.0       Microvascular Dermal EC none   0.0   0.0       Microsvasular Dermal EC TNFalpha + IL-1beta   0.0   0.0       Bronchial epithelium TNFalpha + IL1beta   0.0   0.0       Small airway epithelium none   0.0   0.0       Small airway epithelium TNFalpha + IL-1beta   0.0   0.0       Coronery artery SMC rest   0.0   0.0       Coronery artery SMC TNFalpha + IL-1beta   0.0   0.0       Astrocytes rest   0.0   0.5       Astrocytes TNFalpha + IL-1beta   0.0   0.0       KU-812 (Basophil) rest   0.5   2.4       KU-812 (Basophil) PMA/ionomycin   2.9   1.7       CCD1106 (Keratinocytes) none   0.0   0.7       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0   0.0       Liver cirrhosis   4.8   6.3       Lupus kidney   0.6   0.0       NCI-H292 none   0.0   0.0       NCI-H292 IL-4   0.0   0.0       NCI-H292 IL-9   0.0   0.0       NCI-H292 IL-13   0.0   0.0       NCI-H292 IFN gamma   0.0   0.0       HPAEC none   0.0   0.5       HPAEC TNF alpha + IL-1 beta   0.0   0.0       Lung fibroblast none   0.0   0.0       Lung fibroblast TNF alpha + IL-1 beta   0.0   0.0       Lung fibroblast IL-4   0.0   0.0       Lung fibroblast IL-9   0.0   0.0       Lung fibroblast IL-13   0.0   0.0       Lung fibroblast IFN gamma   0.0   0.0       Dermal fibroblast CCD1070 rest   0.0   0.0       Dermal fibroblast CCD1070 TNF alpha   17.1   20.3       Dermal fibroblast CCD1070 IL-1 beta   0.0   0.0       Dermal fibroblast IFN gamma   0.0   0.0       Dermal fibroblast IL-4   1.1   0.0       IBD Colitis 2   1.1   0.0       IBD Crohn&#39;s   2.2   3.5       Colon   21.5   15.6       Lung   17.6   14.4       Thymus   11.8   7.1       Kidney   33.7   20.3                                    
     [0671] AI_comprehensive panel_v1.0 Summary: Ag2695 Two experiments with same probe-primer sets are in good agreement. Low expression of this gene is mainly seen in normal synovium and synovial fluid cells. Low expression of this gene is also seen in osteoarthritis bone, cartilage, synovium, RA bone, normal lung and a psoriasis sample.  
     [0672] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained using Ag2695 in two experiments with same probe-primer sets are in good agreement. This gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its gene product, or treatment with specific agonists for this protein encoded by this gene may be of use in reversing the dementia/memory loss associated with this disease and neuronal death.  
     [0673] Panel 1.3D Summary: Ag2695 Two experiments with same probe-primer sets are in good agreement. Highest expression of this gene is seen in adrenal gland and spleen (CTS=31.7). Significant expression of this gene is seen mainly in the normal tissues including brain, lymph node, heart, gastrointestinal tract, lung, ovary, placenta and adipose tissue. Interestingly, expression of this gene is low or undetectable in any of the cancer cell lines. Therefore, therapeutic modulation of this gene or its protein product may be useful in the treatment of cancer, metabolic and CNS disorders.  
     [0674] Panel 2D Summary: Ag2695 Two experiments with same probe-primer sets are in good agreement. Highest expression of this gene is detected in metastatic melanoma (CTs=26-27.8). High to moderate expression of this gene is also seen in normal and cancer samples from colon, lung, prostate, liver, prostate, thyroid, uterus, breast, ovary and stomach. Interestingly, expression of this gene is upregulated in ovarian, thyroid and kidney cancers compared to corresponding normal adjacent normal tissues. Therefore, therapeutic modulation of this gene or its protein product may be useful in the treatment of ovarian, thyroid and kidney cancers.  
     [0675] Panel 4D Summary: Ag2695 Two experiments with same probe-primer sets are in good agreement. Highest expression of this gene is seen in resting monocytes (CT=29.6). This gene is expressed by T lymphocytes prepared under a number of conditions at moderate levels and is expressed at significant levels in treated and untreated dendritic cells, LAK cells, PBMC, activated B lymphocytes, activated dermal fibroblasts, liver cirrhosis sample and normal tissues represented by colon, lung, thymus and kidney. Dendritic cells are powerful antigen-presenting cells (APC) whose function is pivotal in the initiation and maintenance of normal immune responses. Autoimmunity and inflammation may also be reduced by suppression of this function. Therefore, small molecule drugs or the antibodies that antagonize the function of this gene or its protein product may reduce or eliminate the symptoms in patients with several types of autoimmune and inflammatory diseases, such as lupus erythematosus, Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, or psoriasis.  
     [0676] E. CG54566-01: Serotonin Receptor  
     [0677] Expression of gene CG54566-01 was assessed using the primer-probe set Ag1252, described in Table EA. Results of the RTQ-PCR runs are shown in Tables EB, EC, ED, EE, EF, EG and EH.  
                   TABLE EA                          Probe Name Ag1252                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-ccagtgccagtaccagaatatc-3′   22   1210   110           Probe   TET-5′-aaccagacactctcagctgcaggcat-3′-TAMRA   26   1232   111       Reverse   5′-ctctctggcctctcagcaa-3′   19   1275   112                  
 
     [0678]               TABLE EB                          AI_comprehensive panel_v1.0                             Tissue Name   A                                         110967 COPD-F   0.0           110980 COPD-F   1.3           110968 COPD-M   5.5           110977 COPD-M   14.9           110989 Emphysema-F   74.7           110992 Emphysema-F   2.0           110993 Emphysema-F   24.5           110994 Emphysema-F   10.0           110995 Emphysema-F   33.9           110996 Emphysema-F   0.0           110997 Asthma-M   0.8           111001 Asthma-F   3.3           111002 Asthma-F   31.2           111003 Atopic Asthma-F   32.8           111004 Atopic Asthma-F   34.4           111005 Atopic Asthma-F   30.1           111006 Atopic Asthma-F   11.9           111417 Allergy-M   21.0           112347 Allergy-M   0.9           112349 Normal Lung-F   1.3           112357 Normal Lung-F   62.4           112354 Normal Lung-M   28.3           112374 Crohns-F   19.8           112389 Match Control Crohns-F   9.3           112375 Crohns-F   25.0           112732 Match Control Crohns-F   16.0           112725 Crohns-M   2.8           112387 Match Control Crohns-M   8.3           112378 Crohns-M   2.6           112390 Match Control Crohns-M   56.6           112726 Crohns-M   37.4           112731 Match Control Crohns-M   24.3           112380 Ulcer Col-F   37.6           112734 Match Control Ulcer Col-F   35.4           112384 Ulcer Col-F   42.3           112737 Match Control Ulcer Col-F   11.2           112386 Ulcer Col-F   10.4           112738 Match Control Ulcer Col-F   2.8           112381 Ulcer Col-M   3.6           112735 Match Control Ulcer Col-M   8.7           112382 Ulcer Col-M   13.9           112394 Match Control Ulcer Col-M   7.6           112383 Ulcer Col-M   36.3           112736 Match Control Ulcer Col-M   11.2           112423 Psoriasis-F   29.1           112427 Match Control Psoriasis-F   100.0           112418 Psoriasis-M   16.2           112723 Match Control Psoriasis-M   39.2           112419 Psoriasis-M   37.9           112424 Match Control Psoriasis-M   19.3           112420 Psoriasis-M   65.1           112425 Match Control Psoriasis-M   95.9           104689 (MF) OA Bone-Backus   80.7           104690 (MF) Adj “Normal” Bone-Backus   58.2           104691 (MF) OA Synovium-Backus   73.2           104692 (BA) OA Cartilage-Backus   27.2           104694 (BA) OA Bone-Backus   45.1           104695 (BA) Adj “Normal” Bone-Backus   44.4           104696 (BA) OA Synovium-Backus   51.8           104700 (SS) OA Bone-Backus   22.4           104701 (SS) Adj “Normal” Bone-Backus   33.4           104702 (SS) OA Synovium-Backus   78.5           117093 OA Cartilage Rep7   18.2           112672 OA Bone5   47.0           112673 OA Synovium5   17.8           112674 OA Synovial Fluid cells5   15.9           117100 OA Cartilage Rep 14   6.3           112756 OA Bone9   23.2           112757 OA Synovium9   7.7           112758 OA Synovial Fluid Cells9   15.7           117125 RA Cartilage Rep2   39.5           113492 Bone2 RA   28.5           113493 Synovium2 RA   8.4           113494 Syn Fluid Cells RA   15.8           113499 Cartilage4 RA   17.7           113500 Bone4 RA   37.9           113501 Synovium4 RA   15.2           113502 Syn Fluid Cells4 RA   15.3           113495 Cartilage3 RA   12.8           113496 Bone3 RA   29.5           113497 Synovium3 RA   8.9           113498 Syn Fluid Cells3 RA   24.5           117106 Normal Cartilage Rep20   2.1           113663 Bone3 Normal   3.4           113664 Synovium3 Normal   0.0           113665 Syn Fluid Cells3 Normal   0.0           117107 Normal Cartilage Rep22   9.9           113667 Bone4 Normal   18.4           113668 Synovium4 Normal   15.6           113669 Syn Fluid Cells4 Normal   26.8                                    
     [0679]               TABLE EC                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   10.0   6.8           AD 2 Hippo   28.1   21.5           AD 3 Hippo   5.9   5.1           AD 4 Hippo   11.6   6.1           AD 5 Hippo   67.4   80.7           AD 6 Hippo   55.5   22.8           Control 2 Hippo   47.3   38.4           Control 4 Hippo   0.0   8.7           Control (Path) 3 Hippo   1.0   2.4           AD 1 Temporal Ctx   6.6   1.4           AD 2 Temporal Ctx   20.0   13.8           AD 3 Temporal Ctx   2.8   0.8           AD 4 Temporal Ctx   15.7   10.9           AD 5 Inf Temporal Ctx   56.3   100.0           AD 5 Sup Temporal Ctx   30.4   62.4           AD 6 Inf Temporal Ctx   33.9   20.0           AD 6 Sup Temporal Ctx   33.4   24.7           Control 1 Temporal Ctx   5.8   4.8           Control 2 Temporal Ctx   77.9   46.0           Control 3 Temporal Ctx   17.3   18.3           Control 3 Temporal Ctx   8.5   3.9           Control (Path) 1 Temporal Ctx   74.7   47.0           Control (Path) 2 Temporal Ctx   70.7   21.0           Control (Path) 3 Temporal Ctx   2.0   1.9           Control (Path) 4 Temporal Ctx   39.8   23.5           AD 1 Occipital Ctx   1.5   2.5           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   1.3   1.7           AD 4 Occipital Ctx   14.6   11.0           AD 5 Occipital Ctx   59.9   77.9           AD 6 Occipital Ctx   11.2   20.4           Control 1 Occipital Ctx   2.5   1.8           Control 2 Occipital Ctx   54.3   45.1           Control 3 Occipital Ctx   18.4   7.3           Control 4 Occipital Ctx   6.3   2.0           Control (Path) 1 Occipital Ctx   100.0   63.3           Control (Path) 2 Occipital Ctx   11.1   5.2           Control (Path) 3 Occipital Ctx   3.8   4.8           Control (Path) 4 Occipital Ctx   12.9   13.5           Control 1 Parietal Ctx   4.8   1.3           Control 2 Parietal Ctx   29.3   94.0           Control 3 Parietal Ctx   18.8   16.0           Control (Path) 1 Parietal Ctx   100.0   83.5           Control (Path) 2 Parietal Ctx   23.5   16.7           Control (Path) 3 Parietal Ctx   3.2   2.0           Control (Path) 4 Parietal Ctx   59.5   30.8                                                
     [0680]               TABLE ED                          General_screening_panel_v1.4                             Tissue Name   A                                         Adipose   11.8           Melanoma* Hs688(A).T   19.5           Melanoma* Hs688(B).T   33.0           Melanoma* M14   19.8           Melanoma* LOXIMVI   35.4           Melanoma* SK-MEL-5   6.3           Squamous cell carcinoma SCC-4   24.1           Testis Pool   9.2           Prostate ca.* (bone met) PC-3   11.2           Prostate Pool   7.6           Placenta   8.1           Uterus Pool   3.0           Ovarian ca. OVCAR-3   12.0           Ovarian ca. SK-OV-3   15.4           Ovarian ca. OVCAR-4   3.8           Ovarian ca. OVCAR-5   21.6           Ovarian ca. IGROV-1   16.5           Ovarian ca. OVCAR-8   9.5           Ovary   18.3           Breast ca. MCF-7   84.1           Breast ca. MDA-MB-231   23.5           Breast ca. BT 549   34.6           Breast ca. T47D   59.5           Breast ca. MDA-N   7.3           Breast Pool   9.5           Trachea   4.8           Lung   3.3           Fetal Lung   10.2           Lung ca. NCI-N417   1.3           Lung ca. LX-1   8.2           Lung ca. NCI-H146   38.2           Lung ca. SHP-77   2.3           Lung ca. A549   15.1           Lung ca. NCI-H526   1.2           Lung ca. NCI-H23   18.9           Lung ca. NCI-H460   11.9           Lung ca. HOP-62   29.9           Lung ca. NCI-H522   40.6           Liver   0.3           Fetal Liver   12.5           Liver ca. HepG2   4.4           Kidney Pool   16.7           Fetal Kidney   11.6           Renal ca. 786-0   15.9           Renal ca. A498   1.2           Renal ca. ACHN   19.2           Renal ca. UO-31   32.1           Renal ca. TK-10   6.0           Bladder   4.8           Gastric ca. (liver met.) NCI-N87   20.0           Gastric ca. KATO III   0.2           Colon ca. SW-948   12.7           Colon ca. SW480   32.8           Colon ca.* (SW480 met) SW620   7.9           Colon ca. HT29   1.3           Colon ca. HCT-116   49.0           Colon ca. CaCo-2   9.3           Colon cancer tissue   10.7           Colon ca. SW1116   4.5           Colon ca. Colo-205   0.8           Colon ca. SW-48   1.3           Colon Pool   10.6           Small Intestine Pool   9.8           Stomach Pool   3.1           Bone Marrow Pool   2.6           Fetal Heart   2.5           Heart Pool   4.2           Lymph Node Pool   10.2           Fetal Skeletal Muscle   1.8           Skeletal Muscle Pool   2.0           Spleen Pool   8.0           Thymus Pool   18.0           CNS cancer (glio/astro) U87-MG   67.4           CNS cancer (glio/astro) U-118-MG   38.4           CNS cancer (neuro; met) SK-N-AS   11.4           CNS cancer (astro) SF-539   10.6           CNS cancer (astro) SNB-75   20.3           CNS cancer (glio) SNB-19   19.6           CNS cancer (glio) SF-295   67.4           Brain (Amygdala) Pool   10.1           Brain (cerebellum)   100.0           Brain (fetal)   17.2           Brain (Hippocampus) Pool   14.0           Cerebral Cortex Pool   20.9           Brain (Substantia nigra) Pool   16.7           Brain (Thalamus) Pool   20.4           Brain (whole)   22.7           Spinal Cord Pool   5.4           Adrenal Gland   10.9           Pituitary gland Pool   3.5           Salivary Gland   2.9           Thyroid (female)   8.4           Pancreatic ca. CAPAN2   11.1           Pancreas Pool   10.0                                    
     [0681]               TABLE EE                          Panel 1.2                             Tissue Name   A                                         Endothelial cells   27.7           Heart (Fetal)   1.5           Pancreas   7.9           Pancreatic ca. CAPAN 2   2.9           Adrenal Gland   8.3           Thyroid   15.7           Salivary gland   4.7           Pituitary gland   8.5           Brain (fetal)   6.0           Brain (whole)   17.2           Brain (amygdala)   10.0           Brain (cerebellum)   4.8           Brain (hippocampus)   12.0           Brain (thalamus)   12.2           Cerebral Cortex   15.7           Spinal cord   2.8           glio/astro U87-MG   12.2           glio/astro U-118-MG   4.5           astrocytoma SW1783   1.9           neuro*; met SK-N-AS   4.2           astrocytoma SF-539   2.8           astrocytoma SNB-75   0.8           glioma SNB-19   11.0           glioma U251   6.9           glioma SF-295   10.0           Heart   5.9           Skeletal Muscle   2.9           Bone marrow   2.4           Thymus   1.5           Spleen   2.9           Lymph node   4.3           Colorectal Tissue   1.1           Stomach   3.3           Small intestine   3.7           Colon ca. SW480   4.5           Colon ca.* SW620 (SW480 met)   5.2           Colon ca. HT29   0.2           Colon ca. HCT-116   8.0           Colon ca. CaCo-2   4.1           Colon ca. Tissue (ODO3866)   1.2           Colon ca. HCC-2998   8.1           Gastric ca.* (liver met) NCI-N87   6.9           Bladder   12.0           Trachea   2.6           Kidney   8.4           Kidney (fetal)   9.2           Renal ca. 786-0   3.7           Renal ca. A498   1.1           Renal ca. RXF 393   0.9           Renal ca. ACHN   10.4           Renal ca. UO-31   11.0           Renal ca. TK-10   3.9           Liver   7.2           Liver (fetal)   3.7           Liver ca. (hepatoblast) HepG2   3.4           Lung   2.7           Lung (fetal)   3.1           Lung ca. (small cell) LX-1   4.3           Lung ca. (small cell) NCI-H69   1.8           Lung ca. (s. cell var.) SHP-77   0.5           Lung ca. (large cell)NCI-H460   27.4           Lung ca. (non-sm. cell) A549   6.4           Lung ca. (non-s. cell) NCI-H23   5.9           Lung ca. (non-s. cell) HOP-62   26.4           Lung ca. (non-s. cl) NCI-H522   100.0           Lung ca. (squam.) SW 900   7.6           Lung ca. (squam.) NCI-H596   2.4           Mammary gland   11.2           Breast ca.* (pl. ef) MCF-7   15.6           Breast ca.* (pl. ef) MDA-MB-231   2.3           Breast ca.* (pl. ef) T47D   2.1           Breast ca. BT-549   6.5           Breast ca. MDA-N   0.0           Ovary   6.0           Ovarian ca. OVCAR-3   7.3           Ovarian ca. OVCAR-4   3.0           Ovarian ca. OVCAR-5   14.1           Ovarian ca. OVCAR-8   3.6           Ovarian ca. IGROV-1   10.4           Ovarian ca. (ascites) SK-OV-3   6.7           Uterus   3.5           Placenta   13.4           Prostate   5.9           Prostate ca.* (bone met) PC-3   12.8           Testis   7.4           Melanoma Hs688(A).T   4.3           Melanoma* (met) Hs688(B).T   3.8           Melanoma UACC-62   11.7           Melanoma M14   3.6           Melanoma LOX IMVI   6.0           Melanoma* (met) SK-MEL-5   4.5                                    
     [0682]               TABLE EF                          Panel 2D                             Tissue Name   A                                         Normal Colon   21.0           CC Well to Mod Diff (ODO3866)   2.6           CC Margin (ODO3866)   2.3           CC Gr.2 rectosigmoid (ODO3868)   2.3           CC Margin (ODO3868)   0.2           CC Mod Diff (ODO3920)   7.7           CC Margin (ODO3920)   4.2           CC Gr.2 ascend colon (ODO3921)   7.3           CC Margin (ODO3921)   3.6           CC from Partial Hepatectomy (ODO4309) Mets   9.1           Liver Margin (ODO4309)   9.4           Colon mets to lung (OD04451-01)   7.0           Lung Margin (OD04451-02)   7.5           Normal Prostate 6546-1   44.1           Prostate Cancer (OD04410)   32.5           Prostate Margin (OD04410)   18.7           Prostate Cancer (OD04720-01)   21.8           Prostate Margin (OD04720-02)   31.2           Normal Lung 061010   9.9           Lung Met to Muscle (ODO4286)   8.1           Muscle Margin (ODO4286)   7.3           Lung Malignant Cancer (OD03126)   9.2           Lung Margin (OD03126)   14.5           Lung Cancer (OD04404)   14.5           Lung Margin (OD04404)   7.9           Lung Cancer (OD04565)   13.5           Lung Margin (OD04565)   7.9           Lung Cancer (OD04237-01)   15.8           Lung Margin (OD04237-02)   11.3           Ocular Mel Met to Liver (ODO4310)   6.7           Liver Margin (ODO4310)   6.5           Melanoma Mets to Lung (OD04321)   4.1           Lung Margin (OD04321)   8.1           Normal Kidney   27.5           Kidney Ca, Nuclear grade 2 (OD04338)   17.9           Kidney Margin (OD04338)   9.9           Kidney Ca Nuclear grade 1/2 (OD04339)   13.3           Kidney Margin (OD04339)   11.8           Kidney Ca, Clear cell type (OD04340)   23.2           Kidney Margin (OD04340)   14.8           Kidney Ca, Nuclear grade 3 (OD04348)   24.3           Kidney Margin (OD04348)   13.7           Kidney Cancer (OD04622-01)   9.8           Kidney Margin (OD04622-03)   2.0           Kidney Cancer (OD04450-01)   11.7           Kidney Margin (OD04450-03)   20.6           Kidney Cancer 8120607   1.1           Kidney Margin 8120608   2.2           Kidney Cancer 8120613   10.7           Kidney Margin 8120614   2.9           Kidney Cancer 9010320   16.0           Kidney Margin 9010321   8.5           Normal Uterus   3.0           Uterus Cancer 064011   14.5           Normal Thyroid   20.2           Thyroid Cancer 064010   8.9           Thyroid Cancer A302152   11.0           Thyroid Margin A302153   21.0           Normal Breast   22.5           Breast Cancer (OD04566)   40.1           Breast Cancer (OD04590-01)   20.4           Breast Cancer Mets (OD04590-03)   26.1           Breast Cancer Metastasis (OD04655-05)   100.0           Breast Cancer 064006   10.7           Breast Cancer 1024   15.7           Breast Cancer 9100266   14.8           Breast Margin 9100265   7.4           Breast Cancer A209073   20.4           Breast Margin A209073   11.4           Normal Liver   11.1           Liver Cancer 064003   2.9           Liver Cancer 1025   4.9           Liver Cancer 1026   5.8           Liver Cancer 6004-T   5.8           Liver Tissue 6004-N   6.1           Liver Cancer 6005-T   8.5           Liver Tissue 6005-N   1.3           Normal Bladder   15.3           Bladder Cancer 1023   2.9           Bladder Cancer A302173   8.5           Bladder Cancer (OD04718-01)   14.1           Bladder Normal Adjacent (OD04718-03)   18.9           Normal Ovary   6.7           Ovarian Cancer 064008   32.3           Ovarian Cancer (OD04768-07)   6.1           Ovary Margin (OD04768-08)   4.6           Normal Stomach   5.6           Gastric Cancer 9060358   3.6           Stomach Margin 9060359   5.3           Gastric Cancer 9060395   8.1           Stomach Margin 9060394   4.5           Gastric Cancer 9060397   11.2           Stomach Margin 9060396   2.0           Gastric Cancer 064005   19.2                                    
     [0683]               TABLE EG                          Panel 4D                             Tissue Name   A                                         Secondary Th1 act   1.0           Secondary Th2 act   4.6           Secondary Tr1 act   1.6           Secondary Th1 rest   1.7           Secondary Th2 rest   4.1           Secondary Tr1 rest   2.3           Primary Th1 act   4.6           Primary Th2 act   4.5           Primary Tr1 act   9.5           Primary Th1 rest   12.9           Primary Th2 rest   8.5           Primary Tr1 rest   15.8           CD45RA CD4 lymphocyte act   12.6           CD45RO CD4 lymphocyte act   5.6           CD8 lymphocyte act   5.4           Secondary CD8 lymphocyte rest   3.2           Secondary CD8 lymphocyte act   1.9           CD4 lymphocyte none   4.9           2ry Th1/Th2/Tr1_anti-CD95 CH11   11.9           LAK cells rest   47.3           LAK cells IL-2   1.9           LAK cells IL-2 + IL-12   5.8           LAK cells IL-2 + IFN gamma   6.0           LAK cells IL-2 + IL-18   5.5           LAK cells PMA/ionomycin   15.2           NK Cells IL-2 rest   1.1           Two Way MLR 3 day   20.9           Two Way MLR 5 day   8.7           Two Way MLR 7 day   1.1           PBMC rest   14.6           PBMC PWM   15.2           PBMC PHA-L   7.0           Ramos (B cell) none   4.0           Ramos (B cell) ionomycin   7.6           B lymphocytes PWM   8.2           B lymphocytes CD40L and IL-4   8.5           EOL-1 dbcAMP   33.4           EOL-1 dbcAMP PMA/ionomycin   82.9           Dendritic cells none   28.1           Dendritic cells LPS   12.8           Dendritic cells anti-CD40   35.1           Monocytes rest   35.8           Monocytes LPS   54.0           Macrophages rest   100.0           Macrophages LPS   23.3           HUVEC none   37.6           HUVEC starved   70.2           HUVEC IL-1beta   23.3           HUVEC IFN gamma   55.9           HUVEC TNF alpha + IFN gamma   8.6           HUVEC TNF alpha + IL4   21.5           HUVEC IL-11   31.9           Lung Microvascular EC none   58.6           Lung Microvascular EC TNFalpha + IL-1beta   32.1           Microvascular Dermal EC none   84.7           Microsvasular Dermal EC TNFalpha + IL-1beta   41.8           Bronchial epithelium TNFalpha + IL1beta   27.4           Small airway epithelium none   13.3           Small airway epithelium TNFalpha + IL-1beta   61.6           Coronery artery SMC rest   50.7           Coronery artery SMC TNFalpha + IL-1beta   20.3           Astrocytes rest   7.0           Astrocytes TNFalpha + IL-1beta   13.2           KU-812 (Basophil) rest   9.2           KU-812 (Basophil) PMA/ionomycin   5.3           CCD1106 (Keratinocytes) none   15.3           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   53.2           Liver cirrhosis   8.9           Lupus kidney   10.9           NCI-H292 none   42.3           NCI-H292 IL-4   34.2                                    
     [0684]               TABLE EH                          Panel CNS_                             Tissue Name   A                                         BA4 Control   46.3           BA4 Control2   77.9           BA4 Alzheimer&#39;s2   4.7           BA4 Parkinson&#39;s   64.2           BA4 Parkinson&#39;s2   80.1           BA4 Huntington&#39;s   37.6           BA4 Huntington&#39;s2   12.2           BA4 PSP   22.5           BA4 PSP2   39.8           BA4 Depression   28.9           BA4 Depression2   4.2           BA7 Control   62.0           BA7 Control2   95.3           BA7 Alzheimer&#39;s2   5.1           BA7 Parkinson&#39;s   23.0           BA7 Parkinson&#39;s2   55.1           BA7 Huntington&#39;s   56.3           BA7 Huntington&#39;s2   44.1           BA7 PSP   32.5           BA7 PSP2   44.4           BA7 Depression   8.1           BA9 Control   33.9           BA9 Control2   77.9           BA9 Alzheimer&#39;s   0.0           BA9 Alzheimer&#39;s2   26.8           BA9 Parkinson&#39;s   16.3           BA9 Parkinson&#39;s2   37.1           BA9 Huntington&#39;s   100.0           BA9 Huntington&#39;s2   35.6           BA9 PSP   13.7           BA9 PSP2   9.4           BA9 Depression   7.1           BA9 Depression2   18.3           BA17 Control   39.2           BA17 Control2   26.1           BA17 Alzheimer&#39;s2   5.2           BA17 Parkinson&#39;s   65.1           BA17 Parkinson&#39;s2   51.8           BA17 Huntington&#39;s   43.2           BA17 Huntington&#39;s2   12.3           BA17 Depression   16.7           BA17 Depression2   5.8           BA17 PSP   12.2           BA17 PSP2   1.4           Sub Nigra Control   28.9           Sub Nigra Control2   44.1           Sub Nigra Alzheimer&#39;s2   25.0           Sub Nigra Parkinson&#39;s2   34.9           Sub Nigra Huntington&#39;s   67.4           Sub Nigra Huntington&#39;s2   32.8           Sub Nigra PSP2   9.7           Sub Nigra Depression   0.0           Sub Nigra Depression2   1.1           Glob Palladus Control   14.4           Glob Palladus Control2   31.2           Glob Palladus Alzheimer&#39;s   12.2           Glob Palladus Alzheimer&#39;s2   0.0           Glob Palladus Parkinson&#39;s   71.7           Glob Palladus Parkinson&#39;s2   19.8           Glob Palladus PSP   8.4           Glob Palladus PSP2   12.8           Glob Palladus Depression   0.9           Temp Pole Control   14.7           Temp Pole Control2   46.3           Temp Pole Alzheimer&#39;s   17.4           Temp Pole Alzheimer&#39;s2   0.0           Temp Pole Parkinson&#39;s   26.4           Temp Pole Parkinson&#39;s2   36.3           Temp Pole Huntington&#39;s   82.9           Temp Pole PSP   5.9           Temp Pole PSP2   5.2           Temp Pole Depression2   5.7           Cing Gyr Control   63.7           Cing Gyr Control2   32.1           Cing Gyr Alzheimer&#39;s   22.1           Cing Gyr Alzheimer&#39;s2   1.2           Cing Gyr Parkinson&#39;s   15.7           Cing Gyr Parkinson&#39;s2   54.0           Cing Gyr Huntington&#39;s   58.2           Cing Gyr Huntington&#39;s2   25.0           Cing Gyr PSP   26.8           Cing Gyr PSP2   17.0           Cing Gyr Depression   3.3           Cing Gyr Depression2   1.4                                    
     [0685] AI_comprehensive panel_v1.0 Summary: Ag1252 Highest expression of this gene is seen in matched control psoriasis sample (CT=32.8). Low expression of this gene is also seen in osteoarthitis/rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples, from normal lung, emphysema, atopic asthma, asthma, Crohn&#39;s disease (normal matched control and diseased), and psoriasis (normal matched control and diseased). Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.  
     [0686] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained using Ag1252 in two experiments with the same probe-primer sets are in good agreement. This gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this receptor may be of use in reversing the dementia/memory loss associated with this disease and neuronal death.  
     [0687] General_screening_panel_v1.4 Summary: Ag1252 This gene shows ubiquitous expression in this panel with highest expression in brain cerebellum (CT=26.8).This gene is expressed at high to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0688] Moderate levels of expression of this gene is also seen in cluster of cancer cell lines derived from pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of pancreatic, gastric, colon, lung, liver, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0689] Among tissues with metabolic or endocrine function, this gene is expressed at moderate levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0690] Panel 1.2 Summary: Ag1252 The expression of this gene shows a significant level of expression across the majority of samples in the panel and correlates with expression seen in panel 1.4. Of interest is the observation that lung cancer cell lines appear to show considerably higher expression compared to other samples, suggesting that this gene may play a role in lung cancer. Please see panel 1.4 for further discussion in the role of this gene.  
     [0691] Panel 2D Summary: Ag1213 This gene shows widespread expression in this panel. Highest expression of this gene is seen in a breast cancer (CT=29.5). There is a slight up-regulation of this gene in lung, kidney, breast and gastric cancer when compared to corresponding normal adjacent controls. Thus, therapies targeted towards this gene or its protein product may be beneficial to the treatment of lung, kidney, breast and gastric cancers.  
     [0692] Panel 4D Summary: Ag1213 Highest expression of this gene is seen in resting macrophage (CT=30.6). This gene shows wide spread expression with higher expression in resting LAK cells, eosinophils, dendritic cells, monocytes, macrophages, endothelial cells, bronchial and small airway epithelial cells, keratinocytes, mucoepidermoid NCI-H292 cells, lung and dermal fibroblasts and normal tissues represented by colon, lung, and thymus. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0693] Panel CNS — 1 Summary: Ag1213 This gene encodes for a homolog of serotinin receptor 7. Serotonin receptors have been implicated in neuropsychiatric disorders including schizophrenia, bipolar disorder, depression, and Alzheimer&#39;s disease. This gene is downregulated in the cingulate gyrus, parietal cortex, and substantia nigra in depression as measured via RTQ-PCR analysis in postmortem brain tissue. Because many antidepressants are serotonin reuptake inhibitors (e.g., fluvoxamine, hypericum perforatum, clomipramine, milnacipran, etc) the downregulation of a serotonin receptor in the brains of patients suffering from chronic depression suggests that this molecule may be a primary role in the etiology of this disease and be an excellent small molecule target for the treatment of psychiatric disease.  
     [0694] F. CG55912-01: CACNG4-Ion Channel  
     [0695] Expression of gene CG55912-01 was assessed using the primer-probe set Ag2841, described in Table FA. Results of the RTQ-PCR runs are shown in Tables FB, FC, FD, FE, FF and FG.  
                   TABLE FA                          Probe Name Ag2841                                                 Start   SEQ ID       Primers   Sequences   Length   Position   No                                         Forward   5′-gtctgcgtgaagatcaatcatt-3′   22   283   113       Probe   TET-5′-aggacacggactacgaccacgacag-3′-TAMRA   25   311   114       Reverse   5′-cggaccgtacggagtagatact-3′   22   341   115                  
 
     [0696]               TABLE FB                          CNS_neurodegeneration_v1.0                             Tissue Name   A                                         AD 1 Hippo   15.8           AD 2 Hippo   34.6           AD 3 Hippo   15.9           AD 4 Hippo   17.0           AD 5 hippo   85.3           AD 6 Hippo   51.1           Control 2 Hippo   21.0           Control 4 Hippo   0.0           Control (Path) 3 Hippo   0.0           AD 1 Temporal Ctx   6.3           AD 2 Temporal Ctx   16.3           AD 3 Temporal Ctx   5.0           AD 4 Temporal Ctx   7.9           AD 5 Inf Temporal Ctx   64.6           AD 5 SupTemporal Ctx   38.4           AD 6 Inf Temporal Ctx   46.3           AD 6 Sup Temporal Ctx   88.3           Control 1 Temporal Ctx   10.4           Control 2 Temporal Ctx   42.9           Control 3 Temporal Ctx   20.3           Control 4 Temporal Ctx   8.4           Control (Path) 1 Temporal Ctx   58.2           Control (Path) 2 Temporal Ctx   49.7           Control (Path) 3 Temporal Ctx   0.0           Control (Path) 4 Temporal Ctx   25.9           AD 1 Occipital Ctx   6.8           AD 2 Occipital Ctx (Missing)   0.0           AD 3 Occipital Ctx   24.0           AD 4 Occipital Ctx   21.8           AD 5 Occipital Ctx   0.0           AD 6 Occipital Ctx   51.8           Control 1 Occipital Ctx   6.0           Control 2 Occipital Ctx   100.0           Control 3 Occipital Ctx   39.2           Control 4 Occipital Ctx   5.1           Control (Path) 1 Occipital Ctx   46.7           Control (Path) 2 Occipital Ctx   23.0           Control (Path) 3 Occipital Ctx   6.3           Control (Path) 4 Occipital Ctx   25.3           Control 1 Parietal Ctx   0.0           Control 2 Parietal Ctx   51.4           Control 3 Parietal Ctx   18.9           Control (Path) 1 Parietal Ctx   86.5           Control (Path) 2 Parietal Ctx   31.0           Control (Path) 3 Parietal Ctx   7.5           Control (Path) 4 Parietal Ctx   63.7                                    
     [0697]               TABLE FC                          Panel 1.3D                                 Tissue Name   A   B                                             Liver adenocarcinoma   3.1   7.2           Pancreas   0.0   0.0           Pancreatic ca. CAPAN 2   5.7   5.9           Adrenal gland   0.0   0.0           Thyroid   0.0   0.0           Salivary gland   0.0   0.0           Pituitary gland   0.0   0.0           Brain (fetal)   18.3   27.0           Brain (whole)   27.0   19.5           Brain (amygdala)   77.4   54.3           Brain (cerebellum)   0.0   0.0           Brain (hippocampus)   100.0   100.0           Brain (substantia nigra)   0.0   3.5           Brain (thalamus)   7.9   0.0           Cerebral Cortex   90.8   8.4           Spinal cord   3.9   0.0           glio/astro U87-MG   2.7   6.5           glio/astro U-118-MG   0.0   0.0           astrocytoma SW1783   0.0   6.6           neuro*; met SK-N-AS   8.4   0.0           astrocytoma SF-539   0.0   0.0           astrocytoma SNB-75   0.0   0.0           glioma SNB-19   27.2   6.2           glioma U251   0.0   0.0           glioma SF-295   0.0   3.4           Heart (fetal)   0.0   0.0           Heart   0.0   0.0           Skeletal muscle (fetal)   0.0   0.0           Skeletal muscle   0.0   0.0           Bone marrow   3.8   0.0           Thymus   0.0   0.0           Spleen   0.0   0.0           Lymph node   0.0   0.0           Colorectal   0.0   0.0           Stomach   0.0   0.0           Small intestine   0.0   0.0           Colon ca. SW480   0.0   2.6           Colon ca.* SW620 (SW480 met)   0.0   0.0           Colon ca. HT29   0.0   0.0           Colon ca. HCT-116   0.0   0.0           Colon ca. CaCo-2   0.0   0.0           Colon ca. tissue (ODO3866)   0.0   0.0           Colon ca. HCC-2998   8.4   0.0           Gastric ca.* (liver met) NCI-N87   18.0   4.2           Bladder   0.0   0.0           Trachea   0.0   0.0           Kidney   0.0   0.0           Kidney (fetal)   0.0   0.0           Renal ca. 786-0   0.0   0.0           Renal ca. A498   0.0   0.0           Renal ca. RXF 393   0.0   0.0           Renal ca. ACHN   0.0   0.0           Renal ca. UO-31   0.0   0.0           Renal ca. TK-10   0.0   0.0           Liver   0.0   0.0           Liver (fetal)   0.0   0.0           Liver ca. (hepatoblast) HepG2   0.0   0.0           Lung   3.0   9.2           Lung (fetal)   0.0   0.0           Lung ca. (small cell) LX-1   0.0   0.0           Lung ca. (small cell) NCI-H69   0.0   0.0           Lung ca. (s. cell var.) SHP-77   0.0   3.9           Lung ca. (large cell) NCI-H460   0.0   0.0           Lung ca. (non-sm. cell) A549   15.0   0.0           Lung ca. (non-s. cell) NCI-H23   7.2   12.5           Lung ca. (non-s. cell) HOP-62   0.0   0.0           Lung ca. (non-s. cl) NCI-H522   12.9   3.2           Lung ca. (squam.) SW 900   0.0   0.0           Lung ca. (squam.) NCI-H596   0.0   0.0           Mammary gland   0.0   0.0           Breast ca.* (pl. ef) MCF-7   0.0   0.0           Breast ca.* (pl. ef) MDA-MB-231   0.0   0.0           Breast ca.* (pl. ef) T47D   0.0   0.0           Breast ca. BT-549   0.0   0.0           Breast ca. MDA-N   0.0   0.0           Ovary   0.0   0.0           Ovarian ca. OVCAR-3   0.0   0.0           Ovarian ca. OVCAR-4   0.0   22.1           Ovarian ca. OVCAR-5   7.0   0.0           Ovarian ca. OVCAR-8   0.0   0.0           Ovarian ca. IGROV-1   0.0   0.0           Ovarian ca.* (ascites) SK-OV-3   0.0   0.0           Uterus   0.0   2.6           Placenta   0.0   0.0           Prostate   0.0   0.0           Prostate ca.* (bone met) PC-3   0.0   2.0           Testis   21.0   0.0           Melanoma Hs688(A).T   0.0   0.0           Melanoma* (met) Hs688(B).T   0.0   0.0           Melanoma UACC-62   0.0   0.0           Melanoma M14   0.0   0.0           Melanoma LOX IMVI   0.0   11.0           Melanoma* (met) SK-MEL-5   0.0   0.0           Adipose   0.0   0.0                                                
     [0698]               TABLE FD                          Panel 2D                             Tissue Name   A                                         Normal Colon   0.0           CC Well to Mod Diff (ODO3866)   0.0           CC Margin (ODO3866)   20.2           CC Gr.2 rectosigmoid (ODO3868)   0.0           CC Margin (ODO3868)   0.0           CC Mod Diff (ODO3920)   100.0           CC Margin (ODO3920)   0.0           CC Gr.2 ascend colon (ODO3921)   41.8           CC Margin (ODO3921)   0.0           CC from Partial Hepatectomy (ODO4309) Mets   0.0           Liver Margin (ODO4309)   0.0           Colon mets to lung (OD04451-01)   0.0           Lung Margin (OD04451-02)   0.0           Normal Prostate 6546-1   0.0           Prostate Cancer (OD04410)   0.0           Prostate Margin (OD04410)   0.0           Prostate Cancer (OD04720-01)   0.0           Prostate Margin (OD04720-02)   0.0           Normal Lung 061010   55.9           Lung Met to Muscle (ODO4286)   0.0           Muscle Margin (ODO4286)   0.0           Lung Malignant Cancer (OD03126)   0.0           Lung Margin (OD03126)   0.0           Lung Cancer (OD04404)   0.0           Lung Margin (OD04404)   0.0           Lung Cancer (OD04565)   0.0           Lung Margin (OD04565)   0.0           Lung Cancer (OD04237-01)   0.0           Lung Margin (OD04237-02)   0.0           Ocular Mel Met to Liver (ODO4310)   0.0           Liver Margin (ODO4310)   0.0           Melanoma Mets to Lung (OD04321)   0.0           Lung Margin (OD04321)   0.0           Normal Kidney   0.0           Kidney Ca, Nuclear grade 2 (OD04338)   0.0           Kidney Margin (OD04338)   0.0           Kidney Ca Nuclear grade 1/2 (OD04339)   0.0           Kidney Margin (OD04339)   0.0           Kidney Ca, Clear cell type (OD04340)   0.0           Kidney Margin (OD04340)   0.0           Kidney Ca, Nuclear grade 3 (OD04348)   0.0           Kidney Margin (OD04348)   0.0           Kidney Cancer (OD04622-01)   0.0           Kidney Margin (OD04622-03)   0.0           Kidney Cancer (OD04450-01)   0.0           Kidney Margin (OD04450-03)   0.0           Kidney Cancer 8120607   0.0           Kidney Margin 8120608   0.0           Kidney Cancer 8120613   0.0           Kidney Margin 8120614   0.0           Kidney Cancer 9010320   0.0           Kidney Margin 9010321   0.0           Normal Uterus   0.0           Uterus Cancer 064011   0.0           Normal Thyroid   0.0           Thyroid Cancer 064010   19.1           Thyroid Cancer A302152   0.0           Thyroid Margin A302153   0.0           Normal Breast   10.5           Breast Cancer (OD04566)   0.0           Breast Cancer (OD04590-01)   0.0           Breast Cancer Mets (OD04590-03)   0.0           Breast Cancer Metastasis (OD04655-05)   0.0           Breast Cancer 064006   0.0           Breast Cancer 1024   45.4           Breast Cancer 9100266   0.0           Breast Margin 9100265   0.0           Breast Cancer A209073   0.0           Breast Margin A209073   49.3           Normal Liver   0.0           Liver Cancer 064003   23.3           Liver Cancer 1025   0.0           Liver Cancer 1026   0.0           Liver Cancer 6004-T   0.0           Liver Tissue 6004-N   0.0           Liver Cancer 6005-T   0.0           Liver Tissue 6005-N   0.0           Normal Bladder   21.6           Bladder Cancer 1023   0.0           Bladder Cancer A302173   14.3           Bladder Cancer (OD04718-01)   0.0           Bladder Normal Adjacent (OD04718-03)   0.0           Normal Ovary   0.0           Ovarian Cancer 064008   16.3           Ovarian Cancer (OD04768-07)   57.8           Ovary Margin (OD04768-08)   0.0           Normal Stomach   0.0           Gastric Cancer 9060358   0.0           Stomach Margin 9060359   0.0           Gastric Cancer 9060395   0.0           Stomach Margin 9060394   0.0           Gastric Cancer 9060397   0.0           Stomach Margin 9060396   0.0           Gastric Cancer 064005   0.0                                    
     [0699]               TABLE FE                          Panel 3D                     Tissue Name   A                             Daoy- Medulloblastoma   11.6       TE671- Medulloblastoma   7.0       D283 Med- Medulloblastoma   0.0       PFSK-1- Primitive Neuroectodermal   0.0       XF-498- CNS   0.0       SNB-78- Glioma   0.0       SF-268- Glioblastoma   12.8       T98G- Glioblastoma   0.0       SK-N-SH- Neuroblastoma (metastasis)   39.0       SF-295- Glioblastoma   0.0       Cerebellum   0.0       Cerebellum   25.7       NCI-H292- Mucoepidermoid lung carcinoma   0.0       DMS-114- Small cell lung cancer   10.7       DMS-79- Small cell lung cancer   100.0       NCI-H146- Small cell lung cancer   0.0       NCI-H526- Small cell lung cancer   16.2       NCI-N417- Small cell lung cancer   0.0       NCI-H82- Small cell lung cancer   0.0       NCI-H157- Squamous cell lung cancer (metastasis)   7.5       NCI-H1155- Large cell lung cancer   16.8       NCI-H1299- Large cell lung cancer   39.8       NCI-H727- Lung carcinoid   10.3       NCI-UMC-11- Lung carcinoid   0.0       LX-1- Small cell lung cancer   0.0       Colo-205- Colon cancer   0.0       KM12- Colon cancer   25.7       KM20L2- Colon cancer   21.6       NCI-H716- Colon cancer   0.0       SW-48- Colon adenocarcinoma   0.0       SW1116- Colon adenocarcinoma   0.0       LS 174T- Colon adenocarcinoma   0.0       SW-948- Colon adenocarcinoma   0.0       SW-480- Colon adenocarcinoma   0.0       NCI-SNU-5- Gastric carcinoma   21.6       KATO III- Gastric carcinoma   4.2       NCI-SNU-16- Gastric carcinoma   0.0       NCI-SNU-1- Gastric carcinoma   0.0       RF-1- Gastric adenocarcinoma   0.0       RF-48- Gastric adenocarcinoma   0.0       MKN-45- Gastric carcinoma   39.5       NCI-N87- Gastric carcinoma   0.0       OVCAR-5- Ovarian carcinoma   0.0       RL95-2- Uterine carcinoma   11.4       HelaS3- Cervical adenocarcinoma   0.0       Ca Ski- Cervical epidermoid carcinoma (metastasis)   0.0       ES-2- Ovarian clear cell carcinoma   3.6       Ramos- Stimulated with PMA/ionomycin 6 h   0.0       Ramos- Stimulated with PMA/ionomycin 14 h   0.0       MEG-01- Chronic myelogenous leukemia (megokaryoblast)   3.6       Raji- Burkitt&#39;s lymphoma   0.0       Daudi- Burkitt&#39;s lymphoma   0.0       U266- B-cell plasmacytoma   0.0       CA46- Burkitt&#39;s lymphoma   0.0       RL- non-Hodgkin&#39;s B-cell lymphoma   0.0       JM1- pre-B-cell lymphoma   0.0       Jurkat- T cell leukemia   0.0       TF-1- Erythroleukemia   0.0       HUT 78- T-cell lymphoma   0.0       U937- Histiocytic lymphoma   0.0       KU-812- Myelogenous leukemia   0.0       769-P- Clear cell renal carcinoma   0.0       Caki-2- Clear cell renal carcinoma   3.8       SW 839- Clear cell renal carcinoma   0.0       Rhabdoid kidney tumor   36.6       Hs766T- Pancreatic carcinoma (LN metastasis)   14.3       CAPAN-1- Pancreatic adenocarcinoma (liver metastasis)   6.7       SU86.86- Pancreatic carcinoma (liver metastasis)   0.0       BxPC-3- Pancreatic adenocarcinoma   0.0       HPAC- Pancreatic adenocarcinoma   0.0       MIA PaCa-2- Pancreatic carcinoma   25.7       CFPAC-1- Pancreatic ductal adenocarcinoma   35.4       PANC-1- Pancreatic epithelioid ductal carcinoma   40.9       T24- Bladder carcinma (transitional cell)   0.0       5637- Bladder carcinoma   0.0       HT-1197- Bladder carcinoma   0.0       UM-UC-3- Bladder carcinma (transitional cell)   12.2       A204- Rhabdomyosarcoma   0.0       HT-1080- Fibrosarcoma   4.6       MG-63- Osteosarcoma   0.0       SK-LMS-1- Leiomyosarcoma (vulva)   31.4       SJRH30- Rhabdomyosarcoma (met to bone marrow)   0.0       A431- Epidermoid carcinoma   0.0       WM266-4- Melanoma   0.0       DU 145- Prostate carcinoma (brain metastasis)   6.7       MDA-MB-468- Breast adenocarcinoma   0.0       SCC-4- Squamous cell carcinoma of tongue   0.0       SCC-9- Squamous cell carcinoma of tongue   0.0       SCC-15- Squamous cell carcinoma of tongue   0.0       CAL 27- Squamous cell carcinoma of tongue   0.0                            
     [0700]               TABLE FF                          Panel 4D                             Tissue Name   A                                         Secondary Th1 act   0.0           Secondary Th2 act   0.0           Secondary Tr1 act   0.0           Secondary Th1 rest   0.0           Secondary Th2 rest   0.0           Secondary Tr1 rest   0.0           Primary Th1 act   0.0           Primary Th2 act   0.0           Primary Tr1 act   0.0           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   0.0           CD45RA CD4 lymphocyte act   0.0           CD45RO CD4 lymphocyte act   0.0           CD8 lymphocyte act   0.0           Secondary CD8 lymphocyte rest   0.0           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   0.0           2ry Th1/Th2/Tr1 anti-CD95 CH11   0.0           LAK cells rest   0.0           LAK cells IL-2   0.0           LAK cells IL-2 + IL-12   0.0           LAK cells IL-2 + IFN gamma   0.0           LAK cells IL-2 + IL-18   0.0           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   0.0           Two Way MLR 3 day   0.0           Two Way MLR 5 day   0.0           Two Way MLR 7 day   0.0           PBMC rest   5.9           PBMC PWM   0.0           PBMC PHA-L   0.0           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   0.0           B lymphocytes CD40L and IL-4   0.0           EOL-1 dbcAMP   0.0           EOL-1 dbcAMP PMA/ionomycin   0.0           Dendritic cells none   0.0           Dendritic cells LPS   0.0           Dendritic cells anti-CD40   0.0           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   0.0           Macrophages LPS   0.0           HUVEC none   5.8           HUVEC starved   6.9           HUVEC IL-1beta   2.7           HUVEC IFN gamma   8.8           HUVEC TNF alpha + IFN gamma   15.9           HUVEC TNF alpha + IL4   2.2           HUVEC IL-11   13.6           Lung Microvascular EC none   21.5           Lung Microvascular EC TNFalpha + IL-1beta   33.7           Microvascular Dermal EC none   12.1           Microsvasular Dermal EC TNFalpha + IL-1beta   0.0           Bronchial epithelium TNFalpha + IL1beta   0.0           Small airway epithelium none   2.4           Small airway epithelium TNFalpha + IL-1beta   0.0           Coronery artery SMC rest   10.8           Coronery artery SMC TNFalpha + IL-1beta   8.3           Astrocytes rest   0.0           Astrocytes TNFalpha + IL-1beta   9.8           KU-812 (Basophil) rest   0.0           KU-812 (Basophil) PMA/ionomycin   0.0           CCD1106 (Keratinocytes) none   0.0           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0           Liver cirrhosis   15.1           Lupus kidney   0.0           NCI-H292 none   0.0           NCI-H292 IL-4   0.0           NCI-H292 IL-9   0.0           NCI-H292 IL-13   0.0           NCI-H292 IFN gamma   0.0           HPAEC none   19.6           HPAEC TNF alpha + IL-1 beta   7.0           Lung fibroblast none   0.0           Lung fibroblast TNF alpha + IL-1 beta   0.0           Lung fibroblast IL-4   0.0           Lung fibroblast IL-9   0.0           Lung fibroblast IL-13   0.0           Lung fibroblast IFN gamma   0.0           Dermal fibroblast CCD1070 rest   3.6           Dermal fibroblast CCD1070 TNF alpha   0.0           Dermal fibroblast CCD1070 IL-1 beta   0.0           Dermal fibroblast IFN gamma   0.0           Dermal fibroblast IL-4   0.0           IBD Colitis 2   0.0           IBD Crohn&#39;s   0.0           Colon   100.0           Lung   40.1           Thymus   0.0           Kidney   0.0                                    
     [0701]               TABLE FG                          Panel CNS_1                             Tissue Name   A                                         BA4 Control   0.0           BA4 Control2   9.2           BA4 Alzheimer&#39;s2   0.0           BA4 Parkinson&#39;s   47.6           BA4 Parkinson&#39;s2   50.3           BA4 Huntington&#39;s   13.2           BA4 Huntington&#39;s2   11.7           BA4 PSP   38.2           BA4 PSP2   14.4           BA4 Depression   0.0           BA4 Depression2   0.0           BA7 Control   10.1           BA7 Control2   0.0           BA7 Alzheimer&#39;s2   0.0           BA7 Parkinson&#39;s   51.4           BA7 Parkinson&#39;s2   17.4           BA7 Huntington&#39;s   46.3           BA7 Huntington&#39;s2   36.3           BA7 PSP   46.3           BA7 PSP2   37.9           BA7 Depression   29.9           BA9 Control   0.0           BA9 Control2   38.2           BA9 Alzheimer&#39;s   8.2           BA9 Alzheimer&#39;s2   41.2           BA9 Parkinson&#39;s   100.0           BA9 Parkinson&#39;s2   54.3           BA9 Huntington&#39;s   9.3           BA9 Huntington&#39;s2   57.8           BA9 PSP   0.0           BA9 PSP2   0.0           BA9 Depression   0.0           BA9 Depression2   14.1           BA17 Control   51.4           BA17 Control2   25.9           BA17 Alzheimer&#39;s2   0.0           BA17 Parkinson&#39;s   16.3           BA17 Parkinson&#39;s2   47.3           BA17 Huntington&#39;s   89.5           BA17 Huntington&#39;s2   13.0           BA17 Depression   0.0           BA17 Depression2   66.4           BA17 PSP   9.2           BA17 PSP2   0.0           Sub Nigra Control   8.7           Sub Nigra Control2   35.1           Sub Nigra Alzheimer&#39;s2   0.0           Sub Nigra Parkinson&#39;s2   0.0           Sub Nigra Huntington&#39;s   10.0           Sub Nigra Huntington&#39;s2   25.9           Sub Nigra PSP2   0.0           Sub Nigra Depression   0.0           Sub Nigra Depression2   0.0           Glob Palladus Control   0.0           Glob Palladus Control2   0.0           Glob Palladus Alzheimer&#39;s   0.0           Glob Palladus Alzheimer&#39;s2   0.0           Glob Palladus Parkinson&#39;s   18.2           Glob Palladus Parkinson&#39;s2   0.0           Glob Palladus PSP   0.0           Glob Palladus PSP2   0.0           Glob Palladus Depression   0.0           Temp Pole Control   20.3           Temp Pole Control2   28.5           Temp Pole Alzheimer&#39;s   0.0           Temp Pole Alzheimer&#39;s2   0.0           Temp Pole Parkinson&#39;s   17.2           Temp Pole Parkinson&#39;s2   0.0           Temp Pole Huntington&#39;s   51.4           Temp Pole PSP   0.0           Temp Pole PSP2   0.0           Temp Pole Depression2   21.5           Cing Gyr Control   51.4           Cing Gyr Control2   0.0           Cing Gyr Alzheimer&#39;s   0.0           Cing Gyr Alzheimer&#39;s2   0.0           Cing Gyr Parkinson&#39;s   38.7           Cing Gyr Parkinson&#39;s2   13.3           Cing Gyr Huntington&#39;s   27.2           Cing Gyr Huntington&#39;s2   30.4           Cing Gyr PSP   0.0           Cing Gyr PSP2   0.0           Cing Gyr Depression   0.0           Cing Gyr Depression2   0.0                                    
     [0702] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyzed using multivariate analysis (ANOVA). The multivariate results obtained using Ag2841 indicates expression of this gene is low (CTs&gt;35) across all of the samples on this panel. Although levels are low for this gene, there is a significant difference in expression levels between non-demented controls and patients suffering from Alzheimer&#39;s disease, such that the levels of mRNA appear to be downregulated 2-fold in the postmortem AD brain (p=0.0018 when analyzed by ANCOVA; estimate of RNA loaded per well used as a covariate). This gene may therefore represent a drug target for the treatment of Alzheimer&#39;s disease or other dementias.  
     [0703] Panel 1.3D Summary: Ag2841 Two experiments with same primer and probe set are in excellent agreement, with highest expression of this gene in brain hippocampus region (CT=34). Expression of this gene is exclusive to the brain region. In addition, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0704] This gene codes for a homolog of neuronal voltage-gated calcium channel. In Caenorhabditis elegans voltage-gated calcium channels have been shown to direct neuronal migration. In  C. elegans  mutants carrying loss-of-function alleles of the calcium channel gene unc-2, the touch receptor neuron AVM and the intemeuron SDQR often migrated inappropriately, leading to misplacement of their cell bodies (Tam T, Mathews E, Snutch T P, Schafer W R. (2000) Voltage-gated calcium channels direct neuronal migration in Caenorhabditis elegans. Dev Biol 226(1):104-17, PMID: 10993677). Therefore, in analogy with  C. elegan  unc-2, neuronal voltage-gated calcium channel encoded by this gene may also play a role in directing neuronal migration. In addition, calcium channels have been implicated in number of neurological diseases such as familial hemiplegic migraine, episodic ataxia type 2, spinocerebellar ataxia 6, and Lambert-Eaton myasthenic syndrome and other diseases (Greenberg D A. (1997) Calcium channels in neurological disease. Ann Neurol 42(3):275-82, PMID: 9307247). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of the different neurological diseases.  
     [0705] Panel 4D Summary: Ag2841 Low but significant expression of this gene is detected exclusively in colon (CT=34). Therefore, expression of this gene may be used to distinguish colon from the other tissues on this panel. Furthermore, expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn&#39;s disease relative to normal colon. Therefore, therapeutic modulation of the activity of the calcium channel encoded by this gene may be useful in the treatment of inflammatory bowel disease.  
     [0706] G. CG56001-01: 3-Hydroxybutyrate Dehydrogenase  
     [0707] Expression of gene CG56001-01 was assessed using the primer-probe set Ag2868, described in Table GA. Results of the RTQ-PCR runs are shown in Tables GB, GC, GD, GE and GF.  
               TABLE GA                          Probe Name Ag2868                                             Start   SEQ ID       Primers   Sequences   Length   Position   No                                         Forward   5′-ctactactggtggctgcgaat-3′   21   1025   116       Probe   TET-5′-cagatcatgacccacttgcctggag-3′-TAMRA   25   1047   117       Reverse   5′-actcttcagcggatgtagatca-3′   22   1084   118                  
 
     [0708]               TABLE GB                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   10.7   11.1           AD 2 Hippo   32.1   39.2           AD 3 Hippo   8.7   4.0           AD 4 Hippo   12.3   9.6           AD 5 Hippo   99.3   74.2           AD 6 Hippo   34.4   35.8           Control 2 Hippo   27.9   29.3           Control 4 Hippo   15.4   13.1           Control (Path) 3 Hippo   8.7   12.9           AD 1 Temporal Ctx   12.4   9.7           AD 2 Temporal Ctx   34.9   40.6           AD 3 Temporal Ctx   6.3   5.0           AD 4 Temporal Ctx   13.4   28.9           AD 5 Inf Temporal Ctx   100.0   100.0           AD 5 Sup Temporal Ctx   57.0   46.3           AD 6 Inf Temporal Ctx   32.3   33.4           AD 6 Sup Temporal Ctx   45.4   39.0           Control 1 Temporal Ctx   10.0   12.6           Control 2 Temporal Ctx   53.6   43.2           Control 3 Temporal Ctx   28.1   20.7           Control 3 Temporal Ctx   16.8   15.6           Control (Path) 1 Temporal Ctx   73.2   63.3           Control (Path) 2 Temporal Ctx   57.8   43.2           Control (Path) 3 Temporal Ctx   8.2   9.7           Control (Path) 4 Temporal Ctx   50.7   56.3           AD 1 Occipital Ctx   16.0   20.6           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   6.3   8.4           AD 4 Occipital Ctx   24.8   22.7           AD 5 Occipital Ctx   48.3   19.3           AD 6 Occipital Ctx   18.2   43.5           Control 1 Occipital Ctx   6.6   5.5           Control 2 Occipital Ctx   67.4   60.7           Control 3 Occipital Ctx   26.2   28.9           Control 4 Occipital Ctx   7.6   5.5           Control (Path) 1 Occipital Ctx   92.0   68.8           Control (Path) 2 Occipital Ctx   18.9   15.6           Control (Path) 3 Occipital Ctx   3.8   2.7           Control (Path) 4 Occipital Ctx   35.1   30.6           Control 1 Parietal Ctx   15.5   10.1           Control 2 Parietal Ctx   47.0   36.3           Control 3 Parietal Ctx   17.3   29.5           Control (Path) 1 Parietal Ctx   94.6   77.9           Control (Path) 2 Parietal Ctx   35.4   41.2           Control (Path) 3 Parietal Ctx   4.3   6.2           Control (Path) 4 Parietal Ctx   68.8   59.5                                                
     [0709]               TABLE GC                          Panel 1.3D                             Tissue Name   A                                         Liver adenocarcinoma   0.5           Pancreas   1.1           Pancreatic ca. CAPAN 2   1.6           Adrenal gland   1.0           Thyroid   9.9           Salivary gland   7.0           Pituitary gland   3.0           Brain (fetal)   3.3           Brain (whole)   23.5           Brain (amygdala)   13.7           Brain (cerebellum)   28.3           Brain (hippocampus)   31.6           Brain (substantia nigra)   8.5           Brain (thalamus)   16.8           Cerebral Cortex   100.0           Spinal cord   10.2           glio/astro U87-MG   1.3           glio/astro U-118-MG   0.4           astrocytoma SW1783   4.7           neuro*; met SK-N-AS   1.0           astrocytoma SF-539   6.5           astrocytoma SNB-75   1.4           glioma SNB-19   11.5           glioma U251   5.1           glioma SF-295   0.5           Heart (fetal)   45.1           Heart   21.9           Skeletal muscle (fetal)   27.9           Skeletal muscle   20.2           Bone marrow   3.5           Thymus   30.1           Spleen   3.0           Lymph node   2.4           Colorectal   52.5           Stomach   6.7           Small intestine   17.1           Colon ca. SW480   9.7           Colon ca.* SW620(SW480 met)   3.8           Colon ca. HT29   13.1           Colon ca. HCT-116   3.5           Colon ca. CaCo-2   14.1           Colon ca. tissue(ODO3866)   17.8           Colon ca. HCC-2998   18.0           Gastric ca.* (liver met) NCI-N87   7.9           Bladder   5.6           Trachea   28.5           Kidney   29.9           Kidney (fetal)   9.1           Renal ca. 786-0   0.0           Renal ca. A498   1.1           Renal ca. RXF 393   2.8           Renal ca. ACHN   1.5           Renal ca. UO-31   2.7           Renal ca. TK-10   3.4           Liver   36.9           Liver (fetal)   24.7           Liver ca. (hepatoblast) HepG2   5.0           Lung   1.4           Lung (fetal)   3.4           Lung ca. (small cell) LX-1   2.8           Lung ca. (small cell) NCI-H69   7.1           Lung ca. (s. cell var.) SHP-77   3.1           Lung ca. (large cell)NCI-H460   0.3           Lung ca. (non-sm. cell) A549   0.7           Lung ca. (non-s. cell) NCI-H23   0.6           Lung ca. (non-s. cell) HOP-62   2.8           Lung ca. (non-s. cl) NCI-H522   0.4           Lung ca. (squam.) SW 900   0.9           Lung ca. (squam.) NCI-H596   3.4           Mammary gland   9.9           Breast ca.* (pl. ef) MCF-7   13.3           Breast ca.* (pl. ef) MDA-MB-231   3.2           Breast ca.* (pl. ef) T47D   12.2           Breast ca. BT-549   1.6           Breast ca. MDA-N   3.9           Ovary   10.4           Ovarian ca. OVCAR-3   4.5           Ovarian ca. OVCAR-4   2.6           Ovarian ca. OVCAR-5   3.7           Ovarian ca. OVCAR-8   5.3           Ovarian ca. IGROV-1   0.7           Ovarian ca.* (ascites) SK-OV-3   1.0           Uterus   1.2           Placenta   0.2           Prostate   14.5           Prostate ca.* (bone met)PC-3   1.1           Testis   2.3           Melanoma Hs688(A).T   0.1           Melanoma* (met) Hs688(B).T   0.6           Melanoma UACC-62   0.0           Melanoma M14   2.3           Melanoma LOX IMVI   0.2           Melanoma* (met) SK-MEL-5   0.1           Adipose   1.0                                    
     [0710]               TABLE GD                          Panel 2D                             Tissue Name   A                                         Normal Colon   43.8           CC Well to Mod Diff (ODO3866)   5.9           CC Margin (ODO3866)   8.9           CC Gr.2 rectosigmoid (ODO3868)   19.1           CC Margin (ODO3868)   1.4           CC Mod Diff (ODO3920)   34.2           CC Margin (ODO3920)   15.7           CC Gr.2 ascend colon (ODO3921)   38.4           CC Margin (ODO3921)   16.0           CC from Partial Hepatectomy (ODO4309) Mets   28.7           Liver Margin (ODO4309)   100.0           Colon mets to lung (OD04451-01)   6.7           Lung Margin (OD04451-02)   0.8           Normal Prostate 6546-1   4.1           Prostate Cancer (OD04410)   20.3           Prostate Margin (OD04410)   16.3           Prostate Cancer (OD04720-01)   8.4           Prostate Margin (OD04720-02)   11.2           Normal Lung 061010   6.7           Lung Met to Muscle (ODO4286)   0.5           Muscle Margin (ODO4286)   0.3           Lung Malignant Cancer (OD03126)   10.4           Lung Margin (OD03126)   4.1           Lung Cancer (OD04404)   20.9           Lung Margin (OD04404)   1.4           Lung Cancer (OD04565)   3.7           Lung Margin (OD04565)   1.3           Lung Cancer (OD04237-01)   14.2           Lung Margin (OD04237-02)   1.0           Ocular Mel Met to Liver (ODO4310)   6.8           Liver Margin (ODO4310)   58.6           Melanoma Mets to Lung (OD04321)   5.7           Lung Margin (OD04321)   2.9           Normal Kidney   30.1           Kidney Ca, Nuclear grade 2 (OD04338)   42.9           Kidney Margin (OD04338)   17.6           Kidney Ca Nuclear grade 1/2 (OD04339)   7.3           Kidney Margin (OD04339)   14.7           Kidney Ca, Clear cell type (OD04340)   0.3           Kidney Margin (OD04340)   14.1           Kidney Ca, Nuclear grade 3 (OD04348)   0.2           Kidney Margin (OD04348)   7.3           Kidney Cancer (OD04622-01)   9.3           Kidney Margin (OD04622-03)   4.0           Kidney Cancer (OD04450-01)   10.7           Kidney Margin (OD04450-03)   11.7           Kidney Cancer 8120607   2.4           Kidney Margin 8120608   9.7           Kidney Cancer 8120613   31.9           Kidney Margin 8120614   13.8           Kidney Cancer 9010320   4.9           Kidney Margin 9010321   17.1           Normal Uterus   0.3           Uterus Cancer 064011   3.4           Normal Thyroid   8.0           Thyroid Cancer 064010   7.5           Thyroid Cancer A302152   6.8           Thyroid Margin A302153   8.2           Normal Breast   4.6           Breast Cancer (OD04566)   12.1           Breast Cancer (OD04590-01)   22.1           Breast Cancer Mets (OD04590-03)   22.7           Breast Cancer Metastasis (OD04655-05)   23.8           Breast Cancer 064006   4.8           Breast Cancer 1024   41.2           Breast Cancer 9100266   16.0           Breast Margin 9100265   6.9           Breast Cancer A209073   5.5           Breast Margin A209073   7.8           Normal Liver   55.5           Liver Cancer 064003   17.7           Liver Cancer 1025   70.7           Liver Cancer 1026   20.3           Liver Cancer 6004-T   90.1           Liver Tissue 6004-N   5.2           Liver Cancer 6005-T   17.2           Liver Tissue 6005-N   32.5           Normal Bladder   5.4           Bladder Cancer 1023   2.8           Bladder Cancer A302173   2.5           Bladder Cancer (OD04718-01)   7.2           Bladder Normal Adjacent (OD04718-03)   1.4           Normal Ovary   1.5           Ovarian Cancer 064008   9.6           Ovarian Cancer (OD04768-07)   1.4           Ovary Margin (OD04768-08)   0.2           Normal Stomach   4.8           Gastric Cancer 9060358   0.6           Stomach Margin 9060359   5.0           Gastric Cancer 9060395   7.9           Stomach Margin 9060394   6.8           Gastric Cancer 9060397   16.8           Stomach Margin 9060396   3.4           Gastric Cancer 064005   8.0                                    
     [0711]               TABLE GE                          Panel 4D                             Tissue Name   A                                         Secondary Th1 act   48.0           Secondary Th2 act   40.9           Secondary Tr1 act   55.1           Secondary Th1 rest   3.1           Secondary Th2 rest   7.8           Secondary Tr1 rest   12.5           Primary Th1 act   64.6           Primary Th2 act   52.9           Primary Tr1 act   88.3           Primary Th1 rest   54.0           Primary Th2 rest   30.6           Primary Tr1 rest   100.0           CD45RA CD4 lymphocyte act   17.0           CD45RO CD4 lymphocyte act   33.0           CD8 lymphocyte act   30.8           Secondary CD8 lymphocyte rest   30.8           Secondary CD8 lymphocyte act   16.4           CD4 lymphocyte none   3.5           2ry Th1/Th2/Tr1 anti-CD95 CH11   9.9           LAK cells rest   10.2           LAK cells IL-2   24.5           LAK cells IL-2 + IL-12   30.4           LAK cells IL-2 + IFN gamma   31.4           LAK cells IL-2 + IL-18   33.0           LAK cells PMA/ionomycin   1.8           NK Cells IL-2 rest   14.5           Two Way MLR 3 day   6.4           Two Way MLR 5 day   13.6           Two Way MLR 7 day   11.7           PBMC rest   2.0           PBMC PWM   43.8           PBMC PHA-L   22.7           Ramos (B cell) none   23.7           Ramos (B cell) ionomycin   62.9           B lymphocytes PWM   76.8           B lymphocytes CD40L and IL-4   26.6           EOL-1 dbcAMP   27.2           EOL-1 dbcAMP PMA/ionomycin   12.3           Dendritic cells none   8.1           Dendritic cells LPS   3.1           Dendritic cells anti-CD40   5.9           Monocytes rest   1.2           Monocytes LPS   0.9           Macrophages rest   15.1           Macrophages LPS   1.4           HUVEC none   1.7           HUVEC starved   1.8           HUVEC IL-1beta   0.1           HUVEC IFN gamma   2.7           HUVEC TNF alpha + IFN gamma   0.3           HUVEC TNF alpha + IL4   1.1           HUVEC IL-11   2.6           Lung Microvascular EC none   1.9           Lung Microvascular EC TNFalpha + IL-1beta   1.8           Microvascular Dermal EC none   1.0           Microsvasular Dermal EC TNFalpha + IL-1beta   1.4           Bronchial epithelium TNFalpha + IL1beta   1.1           Small airway epithelium none   3.8           Small airway epithelium TNFalpha + IL-1beta   14.2           Coronery artery SMC rest   0.3           Coronery artery SMC TNFalpha + IL-1beta   0.0           Astrocytes rest   3.0           Astrocytes TNFalpha + IL-1beta   1.7           KU-812 (Basophil) rest   25.3           KU-812 (Basophil) PMA/ionomycin   50.0           CCD1106 (Keratinocytes) none   12.7           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.5           Liver cirrhosis   3.8           Lupus kidney   2.0           NCI-H292 none   31.4           NCI-H292 IL-4   36.1           NCI-H292 IL-9   41.8           NCI-H292 IL-13   25.5           NCI-H292 IFN gamma   23.7           HPAEC none   1.0           HPAEC TNF alpha + IL-1 beta   0.2           Lung fibroblast none   1.5           Lung fibroblast TNF alpha + IL-1 beta   0.3           Lung fibroblast IL-4   1.0           Lung fibroblast IL-9   1.9           Lung fibroblast IL-13   0.7           Lung fibroblast IFN gamma   0.5           Dermal fibroblast CCD1070 rest   1.8           Dermal fibroblast CCD1070 TNF alpha   31.6           Dermal fibroblast CCD1070 IL-1 beta   2.3           Dermal fibroblast IFN gamma   0.2           Dermal fibroblast IL-4   2.6           IBD Colitis 2   0.6           IBD Crohn&#39;s   3.0           Colon   31.6           Lung   2.9           Thymus   29.5           Kidney   11.9                                    
     [0712]               TABLE GF                          Panel 5 Islet                             Tissue Name   A                                         97457_Patient-02go_adipose   1.6           97476_Patient-07sk_skeletal muscle   0.0           97477_Patient-07ut_uterus   3.5           97478_Patient-07p1_placenta   9.4           99167_Bayer Patient 1   12.2           97482_Patient-08ut_uterus   0.7           97483_Patient-08p1_placenta   4.0           97486_Patient-09sk_skeletal muscle   0.0           97487_Patient-09ut_uterus   4.0           97488_Patient-09p1_placenta   9.8           97492_Patient-10ut_uterus   6.6           97493_Patient-10p1_placenta   6.1           97495_Patient-11go_adipose   7.5           97496_Patient-11sk_skeletal muscle   12.5           97497_Patient-11ut_uterus   3.9           97498_Patient-11p1_placenta   5.0           97500_Patient-12go_adipose   13.8           97501_Patient-12sk_skeletal muscle   20.6           97502_Patient-12ut_uterus   1.3           97503_Patient-12p1_placenta   2.1           94721_Donor2 U- A_Mesenchymal Stem Cells   2.9           94722_Donor 2 U - B_Mesenchymal Stem Cells   1.5           94723_Donor 2 U - C_Mesenchymal Stem Cells   3.3           94709_Donor 2 AM - A_adipose   6.4           94710_Donor 2 AM - B_adipose   0.0           94711_Donor 2 AM - C_adipose   0.0           94712_Donor 2 AD - A_adipose   4.0           94713_Donor 2 AD - B_adipose   2.0           94714_Donor 2 AD - C_adipose   0.0           94742_Donor 3 U - A_Mesenchymal Stem Cells   0.0           94743_Donor 3 U - B_Mesenchymal Stem Cells   0.0           94730_Donor 3 AM - A_adipose   3.9           94731_Donor 3 AM - B_adipose   1.7           94732_Donor 3 AM - C_adipose   4.1           94733_Donor 3 AD - A_adipose   1.2           94734_Donor 3 AD - B_adipose   2.0           94735_Donor 3 AD - C_adipose   3.7           77138_Liver_HepG2untreated   85.3           73556_Heart_Cardiac stromal cells (primary)   0.0           81735_Small Intestine   58.2           72409_Kidney_Proximal Convoluted Tubule   11.6           82685_Small intestine_Duodenum   58.2           90650_Adrenal_Adrenocortical adenoma   5.4           72410_Kidney_HRCE   100.0           72411_Kidney_HRE   35.1           73139_Uterus_Uterine smooth muscle cells   0.0                                    
     [0713] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained using Ag2868 indicates this gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this receptor may be of use in reversing the dementia/memory loss associated with this disease and neuronal death. This gene encodes for D-beta-hydroxybutyrate dehydrogenase homolog. D-beta-hydroxybutyrate dehydrogenase function is also controlled at the translational, post-translational and catalytic levels. (Kante A, et al., 1990, Biochim Biophys Acta 1033(3):291-7). Please see Panel 1.3D for additional discussion of role of this gene in the central nervous system.  
     [0714] Panel 1.3D Summary: Ag2868 Expression of this gene is highest in the cerebral cortex (CT=27.6). The expression of this gene in multiple brain regions is consistent with a published role for this gene in CNS energetic processes. This gene encodes a hydroxybutyrate dehydrogenase homolog. D-beta-hydroxybutyrate protects neurons in models of Alzheimer&#39;s and Parkinson&#39;s disease. Other enzymes, such as amyloid beta-peptide-binding alcohol dehydrogenase, which have been shown to possess D-beta-hydroxybutyrate dehydrogenase activity, contribute to the protective response to metabolic stress, especially in the setting of ischemia (Kashiwaya Y, et al. Proc Natl Acad Sci USA May 9, 2000;97(10):5440-4; Du Yan S, et al. J Biol Chem Sep. 1, 2000;275(35):27100-9). Since this protein encoded by this gene processes D-beta-hydroxybutyrate to provide a neuronal energy source, activators of the protein encoded by this gene may be useful in treating and protecting the CNS of Alzheimer&#39;s and Parkinson&#39;s disease patients, as well as stroke.  
     [0715] Overall, expression of this gene appears to be largely associated with normal tissues when compared to cancer cell lines. Thus, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of cancer.  
     [0716] This gene is also moderately expressed in a variety of metabolic tissues, including pancreas, adrenal, thyroid, pituitary, adult and fetal heart, adult and fetal skeletal muscle, adult and fetal liver and adipose. Mutations in the hydroxybutyrate dehydrogenase enzyme are associated with hypoglycemia and cardiac arrest. Activators of this enzyme could be drug targets for obesity because increased fatty acid oxidation may prevent the incorporation of fatty acids into triglylcerides, thus decreasing adipose mass.  
     [0717] Panel 2D Summary: Ag2868 The expression of this gene appears to be highest in a sample derived from normal liver tissue adjacent to a metastatic colon cancer (CT=25.9). In addition, there appears to be substantial expression associated with malignant liver tissue when compared to their associated normal adjacent tissue. Thus, therapeutic modulation of this gene, through the use of small molecule drugs, antibodies or protein therapeutics might be of benefit in the treatment of liver cancer.  
     [0718] Panel 4D Summary: Ag2868 This gene is expressed primarily in activated leukocytes, especially in T cells and B cells (CTs=27-30). It is also expressed in NCI-H292 cells and in TNF alpha treated dermal fibroblasts. The protein encoded for by this trancript has homology to hydroxybutyrate dehydrogenase, a protein that has been found in lymphocytes (Curi R, Williams J F, Newsholme E A., 1989, Pyruvate metabolism by lymphocytes: evidence for an additional ketogenic tissue. Biochem Int 19(4):755-67). Thus, the protein encoded for by this transcript may be important for cellular responses to inflammatory/activating stimuli. Therefore, therapeutics designed with the protein encoded for by this transcript could be used for the treatment of inflammatory diseases such as asthma, emphysema, COPD, arthritis, IBD and psoriasis.  
     [0719] Panel 5 Islet Summary: Ag2868 Expression of this gene is highest a in kidney cell line (CT=32.8). In addition low expression of this gene is also seen in a liver cancer cell line, and small intestine. Please see panel 1.3D for further discussion of this gene.  
     [0720] H. CG56151-01: Glucose Transporter Type2  
     [0721] Expression of gene CG56151-01 was assessed using the primer-probe set Ag1681, described in Table HA. Results of the RTQ-PCR runs are shown in Tables HB, HC, HD, HE, HF and HG.  
               TABLE HA                          Probe Name Ag1681                                             Start   SEQ ID       Primers   Sequences   Length   Position   No                                             Forward   5′-ggacttctgtggaccttatgtg-3′   22   1412   119           Probe   TET-5′-ttttcctctttgctggagtgctcctg-3′-TAMRA   26   1435   120       Reverse   5′-ttcctttggtttctggaacttt-3′   22   1485   121                  
 
     [0722]               TABLE HB                          General screening panel_v1.4                             Tissue Name   A                       Adipose   0.0           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   0.2           Melanoma* LOXIMVI   0.2           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.0           Testis Pool   0.4           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.0           Placenta   0.0           Uterus Pool   0.0           Ovarian ca. OVCAR-3   0.4           Ovarian ca. SK-OV-3   0.0           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.1           Ovarian ca. IGROV-1   0.0           Ovarian ca. OVCAR-8   0.1           Ovary   0.2           Breast ca. MCF-7   0.2           Breast ca. MDA-MB-231   0.0           Breast ca. BT 549   0.0           Breast ca. T47D   0.1           Breast ca. MDA-N   0.2           Breast Pool   0.1           Trachea   0.0           Lung   0.1           Fetal Lung   1.2           Lung ca. NCI-N417   0.0           Lung ca. LX-1   0.1           Lung ca. NCI-H146   0.0           Lung ca. SHP-77   0.0           Lung ca. A549   0.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.2           Lung ca. NCI-H460   0.0           Lung ca. HOP-62   0.6           Lung ca. NCI-H522   0.0           Liver   23.2            Fetal Liver   100.0            Liver ca. HepG2   7.4           Kidney Pool   0.1           Fetal Kidney   1.9           Renal ca. 786-0   0.6           Renal ca. A498   0.1           Renal ca. ACHN   4.8           Renal ca. UO-31   0.1           Renal ca. TK-10   0.1           Bladder   0.4           Gastric ca. (liver met.) NCI-N87   0.7           Gastric ca. KATO III   0.1           Colon ca. SW-948   0.0           Colon ca. SW480   0.2           Colon ca.* (SW480 met) SW620   0.0           Colon ca. HT29   0.1           Colon ca. HCT-116   0.1           Colon ca. CaCo-2   3.7           Colon cancer tissue   0.0           Colon ca. SW1116   0.0           Colon ca. Colo-205   0.1           Colon ca. SW-48   0.0           Colon Pool   0.0           Small Intestine Pool   0.0           Stomach Pool   0.2           Bone Marrow Pool   0.0           Fetal Heart   0.0           Heart Pool   0.1           Lymph Node Pool   0.1           Fetal Skeletal Muscle   0.1           Skeletal Muscle Pool   0.0           Spleen Pool   0.1           Thymus Pool   0.0           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   0.0           CNS cancer (astro) SF-539   0.0           CNS cancer (astro) SNB-75   0.1           CNS cancer (glio) SNB-19   0.0           CNS cancer (glio) SF-295   0.0           Brain (Amygdala) Pool   0.2           Brain (cerebellum)   0.0           Brain (fetal)   0.0           Brain (Hippocampus) Pool   0.1           Cerebral Cortex Pool   0.2           Brain (Substantia nigra) Pool   0.4           Brain (Thalamus) Pool   0.1           Brain (whole)   0.4           Spinal Cord Pool   0.3           Adrenal Gland   0.1           Pituitary gland Pool   0.1           Salivary Gland   0.0           Thyroid (female)   0.0           Pancreatic ca. CAPAN2   0.5           Pancreas Pool   0.5                                    
     [0723]               TABLE HC                          Human Metabolic                     Tissue Name   A               137857_psoas-AA.M.Diab.-hi BMI-6   0.0       135760_psoas-HI.M.Diab.-hi BMI-21   0.7       134827_psoas-CC.M.Diab.-hi BMI-4   0.0       137860_psoas-AA.M.Diab.-med BMI-8   0.0       137834_psoas-CC.M.Diab.-med BMI-2   0.0       137828_psoas-CC.M.Diab.-med BMI-1   0.0       135763_psoas-HI.M.Diab.-med BMI-23   0.0       142740_psoas-AS.M.Diab.-low BMI-20   0.0       134834_psoas-AA.M.Diab.-low BMI-17   0.1       137850_psoas-AS.M.Norm-hi BMI-34   0.0       135769_psoas-HI.M.Norm-hi BMI-31   0.0       135766_psoas-AA.M.Norm-hi BMI-25   0.0       142746_psoas-AA.M.Norm-med BMI-37   0.0       142745_psoas-HI.M.Norm-med BMI-35   0.0       137855_psoas-AA.M.Norm-med BMI-47   0.0       137844_psoas-CC.M.Norm-med BMI-26   0.0       142742_psoas-CC.M.Norm-low BMI-40   0.0       137873_psoas-AS.M.Norm-low BMI-28   0.0       137853_psoas-HI.M.Norm-low BMI-41   0.0       135775_psoas-CC.M.Norm-low BMI-39   0.0       137858_diaphragm-AA.M.Diab.-hi BMI-6   0.0       135772_diaphragm-AS.M.Diab-hi BMI-9   0.0       135761_diaphragm-HI.M.Diab.-hi BMI-21   0.1       134828_diaphragm-CC.M.Diab.-hi BMI-4   0.0       137835_diaphragm-CC.M.Diab.-med BMI-2   0.0       135764_diaphragm-HI.M.Diab.-med BMI-23   0.0       134835_diaphragm-AA.M.Diab.-low BMI-17   0.0       142738_diaphragm-CC.M.Norm-hi BMI-29   0.0       139517_diaphragm-AS.M.Norm-hi BMI-34   0.0       137848_diaphragm-HI.M.Norm-hi BMI-31   0.0       137843_diaphragm-AA.M.Norm-hi BMI-25   0.0       137879_diaphragm-AA.M.Norm-med BMI-47   0.0       137872_diaphragm-CC.M.Norm-med BMI-26   0.0       135773_diaphragm-HI.M.Norm-med BMI-35   0.0       139542_diaphragm-HI.M.Norm-low BMI-41   0.0       137877_diaphragm-CC.M.Norm-low BMI-39   0.0       137874_diaphragm-AS.M.Norm-low BMI-28   0.0       141340_subQadipose-AA.M.Diab.-hi BMI-6   0.0       137836_subQadipose-HI.M.Diab.-hi BMI-21   0.0       135771_subQadipose-AS.M.Diab-hi BMI-9   0.0       141329_subQadipose-AA.M.Diab-medbmi-8   0.0       137862_subQadipose-CC.M.Diab.-med BMI-1   0.0       135762_subQadipose-HI.M.Diab.-med BMI-23   0.0       141338_subQadipose-AS.M.Diab.-low BMI-20   0.0       139547_subQadipose-HI.M.Diab.-low BMI-22   0.1       135757_subQadipose-CC.M.Diab.-low BMI-13   0.0       134832_subQadipose-AA.M.Diab.-low BMI-17   0.0       141332_subQadipose-HI.M.Norm-hi BMI-31   0.0       135767_subQadipose-CC.M.Norm-hi BMI-29   0.0       135765_subQadipose-AS.M.Norm-hi BMI-34   0.0       141339_subQadipose-HI.M.Norm-med BMI-35   0.0       141334_subQadipose-CC.M.Norm-med BMI-26   0.0       139544_subQadipose-AA.M.Norm-med BMI-47   0.0       137875_subQadipose-AA.M.Norm-med BMI-37   0.0       141331_subQadipose-AS.M.Norm-low BMI-28   0.0       137878_subQadipose-HI.M.Norm-low BMI-41   0.0       137876_subQadipose-CC.M.Norm-low BMI-39   0.0       137859_vis.adipose-AA.M.Diab.-hi BMI-6   0.0       135770_vis.adipose-AS.M.Diab-hi BMI-9   0.0       135759_vis.adipose-HI.M.Diab.-hi BMI-21   0.0       143502_vis.adipose-CC.M.Diab.-med BMI-2   0.0       139510_vis.adipose-AA.M.Diab.-med BMI-8   0.0       137861_vis.adipose-CC.M.Diab.-med-1   0.0       137839_vis.adipose-HI.M.Diab.-med BMI-23   0.0       139546_vis.adipose-HI.M.Diab.-low BMI-22   0.0       137831_vis.adipose-CC.M.Diab.-low BMI-13   0.0       139522_vis.adipose-HI.M.Norm-hi BMI-31   0.0       139516_vis.adipose-AS.M.Norm-hi BMI-34   0.0       137846_vis.adipose-CC.M.Norm-hi BMI-29   0.0       137841_vis.adipose-AA.M.Norm-hi BMI-25   0.0       139543_vis.adipose-AA.M.Norm-med BMI-47   0.0       139532_vis.adipose-AA.M.Norm-med BMI-37   0.0       139530_vis.adipose-HI.M.Norm-med BMI-35   0.0       139539_vis.adipose-HI.M.Norm-low BMI-41   0.0       139535_vis.adipose-CC.M.Norm-low BMI-40   0.1       137852_vis.adipose-CC.M.Norm-low BMI-39   0.0       135768_vis.adipose-AS.M.Norm-low BMI-28   0.0       141327_liver-CC.M.Diab.-hi BMI-4   0.2       139514_liver-HI.M.Diab.-hi BMI-21   3.7       139526_liver-CC.M.Diab.-med BMI-2   2.0       139511_liver-AA.M.Diab.-med BMI-8   1.4       137840_liver-HI.M.Diab.-med BMI-23   31.0        137827_liver-CC.M.Diab.-med BMI-1   27.2        137838_liver-HI.M.Diab.-low BMI-22   28.9        135758_liver-CC.M.Diab.-low BMI-13   23.5        139519_liver-CC.M.Norm-hi BMI-29   7.9       139518_liver-AA.M.Norm-hi BMI-25   16.2        137849_liver-AS.M.Norm-hi BMI-34   72.2        137847_liver-HI.M.Norm-hi BMI-31   26.2        142741_liver-AA.M.Norm-med BMI-37   100.0        141341_liver-HI.M.Norm-med BMI-35   8.6       141335_liver-CC.M.Norm-med BMI-26   1.7       139540_liver-HI.M.Norm-low BMI-41   1.6       139534_liver-CC.M.Norm-low BMI-39   7.4       139521_liver-AS.M.Norm-low BMI-28   15.2        141328_pancreas-CC.M.Diab.-hi BMI-4   0.0       139525_pancreas-AS.M.Diab.-hi BMI-9   0.0       137856_pancreas-AA.M.Diab.-hi BMI-6   0.1       137837_pancreas-HI.M.Diab.-hi BMI-21   0.6       141337_pancreas-CC.M.Diab.-med BMI-2   0.0       139527_pancreas-CC.M.Diab.-med BMI-1   0.0       139515_pancreas-HI.M.Diab.-med BMI-23   0.0       139512_pancreas-AA.M.Diab.-med BMI-8   0.0       142739_pancreas-AS.M.Diab.-low BMI-20   0.0       139513_pancreas-CC.M.Diab.-low BMI-13   0.0       142743_pancreas-AA.M.Norm-hi BMI-25   0.0       139523_pancreas-HI.M.Norm-hi BMI-31   0.0       139520_pancreas-CC.M.Norm-hi BMI-29   0.0       142744_pancreas-HI.M.Norm-med BMI-35   0.0       139545_pancreas-AA.M.Norm-med BMI-47   0.0       13953l_pancreas-AA.M.Norm-med BMI-37   0.0       13787l_pancreas-CC.M.Norm-med BMI-26   0.7       139541_pancreas-Hi.M.Norm-low BMI-41   0.0       139537_pancreas-CC.M.Norm-low BMI-40   0.0       139533_pancreas-CC.M.Norm-low BMI-39   0.0       137845_pancreas-AS.M.Norm-low BMI-28   0.1       143530_small intestine-AA.M.Diab.-hi BMI-6   0.0       143529_small intestine-CC.M.Diab.-hi BMI-4   0.1       143538_small intestine-HI.M.Diab.-med BMI-23   0.0       143531_small intestine-AA.M.Diab.-med BMI-8   0.1       143528_small intestine-CC.M.Diab.-med BMI-2   0.0       143537_small intestine-HI.M.Diab.-low BMI-22   0.0       143535_small intestine-AS.M.Diab.-low BMI-20   0.0       143534_small intestine-AA.M.Diab.-low BMI-17   0.0       143544_small intestine-AS.M.Norm-hi BMI-34   0.1       143543_small intestine-HI.M.Norm-hi BMI-31   1.4       143542_small intestine-CC.M.Norm-hi BMI-29   0.0       143539_small intestine-AA.M.Norm-hi BMI-25   0.0       143548_small intestine-AA.M.Norm-med BMI-47   0.1       143547_small intestine-AA.M.Norm-med BMI-37   0.1       143540_small intestine-CC.M.Norm-med BMI-26   0.0       143550_small intestine-CC.M.Norm-low BMI-40   0.0       143549_small intestine-CC.M.Norm-low BMI-39   0.0       143546_small intestine-HI.M.Norm-low BMI-41   0.1       143525_hypothalamus-HI.M.Diab.-hi BMI-21   0.0       143515_hypothalamus-CC.M.Diab.-hi BMI-4   0.0       143513_hypothalamus-AA.M.Diab.-hi BMI-6   0.2       143507_hypothalamus-AS.M.Diab.-hi BMI-9   0.1       143506_hypothalamus-CC.M.Diab.-med BMI-1   0.2       143505_hypothalamus-HI.M.Diab.-med BMI-23   0.1       143509_hypothalamus-AA.M.Diab.-low BMI-17   0.1       143508_hypothalamus-CC.M.Diab.-low BMI-13   0.1       143503_hypothalamus-AS.M.Diab.-low BMI-20   0.1       143522_hypothalamus-HI.M.Norm-hi BMI-31   0.0       143516_hypothalamus-AS.M.Norm-hi BMI-34   0.0       143511_hypothalamus-CC.M.Norm-hi BMI-29   0.2       143504_hypothalamus-AA.M.Norm-hi BMI-25   0.1       143517_hypothalamus-AA.M.Norm-med BMI-47   0.1       143514_hypothalamus-HI.M.Norm-med BMI-35   0.0       143521_hypothalamus-AS.M.Norm-low BMI-28   0.0       143512_hypothalamus-CC.M.Norm-low BMI-40   0.0       145454_Patient-25pl (CC.Diab.low BMI.no insulin)   0.0       110916_Patient-18pl (HI.Diab.obese.no insulin)   0.0       110913_Patient-18go (HI.Diab.obese.no insulin)   0.0       110911_Patient-17pl (CC.Diab.low BMI.no insulin)   0.0       110908_Patient-17go (CC.Diab.low BMI.no insulin)   0.0       100752_Patient-15sk (CC.Diab.obese.no insulin)   0.0       97828_Patient-13pl (CC.Diab.overwt.no insulin)   0.1       160114_Patient27-ut (CC.Diab.obese.insulin)   0.0       160113_Patient27-pl (CC.Diab.obese.insulin)   0.0       160112_Patient27-sk (CC.Diab.obese.insulin)   0.0       160111_Patient27-go (CC.Diab.obese.insulin)   0.1       145461_Patient-26sk (CC.Diab.obese.insulin)   0.0       145441_Patient-22sk (CC.Diab.low BMI.insulin)   0.1       145438_Patient-22pl (CC.Diab.low BMI.insulin)   0.0       145427_Patient-20pl (CC.Diab.overwt.insulin)   0.1       97503_Patient-12pl (CC.Diab.unknown BMI.insulin)   0.0       145443_Patient-23pl (CC.Non-diab.overwt)   0.0       145435_Patient-21pl (CC.Non-diab.overwt)   0.0       110921_Patient-19pl (CC.Non-diab.low BMI)   0.0       110918_Patient-19go (CC.Non-diab.low BMI)   0.1       97481_Patient-08sk (CC.Non-diab.obese)   0.0       97478_Patient-07pl (CC.Non-diab.obese)   0.0       160117_Human Islets-male, obese   0.5       145474_PANC1 (pancreas carcinoma) 1   0.7       154911_Capan2 (pancreas adenocarcinoma)   4.4       141190_SW579 (thyroid carcinoma)   0.0       145489_SK-N-MC (neuroblastoma) 1   0.0       145495_SK-N-SH (neuroblastoma) 1   0.5       145498_U87 MG (glioblastoma) 2   0.0       145484_HEp-2 (larynx carcinoma) 1   0.0       145479_A549 (lung carcinoma)   0.0       145488_A427 (lung carcinoma) 2   0.0       145472_FHs 738Lu (normal lung) 1   0.1       141187_SKW6.4 (B lymphocytes)   0.0       154644_IM-9 (immunoglobulin secreting lymphoblast)   0.0       154645_MOLT-4 (acute lymphoblastic   0.0       leukemia derived from peripheral blood)       154648_U-937 (histiocystic lymphoma)   0.1       154647_Daudi (Burkitt&#39;s lymphoma)   0.1       145494_SK-MEL-2 (melanoma) 2   0.3       141176_A375 (melanoma)   0.0       154642_SW 1353 (humerus chondrosarcoma)   0.1       141179_HT-1080 (fibrosarcoma)   0.0       145491_MG-63 (osteosarcoma) 1   0.0       141186_MCF7 (breast carcinoma)   0.0       141193_T47D (breast carcinoma)   0.1       154641_BT-20 (breast carcinoma)   1.6       141175_293 (kidney transformed with adenovirus 5 DNA)   0.0       141182_HUH hepatoma 1   0.6       141184_HUH7 hepatoma 1   0.8       145478_HT1376 (bladder carcinoma)   0.0       14548l_SCaBER (bladder carcinoma)   0.3       141192_SW620 (lymph node metastatsis, colon carcinoma) 2   0.1       141180_HT29 (colon carcinoma) 1   0.2       141188_SW480 (colon carcinoma) 1   0.2       154646_CAOV-3 (ovary adenocarcinoma)   0.2       141194_HeLa (cervix carcinoma)- 2   0.0       145482_HeLa S3 (cervix carcinoma) 1   0.0       145486_DU145 (prostate carcinoma)   0.0       154643_PC-3 (prostate adenocarcinoma)   0.0       154649_HCT-8 (ileocecal adenocarcinoma)   0.2                            
     [0724]               TABLE HD                          Panel 1.3D                             Tissue Name   A                       Liver adenocarcinoma   0.0           Pancreas   1.5           Pancreatic ca. CAPAN 2   0.3           Adrenal gland   0.1           Thyroid   0.0           Salivary gland   0.0           Pituitary gland   0.2           Brain (fetal)   0.0           Brain (whole)   0.0           Brain (amygdala)   0.0           Brain (cerebellum)   0.0           Brain (hippocampus)   0.1           Brain (substantia nigra)   0.0           Brain (thalamus)   0.0           Cerebral Cortex   0.1           Spinal cord   0.1           glio/astro U87-MG   0.2           glio/astro U-118-MG   0.0           astrocytoma SW1783   0.2           neuro*; met SK-N-AS   0.1           astrocytoma SF-539   0.2           astrocytoma SNB-75   0.0           glioma SNB-19   0.1           glioma U251   0.0           glioma SF-295   0.0           Heart (fetal)   0.0           Heart   0.0           Skeletal muscle (fetal)   0.0           Skeletal muscle   0.0           Bone marrow   0.0           Thymus   0.0           Spleen   0.0           Lymph node   0.0           Colorectal   0.3           Stomach   0.1           Small intestine   7.6           Colon ca. SW480   0.3           Colon ca.* SW620(SW480 met)   0.0           Colon ca. HT29   0.2           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   8.8           Colon ca. tissue (ODO3866)   0.1           Colon ca. HCC-2998   1.7           Gastric ca.* (liver met) NCI-N87   0.8           Bladder   0.4           Trachea   0.0           Kidney   8.9           Kidney (fetal)   5.8           Renal ca. 786-0   0.5           Renal ca. A498   0.5           Renal ca. RXF 393   0.1           Renal ca. ACHN   11.7           Renal ca. UO-31   0.2           Renal ca. TK-10   0.1           Liver   100.0           Liver (fetal)   99.3           Liver ca. (hepatoblast) HepG2   22.2           Lung   0.0           Lung (fetal)   0.0           Lung ca. (small cell) LX-1   0.0           Lung ca. (small cell) NCI-H69   0.0           Lung ca. (s. cell var.) SHP-77   0.0           Lung ca. (large cell)NCI-H460   0.0           Lung ca. (non-sm. cell) A549   0.1           Lung ca. (non-s. cell) NCI-H23   0.7           Lung ca. (non-s. cell) HOP-62   0.5           Lung ca. (non-s. cl) NCI-H522   0.0           Lung ca. (squam.) SW 900   0.1           Lung ca. (squam.) NCI-H596   0.0           Mammary gland   0.0           Breast ca.* (pl. ef) MCF-7   0.2           Breast ca.* (pl. ef) MDA-MB-231   0.2           Breast ca.* (pl. ef) T47D   0.2           Breast ca. BT-549   0.0           Breast ca. MDA-N   0.4           Ovary   0.1           Ovarian ca. OVCAR-3   0.3           Ovarian ca. OVCAR-4   0.1           Ovarian ca. OVCAR-5   0.2           Ovarian ca. OVCAR-8   0.2           Ovarian ca. IGROV-1   0.0           Ovarian ca.* (ascites) SK-OV-3   0.0           Uterus   0.0           Placenta   0.0           Prostate   0.0           Prostate ca.* (bone met)PC-3   0.0           Testis   0.2           Melanoma Hs688(A).T   0.0           Melanoma* (met) Hs688(B).T   0.1           Melanoma UACC-62   0.0           Melanoma M14   0.2           Melanoma LOX IMVI   0.0           Melanoma* (met) SK-MEL-5   0.0           Adipose   0.1                                    
     [0725]               TABLE HE                          Panel 2D                             Tissue Name   A                       Normal Colon   0.5           CC Well to Mod Diff (ODO3866)   0.0           CC Margin (ODO3866)   0.0           CC Gr.2 rectosigmoid (ODO3868)   0.0           CC Margin (ODO3868)   0.0           CC Mod Diff (ODO3920)   0.1           CC Margin (ODO3920)   0.0           CC Gr.2 ascend colon (ODO3921)   0.0           CC Margin (ODO3921)   0.0           CC from Partial Hepatectomy (ODO4309) Mets   6.6           Liver Margin (ODO4309)   100.0            Colon mets to lung (OD04451-01)   0.0           Lung Margin (OD04451-02)   0.0           Normal Prostate 6546-1   0.0           Prostate Cancer (OD04410)   0.0           Prostate Margin (OD04410)   0.0           Prostate Cancer (OD04720-01)   0.0           Prostate Margin (OD04720-02)   0.0           Normal Lung 061010   0.1           Lung Met to Muscle (ODO4286)   0.0           Muscle Margin (ODO4286)   0.0           Lung Malignant Cancer (OD03126)   0.0           Lung Margin (OD03126)   0.0           Lung Cancer (OD04404)   0.0           Lung Margin (OD04404)   0.0           Lung Cancer (OD04565)   0.0           Lung Margin (OD04565)   0.0           Lung Cancer (OD04237-01)   0.0           Lung Margin (OD04237-02)   0.0           Ocular Mel Met to Liver (ODO4310)   0.0           Liver Margin (ODO4310)   62.0            Melanoma Mets to Lung (OD04321)   0.0           Lung Margin (OD04321)   0.0           Normal Kidney   9.2           Kidney Ca, Nuclear grade 2 (OD04338)   1.0           Kidney Margin (OD04338)   1.5           Kidney Ca Nuclear grade 1/2 (OD04339)   0.0           Kidney Margin (OD04339)   12.9            Kidney Ca, Clear cell type (OD04340)   10.4            Kidney Margin (OD04340)   3.7           Kidney Ca, Nuclear grade 3 (OD04348)   0.3           Kidney Margin (OD04348)   2.1           Kidney Cancer (OD04622-01)   1.0           Kidney Margin (OD04622-03)   0.5           Kidney Cancer (OD04450-01)   0.4           Kidney Margin (OD04450-03)   2.2           Kidney Cancer 8120607   0.0           Kidney Margin 8120608   1.7           Kidney Cancer 8120613   0.0           Kidney Margin 8120614   2.2           Kidney Cancer 9010320   0.1           Kidney Margin 9010321   4.0           Normal Uterus   0.0           Uterus Cancer 064011   0.0           Normal Thyroid   0.1           Thyroid Cancer 064010   0.2           Thyroid Cancer A302152   0.1           Thyroid Margin A302153   0.1           Normal Breast   0.1           Breast Cancer (OD04566)   0.1           Breast Cancer (OD04590-01)   0.0           Breast Cancer Mets (OD04590-03)   0.1           Breast Cancer Metastasis (OD04655-05)   0.0           Breast Cancer 064006   0.5           Breast Cancer 1024   0.0           Breast Cancer 9100266   0.0           Breast Margin 9100265   0.0           Breast Cancer A209073   0.1           Breast Margin A209073   0.1           Normal Liver   86.5            Liver Cancer 064003   23.5            Liver Cancer 1025   39.8            Liver Cancer 1026   13.6            Liver Cancer 6004-T   47.0            Liver Tissue 6004-N   8.1           Liver Cancer 6005-T   12.6            Liver Tissue 6005-N   14.1            Normal Bladder   0.3           Bladder Cancer 1023   0.0           Bladder Cancer A302173   0.0           Bladder Cancer (OD04718-01)   0.0           Bladder Normal Adjacent (OD04718-03)   0.0           Normal Ovary   0.0           Ovarian Cancer 064008   0.0           Ovarian Cancer (OD04768-07)   0.8           Ovary Margin (OD04768-08)   0.0           Normal Stomach   0.0           Gastric Cancer 9060358   0.0           Stomach Margin 9060359   0.0           Gastric Cancer 9060395   0.0           Stomach Margin 9060394   0.3           Gastric Cancer 9060397   0.0           Stomach Margin 9060396   0.0           Gastric Cancer 064005   0.4                                    
     [0726]               TABLE HF                          Panel 5 Islet                             Tissue Name   A                       97457_Patient-02go_adipose   0.0           97476_Patient-07sk_skeletal muscle   0.0           97477_Patient-07ut_uterus   0.0           97478_Patient-07pl_placenta   0.7           99167_Bayer Patient 1   1.3           97482_Patient-08ut_uterus   0.0           97483_Patient-08pl_placenta   0.0           97486_Patient-09sk_skeletal muscle   0.0           97487_Patient-09ut_uterus   0.0           97488_Patient-09pl_placenta   0.0           97492_Patient-10ut_uterus   0.0           97493_Patient-l0pl_placenta   0.0           97495_Patient-11go_adipose   1.0           97496_Patient-11sk_skeletal muscle   0.0           97497_Patient-11ut_uterus   0.0           97498_Patient-11pl_placenta   0.0           97500_Patient-12go_adipose   2.1           97501_Patient-12sk_skeletal muscle   0.0           97502_Patient-12ut_uterus   0.0           97503_Patient-12pl_placenta   0.0           94721_Donor 2 U - A_Mesenchymal Stem Cells   0.0           94722_Donor 2 U - B_Mesenchymal Stem Cells   0.0           94723_Donor 2 U - C_Mesenchymal Stem Cells   0.0           94709_Donor 2 AM - A_adipose   0.0           94710_Donor 2 AM - B_adipose   0.0           94711_Donor 2 AM - C_adipose   0.0           94712_Donor 2 AD - A_adipose   0.0           94713_Donor 2 AD - B_adipose   0.0           94714_Donor 2 AD - C_adipose   0.0           94742_Donor 3 U - A_Mesenchymal Stem Cells   0.0           94743_Donor 3 U - B_Mesenchymal Stem Cells   0.0           94730_Donor 3 AM - A_adipose   0.0           94731_Donor 3 AM - B_adipose   0.0           94732_Donor 3 AM - C_adipose   0.0           94733_Donor 3 AD - A_adipose   0.0           94734_Donor 3 AD - B_adipose   0.0           94735_Donor 3 AD - C_adipose   0.0           77138_Liver_HepG2untreated   30.1            73556_Heart_Cardiac stromal cells (primary)   0.4           81735_Small Intestine   17.9            72409_Kidney_Proximal Convoluted Tubule   1.6           82685_Small intestine_Duodenum   100.0            90650_Adrenal_Adrenocortical adenoma   0.0           72410_Kidney_HRCE   9.3           72411_Kidney_HRE   0.0           73139_Uterus_Uterine smooth muscle cells   0.7                                    
     [0727]               TABLE HG                          Panel 5D                             Tissue Name   A                       97457_Patient-02go_adipose   0.2           97476_Patient-07sk_skeletal muscle   0.0           97477_Patient-07ut_uterus   0.0           97478_Patient-07pl_placenta   0.0           9748l_Patient-08sk_skeletal muscle   0.0           97482_Patient-08ut_uterus   0.0           97483_Patient-08pl_placenta   0.2           97486_Patient-09sk_skeletal muscle   0.0           97487_Patient-09ut_uterus   0.1           97488_Patient-09pl_placenta   0.0           97492_Patient-1Out_uterus   0.0           97493_Patient-1Opl_placenta   0.0           97495_Patient-11go_adipose   0.0           97496_Patient-11sk_skeletal muscle   0.0           97497_Patient-11ut_uterus   0.0           97498_Patient-11pl_placenta   0.0           97500_Patient-12go_adipose   0.3           97501_Patient-12sk_skeletal muscle   0.0           97502_Patient-12ut_uterus   0.2           97503_Patient-12pl_placenta   0.0           94721_Donor 2 U - A_Mesenchymal Stem Cells   0.0           94722_Donor 2 U - B_Mesenchymal Stem Cells   0.0           94723_Donor 2 U - C_Mesenchymal Stem Cells   0.0           94709_Donor 2 AM - A_adipose   0.0           94710_Donor 2 AM - B_adipose   0.0           94711_Donor 2 AM - C_adipose   0.0           94712_Donor 2 AD - A_adipose   0.0           94713_Donor 2 AD - B_adipose   0.0           94714_Donor 2 AD - C_adipose   0.0           94742_Donor 3 U - A_Mesenchymal Stem Cells   0.0           94743_Donor 3 U - B_Mesenchymal Stem Cells   0.0           94730_Donor 3 AM - A_adipose   0.0           94731_Donor 3 AM - B_adipose   0.0           94732_Donor 3 AM - C_adipose   0.0           94733_Donor 3 AD - A_adipose   0.0           94734_Donor 3 AD - B_adipose   0.0           94735_Donor 3 AD - C_adipose   0.0           77138_Liver_HepG2untreated   28.3            73556_Heart_Cardiac stromal cells (primary)   0.0           81735_Small Intestine   12.3            72409_Kidney_Proximal Convoluted Tubule   4.3           82685_Small intestine_Duodenum   100.0            90650_Adrenal_Adrenocortical adenoma   0.0           72410_Kidney_HRCE   3.6           72411_Kidney_HRE   0.1           73139_Uterus_Uterine smooth muscle cells   0.0                                    
     [0728] General_screening_panel_v1.4 Summary: Ag1681 The CG56151-01 gene, a glucose transporter type 2 homolog, is predominantly expressed in liver. GLUT2 facilitates the transport of glucose into the liver. This gene is also expressed in brain, pancreas, and testis. This is consistent with immunocytochemistry data that shows that the Glut2 gene is expressed in insulin producing beta cells in the pancreas and aids in regulation of insulin secretion. Since the liver is responsible for gluconeogenesis, enhancing glucose uptake through GLUT2 may produce a negative feedback loop that would decrease hepatic glucose production. This could result in a lowering of blood glucose, a major therapeutic goal for the treatment of Type II (non-insulin dependent) diabetes. Thus, enhancing the function of the protein encoded by the CG56151-01 gene with an agonist antibody therapeutic could restore balance to blood glucose levels in patients with Type II diabetes.  
     [0729] In addition, this gene is expressed at higher levels in fetal liver and lung (CTs=29) than in the adult sources of-these tissues. Thus, expression of this gene could be used to differentiate disorders or predisposition to disorders between the two sources of these tissues.  
     [0730] References:  
     [0731] Waeber G, et al. Mol Cell Endocrinol Oct. 30, 1995;114(1-2):205-15. (PMID: 8674846)  
     [0732] Human Metabolic Summary: Ag1681 Highest expression is seen in normal liver (CT=22)samples, with lower expression seen in liver samples from diabetic patients.  
     [0733] Panel 1.3D Summary: Ag1681 Expression of the CG56151-01 gene is restricted to liver derived tissue, an important metabolic tissue, in this panel (CTs=27). This liver specific expression is consistent with expression in other panels and with published data (see reference below.) Thus, expression of this gene could be used as a marker for liver tissue. This gene encodes a glut2 homolog. Please see General_screening_panel_v1.4 for disscussion of this gene in metabolic disease.  
     [0734] References:  
     [0735] Rencurel F, et al. Biochem J Mar. 15, 1996;314 (Pt 3):903-9. (PMID: 8615787)  
     [0736] Panel 2D Summary: Ag1681 The expression of the CG56151-01 gene appears to be highest in a sample of normal liver tissue adjacent to a colon cancer metastasis (CT=24.6). In addition, there is substantial expression in both normal and malignant liver tissue. This restricted pattern of expression in liver derived tissue is consistent with expression in the previous panels. Moreover, therapeutic modulation of this gene, through the use of small molecule drugs, protein therapeutics or antibodies might be benefical in the treatment of liver cancer.  
     [0737] Panel 5 Islet Summary: Ag1681 Moderate expression is seen in samples derived from small intestine and a liver cell line.  
     [0738] Panel 5D Summary: Ag1681 The expression pattern of the CG56151-01 gene, a Glut2 homolog, is limited to a liver cell line (HepG2) and small intestines. The presence of this isoform in the intestines may indicate an important role in glucose uptake from the digestive tract. Please refer to panel 1.4 for a further discussion of this gene in metabolic disease.  
     [0739] I. CG56155-02: Plasma Kallikrein Precursor  
     [0740] Expression of gene CG56155-02 was assessed using the primer-probe set Ag1688, described in Table IA. Results of the RTQ-PCR runs are shown in Tables IB, IC, ID, IE, IF, IG and IH.  
               TABLE IA                          Probe Name Ag1688                                             Start   SEQ ID       Primers   Sequences   Length   Position   No                                         Forward   5′-tcagaagggaatcatgatatcg-3′   22   577   122       Probe   TET-5′-ccttgataaaactccaggctcctttga-3′-TAMRA   27   550   123       Reverse   5′-tttggaaggtaggcatattgg-3′   21   509   124                  
 
     [0741]               TABLE IB                          AI_comprehensive panel_v1.0                             Tissue Name   A                       110967 COPD-F   53.6           110980 COPD-F   14.2           110968 COPD-M   48.3           110977 COPD-M   53.6           110989 Emphysema-F   61.6           110992 Emphysema-F   21.6           110993 Emphysema-F   23.8           110994 Emphysema-F   20.7           110995 Emphysema-F   55.1           110996 Emphysema-F   17.8           110997 Asthma-M   25.2           111001 Asthma-F   23.0           111002 Asthma-F   22.1           111003 Atopic Asthma-F   15.5           111004 Atopic Asthma-F   19.9           111005 Atopic Asthma-F   23.8           111006 Atopic Asthma-F   6.0           111417 Allergy-M   4.6           112347 Allergy-M   0.0           112349 Normal Lung-F   0.0           112357 Normal Lung-F   38.7           112354 Normal Lung-M   24.0           112374 Crohns-F   10.4           112389 Match Control Crohns-F   7.4           112375 Crohns-F   4.6           112732 Match Control Crohns-F   25.0           112725 Crohns-M   11.3           112387 Match Control Crohns-M   1.0           112378 Crohns-M   0.0           112390 Match Control Crohns-M   44.1           112726 Crohns-M   19.5           112731 Match Control Crohns-M   58.2           112380 Ulcer Col-F   3.2           112734 Match Control Ulcer Col-F   56.6           112384 Ulcer Col-F   10.1           112737 Match Control Ulcer Col-F   21.6           112386 Ulcer Col-F   0.0           112738 Match Control Ulcer Col-F   9.3           112381 Ulcer Col-M   0.0           112735 Match Control Ulcer Col-M   41.8           112382 Ulcer Col-M   3.8           112394 Match Control Ulcer Col-M   5.2           112383 Ulcer Col-M   31.6           112736 Match Control Ulcer Col-M   12.9           112423 Psoriasis-F   9.2           112427 Match Control Psoriasis-F   77.4           112418 Psoriasis-M   12.7           112723 Match Control Psoriasis-M   0.0           112419 Psoriasis-M   100.0           112424 Match Control Psoriasis-M   35.6           112420 Psoriasis-M   87.7           112425 Match Control Psoriasis-M   29.1           104689 (MF) OA Bone-Backus   50.0           104690 (MF) Adj “Normal” Bone-Backus   34.9           104691 (MF) OA Synovium-Backus   25.5           104692 (BA) OA Cartilage-Backus   37.6           104694 (BA) OA Bone-Backus   8.4           104695 (BA) Adj “Normal” Bone-Backus   34.4           104696 (BA) OA Synovium-Backus   6.9           104700 (SS) OA Bone-Backus   22.8           104701 (SS) Adj “Normal” Bone-Backus   42.3           104702 (SS) OA Synovium-Backus   29.5           117093 OA Cartilage Rep7   10.6           112672 OA Bone5   94.0           112673 OA Synovium5   43.2           112674 OA Synovial Fluid cells5   58.6           117100 OA Cartilage Rep 14   0.0           112756 OA Bone9   2.6           112757 OA Synovium9   8.0           112758 OA Synovial Fluid Cells9   22.1           117125 RA Cartilage Rep2   22.1           113492 Bone2 RA   10.0           113493 Synovium2 RA   11.0           113494 Syn Fluid Cells RA   31.6           113499 Cartilage4 RA   47.6           113500 Bone4 RA   37.9           113501 Synovium4 RA   55.5           113502 Syn Fluid Cells4 RA   10.0           113495 Cartilage3 RA   20.7           113496 Bone3 RA   16.2           113497 Synovium3 RA   11.5           113498 Syn Fluid Cells3 RA   25.3           117106 Normal Cartilage Rep20   0.0           113663 Bone3 Normal   0.9           113664 Synovium3 Normal   0.0           113665 Syn Fluid Cells3 Normal   1.1           117107 Normal Cartilage Rep22   2.7           113667 Bone4 Normal   8.1           113668 Synovium4 Normal   5.8           113669 Syn Fluid Cells4 Normal   5.3                                    
     [0742]               TABLE IC                          CNS_neurodegeneration_v1.0                             Tissue Name   A                       AD 1 Hippo   24.5           AD 2 Hippo   34.4           AD 3 Hippo   17.9           AD 4 Hippo   18.0           AD 5 hippo   94.6           AD 6 Hippo   34.9           Control 2 Hippo   35.4           Control 4 Hippo   50.7           Control (Path) 3 Hippo    9.3           AD 1 Temporal Ctx   31.9           AD 2 Temporal Ctx   31.4           AD 3 Temporal Ctx   20.4           AD 4 Temporal Ctx   29.5           AD 5 Inf Temporal Ctx   100.0            AD 5 Sup Temporal Ctx   92.0           AD 6 Inf Temporal Ctx   43.8           AD 6 Sup Temporal Ctx   69.7           Control 1 Temporal Ctx   16.5           Control 2 Temporal Ctx   34.9           Control 3 Temporal Ctx   32.3           Control 4 Temporal Ctx   35.4           Control (Path) 1 Temporal Ctx   46.0           Control (Path) 2 Temporal Ctx   45.7           Control (Path) 3 Temporal Ctx    9.7           Control (Path) 4 Temporal Ctx   41.8           AD 1 Occipital Ctx   42.3           AD 2 Occipital Ctx (Missing)    0.0           AD 3 Occipital Ctx    7.1           AD 4 Occipital Ctx   26.4           AD 5 Occipital Ctx    9.9           AD 6 Occipital Ctx   27.2           Control 1 Occipital Ctx    6.3           Control 2 Occipital Ctx   49.7           Control 3 Occipital Ctx   39.2           Control 4 Occipital Ctx   26.6           Control (Path) 1 Occipital Ctx   47.3           Control (Path) 2 Occipital Ctx   21.3           Control (Path) 3 Occipital Ctx    3.5           Control (Path) 4 Occipital Ctx   17.8           Control 1 Parietal Ctx   19.5           Control 2 Parietal Ctx   85.3           Control 3 Parietal Ctx   15.5           Control (Path) 1 Parietal Ctx   44.4           Control (Path) 2 Parietal Ctx   52.9           Control (Path) 3 Parietal Ctx    9.7           Control (Path) 4 Parietal Ctx   52 1                                    
     [0743]               TABLE ID                          Panel 1.3D                             Tissue Name   A                       Liver adenocarcinoma   0.0           Pancreas   6.7           Pancreatic ca. CAPAN 2   0.2           Adrenal gland   1.8           Thyroid   3.8           Salivary gland   1.5           Pituitary gland   6.1           Brain (fetal)   0.5           Brain (whole)   3.6           Brain (amygdala)   3.3           Brain (cerebellum)   0.4           Brain (hippocampus)   6.2           Brain (substantia nigra)   1.0           Brain (thalamus)   2.1           Cerebral Cortex   6.3           Spinal cord   3.1           glio/astro U87-MG   0.0           glio/astro U-118-MG   0.0           astrocytoma SW1783   0.0           neuro*; met SK-N-AS   0.2           astrocytoma SF-539   0.0           astrocytoma SNB-75   0.1           glioma SNB-19   0.2           glioma U251   1.2           glioma SF-295   0.0           Heart (fetal)   0.2           Heart   1.6           Skeletal muscle (fetal)   0.7           Skeletal muscle   1.2           Bone marrow   0.5           Thymus   3.2           Spleen   1.0           Lymph node   2.9           Colorectal   0.8           Stomach   3.3           Small intestine   6.2           Colon ca. SW480   0.0           Colon ca.* SW620(SW480 met)   0.0           Colon ca. HT29   0.0           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   0.2           Colon ca. tissue(ODO3866)   0.0           Colon ca. HCC-2998   0.2           Gastric ca.* (liver met) NCI-N87   4.4           Bladder   3.1           Trachea   3.0           Kidney   6.8           Kidney (fetal)   9.2           Renal ca. 786-0   0.0           Renal ca. A498   1.7           Renal ca. RXF 393   0.0           Renal ca. ACHN   0.0           Renal ca. UO-31   0.0           Renal ca. TK-10   0.0           Liver   100.0            Liver (fetal)   99.3            Liver ca. (hepatoblast) HepG2   0.0           Lung   1.3           Lung (fetal)   1.8           Lung ca. (small cell) LX-1   0.0           Lung ca. (small cell) NCI-H69   0.0           Lung ca. (s. cell var.) SHP-77   0.8           Lung ca. (large cell)NCI-H460   0.0           Lung ca. (non-sm. cell) A549   0.2           Lung ca. (non-s. cell) NCI-H23   0.0           Lung ca. (non-s. cell) HOP-62   0.0           Lung ca. (non-s. cl) NCI-H522   0.0           Lung ca. (squam.) SW 900   0.2           Lung ca. (squam.) NCI-H596   0.0           Mammary gland   2.9           Breast ca.* (pl. ef) MCF-7   0.0           Breast ca.* (pl. ef) MDA-MB-231   0.0           Breast ca.* (pl. ef) T47D   0.0           Breast ca. BT-549   0.0           Breast ca. MDA-N   0.0           Ovary   0.0           Ovarian ca. OVCAR-3   0.2           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.3           Ovarian ca. OVCAR-8   0.0           Ovarian ca. IGROV-1   0.0           Ovarian ca.* (ascites) SK-OV-3   1.0           Uterus   1.4           Placenta   0.4           Prostate   1.0           Prostate ca.* (bone met)PC-3   0.0           Testis   6.1           Melanoma Hs688(A).T   0.4           Melanoma* (met) Hs688(B).T   0.9           Melanoma UACC-62   0.0           Melanoma M14   0.0           Melanoma LOX IMVI   0.0           Melanoma* (met) SK-MEL-5   0.0           Adipose   0.5                                    
     [0744]               TABLE IE                          Panel 2D                             Tissue Name   A                       Normal Colon   1.7           CC Well to Mod Diff (ODO3866)   0.0           CC Margin (ODO3866)   0.2           CC Gr.2 rectosigmoid (ODO3868)   0.2           CC Margin (ODO3868)   0.1           CC Mod Diff (ODO3920)   0.1           CC Margin (ODO3920)   0.9           CC Gr.2 ascend colon (ODO3921)   0.1           CC Margin (ODO3921)   0.1           CC from Partial Hepatectomy (ODO4309) Mets   4.7           Liver Margin (ODO4309)   100.0            Colon mets to lung (OD04451-01)   0.1           Lung Margin (OD04451-02)   0.1           Normal Prostate 6546-1   2.1           Prostate Cancer (OD04410)   0.6           Prostate Margin (OD04410)   0.5           Prostate Cancer (OD04720-01)   1.1           Prostate Margin (OD04720-02)   1.6           Normal Lung 061010   2.0           Lung Met to Muscle (ODO4286)   0.0           Muscle Margin (ODO4286)   0.2           Lung Malignant Cancer (OD03126)   0.1           Lung Margin (OD03126)   0.5           Lung Cancer (OD04404)   0.1           Lung Margin (OD04404)   0.2           Lung Cancer (OD04565)   0.0           Lung Margin (OD04565)   0.1           Lung Cancer (OD04237-01)   0.1           Lung Margin (OD04237-02)   0.4           Ocular Mel Met to Liver (ODO4310)   0.1           Liver Margin (ODO4310)   77.4            Melanoma Mets to Lung (OD04321)   0.0           Lung Margin (OD04321)   0.1           Normal Kidney   12.9            Kidney Ca, Nuclear grade 2 (OD04338)   3.8           Kidney Margin (OD04338)   1.6           Kidney Ca Nuclear grade 1/2 (OD04339)   2.8           Kidney Margin (OD04339)   9.3           Kidney Ca, Clear cell type (OD04340)   1.4           Kidney Margin (OD04340)   4.1           Kidney Ca, Nuclear grade 3 (OD04348)   0.1           Kidney Margin (OD04348)   3.8           Kidney Cancer (OD04622-01)   0.2           Kidney Margin (OD04622-03)   0.7           Kidney Cancer (OD04450-01)   0.2           Kidney Margin (OD04450-03)   2.6           Kidney Cancer 8120607   0.0           Kidney Margin 8120608   0.7           Kidney Cancer 8120613   0.0           Kidney Margin 8120614   0.5           Kidney Cancer 9010320   0.2           Kidney Margin 9010321   1.0           Normal Uterus   0.2           Uterus Cancer 064011   0.8           Normal Thyroid   0.9           Thyroid Cancer 064010   0.2           Thyroid Cancer A302152   0.5           Thyroid Margin A302153   1.0           Normal Breast   0.3           Breast Cancer (OD04566)   0.1           Breast Cancer (OD04590-01)   0.1           Breast Cancer Mets (OD04590-03)   0.4           Breast Cancer Metastasis (OD04655-05)   0.9           Breast Cancer 064006   0.6           Breast Cancer 1024   1.2           Breast Cancer 9100266   0.1           Breast Margin 9100265   0.1           Breast Cancer A209073   0.3           Breast Margin A209073   0.3           Normal Liver   69.7            Liver Cancer 064003   13.7            Liver Cancer 1025   18.0            Liver Cancer 1026   1.2           Liver Cancer 6004-T   22.2            Liver Tissue 6004-N   1.0           Liver Cancer 6005-T   1.9           Liver Tissue 6005-N   4.2           Normal Bladder   2.7           Bladder Cancer 1023   0.0           Bladder Cancer A302173   0.2           Bladder Cancer (OD04718-01)   0.1           Bladder Normal Adjacent (OD04718-03)   0.5           Normal Ovary   0.0           Ovarian Cancer 064008   0.1           Ovarian Cancer (OD04768-07)   0.2           Ovary Margin (OD04768-08)   0.1           Normal Stomach   0.3           Gastric Cancer 9060358   0.1           Stomach Margin 9060359   0.0           Gastric Cancer 9060395   0.2           Stomach Margin 9060394   0.3           Gastric Cancer 9060397   0.3           Stomach Margin 9060396   0.0           Gastric Cancer 064005   1.1                                    
     [0745]               TABLE IF                          Panel 4.1D                             Tissue Name   A                                         Secondary Th1 act   1.6           Secondary Th2 act   1.7           Secondary Tr1 act   0.0           Secondary Th1 rest   0.0           Secondary Th2 rest   0.0           Secondary Tr1 rest   0.0           Primary Th1 act   0.0           Primary Th2 act   0.0           Primary Tr1 act   0.0           Primary Th1 rest   1.3           Primary Th2 rest   1.3           Primary Tr1 rest   1.6           CD45RA CD4 lymphocyte act   3.5           CD45RO CD4 lymphocyte act   4.2           CD8 lymphocyte act   3.2           Secondary CD8 lymphocyte rest   1.8           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   3.8           2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0           LAK cells rest   0.0           LAK cells IL-2   6.2           LAK cells IL-2 + IL-12   0.0           LAK cells IL-2 + IFN gamma   1.7           LAK cells IL-2 + IL-18   3.4           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   22.1           Two Way MLR 3 day   3.3           Two Way MLR 5 day   1.9           Two Way MLR 7 day   1.7           PBMC rest   1.5           PBMC PWM   5.1           PBMC PHA-L   0.7           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   2.8           B lymphocytes CD40L and IL-4   21.5           EOL-1 dbcAMP   0.0           EOL-1 dbcAMP PMA/ionomycin   0.0           Dendritic cells none   2.0           Dendritic cells LPS   0.0           Dendritic cells anti-CD40   4.9           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   0.0           Macrophages LPS   0.0           HUVEC none   0.0           HUVEC starved   0.0           HUVEC IL-1beta   0.0           HUVEC IFN gamma   0.0           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   0.0           HUVEC IL-11   0.0           Lung Microvascular EC none   0.0           Lung Microvascular EC TNFalpha + IL-1beta   0.0           Microvascular Dermal EC none   0.0           Microsvasular Dermal EC TNFalpha + IL-1beta   0.0           Bronchial epithelium TNFalpha + IL1beta   0.0           Small airway epithelium none   0.0           Small airway epithelium TNFalpha + IL-1beta   0.0           Coronery artery SMC rest   0.0           Coronery artery SMC TNFalpha + IL-1beta   0.0           Astrocytes rest   0.0           Astrocytes TNFalpha + IL-1beta   2.4           KU-812 (Basophil) rest   1.8           KU-812 (Basophil) PMA/ionomycin   0.0           CCD1106 (Keratinocytes) none   0.0           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0           Liver cirrhosis   100.0           NCI-H292 none   0.0           NCI-H292 IL-4   1.5           NCI-H292 IL-9   1.9           NCI-H292 IL-13   0.0           NCI-H292 IFN gamma   0.0           HPAEC none   0.0           HPAEC TNF alpha + IL-1 beta   0.0           Lung fibroblast none   2.6           Lung fibroblast TNF alpha + IL-1 beta   10.4           Lung fibroblast IL-4   1.8           Lung fibroblast IL-9   12.3           Lung fibroblast IL-13   0.0           Lung fibroblast IFN gamma   3.1           Dermal fibroblast CCD1070 rest   0.0           Dermal fibroblast CCD1070 TNF alpha   0.0           Dermal fibroblast CCD1070 IL-1 beta   0.0           Dermal fibroblast IFN gamma   6.8           Dermal fibroblast IL-4   5.8           Dermal Fibroblasts rest   0.0           Neutrophils TNFa + LPS   0.0           Neutrophils rest   0.0           Colon   0.0           Lung   1.2           Thymus   0.0           Kidney   82.9                                    
     [0746]               TABLE IG                          Panel 5 Islet                             Tissue Name   A                                         97457_Patient-02go_adipose   41.2           97476_Patient-07sk_skeletal muscle   9.9           97477_Patient-07ut_uterus   8.1           97478_Patient-07pl_placenta   0.0           99167_Bayer Patient 1   84.7           97482_Patient-08ut_uterus   2.4           97483_Patient-08pl_placenta   0.0           97486_Patient-09sk_skeletal muscle   8.0           97487_Patient-09ut_uterus   9.6           97488_Patient-09pl_placenta   0.0           97492_Patient-10ut_uterus   0.0           97493_Patient-10pl_placenta   0.0           97495_Patient-11go_adipose   0.0           97496_Patient-11sk_skeletal muscle   52.9           97497_Patient-11ut_uterus   35.8           97498_Patient-11pl_placenta   10.5           97500_Patient-12go_adipose   0.0           97501_Patient-12sk_skeletal muscle   35.4           97502_Patient-12ut_uterus   20.7           97503_Patient-12pl_placenta   0.0           94721_Donor 2 U - A_Mesenchymal Stem Cells   0.0           94722_Donor 2 U - B_Mesenchymal Stem Cells   0.0           94723_Donor 2 U - C_Mesenchymal Stem Cells   0.0           94709_Donor 2 AM - A_adipose   0.0           94710_Donor 2 AM - B_adipose   0.0           94711_Donor 2 AM - C_adipose   0.0           94712_Donor 2 AD - A_adipose   11.4           94713_Donor 2 AD - B_adipose   0.0           94714_Donor 2 AD - C_adipose   29.1           94742_Donor 3 U - A_Mesenchymal Stem Cells   19.2           94743_Donor 3 U - B_Mesenchymal Stem Cells   0.0           94730_Donor 3 AM - A_adipose   15.0           94731_Donor 3 AM - B_adipose   37.9           94732_Donor 3 AM - C_adipose   0.0           94733_Donor 3 AD - A_adipose   39.2           94734_Donor 3 AD - B_adipose   11.4           94735_Donor 3 AD - C_adipose   34.4           77138_Liver_HepG2untreated   8.4           73556_Heart_Cardiac stromal cells (primary)   0.0           81735_Small Intestine   100.0           72409_Kidney_Proximal Convoluted Tubule   9.9           82685_Small intestine_Duodenum   70.2           90650_Adrenal_Adrenocortical adenoma   25.5           72410_Kidney_HRCE   10.4           72411_Kidney_HRE   7.2           73139_Uterus_Uterine smooth muscle cells   0.0                                    
     [0747]               TABLE IH                          general oncology screening panel_v_2.4                             Tissue Name   A                                         Colon cancer 1   1.8           Colon cancer NAT 1   1.0           Colon cancer 2   0.4           Colon cancer NAT 2   1.2           Colon cancer 3   0.8           Colon cancer NAT 3   2.5           Colon malignant cancer 4   2.1           Colon normal adjacent tissue 4   0.2           Lung cancer 1   0.2           Lung NAT 1   0.2           Lung cancer 2   1.0           Lung NAT 2   0.8           Squamous cell carcinoma 3   0.5           Lung NAT 3   0.0           metastatic melanoma 1   1.1           Melanoma 2   0.1           Melanoma 3   0.0           metastatic melanoma 4   2.0           metastatic melanoma 5   3.0           Bladder cancer 1   0.6           Bladder cancer NAT 1   0.0           Bladder cancer 2   0.3           Bladder cancer NAT 2   0.1           Bladder cancer NAT 3   0.0           Bladder cancer NAT 4   1.1           Prostate adenocarcinoma 1   3.7           Prostate adenocarcinoma 2   0.2           Prostate adenocarcinoma 3   1.2           Prostate adenocarcinoma 4   3.5           Prostate cancer NAT 5   0.6           Prostate adenocarcinoma 6   0.2           Prostate adenocarcinoma 7   0.0           Prostate adenocarcinoma 8   0.0           Prostate adenocarcinoma 9   0.0           Prostate cancer NAT 10   0.1           Kidney cancer 1   7.7           Kidney NAT 1   5.7           Kidney cancer 2   40.1           Kidney NAT 2   23.8           Kidney cancer 3   100.0           Kidney NAT 3   5.6           Kidney cancer 4   2.0           Kidney NAT 4   4.2                                    
     [0748] AI_comprehensive panel_v1.0 Summary: Ag1688 Highest expression of this gene is detected in psoriasis sample (CT=31.9). Moderate to low levels of expression of this gene is also seen in samples derived from ostcooarthitis/rheumatoid arthritis bone, cartilage, synovium and synovial fluid samples, from normal lung, COPD lung, emphysema, atopic asthma, asthma, Crohn&#39;s disease (normal matched control and diseased), ulcerative colitis(normal matched control and diseased), and psoriasis (normal matched control and diseased). Therefore, therapeutic modulation of this gene product may ameliorate symptoms/conditions associated with autoimmune and inflammatory disorders including psoriasis, asthma, inflammatory bowel disease, rheumatoid arthritis and osteoarthritis.  
     [0749] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag1688 confirms the expression of this gene at low levels in the brains of an independent group of individuals. However, no differential expression of this gene was detected between Alzheimer&#39;s diseased postmortem brains and those of non-demented controls in this experiment. Please see Panel 1.3D for a discussion of the potential role of this gene in treatment of central nervous system disorders.  
     [0750] Panel 1.3D Summary: Ag1688 Expression of this gene, a plasma kallikrein, is significantly higher in liver (CTs=28) than in any other sample on this panel. Thus, expression of this gene could be used as a marker of liver tissue. In addition, low levels of expression of this gene is also detected in tissues with metabolic/endocrine functions including pancreas, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, and the gastrointestinal tract. Plasma prekallikrein is a glycoprotein that participates in the surface-dependent activation of blood coagulation, fibrinolysis, kinin generation and inflammation. It is synthesized in the liver and secreted into the blood as a single polypeptide chain. It is converted to plasma kallikrein by factor XIIa. Recently, plasma kallikrein has been implicated in adipose differentiation by remodeling of the fibronectin-rich ECM of preadipocytes. Pig −/− mice show a reduction of fat deposit (Ref. 1, 2). At Curagen, it was found that plasma kallikrein significantly down-regulated in the liver of mice with ‘lean’ phenotype. Thus, based on Curagen GeneCalling data it is hypothesized that plasma kallikrein might cause disruption of adipose differentiation thus leading to obesity if over expressed and to a leaner phenotype if expression is below normal. Therefore, an antagonist to this gene product may be beneficial in the treatment of obesity.  
     [0751] Moderate to low levels of expression of this gene is also seen in some of the regions of central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0752] References:  
     [0753] Hoover-Plow J, et al. Biochem.Biophys.Res.Commun. (2001) 284, 389-394. (PMID: 11394891).  
     [0754] Selvarajan S, et al. Nature Cell Biol. (2001) 3, 267-275. (PMID: 11231576)  
     [0755] Panel 2D Summary: Ag1688 The expression of the CG56155-01 gene appears to be highest in a sample derived from a sample of normal liver tissue adjacent to a metastatic colon cancer CT=26.2). In addition, there is substantial expression in other samples of normal liver, and to a much lesser degree, malignant liver tissue. This liver specific expression is consistent with the expression seen in Panel 1.3D.  
     [0756] Panel 4.1D Summary: Ag1688 Highest expression of this gene is detected in liver cirrhosis (CT=31.8). In addition, moderate to low levels of expression of this gene in IL-2 treated NK cells, CD40L and IL-4 treated B lymphocytes and normal kidney. Therefore, therapeutic modulation of the protein encoded for by this gene may be useful in the treatment of inflammatory or autoimmune diseases, liver cirrhosis and fibrosis, lupus erythematosus and glomerulonephritis.  
     [0757] Panel 5 Islet Summary: Ag1688 Expression of the CG56155-01 gene is limited to pancreatic islets and small intestines. Please see Panel 1.3 for discussion of this gene in metabolic disease.  
     [0758] general oncology screening panel_v — 2.4 Summary: Ag1688 Highest expression of this gene is detected in kidney cancer (CT=28.4). Higher expression of this gene is associated with cancer compared to normal kidney. Therefore, expression of this gene may be used as diagnostic marker for kidney cancer and therapeutic modulation of this gene or protein encoded by this gene may through the use of antibodies or small molecule drug may be useful in the treatment of kidney cancer.  
     [0759] J. CG56262-01: Ca-binding Transporter  
     [0760] Expression of gene CG56262-01 was assessed using the primer-probe sets Ag2896 and Ag2920, described in Tables JA and JB. Results of the RTQ-PCR runs are shown in Tables JC, JD, JE, JF and JG.  
               TABLE JA                          Probe Name Ag2896                                             Start   SEQ ID       Primers   Sequences   Length   Position   No                                         Forward   5′-gtcagcttctcttgctttgaga-3′   22   900   125       Probe   TET-5′-cactgtcaggcactcgccaatgt-3′-TAMRA   23   932   126       Reverse   5′-ctgtatttctggaagcattcca-3′   22   964   127                  
 
     [0761]                   TABLE JB                          Probe Name Ag2920                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-ttgatgtctctgagatccaaca-3′   22   1134   128           Probe   TET-5′-agtttccgagctctgggcatttccat-3′-TAMRA   26   1107   129       Reverse   5′-catgctgtgcaaaattttctc-3′   21   1070   130                    
     [0762]               TABLE JC                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   17.7   21.6           AD 2 Hippo   41.5   40.3           AD 3 Hippo   13.9   18.2           AD 4 Hippo   10.7   11.3           AD 5 Hippo   65.1   54.7           AD 6 Hippo   62.4   73.2           Control 2 Hippo   45.4   51.8           Control 4 Hippo   15.8   19.8           Control (Path) 3 Hippo   10.6   12.9           AD 1 Temporal Ctx   17.6   18.9           AD 2 Temporal Ctx   41.5   41.8           AD 3 Temporal Ctx   10.1   12.9           AD 4 Temporal Ctx   29.9   27.5           AD 5 Inf Temporal Ctx   78.5   79.6           AD 5 Sup Temporal Ctx   47.0   43.5           AD 6 Inf Temporal Ctx   48.0   47.6           AD 6 Sup Temporal Ctx   47.3   55.5           Control 1 Temporal Ctx   14.8   16.6           Control 2 Temporal Ctx   53.6   66.9           Control 3 Temporal Ctx   24.3   22.8           Control 3 Temporal Ctx   18.0   15.8           Control (Path) 1 Temporal Ctx   86.5   88.3           Control (Path) 2 Temporal Ctx   45.1   50.0           Control (Path) 3 Temporal Ctx   11.0   15.3           Control (Path) 4 Temporal Ctx   41.2   36.9           AD 1 Occipital Ctx   10.7   13.1           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   8.1   9.2           AD 4 Occipital Ctx   23.5   25.3           AD 5 Occipital Ctx   45.4   15.7           AD 6 Occipital Ctx   14.7   44.4           Control 1 Occipital Ctx   6.8   8.4           Control 2 Occipital Ctx   52.1   57.4           Control 3 Occipital Ctx   14.3   18.8           Control 4 Occipital Ctx   11.0   12.3           Control (Path) 1 Occipital Ctx   80.7   100.0           Control (Path) 2 Occipital Ctx   11.1   11.5           Control (Path) 3 Occipital Ctx   5.3   7.0           Control (Path) 4 Occipital Ctx   14.2   12.3           Control 1 Parietal Ctx   13.8   15.4           Control 2 Parietal Ctx   40.6   40.6           Control 3 Parietal Ctx   2.8   17.8           Control (Path) 1 Parietal Ctx   100.0   100.0           Control (Path) 2 Parietal Ctx   25.0   23.2           Control (Path) 3 Parietal Ctx   7.1   9.7           Control (Path) 4 Parietal Ctx   46.3   47.6                                                
     [0763]               TABLE JD                          Panel 1.3D                                 Tissue Name   A   B                                             Liver adenocarcinoma   36.6   40.1           Pancreas   4.2   7.4           Pancreatic ca. CAPAN 2   10.1   9.3           Adrenal gland   3.3   2.8           Thyroid   11.8   18.9           Salivary gland   6.7   6.6           Pituitary gland   2.2   2.7           Brain (fetal)   27.0   27.7           Brain (whole)   81.2   74.2           Brain (amygdala)   40.1   40.3           Brain (cerebellum)   30.8   33.0           Brain (hippocampus)   44.8   42.0           Brain (substantia nigra)   23.0   21.5           Brain (thalamus)   25.5   31.6           Cerebral Cortex   100.0   100.0           Spinal cord   12.6   12.9           glio/astro U87-MG   2.2   2.4           glio/astro U-118-MG   9.9   8.1           astrocytoma SW1783   8.8   10.1           neuro*; met SK-N-AS   4.2   3.3           astrocytoma SF-539   5.8   5.4           astrocytoma SNB-75   10.2   10.5           glioma SNB-19   10.1   11.0           glioma U251   14.1   15.8           glioma SF-295   6.0   5.9           Heart (fetal)   38.7   40.1           Heart   10.7   9.9           Skeletal muscle (fetal)   16.0   11.8           Skeletal muscle   31.2   28.7           Bone marrow   0.4   0.6           Thymus   2.5   2.5           Spleen   1.1   1.4           Lymph node   2.6   1.7           Colorectal   14.0   12.3           Stomach   4.4   4.0           Small intestine   4.4   4.9           Colon ca. SW480   5.1   5.3           Colon ca.* SW620 (SW480 met)   14.9   18.7           Colon ca. HT29   6.8   7.2           Colon ca. HCT-116   10.7   10.4           Colon ca. CaCo-2   17.0   21.9           Colon ca. tissue (ODO3866)   2.4   2.4           Colon ca. HCC-2998   9.3   7.6           Gastric ca.* (liver met) NCI-N87   5.7   5.5           Bladder   5.1   5.1           Trachea   1.9   2.8           Kidney   12.4   17.0           Kidney (fetal)   23.2   21.6           Renal ca. 786-0   15.5   19.6           Renal ca. A498   9.5   9.4           Renal ca. RXF 393   17.3   16.6           Renal ca. ACHN   10.5   14.5           Renal ca. UO-31   7.7   9.9           Renal ca. TK-10   12.4   14.7           Liver   4.3   3.5           Liver (fetal)   1.8   2.6           Liver ca. (hepatoblast) HepG2   4.7   4.9           Lung   5.4   3.2           Lung (fetal)   4.8   4.7           Lung ca. (small cell) LX-1   6.7   6.2           Lung ca. (small cell) NCI-H69   0.0   0.1           Lung ca. (s. cell var.) SHP-77   26.1   31.9           Lung ca. (large cell) NCI-H460   1.2   1.4           Lung ca. (non-sm. cell) A549   10.4   8.9           Lung ca. (non-s. cell) NCI-H23   11.0   12.7           Lung ca. (non-s. cell) HOP-62   4.9   4.7           Lung ca. (non-s. cl) NCI-H522   11.4   11.4           Lung ca. (squam.) SW 900   7.9   8.6           Lung ca. (squam.) NCI-H596   0.3   0.4           Mammary gland   8.3   8.5           Breast ca.* (pl. ef) MCF-7   7.5   8.1           Breast ca.* (pl. ef) MDA-MB-231   6.6   7.1           Breast ca.* (pl. ef) T47D   16.2   17.0           Breast ca. BT-549   5.8   5.1           Breast ca. MDA-N   19.5   22.5           Ovary   10.4   10.3           Ovarian ca. OVCAR-3   11.5   9.2           Ovarian ca. OVCAR-4   35.6   32.5           Ovarian ca. OVCAR-5   31.0   34.2           Ovarian ca. OVCAR-8   5.4   5.5           Ovarian ca. IGROV-1   10.3   10.2           Ovarian ca.* (ascites) SK-OV-3   13.8   18.0           Uterus   6.3   8.4           Placenta   0.0   0.0           Prostate   3.2   3.8           Prostate ca.* (bone met) PC-3   16.5   18.3           Testis   1.4   1.3           Melanoma Hs688(A).T   2.8   2.6           Melanoma* (met) Hs688(B).T   2.6   3.8           Melanoma UACC-62   10.9   11.2           Melanoma M14   8.6   5.8           Melanoma LOX IMVI   12.2   10.8           Melanoma* (met) SK-MEL-5   24.0   25.2           Adipose   6.1   6.4                                                
     [0764]               TABLE JE                          Panel 4D                         Tissue Name   A   B                                 Secondary Th1 act   5.6   7.3       Secondary Th2 act   6.8   6.0       Secondary Tr1 act   7.4   7.7       Secondary Th1 rest   6.4   6.7       Secondary Th2 rest   7.6   7.1       Secondary Tr1 rest   12.2   9.7       Primary Th1 act   12.7   14.5       Primary Th2 act   16.0   15.1       Primary Tr1 act   26.4   22.1       Primary Th1 rest   31.6   33.4       Primary Th2 rest   19.3   18.7       Primary Tr1 rest   14.7   16.5       CD45RA CD4 lymphocyte act   6.2   5.1       CD45RO CD4 lymphocyte act   11.2   12.3       CD8 lymphocyte act   11.6   10.8       Secondary CD8 lymphocyte rest   8.2   9.9       Secondary CD8 lymphocyte act   3.0   3.3       CD4 lymphocyte none   2.8   3.4       2ry Th1/Th2/Tr1_anti-CD95 CH11   7.3   7.4       LAK cells rest   7.1   6.7       LAK cells IL-2   14.7   17.0       LAK cells IL-2 + IL-12   6.9   7.0       LAK cells IL-2 + IFN gamma   12.8   11.0       LAK cells IL-2 + IL-18   6.7   9.0       LAK cells PMA/ionomycin   0.9   0.6       NK Cells IL-2 rest   7.2   6.5       Two Way MLR 3 day   6.3   6.8       Two Way MLR 5 day   3.5   3.0       Two Way MLR 7 day   4.2   4.5       PBMC rest   2.0   1.6       PBMC PWM   27.9   26.2       PBMC PHA-L   27.5   26.8       Ramos (B cell) none   16.8   16.0       Ramos (B cell) ionomycin   100.0   100.0       B lymphocytes PWM   36.6   22.8       B lymphocytes CD40L and IL-4   13.5   14.9       EOL-1 dbcAMP   14.5   15.5       EOL-1 dbcAMP PMA/ionomycin   7.1   6.3       Dendritic cells none   0.8   1.5       Dendritic cells LPS   0.1   0.2       Dendritic cells anti-CD40   0.9   0.7       Monocytes rest   0.1   0.0       Monocytes LPS   0.2   0.0       Macrophages rest   4.0   3.4       Macrophages LPS   0.5   0.4       HUVEC none   12.2   12.8       HUVEC starved   21.6   20.4       HUVEC IL-1beta   4.9   4.3       HUVEC IFN gamma   19.6   19.8       HUVEC TNF alpha + IFN gamma   7.8   8.9       HUVEC TNF alpha + IL4   6.1   7.9       HUVEC IL-11   10.4   11.8       Lung Microvascular EC none   7.5   9.8       Lung Microvascular EC TNF alpha + IL-1beta   5.5   6.1       Microvascular Dermal EC none   13.7   12.6       Microsvasular Dermal EC TNFalpha + IL-1beta   5.7   6.6       Bronchial epithelium TNFalpha + IL1beta   15.9   11.9       Small airway epithelium none   4.7   5.3       Small airway epithelium TNFalpha + IL-1beta   35.6   37.1       Coronery artery SMC rest   7.1   6.7       Coronery artery SMC TNFalpha + IL-1beta   4.6   5.9       Astrocytes rest   27.0   23.8       Astrocytes TNFalpha + IL-1beta   30.8   28.1       KU-812 (Basophil) rest   8.2   6.3       KU-812 (Basophil) PMA/ionomycin   22.5   19.9       CCD1106 (Keratinocytes) none   11.1   11.7       CCD1106 (Keratinocytes) TNFalpha + IL-1beta   6.8   6.3       Liver cirrhosis   3.0   3.0       Lupus kidney   6.5   6.2       NCI-H292 none   63.3   72.7       NCI-H292 IL-4   57.4   69.7       NCI-H292 IL-9   57.0   65.5       NCI-H292 IL-13   30.8   35.6       NCI-H292 IFN gamma   29.3   34.4       HPAEC none   10.8   11.7       HPAEC TNF alpha + IL-1 beta   6.9   6.4       Lung fibroblast none   16.8   17.4       Lung fibroblast TNF alpha + IL-1 beta   7.4   8.0       Lung fibroblast IL-4   30.6   34.6       Lung fibroblast IL-9   24.8   24.1       Lung fibroblast IL-13   19.6   21.8       Lung fibroblast IFN gamma   31.4   37.6       Dermal fibroblast CCD1070 rest   10.7   12.0       Dermal fibroblast CCD1070 TNF alpha   20.6   21.3       Dermal fibroblast CCD1070 IL-1 beta   6.5   5.9       Dermal fibroblast IFN gamma   10.1   11.3       Dermal fibroblast IL-4   23.0   23.2       IBD Colitis 2   2.0   2.3       IBD Crohn&#39;s   3.4   4.8       Colon   41.5   50.7       Lung   15.8   17.2       Thymus   57.8   55.5       Kidney   5.0   8.5                                    
     [0765]               TABLE JF                          Panel 5 Islet                             Tissue Name   A                                         97457_Patient-02go_adipose   19.6           97476_Patient-07sk_skeletal muscle   6.6           97477_Patient-07ut_uterus   31.6           97478_Patient-07pl_placenta   2.6           99167_Bayer Patient 1   32.5           97482_Patient-08ut_uterus   26.6           97483_Patient-08pl_placenta   1.2           97486_Patient-09sk_skeletal muscle   8.3           97487_Patient-09ut_uterus   47.6           97488_Patient-09pl_placenta   1.3           97492_Patient-10ut_uterus   28.3           97493_Patient-10pl_placenta   3.0           97495_Patient-11go_adipose   47.6           97496_Patient-11sk_skeletal muscle   35.1           97497_Patient-11ut_uterus   100.0           97498_Patient-11pl_placenta   0.4           97500_Patient-12go_adipose   17.3           97501_Patient-12sk_skeletal muscle   37.4           97502_Patient-12ut_uterus   76.3           97503_Patient-12pl_placenta   0.9           94721_Donor 2 U - A_Mesenchymal Stem Cells   15.2           94722_Donor 2 U - B_Mesenchymal Stem Cells   11.9           94723_Donor 2 U - C_Mesenchymal Stem Cells   9.7           94709_Donor 2 AM - A_adipose   8.3           94710_Donor 2 AM - B_adipose   8.1           94711_Donor 2 AM - C_adipose   5.0           94712_Donor 2 AD - A_adipose   17.6           94713_Donor 2 AD - B_adipose   29.5           94714_Donor 2 AD - C_adipose   25.7           94742_Donor 3 U - A_Mesenchymal Stem Cells   5.7           94743_Donor 3 U - B_Mesenchymal Stem Cells   5.1           94730_Donor 3 AM - A_adipose   8.7           94731_Donor 3 AM - B_adipose   4.4           94732_Donor 3 AM - C_adipose   3.4           94733_Donor 3 AD - A_adipose   9.9           94734_Donor 3 AD - B_adipose   4.4           94735_Donor 3 AD - C_adipose   4.6           77138_Liver_HepG2untreated   54.7           73556_Heart_Cardiac stromal cells (primary)   10.6           81735_Small Intestine   60.7           72409_Kidney_Proximal Convoluted Tubule   24.1           82685_Small intestine Duodenum   18.8           90650_Adrenal_Adrenocortical adenoma   3.8           72410_Kidney_HRCE   70.2           72411_Kidney_HRE   59.5           73139_Uterus_Uterine smooth muscle cells   8.7                                    
     [0766]               TABLE JG                          Panel CNS_1                             Tissue Name   A                                         BA4 Control   22.1           BA4 Control2   41.8           BA4 Alzheimer&#39;s2   5.2           BA4 Parkinson&#39;s   39.2           BA4 Parkinson&#39;s2   68.8           BA4 Huntington&#39;s   28.1           BA4 Huntington&#39;s2   13.9           BA4 PSP   9.9           BA4 PSP2   25.5           BA4 Depression   22.7           BA4 Depression2   6.7           BA7 Control   34.9           BA7 Control2   21.1           BA7 Alzheimer&#39;s2   6.2           BA7 Parkinson&#39;s   18.3           BA7 Parkinson&#39;s2   38.2           BA7 Huntington&#39;s   51.1           BA7 Huntington&#39;s2   38.7           BA7 PSP   44.4           BA7 PSP2   18.9           BA7 Depression   10.5           BA9 Control   27.9           BA9 Control2   83.5           BA9 Alzheimer&#39;s   4.7           BA9 Alzheimer&#39;s2   12.6           BA9 Parkinson&#39;s   22.5           BA9 Parkinson&#39;s2   45.4           BA9 Huntington&#39;s   39.2           BA9 Huntington&#39;s2   20.0           BA9 PSP   12.1           BA9 PSP2   3.9           BA9 Depression   8.5           BA9 Depression2   9.2           BA17 Control   25.3           BA17 Control2   34.6           BA17 Alzheimer&#39;s2   4.3           BA17 Parkinson&#39;s   20.0           BA17 Parkinson&#39;s2   28.3           BA17 Huntington&#39;s   24.1           BA17 Huntington&#39;s2   12.1           BA17 Depression   8.7           BA17 Depression2   16.6           BA17 PSP   22.4           BA17 PSP2   6.5           Sub Nigra Control   21.3           Sub Nigra Control2   18.3           Sub Nigra Alzheimer&#39;s2   7.2           Sub Nigra Parkinson&#39;s2   27.7           Sub Nigra Huntington&#39;s   25.5           Sub Nigra Huntington&#39;s2   13.6           Sub Nigra PSP2   3.4           Sub Nigra Depression   6.3           Sub Nigra Depression2   6.1           Glob Palladus Control   18.9           Glob Palladus Control2   19.9           Glob Palladus Alzheimer&#39;s   7.2           Glob Palladus Alzheimer&#39;s2   9.8           Glob Palladus Parkinson&#39;s   100.0           Glob Palladus Parkinson&#39;s2   20.9           Glob Palladus PSP   13.8           Glob Palladus PSP2   12.4           Glob Palladus Depression   7.5           Temp Pole Control   20.0           Temp Pole Control2   66.9           Temp Pole Alzheimer&#39;s   6.1           Temp Pole Alzheimer&#39;s2   6.6           Temp Pole Parkinson&#39;s   34.6           Temp Pole Parkinson&#39;s2   24.0           Temp Pole Huntington&#39;s   33.4           Temp Pole PSP   8.4           Temp Pole PSP2   6.4           Temp Pole Depression2   6.7           Cing Gyr Control   53.6           Cing Gyr Control2   34.6           Cing Gyr Alzheimer&#39;s   15.9           Cing Gyr Alzheimer&#39;s2   12.2           Cing Gyr Parkinson&#39;s   24.5           Cing Gyr Parkinson&#39;s2   30.8           Cing Gyr Huntington&#39;s   48.0           Cing Gyr Huntington&#39;s2   16.4           Cing Gyr PSP   15.2           Cing Gyr PSP2   6.0           Cing Gyr Depression   7.3           Cing Gyr Depression2   11.7                                    
     [0767] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing both Ag2896/Ag2920 indicates this gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its gene product, or treatment with specific agonists for this receptor may be of use in treating dementia/memory loss associated with this disease and neuronal death.  
     [0768] Panel 1.3D Summary: Ag2896/Ag2920 Two experiments produce results that are in excellent agreement, with highest expression of this gene in the brain cerebral cortex (CTs=26). High expression of this gene is seen mainly in all the regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This gene encodes a Ca binding transporter. Ca++ is critical for synaptic vesicle release (Kovacs I, Szarics E, Nyitrai G, Blandl T, Kardos J. Matching kinetics of synaptic vesicle recycling and enhanced neurotransmitter influx by Ca2+ in brain plasma membrane vesicles. Neurochem Int November 1998;33(5):399-405). Thus, this gene would be an excellent small molecule target for diseases resulting from altered/inappropriate synaptic transmission such as epilepsy, schizophrenia, bipolar disorder, depression, and mania.  
     [0769] This gene also has moderate levels of expression adult and fetal heart, skeletal muscle and liver, and adipose. This gene product is homologous to a mitochondrial calcium-dependent transporter. Since intracellular calcium homeostasis is critically important for energy metabolism and signal transduction, modulation of this gene product may therefore be a therapeutic for metabolic and endocrine diseases.  
     [0770] Panel 4D Summary: Ag2896/Ag2920 Two experiments show moderate to low expression of this gene across a wide range of cells of this panel including epithelium, fibroblasts, and endothelial cells. Lower but still significant levels of expression are also seen in the key players of innate and adaptive immunity: monocytes/macrophages, T and B cells. However, the expression of this transcript is highest in the B lymphoma cell line, and NCI H292, a mucoepidermoid cell line (CTs=26.4-27). Thus, inhibition of the function of the protein encoded by this transcript with a small molecule drug, could lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, COPD, emphysema, psoriasis, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis.  
     [0771] Panel 5 Islet Summary: Ag2896 This gene shows widespread expression in this panel with highest expression seen in uterus from a non-diabetic patient (CT=28.8). Significant expression of this gene is seen in adipose, skeletal muscle, uterus, kidney, small intestine and a liver cancer cell line, which is in agreement with expression seen in panel 1.3D. Please see panel 1.3D for further discussion on the role of this gene.  
     [0772] Panel CNS — 1 Summary: Ag2896 This expression profile confirms the presence of this gene in the brain.  
     [0773] K CG56829-01: Human Testis Specific Serine Kinase-3  
     [0774] Expression of gene CG56829-01 was assessed using the primer-probe sets Ag1301b, Ag1415 and Ag3031, described in Tables KA, KB and KC. Results of the RTQ-PCR runs are shown in Tables KD, KE, KF and KG.  
                   TABLE KA                          Probe Name Ag1301b                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-aaaaggtgatgtctggagcat-3′   21   616   131           Probe   TET-5′-tgtatgtcatgctctgtgccagccta-3′-TAMRA   26   648   132       Reverse   5′-gatgtctgtgtcgtcaaaagg-3′   21   674   133                  
 
     [0775]                   TABLE KB                          Probe Name Ag1415                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-aaaaggtgatgtctggagcat-3′   21   616   134           Probe   TET-5′-tgtatgtcatgctctgtgccagccta-3′-TAMRA   26   648   135       Reverse   5′-gatgtctgtgtcgtcaaaagg-3′   21   674   136                    
     [0776]                   TABLE KC                          Probe Name Ag3031                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-aaaaggtgatgtctggagcat-3′   21   616   137           Probe   TET-5′-tgtatgtcatgctctgtgccagccta-3′-TAMRA   26   648   138       Reverse   5′-gatgtctgtgtcgtcaaaagg-3′   21   674   139                    
     [0777]               TABLE KD                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   23.8   46.7           AD 2 Hippo   21.2   21.9           AD 3 Hippo   14.2   11.6           AD 4 Hippo   7.4   10.5           AD 5 hippo   94.0   94.0           AD 6 Hippo   53.6   61.6           Control 2 Hippo   12.7   17.0           Control 4 Hippo   14.6   15.2           Control (Path) 3 Hippo   22.2   7.2           AD 1 Temporal Ctx   42.3   42.9           AD 2 Temporal Ctx   78.5   29.9           AD 3 Temporal Ctx   17.9   20.4           AD 4 Temporal Ctx   30.1   31.2           AD 5 Inf Temporal Ctx   100.0   94.6           AD 5 Sup Temporal Ctx   59.9   52.5           AD 6 Inf Temporal Ctx   75.3   95.9           AD 6 Sup Temporal Ctx   94.6   100.0           Control 1 Temporal Ctx   8.5   7.3           Control 2 Temporal Ctx   16.3   18.8           Control 3 Temporal Ctx   13.0   15.3           Control 4 Temporal Ctx   12.8   16.6           Control (Path) 1 Temporal Ctx   26.8   31.0           Control (Path) 2 Temporal Ctx   25.5   17.8           Control (Path) 3 Temporal Ctx   6.0   10.2           Control (Path) 4 Temporal Ctx   26.4   28.1           AD 1 Occipital Ctx   31.9   41.8           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   17.9   17.4           AD 4 Occipital Ctx   12.9   17.3           AD 5 Occipital Ctx   35.1   20.9           AD 6 Occipital Ctx   20.9   27.5           Control 1 Occipital Ctx   4.9   4.9           Control 2 Occipital Ctx   46.7   32.1           Control 3 Occipital Ctx   17.8   19.2           Control 4 Occipital Ctx   13.2   12.1           Control (Path) 1 Occipital Ctx   49.3   59.9           Control (Path) 2 Occipital Ctx   13.6   8.8           Control (Path) 3 Occipital Ctx   6.1   4.7           Control (Path) 4 Occipital Ctx   31.2   21.2           Control 1 Parietal Ctx   10.3   11.1           Control 2 Parietal Ctx   56.6   60.7           Control 3 Parietal Ctx   15.4   15.0           Control (Path) 1 Parietal Ctx   34.2   41.8           Control (Path) 2 Parietal Ctx   15.4   20.3           Control (Path) 3 Parietal Ctx   8.4   7.0           Control (Path) 4 Parietal Ctx   44.1   31.6                                                
     [0778]               TABLE KE                          Panel 1.3D                                 Tissue Name   A   B                                             Liver adenocarcinoma   18.4   32.3           Pancreas   4.7   11.9           Pancreatic ca. CAPAN 2   4.9   4.9           Adrenal gland   23.0   11.0           Thyroid   7.1   8.5           Salivary gland   10.1   13.7           Pituitary gland   18.2   9.2           Brain (fetal)   24.0   42.3           Brain (whole)   43.8   19.6           Brain (amygdala)   20.4   9.6           Brain (cerebellum)   50.7   50.3           Brain (hippocampus)   18.7   8.1           Brain (substantia nigra)   8.4   8.9           Brain (thalamus)   20.0   10.6           Cerebral Cortex   5.3   7.2           Spinal cord   9.6   7.0           glio/astro U87-MG   12.1   16.5           glio/astro U-118-MG   15.5   13.4           astrocytoma SW1783   6.9   11.1           neuro*; met SK-N-AS   11.4   10.9           astrocytoma SF-539   12.5   25.5           astrocytoma SNB-75   10.9   18.9           glioma SNB-19   32.1   25.3           glioma U251   100.0   100.0           glioma SF-295   18.4   46.0           Heart (fetal)   2.3   6.2           Heart   8.4   8.2           Skeletal muscle (fetal)   6.3   24.1           Skeletal muscle   20.2   7.9           Bone marrow   21.8   25.2           Thymus   18.2   38.4           Spleen   26.6   14.0           Lymph node   42.6   23.7           Colorectal   16.8   16.8           Stomach   37.4   5.9           Small intestine   36.6   14.2           Colon ca. SW480   3.7   4.5           Colon ca.* SW620 (SW480 met)   3.8   24.0           Colon ca. HT29   1.6   4.6           Colon ca. HCT-116   3.0   9.9           Colon ca. CaCo-2   2.1   5.1           Colon ca. tissue (ODO3866)   5.4   3.6           Colon ca. HCC-2998   6.2   15.6           Gastric ca.* (liver met) NCI-N87   20.0   13.3           Bladder   8.4   12.2           Trachea   13.6   6.4           Kidney   10.4   23.8           Kidney (fetal)   10.7   66.0           Renal ca. 786-0   15.3   25.5           Renal ca. A498   11.9   12.5           Renal ca. RXF 393   14.9   18.0           Renal ca. ACHN   8.0   10.5           Renal ca. UO-31   6.0   1.1           Renal ca. TK-10   7.4   18.6           Liver   11.9   17.8           Liver (fetal)   20.6   14.7           Liver ca. (hepatoblast) HepG2   22.2   28.7           Lung   17.0   22.8           Lung (fetal)   10.4   26.4           Lung ca. (small cell) LX-1   9.1   17.4           Lung ca. (small cell) NCI-H69   1.5   4.0           Lung ca. (s. cell var.) SHP-77   18.4   57.4           Lung ca. (large cell) NCI-H460   50.3   4.2           Lung ca. (non-sm. cell) A549   8.0   28.1           Lung ca. (non-s. cell) NCI-H23   10.2   18.2           Lung ca. (non-s. cell) HOP-62   20.3   33.0           Lung ca. (non-s. cl) NCI-H522   9.7   23.5           Lung ca. (squam.) SW 900   4.0   8.5           Lung ca. (squam.) NCI-H596   1.6   4.8           Mammary gland   36.9   22.5           Breast ca.* (pl. ef) MCF-7   5.4   6.7           Breast ca.* (pl. ef) MDA-MB-231   16.7   7.9           Breast ca.* (pl. ef) T47D   13.2   46.7           Breast ca. BT-549   9.9   6.6           Breast ca. MDA-N   1.6   11.9           Ovary   3.0   5.1           Ovarian ca. OVCAR-3   5.1   12.0           Ovarian ca. OVCAR-4   4.7   8.8           Ovarian ca. OVCAR-5   8.3   42.3           Ovarian ca. OVCAR-8   2.8   0.9           Ovarian ca. IGROV-1   2.6   11.7           Ovarian ca.* (ascites) SK-OV-3   10.0   29.9           Uterus   38.4   17.4           Placenta   11.1   9.4           Prostate   18.6   8.5           Prostate ca.* (bone met) PC-3   6.9   14.1           Testis   45.1   26.6           Melanoma Hs688(A).T   0.8   1.2           Melanoma* (met) Hs688(B).T   3.8   3.4           Melanoma UACC-62   4.6   8.0           Melanoma M14   28.5   9.9           Melanoma LOX IMVI   0.7   8.1           Melanoma* (met) SK-MEL-5   2.2   2.9           Adipose   8.1   12.3                                                
     [0779]               TABLE KF                          Panel 2.2                             Tissue Name   A                                         Normal Colon   39.2           Colon cancer (OD06064)   6.3           Colon Margin (OD06064)   13.0           Colon cancer (OD06159)   0.0           Colon Margin (OD06159)   27.0           Colon cancer (OD06297-04)   2.5           Colon Margin (OD06297-05)   39.8           CC Gr.2 ascend colon (ODO3921)   3.8           CC Margin (ODO3921)   4.4           Colon cancer metastasis (OD06104)   14.3           Lung Margin (OD06104)   17.2           Colon mets to lung (OD04451-01)   0.0           Lung Margin (OD04451-02)   10.2           Normal Prostate   30.6           Prostate Cancer (OD04410)   7.6           Prostate Margin (OD04410)   25.5           Normal Ovary   25.0           Ovarian cancer (OD06283-03)   8.1           Ovarian Margin (OD06283-07)   34.4           Ovarian Cancer 064008   46.3           Ovarian cancer (OD06145)   34.4           Ovarian Margin (OD06145)   52.9           Ovarian cancer (OD06455-03)   11.6           Ovarian Margin (OD06455-07)   18.8           Normal Lung   22.8           Invasive poor diff. lung adeno (ODO4945-01   18.7           Lung Margin (ODO4945-03)   13.9           Lung Malignant Cancer (OD03126)   11.7           Lung Margin (OD03126)   12.2           Lung Cancer (OD05014A)   9.0           Lung Margin (OD05014B)   35.4           Lung cancer (OD06081)   23.7           Lung Margin (OD06081)   27.9           Lung Cancer (OD04237-01)   13.3           Lung Margin (OD04237-02)   28.5           Ocular Melanoma Metastasis   11.5           Ocular Melanoma Margin (Liver)   27.0           Melanoma Metastasis   21.6           Melanoma Margin (Lung)   14.7           Normal Kidney   17.8           Kidney Ca, Nuclear grade 2 (OD04338)   50.3           Kidney Margin (OD04338)   24.3           Kidney Ca Nuclear grade 1/2 (OD04339)   62.0           Kidney Margin (OD04339)   16.3           Kidney Ca, Clear cell type (OD04340)   7.3           Kidney Margin (OD04340)   10.7           Kidney Ca, Nuclear grade 3 (OD04348)   4.6           Kidney Margin (OD04348)   79.0           Kidney malignant cancer (OD06204B)   6.0           Kidney normal adjacent tissue (OD06204E)   15.4           Kidney Cancer (OD04450-01)   24.5           Kidney Margin (OD04450-03)   23.7           Kidney Cancer 8120613   3.0           Kidney Margin 8120614   38.2           Kidney Cancer 9010320   8.0           Kidney Margin 9010321   10.8           Kidney Cancer 8120607   15.2           Kidney Margin 8120608   3.8           Normal Uterus   33.7           Uterine Cancer 064011   33.9           Normal Thyroid   2.9           Thyroid Cancer 064010   4.4           Thyroid Cancer A302152   29.9           Thyroid Margin A302153   7.3           Normal Breast   37.6           Breast Cancer (OD04566)   21.6           Breast Cancer 1024   100.0           Breast Cancer (OD04590-01)   25.2           Breast Cancer Mets (OD04590-03)   35.6           Breast Cancer Metastasis (OD04655-05)   45.1           Breast Cancer 064006   21.2           Breast Cancer 9100266   26.6           Breast Margin 9100265   19.3           Breast Cancer A209073   6.1           Breast Margin A2090734   35.8           Breast cancer (OD06083)   49.3           Breast cancer node metastasis (OD06083)   25.9           Normal Liver   36.3           Liver Cancer 1026   2.5           Liver Cancer 1025   45.7           Liver Cancer 6004-T   30.1           Liver Tissue 6004-N   27.7           Liver Cancer 6005-T   6.7           Liver Tissue 6005-N   17.4           Liver Cancer 064003   32.3           Normal Bladder   13.2           Bladder Cancer 1023   23.0           Bladder Cancer A302173   20.0           Normal Stomach   89.5           Gastric Cancer 9060397   5.7           Stomach Margin 9060396   17.7           Gastric Cancer 9060395   19.6           Stomach Margin 9060394   42.6           Gastric Cancer 064005   7.5                                    
     [0780]               TABLE KG                          Panel 4D                             Tissue Name   A   B   C                                     Secondary Th1 act   17.0   25.3   13.8       Secondary Th2 act   22.7   18.9   20.0       Secondary Tr1 act   32.3   26.4   20.0       Secondary Th1 rest   22.2   20.3   12.0       Secondary Th2 rest   42.6   37.9   21.0       Secondary Tr1 rest   27.9   27.5   26.8       Primary Th1 act   33.4   29.9   19.1       Primary Th2 act   28.1   41.2   13.3       Primary Tr1 act   49.0   52.5   20.9       Primary Th1 rest   80.7   87.1   80.7       Primary Th2 rest   67.4   68.8   64.2       Primary Tr1 rest   46.0   50.3   54.7       CD45RA CD4 lymphocyte act   12.9   8.0   16.5       CD45RO CD4 lymphocyte act   33.4   44.8   22.4       CD8 lymphocyte act   22.8   23.0   18.4       Secondary CD8 lymphocyte rest   22.2   25.5   25.0       Secondary CD8 lymphocyte act   19.3   21.8   22.5       CD4 lymphocyte none   41.5   42.3   34.6       2ry Th1/Th2/Tr1_anti-CD95 CH11   65.1   54.7   41.2       LAK cells rest   28.7   37.1   32.3       LAK cells IL-2   38.7   49.0   36.3       LAK cells IL-2 + IL-12   26.8   27.4   26.8       LAK cells IL-2 + IFN gamma   43.5   45.4   42.9       LAK cells IL-2 + IL-18   26.2   25.2   35.6       LAK cells PMA/ionomycin   8.3   8.6   3.3       NK Cells IL-2 rest   28.7   35.8   32.8       Two Way MLR 3 day   42.3   49.0   46.3       Two Way MLR 5 day   17.9   16.2   13.5       Two Way MLR 7 day   14.7   12.6   14.4       PBMC rest   21.9   29.9   19.2       PBMC PWM   66.9   53.2   50.3       PBMC PHA-L   35.6   46.7   23.3       Ramos (B cell) none   23.5   33.2   16.5       Ramos (B cell) ionomycin   53.2   53.2   49.3       B lymphocytes PWM   29.9   36.3   34.2       B lymphocytes CD40L and IL-4   33.2   36.6   35.8       EOL-1 dbcAMP   18.9   14.8   12.8       EOL-1 dbcAMP   30.4   29.1   25.5       PMA/ionomycin       Dendritic cells none   14.9   10.0   13.7       Dendritic cells LPS   15.7   5.8   8.7       Dendritic cells anti-CD40   12.7   17.7   15.2       Monocytes rest   35.6   27.5   36.6       Monocytes LPS   34.6   43.8   25.0       Macrophages rest   19.2   16.6   17.2       Macrophages LPS   17.9   16.2   6.7       HUVEC none   9.8   13.2   17.3       HUVEC starved   27.2   27.5   28.3       HUVEC IL-1beta   11.5   13.0   11.3       HUVEC IFN gamma   28.3   24.7   20.2       HUVEC TNF alpha + IFN gamma   3.2   6.6   12.3       HUVEC TNF alpha + IL4   11.7   9.7   9.7       HUVEC IL- 11   10.1   8.2   11.6       Lung Microvascular EC none   33.9   28.7   25.2       Lung Microvascular EC TNFalpha + IL-   23.2   19.1   24.8       1beta       Microvascular Dermal EC none   41.8   45.1   25.7       Microsvasular Dermal EC TNFalpha +   27.5   40.3   22.4       IL-1beta       Bronchial epithelium TNFalpha +   20.3   32.3   22.1       IL1beta       Small airway epithelium none   7.3   3.3   4.8       Small airway epithelium TNFalpha +   34.4   35.1   26.8       IL-1beta       Coronery artery SMC rest   7.9   7.9   12.3       Coronery artery SMC TNFalpha + IL-   7.6   10.7   8.1       1beta       Astrocytes rest   7.9   10.3   12.7       Astrocytes TNFalpha + IL-1beta   8.7   5.8   13.3       KU-812 (Basophil) rest   40.1   35.4   48.0       KU-812 (Basophil) PMA/ionomycin   57.8   61.1   78.5       CCD1106 (Keratinocytes) none   3.8   8.0   6.6       CCD1106 (Keratinocytes) TNFalpha +   27.4   24.5   5.3       IL-1beta       Liver cirrhosis   17.0   9.4   5.0       Lupus kidney   24.1   23.8   9.5       NCI-H292 none   38.7   49.3   45.4       NCI-H292 IL-4   58.6   51.4   46.7       NCI-H292 IL-9   56.3   46.0   54.3       NCI-H292 IL-13   30.4   31.9   23.3       NCI-H292 IFN gamma   16.7   28.3   29.1       HPAEC none   15.7   26.4   19.1       HPAEC TNF alpha + IL-1 beta   23.8   32.5   27.9       Lung fibroblast none   13.0   11.0   11.9       Lung fibroblast TNF alpha + IL-1   8.7   7.2   13.2       beta       Lung fibroblast IL-4   5.6   12.0   10.5       Lung fibroblast IL-9   8.5   7.4   15.3       Lung fibroblast IL-13   20.3   16.3   8.9       Lung fibroblast IFN gamma   11.1   10.4   13.0       Dermal fibroblast CCD1070 rest   47.0   11.3   13.8       Dermal fibroblast CCD1070 TNF alpha   45.7   53.6   55.1       Dermal fibroblast CCD1070 IL-1 beta   16.8   17.3   15.4       Dermal fibroblast IFN gamma   5.8   8.8   6.5       Dermal fibroblast IL-4   17.6   20.0   13.6       IBD Colitis 2   2.0   1.3   1.1       IBD Crohn&#39;s   3.0   1.4   1.4       Colon   33.0   26.2   34.6       Lung   6.8   13.5   7.5       Thymus   100.0   100.0   55.5       Kidney   87.1   79.0   100.0                                            
     [0781] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3031 in two experiments with the same probe and primer set produce results that are in excellent agreement. This gene, a kinase homolog, is upregulated in the temporal cortex of brains from Alzheimer&#39;s disease patients compared to th expression in temporal cortex of normal brains. Kinases have been shown to play a role in the pathogenesis of Alzheimer&#39;s disease (Morishima Y, et al. J Neurosci Oct. 1, 2001;21(19):7551-60). The dysregulation of this kinase, CG56829-01, indicates an active role for this pathway in disease pathogenesis. Thus, inhibitors of this gene or the kinase encoded by this gene may have utility in the treatment of Alzheimer&#39;s disease and other neurodegenerative diseases.  
     [0782] Panel 1.3D Summary: Ag1301b/Ag3031 Two experiments with the same probe and primer set produce results that are in excellent agreement, with highest expression of the CG56829-01 gene in a brain cancer cell line (CTs=29-30). Overall, this gene is expressed at moderate to low levels in all the samples in this panel.  
     [0783] This gene has low to moderate expression in several endocrine/metabolic-related tissues, including adipose, pancreas, liver, skeletal muscle and thyroid. Thus, a therapeutic modulator to this gene and/or gene-product may be useful in the treatment of diseases which affect the endocrine system.  
     [0784] Panel 2.2 Summary: Ag1301b The CG56829-01 gene is expressed in breast cancer at a moderate level. It is also expressed at a higher level in normal gastric, prostate and colon tissues compared to the adjacent tumors. Hence, inhibition of this drug might be used for treatment of breast cancer. It could also be used as a diagnostic marker for gastric, prostate and colon cancers.  
     [0785] Panel 4D Summary: Ag1301b/Ag1415/Ag3031 Three experiments with the same probe and primer sets produce results that are in excellent agreement, with highest expression of the CG56829-01 gene in the thymus and kidney. This gene is also expressed at higher levels in resting Th1and Th2 lymphocytes than in activated Th1and Th2 lymphocytes. Therefore, modulation of the gene product with small molecule compounds and biomolecules may be useful as therapeutics to reduce the activation of Th1 and Th2 cells and thus reduce symptoms in patients with autoimmune and inflammatory diseases, such as Crohn&#39;s disease, ulcerative colitis, multiple sclerosis, chronic obstructive pulmonary disease, asthma, emphysema, rheumatoid arthritis, lupus erythematosus, or psoriasis.  
     [0786] L. CG57183-01: Fibroblast Growth Factor Receptor  
     [0787] Expression of gene CG57183-01 was assessed using the primer-probe sets Ag4039, Ag4040 and Ag4045, described in Tables LA, LB and LC. Results of the RTQ-PCR runs are shown in Tables LD, LE, LF, LG, LH, LI, LJ and LK.  
                   TABLE LA                          Probe Name Ag4039                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-cctacgttaccgtgctcaag-3′   20   950   140           Probe   TET-5′-cgctaacaccaccgacaaggagctag-3′-TAMRA   26   978   141       Reverse   5′-gacgttgtgcaaggagagaac-3′   21   1006   142                  
 
     [0788]                   TABLE LB                          Probe Name Ag4040                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-cctacgttaccgtgctcaag-3′   20   950   143           Probe   TET-5′-cgctaacaccaccgacaaggagctag-3′-TAMRA   26   978   144       Reverse   5′-gacgttgtgcaaggagagaac-3′   21   1006   145                    
     [0789]                   TABLE LC                          Probe Name Ag4045                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-tcaccgtagccgtgaagat-3′   19   1547   146           Probe   TET-5′-aaagacgatgccactgacaaggacct-3′-TAMRA   26   1570   147       Reverse   5′-ttcatcatctccatctcagaca-3′   22   1607   148                    
     [0790]               TABLE LD                          A1.05 chondrosarcoma                                 Tissue Name   A   B                                             138353_PMA (18 hrs)   17.9   5.6           138352_IL-1beta + Oncostatin M (18 hrs)   27.4   2.4           138351_IL-1beta + TNFa (18 hrs)   12.5   0.4           138350_IL-1beta (18 hrs)   1.0   11.8           138354_Untreated-complete medium (18 hrs)   15.0   6.3           138347_PMA (6 hrs)   54.0   73.2           138346_IL-1beta + Oncostatin M (6 hrs)   43.5   50.0           138345_IL-1beta + TNFa (6 hrs)   42.3   30.8           138344_IL-1beta (6 hrs)   51.1   22.5           138348_Untreated-complete medium (6 hrs)   41.8   54.7           138349_Untreated-serum starved (6 hrs)   100.0   100.0                                                
     [0791]               TABLE LE                          A1_comprehensive panel_v1.0                             Tissue Name   A   B   C                                     110967 COPD-F   0.0   0.0   0.0       110980 COPD-F   0.6   0.0   0.6       110968 COPD-M   0.7   1.5   0.2       110977 COPD-M   2.1   0.0   0.4       110989 Emphysema-F   1.0   2.4   1.8       110992 Emphysema-F   1.3   0.9   0.7       110993 Emphysema-F   0.4   0.6   0.3       110994 Emphysema-F   0.4   0.2   0.0       110995 Emphysema-F   0.0   1.8   2.3       110996 Emphysema-F   0.0   0.5   0.4       110997 Asthma-M   0.2   0.0   1.7       111001 Asthma-F   1.2   0.8   0.8       111002 Asthma-F   1.1   3.4   1.6       111003 Atopic Asthma-F   2.0   1.0   2.6       111004 Atopic Asthma-F   2.6   2.3   10.3       111005 Atopic Asthma-F   1.0   1.0   9.9       111006 Atopic Asthma-F   1.1   0.0   0.6       111417 Allergy-M   0.0   0.5   3.3       112347 Allergy-M   0.0   0.0   0.0       112349 Normal Lung-F   0.0   0.0   0.0       112357 Normal Lung-F   0.1   0.6   1.2       112354 Normal Lung-M   0.4   0.0   0.0       112374 Crohns-F   0.0   0.5   0.9       112389 Match Control Crohns-F   0.5   0.6   61.6       112375 Crohns-F   1.6   1.1   1.0       112732 Match Control Crohns-F   1.6   0.7   49.0       112725 Crohns-M   0.0   0.4   0.0       112387 Match Control Crohns-M   0.8   1.3   0.4       112378 Crohns-M   0.0   0.0   0.0       112390 Match Control Crohns-M   0.1   1.4   1.4       112726 Crohns-M   1.5   1.8   4.2       112731 Match Control Crohns-M   0.2   1.4   3.6       112380 Ulcer Col-F   2.5   1.2   5.8       112734 Match Control Ulcer Col-F   1.6   2.1   62.4       112384 Ulcer Col-F   1.4   1.8   1.0       112737 Match Control Ulcer Col-F   1.1   1.1   1.5       112386 Ulcer Col-F   0.0   0.2   1.0       112738 Match Control Ulcer Col-F   0.5   1.2   4.5       112381 Ulcer Col-M   0.0   0.0   0.0       112735 Match Control Ulcer Col-M   0.0   0.5   0.1       112382 Ulcer Col-M   0.1   0.0   19.1       112394 Match Control Ulcer Col-M   0.4   0.0   0.1       112383 Ulcer Col-M   2.3   2.9   3.6       112736 Match Control Ulcer Col-M   0.2   0.2   19.2       112423 Psoriasis-F   0.0   0.0   0.2       112427 Match Control Psoriasis-F   1.9   2.8   1.4       112418 Psoriasis-M   0.2   0.0   0.1       112723 Match Control Psoriasis-M   0.5   0.0   0.7       112419 Psoriasis-M   0.0   0.5   0.1       112424 Match Control Psoriasis-M   0.5   0.6   0.0       112420 Psoriasis-M   1.4   2.0   1.9       112425 Match Control Psoriasis-M   2.4   1.1   1.5       104689 (MF) OA Bone-Backus   52.5   63.7   65.1       104690 (MF) Adj “Normal” Bone-Backus   14.1   18.3   23.8       104691 (MF) OA Synovium-Backus   0.3   1.1   0.9       104692 (BA) OA Cartilage-Backus   100.0   83.5   94.0       104694 (BA) OA Bone-Backus   83.5   100.0   100.0       104695 (BA) Adj “Normal” Bone-Backus   55.9   58.6   51.4       104696 (BA) OA Synovium-Backus   2.1   1.7   0.9       104700 (SS) OA Bone-Backus   22.2   27.7   34.9       104701 (SS) Adj “Normal” Bone-Backus   42.0   47.3   57.0       104702 (SS) OA Synovium-Backus   5.8   2.8   5.9       117093 OA Cartilage Rep7   0.0   1.6   1.1       112672 OA Bone5   1.0   1.3   2.4       112673 OA Synovium5   0.0   0.0   0.9       112674 OA Synovial Fluid cells5   0.0   0.3   0.3       117100 OA Cartilage Rep14   0.5   0.5   0.4       112756 OA Bone9   1.1   1.5   3.1       112757 OA Synovium9   0.8   0.8   0.0       112758 OA Synovial Fluid Cells9   0.0   0.9   0.3       117125 RA Cartilage Rep2   0.3   0.4   0.8       113492 Bone2 RA   1.0   4.8   11.6       113493 Synovium2 RA   1.0   0.8   3.8       113494 Syn Fluid Cells RA   2.7   1.5   7.5       113499 Cartilage4 RA   1.1   2.0   3.8       113500 Bone4 RA   0.7   0.0   5.6       113501 Synovium4 RA   0.0   1.1   3.9       113502 Syn Fluid Cells4 RA   0.3   0.1   3.4       113495 Cartilage3 RA   1.1   2.5   8.3       113496 Bone3 RA   2.2   1.4   9.3       113497 Synovium3 RA   1.5   0.7   3.8       113498 Syn Fluid Cells3 RA   4.2   0.6   10.1       117106 Normal Cartilage Rep20   0.0   0.7   2.0       113663 Bone3 Normal   0.0   0.0   0.0       113664 Synovium3 Normal   0.0   0.0   0.0       113665 Syn Fluid Cells3 Normal   0.0   0.0   0.0       117107 Normal Cartilage Rep22   0.4   0.0   0.0       113667 Bone4 Normal   0.0   0.4   0.5       113668 Synovium4 Normal   0.5   0.2   0.1       113669 Syn Fluid Cells4 Normal   0.5   0.6   0.0                                            
     [0792]               TABLE KG                          Panel 4D                                 Tissue Name   A   B   C   D                                         AD 1 Hippo   25.2   31.6   23.8   19.8       AD 2 Hippo   61.1   98.6   64.6   58.6       AD 3 Hippo   9.9   9.7   11.7   23.8       AD 4 Hippo   34.6   26.8   33.0   39.5       AD 5 hippo   47.3   48.0   33.9   53.2       AD 6 Hippo   50.3   60.7   42.0   57.4       Control 2 Hippo   38.7   41.2   39.0   41.2       Control 4 Hippo   60.3   58.6   64.6   82.4       Control (Path) 3 Hippo   24.0   20.7   13.0   18.2       AD 1 Temporal Ctx   19.2   23.5   21.3   30.6       AD 2 Temporal Ctx   57.4   52.1   52.1   41.5       AD 3 Temporal Ctx   10.2   11.3   10.0   12.8       AD 4 Temporal Ctx   39.0   47.3   44.4   36.9       AD 5 Inf Temporal Ctx   52.1   52.5   45.7   45.4       AD 5 Sup Temporal Ctx   42.0   52.9   33.9   58.2       AD 6 Inf Temporal Ctx   36.6   40.9   40.9   34.2       AD 6 Sup Temporal Ctx   33.2   48.6   35.6   31.6       Control 1 Temporal Ctx   37.9   31.4   33.0   32.5       Control 2 Temporal Ctx   52.1   52.9   46.3   39.8       Control 3 Temporal Ctx   34.2   33.4   32.8   33.7       Control 4 Temporal Ctx   44.4   50.7   40.9   46.0       Control (Path) 1 Temporal Ctx   70.7   77.4   61.6   66.4       Control (Path) 2 Temporal Ctx   41.2   72.2   46.0   57.0       Control (Path) 3 Temporal Ctx   20.4   27.9   26.8   26.8       Control (Path) 4 Temporal Ctx   58.2   76.8   50.3   66.4       AD 1 Occipital Ctx   23.0   24.5   13.0   20.3       AD 2 Occipital Ctx (Missing)   0.0   0.0   0.0   0.0       AD 3 Occipital Ctx   12.6   20.3   13.2   15.6       AD 4 Occipital Ctx   35.1   39.2   27.4   37.1       AD 5 Occipital Ctx   26.6   42.3   16.2   31.9       AD 6 Occipital Ctx   36.3   28.1   30.4   40.1       Control 1 Occipital Ctx   26.4   34.2   28.9   24.0       Control 2 Occipital Ctx   52.9   57.4   60.3   73.7       Control 3 Occipital Ctx   36.9   55.9   46.7   46.3       Control 4 Occipital Ctx   35.4   34.9   35.1   36.6       Control (Path) 1 Occipital Ctx   100.0   92.0   100.0   100.0       Control (Path) 2 Occipital Ctx   25.7   27.0   25.0   28.7       Control (Path) 3 Occipital Ctx   19.5   23.5   17.1   18.9       Control (Path) 4 Occipital Ctx   31.9   42.3   23.3   48.6       Control 1 Parietal Ctx   35.6   37.4   31.6   33.9       Control 2 Parietal Ctx   30.6   58.6   31.0   51.4       Control 3 Parietal Ctx   35.8   42.0   30.8   26.4       Control (Path) 1 Parietal Ctx   79.6   100.0   67.4   73.7       Control (Path) 2 Parietal Ctx   41.2   50.7   43.2   58.6       Control (Path) 3 Parietal Ctx   24.8   32.3   19.9   31.6       Control (Path) 4 Parietal Ctx   76.8   90.8   49.7   85.9                                                    
     [0793]               TABLE LG                          General_screening_panel_v1.4                                     Tissue Name   A   B   C                                                 Adipose   1.3   0.7   0.9           Melanoma* Hs688(A).T   0.2   0.8   0.2           Melanoma* Hs688(B).T   1.0   1.4   0.7           Melanoma* M14   0.2   0.2   0.0           Melanoma* LOXIMVI   0.5   1.3   0.4           Melanoma* SK-MEL-5   1.5   1.5   1.8           Squamous cell carcinoma   0.1   0.1   16.3           SCC-4           Testis Pool   7.0   5.4   4.0           Prostate ca.*   0.0   0.0   0.0           (bone met) PC-3           Prostate Pool   1.5   1.2   4.9           Placenta   7.7   5.7   4.5           Uterus Pool   0.4   0.0   1.0           Ovarian ca. OVCAR-3   0.0   0.0   6.0           Ovarian ca. SK-OV-3   6.8   6.5   8.7           Ovarian ca. OVCAR-4   0.0   0.0   3.1           Ovarian ca. OVCAR-5   18.4   17.8   42.9           Ovarian ca. IGROV-1   42.0   22.8   14.6           Ovarian ca. OVCAR-8   26.2   26.4   13.9           Ovary   0.0   0.2   0.6           Breast ca. MCF-7   0.0   0.0   1.4           Breast ca. MDA-MB-231   4.0   1.7   1.6           Breast ca. BT 549   2.0   1.8   1.8           Breast ca. T47D   48.3   47.0   100.0           Breast ca. MDA-N   0.0   0.0   0.0           Breast Pool   0.3   0.3   1.1           Trachea   6.8   4.2   17.8           Lung   0.0   0.1   0.0           Fetal Lung   12.6   10.3   31.4           Lung ca. NCI-N417   0.7   0.3   0.3           Lung ca. LX-1   0.2   0.3   12.9           Lung ca. NCI-H146   0.0   0.0   0.2           Lung ca. SHP-77   0.0   0.0   0.0           Lung ca. A549   5.1   4.8   3.6           Lung ca. NCI-H526   0.0   0.1   1.2           Lung ca. NCI-H23   6.7   6.8   4.2           Lung ca. NCI-H460   0.0   0.1   0.1           Lung ca. HOP-62   5.3   4.6   2.1           Lung ca. NCI-H522   6.0   3.0   2.5           Liver   1.5   1.3   3.4           Fetal Liver   4.0   4.4   22.8           Liver ca. HepG2   74.2   70.2   61.1           Kidney Pool   0.3   0.8   0.7           Fetal Kidney   20.6   10.4   31.0           Renal ca. 786-0   31.9   20.4   14.9           Renal ca. A498   5.6   1.4   2.2           Renal ca. ACHN   5.8   3.0   2.0           Renal ca. UO-31   0.9   0.8   0.9           Renal ca. TK-10   31.9   32.8   27.7           Bladder   4.0   3.9   28.1           Gastric ca. (liver met.) NCI-N87   0.0   0.0   2.2           Gastric ca. KATO III   0.0   0.0   0.0           Colon ca. SW-948   0.1   0.0   4.5           Colon ca. SW480   0.0   0.1   2.8           Colon ca.* (SW480 met)   0.7   0.3   2.3           SW620           Colon ca. HT29   0.3   0.1   17.6           Colon ca. HCT-116   0.4   0.6   21.6           Colon ca. CaCo-2   4.2   4.7   77.4           Colon cancer tissue   0.1   0.0   2.2           Colon ca. SW1116   0.1   0.0   4.5           Colon ca. Colo-205   0.0   0.1   3.0           Colon ca. SW-48   0.0   0.0   1.9           Colon Pool   0.9   0.4   0.7           Small Intestine Pool   0.0   0.1   2.1           Stomach Pool   0.6   0.2   1.1           Bone Marrow Pool   0.1   0.0   1.0           Fetal Heart   1.0   0.3   0.7           Heart Pool   0.1   0.4   0.8           Lymph Node Pool   0.7   0.1   1.0           Fetal Skeletal Muscle   0.4   0.1   0.3           Skeletal Muscle Pool   0.7   0.4   0.8           Spleen Pool   3.5   1.3   2.0           Thymus Pool   1.0   0.3   3.3           CNS cancer (glio/astro)   0.0   0.0   0.0           U87-MG           CNS cancer (glio/astro) U-   0.0   0.0   0.1           118-MG           CNS cancer (neuro; met)   0.4   0.1   0.1           SK-N-AS           CNS cancer (astro) SF-539   2.0   0.0   1.4           CNS cancer (astro) SNB-75   15.3   10.2   8.9           CNS cancer (glio) SNB-19   30.8   29.5   17.1           CNS cancer (glio) SF-295   0.9   0.8   0.8           Brain (Amygdala) Pool   51.8   32.5   47.6           Brain (cerebellum)   68.8   47.6   60.7           Brain (fetal)   10.4   9.3   12.8           Brain (Hippocampus) Pool   79.0   39.8   46.7           Cerebral Cortex Pool   60.7   55.5   66.0           Brain (Substantia nigra)   90.8   100.0   78.5           Pool           Brain (Thalamus) Pool   59.5   55.9   64.6           Brain (whole)   43.8   26.8   24.7           Spinal Cord Pool   100.0   57.8   95.3           Adrenal Gland   1.1   0.5   0.3           Pituitary gland Pool   0.7   0.6   4.9           Salivary Gland   0.3   0.0   0.5           Thyroid (female)   0.4   0.2   1.1           Pancreatic ca. CAPAN2   0.0   0.0   0.6           Pancreas Pool   1.5   1.2   10.9                                                            
     [0794]               TABLE LH                          Oncology_cell_line_screening_panel_v3.2                                     Tissue Name   A   B   C                                                 94905_Daoy_Medulloblas-   0.0   0.7   1.6           toma/Cerebellum_sscDNA           94906_TE671_Medullob-   0.7   2.3   1.0           lastom/Cerebellum_sscDNA           94907_D283   7.4   4.6   0.3           Med_Medulloblastoma/           Cerebellum_sscDNA           94908_PFSK-   75.3   82.4   31.9           1_Primitive           Neuroectodermal/           Cerebellum_sscDNA           94909_XF-   27.0   24.7   9.9           498_CNS_sscDNA           94910_SNB-   0.0   0.0   0.0           78_CNS/glioma_sscDNA           94911_SF-   0.0   0.0   0.4           268_CNS/glioblastoma —             sscDNA           94912_T98G_Glioblasto-   3.5   3.1   4.4           ma_sscDNA           96776_SK-N-   0.9   1.5   0.4           SH_Neuroblastoma           (metastasis)_sscDNA           94913_SF-   2.8   1.6   0.9           295_CNS/glioblastoma —             sscDNA           132565_NT2   90.1   76.3   52.1           pool_sscDNA           94914_Cerebellum_sscDNA   100.0   97.9   25.2           96777_Cerebellum_sscDNA   100.0   100.0   6.5           94916_NCI-   0.0   0.0   6.7           H292_Mucoepidermoid           lung carcinoma_sscDNA           94917_DMS-114_Small   10.5   9.1   6.4           cell lung cancer_sscDNA           94918_DMS-79_Small   4.4   1.6   33.4           cell lung           cancer/neuroendocrine —             sscDNA           94919_NCI-H146_Small   0.0   0.0   1.1           cell lung           cancer/neuroendocrine —             sscDNA           94920_NCI-H526_Small   0.9   2.0   8.6           cell lung           cancer/neuroendocrine —             sscDNA           94921_NCI-N417_Small   0.7   0.4   0.5           cell lung           cancer/neuroendocrine —             sscDNA           94923_NCI-H82_Small   5.8   1.3   2.6           cell lung           cancer/neuroendocrine —             sscDNA           94924_NCI-   2.1   1.6   0.6           H157_Squamous cell           lung cancer           (metastasis)_sscDNA           94925_NCI-   0.0   1.3   1.8           H1155_Large cell lung           cancer/neuroendocrine —             sscDNA           94926_NCI-   5.4   4.9   3.5           H1299_Large cell lung           cancer/neuroendocrine —             sscDNA           94927_NCI-H727_Lung   0.2   0.0   4.8           carcinoid_sscDNA           94928_NCI-UMC-   0.0   0.0   0.2           11_Lung           carcinoid_sscDNA           94929_LX-1_Small cell   0.0   0.0   18.7           lung cancer_sscDNA           94930_Colo-205_Colon   0.0   0.0   14.8           cancer_sscDNA           94931_KM12_Colon   0.0   0.0   1.2           cancer_sscDNA           94932_KM20L2_Colon   0.0   0.0   11.2           cancer_sscDNA           94933_NCI-H716_Colon   18.0   20.9   0.0           cancer_sscDNA           94935_SW-48_Colon   0.0   0.8   6.2           adenocarcinoma —             sscDNA           94936_SW1116_Colon   0.0   0.0   18.6           adenocarcinoma —             sscDNA           94937_LS 174T_Colon   0.7   0.6   30.4           adenocarcinoma —             sscDNA           94938_SW-948_Colon   0.0   0.0   2.1           adenocarcinoma —             sscDNA           94939_SW-480_Colon   0.0   0.0   8.5           adenocarcinoma —             sscDNA           94940_NCI-SNU-   0.0   0.0   3.5           5_Gastric           carcinoma_sscDNA           112197_KATO   0.0   0.0   0.0           III_Stomach_sscDNA           94943_NCI-SNU-   0.0   0.0   0.0           16_Gastric           carcinoma_sscDNA           94944_NCI-SNU-   0.0   0.0   0.0           1_Gastric           carcinoma_sscDNA           94946_RF-1_Gastric   80.1   0.0   0.0           adenocarcinoma —             sscDNA           94947_RF-48_Gastric   0.0   0.0   0.0           adenocarcinoma_sscDNA           96778_MKN-45_Gastric   0.0   0.3   23.5           carcinoma_sscDNA           94949_NCI-N87_Gastric   0.2   0.0   6.8           carcinoma_sscDNA           94951_OVCAR-   0.0   0.0   12.1           5_Ovarian           carcinoma_sscDNA           94952_RL95-2_Uterine   0.8   0.0   19.1           carcinoma_sscDNA           94953_HelaS3_Cervical   3.6   1.0   7.2           adenocarcinoma —             sscDNA           94954_Ca Ski_Cervical   0.8   0.0   2.3           epidermoid carcinoma           (metastasis)_sscDNA           94955_ES-2_Ovarian clear   0.0   0.0   0.0           cell carcinoma_sscDNA           94957_Ramos/6h stim —     0.0   0.0   0.0           Stimulated with           PMA/ionomycin           6h_sscDNA           94958_Ramos/14h stim —     0.0   0.0   0.0           Stimulated with           PMA/ionomycin           14h_sscDNA           94962_MEG-01_Chronic   5.8   3.8   3.6           myelogenous leukemia           (megokaryoblast)_sscDNA           94963_Raji_Burkitt&#39;s   0.0   0.0   0.0           lymphoma_sscDNA           94964_Daudi_Burkitt&#39;s   0.0   0.0   0.0           lymphoma_sscDNA           94965_U266_B-cell   0.0   0.4   0.3           plasmacytoma/myeloma —             sscDNA           94968_CA46_Burkitt&#39;s   0.0   0.0   0.0           lymphoma_sscDNA           94970_RL_non-Hodgkin&#39;s   0.0   0.0   0.0           B-cell lymphoma_sscDNA           94972_JM1_pre-B-cell   0.0   0.0   1.0           lymphoma/leukemia_sscDNA           94973_Jurkat_T cell   5.5   6.3   2.0           leukemia_sscDNA           94974_TF-   2.6   9.7   4.5           1_Erythroleukemia_sscDNA           94975_HUT 78_T-cell   6.0   2.9   4.8           lymphoma_sscDNA           94977_U937_Histiocytic   2.4   1.0   0.0           lymphoma_sscDNA           94980_KU-   19.6   18.2   7.5           812_Myelogenous           leukemia_sscDNA           94981_769-P_Clear cell   57.0   61.1   50.3           renal carcinoma_sscDNA           94983_Caki-2_Clear cell   0.8   4.3   4.0           renal carcinoma_sscDNA           94984_SW 839_Clear cell   0.0   0.0   0.0           renal carcinoma_sscDNA           94986_G401_Wilms&#39;   10.2   6.8   3.5           tumor_sscDNA           126768_293 cells_sscDNA   15.8   23.8   18.6           94987_Hs766T_Pancreatic   0.6   1.0   2.1           carcinoma (LN           metastasis)_sscDNA           94988_CAPAN-   1.9   0.0   0.8           1_Pancreatic           adenocarcinoma (liver           metastasis)_sscDNA           94989_SU86.86_Pancreatic   0.0   0.0   6.1           carcinoma (liver           metastasis)_sscDNA           94990_BxPC-3_Pancreatic   0.8   0.4   100.0           adenocarcinoma_sscDNA           94991_HPAC_Pancreatic   0.0   0.0   1.2           adenocarcinoma_sscDNA           94992_MIA PaCa-   0.7   0.8   3.1           2_Pancreatic           carcinoma_sscDNA           94993_CFPAC-   0.7   1.8   24.0           1_Pancreatic ductal           adenocarcinoma_sscDNA           94994_PANC-1_Pancreatic   5.8   5.3   11.8           epithelioid ductal           carcinoma_sscDNA           94996_T24_Bladder   0.0   0.0   0.0           carcinma (transitional           cell)_sscDNA           94997_5637_Bladder   0.0   0.0   0.8           carcinoma_sscDNA           94998_HT-1197_Bladder   0.0   0.0   10.2           carcinoma_sscDNA           94999_UM-UC-3_Bladder   0.6   5.5   1.7           carcinma (transitional           cell)_sscDNA           95000_A204_Rhabdomyos-   8.3   20.9   10.4           arcoma_sscDNA           95001_HT-   2.3   4.0   3.0           1080_Fibrosarcoma —             sscDNA           95002_MG-   0.0   0.9   0.7           63_Osteosarcoma           (bone)_sscDNA           95003_SK-LMS-   0.0   0.0   0.0           1_Leiomyosarcoma           (vulva)_sscDNA           95004_SJRH30_Rhabdomy-   1.4   0.0   4.5           osarcoma (met to bone           marrow)_sscDNA           95005_A431_Epidermoid   0.0   0.0   18.6           carcinoma_sscDNA           95007_WM266-   0.0   0.0   0.0           4_Melanoma_sscDNA           112195_DU   0.7   0.0   3.6           145_Prostate_sscDNA           95012_MDA-MB-   0.0   0.0   11.5           468_Breast           adenocarcinoma_sscDNA           112196_SSC-   1.5   0.0   39.5           4_Tongue_sscDNA           112194_SSC-   0.7   0.0   11.5           9_Tongue_sscDNA           112191_SSC-   0.0   0.0   26.2           15_Tongue_sscDNA           95017_CAL 27_Squamous   0.0   0.5   54.0           cell carcinoma of           tongue_sscDNA                                                            
     [0795]               TABLE LI                          Panel 4.1D                                     Tissue Name   A   B   C                                                 Secondary Th1 act   0.0   0.0   0.0           Secondary Th2 act   0.0   0.0   0.0           Secondary Tr1 act   6.2   0.0   0.4           Secondary Th1 rest   2.4   0.0   0.0           Secondary Th2 rest   0.0   0.0   0.0           Secondary Tr1 rest   0.0   2.6   0.0           Primary Th1 act   0.0   0.0   0.0           Primary Th2 act   0.0   0.0   0.5           Primary Tr1 act   0.0   0.0   0.0           Primary Th1 rest   0.0   0.0   0.0           Primary Th2 rest   0.0   0.0   0.0           Primary Tr1 rest   2.4   3.5   0.0           CD45RA CD4   0.0   6.5   0.9           lymphocyte act           CD45RO CD4   0.0   0.0   0.0           lymphocyte act           CD8 lymphocyte act   0.0   0.0   0.0           Secondary CD8   0.0   0.0   0.0           lymphocyte rest           Secondary CD8   0.0   0.0   0.4           lymphocyte act           CD4 lymphocyte none   0.0   0.0   0.0           2ry Th1/Th2/Tr1_anti-   2.3   0.0   0.0           CD95 CH11           LAK cells rest   2.4   0.0   0.0           LAK cells IL-2   0.0   0.0   0.0           LAK cells IL-2 + IL-12   0.0   0.0   0.0           LAK cells IL-2 + IFN   0.0   0.0   0.6           gamma           LAK cells IL-2 + IL-18   0.0   0.0   0.0           LAK cells   2.9   0.0   0.4           PMA/ionomycin           NK Cells IL-2 rest   0.0   0.0   0.0           Two Way MLR 3 day   0.0   0.0   0.0           Two Way MLR 5 day   0.0   0.0   0.0           Two Way MLR 7 day   0.0   0.0   0.0           PBMC rest   4.2   0.0   0.0           PBMC PWM   0.0   0.0   0.0           PBMC PHA-L   0.0   0.0   0.0           Ramos (B cell) none   0.0   0.0   0.0           Ramos (B cell)   0.0   0.0   0.0           ionomycin           B lymphocytes PWM   0.0   0.0   0.0           B lymphocytes CD40L   0.0   0.0   0.1           and IL-4           EOL-1 dbcAMP   14.9   16.3   9.3           EOL-1 dbcAMP   15.9   14.0   6.2           PMA/ionomycin           Dendritic cells none   0.0   0.0   0.0           Dendritic cells LPS   0.0   0.0   0.0           Dendritic cells anti-CD40   0.0   0.0   0.0           Monocytes rest   0.0   0.0   0.0           Monocytes LPS   0.0   0.0   0.0           Macrophages rest   0.0   0.0   0.0           Macrophages LPS   0.0   0.0   0.0           HUVEC none   0.0   0.0   0.0           HUVEC starved   8.4   2.3   2.0           HUVEC IL-1beta   1.8   1.9   0.6           HUVEC IFN gamma   3.4   4.7   0.4           HUVEC TNF alpha + IFN   1.6   0.0   0.5           gamma           HUVEC TNF alpha + IL4   0.0   0.5   1.1           HUVEC IL-11   1.6   3.1   1.2           Lung Microvascular EC none   25.7   36.9   7.6           Lung Microvascular EC   5.4   13.0   4.4           TNFalpha + IL-1beta           Microvascular Dermal EC   1.4   2.0   0.0           none           Microsvasular Dermal EC   0.0   1.9   1.7           TNFalpha + IL-1beta           Bronchial epithelium   4.3   5.6   27.4           TNFalpha + IL1beta           Small airway epithelium   1.6   0.0   35.4           none           Small airway epithelium   4.3   0.9   94.0           TNFalpha + IL-1beta           Coronery artery SMC rest   0.0   4.0   0.0           Coronery artery SMC   2.0   0.0   0.6           TNFalpha + IL-1beta           Astrocytes rest   27.9   49.3   3.6           Astrocytes TNFalpha + IL-   14.5   34.2   2.9           1beta           KU-812 (Basophil) rest   24.1   35.1   8.2           KU-812 (Basophil)   5.1   9.4   2.7           PMA/ionomycin           CCD1106 (Keratinocytes)   1.9   0.0   15.8           none           CCD1106 (Keratinocytes)   1.8   4.4   16.5           TNFalpha + IL-1beta           Liver cirrhosis   3.3   7.8   25.2           NCI-H292 none   0.0   2.7   5.9           NCI-H292 IL-4   0.0   0.0   7.4           NCI-H292 IL-9   0.0   0.0   2.9           NCI-H292 IL-13   0.0   0.0   5.6           NCI-H292 IFN gamma   6.1   0.0   2.3           HPAEC none   0.0   5.1   1.8           HPAEC TNF alpha + IL-1   0.0   2.1   0.0           beta           Lung fibroblast none   0.0   0.0   0.2           Lung fibroblast TNF alpha +   0.0   7.8   0.0           IL-1 beta           Lung fibroblast IL-4   1.6   0.0   0.5           Lung fibroblast IL-9   0.0   0.0   0.0           Lung fibroblast IL-13   0.0   0.0   0.0           Lung fibroblast IFN gamma   6.0   2.4   1.3           Dermal fibroblast CCD1070   3.3   18.3   2.4           rest           Dermal fibroblast CCD1070   15.2   11.4   2.8           TNF alpha           Dermal fibroblast CCD1070   1.6   3.2   2.3           IL-1 beta           Dermal fibroblast IFN   11.3   3.4   1.0           gamma           Dermal fibroblast IL-4   8.2   0.0   1.0           Dermal Fibroblasts rest   0.0   3.0   0.3           Neutrophils TNFa + LPS   0.0   0.0   0.4           Neutrophils rest   0.0   0.0   0.7           Colon   2.8   2.9   11.1           Lung   0.0   0.0   4.2           Thymus   22.8   8.2   8.7           Kidney   100.0   100.0   100.0                                                            
     [0796]               TABLE LJ                          Panel 5D                                     Tissue Name   A   B   C                                                 97457_Patient-   0.0   2.0   0.0           02go_adipose           97476_Patient-   1.4   0.0   0.7           07sk_skeletal muscle           97477_Patient-   0.0   1.4   0.2           07ut_uterus           97478_Patient-   8.7   12.7   4.4           07pl_placenta           97481_Patient-   0.0   0.0   0.3           08sk_skeletal muscle           97482_Patient-   0.0   0.0   0.0           08ut_uterus           97483_Patient-   5.8   12.2   4.9           08pl_placenta           97486_Patient-   0.0   0.0   0.0           09sk_skeletal muscle           97487_Patient-   0.0   2.3   0.0           09ut_uterus           97488_Patient-   13.5   7.7   6.9           09pl_placenta           97492_Patient-   0.0   2.1   0.0           10ut_uterus           97493_Patient-   22.1   14.6   8.5           10pl_placenta           97495_Patient-   1.6   0.0   0.8           11go_adipose           97496_Patient-   0.0   1.3   0.3           11sk_skeletal muscle           97497_Patient-   0.0   0.0   0.0           11ut_uterus           97498_Patient-   14.0   15.7   5.0           11pl_placenta           97500_Patient-   1.8   1.5   1.7           12go_adipose           97501_Patient-   1.5   1.1   0.5           12sk_skeletal muscle           97502_Patient-   1.6   1.7   1.1           12ut_uterus           97503_Patient-   11.3   11.3   2.7           12pl_placenta           94721_Donor 2 U -   0.0   0.0   0.9           A_Mesenchymal           Stem Cells           94722_Donor 2 U -   0.0   0.0   0.0           B_Mesenchymal           Stem Cells           94723_Donor 2 U -   0.0   2.1   1.2           C_Mesenchymal           Stem Cells           94709_Donor 2 AM - A_adipose   1.0   9.0   0.3           94710_Donor 2 AM - B_adipose   0.9   0.0   0.9           94711_Donor 2 AM - C_adipose   0.0   2.4   0.4           94712_Donor 2 AD - A_adipose   0.0   0.0   0.0           94713_Donor 2 AD - B_adipose   0.0   0.0   0.0           94714_Donor 2 AD - C_adipose   1.4   0.0   0.3           94742_Donor 3 U -   0.0   0.0   1.2           A_Mesenchymal Stem Cells           94743_Donor 3 U -   2.7   0.0   0.4           B_Mesenchymal Stem Cells           94730_Donor 3 AM - A_adipose   1.6   6.2   1.2           94731_Donor 3 AM - B_adipose   3.8   4.1   0.4           94732_Donor 3 AM - C_adipose   1.3   2.3   0.8           94733_Donor 3 AD - A_adipose   6.7   0.0   1.7           94734_Donor 3 AD - B_adipose   3.1   0.0   0.7           94735_Donor 3 AD - C_adipose   0.2   0.9   1.7           77138_Liver_HepG2untreated   100.0   100.0   100.0           73556_Heart_Cardiac stromal   0.0   0.0   0.0           cells (primary)           81735_Small Intestine   0.0   0.0   8.1           72409_Kidney_Proximal   0.0   0.0   0.0           Convoluted Tubule           82685_Small   2.0   2.0   7.0           intestine_Duodenum           90650_Adrenal_Adrenocortical   0.0   0.0   0.3           adenoma           72410_Kidney_HRCE   0.0   1.9   0.4           72411_Kidney_HRE   2.6   0.0   1.7           73139_Uterus_Uterine smooth   0.0   2.2   0.2           muscle cells                                                            
     [0797]               TABLE LK                          general oncology screening panel_v_2.4                                     Tissue Name   A   B   C                                                 Colon cancer 1   2.3   1.0   6.8           Colon NAT 1   0.5   1.3   6.2           Colon cancer 2   2.6   1.9   0.3           Colon NAT 2   0.5   0.7   7.7           Colon cancer 3   1.3   3.8   9.7           Colon NAT 3   3.6   0.8   12.4           Colon malignant cancer 4   0.5   0.0   8.4           Colon NAT 4   1.3   1.0   1.3           Lung cancer 1   1.3   0.0   2.2           Lung NAT 1   0.0   0.9   0.4           Lung cancer 2   100.0   100.0   100.0           Lung NAT 2   2.7   1.9   1.2           Squamous cell carcinoma 3   0.0   1.3   33.2           Lung NAT 3   0.0   0.0   0.5           Metastatic melanoma 1   0.0   1.0   0.3           Melanoma 2   1.0   0.0   22.4           Melanoma 3   0.0   0.0   2.5           Metastatic melanoma 4   1.9   1.2   0.3           Metastatic melanoma 5   3.7   3.4   0.1           Bladder cancer 1   0.0   0.0   0.0           Bladder NAT 1   0.0   0.0   0.0           Bladder cancer 2   0.0   0.0   2.7           Bladder NAT 2   0.0   0.0   0.0           Bladder NAT 3   0.0   0.0   1.3           Bladder NAT 4   0.2   0.7   0.4           Prostate adenocarcinoma 1   0.0   0.0   2.0           Prostate adenocarcinoma 2   1.0   2.0   1.4           Prostate adenocarcinoma 3   4.3   0.8   5.2           Prostate adenocarcinoma 4   0.7   0.0   7.6           Prostate NAT 5   0.0   0.0   6.0           Prostate adenocarcinoma 6   0.9   1.4   2.1           Prostate adenocarcinoma 7   1.3   1.2   0.7           Prostate adenocarcinoma 8   1.1   0.0   0.3           Prostate adenocarcinoma 9   0.8   1.3   0.7           Prostate NAT 10   0.8   1.3   1.1           Kidney cancer 1   13.9   11.6   8.7           Kidney NAT 1   3.5   6.8   18.4           Kidney cancer 2   66.4   66.9   32.3           Kidney NAT 2   60.3   28.5   76.3           Kidney cancer 3   25.2   42.3   49.0           Kidney NAT 3   21.5   13.2   91.4           Kidney cancer 4   72.2   43.5   15.7           Kidney NAT 4   48.6   53.6   18.7                                                            
     [0798] AI.05 chondrosarcoma Summary: Ag4039/Ag4045 Highest expression of this gene is detected in untreated serum starved chondrosarcoma cell line (SW1353) (CTs29-32). Interestingly, expression of this gene appears to be somewhat down regulated upon IL-1 treatment, a potent activator of pro-inflammatory cytokines and matrix metalloproteinases which participate in the destruction of cartilage observed in Osteoarthritis (OA). Therefore, therapeutic modulation of the activity of this gene or its protein product may be important for preventing the degeneration of cartilage observed in osteoarthritis.  
     [0799] AI_comprehensive panel_v1.0 Summary: Ag4039/Ag4040/Ag4045 Three experiments with two different probe-primer sets are in good agreement with highest expression of this gene seen in osteoarthritis (OA) cartilage samples (CTs=29). Significant expression of this gene is mainly detected in samples derived from OA bone and adjacent normal bone, and OA cartilage. Therefore, therapeutic modulation of this gene or its protein product may be useful in the treatment of osteoarthritis.  
     [0800] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag4039/Ag4040/Ag4045 confirms the expression of this gene at low levels in the brain in an independent group of individuals. This gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients (p=0.0007). Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this receptor may be of use in reversing the dementia/memory loss associated with this disease and neuronal death.  
     [0801] General_screening_panel_v1.4 Summary: Ag4039/Ag4040/Ag4045 Three experiments with two different probe-primer sets are in good agreement with highest expression of this gene seen in spinal cord, brain substantia nigra and a breast cancer T47D cell line (CTs=26-27.4). High expression of this gene is mainly seen in all the regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0802] Oncology_cell_line_screening_panel_v3.2 Summary: Ag4039/Ag4040 Two experiments with same probe-primer sets are in good agreement. Highest expression of this gene seen in cerebellum samples (CTs=31). Significant expression of this gene is seen in number of cell lines derived from brain, colon, gastric, renal and bone marrow cancers.  
     [0803] Ag4045 Highest expression of this gene is seen in pancreatic adenocarcinoma cell line samples (CT=30.7). Moderate to low expression of this gene is seen in several cancer cell lines derived from brain, lung, colon, gastric, ovarian, uterine, pancreatic, renal, bone marrow, bladder, epidermoid, ovarian and tongue cancers. Therefore, therapeutic modulation of this gene or its gene product may be useful in the treatment of these cancers.  
     [0804] Panel 4.1D Summary: Ag4039/Ag4040/Ag4045 Highest expression of this gene is seen in kidney (CT=31.3). Moderate to low expression of this gene is seen in eosinophils, lung microvascular endothelial cells, astrocytes, basophils, and activated dermal fibroblasts. The variant gene recognized by the probe-primer set Ag4045 also shows expression in bronchial and small airway epithelium, mucoepidermoid NCI-H292 cell line, keratinocytes, and normal tissues represented by colon, lung and thymus. Therefore, therapeutic modulation of this gene or its protein product may be useful in treatment of autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0805] Panel 5D Summary: Ag4039/Ag4040/Ag4045 Highest expression of this gene is seen in liver cancer HepG2 cell line (CTs=31.3). Low expression of this gene is also seen in placenta from diabetic and non-diabetic patient.  
     [0806] general oncology screening panel_v — 2.4 Summary: Ag4039/Ag4040/Ag4045 Three experiments with two different probe-primer sets are in good agreement with highest expression of this gene seen in lung cancer sample (CTs=28-30.8). Significant expression of this gene is also seen in normal and cancer samples from kidney. The variant gene recognized by the probe-primer set Ag4045 also shows expression in normal and cancer samples derived from prostate, metastatic melanoma, lung and colon.  
     [0807] M. CG57341-01: Short Chain Dehydrogenase/reductase 1  
     [0808] Expression of gene CG57341-01 was assessed using the primer-probe set Ag3204, described in Table MA. Results of the RTQ-PCR runs are shown in Tables MB, MC and MD.  
                   TABLE MA                          Probe Name Ag3204                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-ggactttgatcccctacagatg-3′   22   170   149           Probe   TET-5′-tcaaatgaagaggacatcctctccat-3′-TAMRA   26   199   150       Reverse   5′-ctgagaacggatagctgagaac-3′   22   225   151                  
 
     [0809]               TABLE MB                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   3.9   0.1           AD 2 Hippo   15.3   0.2           AD 3 Hippo   3.3   0.1           AD 4 Hippo   3.9   0.1           AD 5 hippo   67.4   0.9           AD 6 Hippo   20.9   0.3           Control 2 Hippo   24.7   0.4           Control 4 Hippo   5.4   0.1           Control (Path) 3 Hippo   3.9   0.1           AD 1 Temporal Ctx   7.5   0.1           AD 2 Temporal Ctx   10.5   0.3           AD 3 Temporal Ctx   2.7   0.1           AD 4 Temporal Ctx   12.8   0.2           AD 5 Inf Temporal Ctx   57.0   0.0           AD 5 Sup Temporal Ctx   22.8   0.4           AD 6 Inf Temporal Ctx   26.2   0.5           AD 6 Sup Temporal Ctx   30.6   0.4           Control 1 Temporal Ctx   7.7   0.1           Control 2 Temporal Ctx   48.0   0.9           Control 3 Temporal Ctx   17.1   0.2           Control 4 Temporal Ctx   4.6   0.1           Control (Path) 1 Temporal Ctx   55.1   0.8           Control (Path) 2 Temporal Ctx   39.5   0.5           Control (Path) 3 Temporal Ctx   3.7   0.1           Control (Path) 4 Temporal Ctx   25.5   0.3           AD 1 Occipital Ctx   7.2   0.1           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   3.9   0.0           AD 4 Occipital Ctx   14.7   0.2           AD 5 Occipital Ctx   16.8   0.7           AD 6 Occipital Ctx   64.2   0.2           Control 1 Occipital Ctx   5.1   0.1           Control 2 Occipital Ctx   100.0   1.5           Control 3 Occipital Ctx   18.6   0.3           Control 4 Occipital Ctx   5.3   100.0           Control (Path) 1 Occipital Ctx   78.5   1.1           Control (Path) 2 Occipital Ctx   12.1   0.2           Control (Path) 3 Occipital Ctx   3.3   0.1           Control (Path) 4 Occipital Ctx   22.5   0.3           Control 1 Parietal Ctx   7.1   0.1           Control 2 Parietal Ctx   29.1   0.3           Control 3 Parietal Ctx   23.7   0.3           Control (Path) 1 Parietal Ctx   92.7   1.2           Control (Path) 2 Parietal Ctx   24.5   0.5           Control (Path) 3 Parietal Ctx   5.3   0.1           Control (Path) 4 Parietal Ctx   44.1   0.5                                                
     [0810]               TABLE MC                          Panel 1.3D                             Tissue Name   A                                         Liver adenocarcinoma   23.8           Pancreas   9.9           Pancreatic ca. CAPAN 2   9.6           Adrenal gland   3.8           Thyroid   10.0           Salivary gland   5.9           Pituitary gland   10.5           Brain (fetal)   14.0           Brain (whole)   46.3           Brain (amygdala)   16.8           Brain (cerebellum)   22.7           Brain (hippocampus)   18.9           Brain (substantia nigra)   20.3           Brain (thalamus)   26.6           Cerebral Cortex   66.4           Spinal cord   6.9           glio/astro U87-MG   11.8           glio/astro U-118-MG   5.0           astrocytoma SW1783   23.7           neuro*; met SK-N-AS   12.9           astrocytoma SF-539   5.4           astrocytoma SNB-75   9.4           glioma SNB-19   13.9           glioma U251   28.5           glioma SF-295   21.9           Heart (fetal)   21.9           Heart   9.7           Skeletal muscle (fetal)   13.3           Skeletal muscle   18.8           Bone marrow   5.2           Thymus   4.7           Spleen   3.1           Lymph node   6.5           Colorectal   69.7           Stomach   8.7           Small intestine   77.4           Colon ca. SW480   26.4           Colon ca.* SW620 (SW480 met)   47.3           Colon ca. HT29   47.0           Colon ca. HCT-116   14.0           Colon ca. CaCo-2   100.0           Colon ca. tissue (ODO3866)   4.9           Colon ca. HCC-2998   28.1           Gastric ca.* (liver met) NCI-N87   18.6           Bladder   5.3           Trachea   1.9           Kidney   27.2           Kidney (fetal)   23.2           Renal ca. 786-0   7.0           Renal ca. A498   11.7           Renal ca. RXF 393   8.8           Renal ca. ACHN   9.7           Renal ca. UO-31   2.6           Renal ca. TK-10   22.8           Liver   7.8           Liver (fetal)   8.2           Liver ca. (hepatoblast) HepG2   36.9           Lung   2.2           Lung (fetal)   5.6           Lung ca. (small cell) LX-1   19.1           Lung ca. (small cell) NCI-H69   6.1           Lung ca. (s. cell var.) SHP-77   75.3           Lung ca. (large cell) NCI-H460   1.5           Lung ca. (non-sm. cell) A549   13.4           Lung ca. (non-s. cell) NCI-H23   5.0           Lung ca. (non-s. cell) HOP-62   10.7           Lung ca. (non-s. cl) NCI-H522   46.3           Lung ca. (squam.) SW 900   4.8           Lung ca. (squam.) NCI-H596   23.5           Mammary gland   16.5           Breast ca.* (pl. ef) MCF-7   1.5           Breast ca.* (pl. ef) MDA-MB-231   13.0           Breast ca.* (pl. ef) T47D   35.6           Breast ca. BT-549   5.1           Breast ca. MDA-N   12.0           Ovary   8.1           Ovarian ca. OVCAR-3   10.2           Ovarian ca. OVCAR-4   15.3           Ovarian ca. OVCAR-5   46.0           Ovarian ca. OVCAR-8   3.5           Ovarian ca. IGROV-1   4.4           Ovarian ca.* (ascites) SK-OV-3   45.4           Uterus   2.6           Placenta   0.6           Prostate   5.8           Prostate ca.* (bone met) PC-3   4.5           Testis   7.9           Melanoma Hs688(A).T   0.9           Melanoma* (met) Hs688(B).T   0.8           Melanoma UACC-62   13.0           Melanoma M14   3.2           Melanoma LOX IMVI   18.2           Melanoma* (met) SK-MEL-5   15.6           Adipose   6.6                                    
     [0811]               TABLE MD                          Panel 4D                             Tissue Name   A                                         Secondary Th1 act   5.0           Secondary Th2 act   3.3           Secondary Tr1 act   4.0           Secondary Th1 rest   0.7           Secondary Th2 rest   0.6           Secondary Tr1 rest   0.2           Primary Th1 act   7.4           Primary Th2 act   4.6           Primary Tr1 act   5.4           Primary Th1 rest   1.9           Primary Th2 rest   1.1           Primary Tr1 rest   1.8           CD45RA CD4 lymphocyte act   1.4           CD45RO CD4 lymphocyte act   3.6           CD8 lymphocyte act   3.8           Secondary CD8 lymphocyte rest   1.8           Secondary CD8 lymphocyte act   2.5           CD4 lymphocyte none   0.6           2ry Th1/Th2/Tr1_anti-CD95 CH11   0.8           LAK cells rest   2.2           LAK cells IL-2   2.1           LAK cells IL-2 + IL-12   2.4           LAK cells IL-2 + IFN gamma   2.9           LAK cells IL-2 + IL-18   2.4           LAK cells PMA/ionomycin   1.2           NK Cells IL-2 rest   1.4           Two Way MLR 3 day   1.5           Two Way MLR 5 day   1.6           Two Way MLR 7 day   1.4           PBMC rest   0.0           PBMC PWM   6.7           PBMC PHA-L   3.4           Ramos (B cell) none   3.6           Ramos (B cell) ionomycin   10.7           B lymphocytes PWM   9.4           B lymphocytes CD40L and IL-4   2.1           EOL-1 dbcAMP   2.2           EOL-1 dbcAMP PMA/ionomycin   0.8           Dendritic cells none   27.0           Dendritic cells LPS   28.9           Dendritic cells anti-CD40   41.8           Monocytes rest   0.9           Monocytes LPS   0.2           Macrophages rest   22.5           Macrophages LPS   0.8           HUVEC none   2.8           HUVEC starved   7.4           HUVEC IL-1beta   1.2           HUVEC IFN gamma   2.0           HUVEC TNF alpha + IFN gamma   1.0           HUVEC TNF alpha + IL4   2.9           HUVEC IL-11   2.5           Lung Microvascular EC none   2.9           Lung Microvascular EC TNFalpha + IL-1beta   2.4           Microvascular Dermal EC none   3.6           Microsvasular Dermal EC TNFalpha + IL-1beta   2.8           Bronchial epithelium TNFalpha + IL1beta   2.5           Small airway epithelium none   2.9           Small airway epithelium TNFalpha + IL-1beta   8.8           Coronery artery SMC rest   0.6           Coronery artery SMC TNFalpha + IL-1beta   0.1           Astrocytes rest   4.8           Astrocytes TNFalpha + IL-1beta   3.6           KU-812 (Basophil) rest   6.6           KU-812 (Basophil) PMA/ionomycin   10.2           CCD1106 (Keratinocytes) none   4.0           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   1.8           Liver cirrhosis   1.1           Lupus kidney   0.4           NCI-H292 none   7.0           NCI-H292 IL-4   8.8           NCI-H292 IL-9   7.4           NCI-H292 IL-13   3.9           NCI-H292 IFN gamma   4.1           HPAEC none   1.8           HPAEC TNF alpha + IL-1 beta   2.0           Lung fibroblast none   1.4           Lung fibroblast TNF alpha + IL-1 beta   0.6           Lung fibroblast IL-4   2.4           Lung fibroblast IL-9   2.8           Lung fibroblast IL-13   1.7           Lung fibroblast IFN gamma   1.6           Dermal fibroblast CCD1070 rest   3.8           Dermal fibroblast CCD1070 TNF alpha   4.1           Dermal fibroblast CCD1070 IL-1 beta   0.4           Dermal fibroblast IFN gamma   1.0           Dermal fibroblast IL-4   2.8           IBD Colitis 2   0.1           IBD Crohn&#39;s   6.0           Colon   100.0           Lung   2.0           Thymus   11.6           Kidney   1.6                                    
     [0812] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3204 shows this gene is found to be significantly (p=0.0008) downregulated in the temporal cortex of Alzheimer&#39;s disease patients when compared to controls. A close homolog of this gene has been shown to mediate neurotoxicity via amyloid beta binding. This gene may therefore be an excellent drug target for the treatment of Alzheimer&#39;s disease, specifically for blocking amyloid beta induced neuronal death. Results from a second experiment with the same probe and primer are not included. The amp plot indicates there were experimental difficulties with this run.  
     [0813] References:  
     [0814] He X Y, et al. J Biol Chem Apr. 1, 1998;273(17):10741-6  
     [0815] Panel 1.3D Summary: Ag3204 The CG57341-01 gene is expressed at a low level in most of the cancer cell lines and normal tissues. There appears to be significantly higher expression in colon, lung, breast and ovarian cancer cell lines with the highest expression shown by a colon cancer cell line (CT=30.94). Thus, therapeutic inhibition of this gene product, through the use of small molecule drugs, might be of utility in the treatment of the above listed cancer types.  
     [0816] Among tissues with metabolic function, this gene has low levels of expression in pancreas, thyroid, pituitary, adult and fetal heart, adult and fetal liver, adult and fetal skeletal muscle, and adipose. This gene product may be a small molecule target for the treatment of metabolic and endocrine disease, including the thyroidopathies, Types 1 and 2 diabetes and obesity.  
     [0817] Panel 4D Summary: Ag3204 The CG57341-01 transcript is expressed at significant levels in the colon and in some types of antigen presenting cells (APC&#39;S) including activated dendritic cells, resting macrophages, and activated B cells. This pattern of expression suggests that the protein encoded by this transcript may be involved in gut immunity, particularly in the function or maintenance of APC&#39;s. This transcript encodes a putative reductase. Therefore, regulation of reductase expression could function by modulating gut immunity and be important in the treatment of inflammatory bowel diseases.  
     [0818] N. CG57460-01: N-Acetyltransferase Camello 2  
     [0819] Expression of gene CG57460-01 was assessed using the primer-probe sets Ag3273 and Ag3322, described in Tables NA and NB. Results of the RTQ-PCR runs are shown in Tables NC, ND and NE.  
                   TABLE NA                          Probe Name Ag3273                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-cgctactactacagccgcaa-3′   20   205   152           Probe   TET-5′-gtgatccgcgcctacctggagtg-3′-TAMRA   23   226   153       Reverse   5′-gggcggcttcatgtagtact-3′   20   281   154                  
 
     [0820]                   TABLE NB                          Probe Name Ag3322                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-cgctactactacagccgcaa-3′   20   205   155           Probe   TET-5′-gtgatccgcgcctacctggagtg-3′-TAMRA   23   226   156       Reverse   5′-gggcggcttcatgtagtact-3′   20   281   157                    
     [0821]               TABLE NC                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   15.7   18.6           AD 2 Hippo   28.9   23.2           AD 3 Hippo   11.0   11.0           AD 4 Hippo   10.2   13.8           AD 5 hippo   100.0   100.0           AD 6 Hippo   21.8   22.4           Control 2 Hippo   27.0   27.9           Control 4 Hippo   22.5   21.8           Control (Path) 3 Hippo   8.4   9.0           AD 1 Temporal Ctx   16.5   15.1           AD 2 Temporal Ctx   29.3   26.2           AD 3 Temporal Ctx   10.9   12.9           AD 4 Temporal Ctx   22.5   20.3           AD 5 Inf Temporal Ctx   57.0   59.5           AD 5 Sup Temporal Ctx   30.6   26.8           AD 6 Inf Temporal Ctx   27.2   30.1           AD 6 Sup Temporal Ctx   34.2   37.4           Control 1 Temporal Ctx   12.2   11.1           Control 2 Temporal Ctx   43.2   39.8           Control 3 Temporal Ctx   16.7   18.3           Control 4 Temporal Ctx   18.3   19.8           Control (Path) 1 Temporal Ctx   51.4   48.0           Control (Path) 2 Temporal Ctx   39.2   45.7           Control (Path) 3 Temporal Ctx   12.2   12.7           Control (Path) 4 Temporal Ctx   40.3   35.4           AD 1 Occipital Ctx   20.9   18.8           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   15.2   13.1           AD 4 Occipital Ctx   22.1   23.2           AD 5 Occipital Ctx   18.4   18.4           AD 6 Occipital Ctx   46.3   48.3           Control 1 Occipital Ctx   8.0   11.2           Control 2 Occipital Ctx   80.1   82.4           Control 3 Occipital Ctx   26.2   27.2           Control 4 Occipital Ctx   14.8   14.1           Control (Path) 1 Occipital Ctx   70.2   68.8           Control (Path) 2 Occipital Ctx   21.6   20.6           Control (Path) 3 Occipital Ctx   8.8   7.4           Control (Path) 4 Occipital Ctx   36.1   34.2           Control 1 Parietal Ctx   14.1   13.7           Control 2 Parietal Ctx   33.9   36.9           Control 3 Parietal Ctx   33.0   28.7           Control (Path) 1 Parietal Ctx   63.7   67.8           Control (Path) 2 Parietal Ctx   30.6   30.4           Control (Path) 3 Parietal Ctx   8.1   9.7           Control (Path) 4 Parietal Ctx   64.2   59.5                                                
     [0822]               TABLE ND                          General_screening_panel_v1.4                             Tissue Name   A                                         Adipose   7.1           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.0           Melanoma* M14   17.6           Melanoma* LOXIMVI   0.9           Melanoma* SK-MEL-5   4.2           Squamous cell carcinoma SCC-4   0.2           Testis Pool   13.5           Prostate ca.* (bone met) PC-3   2.7           Prostate Pool   0.2           Placenta   0.0           Uterus Pool   0.0           Ovarian ca. OVCAR-3   5.4           Ovarian ca. SK-OV-3   6.8           Ovarian ca. OVCAR-4   1.6           Ovarian ca. OVCAR-5   2.1           Ovarian ca. IGROV-1   7.7           Ovarian ca. OVCAR-8   9.6           Ovary   0.8           Breast ca. MCF-7   1.7           Breast ca. MDA-MB-231   0.8           Breast ca. BT 549   7.7           Breast ca. T47D   9.3           Breast ca. MDA-N   0.0           Breast Pool   0.4           Trachea   0.2           Lung   0.0           Fetal Lung   0.3           Lung ca. NCI-N417   5.1           Lung ca. LX-1   0.4           Lung ca. NCI-H146   12.2           Lung ca. SHP-77   2.4           Lung ca. A549   3.4           Lung ca. NCI-H526   12.0           Lung ca. NCI-H23   5.8           Lung ca. NCI-H460   2.3           Lung ca. HOP-62   1.0           Lung ca. NCI-H522   7.4           Liver   0.0           Fetal Liver   0.1           Liver ca. HepG2   0.3           Kidney Pool   0.2           Fetal Kidney   0.7           Renal ca. 786-0   0.2           Renal ca. A498   1.0           Renal ca. ACHN   4.5           Renal ca. UO-31   3.7           Renal ca. TK-10   4.9           Bladder   0.9           Gastric ca. (liver met.) NCI-N87   2.4           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.0           Colon ca. SW480   2.7           Colon ca.* (SW480 met) SW620   1.0           Colon ca. HT29   0.1           Colon ca. HCT-116   6.0           Colon ca. CaCo-2   2.0           Colon cancer tissue   0.6           Colon ca. SW1116   0.4           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.0           Colon Pool   0.4           Small Intestine Pool   0.1           Stomach Pool   0.3           Bone Marrow Pool   0.1           Fetal Heart   100.0           Heart Pool   0.2           Lymph Node Pool   0.0           Fetal Skeletal Muscle   0.3           Skeletal Muscle Pool   1.3           Spleen Pool   0.0           Thymus Pool   0.4           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   0.0           CNS cancer (astro) SF-539   0.2           CNS cancer (astro) SNB-75   0.6           CNS cancer (glio) SNB-19   7.1           CNS cancer (glio) SF-295   1.8           Brain (Amygdala) Pool   31.4           Brain (cerebellum)   32.3           Brain (fetal)   9.3           Brain (Hippocampus) Pool   22.5           Cerebral Cortex Pool   40.3           Brain (Substantia nigra) Pool   57.4           Brain (Thalamus) Pool   36.6           Brain (whole)   24.8           Spinal Cord Pool   20.2           Adrenal Gland   0.0           Pituitary gland Pool   2.2           Salivary Gland   0.2           Thyroid (female)   1.1           Pancreatic ca. CAPAN2   0.0           Pancreas Pool   0.6                                    
     [0823]               TABLE NE                          Panel 4D                             Tissue Name   A                                         Secondary Th1 act   1.0           Secondary Th2 act   2.5           Secondary Tr1 act   3.7           Secondary Th1 rest   5.0           Secondary Th2 rest   0.9           Secondary Tr1 rest   6.9           Primary Th1 act   6.2           Primary Th2 act   5.9           Primary Tr1 act   9.5           Primary Th1 rest   3.1           Primary Th2 rest   0.0           Primary Tr1 rest   0.0           CD45RA CD4 lymphocyte act   0.0           CD45RO CD4 lymphocyte act   0.0           CD8 lymphocyte act   0.0           Secondary CD8 lymphocyte rest   0.0           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   0.0           2ry Th1/Th2/Tr1_anti-CD95 CH11   19.1           LAK cells rest   0.0           LAK cells IL-2   1.2           LAK cells IL-2 + IL-12   2.5           LAK cells IL-2 + IFN gamma   4.1           LAK cells IL-2 + IL-18   0.0           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   0.0           Two Way MLR 3 day   1.1           Two Way MLR 5 day   0.0           Two Way MLR 7 day   0.0           PBMC rest   0.0           PBMC PWM   1.2           PBMC PHA-L   0.0           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   3.5           B lymphocytes CD40L and IL-4   0.0           EOL-1 dbcAMP   100.0           EOL-1 dbcAMP PMA/ionomycin   25.9           Dendritic cells none   3.8           Dendritic cells LPS   2.6           Dendritic cells anti-CD40   5.0           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   4.2           Macrophages LPS   0.0           HUVEC none   0.0           HUVEC starved   0.0           HUVEC IL-1beta   0.0           HUVEC IFN gamma   0.0           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   0.0           HUVEC IL-11   0.0           Lung Microvascular EC none   0.0           Lung Microvascular EC TNFalpha + IL-1beta   0.0           Microvascular Dermal EC none   0.0           Microsvasular Dermal EC TNFalpha + IL-1beta   0.0           Bronchial epithelium TNFalpha + IL1beta   0.0           Small airway epithelium none   2.9           Small airway epithelium TNFalpha + IL-1beta   0.0           Coronery artery SMC rest   1.8           Coronery artery SMC TNFalpha + IL-1beta   0.0           Astrocytes rest   16.5           Astrocytes TNFalpha + IL-1beta   10.4           KU-812 (Basophil) rest   0.0           KU-812 (Basophil) PMA/ionomycin   0.0           CCD1106 (Keratinocytes) none   0.0           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0           Liver cirrhosis   12.7           Lupus kidney   3.9           NCI-H292 none   10.8           NCI-H292 IL-4   23.2           NCI-H292 IL-9   22.4           NCI-H292 IL-13   10.3           NCI-H292 IFN gamma   18.0           HPAEC none   0.0           HPAEC TNF alpha + IL-1 beta   0.0           Lung fibroblast none   1.9           Lung fibroblast TNF alpha + IL-1 beta   0.0           Lung fibroblast IL-4   3.8           Lung fibroblast IL-9   0.5           Lung fibroblast IL-13   5.7           Lung fibroblast IFN gamma   2.9           Dermal fibroblast CCD1070 rest   0.0           Dermal fibroblast CCD1070 TNF alpha   0.0           Dermal fibroblast CCD1070 IL-1 beta   0.0           Dermal fibroblast IFN gamma   2.8           Dermal fibroblast IL-4   4.8           IBD Colitis 2   0.0           IBD Crohn&#39;s   0.0           Colon   37.4           Lung   8.4           Thymus   40.9           Kidney   6.3                                    
     [0824] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3273 shows the two experiments with the same probe and primer set produced results that are in excellent agreement. This panel confirms the expression of this gene at low to moderate levels in the brains of an independent group of individuals. Expression of this gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this protein, may be of use in reversing the dementia/memory loss associated with Alzheimer&#39;s disease and neuronal death.  
     [0825] General_screening_panel_v1.4 Summary: Ag3273 Highest expression of the CG57460-01 gene is seen in fetal heart (CT=28.6). In addition, this gene is expressed at much higher levels in fetal heart when compared to expression in the adult heart (CT=38). Thus, expression of this gene may be used to differentiate between disorders or predispositions that differ between the fetal and adult source of this tissue. In addition, the higher expression in fetal heart suggests that this protein product may be involved in the development of this organ. Therefore, therapeutic modulation of the expression or function of this gene may be useful in the treatment of heart disease.  
     [0826] In addition, expression of this gene appears to be upregulated in a number of cancer cell lines when compared to the normal tissues. Specifically, expression of this gene appears to be higher in ovarian, breast, lung and renal cancer cell lines when compared to their respective normal tissues. Therefore, therapeutic modulation of the activity of this gene or its protein product, using small molecule drugs, antibodies, or protein therapeutics, may be of benefit in the treatment of ovarian, breast, lung and renal cancer. The CG57460-01 gene encodes a transmembrane protein with homology to N-acetyltransferase Camello 2, a protein involved in cellular adhesion (ref. 1).  
     [0827] References:  
     [0828] Popsueva A E, et al. Dev Biol Jun. 15, 2001;234(2):483-96 (PMID: 11397015)  
     [0829] Panel 4D Summary: Ag3273 Highest expression of the CG57460-01 is seen in eosinophils. In addition, differential expression is observed in the eosinophil cell line EOL-1 under resting conditions over that in EOL-1 cells stimulated by phorbol ester and ionomycin. Thus, this gene may be involved in eosinophil function. Therefore, therapeutic modulation of the expression or function of this gene may reduce eosinophil activation and be useful in the treatment of asthma and allergies.  
     [0830] In addition, significant expression in normal colon and thymus suggest a role for this gene in the normal homeostasis of these tissues. Therefore, therapeutic modulation of the expression or function of this gene may modulate immune function (T cell development) and be important for organ transplant, AIDS treatment or post chemotherapy immune reconstitiution. Furthermore, since expression of this gene is decreased in colon samples from patients with IBD colitis and Crohn&#39;s disease relative to normal colon, therapeutic modulation of the activity of the protein encoded by this gene may be useful in the treatment of inflammatory bowel disease.  
     [0831] O. CG57570-01: Cation Transporter  
     [0832] Expression of gene CG57570-01 was assessed using the primer-probe set Ag3288, described in Table OA. Results of the RTQ-PCR runs are shown in Tables OB, OC and OD.  
                   TABLE OA                          Probe Name Ag3288                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-tctacaccatcagctgtatgca-3′   22   1380   158           Probe   TET-5′-caccaccctcacactcatcttcatca-3′-TAMRA   26   1411   159       Reverse   5′-gcagtgcagctgtcatatagaa-3′   22   1439   160                  
 
     [0833]               TABLE OB                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   26.6   31.0           AD 2 Hippo   43.5   48.0           AD 3 Hippo   15.0   14.8           AD 4 Hippo   13.0   11.5           AD 5 hippo   97.3   100.0           AD 6 Hippo   100.0   90.1           Control 2 Hippo   29.3   28.9           Control 4 Hippo   33.7   41.2           Control (Path) 3 Hippo   22.8   27.9           AD 1 Temporal Ctx   34.2   35.8           AD 2 Temporal Ctx   47.3   52.1           AD 3 Temporal Ctx   14.0   18.6           AD 4 Temporal Ctx   34.6   46.7           AD 5 Inf Temporal Ctx   80.1   100.0           AD 5 Sup Temporal Ctx   64.2   85.9           AD 6 Inf Temporal Ctx   68.8   87.1           AD 6 Sup Temporal Ctx   66.4   87.1           Control 1 Temporal Ctx   11.3   16.2           Control 2 Temporal Ctx   33.0   36.3           Control 3 Temporal Ctx   19.2   18.9           Control 4 Temporal Ctx   14.7   17.8           Control (Path) 1 Temporal Ctx   32.3   50.7           Control (Path) 2 Temporal Ctx   36.9   13.2           Control (Path) 3 Temporal Ctx   13.3   15.1           Control (Path) 4 Temporal Ctx   33.7   36.3           AD 1 Occipital Ctx   25.7   15.5           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   16.5   15.8           AD 4 Occipital Ctx   26.1   35.1           AD 5 Occipital Ctx   26.4   28.5           AD 6 Occipital Ctx   33.2   37.6           Control 1 Occipital Ctx   8.8   10.4           Control 2 Occipital Ctx   51.8   59.9           Control 3 Occipital Ctx   28.5   12.8           Control 4 Occipital Ctx   16.5   17.8           Control (Path) 1 Occipital Ctx   66.0   82.4           Control (Path) 2 Occipital Ctx   11.3   14.4           Control (Path) 3 Occipital Ctx   9.5   8.5           Control (Path) 4 Occipital Ctx   13.9   17.7           Control 1 Parietal Ctx   11.1   15.8           Control 2 Parietal Ctx   48.0   66.0           Control 3 Parietal Ctx   17.0   22.2           Control (Path) 1 Parietal Ctx   55.5   66.4           Control (Path) 2 Parietal Ctx   30.6   34.2           Control (Path) 3 Parietal Ctx   14.3   11.3           Control (Path) 4 Parietal Ctx   37.1   43.2                                                
     [0834]               TABLE OC                          General_screening_panel_v1.4                             Tissue Name   A                                         Adipose   15.8           Melanoma* Hs688(A).T   38.4           Melanoma* Hs688(B).T   51.4           Melanoma* M14   43.5           Melanoma* LOXIMVI   25.0           Melanoma* SK-MEL-5   52.9           Squamous cell carcinoma SCC-4   16.5           Testis Pool   44.4           Prostate ca.* (bone met) PC-3   57.4           Prostate Pool   16.2           Placenta   4.3           Uterus Pool   4.9           Ovarian ca. OVCAR-3   37.9           Ovarian ca. SK-OV-3   39.0           Ovarian ca. OVCAR-4   18.0           Ovarian ca. OVCAR-5   63.3           Ovarian ca. IGROV-1   14.5           Ovarian ca. OVCAR-8   12.1           Ovary   17.2           Breast ca. MCF-7   32.5           Breast ca. MDA-MB-231   47.3           Breast ca. BT 549   58.2           Breast ca. T47D   73.7           Breast ca. MDA-N   12.6           Breast Pool   14.6           Trachea   14.6           Lung   7.5           Fetal Lung   63.7           Lung ca. NCI-N417   2.7           Lung ca. LX-1   19.5           Lung ca. NCI-H146   4.9           Lung ca. SHP-77   12.0           Lung ca. A549   24.8           Lung ca. NCI-H526   8.8           Lung ca. NCI-H23   23.8           Lung ca. NCI-H460   29.5           Lung ca. HOP-62   23.0           Lung ca. NCI-H522   36.1           Liver   0.5           Fetal Liver   27.2           Liver ca. HepG2   0.2           Kidney Pool   23.0           Fetal Kidney   21.2           Renal ca. 786-0   32.1           Renal ca. A498   17.6           Renal ca. ACHN   36.1           Renal ca. UO-31   21.0           Renal ca. TK-10   24.0           Bladder   26.8           Gastric ca. (liver met.) NCI-N87   55.1           Gastric ca. KATO III   53.6           Colon ca. SW-948   19.1           Colon ca. SW480   41.2           Colon ca.* (SW480 met) SW620   14.4           Colon ca. HT29   9.5           Colon ca. HCT-116   50.7           Colon ca. CaCo-2   9.5           Colon cancer tissue   7.3           Colon ca. SW1116   6.7           Colon ca. Colo-205   10.5           Colon ca. SW-48   7.3           Colon Pool   15.9           Small Intestine Pool   15.0           Stomach Pool   9.6           Bone Marrow Pool   9.4           Fetal Heart   72.7           Heart Pool   66.9           Lymph Node Pool   19.3           Fetal Skeletal Muscle   17.6           Skeletal Muscle Pool   63.7           Spleen Pool   11.0           Thymus Pool   7.5           CNS cancer (glio/astro) U87-MG   30.8           CNS cancer (glio/astro) U-118-MG   44.1           CNS cancer (neuro; met) SK-N-AS   37.9           CNS cancer (astro) SF-539   33.2           CNS cancer (astro) SNB-75   34.6           CNS cancer (glio) SNB-19   18.9           CNS cancer (glio) SF-295   64.2           Brain (Amygdala) Pool   13.4           Brain (cerebellum)   100.0           Brain (fetal)   28.5           Brain (Hippocampus) Pool   21.5           Cerebral Cortex Pool   22.8           Brain (Substantia nigra) Pool   19.2           Brain (Thalamus) Pool   26.8           Brain (whole)   40.9           Spinal Cord Pool   19.8           Adrenal Gland   40.3           Pituitary gland Pool   5.8           Salivary Gland   6.4           Thyroid (female)   17.2           Pancreatic ca. CAPAN2   14.8           Pancreas Pool   22.8                                    
     [0835]               TABLE OD                          Panel 4D                             Tissue Name   A                                         Secondary Th1 act   15.0           Secondary Th2 act   15.8           Secondary Tr1 act   15.0           Secondary Th1 rest   3.0           Secondary Th2 rest   8.5           Secondary Tr1 rest   4.4           Primary Th1 act   28.5           Primary Th2 act   19.5           Primary Tr1 act   24.0           Primary Th1 rest   11.5           Primary Th2 rest   8.5           Primary Tr1 rest   4.6           CD45RA CD4 lymphocyte act   12.2           CD45RO CD4 lymphocyte act   21.2           CD8 lymphocyte act   14.2           Secondary CD8 lymphocyte rest   22.1           Secondary CD8 lymphocyte act   10.8           CD4 lymphocyte none   5.1           2ry Th1/Th2/Tr1_anti-CD95 CH11   4.0           LAK cells rest   4.8           LAK cells IL-2   10.6           LAK cells IL-2 + IL-12   15.7           LAK cells IL-2 + IFN gamma   19.3           LAK cells IL-2 + IL-18   14.2           LAK cells PMA/ionomycin   5.7           NK Cells IL-2 rest   7.9           Two Way MLR 3 day   11.5           Two Way MLR 5 day   9.7           Two Way MLR 7 day   6.7           PBMC rest   3.6           PBMC PWM   61.6           PBMC PHA-L   31.6           Ramos (B cell) none   13.7           Ramos (B cell) ionomycin   94.6           B lymphocytes PWM   63.7           B lymphocytes CD40L and IL-4   100.0           EOL-1 dbcAMP   3.9           EOL-1 dbcAMP PMA/ionomycin   6.7           Dendritic cells none   2.2           Dendritic cells LPS   1.9           Dendritic cells anti-CD40   0.8           Monocytes rest   0.5           Monocytes LPS   5.8           Macrophages rest   1.0           Macrophages LPS   7.2           HUVEC none   10.6           HUVEC starved   17.3           HUVEC IL-1beta   10.7           HUVEC IFN gamma   9.3           HUVEC TNF alpha + IFN gamma   20.9           HUVEC TNF alpha + IL4   14.9           HUVEC IL-11   6.6           Lung Microvascular EC none   9.3           Lung Microvascular EC TNFalpha + IL-1beta   58.2           Microvascular Dermal EC none   22.4           Microsvasular Dermal EC TNFalpha + IL-1beta   63.3           Bronchial epithelium TNFalpha + IL1beta   20.6           Small airway epithelium none   3.8           Small airway epithelium TNFalpha + IL-1beta   48.6           Coronery artery SMC rest   11.7           Coronery artery SMC TNFalpha + IL-1beta   9.1           Astrocytes rest   16.4           Astrocytes TNFalpha + IL-1beta   12.9           KU-812 (Basophil) rest   16.8           KU-812 (Basophil) PMA/ionomycin   50.3           CCD1106 (Keratinocytes) none   14.0           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   10.8           Liver cirrhosis   3.3           Lupus kidney   1.6           NCI-H292 none   14.6           NCI-H292 IL-4   18.9           NCI-H292 IL-9   16.3           NCI-H292 IL-13   13.1           NCI-H292 IFN gamma   11.2           HPAEC none   11.5           HPAEC TNF alpha + IL-1 beta   31.0           Lung fibroblast none   13.9           Lung fibroblast TNF alpha + IL-1 beta   13.6           Lung fibroblast IL-4   28.1           Lung fibroblast IL-9   22.2           Lung fibroblast IL-13   13.5           Lung fibroblast IFN gamma   23.7           Dermal fibroblast CCD1070 rest   30.4           Dermal fibroblast CCD1070 TNF alpha   49.0           Dermal fibroblast CCD1070 IL-1 beta   15.6           Dermal fibroblast IFN gamma   6.4           Dermal fibroblast IL-4   14.2           IBD Colitis 2   1.6           IBD Crohn&#39;s   0.9           Colon   5.9           Lung   13.8           Thymus   48.0           Kidney   20.4                                    
     [0836] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3288 shows results from two experiments using the same probe/primer set are in excellent agreement. This gene was found to upregulated in the temporal cortex of Alzheimer&#39;s disease (AD) patients (p=0.0007 when analyzed by ANCOVA); the temporal cortex shows marked neuronal loss in the early to middle stages of AD. Upregulation of this gene expression, however, was not apparent in the occipital cortex, where neuronal degeneration does not occur in AD. Taken together, these data suggest that the protein encoded by this gene is involved in the pathologic process of Alzheimer&#39;s disease, making this an excellent small molecule drug target.  
     [0837] This gene encodes a protein with homology to cation transporters. For example, iron transporters in the brain have been shown to play an important role in age-related neurodegenerative diseases, including Parkinson&#39;s Disease, Alzheimer&#39;s disease, Huntington&#39;s disease and amyotrophic lateral sclerosis (Qian Z M, et al. Brain Res Brain Res Rev August 1998;27(3):257-67).  
     [0838] General_screening_panel_v1.4 Summary: Ag3288 The CG57570-01 gene is expressed at high to moderate levels across almost all samples in this panel, with highest expression in the cerebellum (CT=26.7). This gene is also moderately expressed in all other regions of the CNS examined, including in amygdala, substantia nigra, thalamus, cerebral cortex, and spinal cord, suggesting that this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0839] This gene is also expressed in a number of tissues with metabolic or endocrine function, including adipose, adrenal gland, gastrointestinal tract, pancreas, skeletal muscle and thyroid. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes. Interestingly, this gene is differentially expressed in adult liver (CT=34) vs fetal liver (CT=29).  
     [0840] In addition, there is substantial expression of this gene associated with cancer cell lines. Therefore, therapeutic modulation of the activity of this gene or its protein product, through the use of small molecule drugs, protein therapeutics or antibodies, might be beneficial in the treatment of cancer.  
     [0841] Panel 4D Summary: Ag3288 This gene is expressed at high to moderate levels in a wide range of cell types of significance in the immune response and tissue response in health and disease, with the highest expression being detected in activated B cells (CT=25.4). Targeting this gene or its protein product with a small molecule drug or antibody therapeutic may modulate the functions of cells of the immune system and in particular of B cells as well as resident tissue cells and lead to improvement of the symptoms of patients suffering from rheumatoid diseases or B hyperglobulinemia and also other autoimmune disorders.  
     [0842] P. CG57758-02: Sodium/Lithium-dependent Dicarboxylate Transporter  
     [0843] Expression of gene CG57758-02 was assessed using the primer-probe sets Ag3326 and Ag3692, described in Tables PA and PB. Results of the RTQ-PCR runs are shown in Tables PC, PD, PE and PF.  
                   TABLE PA                          Probe Name Ag3326                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-ccatttactggtgcacagaagt-3′   22   167   161           Probe   TET-5′-atccctctggctgtcacctctctcat-3′-TAMRA   26   190   162       Reverse   5′-ggagtccagaatctggaagagt-3′   22   234   163                  
 
     [0844]                   TABLE PB                          Probe Name Ag3692                                                     Start   SEQ ID           Primers   Sequences   Length   Position   NO                                             Forward   5′-ccatttactggtgcacagaagt-3′   22   167   164           Probe   TET-5′-atccctctggctgtcacctctctcat-3′-TAMRA   26   190   165       Reverse   5′-ggagtccagaatctggaagagt-3′   22   234   166                    
     [0845]               TABLE PC                          CNS_neurodegeneration_v1.0                                     Tissue Name   A   B   C                                                 AD 1 Hippo   2.1   4.3   1.0           AD 2 Hippo   20.9   28.3   25.0           AD 3 Hippo   0.0   0.9   0.6           AD 4 Hippo   2.1   7.1   2.6           AD 5 hippo   72.7   97.9   85.3           AD 6 Hippo   13.7   18.3   5.5           Control 2 Hippo   14.5   20.2   15.2           Control 4 Hippo   11.7   7.4   5.1           Control (Path) 3 Hippo   6.7   4.4   4.5           AD 1 Temporal Ctx   4.0   1.7   2.8           AD 2 Temporal Ctx   80.7   50.7   37.4           AD 3 Temporal Ctx   3.6   0.0   1.1           AD 4 Temporal Ctx   19.5   30.6   15.2           AD 5 Inf Temporal Ctx   100.0   100.0   99.3           AD 5 Sup Temporal Ctx   32.8   29.1   33.2           AD 6 Inf Temporal Ctx   27.7   21.3   26.6           AD 6 Sup Temporal Ctx   41.8   53.6   17.0           Control 1 Temporal Ctx   12.0   33.9   18.3           Control 2 Temporal Ctx   30.1   49.3   44.4           Control 3 Temporal Ctx   38.7   39.5   33.4           Control 4 Temporal Ctx   17.6   25.2   24.1           Control (Path) 1 Temporal   69.7   70.7   49.7           Ctx           Control (Path) 2 Temporal   35.4   50.7   33.4           Ctx           Control (Path) 3 Temporal   8.5   15.3   12.0           Ctx           Control (Path) 4 Temporal   31.2   36.6   52.1           Ctx           AD 1 Occipital Ctx   2.7   3.0   0.0           AD 2 Occipital Ctx   0.0   0.0   0.0           (Missing)           AD 3 Occipital Ctx   1.5   7.2   1.3           AD 4 Occipital Ctx   71.7   35.6   30.6           AD 5 Occipital Ctx   25.3   31.9   12.4           AD 6 Occipital Ctx   17.2   19.1   11.2           Control 1 Occipital Ctx   7.0   9.0   8.1           Control 2 Occipital Ctx   33.2   44.8   26.1           Control 3 Occipital Ctx   30.1   37.6   21.9           Control 4 Occipital Ctx   16.3   12.6   8.2           Control (Path) 1 Occipital   42.0   55.9   52.9           Ctx           Control (Path) 2 Occipital   6.7   13.0   7.7           Ctx           Control (Path) 3 Occipital   8.7   6.6   5.4           Ctx           Control (Path) 4 Occipital   8.1   9.0   7.4           Ctx           Control 1 Parietal Ctx   21.2   23.0   15.3           Control 2 Parietal Ctx   48.6   38.2   22.1           Control 3 Parietal Ctx   28.3   34.4   32.8           Control (Path) 1 Parietal   78.5   97.3   100.0           Ctx           Control (Path) 2 Parietal   50.7   50.7   37.9           Ctx           Control (Path) 3 Parietal   10.7   10.1   9.6           Ctx           Control (Path) 4 Parietal   30.6   24.5   40.9           Ctx                                                            
     [0846]               TABLE PD                          General_screening_panel_v1.4                                 Tissue Name   A   B                                             Adipose   0.0   0.0           Melanoma* Hs688(A).T   0.0   0.0           Melanoma* Hs688(B).T   0.1   0.0           Melanoma* M14   0.0   0.0           Melanoma* LOXIMVI   0.0   0.0           Melanoma* SK-MEL-5   0.0   0.0           Squamous cell carcinoma   0.9   0.7           SCC-4           Testis Pool   0.1   0.2           Prostate ca.* (bone met) PC-3   0.0   0.0           Prostate Pool   0.0   0.0           Placenta   0.0   0.0           Uterus Pool   0.0   0.0           Ovarian ca. OVCAR-3   0.0   0.0           Ovarian ca. SK-OV-3   0.0   0.0           Ovarian ca. OVCAR-4   0.1   0.0           Ovarian ca. OVCAR-5   0.0   0.0           Ovarian ca. IGROV-1   0.0   0.0           Ovarian ca. OVCAR-8   2.8   2.2           Ovary   0.7   0.6           Breast ca. MCF-7   0.0   0.0           Breast ca. MDA-MB-231   0.0   0.0           Breast ca. BT 549   0.6   0.8           Breast ca. T47D   0.0   0.0           Breast ca. MDA-N   0.0   0.0           Breast Pool   0.0   0.1           Trachea   0.2   0.1           Lung   0.0   0.0           Fetal Lung   0.2   0.1           Lung ca. NCI-N417   0.0   0.0           Lung ca. LX-1   0.0   0.0           Lung ca. NCI-H146   0.0   0.0           Lung ca. SHP-77   0.0   0.0           Lung ca. A549   0.0   0.1           Lung ca. NCI-H526   2.0   0.0           Lung ca. NCI-H23   0.7   0.6           Lung ca. NCI-H460   0.0   0.0           Lung ca. HOP-62   0.1   0.2           Lung ca. NCI-H522   0.0   0.0           Liver   28.7   24.1           Fetal Liver   100.0   100.0           Liver ca. HepG2   29.5   26.2           Kidney Pool   0.0   0.0           Fetal Kidney   0.1   0.1           Renal ca. 786-0   0.0   0.0           Renal ca. A498   0.0   0.0           Renal ca. ACHN   0.0   0.0           Renal ca. UO-31   0.0   0.0           Renal ca. TK-10   11.4   12.0           Bladder   0.0   0.1           Gastric ca. (liver met.) NCI-N87   0.0   0.0           Gastric ca. KATO III   0.0   0.0           Colon ca. SW-948   0.0   0.0           Colon ca. SW480   0.0   0.0           Colon ca.* (SW480 met) SW620   0.0   0.0           Colon ca. HT29   0.0   0.0           Colon ca. HCT-116   0.0   0.0           Colon ca. CaCo-2   0.0   0.0           Colon cancer tissue   0.1   0.0           Colon ca. SW1116   0.0   0.0           Colon ca. Colo-205   0.0   0.0           Colon ca. SW-48   0.0   0.0           Colon Pool   0.6   0.0           Small Intestine Pool   0.1   0.0           Stomach Pool   0.0   0.0           Bone Marrow Pool   0.0   0.1           Fetal Heart   0.0   0.0           Heart Pool   0.0   0.0           Lymph Node Pool   0.1   0.0           Fetal Skeletal Muscle   0.0   0.0           Skeletal Muscle Pool   0.0   0.0           Spleen Pool   0.4   0.2           Thymus Pool   0.0   0.0           CNS cancer (glio/astro) U87-MG   0.0   0.0           CNS cancer (glio/astro) U-118-   0.0   0.0           MG           CNS cancer (neuro; met) SK-N-   0.0   0.0           AS           CNS cancer (astro) SF-539   0.0   0.0           CNS cancer (astro) SNB-75   0.0   0.0           CNS cancer (glio) SNB-19   0.0   0.0           CNS cancer (glio) SF-295   0.1   0.1           Brain (Amygdala) Pool   0.4   0.4           Brain (cerebellum)   1.4   1.0           Brain (fetal)   0.7   0.4           Brain (Hippocampus) Pool   0.5   0.7           Cerebral Cortex Pool   1.4   1.5           Brain (Substantia nigra) Pool   1.4   1.4           Brain (Thalamus) Pool   1.1   0.9           Brain (whole)   4.1   3.7           Spinal Cord Pool   0.1   0.2           Adrenal Gland   2.6   1.9           Pituitary gland Pool   0.0   0.2           Salivary Gland   40.9   35.1           Thyroid (female)   0.0   0.0           Pancreatic ca. CAPAN2   0.5   0.8           Pancreas Pool   0.0   0.0                                                
     [0847]               TABLE PE                          Panel 4.1D                             Tissue Name   A                                         Secondary Th1 act   0.0           Secondary Th2 act   0.0           Secondary Tr1 act   0.0           Secondary Th1 rest   0.0           Secondary Th2 rest   0.0           Secondary Tr1 rest   0.0           Primary Th1 act   0.0           Primary Th2 act   0.0           Primary Tr1 act   4.2           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   0.0           CD45RA CD4 lymphocyte act   3.9           CD45RO CD4 lymphocyte act   0.0           CD8 lymphocyte act   0.0           Secondary CD8 lymphocyte rest   0.0           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   0.0           2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0           LAK cells rest   0.0           LAK cells IL-2   0.0           LAK cells IL-2 + IL-12   0.0           LAK cells IL-2 + IFN gamma   0.0           LAK cells IL-2 + IL-18   0.0           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   0.0           Two Way MLR 3 day   0.0           Two Way MLR 5 day   3.2           Two Way MLR 7 day   0.0           PBMC rest   0.0           PBMC PWM   0.0           PBMC PHA-L   0.0           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   0.0           B lymphocytes CD40L and IL-4   0.0           EOL-1 dbcAMP   0.0           EOL-1 dbcAMP PMA/ionomycin   0.0           Dendritic cells none   0.0           Dendritic cells LPS   0.0           Dendritic cells anti-CD40   0.0           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   0.0           Macrophages LPS   0.0           HUVEC none   0.0           HUVEC starved   0.0           HUVEC IL-1beta   0.0           HUVEC IFN gamma   0.0           HUVEC TNF alpha + IFN gamma   0.0           HUVEC TNF alpha + IL4   0.0           HUVEC IL-11   0.0           Lung Microvascular EC none   0.0           Lung Microvascular EC TNFalpha + IL-1beta   0.0           Microvascular Dermal EC none   11.3           Microsvasular Dermal EC TNFalpha + IL-1beta   0.0           Bronchial epithelium TNFalpha + IL1beta   28.5           Small airway epithelium none   5.7           Small airway epithelium TNFalpha + IL-1beta   0.0           Coronery artery SMC rest   0.0           Coronery artery SMC TNFalpha + IL-1beta   0.0           Astrocytes rest   0.0           Astrocytes TNFalpha + IL-1beta   0.0           KU-812 (Basophil) rest   3.6           KU-812 (Basophil) PMA/ionomycin   4.3           CCD1106 (Keratinocytes) none   10.7           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   0.0           Liver cirrhosis   94.0           NCI-H292 none   0.0           NCI-H292 IL-4   0.0           NCI-H292 IL-9   0.0           NCI-H292 IL-13   0.0           NCI-H292 IFN gamma   0.0           HPAEC none   0.0           HPAEC TNF alpha + IL-1 beta   0.0           Lung fibroblast none   0.0           Lung fibroblast TNF alpha + IL-1 beta   0.0           Lung fibroblast IL-4   0.0           Lung fibroblast IL-9   0.0           Lung fibroblast IL-13   0.0           Lung fibroblast IFN gamma   0.0           Dermal fibroblast CCD1070 rest   0.0           Dermal fibroblast CCD1070 TNF alpha   0.0           Dermal fibroblast CCD1070 IL-1 beta   0.0           Dermal fibroblast IFN gamma   0.0           Dermal fibroblast IL-4   0.0           Dermal Fibroblasts rest   0.0           Neutrophils TNFa + LPS   0.0           Neutrophils rest   0.0           Colon   0.0           Lung   0.0           Thymus   2.4           Kidney   100.0                                    
     [0848]               TABLE PF                          Panel 5 Islet                             Tissue Name   A                                         97457_Patient-02go_adipose   0.0           97476_Patient-07sk_skeletal muscle   0.0           97477_Patient-07ut_uterus   0.0           97478_Patient-07pl_placenta   0.0           99167_Bayer Patient 1   0.3           97482_Patient-08ut_uterus   0.0           97483_Patient-08pl_placenta   0.0           97486_Patient-09sk_skeletal muscle   0.0           97487_Patient-09ut_uterus   0.0           97488_Patient-09pl_placenta   0.0           97492_Patient-10ut_uterus   0.0           97493_Patient-10pl_placenta   0.0           97495_Patient-11go_adipose   0.0           97496_Patient-11sk_skeletal muscle   0.0           97497_Patient-11ut_uterus   0.0           97498_Patient-11pl_placenta   0.0           97500_Patient-12go_adipose   0.1           97501_Patient-12sk_skeletal muscle   0.3           97502_Patient-12ut_uterus   0.0           97503_Patient-12pl_placenta   0.0           94721_Donor 2 U - A_Mesenchymal Stem Cells   0.0           94722_Donor 2 U - B_Mesenchymal Stem Cells   0.0           94723_Donor 2 U - C_Mesenchymal Stem Cells   0.0           94709_Donor 2 AM - A_adipose   0.2           94710_Donor 2 AM - B_adipose   0.0           94711_Donor 2 AM - C_adipose   0.0           94712_Donor 2 AD - A_adipose   0.0           94713_Donor 2 AD - B_adipose   0.0           94714_Donor 2 AD - C_adipose   0.0           94742_Donor 3 U - A_Mesenchymal Stem Cells   0.0           94743_Donor 3 U - B_Mesenchymal Stem Cells   0.0           94730_Donor 3 AM - A_adipose   0.0           94731_Donor 3 AM - B_adipose   0.0           94732_Donor 3 AM - C_adipose   0.0           94733_Donor 3 AD - A_adipose   0.0           94734_Donor 3 AD - B_adipose   0.0           94735_Donor 3 AD - C_adipose   0.0           77138_Liver_HepG2untreated   100.0           73556_Heart_Cardiac stromal cells (primary)   0.0           81735_Small Intestine   39.5           72409_Kidney_Proximal Convoluted Tubule   0.0           82685_Small intestine_Duodenum   0.0           90650_Adrenal_Adrenocortical adenoma   0.0           72410_Kidney_HRCE   0.0           72411_Kidney_HRE   0.0           73139_Uterus_Uterine smooth muscle cells   0.0                                    
     [0849] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3326/Ag3692 shows three experiments tested with two primer pairs (same sequence) are in excellent agreement. This gene is found to be down-regulated in the temporal cortex of Alzheimer&#39;s disease patients. Therefore, up-regulation of this gene or its protein product, or treatment with specific agonists for this gene may be of use in reversing the dementia/memory loss associated with this disease and neuronal death.  
     [0850] General_screening_panel_v1.4 Summary: Ag3326/Ag3692 Two experiments with the same probe and primer set produce results that are in excellent agreement. This gene is highly expressed in fetal liver (CT=26.5-27.0) and moderately expressed in adult liver and liver cancer cell line HepG2. This result agrees with the results seen in Panel 5 (expression in HepG2). These results are in agreement with published data that show a novel sodium dicarboxylate transporter in brain, choroid plexus kidney, intestine and liver (Chen X Z, et al. J Biol Chem Aug. 14, 1998;273(33):20972-81; Pajor A M, et al. Am J Physiol Cell Physiol May 2001;280(5):C1215-23).  
     [0851] This gene is expressed at low levels throughout the CNS, including in amygdala, substantia nigra, thalamus, cerebellum, and cerebral cortex. Therefore, this gene may play a role in central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0852] Low but significant levels of expression are also seen in the adrenal gland. Thus, this gene product may also be involved in metabolic disorders of this gland, including adrenoleuleukodystrophy and congenital adrenal hyperplasia.  
     [0853] Panel 4.1D Summary: Ag3692 Significant expression of this gene is seen only in kidney and a liver cirrhosis samples in this panel (CTs=34.0). These results confirm that this gene is expressed in liver derived samples.  
     [0854] Panel 5 Islet Summary: Ag3326—The highest expression of this gene is in liver cancer cell line HepG2 (CT=29.2). There is also moderate expression in the small intestine (CT=30.5).  
     [0855] Q. CG59693-01: 20 Alpha-hydroxysteroid Dehydrogenase  
     [0856] Expression of gene CG59693-01 was assessed using the primer-probe set Ag3562, described in Table QA. Results of the RTQ-PCR runs are shown in Tables QB, QE, QF, QG, QH, QI and QJ.  
                   TABLE QA                          Probe Name Ag3562                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-ctggccaagagctacaatga-3′   20   802   168           Probe   TET-5′-catcagacagaacgtgcaggtgtttg-3′-TAMRA   26   828   169       Reverse   5′-aggccatctatggctttcat-3′   20   877   170                  
 
     [0857]               TABLE QB                          Ardais Panel v.1.0                             Tissue Name   A                                         136799_Lung cancer (362)   52.9           136800_Lung NAT (363)   0.8           136813_Lung cancer (372)   100.0           136814_Lung NAT (373)   0.4           136815_Lung cancer (374)   1.1           136816_Lung NAT (375)   1.6           136791_Lung cancer (35A)   0.4           136795_Lung cancer (35E)   1.6           136797_Lung cancer (360)   0.4           136794_lung NAT (35D)   1.2           136818_Lung NAT (377)   0.5           136787_lung cancer (356)   0.1           136788_lung NAT (357)   1.1           136806_Lung cancer (36B)   0.1           136807_Lung NAT (36C)   0.4           136789_lung cancer (358)   0.4           136802_Lung cancer (365)   1.6           136803_Lung cancer (368)   0.5           136804_Lung cancer (369)   1.4           136811_Lung cancer (370)   64.2           136810_Lung NAT (36F)   3.9                                    
     [0858]               TABLE QC                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   47.3   54.7           AD 2 Hippo   30.1   31.2           AD 3 Hippo   9.9   14.6           AD 4 Hippo   10.4   11.6           AD 5 Hippo   57.4   74.2           AD 6 Hippo   100.0   100.0           Control 2 Hippo   22.7   27.7           Control 4 Hippo   15.7   20.6           Control (Path) 3 Hippo   8.2   8.3           AD 1 Temporal Ctx   33.2   42.6           AD 2 Temporal Ctx   28.3   28.5           AD 3 Temporal Ctx   8.3   10.4           AD 4 Temporal Ctx   15.5   18.8           AD 5 Inf Temporal Ctx   55.1   83.5           AD 5 Sup Temporal Ctx   64.6   74.2           AD 6 Inf Temporal Ctx   58.2   68.3           AD 6 Sup Temporal Ctx   59.5   70.7           Control 1 Temporal Ctx   7.6   9.2           Control 2 Temporal Ctx   15.2   27.7           Control 3 Temporal Ctx   14.1   12.3           Control 3 Temporal Ctx   7.7   8.3           Control (Path) 1 Temporal Ctx   24.5   29.1           Control (Path) 2 Temporal Ctx   15.3   17.6           Control (Path) 3 Temporal Ctx   5.0   8.5           Control (Path) 4 Temporal Ctx   18.9   20.6           AD 1 Occipital Ctx   23.0   41.5           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   10.4   10.2           AD 4 Occipital Ctx   13.1   8.2           AD 5 Occipital Ctx   24.5   29.3           AD 6 Occipital Ctx   24.8   35.4           Control 1 Occipital Ctx   4.7   5.0           Control 2 Occipital Ctx   18.0   29.9           Control 3 Occipital Ctx   11.0   13.6           Control 4 Occipital Ctx   7.3   9.2           Control (Path) 1 Occipital Ctx   32.3   31.0           Control (Path) 2 Occipital Ctx   5.2   8.0           Control (Path) 3 Occipital Ctx   7.6   5.6           Control (Path) 4 Occipital Ctx   10.5   12.5           Control 1 Parietal Ctx   6.1   8.1           Control 2 Parietal Ctx   66.0   67.8           Control 3 Parietal Ctx   19.1   18.3           Control (Path) 1 Parietal Ctx   29.9   35.6           Control (Path) 2 Parietal Ctx   11.5   13.0           Control (Path) 3 Parietal Ctx   5.9   8.1           Control (Path) 4 Parietal Ctx   23.2   28.1                                                
     [0859]               TABLE QD                          General_screening_panel_v1.4                             Tissue Name   A                                         Adipose   2.1           Melanoma* Hs688(A).T   0.2           Melanoma* Hs688(B).T   0.3           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.5           Testis Pool   0.2           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.1           Placenta   0.0           Uterus Pool   0.1           Ovarian ca. OVCAR-3   0.0           Ovarian ca. SK-OV-3   11.8           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.3           Ovarian ca. IGROV-1   0.5           Ovarian ca. OVCAR-8   0.2           Ovary   0.2           Breast ca. MCF-7   0.5           Breast ca. MDA-MB-231   1.1           Breast ca. BT 549   1.2           Breast ca. T47D   0.6           Breast ca. MDA-N   0.0           Breast Pool   0.1           Trachea   1.3           Lung   0.2           Fetal Lung   0.3           Lung ca. NCI-N417   0.0           Lung ca. LX-1   1.6           Lung ca. NCI-H146   1.0           Lung ca. SHP-77   14.7           Lung ca. A549   100.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.2           Lung ca. NCI-H460   11.1           Lung ca. HOP-62   0.1           Lung ca. NCI-H522   0.6           Liver   0.7           Fetal Liver   4.1           Liver ca. HepG2   2.4           Kidney Pool   0.2           Fetal Kidney   0.1           Renal ca. 786-0   0.3           Renal ca. A498   11.2           Renal ca. ACHN   0.2           Renal ca. UO-31   0.1           Renal ca. TK-10   1.5           Bladder   0.8           Gastric ca. (liver met.) NCI-N87   0.1           Gastric ca. KATO III   0.4           Colon ca. SW-948   0.6           Colon ca. SW480   0.1           Colon ca.* (SW480 met) SW620   0.5           Colon ca. HT29   0.5           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   2.6           Colon cancer tissue   0.4           Colon ca. SW1116   0.0           Colon ca. Colo-205   3.0           Colon ca. SW-48   0.9           Colon Pool   0.1           Small Intestine Pool   0.1           Stomach Pool   0.1           Bone Marrow Pool   0.1           Fetal Heart   0.0           Heart Pool   0.1           Lymph Node Pool   0.2           Fetal Skeletal Muscle   0.1           Skeletal Muscle Pool   0.7           Spleen Pool   0.0           Thymus Pool   0.2           CNS cancer (glio/astro) U87-MG   0.9           CNS cancer (glio/astro) U-118-MG   1.0           CNS cancer (neuro; met) SK-N-AS   0.3           CNS cancer (astro) SF-539   0.1           CNS cancer (astro) SNB-75   10.2           CNS cancer (glio) SNB-19   0.4           CNS cancer (glio) SF-295   4.0           Brain (Amygdala) Pool   0.2           Brain (cerebellum)   0.1           Brain (fetal)   0.5           Brain (Hippocampus) Pool   0.1           Cerebral Cortex Pool   0.1           Brain (Substantia nigra) Pool   0.2           Brain (Thalamus) Pool   0.2           Brain (whole)   0.4           Spinal Cord Pool   0.3           Adrenal Gland   0.2           Pituitary gland Pool   0.0           Salivary Gland   0.1           Thyroid (female)   0.1           Pancreatic ca. CAPAN2   0.2           Pancreas Pool   0.2                                    
     [0860]               TABLE QE                          General_screening_panel_v1.6                             Tissue Name   A                                         Adipose   0.3           Melanoma* Hs688(A).T   0.3           Melanoma* Hs688(B).T   0.3           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.0           Squamous cell carcinoma SCC-4   0.5           Testis Pool   0.2           Prostate ca.* (bone met) PC-3   0.0           Prostate Pool   0.1           Placenta   0.0           Uterus Pool   0.1           Ovarian ca. OVCAR-3   0.0           Ovarian ca. SK-OV-3   14.7           Ovarian ca. OVCAR-4   0.0           Ovarian ca. OVCAR-5   0.3           Ovarian ca. IGROV-1   0.4           Ovarian ca. OVCAR-8   0.2           Ovary   0.2           Breast ca. MCF-7   0.4           Breast ca. MDA-MB-231   1.1           Breast ca. BT 549   1.0           Breast ca. T47D   0.0           Breast ca. MDA-N   0.0           Breast Pool   0.1           Trachea   1.3           Lung   0.1           Fetal Lung   0.3           Lung ca. NCI-N417   0.0           Lung ca. LX-1   1.6           Lung ca. NCI-H146   0.8           Lung ca. SHP-77   13.9           Lung ca. A549   100.0           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   0.2           Lung ca. NCI-H460   13.7           Lung ca. HOP-62   0.0           Lung ca. NCI-H522   0.7           Liver   0.6           Fetal Liver   4.6           Liver ca. HepG2   1.9           Kidney Pool   0.2           Fetal Kidney   0.1           Renal ca. 786-0   0.3           Renal ca. A498   11.3           Renal ca. ACHN   0.2           Renal ca. UO-31   0.1           Renal ca. TK-10   1.5           Bladder   0.8           Gastric ca. (liver met.) NCI-N87   0.1           Gastric ca. KATO III   0.3           Colon ca. SW-948   0.5           Colon ca. SW480   0.0           Colon ca.* (SW480 met) SW620   0.6           Colon ca. HT29   0.6           Colon ca. HCT-116   0.0           Colon ca. CaCo-2   2.4           Colon cancer tissue   0.4           Colon ca. SW1116   0.0           Colon ca. Colo-205   4.7           Colon ca. SW-48   0.9           Colon Pool   0.1           Small Intestine Pool   0.1           Stomach Pool   0.1           Bone Marrow Pool   0.0           Fetal Heart   0.1           Heart Pool   0.1           Lymph Node Pool   0.2           Fetal Skeletal Muscle   0.0           Skeletal Muscle Pool   0.2           Spleen Pool   0.0           Thymus Pool   0.2           CNS cancer (glio/astro) U87-MG   4.7           CNS cancer (glio/astro) U-118-MG   1.0           CNS cancer (neuro; met) SK-N-AS   0.3           CNS cancer (astro) SF-539   0.1           CNS cancer (astro) SNB-75   9.5           CNS cancer (glio) SNB-19   0.4           CNS cancer (glio) SF-295   3.4           Brain (Amygdala) Pool   0.1           Brain (cerebellum)   0.2           Brain (fetal)   0.4           Brain (Hippocampus) Pool   0.1           Cerebral Cortex Pool   0.1           Brain (Substantia nigra) Pool   0.1           Brain (Thalamus) Pool   0.2           Brain (whole)   0.4           Spinal Cord Pool   0.4           Adrenal Gland   0.2           Pituitary gland Pool   0.0           Salivary Gland   0.1           Thyroid (female)   0.1           Pancreatic ca. CAPAN2   0.1           Pancreas Pool   0.1                                    
     [0861]               TABLE QF                          HASS Panel v1.0                             Tissue Name   A                                         MCF-7 C1   8.5           MCF-7 C2   12.0           MCF-7 C3   15.7           MCF-7 C4   13.2           MCF-7 C5   20.2           MCF-7 C6   10.4           MCF-7 C7   8.8           MCF-7 C9   6.9           MCF-7 C10   10.2           MCF-7 C11   5.8           MCF-7 C12   8.7           MCF-7 C13   7.6           MCF-7 C15   3.6           MCF-7 C16   13.2           MCF-7 C17   9.8           T24 D1   32.8           T24 D2   12.2           T24 D3   26.4           T24 D4   48.3           T24 D5   18.2           T24 D6   0.2           T24 D7   1.0           T24 D9   0.0           T24 D10   23.7           T24 D11   2.7           T24 D12   0.1           T24 D13   0.3           T24 D15   0.3           T24 D16   0.2           T24 D17   0.5           CAPaN B1   4.4           CAPaN B2   6.3           CAPaN B3   4.3           CAPaN B4   3.4           CAPaN B5   14.9           CAPaN B6   2.1           CAPaN B7   1.8           CAPaN B8   10.7           CAPaN B9   2.6           CAPaN B10   6.4           CAPaN B11   16.3           CAPaN B12   1.7           CAPaN B13   1.3           CAPaN B14   7.4           CAPaN B15   1.2           CAPaN B16   4.2           CAPaN B17   4.2           U87-MG F1 (B)   19.6           U87-MG F2   5.2           U87-MG F3   15.8           U87-MG F4   10.2           U87-MG F5   40.3           U87-MG F6   92.7           U87-MG F7   5.9           U87-MG F8   9.1           U87-MG F9   1.9           U87-MG F10   57.4           U87-MG F11   100.0           U87-MG F12   30.4           U87-MG F13   10.2           U87-MG F14   16.7           U87-MG F15   9.5           U87-MG F16   66.4           U87-MG F17   67.4           LnCAP A1   0.2           LnCAP A2   0.2           LnCAP A3   0.1           LnCAP A4   0.1           LnCAP A5   0.2           LnCAP A6   0.2           LnCAP A7   0.4           LnCAP A8   0.6           LnCAP A9   0.8           LnCAP A10   0.2           LnCAP A11   0.4           LnCAP A12   0.1           LnCAP A13   0.0           LnCAP A14   0.2           LnCAP A15   0.3           LnCAP A16   0.2           LnCAP A17   0.5           Primary Astrocytes   0.4           Primary Renal Proximal Tubule Epithelial cell A2   25.0           Primary melanocytes A5   1.7           126443 - 341 medullo   0.1           126444 - 487 medullo   0.0           126445 - 425 medullo   0.0           126446 - 690 medullo   0.2           126447 - 54 adult glioma   3.8           126448 - 245 adult glioma   0.0           126449 - 317 adult glioma   0.0           126450 - 212 glioma   0.1           126451 - 456 glioma   0.0                                    
     [0862]               TABLE QG                          Oncology_cell_line_screening_panel_v3.1                     Tissue Name   A                             Daoy Medulloblastoma/Cerebellum   0.0       TE671 Medulloblastom/Cerebellum   0.2       D283 Med Medulloblastoma/Cerebellum   0.0       PFSK-1 Primitive Neuroectodermal/Cerebellum   0.1       XF-498_CNS   0.0       SNB-78_CNS/glioma   0.3       SF-268_CNS/glioblastoma   0.0       T98G_Glioblastoma   33.2       SK-N-SH_Neuroblastoma (metastasis)   0.0       SF-295_CNS/glioblastoma   2.3       Cerebellum   0.4       Cerebellum   0.1       NCI-H292_Mucoepidermoid lung ca.   0.3       DMS-114_Small cell lung cancer   0.0       DMS-79_Small cell lung cancer/neuroendocrine   0.0       NCI-H146_Small cell lung cancer/neuroendocrine   2.2       NCI-H526_Small cell lung cancer/neuroendocrine   0.0       NCI-N417_Small cell lung cancer/neuroendocrine   0.0       NCI-H82_Small cell lung cancer/neuroendocrine   0.0       NCI-H157_Squamous cell lung cancer (metastasis)   0.0       NCI-H1155_Large cell lung cancer/neuroendocrine   0.0       NCI-H1299_Large cell lung cancer/neuroendocrine   0.0       NCI-H727_Lung carcinoid   1.3       NCI-UMC-11_Lung carcinoid   100.0       LX-1_Small cell lung cancer   1.6       Colo-205_Colon cancer   7.5       KM12_Colon cancer   0.1       KM20L2_Colon cancer   0.1       NCI-H716_Colon cancer   19.2       SW-48_Colon adenocarcinoma   2.3       SW1116_Colon adenocarcinoma   0.0       LS 174T_Colon adenocarcinoma   0.9       SW-948_Colon adenocarcinoma   0.3       SW-480_Colon adenocarcinoma   0.5       NCI-SNU-5_Gastric ca.   0.0       KATO III_Stomach   0.1       NCI-SNU-16_Gastric ca.   2.7       NCI-SNU-1_Gastric ca.   16.8       RF-1_Gastric adenocarcinoma   0.5       RF-48_Gastric adenocarcinoma   0.0       MKN-45_Gastric ca.   1.6       NCI-N87_Gastric ca.   0.8       OVCAR-5_Ovarian ca.   0.4       RL95-2_Uterine carcinoma   0.5       HelaS3_Cervical adenocarcinoma   0.9       Ca Ski_Cervical epidermoid carcinoma (metastasis)   0.3       ES-2_Ovarian clear cell carcinoma   0.0       Ramos/6 h stim_Stimulated with PMA/ionomycin 6 h   0.0       Ramos/14 h stim_Stimulated with PMA/ionomycin 14 h   0.0       MEG-01_Chronic myelogenous leukemia (megokaryoblast)   0.1       Raji_Burkitt&#39;s lymphoma   0.0       Daudi_Burkitt&#39;s lymphoma   0.0       U266_B-cell plasmacytoma/myeloma   0.0       CA46_Burkitt&#39;s lymphoma   0.0       RL_non-Hodgkin&#39;s B-cell lymphoma   0.0       JM1_pre-B-cell lymphoma/leukemia   0.0       Jurkat_T cell leukemia   0.0       TF-1_Erythroleukemia   1.6       HUT 78_T-cell lymphoma   0.0       U937_Histiocytic lymphoma   0.0       KU-812_Myelogenous leukemia   0.9       769-P_Clear cell renal ca.   1.0       Caki-2_Clear cell renal ca.   63.7       SW 839_Clear cell renal ca.   0.4       G401_Wilms&#39; tumor   0.0       Hs766T_Pancreatic ca. (LN metastasis)   0.2       CAPAN-1_Pancreatic adenocarcinoma (liver metastasis)   0.3       SU86.86_Pancreatic carcinoma (liver metastasis)   1.2       BxPC-3_Pancreatic adenocarcinoma   3.6       HPAC_Pancreatic adenocarcinoma   3.1       MIA PaCa-2_Pancreatic ca.   0.0       CFPAC-1_Pancreatic ductal adenocarcinoma   3.9       PANC-1_Pancreatic epithelioid ductal ca.   0.0       T24_Bladder ca. (transitional cell)   2.0       5637_Bladder ca.   0.1       HT-1197_Bladder ca.   0.0       UM-UC-3_Bladder ca. (transitional cell)   0.1       A204_Rhabdomyosarcoma   0.8       HT-1080_Fibrosarcoma   0.0       MG-63_Osteosarcoma (bone)   0.0       SK-LMS-1_Leiomyosarcoma (vulva)   0.0       SJRH30_Rhabdomyosarcoma (met to bone marrow)   0.1       A431_Epidermoid ca.   3.8       WM266-4_Melanoma   0.1       DU 145_Prostate   0.1       MDA-MB-468_Breast adenocarcinoma   0.5       SSC-4_Tongue   0.4       SSC-9_Tongue   0.2       SSC-15_Tongue   0.3       CAL 27_Squamous cell ca. of tongue   0.1                            
     [0863]               TABLE QH                          Panel 2D                             Tissue Name   A                                         Normal Colon   5.0           CC Well to Mod Diff (ODO3866)   1.5           CC Margin (ODO3866)   2.0           CC Gr.2 rectosigmoid (ODO3868)   0.5           CC Margin (ODO3868)   0.5           CC Mod Diff (ODO3920)   0.5           CC Margin (ODO3920)   1.2           CC Gr.2 ascend colon (ODO3921)   2.1           CC Margin (ODO3921)   1.4           CC from Partial Hepatectomy (ODO4309) Mets   5.5           Liver Margin (ODO4309)   27.0           Colon mets to lung (OD04451-01)   0.4           Lung Margin (OD04451-02)   1.8           Normal Prostate 6546-1   1.3           Prostate Cancer (OD04410)   0.4           Prostate Margin (OD04410)   0.5           Prostate Cancer (OD04720-01)   0.6           Prostate Margin (OD04720-02)   1.6           Normal Lung 061010   4.1           Lung Met to Muscle (ODO4286)   41.8           Muscle Margin (ODO4286)   1.7           Lung Malignant Cancer (OD03126)   2.0           Lung Margin (OD03126)   2.1           Lung Cancer (OD04404)   100.0           Lung Margin (OD04404)   1.7           Lung Cancer (OD04565)   43.2           Lung Margin (OD04565)   0.7           Lung Cancer (OD04237-01)   0.5           Lung Margin (OD04237-02)   2.2           Ocular Mel Met to Liver (ODO4310)   0.1           Liver Margin (ODO4310)   14.8           Melanoma Mets to Lung (OD04321)   0.1           Lung Margin (OD04321)   2.3           Normal Kidney   5.0           Kidney Ca, Nuclear grade 2 (OD04338)   29.1           Kidney Margin (OD04338)   3.1           Kidney Ca Nuclear grade 1/2 (OD04339)   3.7           Kidney Margin (OD04339)   5.1           Kidney Ca, Clear cell type (OD04340)   6.3           Kidney Margin (OD04340)   3.6           Kidney Ca, Nuclear grade 3 (OD04348)   0.1           Kidney Margin (OD04348)   1.8           Kidney Cancer (OD04622-01)   1.9           Kidney Margin (OD04622-03)   1.5           Kidney Cancer (OD04450-01)   12.0           Kidney Margin (OD04450-03)   4.5           Kidney Cancer 8120607   34.2           Kidney Margin 8120608   2.3           Kidney Cancer 8120613   4.4           Kidney Margin 8120614   4.2           Kidney Cancer 9010320   1.5           Kidney Margin 9010321   2.6           Normal Uterus   0.4           Uterus Cancer 064011   0.5           Normal Thyroid   1.2           Thyroid Cancer 064010   0.1           Thyroid Cancer A302152   0.2           Thyroid Margin A302153   1.6           Normal Breast   5.3           Breast Cancer (OD04566)   0.2           Breast Cancer (OD04590-01)   1.4           Breast Cancer Mets (OD04590-03)   5.2           Breast Cancer Metastasis (OD04655-05)   1.1           Breast Cancer 064006   0.3           Breast Cancer 1024   0.8           Breast Cancer 9100266   0.3           Breast Margin 9100265   0.5           Breast Cancer A209073   0.6           Breast Margin A209073   0.5           Normal Liver   11.9           Liver Cancer 064003   5.0           Liver Cancer 1025   14.7           Liver Cancer 1026   3.9           Liver Cancer 6004-T   14.0           Liver Tissue 6004-N   20.9           Liver Cancer 6005-T   3.7           Liver Tissue 6005-N   6.3           Normal Bladder   5.6           Bladder Cancer 1023   0.3           Bladder Cancer A302173   0.8           Bladder Cancer (OD04718-01)   0.1           Bladder Normal Adjacent (OD04718-03)   0.9           Normal Ovary   0.4           Ovarian Cancer 064008   0.5           Ovarian Cancer (OD04768-07)   0.6           Ovary Margin (OD04768-08)   0.3           Normal Stomach   5.5           Gastric Cancer 9060358   1.0           Stomach Margin 9060359   11.7           Gastric Cancer 9060395   14.4           Stomach Margin 9060394   15.3           Gastric Cancer 9060397   2.1           Stomach Margin 9060396   6.7           Gastric Cancer 064005   7.6                                    
     [0864]               TABLE RI                          Panel 4.1D                             Tissue Name   A                                         Secondary Th1 act   0.0           Secondary Th2 act   0.1           Secondary Tr1 act   0.2           Secondary Th1 rest   0.2           Secondary Th2 rest   0.1           Secondary Tr1 rest   0.1           Primary Th1 act   0.0           Primary Th2 act   0.1           Primary Tr1 act   0.0           Primary Th1 rest   0.4           Primary Th2 rest   0.2           Primary Tr1 rest   0.1           CD45RA CD4 lymphocyte act   6.7           CD45RO CD4 lymphocyte act   0.4           CD8 lymphocyte act   0.3           Secondary CD8 lymphocyte rest   0.0           Secondary CD8 lymphocyte act   0.0           CD4 lymphocyte none   0.6           2ry Th1/Th2/Tr1_anti-CD95 CH11   0.2           LAK cells rest   0.5           LAK cells IL-2   1.3           LAK cells IL-2 + IL-12   0.5           LAK cells IL-2 + IFN gamma   1.1           LAK cells IL-2 + IL-18   0.7           LAK cells PMA/ionomycin   1.2           NK Cells IL-2 rest   3.5           Two Way MLR 3 day   1.4           Two Way MLR 5 day   0.6           Two Way MLR 7 day   0.3           PBMC rest   0.8           PBMC PWM   15.0           PBMC PHA-L   0.3           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   0.2           B lymphocytes CD40L and IL-4   0.3           EOL-1 dbcAMP   0.1           EOL-1 dbcAMP PMA/ionomycin   0.1           Dendritic cells none   0.8           Dendritic cells LPS   2.9           Dendritic cells anti-CD40   0.6           Monocytes rest   0.1           Monocytes LPS   9.7           Macrophages rest   2.4           Macrophages LPS   2.9           HUVEC none   1.0           HUVEC starved   0.9           HUVEC IL-1beta   0.7           HUVEC IFN gamma   2.1           HUVEC TNF alpha + IFN gamma   0.7           HUVEC TNF alpha + IL4   0.5           HUVEC IL-11   2.4           Lung Microvascular EC none   13.1           Lung Microvascular EC TNFalpha + IL-1beta   10.1           Microvascular Dermal EC none   11.8           Microsvasular Dermal EC TNFalpha + IL-1beta   12.8           Bronchial epithelium TNFalpha + IL1beta   92.7           Small airway epithelium none   29.9           Small airway epithelium TNFalpha + IL-1beta   50.3           Coronery artery SMC rest   5.4           Coronery artery SMC TNFalpha + IL-1beta   7.0           Astrocytes rest   0.6           Astrocytes TNFalpha + IL-1beta   0.7           KU-812 (Basophil) rest   16.4           KU-812 (Basophil) PMA/ionomycin   33.2           CCD1106 (Keratinocytes) none   2.9           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   2.3           Liver cirrhosis   38.2           NCI-H292 none   11.8           NCI-H292 IL-4   7.1           NCI-H292 IL-9   22.5           NCI-H292 IL-13   5.2           NCI-H292 IFN gamma   4.7           HPAEC none   5.1           HPAEC TNF alpha + IL-1 beta   7.6           Lung fibroblast none   6.8           Lung fibroblast TNF alpha + IL-1 beta   48.6           Lung fibroblast IL-4   7.5           Lung fibroblast IL-9   7.2           Lung fibroblast IL-13   8.8           Lung fibroblast IFN gamma   6.8           Dermal fibroblast CCD1070 rest   13.9           Dermal fibroblast CCD1070 TNF alpha   19.9           Dermal fibroblast CCD1070 IL-1 beta   24.7           Dermal fibroblast IFN gamma   38.4           Dermal fibroblast IL-4   100.0           Dermal Fibroblasts rest   68.3           Neutrophils TNFa + LPS   0.2           Neutrophils rest   0.1           Colon   14.0           Lung   5.8           Thymus   6.6           Kidney   20.7                                    
     [0865]               TABLE QJ                          Panel 5 Islet                             Tissue Name   A                                         97457_Patient-02go_adipose   12.8           97476_Patient-07sk_skeletal muscle   12.4           97477_Patient-07ut_uterus   1.6           97478_Patient-07pl_placenta   0.3           99167_Bayer Patient 1   100.0           97482_Patient-08ut_uterus   0.7           97483_Patient-08pl_placenta   0.0           97486_Patient-09sk_skeletal muscle   7.6           97487_Patient-09ut_uterus   3.9           97488_Patient-09pl_placenta   0.4           97492_Patient-10ut_uterus   1.9           97493_Patient-10pl_placenta   0.5           97495_Patient-11go_adipose   7.4           97496_Patient-11sk_skeletal muscle   8.0           97497_Patient-11ut_uterus   2.8           97498_Patient-11pl_placenta   0.1           97500_Patient-12go_adipose   11.3           97501_Patient-12sk_skeletal muscle   33.2           97502_Patient-12ut_uterus   3.1           97503_Patient-12pl_placenta   0.4           94721_Donor 2 U - A_Mesenchymal Stem Cells   3.8           94722_Donor 2 U - B_Mesenchymal Stem Cells   4.3           94723_Donor 2 U - C_Mesenchymal Stem Cells   6.0           94709_Donor 2 AM - A_adipose   10.2           94710_Donor 2 AM - B_adipose   7.1           94711_Donor 2 AM - C_adipose   6.4           94712_Donor 2 AD - A_adipose   17.9           94713_Donor 2 AD - B_adipose   15.6           94714_Donor 2 AD - C_adipose   19.1           94742_Donor 3 U - A_Mesenchymal Stem Cells   2.0           94743_Donor 3 U - B_Mesenchymal Stem Cells   3.4           94730_Donor 3 AM - A_adipose   17.6           94731_Donor 3 AM - B_adipose   7.6           94732_Donor 3 AM - C_adipose   9.7           94733_Donor 3 AD - A_adipose   32.5           94734_Donor 3 AD - B_adipose   6.7           94735_Donor 3 AD - C_adipose   23.2           77138_Liver_HepG2untreated   82.9           73556_Heart_Cardiac stromal cells (primary)   1.9           81735_Small Intestine   13.4           72409_Kidney_Proximal Convoluted Tubule   3.6           82685_Small intestine_Duodenum   2.5           90650_Adrenal_Adrenocortical adenoma   2.4           72410_Kidney_HRCE   11.6           72411_Kidney_HRE   1.3           73139_Uterus_Uterine smooth muscle cells   0.4                                    
     [0866] Ardais Panel v.1.0 Summary: Ag3562 Highest expression of this gene is seen in lung cancer (CT=19.1). In addition, this gene is more highly expressed in three lung cancer samples than in the corresponding normal adjacent tissue. Thus, expression of this gene could be used as a marker of this cancer. Furthemore, therapeutic modulation of the expression or function of this gene product may be useful in the treatment of lung cancer.  
     [0867] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3562 in this panel confirms the expression of the CG59693-02 gene at low levels in the brain in an independent group of individuals. This gene is found to be upregulated in the temporal cortex of Alzheimer&#39;s disease patients when analyzed by ANCOVA, (p=0.002). Therefore, modulation of gene expression with small molecule therapeutic or biomolecules may prevent or slow the progression of Alzheimer&#39;s disease.  
     [0868] General_screening_panel_v1.4 Summary: Ag3562 Highest expression of the CG59693-02 gene is detected in lung cancer A549 cell line (CT=20.01). High expression of this gene is also seen in cluster of cancer cell lines derived from gastric, colon, lung, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Thus, expression of this gene could be used as a marker to detect the presence of these cancers. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of gastric, colon, lung, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers.  
     [0869] Among tissues with metabolic or endocrine function, this gene is expressed at moderate to high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0870] In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0871] General_screening_panel_v1.6 Summary: Ag3562 Highest expression of the CG59693-02 gene is detected in lung cancer A549 cell line (CT=20.7). High expression of this gene is also seen in cluster of cancer cell lines derived from gastric, colon, lung, renal, breast, ovarian, prostate, squamous cell carcinoma, melanoma and brain cancers. Among tissues with metabolic or endocrine function, this gene is expressed at moderate to high levels in pancreas, adipose, adrenal gland, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. In addition, this gene is expressed at high levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. This pattern is in agreement with the expression profile in General_screening_panel_v1.4. Please see panel 1.4 for a discussion of this gene  
     [0872] HASS Panel v1.0 Summary: Ag3562. The expression of CG59693-02 gene is not increased by oxygen deprivation, acidic or a serum starved environment in the breast, bladder, pancreatic and prostate cell line in this panel.  
     [0873] However expression is increased in a glioblastoma/astrocytoma cell line when these cells are subjected to an acidic environment (Maximum expression U87-MG F21; CT=23.96) which suggests that expression may also be upregulated in the acidic regions of brain cancers. Moderate to low expression is also shown in 2 of 5 glioma and 2 of 4 medulloblastoma tissue samples in this panel. Therapeutic modulation of this gene product using small molecule drugs may be useful in the treatment of brain cancer.  
     [0874] Oncology_cell_line_screening_panel_v3.1 Summary: Ag3562 Highest expression of the CG59693-02 gene is detected in lung carcinoid sample (CT=21.7). High to moderate levels of expression of this gene is also seen in number of cancer samples including tongue, breast, prostate, melanoma, bone marrow, bladder, pancreatic, renal, lymphoma, ovarian, cervical, uterine, gastric, lung and brain cancer. Therefore, therapeutic modulation of this gene through the use of small molecule drug may be beneficial in the treatment of these cancers.  
     [0875] Panel 2D Summary: Ag3562 Highest expression of the CG59693-02 gene is detected in lung cancer (CT=23.5). High expression of this gene is seen in number of lung cancer samples. Expression of this gene is higher in cancer sample as compared to corresponding adjacent control samples. Therefore, expression of this gene may be used as marker to detect the presence of lung cancer and therapeutic modulation of this gene through the use of small molecule drug may be useful in the treatment of lung cancer.  
     [0876] High to moderate levels of expression of this gene is also seen in number of cancer samples including colon, gastric, ovarian, liver, breast, thyroid, kidney, and prostate cancers. Therefore, therapeutic modulation of this gene through the use of small molecule drug may be beneficial in the treatment of these cancers.  
     [0877] Panel 4.1D Summary: Ag3562 Highest expression of the CG59693-02 gene is detected in IL-4 treated dermal fibroblasts (CT=25.2). This gene is expressed at moderate to low levels in a wide range of cell types of significance in the immune response in health and disease. These cells include members of the T-cell, B-cell, endothelial cell, macrophage/monocyte, and peripheral blood mononuclear cell family, as well as epithelial and fibroblast cell types from lung and skin, and normal tissues represented by colon, lung, thymus and kidney. This ubiquitous pattern of expression suggests that this gene product may be involved in homeostatic processes for these and other cell types and tissues. This pattern is in agreement with the expression profile in General_screening_panel_v1.5 and also suggests a role for the gene product in cell survival and proliferation. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     [0878] Panel 5 Islet Summary: Ag3562 Highest expression of the CG59693-02 gene is detected in islet cells (Bayer patient 1) (CT=25.3). High to moderate levels of expression of this gene is also seen in adipose, skeletal muscle, placenta, uterus, liver, heart, small intestine and kidney. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0879] R. CG93088-01: Moncarboxylate Transporter  
     [0880] Expression of gene CG93088-01 was assessed using the primer-probe set Ag3841, described in Table RA. Results of the RTQ-PCR runs are shown in Tables RB, RC and RD.  
                   TABLE RA                          Probe Name Ag3841                                                     Start   SEQ ID           Primers   Sequences   Length   Position   No                                             Forward   5′-ttcctatggcattgttgtaggt-3′   22   583   171           Probe   TET-5′-tggtttattatacactgcaacagtgacca-3′-TAMRA   29   613   172       Reverse   5′-atcgtcaaaatactggcacgta-3′   22   643   173                  
 
     [0881]               TABLE RB                          CNS_neurodegeneration_v1.0                                 Tissue Name   A   B                                             AD 1 Hippo   59.5   60.7           AD 2 Hippo   91.4   77.4           AD 3 Hippo   15.8   13.0           AD 4 Hippo   15.0   19.3           AD 5 Hippo   43.2   52.5           AD 6 Hippo   92.7   100.0           Control 2 Hippo   25.5   32.3           Control 4 Hippo   45.7   54.7           Control (Path) 3 Hippo   16.6   14.8           AD 1 Temporal Ctx   55.1   54.3           AD 2 Temporal Ctx   61.6   62.0           AD 3 Temporal Ctx   12.9   16.4           AD 4 Temporal Ctx   42.9   44.1           AD 5 Inf Temporal Ctx   96.6   92.0           AD 5 Sup Temporal Ctx   100.0   83.5           AD 6 Inf Temporal Ctx   51.4   48.3           AD 6 Sup Temporal Ctx   56.3   49.0           Control 1 Temporal Ctx   18.4   15.9           Control 2 Temporal Ctx   23.0   27.4           Control 3 Temporal Ctx   12.4   17.9           Control 3 Temporal Ctx   19.9   25.5           Control (Path) 1 Temporal Ctx   22.2   20.7           Control (Path) 2 Temporal Ctx   29.1   26.6           Control (Path) 3 Temporal Ctx   11.8   9.9           Control (Path) 4 Temporal Ctx   26.4   19.1           AD 1 Occipital Ctx   35.1   39.0           AD 2 Occipital Ctx (Missing)   0.0   0.0           AD 3 Occipital Ctx   16.8   16.0           AD 4 Occipital Ctx   31.9   28.1           AD 5 Occipital Ctx   23.8   13.4           AD 6 Occipital Ctx   15.2   28.1           Control 1 Occipital Ctx   7.0   6.1           Control 2 Occipital Ctx   35.4   32.3           Control 3 Occipital Ctx   20.6   18.0           Control 4 Occipital Ctx   16.8   22.7           Control (Path) 1 Occipital Ctx   52.5   50.0           Control (Path) 2 Occipital Ctx   9.2   12.2           Control (Path) 3 Occipital Ctx   5.1   5.3           Control (Path) 4 Occipital Ctx   6.3   6.2           Control 1 Parietal Ctx   14.4   15.9           Control 2 Parietal Ctx   63.7   76.3           Control 3 Parietal Ctx   14.3   14.9           Control (Path) 1 Parietal Ctx   24.0   28.3           Control (Path) 2 Parietal Ctx   25.5   24.8           Control (Path) 3 Parietal Ctx   8.8   7.9           Control (Path) 4 Parietal Ctx   27.7   21.2                                                
     [0882]               TABLE RC                          General_screening_panel_v1.4                             Tissue Name   A                                         Adipose   1.6           Melanoma* Hs688(A).T   0.0           Melanoma* Hs688(B).T   0.1           Melanoma* M14   0.0           Melanoma* LOXIMVI   0.0           Melanoma* SK-MEL-5   0.4           Squamous cell carcinoma SCC-4   5.7           Testis Pool   2.3           Prostate ca.* (bone met) PC-3   10.2           Prostate Pool   2.3           Placenta   0.0           Uterus Pool   3.8           Ovarian ca. OVCAR-3   3.0           Ovarian ca. SK-OV-3   1.9           Ovarian ca. OVCAR-4   1.3           Ovarian ca. OVCAR-5   19.9           Ovarian ca. IGROV-1   0.4           Ovarian ca. OVCAR-8   1.6           Ovary   30.6           Breast ca. MCF-7   2.4           Breast ca. MDA-MB-231   0.0           Breast ca. BT 549   3.8           Breast ca. T47D   33.9           Breast ca. MDA-N   0.0           Breast Pool   9.7           Trachea   8.2           Lung   5.2           Fetal Lung   3.0           Lung ca. NCI-N417   0.7           Lung ca. LX-1   0.3           Lung ca. NCI-H146   0.5           Lung ca. SHP-77   0.0           Lung ca. A549   0.1           Lung ca. NCI-H526   0.0           Lung ca. NCI-H23   3.8           Lung ca. NCI-H460   2.0           Lung ca. HOP-62   0.2           Lung ca. NCI-H522   2.4           Liver   0.1           Fetal Liver   8.0           Liver ca. HepG2   3.1           Kidney Pool   8.7           Fetal Kidney   12.9           Renal ca. 786-0   0.1           Renal ca. A498   0.5           Renal ca. ACHN   0.7           Renal ca. UO-31   1.8           Renal ca. TK-10   5.6           Bladder   3.1           Gastric ca. (liver met.) NCI-N87   2.6           Gastric ca. KATO III   0.0           Colon ca. SW-948   0.8           Colon ca. SW480   1.7           Colon ca.* (SW480 met) SW620   2.4           Colon ca. HT29   0.0           Colon ca. HCT-116   8.7           Colon ca. CaCo-2   0.6           Colon cancer tissue   0.2           Colon ca. SW1116   0.3           Colon ca. Colo-205   0.0           Colon ca. SW-48   0.0           Colon Pool   9.9           Small Intestine Pool   3.8           Stomach Pool   2.9           Bone Marrow Pool   2.7           Fetal Heart   0.8           Heart Pool   1.9           Lymph Node Pool   8.8           Fetal Skeletal Muscle   1.4           Skeletal Muscle Pool   0.7           Spleen Pool   22.4           Thymus Pool   3.1           CNS cancer (glio/astro) U87-MG   0.0           CNS cancer (glio/astro) U-118-MG   0.0           CNS cancer (neuro; met) SK-N-AS   3.0           CNS cancer (astro) SF-539   2.5           CNS cancer (astro) SNB-75   2.6           CNS cancer (glio) SNB-19   0.5           CNS cancer (glio) SF-295   0.4           Brain (Amygdala) Pool   1.0           Brain (cerebellum)   5.5           Brain (fetal)   4.7           Brain (Hippocampus) Pool   2.9           Cerebral Cortex Pool   2.1           Brain (Substantia nigra) Pool   1.8           Brain (Thalamus) Pool   2.6           Brain (whole)   3.1           Spinal Cord Pool   3.8           Adrenal Gland   100.0           Pituitary gland Pool   2.1           Salivary Gland   1.1           Thyroid (female)   5.2           Pancreatic ca. CAPAN2   0.2           Pancreas Pool   5.2                                    
     [0883]               TABLE RD                          Panel 4.1D                             Tissue Name   A                                         Secondary Th1 act   0.3           Secondary Th2 act   0.3           Secondary Tr1 act   0.3           Secondary Th1 rest   0.0           Secondary Th2 rest   0.1           Secondary Tr1 rest   0.0           Primary Th1 act   2.4           Primary Th2 act   1.0           Primary Tr1 act   1.0           Primary Th1 rest   0.0           Primary Th2 rest   0.0           Primary Tr1 rest   0.1           CD45RA CD4 lymphocyte act   0.2           CD45RO CD4 lymphocyte act   0.3           CD8 lymphocyte act   0.2           Secondary CD8 lymphocyte rest   0.1           Secondary CD8 lymphocyte act   0.1           CD4 lymphocyte none   0.0           2ry Th1/Th2/Tr1_anti-CD95 CH11   0.0           LAK cells rest   0.1           LAK cells IL-2   0.1           LAK cells IL-2 + IL-12   0.3           LAK cells IL-2 + IFN gamma   0.2           LAK cells IL-2 + IL-18   0.5           LAK cells PMA/ionomycin   0.0           NK Cells IL-2 rest   0.1           Two Way MLR 3 day   0.0           Two Way MLR 5 day   0.0           Two Way MLR 7 day   0.0           PBMC rest   0.0           PBMC PWM   0.7           PBMC PHA-L   0.1           Ramos (B cell) none   0.0           Ramos (B cell) ionomycin   0.0           B lymphocytes PWM   0.9           B lymphocytes CD40L and IL-4   0.2           EOL-1 dbcAMP   0.0           EOL-1 dbcAMP PMA/ionomycin   0.0           Dendritic cells none   0.0           Dendritic cells LPS   0.1           Dendritic cells anti-CD40   0.2           Monocytes rest   0.0           Monocytes LPS   0.0           Macrophages rest   0.1           Macrophages LPS   0.0           HUVEC none   0.0           HUVEC starved   0.0           HUVEC IL-1beta   0.2           HUVEC IFN gamma   1.3           HUVEC TNF alpha + IFN gamma   0.1           HUVEC TNF alpha + IL4   0.3           HUVEC IL-11   1.0           Lung Microvascular EC none   2.3           Lung Microvascular EC TNFalpha + IL-1beta   1.4           Microvascular Dermal EC none   0.6           Microsvasular Dermal EC TNFalpha + IL-1beta   0.1           Bronchial epithelium TNFalpha + IL1beta   4.9           Small airway epithelium none   2.9           Small airway epithelium TNFalpha + IL-1beta   3.1           Coronery artery SMC rest   3.7           Coronery artery SMC TNFalpha + IL-1beta   2.3           Astrocytes rest   4.4           Astrocytes TNFalpha + IL-1beta   2.9           KU-812 (Basophil) rest   18.6           KU-812 (Basophil) PMA/ionomycin   16.4           CCD1106 (Keratinocytes) none   3.5           CCD1106 (Keratinocytes) TNFalpha + IL-1beta   2.5           Liver cirrhosis   0.1           NCI-H292 none   0.0           NCI-H292 IL-4   0.2           NCI-H292 IL-9   0.2           NCI-H292 IL-13   0.1           NCI-H292 IFN gamma   0.4           HPAEC none   0.1           HPAEC TNF alpha + IL-1 beta   1.5           Lung fibroblast none   0.1           Lung fibroblast TNF alpha + IL-1 beta   0.0           Lung fibroblast IL-4   0.0           Lung fibroblast IL-9   0.0           Lung fibroblast IL-13   0.0           Lung fibroblast IFN gamma   0.0           Dermal fibroblast CCD1070 rest   0.0           Dermal fibroblast CCD1070 TNF alpha   0.0           Dermal fibroblast CCD1070 IL-1 beta   0.0           Dermal fibroblast IFN gamma   0.0           Dermal fibroblast IL-4   0.0           Dermal Fibroblasts rest   0.0           Neutrophils TNFa + LPS   0.0           Neutrophils rest   0.0           Colon   0.3           Lung   0.2           Thymus   0.3           Kidney   100.0                                    
     [0884] CNS_neurodegeneration_v1.0 Summary: Data obtained from RTQPCR assays performed for this panel was analyized using multivariate analysis (ANOVA). The multivariate results obtained analyzing Ag3841 shows two experiments tested with the same probe and primer sets are in excellent agreements. It confirms the expression of the CG93088-01 gene at low levels in the brain in an independent group of individuals. This gene is upregulated in the temporal cortex of Alzheimer&#39;s disease patients when compared with non-demented controls (p=0.02 when analyzed by Ancova, estimate of total cDNA loaded per well used asa covariate). This gene may therefore be a small molecule target, and blockade of this transporter may slow or stop the progression of Alzheimer&#39;s disease.  
     [0885] General_screening_panel_v1.4 Summary: Ag3841 Highest expression of the CG93088-01 gene is detected in adrenal gland (CT=25). In addition, this gene is also expressed at high to moderate levels in other tissues with metabolic or endocrine function, such as pancreas, adipose, thyroid, pituitary gland, skeletal muscle, heart, liver and the gastrointestinal tract. The CG93088-01 gene codes for monocarboxylate transporter, a transporter belonging to sugar transporter family. Recently, a protein belonging to this family was shown to be associated with non-insulin-dependent diabetes mellitus (NIDDM) (Ref.1). Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes including NIDDM.  
     [0886] Interestingly, this gene is expressed at much higher levels in fetal (CT=28.7) when compared to adult liver (CT=35.6). This observation suggests that expression of this gene can be used to distinguish disorders or predisposition thereto between fetal and adult liver.  
     [0887] In addition, this gene is expressed at high to moderate levels in all regions of the central nervous system examined, including amygdala, hippocampus, substantia nigra, thalamus, cerebellum, cerebral cortex, and spinal cord. Therefore, this gene may play a role in central nervous system disorders such as Alzheimer&#39;s disease, Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0888] References.  
     [0889] McVie-Wylie A J, et al. (2001) Genomics 72(1):113-7 (PMID: 11247674)  
     [0890] Panel 4.1D Summary: Ag3841 Highest expression of the CG93088-01 gene is detected in kidney sample (CT=26). Therefore, antibody or small molecule therapies designed with the protein encoded for by this gene could modulate kidney function and be important in the treatment of inflammatory or autoimmune diseases that affect the kidney, including lupus and glomerulonephritis.  
     [0891] In addition, low to moderate expression of this gene is also seen in TNF alpha+IL-1 beta treated HPAEC, keratinocytes, basophils, astrocytes, coronery artery SMC, small airway epithelium, lung microvascular EC, microvascular dermal EC and PWM treated B lymphocytes. Interestingly, expression of this gene is stimulated in TNF alpha+IL-1 beta treated HPAEC, IFN gamma/IL-11 treated HUVEC cells, PWM treated PBMC cells, IL-2+IL-18 treated LAK cells, activated primary and secondary Th1, Th2, Tr1 cells as compared to their corresponding untreated or resting cells. Therefore, modulation of the gene product with a functional therapeutic may lead to the alteration of functions associated with these cell types and lead to improvement of the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, psoriasis, rheumatoid arthritis, and osteoarthritis.  
     Example D  
     Identification of Single Nucleotide Polymorphisms in NOVX Nucleic Acid Sequences  
     [0892] Variant sequences are also included in this application. A variant sequence can include a single nucleotide polymorphism (SNP). A SNP can, in some instances, be referred to as a “cSNP” to denote that the nucleotide sequence containing the SNP originates as a cDNA. A SNP can arise in several ways. For example, a SNP may be due to a substitution of one nucleotide for another at the polymorphic site. Such a substitution can be either a transition or a transversion. A SNP can also arise from a deletion of a nucleotide or an insertion of a nucleotide, relative to a reference allele. In this case, the polymorphic site is a site at which one allele bears a gap with respect to a particular nucleotide in another allele. SNPs occurring within genes may result in an alteration of the amino acid encoded by the gene at the position of the SNP. Intragenic SNPs may also be silent, when a codon including a SNP encodes the same amino acid as a result of the redundancy of the genetic code. SNPs occurring outside the region of a gene, or in an intron within a gene, do not result in changes in any amino acid sequence of a protein but may result in altered regulation of the expression pattern. Examples include alteration in temporal expression, physiological response regulation, cell type expression regulation, intensity of expression, and stability of transcribed message.  
     [0893] SeqCalling assemblies produced by the exon linking process were selected and extended using the following criteria. Genomic clones having regions with 98% identity to all or part of the initial or extended sequence were identified by BLASTN searches using the relevant sequence to query human genomic databases. The genomic clones that resulted were selected for further analysis because this identity indicates that these clones contain the genomic locus for these SeqCalling assemblies. These sequences were analyzed for putative coding regions as well as for similarity to the known DNA and protein sequences. Programs used for these analyses include Grail, Genscan, BLAST, HMMER, FASTA, Hybrid and other relevant programs.  
     [0894] Some additional genomic regions may have also been identified because selected SeqCalling assemblies map to those regions. Such SeqCalling sequences may have overlapped with regions defined by homology or exon prediction. They may also be included because the location of the fragment was in the vicinity of genomic regions identified by similarity or exon prediction that had been included in the original predicted sequence. The sequence so identified was manually assembled and then may have been extended using one or more additional sequences taken from CuraGen Corporation&#39;s human SeqCalling database. SeqCalling fragments suitable for inclusion were identified by the CuraTools™ program SeqExtend or by identifying SeqCalling fragments mapping to the appropriate regions of the genomic clones analyzed.  
     [0895] The regions defined by the procedures described above were then manually integrated and corrected for apparent inconsistencies that may have arisen, for example, from miscalled bases in the original fragments or from discrepancies between predicted exon junctions, EST locations and regions of sequence similarity, to derive the final sequence disclosed herein. When necessary, the process to identify and analyze SeqCalling assemblies and genomic clones was reiterated to derive the full length sequence (Alderborn et al., Determination of Single Nucleotide Polymorphisms by Real-time Pyrophosphate DNA Sequencing. Genome Research. 10 (8) 1249-1265, 2000).  
     [0896] Variants are reported individually but any combination of all or a select subset of variants are also included as contemplated NOVX embodiments of the invention.  
               TABLE D1                          NOV2a SNP Data CG180777-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13382237   566   A   G   171   His   Arg                  
 
     [0897]               TABLE D2                          NOV4a SNP Data CG50183-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13382220   148   T   C   49   Val   Ala                    
     [0898]               TABLE D3                          NOV10a SNP Data CG56151-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13375160   77   T   A   13   Thr   Thr       13375159   86   T   C   16   Thr   Thr       13375158   242   C   T   68   Pro   Pro       13375157   367   C   T   110   Thr   Ile       13375156   421   T   C   128   Met   Thr       13375155   1301   C   T   421   Phe   Phe       13375153   1475   C   T   479   Phe   Phe       13375151   1526   T   C   496   Ala   Ala                    
     [0899]               TABLE D4                          NOV11a: SNP Variants for CG56155-02.                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13374617   437   A   G   143   Asn   Ser       13375310   664   T   G   219   Phe   Val       13382227   1150   G   T   381   Ala   Ser       13375308   1210   G   T   401   Glu   End       13382226   1770   C   T   587   Asn   Asn                    
     [0900]               TABLE D5                          NOV18a SNP Data CG57758-02                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13376438   1466   T   C   479   Val   Ala       13376435   1805   T   C   592   Val   Ala       13376434   1826   T   C   599   Ile   Thr                    
     [0901]               TABLE D6                          NOV19a SNP Data CG59693-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13375931   259   T   A   87   Cys   Ser       13375927   357   A   G   119   Pro   Pro       13375928   593   A   G   198   Asn   Ser       13375925   666   C   T   222   His   His       13375924   783   A   G   261   Leu   Leu                    
     [0902]               TABLE D7                          NOV20a SNP Data CG93088-01                             Nucleotides   Amino Acids                                         Variant   Position   Initial   Modified   Position   Initial   Modified                                                 13377733   1458   C   T   399   Ala   Val                    
     Example E  
     CuraChip Gene Expression  
     [0903] CuraGen has developed a gene microarray (CuraChip 1.2) for target identification. It provides a high-throughput means of global mRNA expression analyses of CuraGen&#39;s collection of cDNA sequences representing the Pharmaceutically Tractable Genome (PTG). This sequence set includes genes which can be developed into protein therapeutics, or used to develop antibody or small molecule therapeutics. CuraChip 1.2 contains ˜11,000 oligos representing approximately 8,500 gene loci, including (but not restricted to) kinases, ion channels, G-protein coupled receptors (GPCRs), nuclear hormone receptors, proteases, transporters, metabolic enzymes, hormones, growth factors, chemokines, cytokines, complement and coagulation factors, and cell surface receptors.  
     [0904] The CuraChip cDNAs were represented as 30-mer oligodeoxyribonucleotides (oligos) on a glass microchip. Hybridization methods using the longer CuraChip oligos are more specific compared to methods using 25-mer oligos. CuraChip oligos were synthesized with a linker, purified to remove truncated oligos (which can influence hybridization strength and specificity), and spotted on a glass slide. Oligo-dT primers were used to generate cRNA probes for hybridization from samples of interest. A biotin-avidin conjugation system was used to detect hybridized probes with a fluorophore-labeled secondary antibody. Gene expression was analyzed using clustering and correlation bioinformatics tools such as Spotfire® (Spotfire, Inc., 212 Elm Street, Somerville, Mass. 02144) and statistical tools such as multivariate analysis (MVA).  
     [0905] Normalization Method Used in CuraChip Software  
     [0906] The median fluorescence intensity of each spot and a background for each spot is read on a scale from 0 to 65,000. CuraGen&#39;s CuraChip software, developed in-house, has the capability to present the user with either the raw data (median intensities) or normalized data. If normalized data is chosen, the CuraChip software uses the following method to do mean normalization. The normalization is based on each slide/experiment.  
     [0907] fg_median is the signal/foreground median for each slide/experiment;  
     [0908] bg_median is the background median for each slide/experiment;  
     [0909] original_value is the difference between fg_median and bg_median;  
     [0910] flag is an indicator of a spot&#39;s success or failure, where 0 means success and 1 means failure;  
     [0911] raw_fg_mean is the raw foreground mean for each slide/experiment;  
     [0912] raw_bg_mean is the raw background mean for each slide/experiment;  
     [0913] trim_percentage is the trim percentage for each slide/experiment; this could be defined by the user; currently we are using 2% as the trim percentage for each slide/experiment;  
     [0914] nSpots is the number of spots on each slide;  
     [0915] nSlides is the number of slides in each experiment;  
     [0916] fg_mean is the trimmed foreground mean for each slide/experiment;  
     [0917] bg_mean is the trimmed background mean for each slide/experiment;  
     [0918] max_fg_mean is a constant among all slides/experiments, currently 2200.0;  
     [0919] normalized_value is the final normalized value;  
     [0920] coeff is the normalization co-efficient;  
     [0921] MAX_VALUE is a constant representing the highest possible fluorescence reading, currently 65,000.  
     Step 1  
     Calculate Trimmed Foreground and Background Means  
     [0922] For each slide/experiment, the trimmed foreground mean and the trimmed background mean of all spots are first calculated, suppose nSpots, on each slide. For _each spot, if the data is acceptable (flag=0), we calculate the raw foreground mean and background mean are calculated by subtracting the background median from the foreground median for each spot. This is designated as a spot&#39;s “original value”. (Note: If flag=1, all values are set to 0.)  
                                                  original_value = fg_median - bg_median;                             if (flag == 0)   // experiment is successful                         {           raw_fg_mean = original_value;           raw_bg_mean = bg_median;           }                             else   // experiment is failed                         {           raw_fg_mean = 0.0;                         raw_bg_mean = 0.0;                         }                      
 
     [0923] After that, the top and bottom 2% of data points are removed (trimmed) from the data set. After the above calculation, there are nSpot number of foreground means and background means for each slide/experiment, and both lists are sorted. For example:  
                                              raw_fg_mean[1], raw_fg_mean[2], ..., raw_fg_mean[N];   N = 1,                     nSpots;                                 raw_bg_mean[1], raw_bg_mean[2], ..., raw_bg_mean[N];   N = 1,                     nSpots;                  
 
     [0924] the trimmed data points are calculated for each slide/experiment. Suppose a is the trimmed start data point and b is the trimmed end data point, there are:  
     [0925] a=ceil(nSpots*trim_percentage);  
     [0926] b=floor(nSpots*(1−trim_percentage);  
     [0927] The “background mean” is calculated from the background medians for the trimmed data set. For the background mean, the average background mean is simply calculated in interval [a, b] then assign to bg_mean:  
                                                  bg_mean = (raw_bg_mean[a] + raw_bg_mean[a+1] +...+                         raw_bg_mean[b] ) / (b−a+1) ;                      
 
     [0928] The “foreground mean” is calculated from the “original values” (i.e. background-subtracted spot signal medians); only “original values” greater than 500 are used for this calculation (excluding the trimmed top and bottom 2% of the data). Suppose the sum of those foreground means is sum_raw_fg_mean and the amount of those foreground means is k.  
     [0929] fg_mean=sum_raw_fg_mean/k;  
     [0930] For clarity, a snippet code in Java looks like the following,  
                                                      int   k = 0;                         double sum_raw_fg_mean = 0.0;           for (int j = a; j &lt; b; j++) {                         if ( raw_fg_mean [j] &gt; 500 ) {                         sum_raw_fg_mean = sum_raw_fg_mean +           raw_fg_mean [j];           k++;                         }                         }           fg_mean = sum_raw_fg_mean / k;                      
 
     [0931] After the calculation of trimmed foreground means and background means for all slides is complete, the normalization procedure is started.  
     Step 2  
     Normalize Data  
     [0932] For each slide a normalization coefficient is calculated which compares the foreground mean of the slide to a fixed maximum foreground mean (2200). This coefficient is:  
     [0933] coeff=max_fg_mean/fg_mean;  
     [0934] The normalized value of each spot is then calculated by multiplying the spot&#39;s “original value” by the normalization coefficient. Note that if this value is greater than the maximum reading of 65,000, then the value of 65,000 is used as the normalized value. Also note that if a spot&#39;s “original value” is less than the background value, the background value is used.  
                                                  Recall that origrinal_value =           fg_median − bg_median           if ( original_value &gt; bg_mean ) {           normalized_value = min(coeff * original_value,           MAX_VALUE);           } else {           normalized_value = coeff*bg_mean;           }                      
 
     [0935] The normalized_value for each spot is the final (normalized) value used in the analysis  
     [0936] Threshhold for CuraChip Data Analysis  
     [0937] A number of control spots are present on CuraChip 1.2 for efficiency calculations and to provide alternative normalization methods. For example, CuraChip 1.2 contains a number of empty or negative control spots, as well as positive control spots containing a dilution series of oligos that detect the highly-expressed genes Ubiquitin and glyceraldehyde-3-phosphate dehydrogenase (GAPD). An analysis of spot signal level was performed using raw data from 67 hybridizations using all oligos. The maximum signal intensity for each oligo across all 67 hybridizations was determined, and the fold-over-background for this maximum signal was calculated (i.e. if the background reading is 20 and the raw spot intensity is 100, then the fold-over-background for that spot is 5×). The negative control or empty spots do occasionally “fire” or give a signal over the background level; however, they do not fire very strongly, with 77.1% of empty spots firing&lt;3×over background and 91.7% &lt;5× (see burgundy bars in figure below). The positive control spots (Ubiquitin and GAPD, the light blue and dark blue bars, respectively) always fired at &gt;100× background. The experimental oligos (CuraOligos, in yellow below) fired over the entire range of intensities, with some at low fold-over-background intensities. Since the negative control spots do fire occasionally at low levels, we have set a suggested threshhold for data analysis at &gt;5× background.  
     [0938] CG180777-01  
     [0939] Results of PTG Chip 1.2: One hundred seventy-eight samples of RNA from tissues obtained from surgically dissected tumors, non-diseased tissues from the corresponding organs and tumor xenografts grown in nude nu/nu mices were used to generate probes and run on PTG Chip 1.2. An oligo (optg2 — 0014957) that corresponds to CG180777-01 on the PTG Chip 1.2 was scrutinized for its expression profile. The statistical analyses identify strong expression in lung, melanomas and breast cancers.  
     [0940] Thus, based upon its profile, the expression of this gene could be of use as a marker for subsets of lung, melanomas and breast cancers, in addition to the subset of Kidney cancers as previously disclosed. In addition, therapeutic inhibition of the activity of the product of this gene, through the use of antibodies or small molecule drugs, may be useful in the therapy of lung, melanomas and breast cancers that express CG180777-01 and are dependent on them.  
     [0941] Expression analysis of CG180777-01 using PTG Chip 1.2: Approximately 418 samples of RNA from tissues obtained from surgically dissected disease- and non-disease tissues, and treated and untreated cell lines, were used to generate labelled nucleic acid which was hybridized to PTG Chip 1.2. An oligo (optg2 — 0014957) that corresponds to CG180777-01 on the PTG Chip 1.2 was analyzed for its expression profile (Table 1).  
     [0942] This gene shows low expression in number of cancer cell lines, normal and cancer samples from lung, prostate, pancreas, breast, pancreas and kidney. Expression of this gene is upregulated in pancreatic and breast cancer. Therefore, expression of this gene may be used as marker to detect the presence of breast and pancreatic cancer. Furthermore, therapeutic modulation of the expression or function of this gene may be effective in the treatment of lung, pancreatic, breast, prostate, and kidney cancers.  
     [0943] In addition, this gene is expressed at low levels in the brains, including amygdala, anterior cingulate, thalamus, hippocampus and astrocytes. Therefore, therapeutic modulation of this gene product may be useful in the treatment of central nervous system disorders such as Parkinson&#39;s disease, epilepsy, multiple sclerosis, schizophrenia and depression.  
     [0944] This gene is also expressed at significant level in thyroid, and pituitary glands. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
     [0945] Significant expression of this gene is also seen in fetal lung. Therefore, therapeutic modulation of this gene may be useful in the treatment of lung related diseases especially development related diseases.  
     [0946] Significant expression of this gene is also seen in resting and activated monocytes (THP1) cells. Upon activation with pathogens such as LPS, monocytes contribute to the innate and specific immunity by migrating to the site of tissue injury and releasing inflammatory cytokines. This release contributes to the inflammation process. Therefore, modulation of the expression of the protein encoded by this transcript may prevent the recruitment of monocytes and the initiation of the inflammatory process, and reduce the symptoms of patients suffering from autoimmune and inflammatory diseases such as asthma, allergies, inflammatory bowel disease, lupus erythematosus, or rheumatoid arthritis.  
                           TABLE E1                           Foreground   Background   optg2 —         Sample   Mean   Mean   1201117                                                Lung cancer (35C)   2536.51   22.17   17       Lung NAT (36A)   2733.37   20.31   152       Lung cancer (35E)   2933.33   21.31   140       Lung cancer (365)   3808.15   19.58   180       Lung cancer (368)   3824.5   21.07   115.5       Lung cancer (369)   2825.08   18.76   550       Lung cancer (36E)   4152.87   26.78   60       Lung NAT (36F)   3538.73   23.55   207.5       Lung cancer (370)   4143.89   21.18   69       Lung cancer (376)   2446.38   20.81   26       Lung cancer (378)   3989.95   27.35   30       Lung cancer (37A)   4136.72   36.64   66       Normal Lung 4   4083.27   28.46   168       Normal Lung 5   4235.38   25.22   138       CuraChip reference 1   3728.44   28.62   214       Melanoma   2915.57   20.5   87.5       Melanoma   2646.56   20.29   98       Melanoma (19585)   2509.13   23.23   38       Normal Lung 1   2759.91   24.22   163.5       Lung cancer (372)   3803.04   27.08   63       Lung NAT (35D)   3771.95   25.68   283       Lung NAT (361)   2214.53   20.77   25       Melanoma   2134.94   21.43   62       Normal Lung 2   3656.2   20.99   381       Lung cancer (374)   3295.08   24.19   746       Lung cancer (36B)   3776.14   21.32   175       Lung cancer (362)   1543.94   26.44   34       Lung cancer (358)   1929.4   30.01   83       Melanoma   2375.7   20.83   81       Normal Lung 3   3157.31   22.69   255.5       Lung NAT (375)   4614.72   32.86   514       Lung cancer (36D)   2785.76   24.74   31       Lung NAT (363)   4348.91   34.21   247       Lung cancer (35A)   3986.34   29.19   184       Melanoma   2189.36   20.44   27       Prostate cancer (B8B)   2957.66   9.6   277       Prostate cancer (B88)   4126.76   33.25   389       Prostate NAT (B93)   3378.81   37.92   286       Prostate cancer (B8C)   3527   42.55   273.5       Prostate cancer (AD5)   4105.44   45.35   395       Prostate NAT (AD6)   4196.5   41.71   522       Prostate cancer (AD7)   2830.59   42.73   193.5       Prostate NAT (AD8)   3404.14   29.72   346       Prostate cancer (ADA)   3700.09   34.54   715       Prostate NAT (AD9)   3022.26   30.92   255.5       Prostate cancer (9E7)   3084.26   30.48   261.5       Prostate cancer (A0A)   3983.11   24.56   499       Prostate cancer (9E2)   2889.43   23.94   426       Pancreatic cancer (9E4)   4473.72   23.53   400.5       Pancreatic cancer (9D8)   3443.44   20.25   193.5       Pancreatic cancer (9D4)   3819.27   17.3   315       Pancreatic cancer (9BE)   3287.48   24.17   588       Pancreatic NAT (ADB)   2358   28.92   63.5       Pancreatic NAT (ADC)   2863.88   36.96   42       Pancreatic NAT (ADD)   3118.81   30.22   32       Pancreatic NAT (AED)   3211.96   26.31   102       Colon cancer (8A3)   1984.83   48.06   51       Colon NAT (8B6)   1682.5   39.46   61       Colon NAT (9F1)   2378.93   48.8   74       Colon cancer (9F2)   1931.28   46.1   20       Colon NAT (A1D)   2029.41   46.05   65       Colon cancer (9DB)   2278.96   44.08   16       Colon NAT (A15)   1674.01   45.41   31       Colon cancer (A14)   1360.97   35.04   11       Colon NAT (ACB)   1707.6   45.03   29       Colon cancer (AC0)   1894.33   46.06   16       Colon cancer (8A4)   1785.56   43.34   10       Colon NAT (ACD)   1797.75   44.1   48       Colon cancer (AC4)   2198.75   49.26   28       Colon NAT (AC2)   1847.84   43.83   32.5       Colon cancer (AC1)   1806.35   39.49   15       Colon NAT (ACC)   2013.34   39.08   68       Colon cancer (AC3)   1539.46   47.71   16.5       Breast cancer (9B7)   1857.03   46.65   122       Breast NAT (9CF)   1462.79   47.35   7       Breast cancer (9B6)   2133.12   47.71   54       Breast cancer (9C7)   2302.99   47.48   116       Colon cancer (8A6)   2093.72   45.39   71       Breast NAT (A11)   1508.35   45.43   29       Breast cancer (A1A)   2246.51   46.55   29       Breast cancer (9F3)   1881.09   46.54   30       Breast cancer (9B8)   2174.46   48.66   69       Breast NAT (9C4)   1670.58   48.93   43       Breast cancer (9EF)   1168.07   23.61   29.5       Breast cancer (9F0)   1506.95   28.54   55       Breast cancer (9B4)   1016.05   32.36   9       Breast cancer (9EC)   2526.83   47.27   74       Colon cancer (8A7)   1594.35   48.21   5       Colon cancer (8B7)   2091.33   40.64   31       Colon cancer (8A9)   2533.34   40.66   102       Colon cancer (8AB)   1638.43   30.62   10       Colon cancer (8AC)   1975.26   41.39   13       Colon NAT (8AD)   1851.09   49.21   86       Colon cancer (8B5)   1920.15   47.11   22.5       Cervical cancer (B08)   1393.31   2.02   0       Brain cancer (9F8)   1400.44   8.86   25.5       Brain cancer (9C0)   655.35   4.73   0       Brain cancer (9F7)   1403.07   0.42   9.5       Brain cancer (A00)   1509.09   3.25   3.5       Brain NAT (A01)   1159.94   0.43   11       Brain cancer (9DA)   1019.67   0.72   0.5       Brain cancer (9FE)   1352.85   2.77   5       Brain cancer (9C6)   1237.61   3.47   0       Brain cancer (9F6)   917.48   2.17   0       Cervical NAT (AEB)   826.9   1.64   0       Bladder NAT (23954)   521.75   0.44   0       Urinary cancer (AF6)   1007.77   1.4   0       Urinary cancer (B0C)   1256.43   1.31   0       Urinary cancer (AE4)   1219.17   1.23   2.5       Urinary NAT (B20)   1222.48   1.23   0       Urinary cancer (AE6)   1114.91   1.03   0       Urinary NAT (B04)   655.35   0.07   0       Urinary cancer (B07)   543.73   1.64   0       Urinary NAT (AF8)   1247.4   0.53   0       Cervical cancer (AFF)   1411.18   4.31   0       Ovarian cancer (9D7)   1221.47   0.63   35       Urinary cancer (AF7)   1138.73   1.3   0       Ovarian cancer (9F5)   1298.98   0   5.5       Ovarian cancer (A05)   1134.77   2.16   17       Ovarian cancer (9BC)   505   0.15   0       Ovarian cancer (9C2)   1025.23   0.93   0       Ovarian cancer (9D9)   1203.34   1.53   0       Ovarian NAT (AC7)   685.35   0.54   0       Ovarian NAT (AC9)   716.79   0.85   0       Ovarian NAT (ACA)   628.62   2.38   0       Cervical NAT (B1E)   1293.21   7.01   0       Ovarian NAT (AC5)   542.12   0.99   0       Cervical cancer (B00)   1512.53   9.92   0       Cervical NAT (AFA)   1136.08   8.76   0       Cervical cancer (B1F)   1782.82   18.96   0       Cervical NAT (B1C)   655.35   2.36   0       Brain cancer (9F9)   1508.5   5.08   5.5       Breast cancer (D34)   2470.88   0   70       Breast cancer (D35)   2602.08   0   63       Breast cancer (D36)   2909.53   0   130.5       Breast cancer (D37)   2811.77   0.05   173       Breast cancer (D38)   2986.78   0.38   150       Breast cancer (D39)   3026.22   0.04   286       Breast cancer (D3A)   3072.62   0.08   235       Breast cancer (D3B)   2571.28   0.02   99.5       Breast cancer (D3C)   3213.98   0.6   271       Breast cancer (D3D)   3484.57   2.5   135       Breast cancer (D3E)   2958.51   0.17   458       Breast cancer (D3F)   2937.01   1.88   135       Breast cancer (D40)   2751.61   1.2   369       Breast cancer (D42)   2171.59   0.8   145       Breast cancer (D43)   2962.09   4.5   166.5       Breast cancer (D44)   2558.08   2.95   176       Breast cancer (D45)   2667.3   3.59   177.5       Breast cancer (D46)   3190.77   2.25   190.5       SK-MES   2804.32   0.56   47       HLaC-79   3402.37   0   83       H226   2562.59   0   0       HCT-116   4221.68   0.09   74       IGROV-1   3243.07   0   130.5       MX-1   3253.75   0   211       C33A   3249.59   0   265       Daudi   2333.08   0.01   0       MV522   2727.7   0.94   95       RWP-2   2906.49   0   28       BON   2502.53   0.01   93       MiaPaCa   3604.78   0   155       H82   2357.18   2.19   98       H69   2759.55   0.12   0       Caki-2   2687.93   0   72       LNCaP   3352.46   0.41   135.5       A549   2593.12   0   0       DU145   3970.51   0.07   78       OVCAR-3   3230.65   0.14   275       HT-29   3381.64   0.07   137       DLD-2   3610.05   0.24   39.5       MCF-7   3326.73   1.78   264       H460   2464.22   0   0       SW620   2732.11   0   0       SK-OV-3   3519.75   0   101.5       MDA-231   3464.04   0.04   0       Caki-1   3801.64   0   88.5       PC-3   2214.23   0   0       LoVo   3237.95   0   27       Kidney NAT (10B1)   3041.27   6.44   235.5       Kidney cancer (10B2)   3798.53   1.31   622.5       Kidney NAT (10B3)   3315.43   0   168       Kidney cancer (10B4)   3519.14   0.16   89.5       Kidney NAT (10B5)   3017.75   0   106.5       Kidney cancer (10B6)   3702.61   0   69.5       Kidney NAT (10B7)   3060.89   0   103.5       Kidney cancer (10BA)   3437.01   0   86.5       Kidney NAT (10BB)   3157.99   0   159.5       Kidney cancer (10C0)   3590.87   0.77   495       Kidney NAT (10C1)   3012.3   0   164.5       Kidney cancer (10C4)   3186.48   0.02   157       Kidney NAT (10C5)   3618.74   0   79       Kidney cancer (10A8)   3514.51   0   35.5       Kidney NAT (10A9)   2771.76   1.14   156.5       Kidney cancer (10AA)   3793.55   0.4   250.5       Kidney NAT (10AB)   2978.06   0   166       Kidney cancer (10AC)   3656.35   0.05   188       Kidney NAT (10AD)   3299.97   2.13   228       Kidney cancer (10AE)   3456.21   0.57   169.5       Kidney NAT (10AF)   2593.7   0   155       Kidney cancer (10B0)   3529.2   0.67   283.5       Lymphoma (9BF)   2333.81   0   0       Lymphoma (9D2)   1327.77   0   0       Lymphoma (A04)   1450.41   0   14       Lymphoma (9DD)   1095.68   0   0       Lymphoma (F68)   865.62   0   0       Lymphoma (F6A)   862.12   0   0       Lymphoma (F6B)   624.66   0   0       Lymphoma (F6C)   1621.52   0   0       Lymphoma (F6D)   864.76   0   0       Lymphoma (F6E)   1030.71   0   0       Lymphoma (F6F)   1120.14   0   0       Lymphoma (F70)   891.53   0   0       Lymphoma (F71)   915.92   0   0       Lymphoma (F72)   1199.28   3.13   0       Lymphoma (F73)   1357.46   0   0       Lymphoma (F74)   993.02   0   0       Lymphoma NAT (1002)   2069.54   0   0       Lymphoma NAT (1004)   1928.51   0   0       Lymphoma NAT (1005)   1412.32   0   0       Lymphoma NAT (1007)   1668.28   0   0       Lymphoma NAT (1003)   1919.49   0   0       Lymphoma (9E3)   1791.94   0   0       Lymphoma (9D0)   1530.59   0   0       Lymphoma (9E1)   1677.97   0   0       Lymphoma (A0D)   2656.34   1.4   1.5       Lymphoma (9B5)   2336.21   0   0       Lymphoma (9D3)   1902.13   0   0       Normal Lung 4   4083.27   28.46   90.52       Normal Lung 5   4235.38   25.22   71.68       Normal Lung 1   2759.91   24.22   130.33       Normal Lung 2   3656.2   20.99   229.25       Normal Lung 3   3157.31   22.69   178.03       SW1353 resting 1 h   3946.45   0.6   22.86       SW1353 resting 6 h   3263.46   0.12   17.86       SW1353 resting 16 h   2311.8   0   0       SW1353 IL-1b (1 ng/) 1 h   2686.83   0.16   7.37       SW1353 IL-1b (1 ng/) 6 h   3159.94   2   6.27       SW1353 IL-1b (1 ng/) 16 h   3557.88   0.62   17.93       SW1353 FGF20 (1 ug/)   3512.56   0.69   26.93       1 h       SW1353 FGF20 (1 ug/)   2510.14   0.06   1.75       16 h       SW1353 FGF20 (5 ug/)   3448.11   1.01   22.33       1 h       SW1353 FGF20 (5 ug/)   3598.07   0.64   18.65       6 h       SW1353 FGF20 (5 ug/)   3687.34   4.42   21.78       16 h       SW1353 FGF20 (1 ug/)   3569.19   0.17   20.34       IL-1b (1 ng/) 6 h       SW1353 FGF20 (1 ug/)   3970.28   0.01   36.57       IL-1b (1 ng/) 16 h       SW1353 FGF20 (5 ug/)   3011.45   0   5.11       IL-1b (1 ng/) 1 h       SW1353 FGF20 (5 ug/)   3184.88   2.69   31.43       IL-1b (1 ng/) 6 h       THP-1 aCD40 (1 ug/) 1 h   3545.99   0.07   181.16       THP-1 aCD40 (1 ug/) 6 h   2882.56   0.44   76.7       THP-1 LPS (100 ng/) 1 h   3131.64   0.74   129.26       THP-1 LPS (100 ng/) 6 h   2356.5   0.05   19.61       CCD1070SK TNFa (5   2888.01   0.78   32.76       ng/) 6 h       CCD1070SK TNFa (5   3029   0.39   51.57       ng/) 24 h       CCD1070SK IL-1b (1 ng/)   3307.91   5.76   35.58       24 h       THP-1 resting   3080.68   0.87   157.47       THP-1 aCD40 (1 ug/) 24 h   2032.49   0.82   33.55       THP-1 LPS (100 ng/) 24 h   1597.29   3.58   44.76       CCD1070SK IL-1b (1 ng/)   3026.56   3.51   43.61       6 h       LC 18 hr   2725.87   0.36   34.7       LC-IL-! 18 hr   1474.79   2.66   0       Astrocyte_IL1B_1 hr_a   3116.77   10.04   264.34       Astrocyte_IL1B_6 hr_a   3119.7   16.51   357.18       Astrocyte_IL1B_24 hr_a   3142.98   13.81   335.99       SHSY 5Y Undifferentiated   3166.23   14.61   105.61       SHSY 5Y Differentiated   2959.01   8.5   100.74       LC 0 hr   1880.7   0   0       Normal Fetal Kidney   2011.8   0   7.65       Normal Liver   2053.67   3.81   0       Normal Fetal Liver   3555.17   0   3.09       Normal Fetal Lung   4164.55   0   208.4       Normal Salivary Gland   3466.36   0   0       Normal Fetal Skeletal   2504.59   0   0       Muscle       Normal Thyroid   3566.17   0   193.71       Normal Trachea   3596.15   0   61.18       LC-IL-1 0 hr   2560.23   0   0.86       Heart pool   3167.78   0   0       Pituitary Pool   2908.48   0   316.94       Spleen Pool   2068.62   0   5.32       Stomach Pool   2826.7   0   9.34       Testis Pool   3348.7   0   268.04       Thymus Pool   2653.82   0   45.59       Small Intestine - 5 donor   3795.64   0   68.39       pool       Lymph node - 5 donor   4339.52   0   69.45       pool       Kidney - 5 donor pool   3347.34   0   138.02       Jurkat Resting   3779.74   0.48   139.11       Jurkat CD3 (500 ng/ml)   2459.46   1.68   71.56       6 hr A       Jurkat CD3 (500 ng/ml)   1897.6   0.08   71.3       24 hr A       Jurkat CD3   1867.35   0.68   24.74       (500 ng/ml) + CD28 (1 ug/ml)       6 hr A       Jurkat CD3   1574.07   0.35   60.1       (500 ng/ml) + CD28 (1 ug/ml)       24 hr A       control (no treatment)_1   5400.28   2.01   65.59       hr       10 ng/ml IL-1b_1 hr   5250.91   1.51   70.39       10 ng/ml TNF-a_1 hr   5668.06   2.55   80.73       200 uM BzATP_1 hr   5619.87   0.31   89.65       control (no treatment)_5   5630.13   1.02   77.56       hr       10 ng/ml IL-1b_5 hr   6332.12   10.52   70.36       10 ng/ml TNF-a_5 hr   6070.17   6.37   75.93       200 uM BzATP_5 hr   6425.22   2.39   99.64       control (no treatment)_24   4825.87   3.5   62       hr       10 ng/ml IL-1b_24 hr   5349.28   9.73   73.41       10 ng/ml TNF-a_24 hr   5672.31   4.97   62.25       200 uM BzATP_24 hr   4814.1   0.51   70.61       Alzheimer&#39;s disease   1854.86   14.76   33.21       B4951       Alzheimer&#39;s disease   2540.02   19.95   108.27       B4953       Alzheimer&#39;s disease   1757.68   22.42   45.06       B5018       Alzheimer&#39;s disease   1491.9   18.37   7.37       B5019       Alzheimer&#39;s disease   2247.49   18.04   66.56       B5086       Alzheimer&#39;s disease   2150.92   19.76   38.87       B5096       Alzheimer&#39;s disease   732.56   15.93   21.02       B5098       Alzheimer&#39;s disease   1841.99   18.04   9.55       B5129       Alzheimer&#39;s disease   3233.87   21.56   168.37       B5210       Control B4810   2987.22   21.85   155.76       Control B4825   2903.91   18.74   187.88       Control B4930   2287.12   22.69   30.78       Control B4932   3424.98   20.12   370.95       Control B5024   3859.32   22.42   398.46       Control B5113   1897   17.87   112.49       Control B5140   1901.93   18.88   68.25       Control B5190   1284.69   15.26   53.94       Control B5220   2225.75   18.7   192.25       Control B5245   2119.39   21.5   143.25       AH3 B3791   2202.74   19.73   173.78       AH3 B3855   1849.89   17.93   267.58       AH3 B3877   2144.15   17.01   402.72       AH3 B3893   2103.76   16.34   81.57       AH3 B3894   1820.82   17.31   166.74       AH3 B3949   1607.86   23.9   58.84       AH3 B4477   1602.58   20.32   123.55       AH3 B4540   2260.92   22.79   252.02       AH3 B4577   2142.42   22.59   257.75       AH3 B4639   1550.43   21.89   28.38       Schizophrenia   2468.43   21.23   58.82       hippocampus 683       Depression hippocampus   1473.83   18   0       487       Depression hippocampus   2481.12   10.69   58.97       600       Normal hippocampus   2624.25   33.19   18.44       2407a       Normal hippocampus   2114.72   21.4   19.25       1042       Depression hippocampus   1448.13   10.6   21.27       2767       Depression hippocampus   1836.77   47.98   19.16       567       Control hippocampus   2752.14   14.38   96.72       3175       Depression hippocampus   1735.6   9.4   30.42       3096       Depression hippocampus   2784.26   17.28   41.09       1491       Depression hippocampus   2241.25   16.73   28.47       2540       Schizophrenia   1923.26   16.97   56.05       hippocampus 2798       Control hippocampus   2605.59   14.97   33.77       1973       Normal hippocampus and   2031.45   13.85   34.11       amygdala 2601       Schizophrenia   1621.43   21.03   0       hippocampus 2785       Schizophrenia   3271.31   39.54   62.21       hippocampus 484       Normal hippocampus   2806.68   21.69   50.95       2556       Depression hippocampus   2705.56   15.83   32.53       1158       Control hippocampus 552   3378.83   21.65   161.48       Schizophrenia   2304.06   12.06   0       hippocampus 1737       Normal hippocampus   3335.3   17.54   67.28       1239       Normal hippocampus   3068.38   14.64   49.47       1465       Normal hippocampus   1323.77   4.6   0       3080       Normal hippocampus 738   4229.67   12.96   146.16       Schizophrenia   2067.82   12.78   6.92       hippocampus 2586       Normal hippocampus   3306.02   13.41   156.38       2551       Depression hippocampus   2352.1   13.53   75.76       588       Depression hippocampus   3291.7   13.05   127.65       529       Depression hippocampus   1686.08   11.37   27.4       and dentate gyrus       Schizophrenia amygdala   2136.57   0.55   40.16       2586       Normal substantia nigra   1240.83   0.03   0       234       Normal substantia nigra   1515.69   14.19   0       1065       formal substantia nigra   1341.77   0   0       3236       Normal substantia nigra   3718.91   0.43   64.19       2551       Normal substantia nigra   1003.1   0   0       1597       Control thalamus 552   948.15   0.02   4.64       Control thalamus 566   1698.42   0   0       Control thalamus 606   2625.59   0.31   96.78       Control thalamus 738   2464.52   0   42.85       Control thalamus 1065   2991.38   0   54.42       Control thalamus 1092   2416.75   0   36.41       Control thalamus 1597   2389.84   0   48.79       Control thalamus 2253   1602.4   0   0       Control thalamus 2551   3017.98   0   120.28       Depression thalamus 588   2245.45   0.29   31.35       Depression thalamus 600   1442.56   0   0       Depression thalamus 721   1921.28   0   0       Depression thalamus 728   3113.17   4.33   48.05       Depression thalamus 759   2433.85   0   56.95       Depression thalamus 881   2456.7   0   15.67       Schizophrenia thalamus   1952.08   0   3.38       477       Schizophrenia thalamus   3553.95   0   68.71       532       Schizophrenia thalamus   3798.02   0   50.11       683       Schizophrenia thalamus   3260.82   0.03   44.87       544       Schizophrenia thalamus   2246.95   0   0       1671       Schizophrenia thalamus   1958.75   0.01   0       1737       Schizophrenia thalamus   1953.64   0   56.31       2464       Schizophrenia thalamus   3338.49   0   28.67       2586       Depression amygdala   1936.43   0   9.09       600       Depression amygdala   2378.2   0   69.38       759       Depression anterior   2808.48   0   75.98       cingulate 759       Control amygdala 552   3675.87   0.36   151.42       Control anterior cingulate   3115.46   0.67   236.56       482       Depression anterior   1964.87   0   1.12       cingulate 721       Control amygdala 3175   2674.16   0.04   134.92       Depression anterior   2389.83   0.06   37.74       cingulate 600       Depression anterior   2629.92   0   92.85       cingulate 588       Control anterior cingulate   3605.03   0.79   238.61       3175       Control anterior cingulate   2414.64   0   273.33       606       Depression anterior   2397.28   1.2   40.38       cingulate 567       Depression amygdala   3410.76   3.1   79.98       588       Control anterior cingulate   2445.09   3.01   54.89       3080       Control anterior cingulate   2520   5.45   75.08       2601       Control anterior cingulate   3118.04   0.76   87.49       1042       Control anterior cingulate   2913.66   1.45   NA       3236       Control amygdala 1502   4253.4   9.62   147.67       Control anterior cingulate   2624.08   8.86   0       807       Control amygdala 1597   3710.89   11.88   141.1       Parkinson&#39;s substantia   2457.51   0.25   11.64       nigra 2842       Parkinson&#39;s substantia   1548.58   0   0       nigra 2917       Schizophrenia amygdala   2009.89   0   71.15       544       Schizophrenia amygdala   730.94   0   0       532       Depression amygdala   2408.1   0   28.32       2540       Parkinson&#39;s substantia   1544.99   0   0       nigra 2899       Depression anterior   3015.65   0   103.59       cingulate 881                  
 
     [0947] CG181825-01  
     [0948] Results of PTG Chip 1.2: One hundred seventy-eight samples of RNA from tissues obtained from surgically dissected tumors, non-diseased tissues from the corresponding organs and tumor xenografts grown in nude nu/nu mices were used to generate probes and run on PTG Chip 1.2. An oligo (optg2 — 1206388) that corresponds to CG181825-01 on the PTG Chip 1.2 was scrutinized for its expression profile. The statistical analysis identify strong expression in lung, melanomas and breast cancers.  
     [0949] Thus, based upon its profile, the expression of this gene could be of use as a marker for subsets of lung, melanomas and breast cancers, in addition to the subset of Kidney cancers as previously disclosed. In addition, therapeutic inhibition of the activity of the product of this gene, through the use of antibodies or small molecule drugs, may be useful in the therapy of lung, melanomas and breast cancers that express CG181825-01 and are dependent on them.  
     [0950] Expression analysis of CG181825-01 using PTG Chip 1.2: Approximately 418 samples of RNA from tissues obtained from surgically dissected disease- and non-disease tissues, and treated and untreated cell lines, were used to generate labelled nucleic acid which was hybridized to PTG Chip 1.2. An oligo (optg2 — 1206388) that corresponds to CG181825-01 on the PTG Chip 1.2 was analyzed for its expression profile (Table 1).  
     [0951] This gene shows low expression in number of cancer cell lines, normal and cancer samples from lung, pancreas, breast, cervix and kidney.  
     [0952] In addition, this gene is expressed at low levels in the brains of an independent group of individuals, especially in substantia nigra and amygdala of samples from normal patients or patients suffering with Parkinson&#39;s diseases and schizophrenia.  
     [0953] This gene is also expressed at significant level in thyroid, pituitary glands, fetal liver, and stomach. Therefore, therapeutic modulation of the activity of this gene may prove useful in the treatment of endocrine/metabolically related diseases, such as obesity and diabetes.  
                           TABLE E2                           Foreground   Background   optg2 —         Sample   Mean   Mean   1206388                                                Lung cancer(35C)   2536.51   22.17   33       Lung NAT(36A)   2733.37   20.31   47.5       Lung cancer(35E)   2933.33   21.31   60       Lung cancer(365)   3808.15   19.58   159       Lung cancer(368)   3824.5   21.07   114.5       Lung cancer(369)   2825.08   18.76   40       Lung cancer(36E)   4152.87   26.78   132       Lung NAT(36F)   3538.73   23.55   87       Lung cancer(370)   4143.89   21.18   40       Lung cancer(376)   2446.38   20.81   34       Lung cancer(378)   3989.95   27.35   30       Lung cancer(37A)   4136.72   36.64   123.5       Normal Lung 4   4083.27   28.46   85       Normal Lung 5   4235.38   25.22   95       CuraChip reference 1   3728.44   28.62   49       Melanoma   2915.57   20.5   25       Melanoma   2646.56   20.29   18       Melanoma (19585)   2509.13   23.23   16.5       Normal Lung 1   2759.91   24.22   32       Lung cancer(372)   3803.04   27.08   30       Lung NAT(35D)   3771.95   25.68   147       Lung NAT(361)   2214.53   20.77   49.5       Melanoma   2134.94   21.43   17       Normal Lung 2   3656.2   20.99   69       Lung cancer(374)   3295.08   24.19   72       Lung cancer(36B)   3776.14   21.32   84       Lung cancer(362)   1543.94   26.44   40       Lung cancer(358)   1929.4   30.01   51       Melanoma   2375.7   20.83   22       Normal Lung 3   3157.31   22.69   34       Lung NAT(375)   4614.72   32.86   96.5       Lung cancer(36D)   2785.76   24.74   66.5       Lung NAT(363)   4348.91   34.21   76       Lung cancer(35A)   3986.34   29.19   117       Melanoma   2189.36   20.44   16       Prostate cancer(B8B)   2957.66   9.6   70.5       Prostate cancer(B88)   4126.76   33.25   18.5       Prostate NAT(B93)   3378.81   37.92   16.5       Prostate cancer(B8C)   3527   42.55   10       Prostate cancer(AD5)   4105.44   45.35   0       Prostate NAT(AD6)   4196.5   41.71   23.5       Prostate cancer(AD7)   2830.59   42.73   0       Prostate NAT(AD8)   3404.14   29.72   25       Prostate cancer(ADA)   3700.09   34.54   1       Prostate NAT(AD9)   3022.26   30.92   10       Prostate cancer(9E7)   3084.26   30.48   0.5       Prostate cancer(A0A)   3983.11   24.56   30       Prostate cancer(9E2)   2889.43   23.94   23       Pancreatic cancer(9E4)   4473.72   23.53   165       Pancreatic cancer(9D8)   3443.44   20.25   24       Pancreatic cancer(9D4)   3819.27   17.3   8.5       Pancreatic cancer(9BE)   3287.48   24.17   43       Pancreatic NAT(ADB)   2358   28.92   0       Pancreatic NAT(ADC)   2863.88   36.96   23.5       Pancreatic NAT(ADD)   3118.81   30.22   1.5       Pancreatic NAT(AED)   3211.96   26.31   42       Colon cancer(8A3)   1984.83   48.06   13       Colon NAT(8B6)   1682.5   39.46   9       Colon NAT(9F1)   2378.93   48.8   2       Colon cancer(9F2)   1931.28   46.1   10.5       Colon NAT(A1D)   2029.41   46.05   4       Colon cancer(9DB)   2278.96   44.08   3.5       Colon NAT(A15)   1674.01   45.41   0       Colon cancer(A14)   1360.97   35.04   4       Colon NAT(ACB)   1707.6   45.03   1       Colon cancer(AC0)   1894.33   46.06   0       Colon cancer(8A4)   1785.56   43.34   5       Colon NAT(ACD)   1797.75   44.1   8       Colon cancer(AC4)   2198.75   49.26   4       Colon NAT(AC2)   1847.84   43.83   1       Colon cancer(AC1)   1806.35   39.49   9       Colon NAT(ACC)   2013.34   39.08   0       Colon cancer(AC3)   1539.46   47.71   2       Breast cancer(9B7)   1857.03   46.65   15       Breast NAT(9CF)   1462.79   47.35   0       Breast cancer(9B6)   2133.12   47.71   9       Breast cancer(9C7)   2302.99   47.48   18       Colon cancer(8A6)   2093.72   45.39   6       Breast NAT(A11)   1508.35   45.43   0       Breast cancer(A1A)   2246.51   46.55   1       Breast cancer(9F3)   1881.09   46.54   6       Breast cancer(9B8)   2174.46   48.66   2       Breast NAT(9C4)   1670.58   48.93   4       Breast cancer(9EF)   1168.07   23.61   4       Breast cancer(9F0)   1506.95   28.54   0       Breast cancer(9B4)   1016.05   32.36   0       Breast cancer(9EC)   2526.83   47.27   8       Colon cancer(8A7)   1594.35   48.21   0       Colon cancer(8B7)   2091.33   40.64   4       Colon cancer(8A9)   2533.34   40.66   24       Colon cancer(8AB)   1638.43   30.62   4       Colon cancer(8AC)   1975.26   41.39   9       Colon NAT(8AD)   1851.09   49.21   1       Colon cancer(8B5)   1920.15   47.11   5.5       Cervical cancer(B08)   1393.31   2.02   186       Brain cancer(9F8)   1400.44   8.86   NA       Brain cancer(9C0)   655.35   4.73   0       Brain cancer(9F7)   1403.07   0.42   0       Brain cancer(A00)   1509.09   3.25   0       Brain NAT(A01)   1159.94   0.43   6       Brain cancer(9DA)   1019.67   0.72   0       Brain cancer(9FE)   1352.85   2.77   0       Brain cancer(9C6)   1237.61   3.47   0       Brain cancer(9F6)   917.48   2.17   0       Cervical NAT(AEB)   826.9   1.64   NA       Bladder NAT(23954)   521.75   0.44   0       Urinary cancer(AF6)   1007.77   1.4   0       Urinary cancer(B0C)   1256.43   1.31   0       Urinary cancer(AE4)   1219.17   1.23   0       Urinary NAT(B20)   1222.48   1.23   0       Urinary cancer(AE6)   1114.91   1.03   0       Urinary NAT(B04)   655.35   0.07   0       Urinary cancer(B07)   543.73   1.64   1       Urinary NAT(AF8)   1247.4   0.53   0       Cervical cancer(AFF)   1411.18   4.31   NA       Ovarian cancer(9D7)   1221.47   0.63   13       Urinary cancer(AF7)   1138.73   1.3   0       Ovarian cancer(9F5)   1298.98   0   NA       Ovarian cancer(A05)   1134.77   2.16   3       Ovarian cancer(9BC)   505   0.15   NA       Ovarian cancer(9C2)   1025.23   0.93   0       Ovarian cancer(9D9)   1203.34   1.53   NA       Ovarian NAT(AC7)   685.35   0.54   NA       Ovarian NAT(AC9)   716.79   0.85   NA       Ovarian NAT(ACA)   628.62   2.38   NA       Cervical NAT(B1E)   1293.21   7.01   NA       Ovarian NAT(AC5)   542.12   0.99   0       Cervical cancer(B00)   1512.53   9.92   185       Cervical NAT(AFA)   1136.08   8.76   NA       Cervical cancer(B1F)   1782.82   18.96   NA       Cervical NAT(B1C)   655.35   2.36   NA       Brain cancer(9F9)   1508.5   5.08   NA       Breast cancer(D34)   2470.88   0   48.5       Breast cancer(D35)   2602.08   0   127       Breast cancer(D36)   2909.53   0   NA       Breast cancer(D37)   2811.77   0.05   75       Breast cancer(D38)   2986.78   0.38   96       Breast cancer(D39)   3026.22   0.04   78       Breast cancer(D3A)   3072.62   0.08   115.5       Breast cancer(D3B)   2571.28   0.02   31       Breast cancer(D3C)   3213.98   0.6   99.5       Breast cancer(D3D)   3484.57   2.5   73       Breast cancer(D3E)   2958.51   0.17   106       Breast cancer(D3F)   2937.01   1.88   30       Breast cancer(D40)   2751.61   1.2   31.5       Breast cancer(D42)   2171.59   0.8   19       Breast cancer(D43)   2962.09   4.5   44       Breast cancer(D44)   2558.08   2.95   24       Breast cancer(D45)   2667.3   3.59   39       Breast cancer(D46)   3190.77   2.25   53.5       SK-MES   2804.32   0.56   130.5       HLaC-79   3402.37   0   103.5       H226   2562.59   0   8       HCT-116   4221.68   0.09   10       IGROV-1   3243.07   0   32       MX-1   3253.75   0   0       C33A   3249.59   0   11       Daudi   2333.08   0.01   65       MV522   2727.71   0.94   0       RWP-2   2906.49   0   0       BON   2502.53   0.01   9       MiaPaCa   3604.78   0   39       H82   2357.18   2.19   15       H69   2759.55   0.12   46.5       Caki-2   2687.93   0   1       LNCaP   3352.46   0.41   64.5       A549   2593.12   0   9       DU145   3970.51   0.07   44       OVCAR-3   3230.65   0.14   51       HT-29   3381.64   0.07   41.5       DLD-2   3610.05   0.24   4       MCF-7   3326.73   1.78   48       H460   2464.22   0   102       SW620   2732.11   0   12       SK-OV-3   3519.75   0   NA       MDA-231   3464.04   0.04   72       Caki-1   3801.64   0   87       PC-3   2214.23   0   77.5       LoVo   3237.95   0   49       Kidney NAT(10B1)   3041.27   6.44   187       Kidney cancer(10B2)   3798.53   1.31   34       Kidney NAT(10B3)   3315.43   0   1197       Kidney cancer(10B4)   3519.14   0.16   73       Kidney NAT(10B5)   3017.75   0   177       Kidney cancer(10B6)   3702.61   0   13403.5       Kidney NAT(10B7)   3060.89   0   330       Kidney cancer(10BA)   3437.01   0   12600.5       Kidney NAT(10BB)   3157.99   0   308       Kidney cancer(10C0)   3590.87   0.77   40       Kidney NAT(10C1)   3012.3   0   157       Kidney cancer(10C4)   3186.48   0.02   270.5       Kidney NAT(10C5)   3618.74   0   64       Kidney cancer(10A8)   3514.51   0   14       Kidney NAT(10A9)   2771.76   1.14   241.5       Kidney cancer(10AA)   3793.55   0.4   86       Kidney NAT(10AB)   2978.06   0   222.5       Kidney cancer(10AC)   3656.35   0.05   26       Kidney NAT(10AD)   3299.97   2.13   436       Kidney cancer(10AE)   3456.21   0.57   49.5       Kidney NAT(10AF)   2593.7   0   100       Kidney cancer(10B0)   3529.2   0.67   35       Lymphoma(9BF)   2333.81   0   0       Lymphoma(9D2)   1327.77   0   0       Lymphoma(A04)   1450.41   0   0       Lymphoma(9DD)   1095.68   0   0       Lymphoma(F68)   865.62   0   0       Lymphoma(F6A)   862.12   0   0       Lymphoma(F6B)   624.66   0   0       Lymphoma(F6C)   1621.52   0   0       Lymphoma(F6D)   864.76   0   0       Lymphoma(F6E)   1030.71   0   0       Lymphoma(F6F)   1120.14   0   54       Lymphoma(F70)   891.53   0   0       Lymphoma(F71)   915.92   0   0       Lymphoma(F72)   1199.28   3.13   15       Lymphoma(F73)   1357.46   0   2       Lymphoma(F74)   993.02   0   0       Lymphoma NAT(1002)   2069.54   0   0       Lymphoma NAT(1004)   1928.51   0   0       Lymphoma NAT(1005)   1412.32   0   0       Lymphoma NAT(1007)   1668.28   0   0       Lymphoma NAT(1003)   1919.49   0   0       Lymphoma(9E3)   1791.94   0   0       Lymphoma(9D0)   1530.59   0   0       Lymphoma(9E1)   1677.97   0   0       Lymphoma(A0D)   2656.34   1.4   61       Lymphoma(9B5)   2336.21   0   8       Lymphoma(9D3)   1902.13   0   0       Normal Lung 4   4083.27   28.46   45.8       Normal Lung 5   4235.38   25.22   49.35       Normal Lung 1   2759.91   24.22   25.51       Normal Lung 2   3656.2   20.99   41.52       Normal Lung 3   3157.31   22.69   23.69       SW1353 resting 1 h   3946.45   0.6   0       SW1353 resting 6 h   3263.46   0.12   0       SW1353 resting 16 h   2311.8   0   25.69       SW1353 IL-1b (1 ng/) 1 h   2686.83   0.16   0       SW1353 IL-1b (1 ng/) 6 h   3159.94   2   8.35       SW1353 IL-1b (1 ng/) 16 h   3557.88   0.62   0.93       SW1353 FGF20 (1 ug/)   3512.56   0.69   0.63       1 h       SW1353 FGF20 (1 ug/)   2510.14   0.06   0       16 h       SW1353 FGF20 (5 ug/)   3448.11   1.01   4.15       1 h       SW1353 FGF20 (5 ug/)   3598.07   0.64   6.73       6 h       SW1353 FGF20 (5 ug/)   3687.34   4.42   12.83       16 h       SW1353 FGF20 (1 ug/)   3569.19   0.17   4.31       IL-1b (1 ng/) 6 h       SW1353 FGF20 (1 ug/)   3970.28   0.01   0       IL-1b (1 ng/) 16 h       SW1353 FGF20 (5 ug/)   3011.45   0   0       IL-1b (1 ng/) 1 h       SW1353 FGF20 (5 ug/)   3184.88   2.69   0       IL-1b (1 ng/) 6 h       THP-1 aCD40 (1 ug/) 1 h   3545.99   0.07   42.81       THP-1 aCD40 (1 ug/) 6 h   2882.56   0.44   28.24       THP-1 LPS (100 ng/) 1 h   3131.64   0.74   77.98       THP-1 LPS (100 ng/) 6 h   2356.5   0.05   75.15       CCD1070SK TNFa (5   2888.01   0.78   0       ng/) 6 h       CCD1070SK TNFa (5   3029   0.39   25.42       ng/) 24 h       CCD1070SK IL-1b (1 ng/)   3307.91   5.76   0       24 h       THP-1 resting   3080.68   0.87   41.42       THP-1 aCD40 (1 ug/) 24 h   2032.49   0.82   2.16       THP-1 LPS (100 ng/) 24 h   1597.29   3.58   0       CCD1070SK IL-1b (1 ng/)   3026.56   3.51   1.09       6 h       LC 18 hr   2725.87   0.36   0       LC-IL-! 18 hr   1474.79   2.66   0       Astrocyte_IL1B_1 hr_a   3116.77   10.04   25.41       Astrocyte_IL1B_6 hr_a   3119.7   16.51   28.21       Astrocyte_IL1B_24 hr_a   3142.98   13.81   26.6       SHSY 5Y Undifferentiated   3166.23   14.61   47.94       SHSY 5Y Differentiated   2959.01   8.5   33.46       LC 0 hr   1880.7   0   1.17       Normal Fetal Kidney   2011.8   0   10.94       Normal Liver   2053.67   3.81   0       Normal Fetal Liver   3555.17   0   157.18       Normal Fetal Lung   4164.55   0   75.01       Normal Salivary Gland   3466.36   0   59.02       Normal Fetal Skeletal   2504.59   0   32.5       Muscle       Normal Thyroid   3566.17   0   160.4       Normal Trachea   3596.15   0   100.33       LC-IL-1 0 hr   2560.23   0   2.58       Heart pool   3167.78   0   22.92       Pituitary Pool   2908.48   0   363.83       Spleen Pool   2068.62   0   36.16       Stomach Pool   2826.7   0   5169.42       Testis Pool   3348.7   0   36.46       Thymus Pool   2653.82   0   75.44       Small Intestine - 5 donor   3795.64   0   41.44       pool       Lymph node - 5 donor   4339.52   0   108.49       pool       Kidney - 5 donor pool   3347.34   0   12.82       Jurkat Resting   3779.74   0.48   32.89       Jurkat CD3 (500 ng/ml)   2459.46   1.68   89.9       6 hr A       Jurkat CD3 (500 ng/ml)   1897.6   0.08   85.79       24 hr A       Jurkat CD3   1867.35   0.68   65.39       (500 ng/ml) + CD28(1 ug/ml)       6 hr A       Jurkat CD3   1574.07   0.35   103.43       (500 ng/ml) + CD28(1 ug/ml)       24 hr A       control (no treatment)_1   5400.28   2.01   46.65       hr       10 ng/ml IL-1b_1 hr   5250.91   1.51   63.47       10 ng/ml TNF-a_1 hr   5668.06   2.55   57.06       200 uM BzATP_1 hr   5619.87   0.31   47.95       control (no treatment)_5 hr   5630.13   1.02   73.66       10 ng/ml IL-1b_5 hr   6332.12   10.52   55.94       10 ng/ml TNF-a_5 hr   6070.17   6.37   52.01       200 uM BzATP_5 hr   6425.22   2.39   155.96       control (no treatment)_24   4825.87   3.5   56.3       hr       10 ng/ml IL-1b_24 hr   5349.28   9.73   55.52       10 ng/ml TNF-a_24 hr   5672.31   4.97   85.13       200 uM BzATP_24 hr   4814.1   0.51   38.39       Alzheimer&#39;s disease   1854.86   14.76   13.05       B4951       Alzheimer&#39;s disease   2540.02   19.95   20.79       B4953       Alzheimer&#39;s disease   1757.68   22.42   23.78       B5018       Alzheimer&#39;s disease   1491.9   18.37   10.32       B5019       Alzheimer&#39;s disease   2247.49   18.04   11.26       B5086       Alzheimer&#39;s disease   2150.92   19.76   23.52       B5096       Alzheimer&#39;s disease   732.56   15.93   0       B5098       Alzheimer&#39;s disease   1841.99   18.04   4.78       B5129       Alzheimer&#39;s disease   3233.87   21.56   24.49       B5210       Control B4810   2987.22   21.85   18.41       Control B4825   2903.91   18.74   18.18       Control B4930   2287.12   22.69   22.12       Control B4932   3424.98   20.12   17.99       Control B5024   3859.32   22.42   27.93       Control B5113   1897   17.87   11.6       Control B5140   1901.93   18.88   11.57       Control B5190   1284.69   15.26   0       Control B5220   2225.75   18.7   20.26       Control B5245   2119.39   21.5   15.57       AH3 B3791   2202.74   19.73   18.98       AH3 B3855   1849.89   17.93   17.84       AH3 B3877   2144.15   17.01   14.36       AH3 B3893   2103.76   16.34   38.69       AH3 B3894   1820.82   17.31   24.16       AH3 B3949   1607.86   23.9   19.16       AH3 B4477   1602.58   20.32   19.91       AH3 B4540   2260.92   22.79   24.33       AH3 B4577   2142.42   22.59   15.4       AH3 B4639   1550.43   21.89   22.7       Schizophrenia   2468.43   21.23   23.17       hippocampus 683       Depression hippocampus   1473.83   18   0       487       Depression hippocampus   2481.12   10.69   19.51       600       Normal hippocampus   2624.25   33.19   5.45       2407a       Normal hippocampus   2114.72   21.4   26.01       1042       Depression hippocampus   1448.13   10.6   0       2767       Depression hippocampus   1836.77   47.98   24.55       567       Control hippocampus   2752.14   14.38   12.79       3175       Depression hippocampus   1735.6   9.4   29.15       3096       Depression hippocampus   2784.26   17.28   43.46       1491       Depression hippocampus   2241.25   16.73   19.63       2540       Schizophrenia   1923.26   16.97   25.74       hippocampus 2798       Control hippocampus   2605.59   14.97   17.73       1973       Normal hippocampus and   2031.45   13.85   4.33       amygdala 2601       Schizophrenia   1621.43   21.03   0       hippocampus 2785       Schizophrenia   3271.31   39.54   13.79       hippocampus 484       Normal hippocampus   2806.68   21.69   43.9       2556       Depression hippocampus   2705.56   15.83   27.65       1158       Control hippocampus 552   3378.83   21.65   42       Schizophrenia   2304.06   12.06   26.74       hippocampus 1737       Normal hippocampus   3335.3   17.54   32.32       1239       Normal hippocampus   3068.38   14.64   20.08       1465       Normal hippocampus   1323.77   4.6   0       3080       Normal hippocampus 738   4229.67   12.96   31.21       Schizophrenia   2067.82   12.78   24.47       hippocampus 2586       Normal hippocampus   3306.02   13.41   40.59       2551       Depression hippocampus   2352.1   13.53   48.17       588       Depression hippocampus   3291.7   13.05   70.51       529       Depression hippocampus   1686.08   11.37   13.7       and dentate gyrus       Schizophrenia amygdala   2136.57   0.55   12.87       2586       Normal substantia nigra   1240.83   0.03   24.82       234       Normal substantia nigra   1515.69   14.19   4.35       1065       Normal substantia nigra   1341.77   0   4.92       3236       Normal substantia nigra   3718.91   0.43   9.47       2551       Normal substantia nigra   1003.1   0   16.45       1597       Control thalamus 552   948.15   0.02   27.84       Control thalamus 566   1698.42   0   0       Control thalamus 606   2625.59   0.31   0       Control thalamus 738   2464.52   0   16.96       Control thalamus 1065   2991.38   0   9.56       Control thalamus 1092   2416.75   0   21.85       Control thalamus 1597   2389.84   0   11.51       Control thalamus 2253   1602.4   0   16.48       Control thalamus 2551   3017.98   0   7.29       Depression thalamus 588   2245.45   0.29   0       Depression thalamus 600   1442.56   0   4.58       Depression thalamus 721   1921.28   0   0       Depression thalamus 728   3113.17   4.33   21.2       Depression thalamus 759   2433.85   0   4.52       Depression thalamus 881   2456.7   0   4.48       Schizophrenia thalamus   1952.08   0   11.27       477       Schizophrenia thalamus   3553.95   0   22.29       532       Schizophrenia thalamus   3798.02   0   8.69       683       Schizophrenia thalamus   3260.82   0.03   11.47       544       Schizophrenia thalamus   2246.95   0   5.39       1671       Schizophrenia thalamus   1958.75   0.01   0       1737       Schizophrenia thalamus   1953.64   0   0       2464       Schizophrenia thalamus   3338.49   0   19.77       2586       Depression amygdala   1936.43   0   NA       600       Depression amygdala   2378.2   0   74.93       759       Depression anterior   2808.48   0   28.2       cingulate 759       Control amygdala 552   3675.87   0.36   7.78       Control anterior cingulate   3115.46   0.67   28.6       482       Depression anterior   1964.87   0   0       cingulate 721       Control amygdala 3175   2674.16   0.04   16.87       Depression anterior   2389.83   0.06   0       cingulate 600       Depression anterior   2629.92   0   10.04       cingulate 588       Control anterior cingulate   3605.03   0.79   21.36       3175       Control anterior cingulate   2414.64   0   NA       606       Depression anterior   2397.28   1.2   9.64       cingulate 567       Depression amygdala   3410.76   3.1   33.86       588       Control anterior cingulate   2445.09   3.01   18.9       3080       Control anterior cingulate   2520   5.45   22.26       2601       Control anterior cingulate   3118.04   0.76   31.75       1042       Control anterior cingulate   2913.66   1.45   34.73       3236       Control amygdala 1502   4253.4   9.62   40.86                  
 
     OTHER EMBODIMENTS  
     [0954] Although particular embodiments have been disclosed herein in detail, this has been done by way of example for purposes of illustration only, and is not intended to be limiting with respect to the scope of the appended claims, which follow. In particular, it is contemplated by the inventors that various substitutions, alterations, and modifications may be made to the invention without departing from the spirit and scope of the invention as defined by the claims. The choice of nucleic acid starting material, clone of interest, or library type is believed to be a matter of routine for a person of ordinary skill in the art with knowledge of the embodiments described herein. Other aspects, advantages, and modifications considered to be within the scope of the following claims. The claims presented are representative of the inventions disclosed herein. Other, unclaimed inventions are also contemplated. Applicants reserve the right to pursue such inventions in later claims.  
 
    
     
       
         0 
         
           
               
            
               
                   
               
               
                   
               
               
                   
               
               
                                                SEQUENCE LISTING  
               
               
                   
               
               
                   
               
               
                 &lt;160&gt; NUMBER OF SEQ ID NOS: 173  
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 1  
               
               
                 &lt;211&gt; LENGTH: 2343  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (36)..(1328)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 1  
               
               
                   
               
               
                 gagcgctaac gtctttctgt ctccccgcgg tggtg atg acg gtg aaa act gag        53  
               
               
                                                        Met Thr Val Lys Thr Glu  
               
               
                                                        1               5  
               
               
                   
               
               
                 gct gct aag ggc acc ctc act tac tcc agg atg agg ggc atg gtg gca      101  
               
               
                 Ala Ala Lys Gly Thr Leu Thr Tyr Ser Arg Met Arg Gly Met Val Ala  
               
               
                             10                  15                  20  
               
               
                   
               
               
                 att ctc atc gct ttc atg aag cag agg agg atg ggt ctg aac gac ttt      149  
               
               
                 Ile Leu Ile Ala Phe Met Lys Gln Arg Arg Met Gly Leu Asn Asp Phe  
               
               
                         25                  30                  35  
               
               
                   
               
               
                 att cag aag att gcc aat aac tcc tat gca tgc aaa cac cct gaa gtt      197  
               
               
                 Ile Gln Lys Ile Ala Asn Asn Ser Tyr Ala Cys Lys His Pro Glu Val  
               
               
                     40                  45                  50  
               
               
                   
               
               
                 cag tcc atc ttg aag atc tcc caa cct cag gag cct gag ctt atg aat      245  
               
               
                 Gln Ser Ile Leu Lys Ile Ser Gln Pro Gln Glu Pro Glu Leu Met Asn  
               
               
                 55                  60                  65                  70  
               
               
                   
               
               
                 gcc aac cct tct cct cca cca agt cct tct cag caa atc aac ctt ggc      293  
               
               
                 Ala Asn Pro Ser Pro Pro Pro Ser Pro Ser Gln Gln Ile Asn Leu Gly  
               
               
                                 75                  80                  85  
               
               
                   
               
               
                 ccg tcg tcc aat cct cat gct aaa cca tct gac ttt cac ttc ttg aaa      341  
               
               
                 Pro Ser Ser Asn Pro His Ala Lys Pro Ser Asp Phe His Phe Leu Lys  
               
               
                             90                  95                  100  
               
               
                   
               
               
                 gtg atc gga aag ggc agt ttt gga aag gtt ctt cta gca aga cac aag      389  
               
               
                 Val Ile Gly Lys Gly Ser Phe Gly Lys Val Leu Leu Ala Arg His Lys  
               
               
                         105                 110                 115  
               
               
                   
               
               
                 gca gaa gaa gtg ttc tat gca gtc aaa gtt tta cag aag aaa gca atc      437  
               
               
                 Ala Glu Glu Val Phe Tyr Ala Val Lys Val Leu Gln Lys Lys Ala Ile  
               
               
                     120                 125                 130  
               
               
                   
               
               
                 ctg aaa aag aaa gag gag aag cat att atg tcg gag cgg aat gtt ctg      485  
               
               
                 Leu Lys Lys Lys Glu Glu Lys His Ile Met Ser Glu Arg Asn Val Leu  
               
               
                 135                 140                 145                 150  
               
               
                   
               
               
                 ttg aag aat gtg aag cac cct ttc ctg gtg ggc ctt cac ttc tct ttc      533  
               
               
                 Leu Lys Asn Val Lys His Pro Phe Leu Val Gly Leu His Phe Ser Phe  
               
               
                                 155                 160                 165  
               
               
                   
               
               
                 cag act gct gac aaa ttg tac ttt gtc cta gac tac att aat ggt gga      581  
               
               
                 Gln Thr Ala Asp Lys Leu Tyr Phe Val Leu Asp Tyr Ile Asn Gly Gly  
               
               
                             170                 175                 180  
               
               
                   
               
               
                 gag ttg ttc tac cat ctc cag agg gaa cgc tgc ttc ctg gaa cca cgg      629  
               
               
                 Glu Leu Phe Tyr His Leu Gln Arg Glu Arg Cys Phe Leu Glu Pro Arg  
               
               
                         185                 190                 195  
               
               
                   
               
               
                 gct cgt ttc tat gct gct gaa ata gcc agt gcc ttg ggc tac ctg cat      677  
               
               
                 Ala Arg Phe Tyr Ala Ala Glu Ile Ala Ser Ala Leu Gly Tyr Leu His  
               
               
                     200                 205                 210  
               
               
                   
               
               
                 tca ctg aac atc gtt tat aga gac tta aaa cca gag aat att ttg cta      725  
               
               
                 Ser Leu Asn Ile Val Tyr Arg Asp Leu Lys Pro Glu Asn Ile Leu Leu  
               
               
                 215                 220                 225                 230  
               
               
                   
               
               
                 gat tca cag gga cac att gtc ctt act gac ttc gga ctc tgc aag gag      773  
               
               
                 Asp Ser Gln Gly His Ile Val Leu Thr Asp Phe Gly Leu Cys Lys Glu  
               
               
                                 235                 240                 245  
               
               
                   
               
               
                 aac att gaa cac aac agc aca aca tcc acc ttc tgt ggc acg ccg gag      821  
               
               
                 Asn Ile Glu His Asn Ser Thr Thr Ser Thr Phe Cys Gly Thr Pro Glu  
               
               
                             250                 255                 260  
               
               
                   
               
               
                 tat ctc gca cct gag gtg ctt cat aag cag cct tat gac agg act gtg      869  
               
               
                 Tyr Leu Ala Pro Glu Val Leu His Lys Gln Pro Tyr Asp Arg Thr Val  
               
               
                         265                 270                 275  
               
               
                   
               
               
                 gac tgg tgg tgc ctg gga gct gtc ttg tat gag atg ctg tat ggc ctg      917  
               
               
                 Asp Trp Trp Cys Leu Gly Ala Val Leu Tyr Glu Met Leu Tyr Gly Leu  
               
               
                     280                 285                 290  
               
               
                   
               
               
                 ccg cct ttt tat agc cga aac aca gct gaa atg tac gac aac att ctg      965  
               
               
                 Pro Pro Phe Tyr Ser Arg Asn Thr Ala Glu Met Tyr Asp Asn Ile Leu  
               
               
                 295                 300                 305                 310  
               
               
                   
               
               
                 aac aag cct ctc cag ctg aaa cca aat att aca aat tcc gca aga cac     1013  
               
               
                 Asn Lys Pro Leu Gln Leu Lys Pro Asn Ile Thr Asn Ser Ala Arg His  
               
               
                                 315                 320                 325  
               
               
                   
               
               
                 ctc ctg gag ggc ctc ctg cag aag gac agg aca aag cgg ctc ggg gcc     1061  
               
               
                 Leu Leu Glu Gly Leu Leu Gln Lys Asp Arg Thr Lys Arg Leu Gly Ala  
               
               
                             330                 335                 340  
               
               
                   
               
               
                 aag gat gac ttc atg gag att aag agt cat gtc ttc ttc tcc tta att     1109  
               
               
                 Lys Asp Asp Phe Met Glu Ile Lys Ser His Val Phe Phe Ser Leu Ile  
               
               
                         345                 350                 355  
               
               
                   
               
               
                 aac tgg gat gat ctc att aat aag aag att act ccc cct ttt aac cca     1157  
               
               
                 Asn Trp Asp Asp Leu Ile Asn Lys Lys Ile Thr Pro Pro Phe Asn Pro  
               
               
                     360                 365                 370  
               
               
                   
               
               
                 aat gtg agt ggg ccc aac gac cta cgg cac ttt gac ccc gag ttt acc     1205  
               
               
                 Asn Val Ser Gly Pro Asn Asp Leu Arg His Phe Asp Pro Glu Phe Thr  
               
               
                 375                 380                 385                 390  
               
               
                   
               
               
                 gaa gag cct gtc ccc aac tcc att ggc aag tcc cct gac agc gtc ctc     1253  
               
               
                 Glu Glu Pro Val Pro Asn Ser Ile Gly Lys Ser Pro Asp Ser Val Leu  
               
               
                                 395                 400                 405  
               
               
                   
               
               
                 gtc aca gcc agc gtc aag gaa gct gcc gag gct ttc cta ggc ttt tcc     1301  
               
               
                 Val Thr Ala Ser Val Lys Glu Ala Ala Glu Ala Phe Leu Gly Phe Ser  
               
               
                             410                 415                 420  
               
               
                   
               
               
                 tat gcg cct ccc acg gac tct ttc ctc tgaaccctgt tagggcttgg           1348  
               
               
                 Tyr Ala Pro Pro Thr Asp Ser Phe Leu  
               
               
                         425                 430  
               
               
                   
               
               
                 ttttaaagga ttttatgtgt gtttccgaat gttttagtta gccttttggt ggagccgcca   1408  
               
               
                   
               
               
                 gctgacagga catcttacaa gagaatttgc acatctctgg aagcttagca atcttattgc   1468  
               
               
                   
               
               
                 acactgttcg ctggaagctt tttgaagagc acattctcct cagtgagctc atgaggtttt   1528  
               
               
                   
               
               
                 catttttatt cttccttcca acgtggtgct atctctgaaa cgagcgttag agtgccgcct   1588  
               
               
                   
               
               
                 tagacggagg caggagtttc gttagaaagc ggacgctgtt ctaaaaaagg tctcctgcag   1648  
               
               
                   
               
               
                 atctgtctgg gctgtgatga cgaatattat gaaatgtgcc ttttctgaag agattgtgtt   1708  
               
               
                   
               
               
                 agctccaaag cttttcctat cgcagtgttt cagttcttta ttttcccttg tggatatgct   1768  
               
               
                   
               
               
                 gtgtgaaccg tcgtgtgagt gtggtatgcc tgatcacaga tggattttgt tataagcatc   1828  
               
               
                   
               
               
                 aatgtgacac ttgcaggaca ctacaacgtg ggacattgtt tgtttcttcc atatttggaa   1888  
               
               
                   
               
               
                 gataaattta tgtgtagact tttttgtaag atacggttaa taactaaaat ttattgaaat   1948  
               
               
                   
               
               
                 ggtcttgcaa tgactcgtat tcagatgctt aaagaaagca ttgctgctac aaatatttct   2008  
               
               
                   
               
               
                 atttttagaa agggttttta tggaccaatg ccccagttgt cagtcagagc cgttggtgtt   2068  
               
               
                   
               
               
                 tttcattgtt taaaatgtca cctgtaaaat gggcattatt tatgtttttt tttttgcatt   2128  
               
               
                   
               
               
                 cctgataatt gtatgtattg tataaagaac gtctgtacat tgggttataa cactagtata   2188  
               
               
                   
               
               
                 tttaaactta caggcttatt tgtaatgtaa accaccattt taatgtactg taattaacat   2248  
               
               
                   
               
               
                 ggttataata cgtacaatcc ttccctcatc ccatcacaca actttttttg tgtgtgataa   2308  
               
               
                   
               
               
                 actgattttg gtttgcaata aaaccttgaa aaata                              2343  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 2  
               
               
                 &lt;211&gt; LENGTH: 431  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 2  
               
               
                   
               
               
                 Met Thr Val Lys Thr Glu Ala Ala Lys Gly Thr Leu Thr Tyr Ser Arg  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Met Arg Gly Met Val Ala Ile Leu Ile Ala Phe Met Lys Gln Arg Arg  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Met Gly Leu Asn Asp Phe Ile Gln Lys Ile Ala Asn Asn Ser Tyr Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Cys Lys His Pro Glu Val Gln Ser Ile Leu Lys Ile Ser Gln Pro Gln  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Glu Pro Glu Leu Met Asn Ala Asn Pro Ser Pro Pro Pro Ser Pro Ser  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gln Gln Ile Asn Leu Gly Pro Ser Ser Asn Pro His Ala Lys Pro Ser  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Asp Phe His Phe Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Lys Val  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Leu Ala Arg His Lys Ala Glu Glu Val Phe Tyr Ala Val Lys Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Gln Lys Lys Ala Ile Leu Lys Lys Lys Glu Glu Lys His Ile Met  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ser Glu Arg Asn Val Leu Leu Lys Asn Val Lys His Pro Phe Leu Val  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Gly Leu His Phe Ser Phe Gln Thr Ala Asp Lys Leu Tyr Phe Val Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Asp Tyr Ile Asn Gly Gly Glu Leu Phe Tyr His Leu Gln Arg Glu Arg  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala Glu Ile Ala Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ala Leu Gly Tyr Leu His Ser Leu Asn Ile Val Tyr Arg Asp Leu Lys  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Pro Glu Asn Ile Leu Leu Asp Ser Gln Gly His Ile Val Leu Thr Asp  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Gly Leu Cys Lys Glu Asn Ile Glu His Asn Ser Thr Thr Ser Thr  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu His Lys Gln  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Pro Tyr Asp Arg Thr Val Asp Trp Trp Cys Leu Gly Ala Val Leu Tyr  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Glu Met Leu Tyr Gly Leu Pro Pro Phe Tyr Ser Arg Asn Thr Ala Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Met Tyr Asp Asn Ile Leu Asn Lys Pro Leu Gln Leu Lys Pro Asn Ile  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Thr Asn Ser Ala Arg His Leu Leu Glu Gly Leu Leu Gln Lys Asp Arg  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Thr Lys Arg Leu Gly Ala Lys Asp Asp Phe Met Glu Ile Lys Ser His  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Val Phe Phe Ser Leu Ile Asn Trp Asp Asp Leu Ile Asn Lys Lys Ile  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Thr Pro Pro Phe Asn Pro Asn Val Ser Gly Pro Asn Asp Leu Arg His  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Phe Asp Pro Glu Phe Thr Glu Glu Pro Val Pro Asn Ser Ile Gly Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Ser Pro Asp Ser Val Leu Val Thr Ala Ser Val Lys Glu Ala Ala Glu  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Ala Phe Leu Gly Phe Ser Tyr Ala Pro Pro Thr Asp Ser Phe Leu  
               
               
                             420                 425                 430  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 3  
               
               
                 &lt;211&gt; LENGTH: 1315  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (14)..(1306)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 3  
               
               
                   
               
               
                 caccggatcc acc atg acg gtg aaa act gag gct gct aag ggc acc ctc       49  
               
               
                                Met Thr Val Lys Thr Glu Ala Ala Lys Gly Thr Leu  
               
               
                                1               5                   10  
               
               
                   
               
               
                 act tac tcc agg atg agg ggc atg gtg gca att ctc atc gct ttc atg      97  
               
               
                 Thr Tyr Ser Arg Met Arg Gly Met Val Ala Ile Leu Ile Ala Phe Met  
               
               
                         15                  20                  25  
               
               
                   
               
               
                 aag cag agg agg atg ggt ctg aac gac ttt att cag aag att gcc aat     145  
               
               
                 Lys Gln Arg Arg Met Gly Leu Asn Asp Phe Ile Gln Lys Ile Ala Asn  
               
               
                     30                  35                  40  
               
               
                   
               
               
                 aac tcc tat gca tgc aaa cac cct gaa gtt cag tcc atc ttg aag atc     193  
               
               
                 Asn Ser Tyr Ala Cys Lys His Pro Glu Val Gln Ser Ile Leu Lys Ile  
               
               
                 45                  50                  55                  60  
               
               
                   
               
               
                 tcc caa cct cag gag cct gag ctt atg aat gcc aac cct tct cct cca     241  
               
               
                 Ser Gln Pro Gln Glu Pro Glu Leu Met Asn Ala Asn Pro Ser Pro Pro  
               
               
                                 65                  70                  75  
               
               
                   
               
               
                 cca agt cct tct cag caa atc aac ctt ggc ccg tcg tcc aat cct cat     289  
               
               
                 Pro Ser Pro Ser Gln Gln Ile Asn Leu Gly Pro Ser Ser Asn Pro His  
               
               
                             80                  85                  90  
               
               
                   
               
               
                 gct aaa cca tct gac ttt cac ttc ttg aaa gtg atc gga aag ggc agt     337  
               
               
                 Ala Lys Pro Ser Asp Phe His Phe Leu Lys Val Ile Gly Lys Gly Ser  
               
               
                         95                  100                 105  
               
               
                   
               
               
                 ttt gga aag gtt ctt cta gca aga cac aag gca gaa gaa gtg ttc tat     385  
               
               
                 Phe Gly Lys Val Leu Leu Ala Arg His Lys Ala Glu Glu Val Phe Tyr  
               
               
                     110                 115                 120  
               
               
                   
               
               
                 gca gtc aaa gtt tta cag aag aaa gca atc ctg aaa aag aaa gag gag     433  
               
               
                 Ala Val Lys Val Leu Gln Lys Lys Ala Ile Leu Lys Lys Lys Glu Glu  
               
               
                 125                 130                 135                 140  
               
               
                   
               
               
                 aag cat att atg tcg gag cgg aat gtt ctg ttg aag aat gtg aag cac     481  
               
               
                 Lys His Ile Met Ser Glu Arg Asn Val Leu Leu Lys Asn Val Lys His  
               
               
                                 145                 150                 155  
               
               
                   
               
               
                 cct ttc ctg gtg ggc ctt cac ttc tct ttc cag act gct gac aaa ttg     529  
               
               
                 Pro Phe Leu Val Gly Leu His Phe Ser Phe Gln Thr Ala Asp Lys Leu  
               
               
                             160                 165                 170  
               
               
                   
               
               
                 tac ttt gtc cta gac tac att aat ggt gga gag ttg ttc tac cat ctc     577  
               
               
                 Tyr Phe Val Leu Asp Tyr Ile Asn Gly Gly Glu Leu Phe Tyr His Leu  
               
               
                         175                 180                 185  
               
               
                   
               
               
                 cag agg gaa cgc tgc ttc ctg gaa cca cgg gct cgt ttc tat gct gct     625  
               
               
                 Gln Arg Glu Arg Cys Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala  
               
               
                     190                 195                 200  
               
               
                   
               
               
                 gaa ata gcc agt gcc ttg ggc tac ctg cat tca ctg aac atc gtt tat     673  
               
               
                 Glu Ile Ala Ser Ala Leu Gly Tyr Leu His Ser Leu Asn Ile Val Tyr  
               
               
                 205                 210                 215                 220  
               
               
                   
               
               
                 aga gac tta aaa cca gag aat att ttg cta gat tca cag gga cac att     721  
               
               
                 Arg Asp Leu Lys Pro Glu Asn Ile Leu Leu Asp Ser Gln Gly His Ile  
               
               
                                 225                 230                 235  
               
               
                   
               
               
                 gtc ctt act gac ttc gga ctc tgc aag gag aac att gaa cac aac agc     769  
               
               
                 Val Leu Thr Asp Phe Gly Leu Cys Lys Glu Asn Ile Glu His Asn Ser  
               
               
                             240                 245                 250  
               
               
                   
               
               
                 aca aca tcc acc ttc tgt ggc acg ccg gag tat ctc gca cct gag gtg     817  
               
               
                 Thr Thr Ser Thr Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val  
               
               
                         255                 260                 265  
               
               
                   
               
               
                 ctt cat aag cag cct tat gac agg act gtg gac tgg tgg tgc ctg gga     865  
               
               
                 Leu His Lys Gln Pro Tyr Asp Arg Thr Val Asp Trp Trp Cys Leu Gly  
               
               
                     270                 275                 280  
               
               
                   
               
               
                 gct gtc ttg tat gag atg ctg tat ggc ctg ccg cct ttt tat agc cga     913  
               
               
                 Ala Val Leu Tyr Glu Met Leu Tyr Gly Leu Pro Pro Phe Tyr Ser Arg  
               
               
                 285                 290                 295                 300  
               
               
                   
               
               
                 aac aca gct gaa atg tac gac aac att ctg aac aag cct ctc cag ctg     961  
               
               
                 Asn Thr Ala Glu Met Tyr Asp Asn Ile Leu Asn Lys Pro Leu Gln Leu  
               
               
                                 305                 310                 315  
               
               
                   
               
               
                 aaa cca aat att aca aat tcc gca aga cac ctc ctg gag ggc ctc ctg     1009  
               
               
                 Lys Pro Asn Ile Thr Asn Ser Ala Arg His Leu Leu Glu Gly Leu Leu  
               
               
                             320                 325                 330  
               
               
                   
               
               
                 cag aag gac agg aca aag cgg ctc ggg gcc aag gat gac ttc atg gag     1057  
               
               
                 Gln Lys Asp Arg Thr Lys Arg Leu Gly Ala Lys Asp Asp Phe Met Glu  
               
               
                         335                 340                 345  
               
               
                   
               
               
                 att aag agt cat gtc ttc ttc tcc tta att aac tgg gat gat ctc att     1105  
               
               
                 Ile Lys Ser His Val Phe Phe Ser Leu Ile Asn Trp Asp Asp Leu Ile  
               
               
                     350                 355                 360  
               
               
                   
               
               
                 aat aag aag att act ccc cct ttt aac cca aat gtg agt ggg ccc aac     1153  
               
               
                 Asn Lys Lys Ile Thr Pro Pro Phe Asn Pro Asn Val Ser Gly Pro Asn  
               
               
                 365                 370                 375                 380  
               
               
                   
               
               
                 gac cta cgg cac ttt gac ccc gag ttt acc gaa gag cct gtc ccc aac     1201  
               
               
                 Asp Leu Arg His Phe Asp Pro Glu Phe Thr Glu Glu Pro Val Pro Asn  
               
               
                                 385                 390                 395  
               
               
                   
               
               
                 tcc att ggc aag tcc cct gac agc gtc ctc gtc aca gcc agc gtc aag     1249  
               
               
                 Ser Ile Gly Lys Ser Pro Asp Ser Val Leu Val Thr Ala Ser Val Lys  
               
               
                             400                 405                 410  
               
               
                   
               
               
                 gaa gct gcc gag gct ttc cta ggc ttt tcc tat gcg cct ccc acg gac     1297  
               
               
                 Glu Ala Ala Glu Ala Phe Leu Gly Phe Ser Tyr Ala Pro Pro Thr Asp  
               
               
                         415                 420                 425  
               
               
                   
               
               
                 tct ttc ctc ctcgagggc                                               1315  
               
               
                 Ser Phe Leu  
               
               
                     430  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 4  
               
               
                 &lt;211&gt; LENGTH: 431  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 4  
               
               
                   
               
               
                 Met Thr Val Lys Thr Glu Ala Ala Lys Gly Thr Leu Thr Tyr Ser Arg  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Met Arg Gly Met Val Ala Ile Leu Ile Ala Phe Met Lys Gln Arg Arg  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Met Gly Leu Asn Asp Phe Ile Gln Lys Ile Ala Asn Asn Ser Tyr Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Cys Lys His Pro Glu Val Gln Ser Ile Leu Lys Ile Ser Gln Pro Gln  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Glu Pro Glu Leu Met Asn Ala Asn Pro Ser Pro Pro Pro Ser Pro Ser  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gln Gln Ile Asn Leu Gly Pro Ser Ser Asn Pro His Ala Lys Pro Ser  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Asp Phe His Phe Leu Lys Val Ile Gly Lys Gly Ser Phe Gly Lys Val  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Leu Ala Arg His Lys Ala Glu Glu Val Phe Tyr Ala Val Lys Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Gln Lys Lys Ala Ile Leu Lys Lys Lys Glu Glu Lys His Ile Met  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ser Glu Arg Asn Val Leu Leu Lys Asn Val Lys His Pro Phe Leu Val  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Gly Leu His Phe Ser Phe Gln Thr Ala Asp Lys Leu Tyr Phe Val Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Asp Tyr Ile Asn Gly Gly Glu Leu Phe Tyr His Leu Gln Arg Glu Arg  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys Phe Leu Glu Pro Arg Ala Arg Phe Tyr Ala Ala Glu Ile Ala Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ala Leu Gly Tyr Leu His Ser Leu Asn Ile Val Tyr Arg Asp Leu Lys  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Pro Glu Asn Ile Leu Leu Asp Ser Gln Gly His Ile Val Leu Thr Asp  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Gly Leu Cys Lys Glu Asn Ile Glu His Asn Ser Thr Thr Ser Thr  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Phe Cys Gly Thr Pro Glu Tyr Leu Ala Pro Glu Val Leu His Lys Gln  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Pro Tyr Asp Arg Thr Val Asp Trp Trp Cys Leu Gly Ala Val Leu Tyr  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Glu Met Leu Tyr Gly Leu Pro Pro Phe Tyr Ser Arg Asn Thr Ala Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Met Tyr Asp Asn Ile Leu Asn Lys Pro Leu Gln Leu Lys Pro Asn Ile  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Thr Asn Ser Ala Arg His Leu Leu Glu Gly Leu Leu Gln Lys Asp Arg  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Thr Lys Arg Leu Gly Ala Lys Asp Asp Phe Met Glu Ile Lys Ser His  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Val Phe Phe Ser Leu Ile Asn Trp Asp Asp Leu Ile Asn Lys Lys Ile  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Thr Pro Pro Phe Asn Pro Asn Val Ser Gly Pro Asn Asp Leu Arg His  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Phe Asp Pro Glu Phe Thr Glu Glu Pro Val Pro Asn Ser Ile Gly Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Ser Pro Asp Ser Val Leu Val Thr Ala Ser Val Lys Glu Ala Ala Glu  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Ala Phe Leu Gly Phe Ser Tyr Ala Pro Pro Thr Asp Ser Phe Leu  
               
               
                             420                 425                 430  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 5  
               
               
                 &lt;211&gt; LENGTH: 1140  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (55)..(1131)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 5  
               
               
                   
               
               
                 attggagttt ggaagttcag gagcacagga gcacaggccc acgactgcag cggg atg      57  
               
               
                                                                             Met  
               
               
                                                                             1  
               
               
                   
               
               
                 gac cag tac tgc atc ctg ggc cgc atc ggg gag ggc gcc cac ggc atc     105  
               
               
                 Asp Gln Tyr Cys Ile Leu Gly Arg Ile Gly Glu Gly Ala His Gly Ile  
               
               
                             5                   10                  15  
               
               
                   
               
               
                 gtc ttc aag gcc aag cac gtg gag ccg agg gtg ggc tgg cag tgt ctg     153  
               
               
                 Val Phe Lys Ala Lys His Val Glu Pro Arg Val Gly Trp Gln Cys Leu  
               
               
                         20                  25                  30  
               
               
                   
               
               
                 cct tct atc ctg cag act ggc gag ata gtt gcc ctc aag aag gtg gcc     201  
               
               
                 Pro Ser Ile Leu Gln Thr Gly Glu Ile Val Ala Leu Lys Lys Val Ala  
               
               
                     35                  40                  45  
               
               
                   
               
               
                 cta agg cgg ttg gag gac ggc ttc cct aac cag gcc ctg cgg gag att     249  
               
               
                 Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gln Ala Leu Arg Glu Ile  
               
               
                 50                  55                  60                  65  
               
               
                   
               
               
                 aag gct ctg cag gag atg gag gac aat cag tat gtg gta caa ctg aag     297  
               
               
                 Lys Ala Leu Gln Glu Met Glu Asp Asn Gln Tyr Val Val Gln Leu Lys  
               
               
                                 70                  75                  80  
               
               
                   
               
               
                 gct gtg ttc cca cac ggt gga ggc ttt gtg ctg gcc ttt gag ttc atg     345  
               
               
                 Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala Phe Glu Phe Met  
               
               
                             85                  90                  95  
               
               
                   
               
               
                 ctg tcg gat ctg gcc gag gtg gtg cgc cat gcc cag agg cca cta gcc     393  
               
               
                 Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gln Arg Pro Leu Ala  
               
               
                         100                 105                 110  
               
               
                   
               
               
                 cag gca cag gtc aag agc tac ctg cag atg ctg ctc aag ggt gtc gcc     441  
               
               
                 Gln Ala Gln Val Lys Ser Tyr Leu Gln Met Leu Leu Lys Gly Val Ala  
               
               
                     115                 120                 125  
               
               
                   
               
               
                 ttc tgc cat gcc aac aac att gta cat cgg gac ctg aaa cct gcc aac     489  
               
               
                 Phe Cys His Ala Asn Asn Ile Val His Arg Asp Leu Lys Pro Ala Asn  
               
               
                 130                 135                 140                 145  
               
               
                   
               
               
                 ctg ctc atc agc gcc tca ggc cag ctc aag ata gcg gac ttt ggc ctg     537  
               
               
                 Leu Leu Ile Ser Ala Ser Gly Gln Leu Lys Ile Ala Asp Phe Gly Leu  
               
               
                                 150                 155                 160  
               
               
                   
               
               
                 gct cga gtc ttt tcc cca gac ggc agc cac ctc tac aca cac cag gtg     585  
               
               
                 Ala Arg Val Phe Ser Pro Asp Gly Ser His Leu Tyr Thr His Gln Val  
               
               
                             165                 170                 175  
               
               
                   
               
               
                 gcc acc agg tgg tac cga gcc ccc gag ctc ctg tat ggt gcc cgc cag     633  
               
               
                 Ala Thr Arg Trp Tyr Arg Ala Pro Glu Leu Leu Tyr Gly Ala Arg Gln  
               
               
                         180                 185                 190  
               
               
                   
               
               
                 tat gac cag ggc gtc gat ctg tgg tct gtg ggc tgc atc atg ggg gag     681  
               
               
                 Tyr Asp Gln Gly Val Asp Leu Trp Ser Val Gly Cys Ile Met Gly Glu  
               
               
                     195                 200                 205  
               
               
                   
               
               
                 ctg ttg aat ggg tcc ccc ctt ttc ccg ggc aag aac gat att gaa cag     729  
               
               
                 Leu Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp Ile Glu Gln  
               
               
                 210                 215                 220                 225  
               
               
                   
               
               
                 ctt tgc tat gtg ctt cgc atc ttg ggc acc cca aac cct caa gtc tgg     777  
               
               
                 Leu Cys Tyr Val Leu Arg Ile Leu Gly Thr Pro Asn Pro Gln Val Trp  
               
               
                                 230                 235                 240  
               
               
                   
               
               
                 ccg gag ctc act gag ctg ccg gac tac aac aag atc tcc ttt aag gag     825  
               
               
                 Pro Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys Ile Ser Phe Lys Glu  
               
               
                             245                 250                 255  
               
               
                   
               
               
                 cag gtg ccc atg ccc ctg gag gag gtg ctg cct gac gtc tct ccc cag     873  
               
               
                 Gln Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gln  
               
               
                         260                 265                 270  
               
               
                   
               
               
                 gca ttg gat ctg ctg ggt caa ttc ctt ctc tac cct cct cac cag cgc     921  
               
               
                 Ala Leu Asp Leu Leu Gly Gln Phe Leu Leu Tyr Pro Pro His Gln Arg  
               
               
                     275                 280                 285  
               
               
                   
               
               
                 atc gca gct tcc aag gct ctc ctc cat cag tac ttc ttc aca gct ccc     969  
               
               
                 Ile Ala Ala Ser Lys Ala Leu Leu His Gln Tyr Phe Phe Thr Ala Pro  
               
               
                 290                 295                 300                 305  
               
               
                   
               
               
                 ctg cct gcc cat cca tct gag ctg ccg att cct cag cgt cta ggg gga     1017  
               
               
                 Leu Pro Ala His Pro Ser Glu Leu Pro Ile Pro Gln Arg Leu Gly Gly  
               
               
                                 310                 315                 320  
               
               
                   
               
               
                 cct gcc ccc aag gcc cat cca ggg ccc ccc cac atc cat gac ttc cac     1065  
               
               
                 Pro Ala Pro Lys Ala His Pro Gly Pro Pro His Ile His Asp Phe His  
               
               
                             325                 330                 335  
               
               
                   
               
               
                 gtg gac cgg cct ctt gag gag tcg ctg ttg aac cca gag ctg att cgg     1113  
               
               
                 Val Asp Arg Pro Leu Glu Glu Ser Leu Leu Asn Pro Glu Leu Ile Arg  
               
               
                         340                 345                 350  
               
               
                   
               
               
                 ccc ttc atc ctg gag ggg tgagaagtt                                   1140  
               
               
                 Pro Phe Ile Leu Glu Gly  
               
               
                     355  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 6  
               
               
                 &lt;211&gt; LENGTH: 359  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 6  
               
               
                   
               
               
                 Met Asp Gln Tyr Cys Ile Leu Gly Arg Ile Gly Glu Gly Ala His Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Ile Val Phe Lys Ala Lys His Val Glu Pro Arg Val Gly Trp Gln Cys  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Leu Pro Ser Ile Leu Gln Thr Gly Glu Ile Val Ala Leu Lys Lys Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gln Ala Leu Arg Glu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Lys Ala Leu Gln Glu Met Glu Asp Asn Gln Tyr Val Val Gln Leu  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala Phe Glu Phe  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gln Arg Pro Leu  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ala Gln Ala Gln Val Lys Ser Tyr Leu Gln Met Leu Leu Lys Gly Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ala Phe Cys His Ala Asn Asn Ile Val His Arg Asp Leu Lys Pro Ala  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Asn Leu Leu Ile Ser Ala Ser Gly Gln Leu Lys Ile Ala Asp Phe Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Leu Ala Arg Val Phe Ser Pro Asp Gly Ser His Leu Tyr Thr His Gln  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Val Ala Thr Arg Trp Tyr Arg Ala Pro Glu Leu Leu Tyr Gly Ala Arg  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gln Tyr Asp Gln Gly Val Asp Leu Trp Ser Val Gly Cys Ile Met Gly  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Glu Leu Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp Ile Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Gln Leu Cys Tyr Val Leu Arg Ile Leu Gly Thr Pro Asn Pro Gln Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Trp Pro Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys Ile Ser Phe Lys  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Glu Gln Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Ala Leu Asp Leu Leu Gly Gln Phe Leu Leu Tyr Pro Pro His Gln  
               
               
                         275                 280                 285  
               
               
                 Arg Ile Ala Ala Ser Lys Ala Leu Leu His Gln Tyr Phe Phe Thr Ala  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Pro Leu Pro Ala His Pro Ser Glu Leu Pro Ile Pro Gln Arg Leu Gly  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Pro Ala Pro Lys Ala His Pro Gly Pro Pro His Ile His Asp Phe  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 His Val Asp Arg Pro Leu Glu Glu Ser Leu Leu Asn Pro Glu Leu Ile  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Arg Pro Phe Ile Leu Glu Gly  
               
               
                         355  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 7  
               
               
                 &lt;211&gt; LENGTH: 2078  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (238)..(1593)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 7  
               
               
                   
               
               
                 caggtgctgc gtgacagcgg agggctagga aaaggcgcag tggggcccgg agctgtcacc     60  
               
               
                   
               
               
                 cctgactcga cgcagcttcc gttctcctgg tgacgtggcc tacaggaacc gccccggtgg    120  
               
               
                   
               
               
                 tcagctgccg cgctgttgct aggcaacagc gtgcgtgctc agatcagcgt ggggtggagg    180  
               
               
                   
               
               
                 agaagtggag tttggaagtt caggggcaca ggggcacagg cccacgactg cagcggg       237  
               
               
                   
               
               
                 atg gac cag tac tgc atc ctg ggc cgc atc ggg gag ggc gcc cac ggc      285  
               
               
                 Met Asp Gln Tyr Cys Ile Leu Gly Arg Ile Gly Glu Gly Ala His Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 atc gtc ttc aag gcc aag cac gtg gag act ggc gag ata att gcc ctc      333  
               
               
                 Ile Val Phe Lys Ala Lys His Val Glu Thr Gly Glu Ile Ile Ala Leu  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 aag aag gtg gcc cta agg cgg ttg gaa gac ggc ttc cct aac cag gcc      381  
               
               
                 Lys Lys Val Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gln Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 ctg cgg gag att aag gct ctg cag gag atg gag gac aat cag tat gtg      429  
               
               
                 Leu Arg Glu Ile Lys Ala Leu Gln Glu Met Glu Asp Asn Gln Tyr Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 gta caa ctg aag gct gtg ttc cca cac ggt gga ggc ttt gtg ctg gcc      477  
               
               
                 Val Gln Leu Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 ttt gag ttc atg ctg tcg gat ctg gcc gag gtg gtg cgc cat gcc cag      525  
               
               
                 Phe Glu Phe Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gln  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 agg cca cta gcc cag gca cag gtc aag agc tac ctg cag atg ctg ctc      573  
               
               
                 Arg Pro Leu Ala Gln Ala Gln Val Lys Ser Tyr Leu Gln Met Leu Leu  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 aag ggt gtc gcc ttc tgc cat gcc aac aac att gta cat cgg gac ctg      621  
               
               
                 Lys Gly Val Ala Phe Cys His Ala Asn Asn Ile Val His Arg Asp Leu  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 aaa cct gcc aac ctg ctc atc agc gcc tca ggc cag ctc aag ata gcg      669  
               
               
                 Lys Pro Ala Asn Leu Leu Ile Ser Ala Ser Gly Gln Leu Lys Ile Ala  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 gac ttt ggc ctg gct cga gtc ttt tcc cca gac ggc agc cgc ctc tac      717  
               
               
                 Asp Phe Gly Leu Ala Arg Val Phe Ser Pro Asp Gly Ser Arg Leu Tyr  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 aca cac cag gtg gcc acc agg tct gtg ggc tgc atc atg ggg gag ctg      765  
               
               
                 Thr His Gln Val Ala Thr Arg Ser Val Gly Cys Ile Met Gly Glu Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 ttg aat ggg tcc ccc ctt ttc ccg ggc aag aac gat att gaa cag ctt      813  
               
               
                 Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp Ile Glu Gln Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 tgc tat gtg ctt cgc atc ttg ggc acc cca aac cct caa gtc tgg ccg      861  
               
               
                 Cys Tyr Val Leu Arg Ile Leu Gly Thr Pro Asn Pro Gln Val Trp Pro  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 gag ctc act gag ctg ccg gac tac aac aag atc tcc ttt aag gag cag      909  
               
               
                 Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys Ile Ser Phe Lys Glu Gln  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 gtg ccc atg ccc ctg gag gag gtg ctg cct gac gtc tct ccc cag gca      957  
               
               
                 Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gln Ala  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ttg gat ctg ctg ggt caa ttc ctt ctc tac cct cct cac cag cgc atc     1005  
               
               
                 Leu Asp Leu Leu Gly Gln Phe Leu Leu Tyr Pro Pro His Gln Arg Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gca gct tcc aag gct ctc ctc cat cag tac ttc ttc aca gct ccc ctg     1053  
               
               
                 Ala Ala Ser Lys Ala Leu Leu His Gln Tyr Phe Phe Thr Ala Pro Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 cct gcc cat cca tct gag ctg ccg att cct cag cgt cta ggg gga cct     1101  
               
               
                 Pro Ala His Pro Ser Glu Leu Pro Ile Pro Gln Arg Leu Gly Gly Pro  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 gcc ccc aag gcc cat cca ggg ccc ccc cac atc cat gac ttc cac gtg     1149  
               
               
                 Ala Pro Lys Ala His Pro Gly Pro Pro His Ile His Asp Phe His Val  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 gac cgg cct ctt gag gga gtc gct gtt gaa ccc aga gct gat tcg gcc     1197  
               
               
                 Asp Arg Pro Leu Glu Gly Val Ala Val Glu Pro Arg Ala Asp Ser Ala  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 ctt cat cct gga ggg gtg aga agt tgg ccc tgg tcc cgt ctg cct gct     1245  
               
               
                 Leu His Pro Gly Gly Val Arg Ser Trp Pro Trp Ser Arg Leu Pro Ala  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 cct cag gac cac tca gtc cac ctg ttc ctc tgc cac ctg cct ggc ttc     1293  
               
               
                 Pro Gln Asp His Ser Val His Leu Phe Leu Cys His Leu Pro Gly Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 acc ctc caa ggc ctc ccc atg gcc aca gtg ggc cca cac cac acc ttg     1341  
               
               
                 Thr Leu Gln Gly Leu Pro Met Ala Thr Val Gly Pro His His Thr Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 ccc ctt agc cct tgc gag ggt tgg tct cga ggc aga ggt cat gtt ccc     1389  
               
               
                 Pro Leu Ser Pro Cys Glu Gly Trp Ser Arg Gly Arg Gly His Val Pro  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 agc caa gag tat gag aac atc cag tcg agc aga gga gat tca tgg cct     1437  
               
               
                 Ser Gln Glu Tyr Glu Asn Ile Gln Ser Ser Arg Gly Asp Ser Trp Pro  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 gtg ctc ggt gag cct tac ctt ctg tgt gct act gac gta ccc atc agg     1485  
               
               
                 Val Leu Gly Glu Pro Tyr Leu Leu Cys Ala Thr Asp Val Pro Ile Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 aca gtg agc tct gct gcc agt caa ggc ctg cat atg cag aat gac gat     1533  
               
               
                 Thr Val Ser Ser Ala Ala Ser Gln Gly Leu His Met Gln Asn Asp Asp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 gcc tgc ctt ggt gct gct tcc ccc gag tgc tgc ctc ctg gtc aag gag     1581  
               
               
                 Ala Cys Leu Gly Ala Ala Ser Pro Glu Cys Cys Leu Leu Val Lys Glu  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 aag tgc aga gag taaggtgtcc ttatgttgga aactcaagtg gaaggaagat         1633  
               
               
                 Lys Cys Arg Glu  
               
               
                     450  
               
               
                   
               
               
                 ttggtttggt tttattctca gagccattaa acactagttc agtatgtgag atatagattc   1693  
               
               
                   
               
               
                 taaaaacctc aggtggtctg cttagtctgt cttcttcctt tctcaaggga aatggctaag   1753  
               
               
                   
               
               
                 gtggcattgt ctcatggctc tcgtttttgg ggtcatgggg agggtagcac cagcatagcc   1813  
               
               
                   
               
               
                 acttttgccc tgagggactc ctgtgtgctt cacatcactg agcactcatt tagaagtgag   1873  
               
               
                   
               
               
                 ggagacagaa gtctaggccc agggatggct ccagttgggg atccagcagg agaccctctg   1933  
               
               
                   
               
               
                 cacatgaggc tggtttacca acatctactc cctcaggatg agcgtgagcc agaagcagct   1993  
               
               
                   
               
               
                 gtgtatttaa ggaaacaagc gttcctggaa ttaatttata aatttaataa atcccaatat   2053  
               
               
                   
               
               
                 aatcccaaaa aaaaaaaaaa aaaaa                                         2078  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 8  
               
               
                 &lt;211&gt; LENGTH: 452  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 8  
               
               
                   
               
               
                 Met Asp Gln Tyr Cys Ile Leu Gly Arg Ile Gly Glu Gly Ala His Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Ile Val Phe Lys Ala Lys His Val Glu Thr Gly Glu Ile Ile Ala Leu  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Lys Val Ala Leu Arg Arg Leu Glu Asp Gly Phe Pro Asn Gln Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Leu Arg Glu Ile Lys Ala Leu Gln Glu Met Glu Asp Asn Gln Tyr Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Val Gln Leu Lys Ala Val Phe Pro His Gly Gly Gly Phe Val Leu Ala  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Phe Glu Phe Met Leu Ser Asp Leu Ala Glu Val Val Arg His Ala Gln  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Arg Pro Leu Ala Gln Ala Gln Val Lys Ser Tyr Leu Gln Met Leu Leu  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Lys Gly Val Ala Phe Cys His Ala Asn Asn Ile Val His Arg Asp Leu  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Lys Pro Ala Asn Leu Leu Ile Ser Ala Ser Gly Gln Leu Lys Ile Ala  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Asp Phe Gly Leu Ala Arg Val Phe Ser Pro Asp Gly Ser Arg Leu Tyr  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Thr His Gln Val Ala Thr Arg Ser Val Gly Cys Ile Met Gly Glu Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Gly Ser Pro Leu Phe Pro Gly Lys Asn Asp Ile Glu Gln Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys Tyr Val Leu Arg Ile Leu Gly Thr Pro Asn Pro Gln Val Trp Pro  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Glu Leu Thr Glu Leu Pro Asp Tyr Asn Lys Ile Ser Phe Lys Glu Gln  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Val Pro Met Pro Leu Glu Glu Val Leu Pro Asp Val Ser Pro Gln Ala  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Asp Leu Leu Gly Gln Phe Leu Leu Tyr Pro Pro His Gln Arg Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Ala Ser Lys Ala Leu Leu His Gln Tyr Phe Phe Thr Ala Pro Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Pro Ala His Pro Ser Glu Leu Pro Ile Pro Gln Arg Leu Gly Gly Pro  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ala Pro Lys Ala His Pro Gly Pro Pro His Ile His Asp Phe His Val  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Asp Arg Pro Leu Glu Gly Val Ala Val Glu Pro Arg Ala Asp Ser Ala  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Leu His Pro Gly Gly Val Arg Ser Trp Pro Trp Ser Arg Leu Pro Ala  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Pro Gln Asp His Ser Val His Leu Phe Leu Cys His Leu Pro Gly Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Thr Leu Gln Gly Leu Pro Met Ala Thr Val Gly Pro His His Thr Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Pro Leu Ser Pro Cys Glu Gly Trp Ser Arg Gly Arg Gly His Val Pro  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Ser Gln Glu Tyr Glu Asn Ile Gln Ser Ser Arg Gly Asp Ser Trp Pro  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Val Leu Gly Glu Pro Tyr Leu Leu Cys Ala Thr Asp Val Pro Ile Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Thr Val Ser Ser Ala Ala Ser Gln Gly Leu His Met Gln Asn Asp Asp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Ala Cys Leu Gly Ala Ala Ser Pro Glu Cys Cys Leu Leu Val Lys Glu  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Lys Cys Arg Glu  
               
               
                     450  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 9  
               
               
                 &lt;211&gt; LENGTH: 958  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (99)..(944)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 9  
               
               
                   
               
               
                 agccagagac aggacaccag aagagacagg agatcagaga ccagaggaac agagaagagg     60  
               
               
                   
               
               
                 ccccagagca aggcaaggaa cggccaaggc accaggac atg gat gca gtg gag cca    116  
               
               
                                                           Met Asp Ala Val Glu Pro  
               
               
                                                           1               5  
               
               
                   
               
               
                 gga gga cgt ggc tgg gcc agc atg ttg gcg tgc agg ctt tgg aaa gcc      164  
               
               
                 Gly Gly Arg Gly Trp Ala Ser Met Leu Ala Cys Arg Leu Trp Lys Ala  
               
               
                             10                  15                  20  
               
               
                   
               
               
                 atc agc agg gcg ctg ttt gca gag ttc ctg gcc acg ggg ctg tat gtg      212  
               
               
                 Ile Ser Arg Ala Leu Phe Ala Glu Phe Leu Ala Thr Gly Leu Tyr Val  
               
               
                         25                  30                  35  
               
               
                   
               
               
                 ttc ttt ggc gtg ggc tca gtc atg cgc tgg ccc aca gca ctt ccc tcc      260  
               
               
                 Phe Phe Gly Val Gly Ser Val Met Arg Trp Pro Thr Ala Leu Pro Ser  
               
               
                     40                  45                  50  
               
               
                   
               
               
                 gtg cta cag att gcc atc acc ttc aac ctg gtc acc gcc atg gct gtg      308  
               
               
                 Val Leu Gln Ile Ala Ile Thr Phe Asn Leu Val Thr Ala Met Ala Val  
               
               
                 55                  60                  65                  70  
               
               
                   
               
               
                 cag gtc acc tgg aag gcc agc ggg gcc cac gcc aac ccc gcc gtg acg      356  
               
               
                 Gln Val Thr Trp Lys Ala Ser Gly Ala His Ala Asn Pro Ala Val Thr  
               
               
                                 75                  80                  85  
               
               
                   
               
               
                 ctg gcc ttc ctc gta ggc tcc cac atc tct ctg ccc cgt gct gtg gcc      404  
               
               
                 Leu Ala Phe Leu Val Gly Ser His Ile Ser Leu Pro Arg Ala Val Ala  
               
               
                             90                  95                  100  
               
               
                   
               
               
                 tat gtg gct gcc cag ctg gtg ggg gcc acg gtg ggg gct gct ctg ctt      452  
               
               
                 Tyr Val Ala Ala Gln Leu Val Gly Ala Thr Val Gly Ala Ala Leu Leu  
               
               
                         105                 110                 115  
               
               
                   
               
               
                 tat ggg gtc atg ccg gga gac atc cga gag acc ctt ggg atc aac gtg      500  
               
               
                 Tyr Gly Val Met Pro Gly Asp Ile Arg Glu Thr Leu Gly Ile Asn Val  
               
               
                     120                 125                 130  
               
               
                   
               
               
                 gtc cgg aac agt gtc tca act ggc cag gcg gtg gca gtg gag ctg ctt      548  
               
               
                 Val Arg Asn Ser Val Ser Thr Gly Gln Ala Val Ala Val Glu Leu Leu  
               
               
                 135                 140                 145                 150  
               
               
                   
               
               
                 ctg acc ctg cag ctg gtg ctc tgt gtc ttc gct tcc acc gac agc cgt      596  
               
               
                 Leu Thr Leu Gln Leu Val Leu Cys Val Phe Ala Ser Thr Asp Ser Arg  
               
               
                                 155                 160                 165  
               
               
                   
               
               
                 cag aca tca ggc tcc ccg gcc acc atg att ggg atc tct gtg gca ctg      644  
               
               
                 Gln Thr Ser Gly Ser Pro Ala Thr Met Ile Gly Ile Ser Val Ala Leu  
               
               
                             170                 175                 180  
               
               
                   
               
               
                 ggc cac ctc att ggg atc cac ttc act ggc tgc tcc atg aat cca gcc      692  
               
               
                 Gly His Leu Ile Gly Ile His Phe Thr Gly Cys Ser Met Asn Pro Ala  
               
               
                         185                 190                 195  
               
               
                   
               
               
                 cgc tcc ttc ggc cct gcc atc atc att ggg aag ttc aca gtc cac tgg      740  
               
               
                 Arg Ser Phe Gly Pro Ala Ile Ile Ile Gly Lys Phe Thr Val His Trp  
               
               
                     200                 205                 210  
               
               
                   
               
               
                 gtc ttc tgg gtg ggg ccc ctg atg gga gcc ctc ctg gcc tca ctg atc      788  
               
               
                 Val Phe Trp Val Gly Pro Leu Met Gly Ala Leu Leu Ala Ser Leu Ile  
               
               
                 215                 220                 225                 230  
               
               
                   
               
               
                 tac aac ttc gtc ctg ttc ccc gac acc aag aac ctg gcg cag cgg ctg      836  
               
               
                 Tyr Asn Phe Val Leu Phe Pro Asp Thr Lys Asn Leu Ala Gln Arg Leu  
               
               
                                 235                 240                 245  
               
               
                   
               
               
                 gct atc ctc aca ggc acc gta gag gtg ggg aca ggg gca ggg gca ggg      884  
               
               
                 Ala Ile Leu Thr Gly Thr Val Glu Val Gly Thr Gly Ala Gly Ala Gly  
               
               
                             250                 255                 260  
               
               
                   
               
               
                 gcg gag ccc ctg aag aag gaa tcc cag ccg ggt tcg gga gcc gtg gag      932  
               
               
                 Ala Glu Pro Leu Lys Lys Glu Ser Gln Pro Gly Ser Gly Ala Val Glu  
               
               
                         265                 270                 275  
               
               
                   
               
               
                 atg gag agt gtg tgaaacagcc taac                                      958  
               
               
                 Met Glu Ser Val  
               
               
                     280  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 10  
               
               
                 &lt;211&gt; LENGTH: 282  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 10  
               
               
                   
               
               
                 Met Asp Ala Val Glu Pro Gly Gly Arg Gly Trp Ala Ser Met Leu Ala  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Cys Arg Leu Trp Lys Ala Ile Ser Arg Ala Leu Phe Ala Glu Phe Leu  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Thr Gly Leu Tyr Val Phe Phe Gly Val Gly Ser Val Met Arg Trp  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Pro Thr Ala Leu Pro Ser Val Leu Gln Ile Ala Ile Thr Phe Asn Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Val Thr Ala Met Ala Val Gln Val Thr Trp Lys Ala Ser Gly Ala His  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ala Asn Pro Ala Val Thr Leu Ala Phe Leu Val Gly Ser His Ile Ser  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Leu Pro Arg Ala Val Ala Tyr Val Ala Ala Gln Leu Val Gly Ala Thr  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Val Gly Ala Ala Leu Leu Tyr Gly Val Met Pro Gly Asp Ile Arg Glu  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Thr Leu Gly Ile Asn Val Val Arg Asn Ser Val Ser Thr Gly Gln Ala  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Val Ala Val Glu Leu Leu Leu Thr Leu Gln Leu Val Leu Cys Val Phe  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Ser Thr Asp Ser Arg Gln Thr Ser Gly Ser Pro Ala Thr Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Ile Ser Val Ala Leu Gly His Leu Ile Gly Ile His Phe Thr Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys Ser Met Asn Pro Ala Arg Ser Phe Gly Pro Ala Ile Ile Ile Gly  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Phe Thr Val His Trp Val Phe Trp Val Gly Pro Leu Met Gly Ala  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Leu Leu Ala Ser Leu Ile Tyr Asn Phe Val Leu Phe Pro Asp Thr Lys  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Asn Leu Ala Gln Arg Leu Ala Ile Leu Thr Gly Thr Val Glu Val Gly  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Thr Gly Ala Gly Ala Gly Ala Glu Pro Leu Lys Lys Glu Ser Gln Pro  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gly Ser Gly Ala Val Glu Met Glu Ser Val  
               
               
                         275                 280  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 11  
               
               
                 &lt;211&gt; LENGTH: 1067  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (3)..(1046)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 11  
               
               
                   
               
               
                 ct ttg gaa cag aac cag tca aca gat tat tat tat gag gaa aat gaa        47  
               
               
                    Leu Glu Gln Asn Gln Ser Thr Asp Tyr Tyr Tyr Glu Glu Asn Glu  
               
               
                    1               5                   10                  15  
               
               
                   
               
               
                 atg aat ggc act tat gac tac agt caa tat gaa ctg atc tgt atc aaa       95  
               
               
                 Met Asn Gly Thr Tyr Asp Tyr Ser Gln Tyr Glu Leu Ile Cys Ile Lys  
               
               
                                 20                  25                  30  
               
               
                   
               
               
                 gaa gat gtc aga gaa ttt gca aaa gtt ttc ctc cct gta ttc ctc aca      143  
               
               
                 Glu Asp Val Arg Glu Phe Ala Lys Val Phe Leu Pro Val Phe Leu Thr  
               
               
                             35                  40                  45  
               
               
                   
               
               
                 ata gtt ttc gtc att gga ctt gca ggc aat tcc atg gta gtg gca att      191  
               
               
                 Ile Val Phe Val Ile Gly Leu Ala Gly Asn Ser Met Val Val Ala Ile  
               
               
                         50                  55                  60  
               
               
                   
               
               
                 tat gcc tat tac aag aaa cag aga acc aaa aca gat gtg tac atc ctg      239  
               
               
                 Tyr Ala Tyr Tyr Lys Lys Gln Arg Thr Lys Thr Asp Val Tyr Ile Leu  
               
               
                     65                  70                  75  
               
               
                   
               
               
                 aat ttg gct gta gca gat tta ctc ctt cta ttc act ctg cct ttt tgg      287  
               
               
                 Asn Leu Ala Val Ala Asp Leu Leu Leu Leu Phe Thr Leu Pro Phe Trp  
               
               
                 80                  85                  90                  95  
               
               
                   
               
               
                 gct gtt aat gca gtt cat ggg tgg gtt tta ggg aaa ata atg tgc aaa      335  
               
               
                 Ala Val Asn Ala Val His Gly Trp Val Leu Gly Lys Ile Met Cys Lys  
               
               
                                 100                 105                 110  
               
               
                   
               
               
                 ata act tca gcc ttg tac aca cta aac ttt gtc tct gga atg cag ttt      383  
               
               
                 Ile Thr Ser Ala Leu Tyr Thr Leu Asn Phe Val Ser Gly Met Gln Phe  
               
               
                             115                 120                 125  
               
               
                   
               
               
                 ctg gct tgt atc agc ata gac aga tat gtg gca gta act aaa gtc ccc      431  
               
               
                 Leu Ala Cys Ile Ser Ile Asp Arg Tyr Val Ala Val Thr Lys Val Pro  
               
               
                         130                 135                 140  
               
               
                   
               
               
                 agc caa tca gga gtg gga aaa cca tgc tgg atc atc tgt ttc tgt gtc      479  
               
               
                 Ser Gln Ser Gly Val Gly Lys Pro Cys Trp Ile Ile Cys Phe Cys Val  
               
               
                     145                 150                 155  
               
               
                   
               
               
                 tgg atg gct gcc atc ttg ctg agc ata ccc cag ctg gtt ttt tat aca      527  
               
               
                 Trp Met Ala Ala Ile Leu Leu Ser Ile Pro Gln Leu Val Phe Tyr Thr  
               
               
                 160                 165                 170                 175  
               
               
                   
               
               
                 gta aat gac aat gct agg tgc att ccc att ttc ccc cgc tac cta gga      575  
               
               
                 Val Asn Asp Asn Ala Arg Cys Ile Pro Ile Phe Pro Arg Tyr Leu Gly  
               
               
                                 180                 185                 190  
               
               
                   
               
               
                 aca tca atg aaa gca ttg att caa atg cta gag atc tgc att gga ttt      623  
               
               
                 Thr Ser Met Lys Ala Leu Ile Gln Met Leu Glu Ile Cys Ile Gly Phe  
               
               
                             195                 200                 205  
               
               
                   
               
               
                 gta gta ccc ttt ctt att atg ggg gtg tgc tac ttt atc acg gca agg      671  
               
               
                 Val Val Pro Phe Leu Ile Met Gly Val Cys Tyr Phe Ile Thr Ala Arg  
               
               
                         210                 215                 220  
               
               
                   
               
               
                 aca ctc atg aag atg cca aac att aaa ata tct cga ccc cta aaa gtt      719  
               
               
                 Thr Leu Met Lys Met Pro Asn Ile Lys Ile Ser Arg Pro Leu Lys Val  
               
               
                     225                 230                 235  
               
               
                   
               
               
                 ctg ctc aca gtc gtt ata gtt ttc att gtc act caa ctg cct tat aac      767  
               
               
                 Leu Leu Thr Val Val Ile Val Phe Ile Val Thr Gln Leu Pro Tyr Asn  
               
               
                 240                 245                 250                 255  
               
               
                   
               
               
                 att gtc aag ttc tgc cga gcc ata gac atc atc tac tct ctg atc acc      815  
               
               
                 Ile Val Lys Phe Cys Arg Ala Ile Asp Ile Ile Tyr Ser Leu Ile Thr  
               
               
                                 260                 265                 270  
               
               
                   
               
               
                 agc tgc aac atg agc aaa cgc atg gac atc gcc atc caa gtc aca gaa      863  
               
               
                 Ser Cys Asn Met Ser Lys Arg Met Asp Ile Ala Ile Gln Val Thr Glu  
               
               
                             275                 280                 285  
               
               
                   
               
               
                 agc atc gca ctc ttt cac agc tgc ctc aac cca atc ctt tat gtt ttt      911  
               
               
                 Ser Ile Ala Leu Phe His Ser Cys Leu Asn Pro Ile Leu Tyr Val Phe  
               
               
                         290                 295                 300  
               
               
                   
               
               
                 atg gga gca tct ttc aaa aac tac gtt atg aaa gtg gcc aag aaa tat      959  
               
               
                 Met Gly Ala Ser Phe Lys Asn Tyr Val Met Lys Val Ala Lys Lys Tyr  
               
               
                     305                 310                 315  
               
               
                   
               
               
                 ggg tcc tgg aga aga cag aga caa agt gtg gag gag ttt cct ttt gat     1007  
               
               
                 Gly Ser Trp Arg Arg Gln Arg Gln Ser Val Glu Glu Phe Pro Phe Asp  
               
               
                 320                 325                 330                 335  
               
               
                   
               
               
                 tct gag ggt cct aca gag cca acc agt act ttt agc att taaaggtaaa      1056  
               
               
                 Ser Glu Gly Pro Thr Glu Pro Thr Ser Thr Phe Ser Ile  
               
               
                                 340                 345  
               
               
                   
               
               
                 actgctctgc c                                                        1067  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 12  
               
               
                 &lt;211&gt; LENGTH: 348  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 12  
               
               
                   
               
               
                 Leu Glu Gln Asn Gln Ser Thr Asp Tyr Tyr Tyr Glu Glu Asn Glu Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Asn Gly Thr Tyr Asp Tyr Ser Gln Tyr Glu Leu Ile Cys Ile Lys Glu  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Asp Val Arg Glu Phe Ala Lys Val Phe Leu Pro Val Phe Leu Thr Ile  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Val Phe Val Ile Gly Leu Ala Gly Asn Ser Met Val Val Ala Ile Tyr  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ala Tyr Tyr Lys Lys Gln Arg Thr Lys Thr Asp Val Tyr Ile Leu Asn  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Leu Ala Val Ala Asp Leu Leu Leu Leu Phe Thr Leu Pro Phe Trp Ala  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Val Asn Ala Val His Gly Trp Val Leu Gly Lys Ile Met Cys Lys Ile  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Thr Ser Ala Leu Tyr Thr Leu Asn Phe Val Ser Gly Met Gln Phe Leu  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ala Cys Ile Ser Ile Asp Arg Tyr Val Ala Val Thr Lys Val Pro Ser  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Gln Ser Gly Val Gly Lys Pro Cys Trp Ile Ile Cys Phe Cys Val Trp  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Met Ala Ala Ile Leu Leu Ser Ile Pro Gln Leu Val Phe Tyr Thr Val  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Asn Asp Asn Ala Arg Cys Ile Pro Ile Phe Pro Arg Tyr Leu Gly Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ser Met Lys Ala Leu Ile Gln Met Leu Glu Ile Cys Ile Gly Phe Val  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Val Pro Phe Leu Ile Met Gly Val Cys Tyr Phe Ile Thr Ala Arg Thr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Leu Met Lys Met Pro Asn Ile Lys Ile Ser Arg Pro Leu Lys Val Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Thr Val Val Ile Val Phe Ile Val Thr Gln Leu Pro Tyr Asn Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Val Lys Phe Cys Arg Ala Ile Asp Ile Ile Tyr Ser Leu Ile Thr Ser  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Cys Asn Met Ser Lys Arg Met Asp Ile Ala Ile Gln Val Thr Glu Ser  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ile Ala Leu Phe His Ser Cys Leu Asn Pro Ile Leu Tyr Val Phe Met  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Gly Ala Ser Phe Lys Asn Tyr Val Met Lys Val Ala Lys Lys Tyr Gly  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Ser Trp Arg Arg Gln Arg Gln Ser Val Glu Glu Phe Pro Phe Asp Ser  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Glu Gly Pro Thr Glu Pro Thr Ser Thr Phe Ser Ile  
               
               
                             340                 345  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 13  
               
               
                 &lt;211&gt; LENGTH: 1953  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (16)..(1929)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 13  
               
               
                   
               
               
                 gtctgagtca cagag atg ggc aag atc gag aac aac gag agg gtg atc ctc      51  
               
               
                                  Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu  
               
               
                                  1               5                   10  
               
               
                   
               
               
                 aat gtc ggg ggc acc cgg cac gaa acc tac cgc agc acc ctc aag acc       99  
               
               
                 Asn Val Gly Gly Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr  
               
               
                         15                  20                  25  
               
               
                   
               
               
                 ctg cct gga aca cgc ctg gcc ctt ctt gcc tcc tcc gag ccc cca ggc      147  
               
               
                 Leu Pro Gly Thr Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly  
               
               
                     30                  35                  40  
               
               
                   
               
               
                 gac tgc ttg acc acg gcg ggc gac aag ctg cag ccg tcg ccg cct cca      195  
               
               
                 Asp Cys Leu Thr Thr Ala Gly Asp Lys Leu Gln Pro Ser Pro Pro Pro  
               
               
                 45                  50                  55                  60  
               
               
                   
               
               
                 ctg tcg ccg ccg ccg aga gcg ccc ccg ctg tcc ccc ggg cca ggc ggc      243  
               
               
                 Leu Ser Pro Pro Pro Arg Ala Pro Pro Leu Ser Pro Gly Pro Gly Gly  
               
               
                                 65                  70                  75  
               
               
                   
               
               
                 tgc ttc gag ggc ggc gcg ggc aac tgc agt tcc cgc ggc ggc agg gcc      291  
               
               
                 Cys Phe Glu Gly Gly Ala Gly Asn Cys Ser Ser Arg Gly Gly Arg Ala  
               
               
                             80                  85                  90  
               
               
                   
               
               
                 agc gac cat ccc ggt ggc ggc cgc gag ttc ttc ttc gac cgg cac ccg      339  
               
               
                 Ser Asp His Pro Gly Gly Gly Arg Glu Phe Phe Phe Asp Arg His Pro  
               
               
                         95                  100                 105  
               
               
                   
               
               
                 ggc gtc ttc gcc tat gtg ctc aat tac tac cgc acc ggc aag ctg cac      387  
               
               
                 Gly Val Phe Ala Tyr Val Leu Asn Tyr Tyr Arg Thr Gly Lys Leu His  
               
               
                     110                 115                 120  
               
               
                   
               
               
                 tgc ccc gca gac gtg tgc ggg ccg ctc ttc gag gag gag ctg gcc ttc      435  
               
               
                 Cys Pro Ala Asp Val Cys Gly Pro Leu Phe Glu Glu Glu Leu Ala Phe  
               
               
                 125                 130                 135                 140  
               
               
                   
               
               
                 tgg ggc atc gac gag acc gac gtg gag ccc tgc tgc tgg atg acc tac      483  
               
               
                 Trp Gly Ile Asp Glu Thr Asp Val Glu Pro Cys Cys Trp Met Thr Tyr  
               
               
                                 145                 150                 155  
               
               
                   
               
               
                 cgg cag cac cgc gac gcc gag gag gcg ctg gac atc ttc gag acc ccc      531  
               
               
                 Arg Gln His Arg Asp Ala Glu Glu Ala Leu Asp Ile Phe Glu Thr Pro  
               
               
                             160                 165                 170  
               
               
                   
               
               
                 gac ctc att ggc ggc gac ccc ggc gac gac gag gac ctg gcg gcc aag      579  
               
               
                 Asp Leu Ile Gly Gly Asp Pro Gly Asp Asp Glu Asp Leu Ala Ala Lys  
               
               
                         175                 180                 185  
               
               
                   
               
               
                 agg ctg ggc atc gag gac gcg gcg ggg ctc ggg ggc ccg gac ggc aaa      627  
               
               
                 Arg Leu Gly Ile Glu Asp Ala Ala Gly Leu Gly Gly Pro Asp Gly Lys  
               
               
                     190                 195                 200  
               
               
                   
               
               
                 tct ggc cgc tgg agg agg ctg cag ccc cgc atg tgg gcc ctc ttc gaa      675  
               
               
                 Ser Gly Arg Trp Arg Arg Leu Gln Pro Arg Met Trp Ala Leu Phe Glu  
               
               
                 205                 210                 215                 220  
               
               
                   
               
               
                 gac ccc tac tcg tcc aga gcc gcc agg ttt att gct ttt gct tct tta      723  
               
               
                 Asp Pro Tyr Ser Ser Arg Ala Ala Arg Phe Ile Ala Phe Ala Ser Leu  
               
               
                                 225                 230                 235  
               
               
                   
               
               
                 ttc ttc atc ctg gtt tca att aca act ttt tgc ctg gaa aca cat gaa      771  
               
               
                 Phe Phe Ile Leu Val Ser Ile Thr Thr Phe Cys Leu Glu Thr His Glu  
               
               
                             240                 245                 250  
               
               
                   
               
               
                 gct ttc aat att gtt aaa aac aag aca gaa cca gtc atc aat ggc aca      819  
               
               
                 Ala Phe Asn Ile Val Lys Asn Lys Thr Glu Pro Val Ile Asn Gly Thr  
               
               
                         255                 260                 265  
               
               
                   
               
               
                 agt gtt gtt cta cag tat gaa att gaa acg gat cct gcc ttg acg tat      867  
               
               
                 Ser Val Val Leu Gln Tyr Glu Ile Glu Thr Asp Pro Ala Leu Thr Tyr  
               
               
                     270                 275                 280  
               
               
                   
               
               
                 gta gaa gga gtg tgt gtg gtg tgg ttt act ttt gaa ttt tta gtc cgt      915  
               
               
                 Val Glu Gly Val Cys Val Val Trp Phe Thr Phe Glu Phe Leu Val Arg  
               
               
                 285                 290                 295                 300  
               
               
                   
               
               
                 att gtt ttt tca ccc aat aaa ctt gaa ttc atc aaa aat ctc ttg aat      963  
               
               
                 Ile Val Phe Ser Pro Asn Lys Leu Glu Phe Ile Lys Asn Leu Leu Asn  
               
               
                                 305                 310                 315  
               
               
                   
               
               
                 atc att gac ttt gtg gcc atc cta cct ttc tac tta gag gtg gga ctc     1011  
               
               
                 Ile Ile Asp Phe Val Ala Ile Leu Pro Phe Tyr Leu Glu Val Gly Leu  
               
               
                             320                 325                 330  
               
               
                   
               
               
                 agt ggg ctg tca tcc aaa gct gct aaa gat gtg ctt ggc ttc ctc agg     1059  
               
               
                 Ser Gly Leu Ser Ser Lys Ala Ala Lys Asp Val Leu Gly Phe Leu Arg  
               
               
                         335                 340                 345  
               
               
                   
               
               
                 gtg gta agg ttt gtg agg atc ctg aga att ttc aag ctc acc cgc cat     1107  
               
               
                 Val Val Arg Phe Val Arg Ile Leu Arg Ile Phe Lys Leu Thr Arg His  
               
               
                     350                 355                 360  
               
               
                   
               
               
                 ttt gta ggt ctg agg gtg ctt gga cat act ctt cga gct agt act aat     1155  
               
               
                 Phe Val Gly Leu Arg Val Leu Gly His Thr Leu Arg Ala Ser Thr Asn  
               
               
                 365                 370                 375                 380  
               
               
                   
               
               
                 gaa ttt ttg ctg ctg ata att ttc ctg gct cta gga gtt ttg ata ttt     1203  
               
               
                 Glu Phe Leu Leu Leu Ile Ile Phe Leu Ala Leu Gly Val Leu Ile Phe  
               
               
                                 385                 390                 395  
               
               
                   
               
               
                 gct acc atg atc tac tat gcc gag aga gtg gga gct caa cct aac gac     1251  
               
               
                 Ala Thr Met Ile Tyr Tyr Ala Glu Arg Val Gly Ala Gln Pro Asn Asp  
               
               
                             400                 405                 410  
               
               
                   
               
               
                 cct tca gct agt gag cac aca cag ttc aaa aac att ccc att ggg ttc     1299  
               
               
                 Pro Ser Ala Ser Glu His Thr Gln Phe Lys Asn Ile Pro Ile Gly Phe  
               
               
                         415                 420                 425  
               
               
                   
               
               
                 tgg tgg gct gta gtg acc atg act acc ctg ggt tat ggg gat atg tac     1347  
               
               
                 Trp Trp Ala Val Val Thr Met Thr Thr Leu Gly Tyr Gly Asp Met Tyr  
               
               
                     430                 435                 440  
               
               
                   
               
               
                 ccc caa aca tgg tca ggc atg ctg gtg gga gcc ctg tgt gct ctg gct     1395  
               
               
                 Pro Gln Thr Trp Ser Gly Met Leu Val Gly Ala Leu Cys Ala Leu Ala  
               
               
                 445                 450                 455                 460  
               
               
                   
               
               
                 gga gtg ctg aca ata gcc atg cca gtg cct gtc att gtc aat aat ttt     1443  
               
               
                 Gly Val Leu Thr Ile Ala Met Pro Val Pro Val Ile Val Asn Asn Phe  
               
               
                                 465                 470                 475  
               
               
                   
               
               
                 gga atg tac tac tcc ttg gca atg gca aag cag aaa ctt cca agg aaa     1491  
               
               
                 Gly Met Tyr Tyr Ser Leu Ala Met Ala Lys Gln Lys Leu Pro Arg Lys  
               
               
                             480                 485                 490  
               
               
                   
               
               
                 aga aag aag cac atc cct cct gct cct cag gca agc tca cct act ttt     1539  
               
               
                 Arg Lys Lys His Ile Pro Pro Ala Pro Gln Ala Ser Ser Pro Thr Phe  
               
               
                         495                 500                 505  
               
               
                   
               
               
                 tgc aag aca gaa tta aat atg gcc tgc aat agt aca cag agt gac aca     1587  
               
               
                 Cys Lys Thr Glu Leu Asn Met Ala Cys Asn Ser Thr Gln Ser Asp Thr  
               
               
                     510                 515                 520  
               
               
                   
               
               
                 tgt ctg ggc aaa gac aat cga ctt ctg gaa cat aac aga tca gtg tta     1635  
               
               
                 Cys Leu Gly Lys Asp Asn Arg Leu Leu Glu His Asn Arg Ser Val Leu  
               
               
                 525                 530                 535                 540  
               
               
                   
               
               
                 tca ggt gac gac agt aca gga agt gag ccg cca cta tca ccc cca gaa     1683  
               
               
                 Ser Gly Asp Asp Ser Thr Gly Ser Glu Pro Pro Leu Ser Pro Pro Glu  
               
               
                                 545                 550                 555  
               
               
                   
               
               
                 agg ctc ccc atc aga cgc tct agt acc aga gac aaa aac aga aga ggg     1731  
               
               
                 Arg Leu Pro Ile Arg Arg Ser Ser Thr Arg Asp Lys Asn Arg Arg Gly  
               
               
                             560                 565                 570  
               
               
                   
               
               
                 gaa aca tgt ttc cta ctg acg aca ggt gat tac acg tgt gct tct gat     1779  
               
               
                 Glu Thr Cys Phe Leu Leu Thr Thr Gly Asp Tyr Thr Cys Ala Ser Asp  
               
               
                         575                 580                 585  
               
               
                   
               
               
                 gga ggg atc agg aaa ggt tat gaa aaa tcc cga agc tta aac aac ata     1827  
               
               
                 Gly Gly Ile Arg Lys Gly Tyr Glu Lys Ser Arg Ser Leu Asn Asn Ile  
               
               
                     590                 595                 600  
               
               
                   
               
               
                 gcg ggc ttg gca ggc aat gct ctg agg ctc tct cca gta aca tca ccc     1875  
               
               
                 Ala Gly Leu Ala Gly Asn Ala Leu Arg Leu Ser Pro Val Thr Ser Pro  
               
               
                 605                 610                 615                 620  
               
               
                   
               
               
                 tac aac tct cct tgt cct ctg agg cgc tct cga tct ccc atc cca tct     1923  
               
               
                 Tyr Asn Ser Pro Cys Pro Leu Arg Arg Ser Arg Ser Pro Ile Pro Ser  
               
               
                                 625                 630                 635  
               
               
                   
               
               
                 atc ttg taaaccaaac aaccaaactg catc                                  1953  
               
               
                 Ile Leu  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 14  
               
               
                 &lt;211&gt; LENGTH: 638  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 14  
               
               
                   
               
               
                 Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu Asn Val Gly Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr Leu Pro Gly Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly Asp Cys Leu Thr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Thr Ala Gly Asp Lys Leu Gln Pro Ser Pro Pro Pro Leu Ser Pro Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Pro Arg Ala Pro Pro Leu Ser Pro Gly Pro Gly Gly Cys Phe Glu Gly  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gly Ala Gly Asn Cys Ser Ser Arg Gly Gly Arg Ala Ser Asp His Pro  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Gly Gly Gly Arg Glu Phe Phe Phe Asp Arg His Pro Gly Val Phe Ala  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Tyr Val Leu Asn Tyr Tyr Arg Thr Gly Lys Leu His Cys Pro Ala Asp  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Val Cys Gly Pro Leu Phe Glu Glu Glu Leu Ala Phe Trp Gly Ile Asp  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Glu Thr Asp Val Glu Pro Cys Cys Trp Met Thr Tyr Arg Gln His Arg  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Asp Ala Glu Glu Ala Leu Asp Ile Phe Glu Thr Pro Asp Leu Ile Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Asp Pro Gly Asp Asp Glu Asp Leu Ala Ala Lys Arg Leu Gly Ile  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Glu Asp Ala Ala Gly Leu Gly Gly Pro Asp Gly Lys Ser Gly Arg Trp  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Arg Arg Leu Gln Pro Arg Met Trp Ala Leu Phe Glu Asp Pro Tyr Ser  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ser Arg Ala Ala Arg Phe Ile Ala Phe Ala Ser Leu Phe Phe Ile Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Val Ser Ile Thr Thr Phe Cys Leu Glu Thr His Glu Ala Phe Asn Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Val Lys Asn Lys Thr Glu Pro Val Ile Asn Gly Thr Ser Val Val Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Tyr Glu Ile Glu Thr Asp Pro Ala Leu Thr Tyr Val Glu Gly Val  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Cys Val Val Trp Phe Thr Phe Glu Phe Leu Val Arg Ile Val Phe Ser  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Pro Asn Lys Leu Glu Phe Ile Lys Asn Leu Leu Asn Ile Ile Asp Phe  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Val Ala Ile Leu Pro Phe Tyr Leu Glu Val Gly Leu Ser Gly Leu Ser  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Lys Ala Ala Lys Asp Val Leu Gly Phe Leu Arg Val Val Arg Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Val Arg Ile Leu Arg Ile Phe Lys Leu Thr Arg His Phe Val Gly Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Arg Val Leu Gly His Thr Leu Arg Ala Ser Thr Asn Glu Phe Leu Leu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Leu Ile Ile Phe Leu Ala Leu Gly Val Leu Ile Phe Ala Thr Met Ile  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Tyr Tyr Ala Glu Arg Val Gly Ala Gln Pro Asn Asp Pro Ser Ala Ser  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Glu His Thr Gln Phe Lys Asn Ile Pro Ile Gly Phe Trp Trp Ala Val  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Val Thr Met Thr Thr Leu Gly Tyr Gly Asp Met Tyr Pro Gln Thr Trp  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ser Gly Met Leu Val Gly Ala Leu Cys Ala Leu Ala Gly Val Leu Thr  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Ile Ala Met Pro Val Pro Val Ile Val Asn Asn Phe Gly Met Tyr Tyr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Ser Leu Ala Met Ala Lys Gln Lys Leu Pro Arg Lys Arg Lys Lys His  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ile Pro Pro Ala Pro Gln Ala Ser Ser Pro Thr Phe Cys Lys Thr Glu  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Leu Asn Met Ala Cys Asn Ser Thr Gln Ser Asp Thr Cys Leu Gly Lys  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Asp Asn Arg Leu Leu Glu His Asn Arg Ser Val Leu Ser Gly Asp Asp  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Ser Thr Gly Ser Glu Pro Pro Leu Ser Pro Pro Glu Arg Leu Pro Ile  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Arg Arg Ser Ser Thr Arg Asp Lys Asn Arg Arg Gly Glu Thr Cys Phe  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Leu Leu Thr Thr Gly Asp Tyr Thr Cys Ala Ser Asp Gly Gly Ile Arg  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Lys Gly Tyr Glu Lys Ser Arg Ser Leu Asn Asn Ile Ala Gly Leu Ala  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Gly Asn Ala Leu Arg Leu Ser Pro Val Thr Ser Pro Tyr Asn Ser Pro  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 Cys Pro Leu Arg Arg Ser Arg Ser Pro Ile Pro Ser Ile Leu  
               
               
                 625                 630                 635  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 15  
               
               
                 &lt;211&gt; LENGTH: 607  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (13)..(603)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 15  
               
               
                   
               
               
                 agatttccca cc atg ggc aag atc gag aac aac gag agg gtg atc ctc aat     51  
               
               
                               Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu Asn  
               
               
                               1               5                   10  
               
               
                   
               
               
                 gtc ggg ggc acc cgg cac gaa acc tac cgc agc acc ctc aag acc ctg       99  
               
               
                 Val Gly Gly Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr Leu  
               
               
                     15                  20                  25  
               
               
                   
               
               
                 cct gga aca cgc ctg gcc ctt ctt gcc tcc tcc gag ccc cca ggc gac      147  
               
               
                 Pro Gly Thr Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly Asp  
               
               
                 30                  35                  40                  45  
               
               
                   
               
               
                 tgc ttg acc aca gcg ggc aac tgc agt tcc cgc ggc ggc agg gcc agc      195  
               
               
                 Cys Leu Thr Thr Ala Gly Asn Cys Ser Ser Arg Gly Gly Arg Ala Ser  
               
               
                                 50                  55                  60  
               
               
                   
               
               
                 gac cat ccc ggt ggc ggc cgc gag ttc ttc ttc gac cgg cat ccg ggc      243  
               
               
                 Asp His Pro Gly Gly Gly Arg Glu Phe Phe Phe Asp Arg His Pro Gly  
               
               
                             65                  70                  75  
               
               
                   
               
               
                 gtc ttc gcc tat gtg ctc aat tac tac cgc acc ggc aag ctg cac tgt      291  
               
               
                 Val Phe Ala Tyr Val Leu Asn Tyr Tyr Arg Thr Gly Lys Leu His Cys  
               
               
                         80                  85                  90  
               
               
                   
               
               
                 ccc gca gac gtg tgc ggg ccg ctc ttc gag gag gag ctg gcc ttc tgg      339  
               
               
                 Pro Ala Asp Val Cys Gly Pro Leu Phe Glu Glu Glu Leu Ala Phe Trp  
               
               
                     95                  100                 105  
               
               
                   
               
               
                 ggc atc gac gag acc gac gtg gag ccc tgc tgc tgg atg acc tac cgg      387  
               
               
                 Gly Ile Asp Glu Thr Asp Val Glu Pro Cys Cys Trp Met Thr Tyr Arg  
               
               
                 110                 115                 120                 125  
               
               
                   
               
               
                 cag cac cgc gac gcc gag gag gcg ctg gac atc ttc gag acc ccc gac      435  
               
               
                 Gln His Arg Asp Ala Glu Glu Ala Leu Asp Ile Phe Glu Thr Pro Asp  
               
               
                                 130                 135                 140  
               
               
                   
               
               
                 ctc att ggc ggc gac ccc ggc gac gac gag gac ctg gcg gcc aag agg      483  
               
               
                 Leu Ile Gly Gly Asp Pro Gly Asp Asp Glu Asp Leu Ala Ala Lys Arg  
               
               
                             145                 150                 155  
               
               
                   
               
               
                 ctg ggc atc gag gac gcg gcg ggg ctc ggg ggc ccc gac ggc aaa tct      531  
               
               
                 Leu Gly Ile Glu Asp Ala Ala Gly Leu Gly Gly Pro Asp Gly Lys Ser  
               
               
                         160                 165                 170  
               
               
                   
               
               
                 ggc cgc tgg agg agg ctg cag ccc cgc atg tgg gcc ctc ttc gaa gac      579  
               
               
                 Gly Arg Trp Arg Arg Leu Gln Pro Arg Met Trp Ala Leu Phe Glu Asp  
               
               
                     175                 180                 185  
               
               
                   
               
               
                 ccc tac tcg tcc aga gcc gcc agg ctcg                                 607  
               
               
                 Pro Tyr Ser Ser Arg Ala Ala Arg  
               
               
                 190                 195  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 16  
               
               
                 &lt;211&gt; LENGTH: 197  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 16  
               
               
                   
               
               
                 Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu Asn Val Gly Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr Leu Pro Gly Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly Asp Cys Leu Thr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Thr Ala Gly Asn Cys Ser Ser Arg Gly Gly Arg Ala Ser Asp His Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Gly Gly Gly Arg Glu Phe Phe Phe Asp Arg His Pro Gly Val Phe Ala  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Val Leu Asn Tyr Tyr Arg Thr Gly Lys Leu His Cys Pro Ala Asp  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Val Cys Gly Pro Leu Phe Glu Glu Glu Leu Ala Phe Trp Gly Ile Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Glu Thr Asp Val Glu Pro Cys Cys Trp Met Thr Tyr Arg Gln His Arg  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Asp Ala Glu Glu Ala Leu Asp Ile Phe Glu Thr Pro Asp Leu Ile Gly  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Gly Asp Pro Gly Asp Asp Glu Asp Leu Ala Ala Lys Arg Leu Gly Ile  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Glu Asp Ala Ala Gly Leu Gly Gly Pro Asp Gly Lys Ser Gly Arg Trp  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Arg Arg Leu Gln Pro Arg Met Trp Ala Leu Phe Glu Asp Pro Tyr Ser  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ser Arg Ala Ala Arg  
               
               
                         195  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 17  
               
               
                 &lt;211&gt; LENGTH: 1815  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (13)..(1809)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 17  
               
               
                   
               
               
                 agatctccca cc atg ggc aag atc gag aac aac gag agg gtg atc ctc aat     51  
               
               
                               Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu Asn  
               
               
                               1               5                   10  
               
               
                   
               
               
                 gtc ggg ggc acc cgg cac gaa acc tac cgc agc acc ctc aag acc ctg       99  
               
               
                 Val Gly Gly Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr Leu  
               
               
                     15                  20                  25  
               
               
                   
               
               
                 cct gga aca cgc ctg gcc ctt ctt gcc tcc tcc gag ccc cca ggc aac      147  
               
               
                 Pro Gly Thr Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly Asn  
               
               
                 30                  35                  40                  45  
               
               
                   
               
               
                 tgc agt tcc cgc ggc ggc agg gcc agc gac cat ccc ggt ggc ggc cgc      195  
               
               
                 Cys Ser Ser Arg Gly Gly Arg Ala Ser Asp His Pro Gly Gly Gly Arg  
               
               
                                 50                  55                  60  
               
               
                   
               
               
                 gag ttc ttc ttc gac cgg cac ccg ggc gtc ttc gcc tat gtg ctc aat      243  
               
               
                 Glu Phe Phe Phe Asp Arg His Pro Gly Val Phe Ala Tyr Val Leu Asn  
               
               
                             65                  70                  75  
               
               
                   
               
               
                 tac tac cgc acc ggc aag ctg cac tgc ccc gca gac gtg tgc ggg ccg      291  
               
               
                 Tyr Tyr Arg Thr Gly Lys Leu His Cys Pro Ala Asp Val Cys Gly Pro  
               
               
                         80                  85                  90  
               
               
                   
               
               
                 ctc ttc gag gag gag ctg gcc ttc tgg ggc atc gac gag acc gac gtg      339  
               
               
                 Leu Phe Glu Glu Glu Leu Ala Phe Trp Gly Ile Asp Glu Thr Asp Val  
               
               
                     95                  100                 105  
               
               
                   
               
               
                 gag ccc tgc tgc tgg atg acc tac cgg cag cac cgc gac gcc gag gag      387  
               
               
                 Glu Pro Cys Cys Trp Met Thr Tyr Arg Gln His Arg Asp Ala Glu Glu  
               
               
                 110                 115                 120                 125  
               
               
                   
               
               
                 gcg ctg gac atc ttc gag acc ccc gac ctc att ggc ggc gac ccc ggc      435  
               
               
                 Ala Leu Asp Ile Phe Glu Thr Pro Asp Leu Ile Gly Gly Asp Pro Gly  
               
               
                                 130                 135                 140  
               
               
                   
               
               
                 gac gac gag gac ctg gcg gcc aag agg ctg ggc atc gag gac gcg gcg      483  
               
               
                 Asp Asp Glu Asp Leu Ala Ala Lys Arg Leu Gly Ile Glu Asp Ala Ala  
               
               
                             145                 150                 155  
               
               
                   
               
               
                 ggg ctc ggg ggc ccc gac ggc aaa tct ggc cgc tgg agg agg ctg cag      531  
               
               
                 Gly Leu Gly Gly Pro Asp Gly Lys Ser Gly Arg Trp Arg Arg Leu Gln  
               
               
                         160                 165                 170  
               
               
                   
               
               
                 ccc cgc atg tgg gcc ctc ttc gaa gac ccc tac tcg tcc aga gcc gcc      579  
               
               
                 Pro Arg Met Trp Ala Leu Phe Glu Asp Pro Tyr Ser Ser Arg Ala Ala  
               
               
                     175                 180                 185  
               
               
                   
               
               
                 agg ttt att gct ttt gct tct tta ttc ttc atc ctg gtt tca att aca      627  
               
               
                 Arg Phe Ile Ala Phe Ala Ser Leu Phe Phe Ile Leu Val Ser Ile Thr  
               
               
                 190                 195                 200                 205  
               
               
                   
               
               
                 act ttt tgc ctg gaa aca cat gaa gct ttc aat att gtt aaa aac aag      675  
               
               
                 Thr Phe Cys Leu Glu Thr His Glu Ala Phe Asn Ile Val Lys Asn Lys  
               
               
                                 210                 215                 220  
               
               
                   
               
               
                 aca gaa cca gtc atc aat ggc aca agt gtt gtt cta cag tat gaa att      723  
               
               
                 Thr Glu Pro Val Ile Asn Gly Thr Ser Val Val Leu Gln Tyr Glu Ile  
               
               
                             225                 230                 235  
               
               
                   
               
               
                 gaa acg gat cct gcc ttg acg tat gta gaa gga gtg tgt gtg gtg tgg      771  
               
               
                 Glu Thr Asp Pro Ala Leu Thr Tyr Val Glu Gly Val Cys Val Val Trp  
               
               
                         240                 245                 250  
               
               
                   
               
               
                 ttt act ttt gaa ttt tta gtc cgt att gtt ttt tca ccc aat aaa ctt      819  
               
               
                 Phe Thr Phe Glu Phe Leu Val Arg Ile Val Phe Ser Pro Asn Lys Leu  
               
               
                     255                 260                 265  
               
               
                   
               
               
                 gaa ttc atc aaa aat ctc ttg aat atc att gac ttt gtg gcc atc cta      867  
               
               
                 Glu Phe Ile Lys Asn Leu Leu Asn Ile Ile Asp Phe Val Ala Ile Leu  
               
               
                 270                 275                 280                 285  
               
               
                   
               
               
                 cct ttc tac tta gag gtg gga ctc agt ggg ctg tca tcc aaa gct gct      915  
               
               
                 Pro Phe Tyr Leu Glu Val Gly Leu Ser Gly Leu Ser Ser Lys Ala Ala  
               
               
                                 290                 295                 300  
               
               
                   
               
               
                 aaa gat gtg ctt ggc ttc ctc agg gtg gta agg ttt gtg agg atc ctg      963  
               
               
                 Lys Asp Val Leu Gly Phe Leu Arg Val Val Arg Phe Val Arg Ile Leu  
               
               
                             305                 310                 315  
               
               
                   
               
               
                 aga att ttc aag ctc acc cgc cat ttt gta ggt ctg agg gtg ctt gga     1011  
               
               
                 Arg Ile Phe Lys Leu Thr Arg His Phe Val Gly Leu Arg Val Leu Gly  
               
               
                         320                 325                 330  
               
               
                   
               
               
                 cat act ctt cga gct agt act aat gaa ttt ttg ctg ctg ata att ttc     1059  
               
               
                 His Thr Leu Arg Ala Ser Thr Asn Glu Phe Leu Leu Leu Ile Ile Phe  
               
               
                     335                 340                 345  
               
               
                   
               
               
                 ctg gct cta gga gtt ttg ata ttt gct acc atg atc tac tat gcc gag     1107  
               
               
                 Leu Ala Leu Gly Val Leu Ile Phe Ala Thr Met Ile Tyr Tyr Ala Glu  
               
               
                 350                 355                 360                 365  
               
               
                   
               
               
                 aga gtg gga gct caa cct aac gac cct tca gct agt gag cac aca cag     1155  
               
               
                 Arg Val Gly Ala Gln Pro Asn Asp Pro Ser Ala Ser Glu His Thr Gln  
               
               
                                 370                 375                 380  
               
               
                   
               
               
                 ttc aaa aac att ccc att ggg ttc tgg tgg gct gta gtg acc atg act     1203  
               
               
                 Phe Lys Asn Ile Pro Ile Gly Phe Trp Trp Ala Val Val Thr Met Thr  
               
               
                             385                 390                 395  
               
               
                   
               
               
                 acc ctg ggt tat gag gat acg tac ccc caa aca tgg tca ggc atg ctg     1251  
               
               
                 Thr Leu Gly Tyr Glu Asp Thr Tyr Pro Gln Thr Trp Ser Gly Met Leu  
               
               
                         400                 405                 410  
               
               
                   
               
               
                 gtg gga gcc ctg tgt gct ctg gct gga gtg ctg aca ata gcc atg cca     1299  
               
               
                 Val Gly Ala Leu Cys Ala Leu Ala Gly Val Leu Thr Ile Ala Met Pro  
               
               
                     415                 420                 425  
               
               
                   
               
               
                 gtg cct gtc att gtc aat aat ttt gga atg tac tac tcc ttg gca atg     1347  
               
               
                 Val Pro Val Ile Val Asn Asn Phe Gly Met Tyr Tyr Ser Leu Ala Met  
               
               
                 430                 435                 440                 445  
               
               
                   
               
               
                 gca aag cag aaa ctt cca agg aaa aga aag aag cac atc cct cct gct     1395  
               
               
                 Ala Lys Gln Lys Leu Pro Arg Lys Arg Lys Lys His Ile Pro Pro Ala  
               
               
                                 450                 455                 460  
               
               
                   
               
               
                 cct cag gca agc tca cct act ttt tgc aag aca gaa tta aat atg gcc     1443  
               
               
                 Pro Gln Ala Ser Ser Pro Thr Phe Cys Lys Thr Glu Leu Asn Met Ala  
               
               
                             465                 470                 475  
               
               
                   
               
               
                 tgc aat agt aca cag agt gac aca tgt ctg ggc aaa gac aat cga ctt     1491  
               
               
                 Cys Asn Ser Thr Gln Ser Asp Thr Cys Leu Gly Lys Asp Asn Arg Leu  
               
               
                         480                 485                 490  
               
               
                   
               
               
                 ctg gaa cat aac aga tca gtg tta tca ggt gac gac agt aca gga agt     1539  
               
               
                 Leu Glu His Asn Arg Ser Val Leu Ser Gly Asp Asp Ser Thr Gly Ser  
               
               
                     495                 500                 505  
               
               
                   
               
               
                 gag ccg cca cta tca ccc cca gaa agg ctc ccc atc aga cgc tct agt     1587  
               
               
                 Glu Pro Pro Leu Ser Pro Pro Glu Arg Leu Pro Ile Arg Arg Ser Ser  
               
               
                 510                 515                 520                 525  
               
               
                   
               
               
                 acc aga gac aaa aac aga aga ggg gaa aca tgt ttc cta ctg acg aca     1635  
               
               
                 Thr Arg Asp Lys Asn Arg Arg Gly Glu Thr Cys Phe Leu Leu Thr Thr  
               
               
                                 530                 535                 540  
               
               
                   
               
               
                 ggt gat tac acg tgt gct tct gat gga ggg atc agg aaa gga tat gaa     1683  
               
               
                 Gly Asp Tyr Thr Cys Ala Ser Asp Gly Gly Ile Arg Lys Gly Tyr Glu  
               
               
                             545                 550                 555  
               
               
                   
               
               
                 aaa tcc cga agc tta aac aac ata gcg ggc ttg gca ggc aat gct ctg     1731  
               
               
                 Lys Ser Arg Ser Leu Asn Asn Ile Ala Gly Leu Ala Gly Asn Ala Leu  
               
               
                         560                 565                 570  
               
               
                   
               
               
                 agg ctc tct cca gta aca tca ccc tac aac tct cct tgt cct ctg agg     1779  
               
               
                 Arg Leu Ser Pro Val Thr Ser Pro Tyr Asn Ser Pro Cys Pro Leu Arg  
               
               
                     575                 580                 585  
               
               
                   
               
               
                 cgc tct cga tct ccc atc cca tct atc ttg ctcgag                      1815  
               
               
                 Arg Ser Arg Ser Pro Ile Pro Ser Ile Leu  
               
               
                 590                 595  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 18  
               
               
                 &lt;211&gt; LENGTH: 599  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 18  
               
               
                   
               
               
                 Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu Asn Val Gly Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr Leu Pro Gly Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly Asn Cys Ser Ser  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Arg Gly Gly Arg Ala Ser Asp His Pro Gly Gly Gly Arg Glu Phe Phe  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Phe Asp Arg His Pro Gly Val Phe Ala Tyr Val Leu Asn Tyr Tyr Arg  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Thr Gly Lys Leu His Cys Pro Ala Asp Val Cys Gly Pro Leu Phe Glu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Glu Glu Leu Ala Phe Trp Gly Ile Asp Glu Thr Asp Val Glu Pro Cys  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Cys Trp Met Thr Tyr Arg Gln His Arg Asp Ala Glu Glu Ala Leu Asp  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Phe Glu Thr Pro Asp Leu Ile Gly Gly Asp Pro Gly Asp Asp Glu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Asp Leu Ala Ala Lys Arg Leu Gly Ile Glu Asp Ala Ala Gly Leu Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Gly Pro Asp Gly Lys Ser Gly Arg Trp Arg Arg Leu Gln Pro Arg Met  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Trp Ala Leu Phe Glu Asp Pro Tyr Ser Ser Arg Ala Ala Arg Phe Ile  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ala Phe Ala Ser Leu Phe Phe Ile Leu Val Ser Ile Thr Thr Phe Cys  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Glu Thr His Glu Ala Phe Asn Ile Val Lys Asn Lys Thr Glu Pro  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Val Ile Asn Gly Thr Ser Val Val Leu Gln Tyr Glu Ile Glu Thr Asp  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Pro Ala Leu Thr Tyr Val Glu Gly Val Cys Val Val Trp Phe Thr Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Glu Phe Leu Val Arg Ile Val Phe Ser Pro Asn Lys Leu Glu Phe Ile  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Lys Asn Leu Leu Asn Ile Ile Asp Phe Val Ala Ile Leu Pro Phe Tyr  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Leu Glu Val Gly Leu Ser Gly Leu Ser Ser Lys Ala Ala Lys Asp Val  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Leu Gly Phe Leu Arg Val Val Arg Phe Val Arg Ile Leu Arg Ile Phe  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Lys Leu Thr Arg His Phe Val Gly Leu Arg Val Leu Gly His Thr Leu  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Arg Ala Ser Thr Asn Glu Phe Leu Leu Leu Ile Ile Phe Leu Ala Leu  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Gly Val Leu Ile Phe Ala Thr Met Ile Tyr Tyr Ala Glu Arg Val Gly  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ala Gln Pro Asn Asp Pro Ser Ala Ser Glu His Thr Gln Phe Lys Asn  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Ile Pro Ile Gly Phe Trp Trp Ala Val Val Thr Met Thr Thr Leu Gly  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Tyr Glu Asp Thr Tyr Pro Gln Thr Trp Ser Gly Met Leu Val Gly Ala  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Gly Val Leu Thr Ile Ala Met Pro Val Pro Val  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Ile Val Asn Asn Phe Gly Met Tyr Tyr Ser Leu Ala Met Ala Lys Gln  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Lys Leu Pro Arg Lys Arg Lys Lys His Ile Pro Pro Ala Pro Gln Ala  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Ser Ser Pro Thr Phe Cys Lys Thr Glu Leu Asn Met Ala Cys Asn Ser  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Thr Gln Ser Asp Thr Cys Leu Gly Lys Asp Asn Arg Leu Leu Glu His  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Asn Arg Ser Val Leu Ser Gly Asp Asp Ser Thr Gly Ser Glu Pro Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Leu Ser Pro Pro Glu Arg Leu Pro Ile Arg Arg Ser Ser Thr Arg Asp  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Lys Asn Arg Arg Gly Glu Thr Cys Phe Leu Leu Thr Thr Gly Asp Tyr  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Thr Cys Ala Ser Asp Gly Gly Ile Arg Lys Gly Tyr Glu Lys Ser Arg  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Ser Leu Asn Asn Ile Ala Gly Leu Ala Gly Asn Ala Leu Arg Leu Ser  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Pro Val Thr Ser Pro Tyr Asn Ser Pro Cys Pro Leu Arg Arg Ser Arg  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Ser Pro Ile Pro Ser Ile Leu  
               
               
                         595  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 19  
               
               
                 &lt;211&gt; LENGTH: 3028  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (22)..(1860)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 19  
               
               
                   
               
               
                 agtcatgtct gagtcacaga g atg ggc aag atc gag aac aac gag agg gtg       51  
               
               
                                         Met Gly Lys Ile Glu Asn Asn Glu Arg Val  
               
               
                                         1               5                   10  
               
               
                   
               
               
                 atc ctc aat gtc ggg ggc acc cgg cac gaa acc tac cgc agc acc ctc       99  
               
               
                 Ile Leu Asn Val Gly Gly Thr Arg His Glu Thr Tyr Arg Ser Thr Leu  
               
               
                                 15                  20                  25  
               
               
                   
               
               
                 aag acc ctg cct gga aca cgc ctg gcc ctt ctt gcc tcc tcc gag ccc      147  
               
               
                 Lys Thr Leu Pro Gly Thr Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro  
               
               
                             30                  35                  40  
               
               
                   
               
               
                 cca ggc gac tgc ttg acc acg gcg ggc gac aag ctg cag ccg tcg ccg      195  
               
               
                 Pro Gly Asp Cys Leu Thr Thr Ala Gly Asp Lys Leu Gln Pro Ser Pro  
               
               
                         45                  50                  55  
               
               
                   
               
               
                 cct cca ctg tcg ccg ccg ccg aga gcg ccc ccg ctg tcc ccc ggg cca      243  
               
               
                 Pro Pro Leu Ser Pro Pro Pro Arg Ala Pro Pro Leu Ser Pro Gly Pro  
               
               
                     60                  65                  70  
               
               
                   
               
               
                 ggc ggc tgc ttc gag ggc ggc gcg ggc aac tgc agt tcc cgc ggc ggc      291  
               
               
                 Gly Gly Cys Phe Glu Gly Gly Ala Gly Asn Cys Ser Ser Arg Gly Gly  
               
               
                 75                  80                  85                  90  
               
               
                   
               
               
                 agg gcc agc gac cat ccc ggt ggc ggc cgc gag ttc ttc ttc gac cgg      339  
               
               
                 Arg Ala Ser Asp His Pro Gly Gly Gly Arg Glu Phe Phe Phe Asp Arg  
               
               
                                 95                  100                 105  
               
               
                   
               
               
                 cac ccg ggc gtc ttc gcc tat gtg ctc aat tac tac cgc acc ggc aag      387  
               
               
                 His Pro Gly Val Phe Ala Tyr Val Leu Asn Tyr Tyr Arg Thr Gly Lys  
               
               
                             110                 115                 120  
               
               
                   
               
               
                 ctg cac tgc ccc gca gac gtg tgc ggg ccg ctc ttc gag gag gag ctg      435  
               
               
                 Leu His Cys Pro Ala Asp Val Cys Gly Pro Leu Phe Glu Glu Glu Leu  
               
               
                         125                 130                 135  
               
               
                   
               
               
                 gcc ttc tgg ggc atc gac gag acc gac gtg gag ccc tgc tgc tgg atg      483  
               
               
                 Ala Phe Trp Gly Ile Asp Glu Thr Asp Val Glu Pro Cys Cys Trp Met  
               
               
                     140                 145                 150  
               
               
                   
               
               
                 acc tac cgg cag cac cgc gac gcc gag gag gcg ctg gac atc ttc gag      531  
               
               
                 Thr Tyr Arg Gln His Arg Asp Ala Glu Glu Ala Leu Asp Ile Phe Glu  
               
               
                 155                 160                 165                 170  
               
               
                   
               
               
                 acc ccc gac ctc att ggc ggc gac ccc ggc gac gac gag gac ctg gcg      579  
               
               
                 Thr Pro Asp Leu Ile Gly Gly Asp Pro Gly Asp Asp Glu Asp Leu Ala  
               
               
                                 175                 180                 185  
               
               
                   
               
               
                 gcc aag agg ctg ggc atc gag gac gcg gcg ggg ctc ggg ggc ccc gac      627  
               
               
                 Ala Lys Arg Leu Gly Ile Glu Asp Ala Ala Gly Leu Gly Gly Pro Asp  
               
               
                             190                 195                 200  
               
               
                   
               
               
                 ggc aaa tct ggc cgc tgg agg agg ctg cag ccc cgc atg tgg gcc ctc      675  
               
               
                 Gly Lys Ser Gly Arg Trp Arg Arg Leu Gln Pro Arg Met Trp Ala Leu  
               
               
                         205                 210                 215  
               
               
                   
               
               
                 ttc gaa gac ccc tac tcg tcc aga gcc gcc agg ttt att gct ttt gct      723  
               
               
                 Phe Glu Asp Pro Tyr Ser Ser Arg Ala Ala Arg Phe Ile Ala Phe Ala  
               
               
                     220                 225                 230  
               
               
                   
               
               
                 tct tta ttc ttc atc ctg gtt tca att aca act ttt tgc ctg gaa aca      771  
               
               
                 Ser Leu Phe Phe Ile Leu Val Ser Ile Thr Thr Phe Cys Leu Glu Thr  
               
               
                 235                 240                 245                 250  
               
               
                   
               
               
                 cat gaa gct ttc aat att gtt aaa aac aag aca gaa cca gtc atc aat      819  
               
               
                 His Glu Ala Phe Asn Ile Val Lys Asn Lys Thr Glu Pro Val Ile Asn  
               
               
                                 255                 260                 265  
               
               
                   
               
               
                 ggc aca agt gtt gtt cta cag tat gaa att gaa acg gat cct gcc ttg      867  
               
               
                 Gly Thr Ser Val Val Leu Gln Tyr Glu Ile Glu Thr Asp Pro Ala Leu  
               
               
                             270                 275                 280  
               
               
                   
               
               
                 acg tat gta gaa gga gtg tgt gtg gtg tgg ttt act ttt gaa ttt tta      915  
               
               
                 Thr Tyr Val Glu Gly Val Cys Val Val Trp Phe Thr Phe Glu Phe Leu  
               
               
                         285                 290                 295  
               
               
                   
               
               
                 gtc cgt att gtt ttt tca ccc aat aaa ctt gaa ttc atc aaa aat ctc      963  
               
               
                 Val Arg Ile Val Phe Ser Pro Asn Lys Leu Glu Phe Ile Lys Asn Leu  
               
               
                     300                 305                 310  
               
               
                   
               
               
                 ttg aat atc att gac ttt gtg gcc atc cta cct ttc tac tta gag gtg     1011  
               
               
                 Leu Asn Ile Ile Asp Phe Val Ala Ile Leu Pro Phe Tyr Leu Glu Val  
               
               
                 315                 320                 325                 330  
               
               
                   
               
               
                 gga ctc agt ggg ctg tca tcc aaa gct gct aaa gat gtg ctt ggc ttc     1059  
               
               
                 Gly Leu Ser Gly Leu Ser Ser Lys Ala Ala Lys Asp Val Leu Gly Phe  
               
               
                                 335                 340                 345  
               
               
                   
               
               
                 ctc agg gtg gta agg ttt gtg agg atc ctg aga att ttc aag ctc acc     1107  
               
               
                 Leu Arg Val Val Arg Phe Val Arg Ile Leu Arg Ile Phe Lys Leu Thr  
               
               
                             350                 355                 360  
               
               
                   
               
               
                 cgc cat ttt gta ggt ctg agg gtg ctt gga cat act ctt cga gct agt     1155  
               
               
                 Arg His Phe Val Gly Leu Arg Val Leu Gly His Thr Leu Arg Ala Ser  
               
               
                         365                 370                 375  
               
               
                   
               
               
                 act aat gaa ttt ttg ctg ctg ata att ttc ctg gct cta gga gtt ttg     1203  
               
               
                 Thr Asn Glu Phe Leu Leu Leu Ile Ile Phe Leu Ala Leu Gly Val Leu  
               
               
                     380                 385                 390  
               
               
                   
               
               
                 ata ttt gct acc atg atc tac tat gcc gag aga gtg gga gct caa cct     1251  
               
               
                 Ile Phe Ala Thr Met Ile Tyr Tyr Ala Glu Arg Val Gly Ala Gln Pro  
               
               
                 395                 400                 405                 410  
               
               
                   
               
               
                 aac gac cct tca gct agt gag cac aca cag ttc aaa aac att ccc att     1299  
               
               
                 Asn Asp Pro Ser Ala Ser Glu His Thr Gln Phe Lys Asn Ile Pro Ile  
               
               
                                 415                 420                 425  
               
               
                   
               
               
                 ggg ttc tgg tgg gct gta gtg acc atg act acc ctg ggt tat ggg gat     1347  
               
               
                 Gly Phe Trp Trp Ala Val Val Thr Met Thr Thr Leu Gly Tyr Gly Asp  
               
               
                             430                 435                 440  
               
               
                   
               
               
                 atg tac ccc caa aca tgg tca ggc atg ctg gtg gga gcc ctg tgt gct     1395  
               
               
                 Met Tyr Pro Gln Thr Trp Ser Gly Met Leu Val Gly Ala Leu Cys Ala  
               
               
                         445                 450                 455  
               
               
                   
               
               
                 ctg gct gga gtg ctg aca ata gcc atg cca gtg cct gtc att gtc aat     1443  
               
               
                 Leu Ala Gly Val Leu Thr Ile Ala Met Pro Val Pro Val Ile Val Asn  
               
               
                     460                 465                 470  
               
               
                   
               
               
                 aat ttt gga atg tac tac tcc ttg gca atg gca aag cag aaa ctt cca     1491  
               
               
                 Asn Phe Gly Met Tyr Tyr Ser Leu Ala Met Ala Lys Gln Lys Leu Pro  
               
               
                 475                 480                 485                 490  
               
               
                   
               
               
                 agg aaa aga aag aag cac atc cct cct gct cct cag gca agc tca cct     1539  
               
               
                 Arg Lys Arg Lys Lys His Ile Pro Pro Ala Pro Gln Ala Ser Ser Pro  
               
               
                                 495                 500                 505  
               
               
                   
               
               
                 act ttt tgc aag aca gaa tta aat atg gcc tgc aat agt aca cag agt     1587  
               
               
                 Thr Phe Cys Lys Thr Glu Leu Asn Met Ala Cys Asn Ser Thr Gln Ser  
               
               
                             510                 515                 520  
               
               
                   
               
               
                 gac aca tgt ctg ggc aaa gac aat cga ctt ctg gaa cat aac aga tca     1635  
               
               
                 Asp Thr Cys Leu Gly Lys Asp Asn Arg Leu Leu Glu His Asn Arg Ser  
               
               
                         525                 530                 535  
               
               
                   
               
               
                 gtg tta tca ggt gac gac agt aca gga agt gag ccg cca cta tca ccc     1683  
               
               
                 Val Leu Ser Gly Asp Asp Ser Thr Gly Ser Glu Pro Pro Leu Ser Pro  
               
               
                     540                 545                 550  
               
               
                   
               
               
                 cca gaa agg ctc ccc atc aga cgc tct agt acc aga gac aaa aac aga     1731  
               
               
                 Pro Glu Arg Leu Pro Ile Arg Arg Ser Ser Thr Arg Asp Lys Asn Arg  
               
               
                 555                 560                 565                 570  
               
               
                   
               
               
                 aga ggg gaa aca tgt ttc cta ctg acg aca ggt gat tac acg tgt gct     1779  
               
               
                 Arg Gly Glu Thr Cys Phe Leu Leu Thr Thr Gly Asp Tyr Thr Cys Ala  
               
               
                                 575                 580                 585  
               
               
                   
               
               
                 tct gat gga ggg atc agg aaa gat aac tgc aaa gag gtt gtc att act     1827  
               
               
                 Ser Asp Gly Gly Ile Arg Lys Asp Asn Cys Lys Glu Val Val Ile Thr  
               
               
                             590                 595                 600  
               
               
                   
               
               
                 ggt tac acg caa gcc gag gcc aga tct ctt act taatgacttg ggggaaggca   1880  
               
               
                 Gly Tyr Thr Gln Ala Glu Ala Arg Ser Leu Thr  
               
               
                         605                 610  
               
               
                   
               
               
                 caaaacatga gagaaagtgt tgtacagaat ttatcatgga ttattgactg ctgagaaagg   1940  
               
               
                   
               
               
                 gacagtggaa tttagccata caaaggacta tactggaaac agacttctgc tgctgaatgt   2000  
               
               
                   
               
               
                 gccctgatgt gaccaggttg cacttggaag agatcctccg cgtcttcatg aggcacttaa   2060  
               
               
                   
               
               
                 agcttataaa agaactgcgg ctggaactca tctggtgctc cccatgagag tgctctgctt   2120  
               
               
                   
               
               
                 gtagactggc cagtgtccat gaaacaactg taaataccaa catgtgtgca tgggtcaaca   2180  
               
               
                   
               
               
                 gtcttggcca tttctcatca aaagaagcca aattcatgat caacatctct gaagtttcaa   2240  
               
               
                   
               
               
                 gtaaggccca cacttctttg aattactctt catgggccca cattaggttg tgctgtgaat   2300  
               
               
                   
               
               
                 tacttaaggc agtgatactg atgtagtata gttttgtctt aatttccctt atttctactt   2360  
               
               
                   
               
               
                 ctttggttga atctatgaac ttgattgtat aattttctta taaattactg atgtaatcag   2420  
               
               
                   
               
               
                 cttgtcaatt atgttgtgaa attgttagta ttcatttatc aaaaatgacc tatgtttagt   2480  
               
               
                   
               
               
                 cacatatttg tttagttctg ggaaattgtt atagcttaaa tggaactcac caacattatt   2540  
               
               
                   
               
               
                 catagtttaa gtcttttatc attattacct caattataaa tattacaaaa acataattct   2600  
               
               
                   
               
               
                 ggcaatgaga gtattttttt attcaatgat caaggagcaa tgtcagtata tagtagaata   2660  
               
               
                   
               
               
                 tcaattaaat tatatcctaa aatgtatatt ttgcataaaa gagatattct ttaatcaatt   2720  
               
               
                   
               
               
                 acttttttgt gagttttgtg gcgaatgaag cttgtacgtg tctttaaaac tgttgtagat   2780  
               
               
                   
               
               
                 gaaactgtat aagattttta catcttgctt aatcaatatt ttcagagtct attagttccc   2840  
               
               
                   
               
               
                 ctgggattct gaatataaca tatagcctat tataaatccc tgtatcgtgg accttttgtg   2900  
               
               
                   
               
               
                 aacatttcaa ggcgcatgca caaccttgat gataaccagt ggaaatgtaa ctaactgaaa   2960  
               
               
                   
               
               
                 tgaagaataa aaggcaaatg agctggggat aaacttgaat gttatctgat taaattactc   3020  
               
               
                   
               
               
                 aaattatt                                                            3028  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 20  
               
               
                 &lt;211&gt; LENGTH: 613  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 20  
               
               
                   
               
               
                 Met Gly Lys Ile Glu Asn Asn Glu Arg Val Ile Leu Asn Val Gly Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Thr Arg His Glu Thr Tyr Arg Ser Thr Leu Lys Thr Leu Pro Gly Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Arg Leu Ala Leu Leu Ala Ser Ser Glu Pro Pro Gly Asp Cys Leu Thr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Thr Ala Gly Asp Lys Leu Gln Pro Ser Pro Pro Pro Leu Ser Pro Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Pro Arg Ala Pro Pro Leu Ser Pro Gly Pro Gly Gly Cys Phe Glu Gly  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gly Ala Gly Asn Cys Ser Ser Arg Gly Gly Arg Ala Ser Asp His Pro  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Gly Gly Gly Arg Glu Phe Phe Phe Asp Arg His Pro Gly Val Phe Ala  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Tyr Val Leu Asn Tyr Tyr Arg Thr Gly Lys Leu His Cys Pro Ala Asp  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Val Cys Gly Pro Leu Phe Glu Glu Glu Leu Ala Phe Trp Gly Ile Asp  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Glu Thr Asp Val Glu Pro Cys Cys Trp Met Thr Tyr Arg Gln His Arg  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Asp Ala Glu Glu Ala Leu Asp Ile Phe Glu Thr Pro Asp Leu Ile Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Asp Pro Gly Asp Asp Glu Asp Leu Ala Ala Lys Arg Leu Gly Ile  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Glu Asp Ala Ala Gly Leu Gly Gly Pro Asp Gly Lys Ser Gly Arg Trp  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Arg Arg Leu Gln Pro Arg Met Trp Ala Leu Phe Glu Asp Pro Tyr Ser  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ser Arg Ala Ala Arg Phe Ile Ala Phe Ala Ser Leu Phe Phe Ile Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Val Ser Ile Thr Thr Phe Cys Leu Glu Thr His Glu Ala Phe Asn Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Val Lys Asn Lys Thr Glu Pro Val Ile Asn Gly Thr Ser Val Val Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Tyr Glu Ile Glu Thr Asp Pro Ala Leu Thr Tyr Val Glu Gly Val  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Cys Val Val Trp Phe Thr Phe Glu Phe Leu Val Arg Ile Val Phe Ser  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Pro Asn Lys Leu Glu Phe Ile Lys Asn Leu Leu Asn Ile Ile Asp Phe  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Val Ala Ile Leu Pro Phe Tyr Leu Glu Val Gly Leu Ser Gly Leu Ser  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Lys Ala Ala Lys Asp Val Leu Gly Phe Leu Arg Val Val Arg Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Val Arg Ile Leu Arg Ile Phe Lys Leu Thr Arg His Phe Val Gly Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Arg Val Leu Gly His Thr Leu Arg Ala Ser Thr Asn Glu Phe Leu Leu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Leu Ile Ile Phe Leu Ala Leu Gly Val Leu Ile Phe Ala Thr Met Ile  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Tyr Tyr Ala Glu Arg Val Gly Ala Gln Pro Asn Asp Pro Ser Ala Ser  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Glu His Thr Gln Phe Lys Asn Ile Pro Ile Gly Phe Trp Trp Ala Val  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Val Thr Met Thr Thr Leu Gly Tyr Gly Asp Met Tyr Pro Gln Thr Trp  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ser Gly Met Leu Val Gly Ala Leu Cys Ala Leu Ala Gly Val Leu Thr  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Ile Ala Met Pro Val Pro Val Ile Val Asn Asn Phe Gly Met Tyr Tyr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Ser Leu Ala Met Ala Lys Gln Lys Leu Pro Arg Lys Arg Lys Lys His  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ile Pro Pro Ala Pro Gln Ala Ser Ser Pro Thr Phe Cys Lys Thr Glu  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Leu Asn Met Ala Cys Asn Ser Thr Gln Ser Asp Thr Cys Leu Gly Lys  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Asp Asn Arg Leu Leu Glu His Asn Arg Ser Val Leu Ser Gly Asp Asp  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Ser Thr Gly Ser Glu Pro Pro Leu Ser Pro Pro Glu Arg Leu Pro Ile  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Arg Arg Ser Ser Thr Arg Asp Lys Asn Arg Arg Gly Glu Thr Cys Phe  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Leu Leu Thr Thr Gly Asp Tyr Thr Cys Ala Ser Asp Gly Gly Ile Arg  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Lys Asp Asn Cys Lys Glu Val Val Ile Thr Gly Tyr Thr Gln Ala Glu  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Ala Arg Ser Leu Thr  
               
               
                     610  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 21  
               
               
                 &lt;211&gt; LENGTH: 1193  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (105)..(1142)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 21  
               
               
                   
               
               
                 tgctccctgt ttcattaaaa cctagagaga tgtaatcagt aagcaagaag gaaaaaggga     60  
               
               
                   
               
               
                 aattcacaaa gtaacttttt gtgtctgttt ctttttaacc cagc atg gag aga aaa     116  
               
               
                                                                  Met Glu Arg Lys  
               
               
                                                                  1  
               
               
                   
               
               
                 ttt atg tcc ttg caa cca tcc atc tcc gta tca gaa atg gaa cca aat      164  
               
               
                 Phe Met Ser Leu Gln Pro Ser Ile Ser Val Ser Glu Met Glu Pro Asn  
               
               
                 5                   10                  15                  20  
               
               
                   
               
               
                 ggc acc ttc agc aat aac aac agc agg aac tgc aca att gaa aac ttc      212  
               
               
                 Gly Thr Phe Ser Asn Asn Asn Ser Arg Asn Cys Thr Ile Glu Asn Phe  
               
               
                                 25                  30                  35  
               
               
                   
               
               
                 aag aga gaa ttt ttc cca att gta tat ctg ata ata ttt ttc tgg gga      260  
               
               
                 Lys Arg Glu Phe Phe Pro Ile Val Tyr Leu Ile Ile Phe Phe Trp Gly  
               
               
                             40                  45                  50  
               
               
                   
               
               
                 gtc ttg gga aat ggg ttg tcc ata tat gtt ttc ctg cag cct tat aag      308  
               
               
                 Val Leu Gly Asn Gly Leu Ser Ile Tyr Val Phe Leu Gln Pro Tyr Lys  
               
               
                         55                  60                  65  
               
               
                   
               
               
                 aag tcc aca tct gtg aac gtt ttc atg cta aat ctg gcc att tca gat      356  
               
               
                 Lys Ser Thr Ser Val Asn Val Phe Met Leu Asn Leu Ala Ile Ser Asp  
               
               
                     70                  75                  80  
               
               
                   
               
               
                 ctc ctg ttc ata agc acg ctt ccc ttc agg gct gac tat tat ctt aga      404  
               
               
                 Leu Leu Phe Ile Ser Thr Leu Pro Phe Arg Ala Asp Tyr Tyr Leu Arg  
               
               
                 85                  90                  95                 100  
               
               
                   
               
               
                 ggc tcc aat tgg ata ttt gga gac ctg gcc tgc agg att atg tct tat      452  
               
               
                 Gly Ser Asn Trp Ile Phe Gly Asp Leu Ala Cys Arg Ile Met Ser Tyr  
               
               
                                 105                 110                 115  
               
               
                   
               
               
                 tcc ttg tat gtc aac atg tac agc agt att tat ttc ctg acc gtg ctg      500  
               
               
                 Ser Leu Tyr Val Asn Met Tyr Ser Ser Ile Tyr Phe Leu Thr Val Leu  
               
               
                             120                 125                 130  
               
               
                   
               
               
                 agt gtt gtg cgt ttc ctg gca atg gtt cac ccc ttt cgg ctt ctg cat      548  
               
               
                 Ser Val Val Arg Phe Leu Ala Met Val His Pro Phe Arg Leu Leu His  
               
               
                         135                 140                 145  
               
               
                   
               
               
                 gtc acc agc atc agg agt gcc tgg atc ctc tgt ggg atc ata tgg atc      596  
               
               
                 Val Thr Ser Ile Arg Ser Ala Trp Ile Leu Cys Gly Ile Ile Trp Ile  
               
               
                     150                 155                 160  
               
               
                   
               
               
                 ctt atc atg gct tcc tca ata atg ctc ctg gac agt ggc tct gag cag      644  
               
               
                 Leu Ile Met Ala Ser Ser Ile Met Leu Leu Asp Ser Gly Ser Glu Gln  
               
               
                 165                 170                 175                 180  
               
               
                   
               
               
                 aac ggc agt gtc aca tca tgc tta gag ctg aat ctc tat aaa att gct      692  
               
               
                 Asn Gly Ser Val Thr Ser Cys Leu Glu Leu Asn Leu Tyr Lys Ile Ala  
               
               
                                 185                 190                 195  
               
               
                   
               
               
                 aag ctg cag acc atg aac tat att gcc ttg gtg gtg ggc tgc ctg ctg      740  
               
               
                 Lys Leu Gln Thr Met Asn Tyr Ile Ala Leu Val Val Gly Cys Leu Leu  
               
               
                             200                 205                 210  
               
               
                   
               
               
                 cca ttt ttc aca ctc agc atc tgt tat ctg ctg atc att cgg gtt ctg      788  
               
               
                 Pro Phe Phe Thr Leu Ser Ile Cys Tyr Leu Leu Ile Ile Arg Val Leu  
               
               
                         215                 220                 225  
               
               
                   
               
               
                 tta aaa gtg gag gtc cca gaa tcg ggg ctg cgg gtt tct cac agg aag      836  
               
               
                 Leu Lys Val Glu Val Pro Glu Ser Gly Leu Arg Val Ser His Arg Lys  
               
               
                     230                 235                 240  
               
               
                   
               
               
                 gca ctg acc acc atc atc atc acc ttg atc atc ttc ttc ttg tgt ttc      884  
               
               
                 Ala Leu Thr Thr Ile Ile Ile Thr Leu Ile Ile Phe Phe Leu Cys Phe  
               
               
                 245                 250                 255                 260  
               
               
                   
               
               
                 ctg ccc tat cac aca ctg agg acc gtc cac ttg acg aca tgg aaa gtg      932  
               
               
                 Leu Pro Tyr His Thr Leu Arg Thr Val His Leu Thr Thr Trp Lys Val  
               
               
                                 265                 270                 275  
               
               
                   
               
               
                 ggt tta tgc aaa gac aga ctg cat aaa gct ttg gtt atc aca ctg gcc      980  
               
               
                 Gly Leu Cys Lys Asp Arg Leu His Lys Ala Leu Val Ile Thr Leu Ala  
               
               
                             280                 285                 290  
               
               
                   
               
               
                 ttg gca gca gcc aat gcc tgc ttc aat cct ctg ctc tat tac ttt gct     1028  
               
               
                 Leu Ala Ala Ala Asn Ala Cys Phe Asn Pro Leu Leu Tyr Tyr Phe Ala  
               
               
                         295                 300                 305  
               
               
                   
               
               
                 ggg gag aat ttt aag gac aga cta aag tct gca ctc aga aaa ggc cat     1076  
               
               
                 Gly Glu Asn Phe Lys Asp Arg Leu Lys Ser Ala Leu Arg Lys Gly His  
               
               
                     310                 315                 320  
               
               
                   
               
               
                 cca cag aag gca aag aca aag tgt gtt ttc cct gtt agt gtg tgg ttg     1124  
               
               
                 Pro Gln Lys Ala Lys Thr Lys Cys Val Phe Pro Val Ser Val Trp Leu  
               
               
                 325                 330                 335                 340  
               
               
                   
               
               
                 aga aag gaa aca aga gta taaggagctc ttagatgaga cctgttcttg            1172  
               
               
                 Arg Lys Glu Thr Arg Val  
               
               
                                 345  
               
               
                   
               
               
                 tatccttgtg tccatcttca t                                             1193  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 22  
               
               
                 &lt;211&gt; LENGTH: 346  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 22  
               
               
                   
               
               
                 Met Glu Arg Lys Phe Met Ser Leu Gln Pro Ser Ile Ser Val Ser Glu  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Met Glu Pro Asn Gly Thr Phe Ser Asn Asn Asn Ser Arg Asn Cys Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ile Glu Asn Phe Lys Arg Glu Phe Phe Pro Ile Val Tyr Leu Ile Ile  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Phe Phe Trp Gly Val Leu Gly Asn Gly Leu Ser Ile Tyr Val Phe Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Gln Pro Tyr Lys Lys Ser Thr Ser Val Asn Val Phe Met Leu Asn Leu  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ala Ile Ser Asp Leu Leu Phe Ile Ser Thr Leu Pro Phe Arg Ala Asp  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Tyr Tyr Leu Arg Gly Ser Asn Trp Ile Phe Gly Asp Leu Ala Cys Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ile Met Ser Tyr Ser Leu Tyr Val Asn Met Tyr Ser Ser Ile Tyr Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Thr Val Leu Ser Val Val Arg Phe Leu Ala Met Val His Pro Phe  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Arg Leu Leu His Val Thr Ser Ile Arg Ser Ala Trp Ile Leu Cys Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ile Ile Trp Ile Leu Ile Met Ala Ser Ser Ile Met Leu Leu Asp Ser  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Ser Glu Gln Asn Gly Ser Val Thr Ser Cys Leu Glu Leu Asn Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Tyr Lys Ile Ala Lys Leu Gln Thr Met Asn Tyr Ile Ala Leu Val Val  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Gly Cys Leu Leu Pro Phe Phe Thr Leu Ser Ile Cys Tyr Leu Leu Ile  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ile Arg Val Leu Leu Lys Val Glu Val Pro Glu Ser Gly Leu Arg Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Ser His Arg Lys Ala Leu Thr Thr Ile Ile Ile Thr Leu Ile Ile Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Phe Leu Cys Phe Leu Pro Tyr His Thr Leu Arg Thr Val His Leu Thr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Thr Trp Lys Val Gly Leu Cys Lys Asp Arg Leu His Lys Ala Leu Val  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ile Thr Leu Ala Leu Ala Ala Ala Asn Ala Cys Phe Asn Pro Leu Leu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Tyr Phe Ala Gly Glu Asn Phe Lys Asp Arg Leu Lys Ser Ala Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Arg Lys Gly His Pro Gln Lys Ala Lys Thr Lys Cys Val Phe Pro Val  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Val Trp Leu Arg Lys Glu Thr Arg Val  
               
               
                             340                 345  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 23  
               
               
                 &lt;211&gt; LENGTH: 1260  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (105)..(1142)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 23  
               
               
                   
               
               
                 tgctccctgt ttcattaaaa cctagagaga tgtaatcagt aagcaagaag gaaaaaggga     60  
               
               
                   
               
               
                 aattcacaaa gtaacttttt gtgtctgttt ctttttaacc cagc atg gag aga aaa     116  
               
               
                                                                  Met Glu Arg Lys  
               
               
                                                                  1  
               
               
                   
               
               
                 ttt atg tcc ttg caa cca tcc atc tcc gta tca gaa atg gaa cca aat      164  
               
               
                 Phe Met Ser Leu Gln Pro Ser Ile Ser Val Ser Glu Met Glu Pro Asn  
               
               
                 5                   10                  15                  20  
               
               
                   
               
               
                 ggc acc ttc agc aat aac aac agc agg aac tgc aca att gaa aac ttc      212  
               
               
                 Gly Thr Phe Ser Asn Asn Asn Ser Arg Asn Cys Thr Ile Glu Asn Phe  
               
               
                                 25                  30                  35  
               
               
                   
               
               
                 aag aga gaa ttt ttc cca att gta tat ctg ata ata ttt ttc tgg gga      260  
               
               
                 Lys Arg Glu Phe Phe Pro Ile Val Tyr Leu Ile Ile Phe Phe Trp Gly  
               
               
                             40                  45                  50  
               
               
                   
               
               
                 gtc ttg gga aat ggg ttg tcc ata tat gtt ttc ctg cag cct tat aag      308  
               
               
                 Val Leu Gly Asn Gly Leu Ser Ile Tyr Val Phe Leu Gln Pro Tyr Lys  
               
               
                         55                  60                  65  
               
               
                   
               
               
                 aag tcc aca tct gtg aac gtt ttc atg cta aat ctg gcc att tca gat      356  
               
               
                 Lys Ser Thr Ser Val Asn Val Phe Met Leu Asn Leu Ala Ile Ser Asp  
               
               
                     70                  75                  80  
               
               
                   
               
               
                 ctc ctg ttc ata agc acg ctt ccc ttc agg gct gac tat tat ctt aga      404  
               
               
                 Leu Leu Phe Ile Ser Thr Leu Pro Phe Arg Ala Asp Tyr Tyr Leu Arg  
               
               
                 85                  90                  95                  100  
               
               
                   
               
               
                 ggc tcc aat tgg ata ttt gga gac ctg gcc tgc agg att atg tct tat      452  
               
               
                 Gly Ser Asn Trp Ile Phe Gly Asp Leu Ala Cys Arg Ile Met Ser Tyr  
               
               
                                 105                 110                 115  
               
               
                   
               
               
                 tcc ttg tat gtc aac atg tac agc agt att tat ttc ctg acc gtg ctg      500  
               
               
                 Ser Leu Tyr Val Asn Met Tyr Ser Ser Ile Tyr Phe Leu Thr Val Leu  
               
               
                             120                 125                 130  
               
               
                   
               
               
                 agt gtt gtg cgt ttc ctg gca atg gtt cac ccc ttt cgg ctt ctg cat      548  
               
               
                 Ser Val Val Arg Phe Leu Ala Met Val His Pro Phe Arg Leu Leu His  
               
               
                         135                 140                 145  
               
               
                   
               
               
                 gtc acc agc atc agg agt gcc tgg atc ctc tgt ggg atc ata tgg atc      596  
               
               
                 Val Thr Ser Ile Arg Ser Ala Trp Ile Leu Cys Gly Ile Ile Trp Ile  
               
               
                     150                 155                 160  
               
               
                   
               
               
                 ctt atc atg gct tcc tca ata atg ctc ctg gac agt ggc tct gag cag      644  
               
               
                 Leu Ile Met Ala Ser Ser Ile Met Leu Leu Asp Ser Gly Ser Glu Gln  
               
               
                 165                 170                 175                 180  
               
               
                   
               
               
                 aac ggc agt gtc aca tca tgc tta gag ctg aat ctc tat aaa att gct      692  
               
               
                 Asn Gly Ser Val Thr Ser Cys Leu Glu Leu Asn Leu Tyr Lys Ile Ala  
               
               
                                 185                 190                 195  
               
               
                   
               
               
                 aag ctg cag acc atg aac tat att gcc ttg gtg gtg ggc tgc ctg ctg      740  
               
               
                 Lys Leu Gln Thr Met Asn Tyr Ile Ala Leu Val Val Gly Cys Leu Leu  
               
               
                             200                 205                 210  
               
               
                   
               
               
                 cca ttt ttc aca ctc agc atc tgt tat ctg ctg atc att cgg gtt ctg      788  
               
               
                 Pro Phe Phe Thr Leu Ser Ile Cys Tyr Leu Leu Ile Ile Arg Val Leu  
               
               
                         215                 220                 225  
               
               
                   
               
               
                 tta aaa gtg gag gtc cca gaa tcg ggg ctg cgg gtt tct cac agg aag      836  
               
               
                 Leu Lys Val Glu Val Pro Glu Ser Gly Leu Arg Val Ser His Arg Lys  
               
               
                     230                 235                 240  
               
               
                   
               
               
                 gca ctg acc acc atc atc atc acc ttg atc atc ttc ttc ttg tgt ttc      884  
               
               
                 Ala Leu Thr Thr Ile Ile Ile Thr Leu Ile Ile Phe Phe Leu Cys Phe  
               
               
                 245                 250                 255                 260  
               
               
                   
               
               
                 ctg ccc tat cac aca ctg agg acc gtc cac ttg acg aca tgg aaa gtg      932  
               
               
                 Leu Pro Tyr His Thr Leu Arg Thr Val His Leu Thr Thr Trp Lys Val  
               
               
                                 265                 270                 275  
               
               
                   
               
               
                 ggt tta tgc aaa gac aga ctg cat aaa gct ttg gtt atc aca ctg gcc      980  
               
               
                 Gly Leu Cys Lys Asp Arg Leu His Lys Ala Leu Val Ile Thr Leu Ala  
               
               
                             280                 285                 290  
               
               
                   
               
               
                 ttg gca gca gcc aat gcc tgc ttc aat cct ctg ctc tat tac ttt gct     1028  
               
               
                 Leu Ala Ala Ala Asn Ala Cys Phe Asn Pro Leu Leu Tyr Tyr Phe Ala  
               
               
                         295                 300                 305  
               
               
                   
               
               
                 ggg gag aat ttt aag gac aga cta aag tct gca ctc aga aaa ggc cat     1076  
               
               
                 Gly Glu Asn Phe Lys Asp Arg Leu Lys Ser Ala Leu Arg Lys Gly His  
               
               
                     310                 315                 320  
               
               
                   
               
               
                 cca cag aag gca aag aca aag tgt gtt ttc cct gtt agt gtg tgg ttg     1124  
               
               
                 Pro Gln Lys Ala Lys Thr Lys Cys Val Phe Pro Val Ser Val Trp Leu  
               
               
                 325                 330                 335                 340  
               
               
                   
               
               
                 aga aag gaa aca aga gta taaggagctc ttagatgaga cctgttcttg            1172  
               
               
                 Arg Lys Glu Thr Arg Val  
               
               
                                 345  
               
               
                   
               
               
                 tatccttgtg tccatcttca ttcactcata gtctccaaat gactttgtat ttacatcact   1232  
               
               
                   
               
               
                 cccaacaaat gttgattctt aatattta                                      1260  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 24  
               
               
                 &lt;211&gt; LENGTH: 346  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 24  
               
               
                   
               
               
                 Met Glu Arg Lys Phe Met Ser Leu Gln Pro Ser Ile Ser Val Ser Glu  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Met Glu Pro Asn Gly Thr Phe Ser Asn Asn Asn Ser Arg Asn Cys Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ile Glu Asn Phe Lys Arg Glu Phe Phe Pro Ile Val Tyr Leu Ile Ile  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Phe Phe Trp Gly Val Leu Gly Asn Gly Leu Ser Ile Tyr Val Phe Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Gln Pro Tyr Lys Lys Ser Thr Ser Val Asn Val Phe Met Leu Asn Leu  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ala Ile Ser Asp Leu Leu Phe Ile Ser Thr Leu Pro Phe Arg Ala Asp  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Tyr Tyr Leu Arg Gly Ser Asn Trp Ile Phe Gly Asp Leu Ala Cys Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ile Met Ser Tyr Ser Leu Tyr Val Asn Met Tyr Ser Ser Ile Tyr Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Thr Val Leu Ser Val Val Arg Phe Leu Ala Met Val His Pro Phe  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Arg Leu Leu His Val Thr Ser Ile Arg Ser Ala Trp Ile Leu Cys Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ile Ile Trp Ile Leu Ile Met Ala Ser Ser Ile Met Leu Leu Asp Ser  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Ser Glu Gln Asn Gly Ser Val Thr Ser Cys Leu Glu Leu Asn Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Tyr Lys Ile Ala Lys Leu Gln Thr Met Asn Tyr Ile Ala Leu Val Val  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Gly Cys Leu Leu Pro Phe Phe Thr Leu Ser Ile Cys Tyr Leu Leu Ile  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ile Arg Val Leu Leu Lys Val Glu Val Pro Glu Ser Gly Leu Arg Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Ser His Arg Lys Ala Leu Thr Thr Ile Ile Ile Thr Leu Ile Ile Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Phe Leu Cys Phe Leu Pro Tyr His Thr Leu Arg Thr Val His Leu Thr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Thr Trp Lys Val Gly Leu Cys Lys Asp Arg Leu His Lys Ala Leu Val  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ile Thr Leu Ala Leu Ala Ala Ala Asn Ala Cys Phe Asn Pro Leu Leu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Tyr Phe Ala Gly Glu Asn Phe Lys Asp Arg Leu Lys Ser Ala Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Arg Lys Gly His Pro Gln Lys Ala Lys Thr Lys Cys Val Phe Pro Val  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Val Trp Leu Arg Lys Glu Thr Arg Val  
               
               
                             340                 345  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 25  
               
               
                 &lt;211&gt; LENGTH: 1358  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (5)..(1348)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 25  
               
               
                   
               
               
                 agtg atg gat gtt aac agc agc ggc cac ccg gac ctc tac ggg cgc ctc      49  
               
               
                      Met Asp Val Asn Ser Ser Gly His Pro Asp Leu Tyr Gly Arg Leu  
               
               
                      1               5                   10                  15  
               
               
                   
               
               
                 tgc tct ttc ctc ctg ccg gag gtg ggg ggc agg ctg ccc gac ctg agc       97  
               
               
                 Cys Ser Phe Leu Leu Pro Glu Val Gly Gly Arg Leu Pro Asp Leu Ser  
               
               
                                 20                  25                  30  
               
               
                   
               
               
                 ccc gac ggt ggc gcc gaa ccg gtc gcg gtc tcc ggg acg ccg cat ctg      145  
               
               
                 Pro Asp Gly Gly Ala Glu Pro Val Ala Val Ser Gly Thr Pro His Leu  
               
               
                             35                  40                  45  
               
               
                   
               
               
                 ctg agc gag gtg acg gcc agc ccg gcg ccc acc tgg gac gca acc ccg      193  
               
               
                 Leu Ser Glu Val Thr Ala Ser Pro Ala Pro Thr Trp Asp Ala Thr Pro  
               
               
                         50                  55                  60  
               
               
                   
               
               
                 ggc aat gcc tcc ggc cgc ggg gag caa atc aat caa gaa agg gcc gag      241  
               
               
                 Gly Asn Ala Ser Gly Arg Gly Glu Gln Ile Asn Gln Glu Arg Ala Glu  
               
               
                     65                  70                  75  
               
               
                   
               
               
                 aaa gtt gtg atc ggc tct gtc ctg acg ctc atc tct ctg tct gcg atc      289  
               
               
                 Lys Val Val Ile Gly Ser Val Leu Thr Leu Ile Ser Leu Ser Ala Ile  
               
               
                 80                  85                  90                  95  
               
               
                   
               
               
                 gcg ggc aac tgc ctg gtg gta atc tct gtg tgc ttc gtc aag aag ctc      337  
               
               
                 Ala Gly Asn Cys Leu Val Val Ile Ser Val Cys Phe Val Lys Lys Leu  
               
               
                                 100                 105                 110  
               
               
                   
               
               
                 cgc cag ccc tcc aac tac ctc atc gtg tcc atg gcg ctg gcc aac ctc      385  
               
               
                 Arg Gln Pro Ser Asn Tyr Leu Ile Val Ser Met Ala Leu Ala Asn Leu  
               
               
                             115                 120                 125  
               
               
                   
               
               
                 tcg gtg gcc atg gcg gtc atg ccc ttc atc agt gtc acc gac ctc atc      433  
               
               
                 Ser Val Ala Met Ala Val Met Pro Phe Ile Ser Val Thr Asp Leu Ile  
               
               
                         130                 135                 140  
               
               
                   
               
               
                 ggg ggc aag tgg atc ttt gga cac ttt ttc tgt aac gtc ttc tcc gtg      481  
               
               
                 Gly Gly Lys Trp Ile Phe Gly His Phe Phe Cys Asn Val Phe Ser Val  
               
               
                     145                 150                 155  
               
               
                   
               
               
                 aat gtc atg tgc tgc acg gcc tgg atc ttg acc ttg tac gtg atc agc      529  
               
               
                 Asn Val Met Cys Cys Thr Ala Trp Ile Leu Thr Leu Tyr Val Ile Ser  
               
               
                 160                 165                 170                 175  
               
               
                   
               
               
                 atc gac agg gac ctt ggg atc atg aag cct ctc acg tac cct atg agg      577  
               
               
                 Ile Asp Arg Asp Leu Gly Ile Met Lys Pro Leu Thr Tyr Pro Met Arg  
               
               
                                 180                 185                 190  
               
               
                   
               
               
                 cag aag ggg aaa tgc atg acg aag atg att ctt tct gtc tgc ctt ctt      625  
               
               
                 Gln Lys Gly Lys Cys Met Thr Lys Met Ile Leu Ser Val Cys Leu Leu  
               
               
                             195                 200                 205  
               
               
                   
               
               
                 tcc gcc ttt gtc act tta cct acc att ttt ggt cgg gct cag aat gta      673  
               
               
                 Ser Ala Phe Val Thr Leu Pro Thr Ile Phe Gly Arg Ala Gln Asn Val  
               
               
                         210                 215                 220  
               
               
                   
               
               
                 aac gat gat aag gtg tgc ttg gtc aat caa gac ttt ggc tac acg att      721  
               
               
                 Asn Asp Asp Lys Val Cys Leu Val Asn Gln Asp Phe Gly Tyr Thr Ile  
               
               
                     225                 230                 235  
               
               
                   
               
               
                 tac tcc ccg cat ttg gca gca ttt atc ccc atg tgc gtc atg ctt ttc      769  
               
               
                 Tyr Ser Pro His Leu Ala Ala Phe Ile Pro Met Cys Val Met Leu Phe  
               
               
                 240                 245                 250                 255  
               
               
                   
               
               
                 atg tac tat cag att tac aag gcc gcc agg aaa agc gcg gcc aaa cac      817  
               
               
                 Met Tyr Tyr Gln Ile Tyr Lys Ala Ala Arg Lys Ser Ala Ala Lys His  
               
               
                                 260                 265                 270  
               
               
                   
               
               
                 agg tta cct ggc ttc cct cga gtg gag cca gac agc gta gtc acc ctg      865  
               
               
                 Arg Leu Pro Gly Phe Pro Arg Val Glu Pro Asp Ser Val Val Thr Leu  
               
               
                             275                 280                 285  
               
               
                   
               
               
                 aat ggc aca gtg aag ttc cag gag gtg gaa gag tgt gca aac ctt tcg      913  
               
               
                 Asn Gly Thr Val Lys Phe Gln Glu Val Glu Glu Cys Ala Asn Leu Ser  
               
               
                         290                 295                 300  
               
               
                   
               
               
                 aga ctc ctc aag cat gaa agg aaa aat atc tcc atc ttt aag cgg aaa      961  
               
               
                 Arg Leu Leu Lys His Glu Arg Lys Asn Ile Ser Ile Phe Lys Arg Lys  
               
               
                     305                 310                 315  
               
               
                   
               
               
                 cag aaa gca gcg act acc ttg ggg atc atc gtc tgg gcc tcc acc atg     1009  
               
               
                 Gln Lys Ala Ala Thr Thr Leu Gly Ile Ile Val Trp Ala Ser Thr Met  
               
               
                 320                 325                 330                 335  
               
               
                   
               
               
                 tgc tgg ccg ccc ttt ttc ctc ctg aca gcc aga ccc ttc tgt cta tgg     1057  
               
               
                 Cys Trp Pro Pro Phe Phe Leu Leu Thr Ala Arg Pro Phe Cys Leu Trp  
               
               
                                 340                 345                 350  
               
               
                   
               
               
                 cac tgc cct tct gtc tat ggc act gcc tgc agc tgc atc cca ctg tgg     1105  
               
               
                 His Cys Pro Ser Val Tyr Gly Thr Ala Cys Ser Cys Ile Pro Leu Trp  
               
               
                             355                 360                 365  
               
               
                   
               
               
                 gtg gag agg ata ttt cca tgg ctg ggc tat gca aac tct ctc att aac     1153  
               
               
                 Val Glu Arg Ile Phe Pro Trp Leu Gly Tyr Ala Asn Ser Leu Ile Asn  
               
               
                         370                 375                 380  
               
               
                   
               
               
                 cct ttt att tat gcc ttc ttc aac tgg gac ctg agg acc acc tat tgc     1201  
               
               
                 Pro Phe Ile Tyr Ala Phe Phe Asn Trp Asp Leu Arg Thr Thr Tyr Cys  
               
               
                     385                 390                 395  
               
               
                   
               
               
                 agc cgg ctc cag tgc cag tac cag aat atc aac cag aca ctc tca gct     1249  
               
               
                 Ser Arg Leu Gln Cys Gln Tyr Gln Asn Ile Asn Gln Thr Leu Ser Ala  
               
               
                 400                 405                 410                 415  
               
               
                   
               
               
                 gca ggc atg cat gaa gcc ctg aag ctt gct gag agg cca gag aga cct     1297  
               
               
                 Ala Gly Met His Glu Ala Leu Lys Leu Ala Glu Arg Pro Glu Arg Pro  
               
               
                                 420                 425                 430  
               
               
                   
               
               
                 gag ttt gtc cta caa aac tct gac tac tgt aga aaa aaa agt cat gat     1345  
               
               
                 Glu Phe Val Leu Gln Asn Ser Asp Tyr Cys Arg Lys Lys Ser His Asp  
               
               
                             435                 440                 445  
               
               
                   
               
               
                 tca tgactgaaag                                                      1358  
               
               
                 Ser  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 26  
               
               
                 &lt;211&gt; LENGTH: 448  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 26  
               
               
                   
               
               
                 Met Asp Val Asn Ser Ser Gly His Pro Asp Leu Tyr Gly Arg Leu Cys  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Ser Phe Leu Leu Pro Glu Val Gly Gly Arg Leu Pro Asp Leu Ser Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Asp Gly Gly Ala Glu Pro Val Ala Val Ser Gly Thr Pro His Leu Leu  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ser Glu Val Thr Ala Ser Pro Ala Pro Thr Trp Asp Ala Thr Pro Gly  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asn Ala Ser Gly Arg Gly Glu Gln Ile Asn Gln Glu Arg Ala Glu Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Val Val Ile Gly Ser Val Leu Thr Leu Ile Ser Leu Ser Ala Ile Ala  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Gly Asn Cys Leu Val Val Ile Ser Val Cys Phe Val Lys Lys Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Gln Pro Ser Asn Tyr Leu Ile Val Ser Met Ala Leu Ala Asn Leu Ser  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Val Ala Met Ala Val Met Pro Phe Ile Ser Val Thr Asp Leu Ile Gly  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Gly Lys Trp Ile Phe Gly His Phe Phe Cys Asn Val Phe Ser Val Asn  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Val Met Cys Cys Thr Ala Trp Ile Leu Thr Leu Tyr Val Ile Ser Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Asp Arg Asp Leu Gly Ile Met Lys Pro Leu Thr Tyr Pro Met Arg Gln  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Lys Gly Lys Cys Met Thr Lys Met Ile Leu Ser Val Cys Leu Leu Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ala Phe Val Thr Leu Pro Thr Ile Phe Gly Arg Ala Gln Asn Val Asn  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Asp Asp Lys Val Cys Leu Val Asn Gln Asp Phe Gly Tyr Thr Ile Tyr  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Ser Pro His Leu Ala Ala Phe Ile Pro Met Cys Val Met Leu Phe Met  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Tyr Tyr Gln Ile Tyr Lys Ala Ala Arg Lys Ser Ala Ala Lys His Arg  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Leu Pro Gly Phe Pro Arg Val Glu Pro Asp Ser Val Val Thr Leu Asn  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Gly Thr Val Lys Phe Gln Glu Val Glu Glu Cys Ala Asn Leu Ser Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Leu Leu Lys His Glu Arg Lys Asn Ile Ser Ile Phe Lys Arg Lys Gln  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Lys Ala Ala Thr Thr Leu Gly Ile Ile Val Trp Ala Ser Thr Met Cys  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Trp Pro Pro Phe Phe Leu Leu Thr Ala Arg Pro Phe Cys Leu Trp His  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Cys Pro Ser Val Tyr Gly Thr Ala Cys Ser Cys Ile Pro Leu Trp Val  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Glu Arg Ile Phe Pro Trp Leu Gly Tyr Ala Asn Ser Leu Ile Asn Pro  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Phe Ile Tyr Ala Phe Phe Asn Trp Asp Leu Arg Thr Thr Tyr Cys Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Arg Leu Gln Cys Gln Tyr Gln Asn Ile Asn Gln Thr Leu Ser Ala Ala  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Met His Glu Ala Leu Lys Leu Ala Glu Arg Pro Glu Arg Pro Glu  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Phe Val Leu Gln Asn Ser Asp Tyr Cys Arg Lys Lys Ser His Asp Ser  
               
               
                         435                 440                 445  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 27  
               
               
                 &lt;211&gt; LENGTH: 1173  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (55)..(1023)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 27  
               
               
                   
               
               
                 aatatagccg gtcctgtccc cgtgttaact ggagtgctga agcgctggaa cgaa atg       57  
               
               
                                                                             Met  
               
               
                                                                             1  
               
               
                   
               
               
                 cgg ggc ctc tgg tgc gag aag ggg gtg cag gtg ctg ctg acg acg gtg      105  
               
               
                 Arg Gly Leu Trp Cys Glu Lys Gly Val Gln Val Leu Leu Thr Thr Val  
               
               
                             5                   10                  15  
               
               
                   
               
               
                 ggc gcc ttc gcc gcc ttc ggc ctc atg acc atc gcc atc agc act gac      153  
               
               
                 Gly Ala Phe Ala Ala Phe Gly Leu Met Thr Ile Ala Ile Ser Thr Asp  
               
               
                         20                  25                  30  
               
               
                   
               
               
                 tac tgg ctc tac acg ggg caa caa gag cga aaa tct gtc tca aaa aat      201  
               
               
                 Tyr Trp Leu Tyr Thr Gly Gln Gln Glu Arg Lys Ser Val Ser Lys Asn  
               
               
                     35                  40                  45  
               
               
                   
               
               
                 aaa aga agt aag aag gac ccc ggc ggc ctc acg cac tcg ggc ctc tgg      249  
               
               
                 Lys Arg Ser Lys Lys Asp Pro Gly Gly Leu Thr His Ser Gly Leu Trp  
               
               
                 50                  55                  60                  65  
               
               
                   
               
               
                 agg atc tgc tgc ctg gaa ggg ttg aaa aga ggc gtc tgc gtg aag atc      297  
               
               
                 Arg Ile Cys Cys Leu Glu Gly Leu Lys Arg Gly Val Cys Val Lys Ile  
               
               
                                 70                  75                  80  
               
               
                   
               
               
                 aat cat ttc ccg gag gac acg gac tac gac cac gac agc gcg gag tat      345  
               
               
                 Asn His Phe Pro Glu Asp Thr Asp Tyr Asp His Asp Ser Ala Glu Tyr  
               
               
                             85                  90                  95  
               
               
                   
               
               
                 cta ctc cgt acg gtc cgg gcc tcc agc atc ttc ccc atc ctt agc gcc      393  
               
               
                 Leu Leu Arg Thr Val Arg Ala Ser Ser Ile Phe Pro Ile Leu Ser Ala  
               
               
                         100                 105                 110  
               
               
                   
               
               
                 atc ctg ctg ctg ctc ggg ggt gtg tgc gtg gcg gcc tcc cgc gtc tac      441  
               
               
                 Ile Leu Leu Leu Leu Gly Gly Val Cys Val Ala Ala Ser Arg Val Tyr  
               
               
                     115                 120                 125  
               
               
                   
               
               
                 aag tcc aag agg aac atc att ctg ggc gca ggg atc ctg ttc gtg gca      489  
               
               
                 Lys Ser Lys Arg Asn Ile Ile Leu Gly Ala Gly Ile Leu Phe Val Ala  
               
               
                 130                 135                 140                 145  
               
               
                   
               
               
                 gca ggt ctg agc aac atc atc ggc gtg atc gtg tac atc tcc gcc aac      537  
               
               
                 Ala Gly Leu Ser Asn Ile Ile Gly Val Ile Val Tyr Ile Ser Ala Asn  
               
               
                                 150                 155                 160  
               
               
                   
               
               
                 gcg ggc gag ccg ggc cga agc aga gcc aag aaa aac cac tac tcg tac      585  
               
               
                 Ala Gly Glu Pro Gly Arg Ser Arg Ala Lys Lys Asn His Tyr Ser Tyr  
               
               
                             165                 170                 175  
               
               
                   
               
               
                 ggc tgg tcc ttc tac ttc ggc ggg ctg tcg ttc atc ctg gcc gag gtg      633  
               
               
                 Gly Trp Ser Phe Tyr Phe Gly Gly Leu Ser Phe Ile Leu Ala Glu Val  
               
               
                         180                 185                 190  
               
               
                   
               
               
                 ata ggc gtg ctg gcc gtc aac atc tac atc gag cca gcc gag gcg cac      681  
               
               
                 Ile Gly Val Leu Ala Val Asn Ile Tyr Ile Glu Pro Ala Glu Ala His  
               
               
                     195                 200                 205  
               
               
                   
               
               
                 tgc cag tct cgg agc ggg acc gcg ggg ggt cgt ccg gct tcc tca cgc      729  
               
               
                 Cys Gln Ser Arg Ser Gly Thr Ala Gly Gly Arg Pro Ala Ser Ser Arg  
               
               
                 210                 215                 220                 225  
               
               
                   
               
               
                 tgc aca acg cct tcc cca agg agg cgg gcg gcg gcg tca cgg tca cgt      777  
               
               
                 Cys Thr Thr Pro Ser Pro Arg Arg Arg Ala Ala Ala Ser Arg Ser Arg  
               
               
                                 230                 235                 240  
               
               
                   
               
               
                 tca ccc ggc cgc ccg ccc cgc ccg cgc cac gcc acc ccg gcc aac acc      825  
               
               
                 Ser Pro Gly Arg Pro Pro Arg Pro Arg His Ala Thr Pro Ala Asn Thr  
               
               
                             245                 250                 255  
               
               
                   
               
               
                 aac tcc acg gac atc tcc atg tac acg ctc agc cgc gac ccc tcc aag      873  
               
               
                 Asn Ser Thr Asp Ile Ser Met Tyr Thr Leu Ser Arg Asp Pro Ser Lys  
               
               
                         260                 265                 270  
               
               
                   
               
               
                 ggc agc ccc cat tcc aat gcc acc acc ccc acc ccc act agc ctc aag      921  
               
               
                 Gly Ser Pro His Ser Asn Ala Thr Thr Pro Thr Pro Thr Ser Leu Lys  
               
               
                     275                 280                 285  
               
               
                   
               
               
                 gat agg aaa aac tca ttt gtg tcc ata aaa ata aag gta aaa aag aaa      969  
               
               
                 Asp Arg Lys Asn Ser Phe Val Ser Ile Lys Ile Lys Val Lys Lys Lys  
               
               
                 290                 295                 300                 305  
               
               
                   
               
               
                 aaa aga aat ata tat ata tat ata tat acg ctc aac agg aaa acc acg     1017  
               
               
                 Lys Arg Asn Ile Tyr Ile Tyr Ile Tyr Thr Leu Asn Arg Lys Thr Thr  
               
               
                                 310                 315                 320  
               
               
                   
               
               
                 cct gtg taggggcgcg gcgggggagc cgaggggcgt gtccggggcg cgtgcgggcg      1073  
               
               
                 Pro Val  
               
               
                   
               
               
                 cgcgtgcatc gaggctgccg gggtcggggg cgcccccgct ttcccccgtg agcgcgctgg   1133  
               
               
                   
               
               
                 agactgctgg gcccgcccca cgcccaccct ccccgccccc                         1173  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 28  
               
               
                 &lt;211&gt; LENGTH: 323  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 28  
               
               
                   
               
               
                 Met Arg Gly Leu Trp Cys Glu Lys Gly Val Gln Val Leu Leu Thr Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Gly Ala Phe Ala Ala Phe Gly Leu Met Thr Ile Ala Ile Ser Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Asp Tyr Trp Leu Tyr Thr Gly Gln Gln Glu Arg Lys Ser Val Ser Lys  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Asn Lys Arg Ser Lys Lys Asp Pro Gly Gly Leu Thr His Ser Gly Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Trp Arg Ile Cys Cys Leu Glu Gly Leu Lys Arg Gly Val Cys Val Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ile Asn His Phe Pro Glu Asp Thr Asp Tyr Asp His Asp Ser Ala Glu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Tyr Leu Leu Arg Thr Val Arg Ala Ser Ser Ile Phe Pro Ile Leu Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ala Ile Leu Leu Leu Leu Gly Gly Val Cys Val Ala Ala Ser Arg Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Tyr Lys Ser Lys Arg Asn Ile Ile Leu Gly Ala Gly Ile Leu Phe Val  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ala Ala Gly Leu Ser Asn Ile Ile Gly Val Ile Val Tyr Ile Ser Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Asn Ala Gly Glu Pro Gly Arg Ser Arg Ala Lys Lys Asn His Tyr Ser  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Tyr Gly Trp Ser Phe Tyr Phe Gly Gly Leu Ser Phe Ile Leu Ala Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Val Ile Gly Val Leu Ala Val Asn Ile Tyr Ile Glu Pro Ala Glu Ala  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 His Cys Gln Ser Arg Ser Gly Thr Ala Gly Gly Arg Pro Ala Ser Ser  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Arg Cys Thr Thr Pro Ser Pro Arg Arg Arg Ala Ala Ala Ser Arg Ser  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Arg Ser Pro Gly Arg Pro Pro Arg Pro Arg His Ala Thr Pro Ala Asn  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Thr Asn Ser Thr Asp Ile Ser Met Tyr Thr Leu Ser Arg Asp Pro Ser  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Lys Gly Ser Pro His Ser Asn Ala Thr Thr Pro Thr Pro Thr Ser Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Lys Asp Arg Lys Asn Ser Phe Val Ser Ile Lys Ile Lys Val Lys Lys  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Lys Lys Arg Asn Ile Tyr Ile Tyr Ile Tyr Thr Leu Asn Arg Lys Thr  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Thr Pro Val  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 29  
               
               
                 &lt;211&gt; LENGTH: 1192  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (69)..(1097)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 29  
               
               
                   
               
               
                 tgctgagggt gcatttatgt ttcagaacca ccgggaggaa ctgggccatt ctaacacccg     60  
               
               
                   
               
               
                 ttgctacc atg ctg gcc acc cgc ctc tcc aga ccc ctg tca cgg ctc cca     110  
               
               
                          Met Leu Ala Thr Arg Leu Ser Arg Pro Leu Ser Arg Leu Pro  
               
               
                          1               5                   10  
               
               
                   
               
               
                 gga aaa acc cta agt gcc tgt gat aga gaa aat gga gca agg cgc cca      158  
               
               
                 Gly Lys Thr Leu Ser Ala Cys Asp Arg Glu Asn Gly Ala Arg Arg Pro  
               
               
                 15                  20                  25                  30  
               
               
                   
               
               
                 cta ttg ctt ggt tct act tcc ttt atc ccg att ggc cgt cgg act tat      206  
               
               
                 Leu Leu Leu Gly Ser Thr Ser Phe Ile Pro Ile Gly Arg Arg Thr Tyr  
               
               
                                 35                  40                  45  
               
               
                   
               
               
                 gcc agt gcg gcg gag ccg gtg agt gga aaa gct gtc ctg gtc aca ggc      254  
               
               
                 Ala Ser Ala Ala Glu Pro Val Ser Gly Lys Ala Val Leu Val Thr Gly  
               
               
                             50                  55                  60  
               
               
                   
               
               
                 tgt gac tct gga ttt ggg ttc tca ttg gcc aag cat ctg cat tca aaa      302  
               
               
                 Cys Asp Ser Gly Phe Gly Phe Ser Leu Ala Lys His Leu His Ser Lys  
               
               
                         65                  70                  75  
               
               
                   
               
               
                 ggc ttc ctt gtg ttt gct ggc tgc ttg atg aag gac aaa ggc cat gat      350  
               
               
                 Gly Phe Leu Val Phe Ala Gly Cys Leu Met Lys Asp Lys Gly His Asp  
               
               
                     80                  85                  90  
               
               
                   
               
               
                 ggg gtc aag gag ctg gac agc cta aac agt gac cga ttg aga acc gtc      398  
               
               
                 Gly Val Lys Glu Leu Asp Ser Leu Asn Ser Asp Arg Leu Arg Thr Val  
               
               
                 95                  100                 105                 110  
               
               
                   
               
               
                 cag ctc aat gtc tgc agc agc gaa gag gtg gag aaa gtg gtg gag att      446  
               
               
                 Gln Leu Asn Val Cys Ser Ser Glu Glu Val Glu Lys Val Val Glu Ile  
               
               
                                 115                 120                 125  
               
               
                   
               
               
                 gtc cgc tcg agc ctg aag gac cct gag aaa ggt atg tgg ggc ctc gtt      494  
               
               
                 Val Arg Ser Ser Leu Lys Asp Pro Glu Lys Gly Met Trp Gly Leu Val  
               
               
                             130                 135                 140  
               
               
                   
               
               
                 aac aat gcc ggc atc tca acg ttc ggg gag gtg gag ttc acc agc ctg      542  
               
               
                 Asn Asn Ala Gly Ile Ser Thr Phe Gly Glu Val Glu Phe Thr Ser Leu  
               
               
                         145                 150                 155  
               
               
                   
               
               
                 gag acc tac aag cag gtg gca gaa gtg aac ctt tgg ggc aca gtg cgg      590  
               
               
                 Glu Thr Tyr Lys Gln Val Ala Glu Val Asn Leu Trp Gly Thr Val Arg  
               
               
                     160                 165                 170  
               
               
                   
               
               
                 atg acg aaa tcc ttt ctc ccc ctc atc cga agg gcc aaa ggt cgc gtc      638  
               
               
                 Met Thr Lys Ser Phe Leu Pro Leu Ile Arg Arg Ala Lys Gly Arg Val  
               
               
                 175                 180                 185                 190  
               
               
                   
               
               
                 gtc aat atc agc agc atg ctg ggc cgc atg gcc aac ccg gcc cgc tcc      686  
               
               
                 Val Asn Ile Ser Ser Met Leu Gly Arg Met Ala Asn Pro Ala Arg Ser  
               
               
                                 195                 200                 205  
               
               
                   
               
               
                 ccg tac tgc atc acc aag ttc ggg gta gag gct ttc tcg gac tgc ctg      734  
               
               
                 Pro Tyr Cys Ile Thr Lys Phe Gly Val Glu Ala Phe Ser Asp Cys Leu  
               
               
                             210                 215                 220  
               
               
                   
               
               
                 cgc tat gag atg tac ccc ctg ggc gtg aag gtc agc gtg gtg gag ccc      782  
               
               
                 Arg Tyr Glu Met Tyr Pro Leu Gly Val Lys Val Ser Val Val Glu Pro  
               
               
                         225                 230                 235  
               
               
                   
               
               
                 ggc aac ttc atc gct gcc acc agc ctt tac agc cct gag agc att cag      830  
               
               
                 Gly Asn Phe Ile Ala Ala Thr Ser Leu Tyr Ser Pro Glu Ser Ile Gln  
               
               
                     240                 245                 250  
               
               
                   
               
               
                 gcc atc gcc aag aag atg tgg gag gag ctg cct gag gtc gtg cgc aag      878  
               
               
                 Ala Ile Ala Lys Lys Met Trp Glu Glu Leu Pro Glu Val Val Arg Lys  
               
               
                 255                 260                 265                 270  
               
               
                   
               
               
                 gac tac ggc aag aag tac ttt gat gaa aag atc gcc aag atg gag acc      926  
               
               
                 Asp Tyr Gly Lys Lys Tyr Phe Asp Glu Lys Ile Ala Lys Met Glu Thr  
               
               
                                 275                 280                 285  
               
               
                   
               
               
                 tac tgc agc agt ggc tcc aca gac acg tcc cct gtc atc gat gct gtc      974  
               
               
                 Tyr Cys Ser Ser Gly Ser Thr Asp Thr Ser Pro Val Ile Asp Ala Val  
               
               
                             290                 295                 300  
               
               
                   
               
               
                 aca cac gcc ctg acc gcc acc acc ccc tac acc cgc tac cac ccc atg     1022  
               
               
                 Thr His Ala Leu Thr Ala Thr Thr Pro Tyr Thr Arg Tyr His Pro Met  
               
               
                         305                 310                 315  
               
               
                   
               
               
                 gac tac tac tgg tgg ctg cga atg cag atc atg acc cac ttg cct gga     1070  
               
               
                 Asp Tyr Tyr Trp Trp Leu Arg Met Gln Ile Met Thr His Leu Pro Gly  
               
               
                     320                 325                 330  
               
               
                   
               
               
                 gcc atc tcc gac atg atc tac atc cgc tgaagagtct cgctgtggcc           1117  
               
               
                 Ala Ile Ser Asp Met Ile Tyr Ile Arg  
               
               
                 335                 340  
               
               
                   
               
               
                 tctgtcaggg atccctggtg gaaggggagg ggagggagga acccatatag tcaactcttg   1177  
               
               
                   
               
               
                 attatccacg tgtgg                                                    1192  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 30  
               
               
                 &lt;211&gt; LENGTH: 343  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 30  
               
               
                   
               
               
                 Met Leu Ala Thr Arg Leu Ser Arg Pro Leu Ser Arg Leu Pro Gly Lys  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Thr Leu Ser Ala Cys Asp Arg Glu Asn Gly Ala Arg Arg Pro Leu Leu  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Leu Gly Ser Thr Ser Phe Ile Pro Ile Gly Arg Arg Thr Tyr Ala Ser  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ala Ala Glu Pro Val Ser Gly Lys Ala Val Leu Val Thr Gly Cys Asp  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ser Gly Phe Gly Phe Ser Leu Ala Lys His Leu His Ser Lys Gly Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Leu Val Phe Ala Gly Cys Leu Met Lys Asp Lys Gly His Asp Gly Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Lys Glu Leu Asp Ser Leu Asn Ser Asp Arg Leu Arg Thr Val Gln Leu  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Asn Val Cys Ser Ser Glu Glu Val Glu Lys Val Val Glu Ile Val Arg  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ser Ser Leu Lys Asp Pro Glu Lys Gly Met Trp Gly Leu Val Asn Asn  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ala Gly Ile Ser Thr Phe Gly Glu Val Glu Phe Thr Ser Leu Glu Thr  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Tyr Lys Gln Val Ala Glu Val Asn Leu Trp Gly Thr Val Arg Met Thr  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Ser Phe Leu Pro Leu Ile Arg Arg Ala Lys Gly Arg Val Val Asn  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ile Ser Ser Met Leu Gly Arg Met Ala Asn Pro Ala Arg Ser Pro Tyr  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Cys Ile Thr Lys Phe Gly Val Glu Ala Phe Ser Asp Cys Leu Arg Tyr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Met Tyr Pro Leu Gly Val Lys Val Ser Val Val Glu Pro Gly Asn  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Ile Ala Ala Thr Ser Leu Tyr Ser Pro Glu Ser Ile Gln Ala Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Lys Lys Met Trp Glu Glu Leu Pro Glu Val Val Arg Lys Asp Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gly Lys Lys Tyr Phe Asp Glu Lys Ile Ala Lys Met Glu Thr Tyr Cys  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ser Ser Gly Ser Thr Asp Thr Ser Pro Val Ile Asp Ala Val Thr His  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Ala Leu Thr Ala Thr Thr Pro Tyr Thr Arg Tyr His Pro Met Asp Tyr  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Tyr Trp Trp Leu Arg Met Gln Ile Met Thr His Leu Pro Gly Ala Ile  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Asp Met Ile Tyr Ile Arg  
               
               
                             340  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 31  
               
               
                 &lt;211&gt; LENGTH: 1166  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (69)..(1097)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 31  
               
               
                   
               
               
                 tgctgagggt gcatttatgt ttcagaacca ccgggaggaa ctgggccatt ctaacacccg     60  
               
               
                   
               
               
                 ttgctacc atg ctg gcc acc cgc ctc tcc aga ccc ctg tca cgg ctc cca     110  
               
               
                          Met Leu Ala Thr Arg Leu Ser Arg Pro Leu Ser Arg Leu Pro  
               
               
                          1               5                   10  
               
               
                   
               
               
                 gga aaa acc cta agt gcc tgt gat aga gaa aat gga gca aga cgc cca      158  
               
               
                 Gly Lys Thr Leu Ser Ala Cys Asp Arg Glu Asn Gly Ala Arg Arg Pro  
               
               
                 15                  20                  25                  30  
               
               
                   
               
               
                 cta ttg ctt ggt tct act tcc ttt atc ccg att ggc cgt cgg act tat      206  
               
               
                 Leu Leu Leu Gly Ser Thr Ser Phe Ile Pro Ile Gly Arg Arg Thr Tyr  
               
               
                                 35                  40                  45  
               
               
                   
               
               
                 gcc agt gcg gcg gag ccg gtt ggc agc aaa gct gtc ctg gtc aca ggc      254  
               
               
                 Ala Ser Ala Ala Glu Pro Val Gly Ser Lys Ala Val Leu Val Thr Gly  
               
               
                             50                  55                  60  
               
               
                   
               
               
                 tgt gac tct gga ttt ggg ttc tca ttg gcc aag cat ctg cat tca aaa      302  
               
               
                 Cys Asp Ser Gly Phe Gly Phe Ser Leu Ala Lys His Leu His Ser Lys  
               
               
                         65                  70                  75  
               
               
                   
               
               
                 ggc ttc ctt gtg ttt gct ggc tgc ttg atg aag gac aaa ggc cat gat      350  
               
               
                 Gly Phe Leu Val Phe Ala Gly Cys Leu Met Lys Asp Lys Gly His Asp  
               
               
                     80                  85                  90  
               
               
                   
               
               
                 ggg gtc aag gag ctg gac agc cta aac agt gac cga ttg aga acc gtc      398  
               
               
                 Gly Val Lys Glu Leu Asp Ser Leu Asn Ser Asp Arg Leu Arg Thr Val  
               
               
                 95                  100                 105                 110  
               
               
                   
               
               
                 cag ctc aat gtc tgc agc agc gaa gag gtg gag aaa gtg gtg gag att      446  
               
               
                 Gln Leu Asn Val Cys Ser Ser Glu Glu Val Glu Lys Val Val Glu Ile  
               
               
                                 115                 120                 125  
               
               
                   
               
               
                 gtc cgc tcg agc ctg aag gac cct gag aaa ggc atg tgg ggc ctc gtt      494  
               
               
                 Val Arg Ser Ser Leu Lys Asp Pro Glu Lys Gly Met Trp Gly Leu Val  
               
               
                             130                 135                 140  
               
               
                   
               
               
                 aac aat gcc ggc atc tca acg ttc ggg gag gtg gag ttc acc agc ctg      542  
               
               
                 Asn Asn Ala Gly Ile Ser Thr Phe Gly Glu Val Glu Phe Thr Ser Leu  
               
               
                         145                 150                 155  
               
               
                   
               
               
                 gag acc tac aag cag gtg gca gaa gtg aac ctt tgg ggc aca gtg cgg      590  
               
               
                 Glu Thr Tyr Lys Gln Val Ala Glu Val Asn Leu Trp Gly Thr Val Arg  
               
               
                     160                 165                 170  
               
               
                   
               
               
                 atg acg aaa tcc ttt ctc ccc ctc atc cga agg gcc aaa ggc cgc gtc      638  
               
               
                 Met Thr Lys Ser Phe Leu Pro Leu Ile Arg Arg Ala Lys Gly Arg Val  
               
               
                 175                 180                 185                 190  
               
               
                   
               
               
                 gtc aat atc agc agc atg ctg ggc cgc atg gcc aac ccg gcc cgc tcc      686  
               
               
                 Val Asn Ile Ser Ser Met Leu Gly Arg Met Ala Asn Pro Ala Arg Ser  
               
               
                                 195                 200                 205  
               
               
                   
               
               
                 ccg tac tgc atc acc aag ttc ggg gta gag gct ttc tcg gac tgc ctg      734  
               
               
                 Pro Tyr Cys Ile Thr Lys Phe Gly Val Glu Ala Phe Ser Asp Cys Leu  
               
               
                             210                 215                 220  
               
               
                   
               
               
                 cgc tat gag atg tac ccc ctg ggc gtg aag gtc agc gtg gtg gag ccc      782  
               
               
                 Arg Tyr Glu Met Tyr Pro Leu Gly Val Lys Val Ser Val Val Glu Pro  
               
               
                         225                 230                 235  
               
               
                   
               
               
                 ggc aac ttc atc gct gcc acc agc ctt tac agc cct gag agc att cag      830  
               
               
                 Gly Asn Phe Ile Ala Ala Thr Ser Leu Tyr Ser Pro Glu Ser Ile Gln  
               
               
                     240                 245                 250  
               
               
                   
               
               
                 gcc atc gcc aag aag atg tgg gag gag ctg cct gag gtc gtg cgc aag      878  
               
               
                 Ala Ile Ala Lys Lys Met Trp Glu Glu Leu Pro Glu Val Val Arg Lys  
               
               
                 255                 260                 265                 270  
               
               
                   
               
               
                 gac tac ggc aag aag tac ttt gat gaa aag atc gcc aag atg gag acc      926  
               
               
                 Asp Tyr Gly Lys Lys Tyr Phe Asp Glu Lys Ile Ala Lys Met Glu Thr  
               
               
                                 275                 280                 285  
               
               
                   
               
               
                 tac tgc agc agt ggc tcc aca gac acg tcc cct gtc atc gat gct gtc      974  
               
               
                 Tyr Cys Ser Ser Gly Ser Thr Asp Thr Ser Pro Val Ile Asp Ala Val  
               
               
                             290                 295                 300  
               
               
                   
               
               
                 aca cac gcc ctg acc gcc acc acc ccc tac acc cgc tac cac ccc atg     1022  
               
               
                 Thr His Ala Leu Thr Ala Thr Thr Pro Tyr Thr Arg Tyr His Pro Met  
               
               
                         305                 310                 315  
               
               
                   
               
               
                 gac tac tac tgg tgg ctg cga atg cag atc atg acc cac ttg cct gga     1070  
               
               
                 Asp Tyr Tyr Trp Trp Leu Arg Met Gln Ile Met Thr His Leu Pro Gly  
               
               
                     320                 325                 330  
               
               
                   
               
               
                 gcc atc tcc gac atg atc tac atc cgc tgaagagtct cgctgtggcc           1117  
               
               
                 Ala Ile Ser Asp Met Ile Tyr Ile Arg  
               
               
                 335                 340  
               
               
                   
               
               
                 tctgtcaggg attcctggtg gaaggggagg ggagggagga acccatata               1166  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 32  
               
               
                 &lt;211&gt; LENGTH: 343  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 32  
               
               
                   
               
               
                 Met Leu Ala Thr Arg Leu Ser Arg Pro Leu Ser Arg Leu Pro Gly Lys  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Thr Leu Ser Ala Cys Asp Arg Glu Asn Gly Ala Arg Arg Pro Leu Leu  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Leu Gly Ser Thr Ser Phe Ile Pro Ile Gly Arg Arg Thr Tyr Ala Ser  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ala Ala Glu Pro Val Gly Ser Lys Ala Val Leu Val Thr Gly Cys Asp  
               
               
                    50                  55                  60  
               
               
                   
               
               
                 Ser Gly Phe Gly Phe Ser Leu Ala Lys His Leu His Ser Lys Gly Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Leu Val Phe Ala Gly Cys Leu Met Lys Asp Lys Gly His Asp Gly Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Lys Glu Leu Asp Ser Leu Asn Ser Asp Arg Leu Arg Thr Val Gln Leu  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Asn Val Cys Ser Ser Glu Glu Val Glu Lys Val Val Glu Ile Val Arg  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ser Ser Leu Lys Asp Pro Glu Lys Gly Met Trp Gly Leu Val Asn Asn  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ala Gly Ile Ser Thr Phe Gly Glu Val Glu Phe Thr Ser Leu Glu Thr  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Tyr Lys Gln Val Ala Glu Val Asn Leu Trp Gly Thr Val Arg Met Thr  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Ser Phe Leu Pro Leu Ile Arg Arg Ala Lys Gly Arg Val Val Asn  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ile Ser Ser Met Leu Gly Arg Met Ala Asn Pro Ala Arg Ser Pro Tyr  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Cys Ile Thr Lys Phe Gly Val Glu Ala Phe Ser Asp Cys Leu Arg Tyr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Met Tyr Pro Leu Gly Val Lys Val Ser Val Val Glu Pro Gly Asn  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Ile Ala Ala Thr Ser Leu Tyr Ser Pro Glu Ser Ile Gln Ala Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Lys Lys Met Trp Glu Glu Leu Pro Glu Val Val Arg Lys Asp Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gly Lys Lys Tyr Phe Asp Glu Lys Ile Ala Lys Met Glu Thr Tyr Cys  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ser Ser Gly Ser Thr Asp Thr Ser Pro Val Ile Asp Ala Val Thr His  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Ala Leu Thr Ala Thr Thr Pro Tyr Thr Arg Tyr His Pro Met Asp Tyr  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Tyr Trp Trp Leu Arg Met Gln Ile Met Thr His Leu Pro Gly Ala Ile  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Asp Met Ile Tyr Ile Arg  
               
               
                             340  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 33  
               
               
                 &lt;211&gt; LENGTH: 3168  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (39)..(1610)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 33  
               
               
                   
               
               
                 cacaagacct ggaattgaca ggactcccaa ctagtaca atg aca gaa gat aag gtc     56  
               
               
                                                           Met Thr Glu Asp Lys Val  
               
               
                                                           1               5  
               
               
                   
               
               
                 act ggg acc ctg gtt ttc act gtc atc act gct gtg ctg ggt tcc ttc      104  
               
               
                 Thr Gly Thr Leu Val Phe Thr Val Ile Thr Ala Val Leu Gly Ser Phe  
               
               
                             10                  15                  20  
               
               
                   
               
               
                 cag ttt gga tat gac att ggt gtg atc aat gca cct caa cag gta ata      152  
               
               
                 Gln Phe Gly Tyr Asp Ile Gly Val Ile Asn Ala Pro Gln Gln Val Ile  
               
               
                         25                  30                  35  
               
               
                   
               
               
                 ata tct cac tat aga cat gtt ttg ggt gtt cca ctg gat gac cga aaa      200  
               
               
                 Ile Ser His Tyr Arg His Val Leu Gly Val Pro Leu Asp Asp Arg Lys  
               
               
                     40                  45                  50  
               
               
                   
               
               
                 gct atc aac aac tat gtt atc aac agt aca gat gaa ctg ccc aca atc      248  
               
               
                 Ala Ile Asn Asn Tyr Val Ile Asn Ser Thr Asp Glu Leu Pro Thr Ile  
               
               
                 55                  60                  65                  70  
               
               
                   
               
               
                 tca tac tca atg aac cca aaa cca acc cct tgg gct gag gaa gag act      296  
               
               
                 Ser Tyr Ser Met Asn Pro Lys Pro Thr Pro Trp Ala Glu Glu Glu Thr  
               
               
                                 75                  80                  85  
               
               
                   
               
               
                 gtg gca gct gct caa cta atc acc atg ctc tgg tcc ctg tct gta tcc      344  
               
               
                 Val Ala Ala Ala Gln Leu Ile Thr Met Leu Trp Ser Leu Ser Val Ser  
               
               
                             90                  95                  100  
               
               
                   
               
               
                 agc ttt gca gtt ggt gga atg act gca tca ttc ttt ggt ggg tgg ctt      392  
               
               
                 Ser Phe Ala Val Gly Gly Met Thr Ala Ser Phe Phe Gly Gly Trp Leu  
               
               
                         105                 110                 115  
               
               
                   
               
               
                 ggg gac aca ctt gga aga atc aaa gcc atg tta gta gca aac att ctg      440  
               
               
                 Gly Asp Thr Leu Gly Arg Ile Lys Ala Met Leu Val Ala Asn Ile Leu  
               
               
                     120                 125                 130  
               
               
                   
               
               
                 tca tta gtt gga gct ctc ttg atg ggg ttt tca aaa ttg gga cca tct      488  
               
               
                 Ser Leu Val Gly Ala Leu Leu Met Gly Phe Ser Lys Leu Gly Pro Ser  
               
               
                 135                 140                 145                 150  
               
               
                   
               
               
                 cat ata ctt ata att gct gga aga agc ata tca gga cta tat tgt ggg      536  
               
               
                 His Ile Leu Ile Ile Ala Gly Arg Ser Ile Ser Gly Leu Tyr Cys Gly  
               
               
                                 155                 160                 165  
               
               
                   
               
               
                 cta att tca ggc ctg gtt cct atg tat atc ggt gaa att gct cca acc      584  
               
               
                 Leu Ile Ser Gly Leu Val Pro Met Tyr Ile Gly Glu Ile Ala Pro Thr  
               
               
                             170                 175                 180  
               
               
                   
               
               
                 gct ctc agg gga gca ctt ggc act ttt cat cag ctg gcc atc gtc acg      632  
               
               
                 Ala Leu Arg Gly Ala Leu Gly Thr Phe His Gln Leu Ala Ile Val Thr  
               
               
                         185                 190                 195  
               
               
                   
               
               
                 ggc att ctt att agt cag att att ggt ctt gaa ttt atc ttg ggc aat      680  
               
               
                 Gly Ile Leu Ile Ser Gln Ile Ile Gly Leu Glu Phe Ile Leu Gly Asn  
               
               
                     200                 205                 210  
               
               
                   
               
               
                 tat gat ctg tgg cac atc ctg ctt ggc ctg tct ggt gtg cga gcc atc      728  
               
               
                 Tyr Asp Leu Trp His Ile Leu Leu Gly Leu Ser Gly Val Arg Ala Ile  
               
               
                 215                 220                 225                 230  
               
               
                   
               
               
                 ctt cag tct ctg cta ctc ttt ttc tgt cca gaa agc ccc aga tac ctt      776  
               
               
                 Leu Gln Ser Leu Leu Leu Phe Phe Cys Pro Glu Ser Pro Arg Tyr Leu  
               
               
                                 235                 240                 245  
               
               
                   
               
               
                 tac atc aag tta gat gag gaa gtc aaa gca aaa caa agc ttg aaa aga      824  
               
               
                 Tyr Ile Lys Leu Asp Glu Glu Val Lys Ala Lys Gln Ser Leu Lys Arg  
               
               
                             250                 255                 260  
               
               
                   
               
               
                 ctc aga gga tat gat gat gtc acc aaa gat att aat gaa atg aga aaa      872  
               
               
                 Leu Arg Gly Tyr Asp Asp Val Thr Lys Asp Ile Asn Glu Met Arg Lys  
               
               
                         265                 270                 275  
               
               
                   
               
               
                 gaa aga gaa gaa gca tcg agt gag cag aaa gtc tct ata att cag ctc      920  
               
               
                 Glu Arg Glu Glu Ala Ser Ser Glu Gln Lys Val Ser Ile Ile Gln Leu  
               
               
                     280                 285                 290  
               
               
                   
               
               
                 ttc acc aat tcc agc tac cga cag cct att cta gtg gca ctg atg ctg      968  
               
               
                 Phe Thr Asn Ser Ser Tyr Arg Gln Pro Ile Leu Val Ala Leu Met Leu  
               
               
                 295                 300                 305                 310  
               
               
                   
               
               
                 cat gtg gct cag caa ttt tcc gga atc aat ggc att ttt tac tac tca     1016  
               
               
                 His Val Ala Gln Gln Phe Ser Gly Ile Asn Gly Ile Phe Tyr Tyr Ser  
               
               
                                 315                 320                 325  
               
               
                   
               
               
                 acc agc att ttt cag acg gct ggt atc agc aaa cct gtt tat gca acc     1064  
               
               
                 Thr Ser Ile Phe Gln Thr Ala Gly Ile Ser Lys Pro Val Tyr Ala Thr  
               
               
                             330                 335                 340  
               
               
                   
               
               
                 att gga gtt ggc gct gta aac atg gtt ttc act gct gtc tct gta ttc     1112  
               
               
                 Ile Gly Val Gly Ala Val Asn Met Val Phe Thr Ala Val Ser Val Phe  
               
               
                         345                 350                 355  
               
               
                   
               
               
                 ctt gtg gag aag gca ggg cga cgt tct ctc ttt cta att gga atg agt     1160  
               
               
                 Leu Val Glu Lys Ala Gly Arg Arg Ser Leu Phe Leu Ile Gly Met Ser  
               
               
                     360                 365                 370  
               
               
                   
               
               
                 ggg atg ttt gtt tgt gcc atc ttc atg tca gtg gga ctt gtg ctg ctg     1208  
               
               
                 Gly Met Phe Val Cys Ala Ile Phe Met Ser Val Gly Leu Val Leu Leu  
               
               
                 375                 380                 385                 390  
               
               
                   
               
               
                 aat aag ttc tct tgg atg agt tat gtg agc atg ata gcc atc ttc ctc     1256  
               
               
                 Asn Lys Phe Ser Trp Met Ser Tyr Val Ser Met Ile Ala Ile Phe Leu  
               
               
                                 395                 400                 405  
               
               
                   
               
               
                 ttt gtc agc ttc ttt gaa att ggg cca ggc ccg atc ccc tgg ttc atg     1304  
               
               
                 Phe Val Ser Phe Phe Glu Ile Gly Pro Gly Pro Ile Pro Trp Phe Met  
               
               
                             410                 415                 420  
               
               
                   
               
               
                 gtg gct gag ttt ttc agt caa gga cca cgt cct gct gct tta gca ata     1352  
               
               
                 Val Ala Glu Phe Phe Ser Gln Gly Pro Arg Pro Ala Ala Leu Ala Ile  
               
               
                         425                 430                 435  
               
               
                   
               
               
                 gct gca ttc agc aat tgg acc tgc aat ttc att gta gct ctg tgt ttc     1400  
               
               
                 Ala Ala Phe Ser Asn Trp Thr Cys Asn Phe Ile Val Ala Leu Cys Phe  
               
               
                     440                 445                 450  
               
               
                   
               
               
                 cag tac att gcg gac ttc tgt gga cct tat gtg ttt ttc ctc ttt gct     1448  
               
               
                 Gln Tyr Ile Ala Asp Phe Cys Gly Pro Tyr Val Phe Phe Leu Phe Ala  
               
               
                 455                 460                 465                 470  
               
               
                   
               
               
                 gga gtg ctc ctg gcc ttt acc ctg ttc aca ttt ttt aaa gtt cca gaa     1496  
               
               
                 Gly Val Leu Leu Ala Phe Thr Leu Phe Thr Phe Phe Lys Val Pro Glu  
               
               
                                 475                 480                 485  
               
               
                   
               
               
                 acc aaa gga aag tct ttt gag gaa att gct gca gaa ttc caa aag aag     1544  
               
               
                 Thr Lys Gly Lys Ser Phe Glu Glu Ile Ala Ala Glu Phe Gln Lys Lys  
               
               
                             490                 495                 500  
               
               
                   
               
               
                 agt ggc tca gcc cac agg cca aaa gct gct gta gaa atg aaa ttc cta     1592  
               
               
                 Ser Gly Ser Ala His Arg Pro Lys Ala Ala Val Glu Met Lys Phe Leu  
               
               
                         505                 510                 515  
               
               
                   
               
               
                 gga gct aca gag act gtg taaaaaaaaa accctgcttt ttgacatgaa            1640  
               
               
                 Gly Ala Thr Glu Thr Val  
               
               
                     520  
               
               
                   
               
               
                 cagaaacaat aagggaaccg tctgttttta aatgatgatt ccttgagcat tttatatcca   1700  
               
               
                   
               
               
                 catctttaag tattgtttta tttttatgtg ctctcatcag aaatgtcatc aaatattacc   1760  
               
               
                   
               
               
                 aaaaaagtat ttttttaagt tagagaatat atttttgatg gtaagactgt aattaagtaa   1820  
               
               
                   
               
               
                 accaaaaagg ctagtttatt ttgttacact aaagggcagg tggttctaat atttttagct   1880  
               
               
                   
               
               
                 ctgttcttta taacaaggtt cttctaaaat tgaagagatt tcaacatatc atttttttaa   1940  
               
               
                   
               
               
                 cacataacta gaaacctgag gatgcaacaa atatttatat atttgaatat cattaaattg   2000  
               
               
                   
               
               
                 gaattttctt acccatatat cttatgttaa aggagatatg gctagtggca ataagttcca   2060  
               
               
                   
               
               
                 tgttaaaata gacaactctt ccatttattg cactcagctt ttttcttgag tactagaatt   2120  
               
               
                   
               
               
                 tgtattttgc ttaaaatttt acttttgttc tgtattttca tgtggaatgg attatagagt   2180  
               
               
                   
               
               
                 atactaaaaa atgtctatag agaaaaactt tcatttttgg taggcttatc aaaatctttc   2240  
               
               
                   
               
               
                 agcactcaga aaagaaaacc attttagttc ctttatttaa tggccaaatg gtttttgcaa   2300  
               
               
                   
               
               
                 gatttaacac taaaaaggtt tcacctgatc atatagcgtg ggttatcagt taacattaac   2360  
               
               
                   
               
               
                 atctattata aaaccatgtt gattcccttc tggtacaatc ctttgagtta tagtttgctt   2420  
               
               
                   
               
               
                 tgctttttaa ttgaggacag cctggttttc acatacactc aaacaatcat gagtcagaca   2480  
               
               
                   
               
               
                 tttggtatat tacctcaaat tcctaataag tttgatcaaa tctaatgtaa gaaaatttga   2540  
               
               
                   
               
               
                 agtaaaggat tgatcacttt gttaaaaata ttttctgaat tattatgtct caaaataagt   2600  
               
               
                   
               
               
                 tgaaaaggta gggtttgagg attcctgagt gtgggcttct gaaacttcat aaatgttcag   2660  
               
               
                   
               
               
                 cttcagactt ttatcaaaat ccctatttaa ttttcctgga aagactgatt gttttatggt   2720  
               
               
                   
               
               
                 gtgttcctaa cataaaataa tcgtctcctt tgacatttcc ttctttgtct tagctgtata   2780  
               
               
                   
               
               
                 cagattctag ccaaactatt ctatggccat tactaacacg cattgtacac tatctatctg   2840  
               
               
                   
               
               
                 cctttaccta cataggcaaa ttggaaatac acagatgatt aaacagactt tagcttacag   2900  
               
               
                   
               
               
                 tcaattttac aattatggaa atatagttct gatgggtccc aaaagcttag cagggtgcta   2960  
               
               
                   
               
               
                 acgtatctct aggctgtttt ctccaccaac tggagcactg atcaatcctt cttatgtttg   3020  
               
               
                   
               
               
                 ctttaatgtg tattgaagaa aagcactttt taaaaagtac tctttaagag tgaaataatt   3080  
               
               
                   
               
               
                 aaaaaccact gaacatttgc tttgttttct aaagttgttc acatatatgt aatttagcag   3140  
               
               
                   
               
               
                 tccaaagaac aagaaattgt ttcttttc                                      3168  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 34  
               
               
                 &lt;211&gt; LENGTH: 524  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 34  
               
               
                   
               
               
                 Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr Val Ile Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly Val Ile Asn  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val Leu Gly Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile Asn Ser Thr  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys Pro Thr Pro  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile Thr Met Leu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met Thr Ala Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile Lys Ala Met  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu Met Gly Phe  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly Arg Ser Ile  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro Met Tyr Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Phe His  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile Ile Gly Leu  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu Leu Gly Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe Phe Cys Pro  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu Val Lys Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val Thr Lys Asp  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser Glu Gln Lys  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg Gln Pro Ile  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser Gly Ile Asn  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala Gly Ile Ser  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn Met Val Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg Arg Ser Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile Phe Met Ser  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser Tyr Val Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile Gly Pro Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln Gly Pro Arg  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr Cys Asn Phe  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys Gly Pro Tyr  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr Leu Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu Glu Ile Ala  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro Lys Ala Ala  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val  
               
               
                         515                 520  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 35  
               
               
                 &lt;211&gt; LENGTH: 1587  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(1587)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 35  
               
               
                   
               
               
                 gga tcc acc atg aca gaa gat aag gtc act ggg acc ctg gtt ttc act       48  
               
               
                 Gly Ser Thr Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 gtc atc act gct gtg ctg ggt tcc ttc cag ttt gga tat gac att ggt       96  
               
               
                 Val Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 gtg atc aat gca cct caa cag gta ata ata tct cac tat aga cat gtt      144  
               
               
                 Val Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 ttg ggt gtt cca ctg gat gac cga aaa gct atc aac aac tat gtt atc      192  
               
               
                 Leu Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 aac agt aca gat gaa ctg ccc aca atc tca tac tca atg aac cca aaa      240  
               
               
                 Asn Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 cca acc cct tgg gct gag gaa gag act gtg gca gct gct caa cta atc      288  
               
               
                 Pro Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 acc atg ctc tgg tcc ctg tct gta tcc agc ttt gca gtt ggt gga atg      336  
               
               
                 Thr Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 att gca tca ttc ttt ggt ggg tgg ctt ggg gac aca ctt gga aga atc      384  
               
               
                 Ile Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 aaa gcc atg tta gta gca aac att ctg tca tta gtt gga gct ctc ttg      432  
               
               
                 Lys Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 atg ggg ttt tca aaa ttg gga cca tct cat ata ctt ata att gct gga      480  
               
               
                 Met Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 aga agc ata tca gga cta tat tgt ggg cta att tca ggc ctg gtt cct      528  
               
               
                 Arg Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 atg tat atc ggt gaa att gct cca acc gct ctc agg gga gca ctt ggc      576  
               
               
                 Met Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 act ttt cat cag ctg gcc atc gtc acg ggc att ctt att agt cag att      624  
               
               
                 Thr Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 att ggt ctt gaa ttt atc ttg ggc aat tat gat ctg tgg cac atc ctg      672  
               
               
                 Ile Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 ctt ggc ctg tct ggt gtg cga gcc atc ctt cag tct ctg cta ctc ttt      720  
               
               
                 Leu Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ttc tgt cca gaa agc ccc aga tac ctt tac atc aag tta gat gag gaa      768  
               
               
                 Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gtc aaa gca aaa caa atc ttg aaa aga ctc aga gga tat gat gat gtc      816  
               
               
                 Val Lys Ala Lys Gln Ile Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 acc aaa gat att aat gaa atg aga aaa gaa aga gaa gaa gca tcg agt      864  
               
               
                 Thr Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 gag cag aaa gtc tct ata att cag ctc ttc acc aat tcc agc tac cga      912  
               
               
                 Glu Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 cag cct att cta gtg gca ctg atg ctg cat gtg gct cag caa ttt tcc      960  
               
               
                 Gln Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gga atc aat ggc att ttt tac tac tca acc agc att ttt cag acg gct     1008  
               
               
                 Gly Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 ggt atc agc aaa cct gtt tat gca acc att gga gtt ggc gct gta aac     1056  
               
               
                 Gly Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 atg gtt ttc act gct gtc tct gta ttc ctt gtg gag aag gca ggg cga     1104  
               
               
                 Met Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 cgt tct ctc ttt cta att gga atg agt ggg atg ttt gtt tgt gcc atc     1152  
               
               
                 Arg Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 ttc atg tca gtg gga ctt gtg ctg ctg aat aag ttc tct tgg atg agt     1200  
               
               
                 Phe Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 tat gtg agc atg ata gcc atc ttc ctc ttt gtc agc ttc ttt gaa att     1248  
               
               
                 Tyr Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 ggg cca ggc ccg atc ccc tgg ttc atg gtg gct gag ttt ttc agt caa     1296  
               
               
                 Gly Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 gga cca cgt cct gct gct tta gca ata gct gca ttc agc aat tgg acc     1344  
               
               
                 Gly Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 tgc aat ttc att gta gct ctg tgt ttc cag tac att gcg gac ttc tgt     1392  
               
               
                 Cys Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 gga cct tat gtg ttt ttc ctc ttt gct gga gtg ctc ctg gcc ttt acc     1440  
               
               
                 Gly Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 ctg ttt aca ttt ttt aaa gtt cca gaa acc aaa gga aag tct ttt gag     1488  
               
               
                 Leu Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 gaa att gct gca gaa ttc caa aag aag agt ggc tca gcc cac agg cca     1536  
               
               
                 Glu Ile Ala Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 aaa gct gct gta gaa atg aaa ttc cta gga gct aca gag act gtg ctc     1584  
               
               
                 Lys Ala Ala Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val Leu  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 gag                                                                 1587  
               
               
                 Glu  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 36  
               
               
                 &lt;211&gt; LENGTH: 529  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 36  
               
               
                   
               
               
                 Gly Ser Thr Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Val Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Leu Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asn Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Pro Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Thr Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ile Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Lys Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Met Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Arg Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Met Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Thr Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ile Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Leu Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Val Lys Ala Lys Gln Ile Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Thr Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Glu Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg  
               
               
                     290                 295                 300  
               
               
                 Gln Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Gly Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Met Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Arg Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Phe Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Tyr Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Gly Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Cys Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Gly Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Leu Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Glu Ile Ala Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Lys Ala Ala Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val Leu  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Glu  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 37  
               
               
                 &lt;211&gt; LENGTH: 1587  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(1587)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 37  
               
               
                   
               
               
                 gga tcc acc atg aca gaa gat aag gtc act ggg acc ctg gtt ttc act       48  
               
               
                 Gly Ser Thr Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 gtc atc act gct gtg ctg ggt tcc ttc cag ttt gga tat gac att ggt       96  
               
               
                 Val Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 gtg atc aat gca cct caa cag gta ata ata tct cac tat aga cat gtt      144  
               
               
                 Val Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 ttg ggt gtt cca ctg gat gac cga aaa gct atc aac aac tat gtt atc      192  
               
               
                 Leu Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 aac agt aca gat gaa ctg ccc aca atc tca tac tca atg aac cca aaa      240  
               
               
                 Asn Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 cca acc cct tgg gct gag gaa gag act gtg gca gct gct caa cta atc      288  
               
               
                 Pro Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 acc atg ctc tgg tcc ctg tct gta tcc agc ttt gca gtt ggt gga atg      336  
               
               
                 Thr Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 att gca tca ttc ttt ggt ggg tgg ctt ggg gac aca ctt gga aga atc      384  
               
               
                 Ile Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 aaa gcc atg tta gta gca aac att ctg tca tta gtt gga gct ctc ttg      432  
               
               
                 Lys Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 atg ggg ttt tca aaa ttg gga cca tct cat ata ctt ata att gct gga      480  
               
               
                 Met Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 aga agc ata tca gga cta tat tgt ggg cta att tca ggc ctg gtt cct      528  
               
               
                 Arg Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 atg tat atc ggt gaa att gct cca acc gct ctc agg gga gca ctt ggc      576  
               
               
                 Met Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 act ttt cat cag ctg gcc atc gtc acg ggc att ctt att agt cag att      624  
               
               
                 Thr Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 att ggt ctt gaa ttt atc ttg ggc aat tat gat ctg tgg cac atc ctg      672  
               
               
                 Ile Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 ctt ggc ctg tct ggt gtg cga gcc atc ctt cag tct ctg cta ctc ttt      720  
               
               
                 Leu Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ttc tgt cca gaa agc ccc aga tac ctt tac atc aag tta gat gag gaa      768  
               
               
                 Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gtc aaa gca aaa caa agc ttg aaa aga ctc aga gga tat gat gat gtc      816  
               
               
                 Val Lys Ala Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 acc aaa gat att aat gaa atg aga aaa gaa aga gaa gaa gca tcg agt      864  
               
               
                 Thr Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 gag cag aaa gtc tct ata att cag ctc ttc acc aat tcc agc tac cga      912  
               
               
                 Glu Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 cag cct att cta gtg gca ctg atg ctg cat gtg gct cag caa ttt tcc      960  
               
               
                 Gln Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gga atc aat ggc att ttt tac tac tca acc agc att ttt cag acg gct     1008  
               
               
                 Gly Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 ggt atc agc aaa cct gtt tat gca acc att gga gtt ggc gct gta aac     1056  
               
               
                 Gly Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 atg gtt ttc act gct gtc tct gta ttc ctt gtg gag aag gca ggg cga     1104  
               
               
                 Met Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 cgt tct ctc ttt cta att gga atg agt ggg atg ttt gtt tgt gcc atc     1152  
               
               
                 Arg Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 ttc atg tca gtg gga ctt gtg ctg ctg aat aag ttc tct tgg atg agt     1200  
               
               
                 Phe Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 tat gtg agc atg ata gcc atc ttc ctc ttt gtc agc ttc ttt gaa att     1248  
               
               
                 Tyr Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 ggg cca ggc ccg atc ccc tgg ttc atg gtg gct gag ttt ttc agt caa     1296  
               
               
                 Gly Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 gga cca cgt cct gct gct tta gca ata gct gca ttc agc aat tgg acc     1344  
               
               
                 Gly Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 tgc aat ttc att gta gct ctg tgt ttc cag tac att gcg gac ttc tgt     1392  
               
               
                 Cys Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 gga cct tat gtg ttt ttc ctc ttt gct gga gtg ctc ctg gcc ttt acc     1440  
               
               
                 Gly Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 ctg ttt aca ttt ttt aaa gtt cca gaa acc aaa gga aag tct ttt gag     1488  
               
               
                 Leu Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 gaa att gct gca gaa ttc caa aag aag agt ggc tca gcc cac agg cca     1536  
               
               
                 Glu Ile Ala Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 aaa gct gct gta gaa atg aaa ttc cta gga gct aca gag act gtg ctc     1584  
               
               
                 Lys Ala Ala Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val Leu  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 gag                                                                 1587  
               
               
                 Glu  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 38  
               
               
                 &lt;211&gt; LENGTH: 529  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 38  
               
               
                   
               
               
                 Gly Ser Thr Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Val Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Leu Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asn Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Pro Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Thr Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ile Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Lys Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Met Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Arg Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Met Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Thr Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ile Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Leu Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Val Lys Ala Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Thr Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Glu Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Gln Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Gly Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Met Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Arg Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Phe Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Tyr Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Gly Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Cys Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Gly Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Leu Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Glu Ile Ala Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Lys Ala Ala Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val Leu  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Glu  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 39  
               
               
                 &lt;211&gt; LENGTH: 1664  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (39)..(1610)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 39  
               
               
                   
               
               
                 cacaagacct ggaattgaca ggactcccaa ctagtaca atg aca gaa gat aag gtc     56  
               
               
                                                           Met Thr Glu Asp Lys Val  
               
               
                                                           1               5  
               
               
                   
               
               
                 act ggg acc ctg gtt ttc act gtc atc act gct gtg ctg ggt tcc ttc      104  
               
               
                 Thr Gly Thr Leu Val Phe Thr Val Ile Thr Ala Val Leu Gly Ser Phe  
               
               
                             10                  15                  20  
               
               
                   
               
               
                 cag ttt gga tat gac att ggt gtg atc aat gca cct caa cag gta ata      152  
               
               
                 Gln Phe Gly Tyr Asp Ile Gly Val Ile Asn Ala Pro Gln Gln Val Ile  
               
               
                         25                  30                  35  
               
               
                   
               
               
                 ata tct cac tat aga cat gtt ttg ggt gtt cca ctg gat gac cga aaa      200  
               
               
                 Ile Ser His Tyr Arg His Val Leu Gly Val Pro Leu Asp Asp Arg Lys  
               
               
                     40                  45                  50  
               
               
                   
               
               
                 gct atc aac aac tat gtt atc aac agt aca gat gaa ctg ccc aca atc      248  
               
               
                 Ala Ile Asn Asn Tyr Val Ile Asn Ser Thr Asp Glu Leu Pro Thr Ile  
               
               
                 55                  60                  65                  70  
               
               
                   
               
               
                 tca tac tca atg aac cca aaa cca acc cct tgg gct gag gaa gag act      296  
               
               
                 Ser Tyr Ser Met Asn Pro Lys Pro Thr Pro Trp Ala Glu Glu Glu Thr  
               
               
                                 75                  80                  85  
               
               
                   
               
               
                 gtg gca gct gct caa cta atc acc atg ctc tgg tcc ctg tct gta tcc      344  
               
               
                 Val Ala Ala Ala Gln Leu Ile Thr Met Leu Trp Ser Leu Ser Val Ser  
               
               
                             90                  95                  100  
               
               
                   
               
               
                 agc ttt gca gtt ggt gga atg act gca tca ttc ttt ggt ggg tgg ctt      392  
               
               
                 Ser Phe Ala Val Gly Gly Met Thr Ala Ser Phe Phe Gly Gly Trp Leu  
               
               
                         105                 110                 115  
               
               
                   
               
               
                 ggg gac aca ctt gga aga atc aaa gcc atg tta gta gca aac att ctg      440  
               
               
                 Gly Asp Thr Leu Gly Arg Ile Lys Ala Met Leu Val Ala Asn Ile Leu  
               
               
                     120                 125                 130  
               
               
                   
               
               
                 tca tta gtt gga gct ctc ttg atg ggg ttt tca aaa ttg gga cca tct      488  
               
               
                 Ser Leu Val Gly Ala Leu Leu Met Gly Phe Ser Lys Leu Gly Pro Ser  
               
               
                 135                 140                 145                 150  
               
               
                   
               
               
                 cat ata ctt ata att gct gga aga agc ata tca gga cta tat tgt ggg      536  
               
               
                 His Ile Leu Ile Ile Ala Gly Arg Ser Ile Ser Gly Leu Tyr Cys Gly  
               
               
                                 155                 160                 165  
               
               
                   
               
               
                 cta att tca ggc ctg gtt cct atg tat atc ggt gaa att gct cca acc      584  
               
               
                 Leu Ile Ser Gly Leu Val Pro Met Tyr Ile Gly Glu Ile Ala Pro Thr  
               
               
                             170                 175                 180  
               
               
                   
               
               
                 gct ctc agg gga gca ctt ggc act ttt cat cag ctg gcc atc gtc acg      632  
               
               
                 Ala Leu Arg Gly Ala Leu Gly Thr Phe His Gln Leu Ala Ile Val Thr  
               
               
                         185                 190                 195  
               
               
                   
               
               
                 ggc att ctt att agt cag att att ggt ctt gaa ttt atc ttg ggc aat      680  
               
               
                 Gly Ile Leu Ile Ser Gln Ile Ile Gly Leu Glu Phe Ile Leu Gly Asn  
               
               
                     200                 205                 210  
               
               
                   
               
               
                 tat gat ctg tgg cac atc ctg ctt ggc ctg tct ggt gtg cga gcc atc      728  
               
               
                 Tyr Asp Leu Trp His Ile Leu Leu Gly Leu Ser Gly Val Arg Ala Ile  
               
               
                 215                 220                 225                 230  
               
               
                   
               
               
                 ctt cag tct ctg cta ctc ttt ttc tgt cca gaa agc ccc aga tac ctt      776  
               
               
                 Leu Gln Ser Leu Leu Leu Phe Phe Cys Pro Glu Ser Pro Arg Tyr Leu  
               
               
                                 235                 240                 245  
               
               
                   
               
               
                 tac atc aag tta gat gag gaa gtc aaa gca aaa caa agc ttg aaa aga      824  
               
               
                 Tyr Ile Lys Leu Asp Glu Glu Val Lys Ala Lys Gln Ser Leu Lys Arg  
               
               
                             250                 255                 260  
               
               
                   
               
               
                 ctc aga gga tat gat gat gtc acc aaa gat att aat gaa atg aga aaa      872  
               
               
                 Leu Arg Gly Tyr Asp Asp Val Thr Lys Asp Ile Asn Glu Met Arg Lys  
               
               
                         265                 270                 275  
               
               
                   
               
               
                 gaa aga gaa gaa gca tcg agt gag cag aaa gtc tct ata att cag ctc      920  
               
               
                 Glu Arg Glu Glu Ala Ser Ser Glu Gln Lys Val Ser Ile Ile Gln Leu  
               
               
                     280                 285                 290  
               
               
                   
               
               
                 ttc acc aat tcc agc tac cga cag cct att cta gtg gca ctg atg ctg      968  
               
               
                 Phe Thr Asn Ser Ser Tyr Arg Gln Pro Ile Leu Val Ala Leu Met Leu  
               
               
                 295                 300                 305                 310  
               
               
                   
               
               
                 cat gtg gct cag caa ttt tcc gga atc aat ggc att ttt tac tac tca     1016  
               
               
                 His Val Ala Gln Gln Phe Ser Gly Ile Asn Gly Ile Phe Tyr Tyr Ser  
               
               
                                 315                 320                 325  
               
               
                   
               
               
                 acc agc att ttt cag acg gct ggt atc agc aaa cct gtt tat gca acc     1064  
               
               
                 Thr Ser Ile Phe Gln Thr Ala Gly Ile Ser Lys Pro Val Tyr Ala Thr  
               
               
                             330                 335                 340  
               
               
                   
               
               
                 att gga gtt ggc gct gta aac atg gtt ttc act gct gtc tct gta ttc     1112  
               
               
                 Ile Gly Val Gly Ala Val Asn Met Val Phe Thr Ala Val Ser Val Phe  
               
               
                         345                 350                 355  
               
               
                   
               
               
                 ctt gtg gag aag gca ggg cga cgt tct ctc ttt cta att gga atg agt     1160  
               
               
                 Leu Val Glu Lys Ala Gly Arg Arg Ser Leu Phe Leu Ile Gly Met Ser  
               
               
                     360                 365                 370  
               
               
                   
               
               
                 ggg atg ttt gtt tgt gcc atc ttc atg tca gtg gga ctt gtg ctg ctg     1208  
               
               
                 Gly Met Phe Val Cys Ala Ile Phe Met Ser Val Gly Leu Val Leu Leu  
               
               
                 375                 380                 385                 390  
               
               
                   
               
               
                 aat aag ttc tct tgg atg agt tat gtg agc atg ata gcc atc ttc ctc     1256  
               
               
                 Asn Lys Phe Ser Trp Met Ser Tyr Val Ser Met Ile Ala Ile Phe Leu  
               
               
                                 395                 400                 405  
               
               
                   
               
               
                 ttt gtc agc ttc ttt gaa att ggg cca ggc ccg atc ccc tgg ttt atg     1304  
               
               
                 Phe Val Ser Phe Phe Glu Ile Gly Pro Gly Pro Ile Pro Trp Phe Met  
               
               
                             410                 415                 420  
               
               
                   
               
               
                 gtg gct gag ttt ttc agt caa gga cca cgt cct gct gct tta gca ata     1352  
               
               
                 Val Ala Glu Phe Phe Ser Gln Gly Pro Arg Pro Ala Ala Leu Ala Ile  
               
               
                         425                 430                 435  
               
               
                   
               
               
                 gct gca ttc agc aat tgg acc tgc aat ttc att gta gct ctg tgt ttc     1400  
               
               
                 Ala Ala Phe Ser Asn Trp Thr Cys Asn Phe Ile Val Ala Leu Cys Phe  
               
               
                     440                 445                 450  
               
               
                   
               
               
                 cag tac att gcg gac ttc tgt gga cct tat gtg ttt ttc ctc ttt gct     1448  
               
               
                 Gln Tyr Ile Ala Asp Phe Cys Gly Pro Tyr Val Phe Phe Leu Phe Ala  
               
               
                 455                 460                 465                 470  
               
               
                   
               
               
                 gga gtg ctc ctg gcc ttt acc ctg ttt aca ttt ttt aaa gtt cca gaa     1496  
               
               
                 Gly Val Leu Leu Ala Phe Thr Leu Phe Thr Phe Phe Lys Val Pro Glu  
               
               
                                 475                 480                 485  
               
               
                   
               
               
                 acc aaa gga aag tct ttt gag gaa att gct gca gaa ttc caa aag aag     1544  
               
               
                 Thr Lys Gly Lys Ser Phe Glu Glu Ile Ala Ala Glu Phe Gln Lys Lys  
               
               
                             490                 495                 500  
               
               
                   
               
               
                 agt ggc tca gcc cac agg cca aaa gct gct gta gaa atg aaa ttc cta     1592  
               
               
                 Ser Gly Ser Ala His Arg Pro Lys Ala Ala Val Glu Met Lys Phe Leu  
               
               
                         505                 510                 515  
               
               
                   
               
               
                 gga gct aca gag act gtg taaaaaaaaa accctgcttt ttggcatgaa            1640  
               
               
                 Gly Ala Thr Glu Thr Val  
               
               
                     520  
               
               
                   
               
               
                 cagaaacaat aagggaaccg tctg                                          1664  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 40  
               
               
                 &lt;211&gt; LENGTH: 524  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 40  
               
               
                   
               
               
                 Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr Val Ile Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly Val Ile Asn  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val Leu Gly Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile Asn Ser Thr  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys Pro Thr Pro  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile Thr Met Leu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met Thr Ala Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile Lys Ala Met  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu Met Gly Phe  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly Arg Ser Ile  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro Met Tyr Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Phe His  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile Ile Gly Leu  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu Leu Gly Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe Phe Cys Pro  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu Val Lys Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val Thr Lys Asp  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser Glu Gln Lys  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg Gln Pro Ile  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser Gly Ile Asn  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala Gly Ile Ser  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn Met Val Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg Arg Ser Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile Phe Met Ser  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser Tyr Val Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile Gly Pro Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln Gly Pro Arg  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr Cys Asn Phe  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys Gly Pro Tyr  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr Leu Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu Glu Ile Ala  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro Lys Ala Ala  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val  
               
               
                         515                 520  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 41  
               
               
                 &lt;211&gt; LENGTH: 1587  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (10)..(1581)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 41  
               
               
                   
               
               
                 ggatccacc atg aca gaa gat aag gtc act ggg acc ctg gtt ttc act gtc     51  
               
               
                           Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr Val  
               
               
                           1               5                   10  
               
               
                   
               
               
                 atc act gct gtg ctg ggt tcc ttc cag ttt gga tat gac att ggt gtg       99  
               
               
                 Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly Val  
               
               
                 15                  20                  25                  30  
               
               
                   
               
               
                 atc aat gca cct caa cag gta ata ata tct cac tat aga cat gtt ttg      147  
               
               
                 Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val Leu  
               
               
                                 35                  40                  45  
               
               
                   
               
               
                 ggt gtt cca ctg gat gac cga aaa gct atc aac aac tat gtt atc aac      195  
               
               
                 Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile Asn  
               
               
                             50                  55                  60  
               
               
                   
               
               
                 agt aca gat gaa ctg ccc aca atc tca tac tca atg aac cca aaa cca      243  
               
               
                 Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys Pro  
               
               
                         65                  70                  75  
               
               
                   
               
               
                 acc cct tgg gct gag gaa gag act gtg gca gct gct caa cta atc acc      291  
               
               
                 Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile Thr  
               
               
                     80                  85                  90  
               
               
                   
               
               
                 atg ctc tgg tcc ctg tct gta tcc agc ttt gca gtt ggt gga atg act      339  
               
               
                 Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met Thr  
               
               
                 95                  100                 105                 110  
               
               
                   
               
               
                 gca tca ttc ttt ggt ggg tgg ctt ggg gac aca ctt gga aga atc aaa      387  
               
               
                 Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile Lys  
               
               
                                 115                 120                 125  
               
               
                   
               
               
                 gcc atg tta gta gca aac att ctg tca tta gtt gga gct ctc ttg atg      435  
               
               
                 Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu Met  
               
               
                             130                 135                 140  
               
               
                   
               
               
                 ggg ttt tca aaa ttg gga cca tct cat ata ctt ata att gct gga aga      483  
               
               
                 Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly Arg  
               
               
                         145                 150                 155  
               
               
                   
               
               
                 agc ata tca gga cta tat tgt ggg cta att tca ggc ctg gtt cct atg      531  
               
               
                 Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro Met  
               
               
                     160                 165                 170  
               
               
                   
               
               
                 tat atc ggt gaa att gct cca acc gct ctc agg gga gca ctt ggc act      579  
               
               
                 Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr  
               
               
                 175                 180                 185                 190  
               
               
                   
               
               
                 ttt cat cag ctg gcc atc gtc acg ggc att ctt att agt cag att att      627  
               
               
                 Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile Ile  
               
               
                                 195                 200                 205  
               
               
                   
               
               
                 ggt ctt gaa ttt atc ttg ggc aat tat gat ctg tgg cac atc ctg ctt      675  
               
               
                 Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu Leu  
               
               
                             210                 215                 220  
               
               
                   
               
               
                 ggc ctg tct ggt gtg cga gcc atc ctt cag tct ctg cta ctc ttt ttc      723  
               
               
                 Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe Phe  
               
               
                         225                 230                 235  
               
               
                   
               
               
                 tgt cca gaa agc ccc aga tac ctt tac atc aag tta gat gag gaa gtc      771  
               
               
                 Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu Val  
               
               
                     240                 245                 250  
               
               
                   
               
               
                 aaa gca aaa caa agc ttg aaa aga ctc aga gga tat gat gat gtc acc      819  
               
               
                 Lys Ala Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val Thr  
               
               
                 255                 260                 265                 270  
               
               
                   
               
               
                 aaa gat att aat gaa atg aga aaa gaa aga gaa gaa gca tcg agt gag      867  
               
               
                 Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser Glu  
               
               
                                 275                 280                 285  
               
               
                   
               
               
                 cag aaa gtc tct ata att cag ctc ttc acc aat tcc agc tac cga cag      915  
               
               
                 Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg Gln  
               
               
                             290                 295                 300  
               
               
                   
               
               
                 cct att cta gtg gca ctg atg ctg cat gtg gct cag caa ttt tcc gga      963  
               
               
                 Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser Gly  
               
               
                         305                 310                 315  
               
               
                   
               
               
                 atc aat ggc att ttt tac tac tca acc agc att ttt cag acg gct ggt     1011  
               
               
                 Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala Gly  
               
               
                     320                 325                 330  
               
               
                   
               
               
                 atc agc aaa cct gtt tat gca acc att gga gtt ggc gct gta aac atg     1059  
               
               
                 Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn Met  
               
               
                 335                 340                 345                 350  
               
               
                   
               
               
                 gtt ttc act gct gtc tct gta ttc ctt gtg gag aag gca ggg cga cgt     1107  
               
               
                 Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg Arg  
               
               
                                 355                 360                 365  
               
               
                   
               
               
                 tct ctc ttt cta att gga atg agt ggg atg ttt gtt tgt gcc atc ttc     1155  
               
               
                 Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile Phe  
               
               
                             370                 375                 380  
               
               
                   
               
               
                 atg tca gtg gga ctt gtg ctg ctg aat aag ttc tct tgg atg agt tat     1203  
               
               
                 Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser Tyr  
               
               
                         385                 390                 395  
               
               
                   
               
               
                 gtg agc atg ata gcc atc ttc ctc ttt gtc agc ttc ttt gaa att ggg     1251  
               
               
                 Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile Gly  
               
               
                     400                 405                 410  
               
               
                   
               
               
                 cca ggc ccg atc ccc tgg ttt atg gtg gct gag ttt ttc agt caa gga     1299  
               
               
                 Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln Gly  
               
               
                 415                 420                 425                 430  
               
               
                   
               
               
                 cca cgt cct gct gct tta gca ata gct gca ttc agc aat tgg acc tgc     1347  
               
               
                 Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr Cys  
               
               
                                 435                 440                 445  
               
               
                   
               
               
                 aat ttc att gta gct ctg tgt ttc cag tac att gcg gac ttc tgt gga     1395  
               
               
                 Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys Gly  
               
               
                             450                 455                 460  
               
               
                   
               
               
                 cct tat gtg ttt ttc ctc ttt gct gga gtg ctc ctg gcc ttt acc ctg     1443  
               
               
                 Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr Leu  
               
               
                         465                 470                 475  
               
               
                   
               
               
                 ttt aca ttt ttt aaa gtt cca gaa acc aaa gga aag tct ttt gag gaa     1491  
               
               
                 Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu Glu  
               
               
                     480                 485                 490  
               
               
                   
               
               
                 att gct gca gaa ttc caa aag aag agt ggc tca gcc cac agg cca aaa     1539  
               
               
                 Ile Ala Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro Lys  
               
               
                 495                 500                 505                 510  
               
               
                   
               
               
                 gct gct gta gaa atg aaa ttc cta gga gct aca gag act gtg ctcgag      1587  
               
               
                 Ala Ala Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val  
               
               
                                 515                 520  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 42  
               
               
                 &lt;211&gt; LENGTH: 524  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 42  
               
               
                   
               
               
                 Met Thr Glu Asp Lys Val Thr Gly Thr Leu Val Phe Thr Val Ile Thr  
               
               
                   1               5                  10                  15  
               
               
                   
               
               
                 Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile Gly Val Ile Asn  
               
               
                              20                  25                  30  
               
               
                   
               
               
                 Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His Val Leu Gly Val  
               
               
                          35                  40                  45  
               
               
                   
               
               
                 Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val Ile Asn Ser Thr  
               
               
                      50                  55                  60  
               
               
                   
               
               
                 Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro Lys Pro Thr Pro  
               
               
                  65                  70                  75                  80  
               
               
                   
               
               
                 Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu Ile Thr Met Leu  
               
               
                                  85                  90                  95  
               
               
                   
               
               
                 Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly Met Thr Ala Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg Ile Lys Ala Met  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu Leu Met Gly Phe  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala Gly Arg Ser Ile  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val Pro Met Tyr Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu Gly Thr Phe His  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln Ile Ile Gly Leu  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile Leu Leu Gly Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu Phe Phe Cys Pro  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu Glu Val Lys Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp Val Thr Lys Asp  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser Ser Glu Gln Lys  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr Arg Gln Pro Ile  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe Ser Gly Ile Asn  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr Ala Gly Ile Ser  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val Asn Met Val Phe  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly Arg Arg Ser Leu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala Ile Phe Met Ser  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met Ser Tyr Val Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu Ile Gly Pro Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser Gln Gly Pro Arg  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp Thr Cys Asn Phe  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe Cys Gly Pro Tyr  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe Thr Leu Phe Thr  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe Glu Glu Ile Ala  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ala Glu Phe Gln Lys Lys Ser Gly Ser Ala His Arg Pro Lys Ala Ala  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Val Glu Met Lys Phe Leu Gly Ala Thr Glu Thr Val  
               
               
                         515                 520  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 43  
               
               
                 &lt;211&gt; LENGTH: 1473  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (7)..(1467)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 43  
               
               
                   
               
               
                 ggatcc act gtc atc act gct gtg ctg ggt tcc ttc cag ttt gga tat        48  
               
               
                        Thr Val Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr  
               
               
                        1               5                   10  
               
               
                   
               
               
                 gac att ggt gtg atc aat gca cct caa cag gta ata ata tct cac tat       96  
               
               
                 Asp Ile Gly Val Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr  
               
               
                 15                  20                  25                  30  
               
               
                   
               
               
                 aga cat gtt ttg ggt gtt cca ctg gat gac cga aaa gct atc aac aac      144  
               
               
                 Arg His Val Leu Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn  
               
               
                                 35                  40                  45  
               
               
                   
               
               
                 tat gtt atc aac agt aca gat gaa ctg ccc aca atc tca tac tca atg      192  
               
               
                 Tyr Val Ile Asn Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met  
               
               
                             50                  55                  60  
               
               
                   
               
               
                 aac cca aaa cca acc cct tgg gct gag gaa gag act gtg gca gct gct      240  
               
               
                 Asn Pro Lys Pro Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala  
               
               
                         65                  70                  75  
               
               
                   
               
               
                 caa cta atc acc atg ctc tgg tcc ctg tct gta tcc agc ttt gca gtt      288  
               
               
                 Gln Leu Ile Thr Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val  
               
               
                     80                  85                  90  
               
               
                   
               
               
                 ggt gga atg act gca tca ttc ttt ggt ggg tgg ctt ggg gac aca ctt      336  
               
               
                 Gly Gly Met Thr Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu  
               
               
                 95                  100                 105                 110  
               
               
                   
               
               
                 gga aga atc aaa gcc atg tta gta gca aac att ctg tca tta gtt gga      384  
               
               
                 Gly Arg Ile Lys Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly  
               
               
                                 115                 120                 125  
               
               
                   
               
               
                 gct ctc ttg atg ggg ttt tca aaa ttg gga cca tct cat ata ctt ata      432  
               
               
                 Ala Leu Leu Met Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile  
               
               
                             130                 135                 140  
               
               
                   
               
               
                 att gct gga aga agc ata tca gga cta tat tgt ggg cta att tca ggc      480  
               
               
                 Ile Ala Gly Arg Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly  
               
               
                         145                 150                 155  
               
               
                   
               
               
                 ctg gtt cct atg tat atc ggt gaa att gct cca acc gct ctc agg gga      528  
               
               
                 Leu Val Pro Met Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly  
               
               
                     160                 165                 170  
               
               
                   
               
               
                 gca ctt ggc act ttt cat cag ctg gcc atc gtc acg ggc att ctt att      576  
               
               
                 Ala Leu Gly Thr Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile  
               
               
                 175                 180                 185                 190  
               
               
                   
               
               
                 agt cag att att ggt ctt gaa ttt atc ttg ggc aat tat gat ctg tgg      624  
               
               
                 Ser Gln Ile Ile Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp  
               
               
                                 195                 200                 205  
               
               
                   
               
               
                 cac atc ctg ctt ggc ctg tct ggt gtg cga gcc atc ctt cag tct ctg      672  
               
               
                 His Ile Leu Leu Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu  
               
               
                             210                 215                 220  
               
               
                   
               
               
                 cta ctc ttt ttc tgt cca gaa agc ccc aga tac ctt tac atc aag tta      720  
               
               
                 Leu Leu Phe Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu  
               
               
                         225                 230                 235  
               
               
                   
               
               
                 gat gag gaa gtc aaa gca aaa caa agc ttg aaa aga ctc aga gga tat      768  
               
               
                 Asp Glu Glu Val Lys Ala Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr  
               
               
                     240                 245                 250  
               
               
                   
               
               
                 gat gat gtc acc aaa gat att aat gaa atg aga aaa gaa aga gaa gaa      816  
               
               
                 Asp Asp Val Thr Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu  
               
               
                 255                 260                 265                 270  
               
               
                   
               
               
                 gca tcg agt gag cag aaa gtc tct ata att cag ctc ttc acc aat tcc      864  
               
               
                 Ala Ser Ser Glu Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser  
               
               
                                 275                 280                 285  
               
               
                   
               
               
                 agc tac cga cag cct att cta gtg gca ctg atg ctg cat gtg gct cag      912  
               
               
                 Ser Tyr Arg Gln Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln  
               
               
                             290                 295                 300  
               
               
                   
               
               
                 caa ttt tcc gga atc aat ggc att ttt tac tac tca acc agc att ttt      960  
               
               
                 Gln Phe Ser Gly Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe  
               
               
                         305                 310                 315  
               
               
                   
               
               
                 cag acg gct ggt atc agc aaa cct gtt tat gca acc att gga gtt ggc     1008  
               
               
                 Gln Thr Ala Gly Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly  
               
               
                     320                 325                 330  
               
               
                   
               
               
                 gct gta aac atg gtt ttc act gct gtc tct gta ttc ctt gtg gag aag     1056  
               
               
                 Ala Val Asn Met Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys  
               
               
                 335                 340                 345                 350  
               
               
                   
               
               
                 gca ggg cga cgt tct ctc ttt cta att gga atg agt ggg atg ttt gtt     1104  
               
               
                 Ala Gly Arg Arg Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val  
               
               
                                 355                 360                 365  
               
               
                   
               
               
                 tgt gcc atc ttc atg tca gtg gga ctt gtg ctg ctg aat aag ttc tct     1152  
               
               
                 Cys Ala Ile Phe Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser  
               
               
                             370                 375                 380  
               
               
                   
               
               
                 tgg atg agt tat gtg agc atg ata gcc atc ttc ctc ttt gtc agc ttc     1200  
               
               
                 Trp Met Ser Tyr Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe  
               
               
                         385                 390                 395  
               
               
                   
               
               
                 ttt gaa att ggg cca ggc ccg atc ccc tgg ttt atg gtg gct gag ttt     1248  
               
               
                 Phe Glu Ile Gly Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe  
               
               
                     400                 405                 410  
               
               
                   
               
               
                 ttc agt caa gga cca cgt cct gct gct tta gca ata gct gca ttc agc     1296  
               
               
                 Phe Ser Gln Gly Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser  
               
               
                 415                 420                 425                 430  
               
               
                   
               
               
                 aat tgg acc tgc aat ttc att gta gct ctg tgt ttc cag tac att gcg     1344  
               
               
                 Asn Trp Thr Cys Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala  
               
               
                                 435                 440                 445  
               
               
                   
               
               
                 gac ttc tgt gga cct tat gtg ttt ttc ctc ttt gct gga gtg ctc ctg     1392  
               
               
                 Asp Phe Cys Gly Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu  
               
               
                             450                 455                 460  
               
               
                   
               
               
                 gcc ttt acc ctg ttt aca ttt ttt aaa gtt cca gaa acc aaa gga aag     1440  
               
               
                 Ala Phe Thr Leu Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys  
               
               
                         465                 470                 475  
               
               
                   
               
               
                 tct ttt gag gaa att gct gca gaa ttc ctcgag                          1473  
               
               
                 Ser Phe Glu Glu Ile Ala Ala Glu Phe  
               
               
                     480                 485  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 44  
               
               
                 &lt;211&gt; LENGTH: 487  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 44  
               
               
                   
               
               
                 Thr Val Ile Thr Ala Val Leu Gly Ser Phe Gln Phe Gly Tyr Asp Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gly Val Ile Asn Ala Pro Gln Gln Val Ile Ile Ser His Tyr Arg His  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Val Leu Gly Val Pro Leu Asp Asp Arg Lys Ala Ile Asn Asn Tyr Val  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asn Ser Thr Asp Glu Leu Pro Thr Ile Ser Tyr Ser Met Asn Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Lys Pro Thr Pro Trp Ala Glu Glu Glu Thr Val Ala Ala Ala Gln Leu  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ile Thr Met Leu Trp Ser Leu Ser Val Ser Ser Phe Ala Val Gly Gly  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Met Thr Ala Ser Phe Phe Gly Gly Trp Leu Gly Asp Thr Leu Gly Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ile Lys Ala Met Leu Val Ala Asn Ile Leu Ser Leu Val Gly Ala Leu  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Leu Met Gly Phe Ser Lys Leu Gly Pro Ser His Ile Leu Ile Ile Ala  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Gly Arg Ser Ile Ser Gly Leu Tyr Cys Gly Leu Ile Ser Gly Leu Val  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Pro Met Tyr Ile Gly Glu Ile Ala Pro Thr Ala Leu Arg Gly Ala Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gly Thr Phe His Gln Leu Ala Ile Val Thr Gly Ile Leu Ile Ser Gln  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ile Ile Gly Leu Glu Phe Ile Leu Gly Asn Tyr Asp Leu Trp His Ile  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Leu Gly Leu Ser Gly Val Arg Ala Ile Leu Gln Ser Leu Leu Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Phe Phe Cys Pro Glu Ser Pro Arg Tyr Leu Tyr Ile Lys Leu Asp Glu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Glu Val Lys Ala Lys Gln Ser Leu Lys Arg Leu Arg Gly Tyr Asp Asp  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Val Thr Lys Asp Ile Asn Glu Met Arg Lys Glu Arg Glu Glu Ala Ser  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Ser Glu Gln Lys Val Ser Ile Ile Gln Leu Phe Thr Asn Ser Ser Tyr  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Arg Gln Pro Ile Leu Val Ala Leu Met Leu His Val Ala Gln Gln Phe  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Ser Gly Ile Asn Gly Ile Phe Tyr Tyr Ser Thr Ser Ile Phe Gln Thr  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Ala Gly Ile Ser Lys Pro Val Tyr Ala Thr Ile Gly Val Gly Ala Val  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Asn Met Val Phe Thr Ala Val Ser Val Phe Leu Val Glu Lys Ala Gly  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Arg Arg Ser Leu Phe Leu Ile Gly Met Ser Gly Met Phe Val Cys Ala  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ile Phe Met Ser Val Gly Leu Val Leu Leu Asn Lys Phe Ser Trp Met  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Ser Tyr Val Ser Met Ile Ala Ile Phe Leu Phe Val Ser Phe Phe Glu  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Ile Gly Pro Gly Pro Ile Pro Trp Phe Met Val Ala Glu Phe Phe Ser  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gln Gly Pro Arg Pro Ala Ala Leu Ala Ile Ala Ala Phe Ser Asn Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Thr Cys Asn Phe Ile Val Ala Leu Cys Phe Gln Tyr Ile Ala Asp Phe  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Cys Gly Pro Tyr Val Phe Phe Leu Phe Ala Gly Val Leu Leu Ala Phe  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Thr Leu Phe Thr Phe Phe Lys Val Pro Glu Thr Lys Gly Lys Ser Phe  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Glu Glu Ile Ala Ala Glu Phe  
               
               
                                 485  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 45  
               
               
                 &lt;211&gt; LENGTH: 2038  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (10)..(1923)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 45  
               
               
                   
               
               
                 gttttcaga atg att tta ttc aag caa gca act tat ttc att tcc ttg ttt     51  
               
               
                           Met Ile Leu Phe Lys Gln Ala Thr Tyr Phe Ile Ser Leu Phe  
               
               
                           1               5                   10  
               
               
                   
               
               
                 gct aca gtt tcc tgt gga tgt ctg act caa ctc tat gaa aac gcc ttc       99  
               
               
                 Ala Thr Val Ser Cys Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe  
               
               
                 15                  20                  25                  30  
               
               
                   
               
               
                 ttc aga ggt ggg gat gta gct tcc atg tac acc cca aat gcc caa tac      147  
               
               
                 Phe Arg Gly Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr  
               
               
                                 35                  40                  45  
               
               
                   
               
               
                 tgc cag atg agg tgc aca ttc cac cca agg tgt ttg cta ttc agt ttt      195  
               
               
                 Cys Gln Met Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe  
               
               
                             50                  55                  60  
               
               
                   
               
               
                 ctt cca gca agt tca atc aat gac atg gag aaa agg ttt ggt tgc ttc      243  
               
               
                 Leu Pro Ala Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe  
               
               
                         65                  70                  75  
               
               
                   
               
               
                 ttg aaa gat agt gtt aca gga acc ctg cca aaa gta cat cga aca ggt      291  
               
               
                 Leu Lys Asp Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly  
               
               
                     80                  85                  90  
               
               
                   
               
               
                 gca gtt tct gga cat tcc ttg aag caa tgt ggt cat caa ata agt gct      339  
               
               
                 Ala Val Ser Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala  
               
               
                 95                  100                 105                 110  
               
               
                   
               
               
                 tgc cat cga gac att tat aaa gga gtt gat atg aga gga gtc aat ttt      387  
               
               
                 Cys His Arg Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe  
               
               
                                 115                 120                 125  
               
               
                   
               
               
                 aat gtg tct aag gtt agc agt gtt gaa gaa tgc caa aaa agg tgc acc      435  
               
               
                 Asn Val Ser Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr  
               
               
                             130                 135                 140  
               
               
                   
               
               
                 aat aac att cgc tgc cag ttt ttt tca tat gcc acg caa aca ttt cac      483  
               
               
                 Asn Asn Ile Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His  
               
               
                         145                 150                 155  
               
               
                   
               
               
                 aag gca gag tac cgg aac aat tgc cta tta aag tac agt ccc gga gga      531  
               
               
                 Lys Ala Glu Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly  
               
               
                     160                 165                 170  
               
               
                   
               
               
                 aca cct acc gct ata aag gtg ctg agt aac gtg gaa tct gga ttc tca      579  
               
               
                 Thr Pro Thr Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser  
               
               
                 175                 180                 185                 190  
               
               
                   
               
               
                 ctg aag ccc tgt gcc ctt tca gaa att ggt tgc cac atg aac atc ttc      627  
               
               
                 Leu Lys Pro Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe  
               
               
                                 195                 200                 205  
               
               
                   
               
               
                 cag cat ctt gcg ttc tca gat gtg gat gtt gcc agg ttt ctc act cca      675  
               
               
                 Gln His Leu Ala Phe Ser Asp Val Asp Val Ala Arg Phe Leu Thr Pro  
               
               
                             210                 215                 220  
               
               
                   
               
               
                 gat gct ttt gtg tgt cgg acc atc tgc acc tat cac ccc aac tgc ctc      723  
               
               
                 Asp Ala Phe Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu  
               
               
                         225                 230                 235  
               
               
                   
               
               
                 ttc ttt aca ttc tat aca aat gta tgg aaa atc gag tca caa aga aat      771  
               
               
                 Phe Phe Thr Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn  
               
               
                     240                 245                 250  
               
               
                   
               
               
                 gtt tgt ctt ctt aaa aca tct gaa agt ggc aca cca agt tcc tct act      819  
               
               
                 Val Cys Leu Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr  
               
               
                 255                 260                 265                 270  
               
               
                   
               
               
                 cct caa gaa aac acc ata tct gga tat agc ctt tta acc tgc aaa aga      867  
               
               
                 Pro Gln Glu Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg  
               
               
                                 275                 280                 285  
               
               
                   
               
               
                 act tta cct gaa ccc tgc cat tct aaa att tac ccg gga gtt gac ttt      915  
               
               
                 Thr Leu Pro Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe  
               
               
                             290                 295                 300  
               
               
                   
               
               
                 gga gga gaa gaa ttg aat gtg act ttt gtt aaa gga gtg aat gtt tgc      963  
               
               
                 Gly Gly Glu Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val Cys  
               
               
                         305                 310                 315  
               
               
                   
               
               
                 caa gag act tgc aca aag atg att cgc tgt cag ttt ttc act tat tct     1011  
               
               
                 Gln Glu Thr Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser  
               
               
                     320                 325                 330  
               
               
                   
               
               
                 tta ctc cca gaa gac tgt aag gaa gag aag tgt aag tgt ttc tta aga     1059  
               
               
                 Leu Leu Pro Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg  
               
               
                 335                 340                 345                 350  
               
               
                   
               
               
                 tta tct atg gat ggt tct cca act agg att gcg tat ggg aca caa ggg     1107  
               
               
                 Leu Ser Met Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly  
               
               
                                 355                 360                 365  
               
               
                   
               
               
                 agc tct ggt tac tct ttg aga ttg tgt aac act ggg gac aac gct gtc     1155  
               
               
                 Ser Ser Gly Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ala Val  
               
               
                             370                 375                 380  
               
               
                   
               
               
                 tgc aca aca aaa aca agc aca cgc att gtt gga gga aca aac tct tct     1203  
               
               
                 Cys Thr Thr Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser  
               
               
                         385                 390                 395  
               
               
                   
               
               
                 tgg gga gag tgg ccc tgg cag gtg agc ctg cag gtg aag ctg aca gct     1251  
               
               
                 Trp Gly Glu Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala  
               
               
                     400                 405                 410  
               
               
                   
               
               
                 cag agg cac ctg tgt gga ggg tca ctc ata gga cac cag tgg gtc ctc     1299  
               
               
                 Gln Arg His Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu  
               
               
                 415                 420                 425                 430  
               
               
                   
               
               
                 act gct gcc cac tgc ttt gat ggg ctt ccc ctg cag gat gtt tgg cgc     1347  
               
               
                 Thr Ala Ala His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg  
               
               
                                 435                 440                 445  
               
               
                   
               
               
                 atc tat agt ggc att tta aat ctg tca gac att aca aaa gat aca cct     1395  
               
               
                 Ile Tyr Ser Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro  
               
               
                             450                 455                 460  
               
               
                   
               
               
                 ttc tca caa ata aaa gag att att att cac caa aac tat aaa gtc tca     1443  
               
               
                 Phe Ser Gln Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser  
               
               
                         465                 470                 475  
               
               
                   
               
               
                 gaa ggg aat cat gat atc gcc ttg ata aaa ctc cag gct cct ttg aat     1491  
               
               
                 Glu Gly Asn His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn  
               
               
                     480                 485                 490  
               
               
                   
               
               
                 tac act gaa ttc caa aaa cca ata tgc cta cct tcc aaa ggt gac aca     1539  
               
               
                 Tyr Thr Glu Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr  
               
               
                 495                 500                 505                 510  
               
               
                   
               
               
                 agc aca att tat acc aac tgt tgg gta acc gga tgg ggc ttc tcg aag     1587  
               
               
                 Ser Thr Ile Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys  
               
               
                                 515                 520                 525  
               
               
                   
               
               
                 gag aaa ggt gaa atc caa aat att cta caa aag gta aat att cct ttg     1635  
               
               
                 Glu Lys Gly Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu  
               
               
                             530                 535                 540  
               
               
                   
               
               
                 gta aca aat gaa gaa tgc cag aaa aga tat caa gat tat aaa ata acc     1683  
               
               
                 Val Thr Asn Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr  
               
               
                         545                 550                 555  
               
               
                   
               
               
                 caa cgg atg gtc tgt gct ggc tat aaa gaa ggg gga aaa gat gct tgt     1731  
               
               
                 Gln Arg Met Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys  
               
               
                     560                 565                 570  
               
               
                   
               
               
                 aag gga gat tca ggt ggt ccc tta gtt tgc aaa cac aac gga atg tgg     1779  
               
               
                 Lys Gly Asp Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met Trp  
               
               
                 575                 580                 585                 590  
               
               
                   
               
               
                 cgt ttg gtg ggc atc acc agc tgg ggt gaa ggc tgt gcc cgc agg gag     1827  
               
               
                 Arg Leu Val Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu  
               
               
                                 595                 600                 605  
               
               
                   
               
               
                 caa cct ggt gtc tac acc aaa gtc gct gag tac atg gac tgg att tta     1875  
               
               
                 Gln Pro Gly Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu  
               
               
                             610                 615                 620  
               
               
                   
               
               
                 gag aaa aca cag agc agt gat gga aaa gct cag atg cag tca cca gca     1923  
               
               
                 Glu Lys Thr Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala  
               
               
                         625                 630                 635  
               
               
                   
               
               
                 tgagaagcag tccagagtct aggcaatttt tacaacctga gttcaagtca aattctgagc   1983  
               
               
                   
               
               
                 ctggggggtc ctcatctgca aagcatgaag agtggcatct tctttgcatc ctaag        2038  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 46  
               
               
                 &lt;211&gt; LENGTH: 638  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 46  
               
               
                   
               
               
                 Met Ile Leu Phe Lys Gln Ala Thr Tyr Phe Ile Ser Leu Phe Ala Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Ser Cys Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe Phe Arg  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Gly Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr Cys Gln  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Met Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe Leu Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ala Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe Leu Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Asp Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly Ala Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ser Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala Cys His  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Arg Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe Asn Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ser Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr Asn Asn  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ile Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His Lys Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Glu Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly Thr Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Thr Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser Leu Lys  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Pro Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe Gln His  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Ala Phe Ser Asp Val Asp Val Ala Arg Phe Leu Thr Pro Asp Ala  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Phe Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu Phe Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Thr Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn Val Cys  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr Pro Gln  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Glu Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg Thr Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Pro Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe Gly Gly  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Glu Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val Cys Gln Glu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Thr Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser Leu Leu  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Pro Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg Leu Ser  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Met Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly Ser Ser  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Gly Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ala Val Cys Thr  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Thr Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser Trp Gly  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Glu Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala Gln Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 His Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu Thr Ala  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Ala His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg Ile Tyr  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ser Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro Phe Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Gln Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser Glu Gly  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Asn His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn Tyr Thr  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Glu Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr Ser Thr  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Ile Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys Glu Lys  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Gly Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu Val Thr  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Asn Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr Gln Arg  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Met Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys Lys Gly  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Asp Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met Trp Arg Leu  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Val Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu Gln Pro  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Gly Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu Glu Lys  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 Thr Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala  
               
               
                 625                 630                 635  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 47  
               
               
                 &lt;211&gt; LENGTH: 1869  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(1869)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 47  
               
               
                   
               
               
                 gga tcc gga tgt ctg act caa ctc tat gaa aac gcc ttc ttc aga ggt       48  
               
               
                 Gly Ser Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe Phe Arg Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 ggg gat gta gct tcc atg tac acc cca aat gcc caa tac tgc cag atg       96  
               
               
                 Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr Cys Gln Met  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 agg tgc aca ttc cac cca agg tgt ttg cta ttc agt ttt ctt cca gca      144  
               
               
                 Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe Leu Pro Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 agt tca atc aat gac atg gag aaa agg ttt ggt tgc ttc ttg aaa gat      192  
               
               
                 Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe Leu Lys Asp  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 agt gtt aca gga acc ctg cca aaa gta cat cga aca ggt gca gtt tct      240  
               
               
                 Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly Ala Val Ser  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 gga cat tcc ttg aag caa tgt ggt cat caa ata agt gct tgc cat cga      288  
               
               
                 Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala Cys His Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 gac att tat aaa gga gtt gat atg aga gga gtc aat ttt aat gtg tct      336  
               
               
                 Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe Asn Val Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 aag gtt agc agt gtt gaa gaa tgc caa aaa agg tgc acc agt aac att      384  
               
               
                 Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr Ser Asn Ile  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 cgc tgc cag ttt ttt tca tat gcc acg caa aca ttt cac aag gca gag      432  
               
               
                 Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His Lys Ala Glu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 tac cgg aac aat tgc cta tta aag tac agt ccc gga gga aca cct acc      480  
               
               
                 Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly Thr Pro Thr  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 gct ata aag gtg ctg agt aac gtg gaa tct gga ttc tca ctg aag ccc      528  
               
               
                 Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser Leu Lys Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 tgt gcc ctt tca gaa att ggt tgc cac atg aac atc ttc cag cat ctt      576  
               
               
                 Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe Gln His Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 gcg ttc tca gat gtg gat gtt gcc agg ttt ctc act cca gat gct ttt      624  
               
               
                 Ala Phe Ser Asp Val Asp Val Ala Arg Phe Leu Thr Pro Asp Ala Phe  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 gtg tgt cgg acc atc tgc acc tat cac ccc aac tgc ctc ttc ttt aca      672  
               
               
                 Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu Phe Phe Thr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 ttc tat aca aat gta tgg aaa atc gag tca caa aga aat gtt tgt ctt      720  
               
               
                 Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn Val Cys Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ctt aaa aca tct gaa agt ggc aca cca agt tcc tct act cct caa gaa      768  
               
               
                 Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr Pro Gln Glu  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 aac acc ata tct gga tat agc ctt tta acc tgc aaa aga act tta cct      816  
               
               
                 Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg Thr Leu Pro  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 gaa ccc tgc cat tct aaa att tac ccg gga gtt gac ttt gga gga gaa      864  
               
               
                 Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe Gly Gly Glu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 gaa ttg aat gtg act ttt gtt aaa gga gtg aat gtt tgc caa gag act      912  
               
               
                 Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val Cys Gln Glu Thr  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 tgc aca aag atg att cgc tgt cag ttt ttc act tat tct tta ctc cca      960  
               
               
                 Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser Leu Leu Pro  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gaa gac tgt aag gaa gag aag tgt aag tgt ttc tta aga tta tct atg     1008  
               
               
                 Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg Leu Ser Met  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 gat ggt tct cca act agg att gcg tat ggg aca caa ggg agc tct ggt     1056  
               
               
                 Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly Ser Ser Gly  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 tac tct ttg aga ttg tgt aac act ggg gac aac gct gtc tgc aca aca     1104  
               
               
                 Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ala Val Cys Thr Thr  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 aaa aca agc aca cgc att gtt gga gga aca aac tct tct tgg gga gag     1152  
               
               
                 Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser Trp Gly Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 tgg ccc tgg cag gtg agc ctg cag gtg aag ctg aca gct cag agg cat     1200  
               
               
                 Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala Gln Arg His  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 ctg tgt gga ggg tca ctc ata gga cac cag tgg gtc ctc act gct gcc     1248  
               
               
                 Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu Thr Ala Ala  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 cac tgc ttt gat ggg ctt ccc ctg cag gat gtt tgg cgc atc tat agt     1296  
               
               
                 His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg Ile Tyr Ser  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 ggc att tta aat ctg tca gac att aca aaa gat aca cct ttc tca caa     1344  
               
               
                 Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro Phe Ser Gln  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 ata aaa gag att att att cac caa aac tat aaa gtc tca gaa ggg aat     1392  
               
               
                 Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser Glu Gly Asn  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 cat gat atc gcc ttg ata aaa ctc cag gct cct ttg aat tac act gaa     1440  
               
               
                 His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn Tyr Thr Glu  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 ttc caa aaa cca ata tgc cta cct tcc aaa ggt gac aca agc aca att     1488  
               
               
                 Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr Ser Thr Ile  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 tat acc aac tgt tgg gta acc gga tgg ggc ttc tcg aag gag aaa ggt     1536  
               
               
                 Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys Glu Lys Gly  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 gaa atc caa aat att cta caa aag gta aat att cct ttg gta aca aat     1584  
               
               
                 Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu Val Thr Asn  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 gaa gaa tgc cag aaa aga tat caa gat tat aaa ata acc caa cgg atg     1632  
               
               
                 Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr Gln Arg Met  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 gtc tgt gct ggc tat aaa gaa ggg gga aaa gat gct tgt aag gga gat     1680  
               
               
                 Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys Lys Gly Asp  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 tca ggt ggt ccc tta gtt tgc aaa cac aat gga atg tgg cgt ttg gtg     1728  
               
               
                 Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met Trp Arg Leu Val  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 ggc atc acc agc tgg ggt gaa ggc tgt gcc cgc agg gag caa cct ggt     1776  
               
               
                 Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu Gln Pro Gly  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 gtc tac acc aaa gtc gct gag tac atg gac tgg att tta gag aaa aca     1824  
               
               
                 Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu Glu Lys Thr  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 cag agc agt gat gga aaa gct cag atg cag tca cca gca ctc gag         1869  
               
               
                 Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala Leu Glu  
               
               
                     610                 615                 620  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 48  
               
               
                 &lt;211&gt; LENGTH: 623  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 48  
               
               
                   
               
               
                 Gly Ser Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe Phe Arg Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr Cys Gln Met  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe Leu Pro Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe Leu Lys Asp  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly Ala Val Ser  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala Cys His Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe Asn Val Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr Ser Asn Ile  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His Lys Ala Glu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly Thr Pro Thr  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser Leu Lys Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe Gln His Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ala Phe Ser Asp Val Asp Val Ala Arg Phe Leu Thr Pro Asp Ala Phe  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu Phe Phe Thr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn Val Cys Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr Pro Gln Glu  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg Thr Leu Pro  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe Gly Gly Glu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val Cys Gln Glu Thr  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser Leu Leu Pro  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg Leu Ser Met  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly Ser Ser Gly  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ala Val Cys Thr Thr  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser Trp Gly Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala Gln Arg His  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu Thr Ala Ala  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg Ile Tyr Ser  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro Phe Ser Gln  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser Glu Gly Asn  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn Tyr Thr Glu  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr Ser Thr Ile  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys Glu Lys Gly  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu Val Thr Asn  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr Gln Arg Met  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys Lys Gly Asp  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met Trp Arg Leu Val  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu Gln Pro Gly  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu Glu Lys Thr  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala Leu Glu  
               
               
                     610                 615                 620  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 49  
               
               
                 &lt;211&gt; LENGTH: 2245  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (72)..(1985)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 49  
               
               
                   
               
               
                 agaacagctt gaagaccgtt catttttaag tgacaagaga ctcacctcca agaagcaatt     60  
               
               
                   
               
               
                 gtgttttcag a atg att tta ttc aag caa gca act tat ttc att tcc ttg     110  
               
               
                              Met Ile Leu Phe Lys Gln Ala Thr Tyr Phe Ile Ser Leu  
               
               
                              1               5                   10  
               
               
                   
               
               
                 ttt gct aca gtt tcc tgt gga tgt ctg act caa ctc tat gaa aac gcc      158  
               
               
                 Phe Ala Thr Val Ser Cys Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala  
               
               
                     15                  20                  25  
               
               
                   
               
               
                 ttc ttc aga ggt ggg gat gta gct tcc atg tac acc cca aat gcc caa      206  
               
               
                 Phe Phe Arg Gly Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln  
               
               
                 30                  35                  40                  45  
               
               
                   
               
               
                 tac tgc cag atg agg tgc aca ttc cac cca agg tgt ttg cta ttc agt      254  
               
               
                 Tyr Cys Gln Met Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser  
               
               
                                 50                  55                  60  
               
               
                   
               
               
                 ttt ctt cca gca agt tca atc aat gac atg gag aaa agg ttt ggt tgc      302  
               
               
                 Phe Leu Pro Ala Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys  
               
               
                             65                  70                  75  
               
               
                   
               
               
                 ttc ttg aaa gat agt gtt aca gga acc ctg cca aaa gta cat cga aca      350  
               
               
                 Phe Leu Lys Asp Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr  
               
               
                         80                  85                  90  
               
               
                   
               
               
                 ggt gca gtt tct gga cat tcc ttg aag caa tgt ggt cat caa ata agt      398  
               
               
                 Gly Ala Val Ser Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser  
               
               
                      95                 100                 105  
               
               
                   
               
               
                 gct tgc cat cga gac att tat aaa gga gtt gat atg aga gga gtc aat      446  
               
               
                 Ala Cys His Arg Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn  
               
               
                 110                 115                 120                 125  
               
               
                   
               
               
                 ttt aat gtg tct aag gtt agc agt gtt gaa gaa tgc caa aaa agg tgc      494  
               
               
                 Phe Asn Val Ser Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys  
               
               
                                 130                 135                 140  
               
               
                   
               
               
                 acc aat aac att cgc tgc cag ttt ttt tca tat gcc acg caa aca ttt      542  
               
               
                 Thr Asn Asn Ile Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe  
               
               
                             145                 150                 155  
               
               
                   
               
               
                 cac aag gca gag tac cgg aac aat tgc cta tta aag tac agt ccc gga      590  
               
               
                 His Lys Ala Glu Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly  
               
               
                         160                 165                 170  
               
               
                   
               
               
                 gga aca cct acc gct ata aag gtg ctg agt aac gtg gaa tct gga ttc      638  
               
               
                 Gly Thr Pro Thr Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe  
               
               
                     175                 180                 185  
               
               
                   
               
               
                 tca ctg aag ccc tgt gcc ctt tca gaa att ggt tgc cac atg aac atc      686  
               
               
                 Ser Leu Lys Pro Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile  
               
               
                 190                 195                 200                 205  
               
               
                   
               
               
                 ttc cag cat ctt gcg ttc tca gat gtg gat gtt gcc agg gtt ctc act      734  
               
               
                 Phe Gln His Leu Ala Phe Ser Asp Val Asp Val Ala Arg Val Leu Thr  
               
               
                                 210                 215                 220  
               
               
                   
               
               
                 cca gat gct ttt gtg tgt cgg acc atc tgc acc tat cac ccc aac tgc      782  
               
               
                 Pro Asp Ala Phe Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys  
               
               
                             225                 230                 235  
               
               
                   
               
               
                 ctc ttc ttt aca ttc tat aca aat gta tgg aaa atc gag tca caa aga      830  
               
               
                 Leu Phe Phe Thr Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg  
               
               
                         240                 245                 250  
               
               
                   
               
               
                 aat gtt tgt ctt ctt aaa aca tct gaa agt ggc aca cca agt tcc tct      878  
               
               
                 Asn Val Cys Leu Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser  
               
               
                     255                 260                 265  
               
               
                   
               
               
                 act cct caa gaa aac acc ata tct gga tat agc ctt tta acc tgc aaa      926  
               
               
                 Thr Pro Gln Glu Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys  
               
               
                 270                 275                 280                 285  
               
               
                   
               
               
                 aga act tta cct gaa ccc tgc cat tct aaa att tac ccg gga gtt gac      974  
               
               
                 Arg Thr Leu Pro Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp  
               
               
                                 290                 295                 300  
               
               
                   
               
               
                 ttt gga gga gaa gaa ttg aat gtg act ttt gtt aaa gga gtg aat gtt     1022  
               
               
                 Phe Gly Gly Glu Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val  
               
               
                             305                 310                 315  
               
               
                   
               
               
                 tgc caa gag act tgc aca aag atg att cgc tgt cag ttt ttc act tat     1070  
               
               
                 Cys Gln Glu Thr Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr  
               
               
                         320                 325                 330  
               
               
                   
               
               
                 tct tta ctc cca gaa gac tgt aag gaa gag aag tgt aag tgt ttc tta     1118  
               
               
                 Ser Leu Leu Pro Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu  
               
               
                     335                 340                 345  
               
               
                   
               
               
                 aga tta tct atg gat ggt tct cca act agg att gcg tat ggg aca caa     1166  
               
               
                 Arg Leu Ser Met Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln  
               
               
                 350                 355                 360                 365  
               
               
                   
               
               
                 ggg agc tct ggt tac tct ttg aga ttg tgt aac act ggg gac aac tct     1214  
               
               
                 Gly Ser Ser Gly Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ser  
               
               
                                 370                 375                 380  
               
               
                   
               
               
                 gtc tgc aca aca aaa aca agc aca cgc att gtt gga gga aca aac tct     1262  
               
               
                 Val Cys Thr Thr Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser  
               
               
                             385                 390                 395  
               
               
                   
               
               
                 tct tgg gga gag tgg ccc tgg cag gtg agc ctg cag gtg aag ctg aca     1310  
               
               
                 Ser Trp Gly Glu Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr  
               
               
                         400                 405                 410  
               
               
                   
               
               
                 gct cag agg cac ctg tgt gga ggg tca ctc ata gga cac cag tgg gtc     1358  
               
               
                 Ala Gln Arg His Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val  
               
               
                     415                 420                 425  
               
               
                   
               
               
                 ctc act gct gcc cac tgc ttt gat ggg ctt ccc ctg cag gat gtt tgg     1406  
               
               
                 Leu Thr Ala Ala His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp  
               
               
                 430                 435                 440                 445  
               
               
                   
               
               
                 cgc atc tat agt ggc att tta aat ctg tca gac att aca aaa gat aca     1454  
               
               
                 Arg Ile Tyr Ser Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr  
               
               
                                 450                 455                 460  
               
               
                   
               
               
                 cct ttc tca caa ata aaa gag att att att cac caa aac tat aaa gtc     1502  
               
               
                 Pro Phe Ser Gln Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val  
               
               
                             465                 470                 475  
               
               
                   
               
               
                 tca gaa ggg aat cat gat atc gcc ttg ata aaa ctc cag gct cct ttg     1550  
               
               
                 Ser Glu Gly Asn His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu  
               
               
                         480                 485                 490  
               
               
                   
               
               
                 aat tac act gaa ttc caa aaa cca ata tgc cta cct tcc aaa ggt gac     1598  
               
               
                 Asn Tyr Thr Glu Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp  
               
               
                     495                 500                 505  
               
               
                   
               
               
                 aca agc aca att tat acc aac tgt tgg gta acc gga tgg ggc ttc tcg     1646  
               
               
                 Thr Ser Thr Ile Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser  
               
               
                 510                 515                 520                 525  
               
               
                   
               
               
                 aag gag aaa ggt gaa atc caa aat att cta caa aag gta aat att cct     1694  
               
               
                 Lys Glu Lys Gly Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro  
               
               
                                 530                 535                 540  
               
               
                   
               
               
                 ttg gta aca aat gaa gaa tgc cag aaa aga tat caa gat tat aaa ata     1742  
               
               
                 Leu Val Thr Asn Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile  
               
               
                             545                 550                 555  
               
               
                   
               
               
                 acc caa cgg atg gtc tgt gct ggc tat aaa gaa ggg gga aaa gat gct     1790  
               
               
                 Thr Gln Arg Met Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala  
               
               
                         560                 565                 570  
               
               
                   
               
               
                 tgt aag gga gat tca ggt ggt ccc tta gtt tgc aaa cac aac gga atg     1838  
               
               
                 Cys Lys Gly Asp Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met  
               
               
                     575                 580                 585  
               
               
                   
               
               
                 tgg cgt ttg gtg ggc atc aca agc tgg ggt gaa ggc tgt gcc cgc agg     1886  
               
               
                 Trp Arg Leu Val Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg  
               
               
                 590                 595                 600                 605  
               
               
                   
               
               
                 gag caa cct ggt gtc tac acc aaa gtc gct gag tac atg gac tgg att     1934  
               
               
                 Glu Gln Pro Gly Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile  
               
               
                                 610                 615                 620  
               
               
                   
               
               
                 tta gag aaa aca cag agc agt gat gga aaa gct cag atg cag tca cca     1982  
               
               
                 Leu Glu Lys Thr Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro  
               
               
                             625                 630                 635  
               
               
                   
               
               
                 gca tgagaagcag tccagagtct aggcaatttt tacaacctga gttcaagtca          2035  
               
               
                 Ala  
               
               
                   
               
               
                 aattctgagc ctggggggtc ctcatctgca aagcatggag agtggcatct tctttgcatc   2095  
               
               
                   
               
               
                 ctaaggacga aagacacagt gcactcagag ctgctgagga caatgtctgc tgaagcccgc   2155  
               
               
                   
               
               
                 tttcagcacg ccgtaaccag gggctgacaa tgcgaggtcg caactgagat ctccatgact   2215  
               
               
                   
               
               
                 gtgtgttgtg aaataaaatg gtgaaagatc                                    2245  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 50  
               
               
                 &lt;211&gt; LENGTH: 638  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 50  
               
               
                   
               
               
                 Met Ile Leu Phe Lys Gln Ala Thr Tyr Phe Ile Ser Leu Phe Ala Thr  
               
               
                 1                5                  10                  15  
               
               
                   
               
               
                 Val Ser Cys Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe Phe Arg  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Gly Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr Cys Gln  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Met Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe Leu Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ala Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe Leu Lys  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Asp Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly Ala Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ser Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala Cys His  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Arg Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe Asn Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ser Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr Asn Asn  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ile Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His Lys Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Glu Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly Thr Pro  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Thr Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser Leu Lys  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Pro Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe Gln His  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Ala Phe Ser Asp Val Asp Val Ala Arg Val Leu Thr Pro Asp Ala  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Phe Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu Phe Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Thr Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn Val Cys  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr Pro Gln  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Glu Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg Thr Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Pro Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe Gly Gly  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Glu Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val Cys Gln Glu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Thr Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser Leu Leu  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Pro Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg Leu Ser  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Met Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly Ser Ser  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Gly Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ser Val Cys Thr  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Thr Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser Trp Gly  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Glu Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala Gln Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 His Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu Thr Ala  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Ala His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg Ile Tyr  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ser Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro Phe Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Gln Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser Glu Gly  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Asn His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn Tyr Thr  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Glu Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr Ser Thr  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Ile Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys Glu Lys  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Gly Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu Val Thr  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Asn Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr Gln Arg  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Met Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys Lys Gly  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Asp Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met Trp Arg Leu  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Val Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu Gln Pro  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Gly Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu Glu Lys  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 Thr Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala  
               
               
                 625                 630                 635  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 51  
               
               
                 &lt;211&gt; LENGTH: 1869  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (7)..(1863)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 51  
               
               
                   
               
               
                 ggatcc gga tgt ctg act caa ctc tat gaa aac gcc ttc ttc aga ggt        48  
               
               
                        Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe Phe Arg Gly  
               
               
                        1               5                   10  
               
               
                   
               
               
                 ggg gat gta gct tcc atg tac acc cca aat gcc caa tac tgc cag atg       96  
               
               
                 Gly Asp Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr Cys Gln Met  
               
               
                 15                  20                  25                  30  
               
               
                   
               
               
                 agg tgc aca ttc cac cca agg tgt ttg cta ttc agt ttt ctt cca gca      144  
               
               
                 Arg Cys Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe Leu Pro Ala  
               
               
                                 35                  40                  45  
               
               
                   
               
               
                 agt tca atc aat gac atg gag aaa agg ttt ggt tgc ttc ttg aaa gat      192  
               
               
                 Ser Ser Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe Leu Lys Asp  
               
               
                             50                  55                  60  
               
               
                   
               
               
                 agt gtt aca gga acc ctg cca aaa gta cat cga aca ggt gca gtt tct      240  
               
               
                 Ser Val Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly Ala Val Ser  
               
               
                         65                  70                  75  
               
               
                   
               
               
                 gga cat tcc ttg aag caa tgt ggt cat caa ata agt gct tgc cat cga      288  
               
               
                 Gly His Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala Cys His Arg  
               
               
                     80                  85                  90  
               
               
                   
               
               
                 gac att tat aaa gga gtt gat atg aga gga gtc aat ttt aat gtg tct      336  
               
               
                 Asp Ile Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe Asn Val Ser  
               
               
                 95                  100                 105                 110  
               
               
                   
               
               
                 aag gtt agc agt gtt gaa gaa tgc caa aaa agg tgc acc agt aac att      384  
               
               
                 Lys Val Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr Ser Asn Ile  
               
               
                                 115                 120                 125  
               
               
                   
               
               
                 cgc tgc cag ttt ttt tca tat gcc acg caa aca ttt cac aag gca gag      432  
               
               
                 Arg Cys Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His Lys Ala Glu  
               
               
                             130                 135                 140  
               
               
                   
               
               
                 tac cgg aac aat tgc cta tta aag tac agt ccc gga gga aca cct acc      480  
               
               
                 Tyr Arg Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly Thr Pro Thr  
               
               
                         145                 150                 155  
               
               
                   
               
               
                 gct ata aag gtg ctg agt aac gtg gaa tct gga ttc tca ctg aag ccc      528  
               
               
                 Ala Ile Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser Leu Lys Pro  
               
               
                     160                 165                 170  
               
               
                   
               
               
                 tgt gcc ctt tca gaa att ggt tgc cac atg aac atc ttc cag cat ctt      576  
               
               
                 Cys Ala Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe Gln His Leu  
               
               
                 175                 180                 185                 190  
               
               
                   
               
               
                 gcg ttc tca gat gtg gat gtt gcc agg ttt ctc act cca gat gct ttt      624  
               
               
                 Ala Phe Ser Asp Val Asp Val Ala Arg Phe Leu Thr Pro Asp Ala Phe  
               
               
                                 195                 200                 205  
               
               
                   
               
               
                 gtg tgt cgg acc atc tgc acc tat cac ccc aac tgc ctc ttc ttt aca      672  
               
               
                 Val Cys Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu Phe Phe Thr  
               
               
                             210                 215                 220  
               
               
                   
               
               
                 ttc tat aca aat gta tgg aaa atc gag tca caa aga aat gtt tgt ctt      720  
               
               
                 Phe Tyr Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn Val Cys Leu  
               
               
                         225                 230                 235  
               
               
                   
               
               
                 ctt aaa aca tct gaa agt ggc aca cca agt tcc tct act cct caa gaa      768  
               
               
                 Leu Lys Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr Pro Gln Glu  
               
               
                     240                 245                 250  
               
               
                   
               
               
                 aac acc ata tct gga tat agc ctt tta acc tgc aaa aga act tta cct      816  
               
               
                 Asn Thr Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg Thr Leu Pro  
               
               
                 255                 260                 265                 270  
               
               
                   
               
               
                 gaa ccc tgc cat tct aaa att tac ccg gga gtt gac ttt gga gga gaa      864  
               
               
                 Glu Pro Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe Gly Gly Glu  
               
               
                                 275                 280                 285  
               
               
                   
               
               
                 gaa ttg aat gtg act ttt gtt aaa gga gtg aat gtt tgc caa gag act      912  
               
               
                 Glu Leu Asn Val Thr Phe Val Lys Gly Val Asn Val Cys Gln Glu Thr  
               
               
                             290                 295                 300  
               
               
                   
               
               
                 tgc aca aag atg att cgc tgt cag ttt ttc act tat tct tta ctc cca      960  
               
               
                 Cys Thr Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser Leu Leu Pro  
               
               
                         305                 310                 315  
               
               
                   
               
               
                 gaa gac tgt aag gaa gag aag tgt aag tgt ttc tta aga tta tct atg     1008  
               
               
                 Glu Asp Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg Leu Ser Met  
               
               
                     320                 325                 330  
               
               
                   
               
               
                 gat ggt tct cca act agg att gcg tat ggg aca caa ggg agc tct ggt     1056  
               
               
                 Asp Gly Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly Ser Ser Gly  
               
               
                 335                 340                 345                 350  
               
               
                   
               
               
                 tac tct ttg aga ttg tgt aac act ggg gac aac gct gtc tgc aca aca     1104  
               
               
                 Tyr Ser Leu Arg Leu Cys Asn Thr Gly Asp Asn Ala Val Cys Thr Thr  
               
               
                                 355                 360                 365  
               
               
                   
               
               
                 aaa aca agc aca cgc att gtt gga gga aca aac tct tct tgg gga gag     1152  
               
               
                 Lys Thr Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser Trp Gly Glu  
               
               
                             370                 375                 380  
               
               
                   
               
               
                 tgg ccc tgg cag gtg agc ctg cag gtg aag ctg aca gct cag agg cac     1200  
               
               
                 Trp Pro Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala Gln Arg His  
               
               
                         385                 390                 395  
               
               
                   
               
               
                 ctg tgt gga ggg tca ctc ata gga cac cag tgg gtc ctc act gct gcc     1248  
               
               
                 Leu Cys Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu Thr Ala Ala  
               
               
                     400                 405                 410  
               
               
                   
               
               
                 cac tgc ttt gat ggg ctt ccc ctg cag gat gtt tgg cgc atc tat agt     1296  
               
               
                 His Cys Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg Ile Tyr Ser  
               
               
                 415                 420                 425                 430  
               
               
                   
               
               
                 ggc att tta aat ctg tca gac att aca aaa gat aca cct ttc tca caa     1344  
               
               
                 Gly Ile Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro Phe Ser Gln  
               
               
                                 435                 440                 445  
               
               
                   
               
               
                 ata aaa gag att att att cac caa aac tat aaa gtc tca gaa ggg aat     1392  
               
               
                 Ile Lys Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser Glu Gly Asn  
               
               
                             450                 455                 460  
               
               
                   
               
               
                 cat gat atc gcc ttg ata aaa ctc cag gct cct ttg aat tac act gaa     1440  
               
               
                 His Asp Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn Tyr Thr Glu  
               
               
                         465                 470                 475  
               
               
                   
               
               
                 ttc caa aaa cca ata tgc cta cct tcc aaa ggt gac aca agc aca att     1488  
               
               
                 Phe Gln Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr Ser Thr Ile  
               
               
                     480                 485                 490  
               
               
                   
               
               
                 tat acc aac tgt tgg gta acc gga tgg ggc ttc tcg aag gag aaa ggt     1536  
               
               
                 Tyr Thr Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys Glu Lys Gly  
               
               
                 495                 500                 505                 510  
               
               
                   
               
               
                 gaa atc caa aat att cta caa aag gta aat att cct ttg gta aca aat     1584  
               
               
                 Glu Ile Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu Val Thr Asn  
               
               
                                 515                 520                 525  
               
               
                   
               
               
                 gaa gaa tgc cag aaa aga tat caa gat tat aaa ata acc caa cgg atg     1632  
               
               
                 Glu Glu Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr Gln Arg Met  
               
               
                             530                 535                 540  
               
               
                   
               
               
                 gtc tgt gct ggc tat aaa gaa ggg gga aaa gat gct tgt aag gga gat     1680  
               
               
                 Val Cys Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys Lys Gly Asp  
               
               
                         545                 550                 555  
               
               
                   
               
               
                 tca ggt ggt ccc tta gtt tgc aaa cac aat gga atg tgg cgt ttg gtg     1728  
               
               
                 Ser Gly Gly Pro Leu Val Cys Lys His Asn Gly Met Trp Arg Leu Val  
               
               
                     560                 565                 570  
               
               
                   
               
               
                 ggc atc acc agc tgg ggt gaa ggc tgt gcc cgc agg gag caa cct ggt     1776  
               
               
                 Gly Ile Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu Gln Pro Gly  
               
               
                 575                 580                 585                 590  
               
               
                   
               
               
                 gtc tac acc aaa gtc gct gag tac atg gac tgg att tta gag aaa aca     1824  
               
               
                 Val Tyr Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu Glu Lys Thr  
               
               
                                 595                 600                 605  
               
               
                   
               
               
                 cag agc agt gat gga aaa gct cag atg cag tca cca gca ctcgag          1869  
               
               
                 Gln Ser Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala  
               
               
                             610                 615  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 52  
               
               
                 &lt;211&gt; LENGTH: 619  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 52  
               
               
                   
               
               
                 Gly Cys Leu Thr Gln Leu Tyr Glu Asn Ala Phe Phe Arg Gly Gly Asp  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Ala Ser Met Tyr Thr Pro Asn Ala Gln Tyr Cys Gln Met Arg Cys  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Thr Phe His Pro Arg Cys Leu Leu Phe Ser Phe Leu Pro Ala Ser Ser  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asn Asp Met Glu Lys Arg Phe Gly Cys Phe Leu Lys Asp Ser Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Thr Gly Thr Leu Pro Lys Val His Arg Thr Gly Ala Val Ser Gly His  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ser Leu Lys Gln Cys Gly His Gln Ile Ser Ala Cys His Arg Asp Ile  
               
               
                                  85                  90                  95  
               
               
                   
               
               
                 Tyr Lys Gly Val Asp Met Arg Gly Val Asn Phe Asn Val Ser Lys Val  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ser Ser Val Glu Glu Cys Gln Lys Arg Cys Thr Ser Asn Ile Arg Cys  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Gln Phe Phe Ser Tyr Ala Thr Gln Thr Phe His Lys Ala Glu Tyr Arg  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Asn Asn Cys Leu Leu Lys Tyr Ser Pro Gly Gly Thr Pro Thr Ala Ile  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Val Leu Ser Asn Val Glu Ser Gly Phe Ser Leu Lys Pro Cys Ala  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Ser Glu Ile Gly Cys His Met Asn Ile Phe Gln His Leu Ala Phe  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ser Asp Val Asp Val Ala Arg Phe Leu Thr Pro Asp Ala Phe Val Cys  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Arg Thr Ile Cys Thr Tyr His Pro Asn Cys Leu Phe Phe Thr Phe Tyr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Thr Asn Val Trp Lys Ile Glu Ser Gln Arg Asn Val Cys Leu Leu Lys  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Thr Ser Glu Ser Gly Thr Pro Ser Ser Ser Thr Pro Gln Glu Asn Thr  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ile Ser Gly Tyr Ser Leu Leu Thr Cys Lys Arg Thr Leu Pro Glu Pro  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Cys His Ser Lys Ile Tyr Pro Gly Val Asp Phe Gly Gly Glu Glu Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Asn Val Thr Phe Val Lys Gly Val Asn Val Cys Gln Glu Thr Cys Thr  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Lys Met Ile Arg Cys Gln Phe Phe Thr Tyr Ser Leu Leu Pro Glu Asp  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Cys Lys Glu Glu Lys Cys Lys Cys Phe Leu Arg Leu Ser Met Asp Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Ser Pro Thr Arg Ile Ala Tyr Gly Thr Gln Gly Ser Ser Gly Tyr Ser  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Leu Arg Leu Cys Asn Thr Gly Asp Asn Ala Val Cys Thr Thr Lys Thr  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ser Thr Arg Ile Val Gly Gly Thr Asn Ser Ser Trp Gly Glu Trp Pro  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Trp Gln Val Ser Leu Gln Val Lys Leu Thr Ala Gln Arg His Leu Cys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Gly Gly Ser Leu Ile Gly His Gln Trp Val Leu Thr Ala Ala His Cys  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Phe Asp Gly Leu Pro Leu Gln Asp Val Trp Arg Ile Tyr Ser Gly Ile  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Leu Asn Leu Ser Asp Ile Thr Lys Asp Thr Pro Phe Ser Gln Ile Lys  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Glu Ile Ile Ile His Gln Asn Tyr Lys Val Ser Glu Gly Asn His Asp  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Ile Ala Leu Ile Lys Leu Gln Ala Pro Leu Asn Tyr Thr Glu Phe Gln  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Lys Pro Ile Cys Leu Pro Ser Lys Gly Asp Thr Ser Thr Ile Tyr Thr  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Asn Cys Trp Val Thr Gly Trp Gly Phe Ser Lys Glu Lys Gly Glu Ile  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Gln Asn Ile Leu Gln Lys Val Asn Ile Pro Leu Val Thr Asn Glu Glu  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Cys Gln Lys Arg Tyr Gln Asp Tyr Lys Ile Thr Gln Arg Met Val Cys  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Ala Gly Tyr Lys Glu Gly Gly Lys Asp Ala Cys Lys Gly Asp Ser Gly  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Gly Pro Leu Val Cys Lys His Asn Gly Met Trp Arg Leu Val Gly Ile  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Thr Ser Trp Gly Glu Gly Cys Ala Arg Arg Glu Gln Pro Gly Val Tyr  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Thr Lys Val Ala Glu Tyr Met Asp Trp Ile Leu Glu Lys Thr Gln Ser  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Ser Asp Gly Lys Ala Gln Met Gln Ser Pro Ala  
               
               
                     610                 615  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 53  
               
               
                 &lt;211&gt; LENGTH: 1551  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (108)..(1511)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 53  
               
               
                   
               
               
                 gcggccgcgg gagctgaccc tgcggggtcc cgggggggga gggggagccg cgaagccccc     60  
               
               
                   
               
               
                 actgaggccg ccgctgccgg gcctcccctc ccccccgggc gggcgcc atg cgg ggg      116  
               
               
                                                                     Met Arg Gly  
               
               
                                                                     1  
               
               
                   
               
               
                 agc ccg ggc gac gcg gag cgg cgg cag cgc tgg ggt cgc ctg ttc gag      164  
               
               
                 Ser Pro Gly Asp Ala Glu Arg Arg Gln Arg Trp Gly Arg Leu Phe Glu  
               
               
                     5                   10                  15  
               
               
                   
               
               
                 gag ctg gac agt aac aag gat ggc cgc gtg gac gtg cac gag ttg cgc      212  
               
               
                 Glu Leu Asp Ser Asn Lys Asp Gly Arg Val Asp Val His Glu Leu Arg  
               
               
                 20                  25                  30                  35  
               
               
                   
               
               
                 cag ggg ctg gcc agg ctg ggc ggg ggc aac cca gac ccc ggc gcc caa      260  
               
               
                 Gln Gly Leu Ala Arg Leu Gly Gly Gly Asn Pro Asp Pro Gly Ala Gln  
               
               
                                 40                  45                  50  
               
               
                   
               
               
                 cag ggt atc tcc tct gag ggt gat gct gac cca gat ggc ggg ctc gac      308  
               
               
                 Gln Gly Ile Ser Ser Glu Gly Asp Ala Asp Pro Asp Gly Gly Leu Asp  
               
               
                             55                  60                  65  
               
               
                   
               
               
                 ctg gag gaa ttt tcc cgc tat ctg cag gag cgg gaa cag cgt ctg ctg      356  
               
               
                 Leu Glu Glu Phe Ser Arg Tyr Leu Gln Glu Arg Glu Gln Arg Leu Leu  
               
               
                         70                  75                  80  
               
               
                   
               
               
                 ctc atg ttt cac agt ctt gac cgg aac cag gat ggt cac att gat gtc      404  
               
               
                 Leu Met Phe His Ser Leu Asp Arg Asn Gln Asp Gly His Ile Asp Val  
               
               
                     85                  90                  95  
               
               
                   
               
               
                 tct gag atc caa cag agt ttc cga gct ctg ggc att tcc atc tcg ctg      452  
               
               
                 Ser Glu Ile Gln Gln Ser Phe Arg Ala Leu Gly Ile Ser Ile Ser Leu  
               
               
                 100                 105                 110                 115  
               
               
                   
               
               
                 gag cag gct gag aaa att ttg cac agc atg gac cga gac ggc aca atg      500  
               
               
                 Glu Gln Ala Glu Lys Ile Leu His Ser Met Asp Arg Asp Gly Thr Met  
               
               
                                 120                 125                 130  
               
               
                   
               
               
                 acc att gac tgg caa gaa tgg cgc gac cac ttc ctg ttg cat tcg ctg      548  
               
               
                 Thr Ile Asp Trp Gln Glu Trp Arg Asp His Phe Leu Leu His Ser Leu  
               
               
                             135                 140                 145  
               
               
                   
               
               
                 gaa aat gtg gag gac gtg ctg tat ttc tgg aag cat tcc acg gtc ctg      596  
               
               
                 Glu Asn Val Glu Asp Val Leu Tyr Phe Trp Lys His Ser Thr Val Leu  
               
               
                         150                 155                 160  
               
               
                   
               
               
                 gac att ggc gag tgc ctg aca gtg ccg gac gag ttc tca aag caa gag      644  
               
               
                 Asp Ile Gly Glu Cys Leu Thr Val Pro Asp Glu Phe Ser Lys Gln Glu  
               
               
                     165                 170                 175  
               
               
                   
               
               
                 aag ctg acg ggc atg tgg tgg aaa cag ctg gtg gcc ggc gca gtg gca      692  
               
               
                 Lys Leu Thr Gly Met Trp Trp Lys Gln Leu Val Ala Gly Ala Val Ala  
               
               
                 180                 185                 190                 195  
               
               
                   
               
               
                 ggt gcc gtg tca cgg aca ggc acg gcc cct ctg gac cgc ctc aag gtc      740  
               
               
                 Gly Ala Val Ser Arg Thr Gly Thr Ala Pro Leu Asp Arg Leu Lys Val  
               
               
                                 200                 205                 210  
               
               
                   
               
               
                 ttc att cag gtc cat gcc tca aag acc aac cgg ctg aac atc ctt ggg      788  
               
               
                 Phe Ile Gln Val His Ala Ser Lys Thr Asn Arg Leu Asn Ile Leu Gly  
               
               
                             215                 220                 225  
               
               
                   
               
               
                 ggg ctt cga agc atg gtc ctt gag gga ggc atc cgc tgc ctg tgg cgc      836  
               
               
                 Gly Leu Arg Ser Met Val Leu Glu Gly Gly Ile Arg Cys Leu Trp Arg  
               
               
                         230                 235                 240  
               
               
                   
               
               
                 ggc aat ggt att aat gta ctc aag att gcc ccc gag tca gct atc aag      884  
               
               
                 Gly Asn Gly Ile Asn Val Leu Lys Ile Ala Pro Glu Ser Ala Ile Lys  
               
               
                     245                 250                 255  
               
               
                   
               
               
                 ttc atg gcc tat gaa cag gtg agg agg gcc atc ctg ggg cag cag gag      932  
               
               
                 Phe Met Ala Tyr Glu Gln Val Arg Arg Ala Ile Leu Gly Gln Gln Glu  
               
               
                 260                 265                 270                 275  
               
               
                   
               
               
                 aca ctg cat gtg cag gag cgc ttc gtg gct ggc tcc ctg gct ggt gcc      980  
               
               
                 Thr Leu His Val Gln Glu Arg Phe Val Ala Gly Ser Leu Ala Gly Ala  
               
               
                                 280                 285                 290  
               
               
                   
               
               
                 aca gcc caa acc atc att tac cct atg gag gtg ctg aag acg cgg ctg     1028  
               
               
                 Thr Ala Gln Thr Ile Ile Tyr Pro Met Glu Val Leu Lys Thr Arg Leu  
               
               
                             295                 300                 305  
               
               
                   
               
               
                 acc ttg cgc cgg acg ggc cag tat aag ggg ctg ctg gac tgc gcc agg     1076  
               
               
                 Thr Leu Arg Arg Thr Gly Gln Tyr Lys Gly Leu Leu Asp Cys Ala Arg  
               
               
                         310                 315                 320  
               
               
                   
               
               
                 cgt atc ctg gag agg gag ggg ccc cgt gcc ttc tac cgc ggc tac ctc     1124  
               
               
                 Arg Ile Leu Glu Arg Glu Gly Pro Arg Ala Phe Tyr Arg Gly Tyr Leu  
               
               
                     325                 330                 335  
               
               
                   
               
               
                 ccc aac gtg ctg ggc atc atc ccc tat gcg ggc atc gac ctg gcc gtc     1172  
               
               
                 Pro Asn Val Leu Gly Ile Ile Pro Tyr Ala Gly Ile Asp Leu Ala Val  
               
               
                 340                 345                 350                 355  
               
               
                   
               
               
                 tac gag gtc ctg aag aac tgg tgg ctt cag cag tac agc cac gac tcg     1220  
               
               
                 Tyr Glu Val Leu Lys Asn Trp Trp Leu Gln Gln Tyr Ser His Asp Ser  
               
               
                                 360                 365                 370  
               
               
                   
               
               
                 gca gac cca ggc atc ctc gtg ctc ctg gcc tgc ggt acc ata tcc agc     1268  
               
               
                 Ala Asp Pro Gly Ile Leu Val Leu Leu Ala Cys Gly Thr Ile Ser Ser  
               
               
                             375                 380                 385  
               
               
                   
               
               
                 acc tgc ggc cag ata gcc agt tac ccg ctg gcc ctg gtc cgg acc cgc     1316  
               
               
                 Thr Cys Gly Gln Ile Ala Ser Tyr Pro Leu Ala Leu Val Arg Thr Arg  
               
               
                         390                 395                 400  
               
               
                   
               
               
                 atg cag gca caa gcc tcc atc gag ggt ggc ccc cag ctg tcc atg ctg     1364  
               
               
                 Met Gln Ala Gln Ala Ser Ile Glu Gly Gly Pro Gln Leu Ser Met Leu  
               
               
                     405                 410                 415  
               
               
                   
               
               
                 ggt ctg cta cgt cac atc ctg tcc cag gag ggc atg cgg ggc ctc tac     1412  
               
               
                 Gly Leu Leu Arg His Ile Leu Ser Gln Glu Gly Met Arg Gly Leu Tyr  
               
               
                 420                 425                 430                 435  
               
               
                   
               
               
                 cgg ggg atc gcc ccc aac ttc atg aag gtt att cca gct gtg agc atc     1460  
               
               
                 Arg Gly Ile Ala Pro Asn Phe Met Lys Val Ile Pro Ala Val Ser Ile  
               
               
                                 440                 445                 450  
               
               
                   
               
               
                 tcc tat gtg gtc tac gag aac atg aag cag gcc ttg ggg gtc acg tcc     1508  
               
               
                 Ser Tyr Val Val Tyr Glu Asn Met Lys Gln Ala Leu Gly Val Thr Ser  
               
               
                             455                 460                 465  
               
               
                   
               
               
                 agg tgagggaccc ggagcccgtc cccccaatcc ctcacccccc                     1551  
               
               
                 Arg  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 54  
               
               
                 &lt;211&gt; LENGTH: 468  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 54  
               
               
                   
               
               
                 Met Arg Gly Ser Pro Gly Asp Ala Glu Arg Arg Gln Arg Trp Gly Arg  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Leu Phe Glu Glu Leu Asp Ser Asn Lys Asp Gly Arg Val Asp Val His  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Glu Leu Arg Gln Gly Leu Ala Arg Leu Gly Gly Gly Asn Pro Asp Pro  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Gly Ala Gln Gln Gly Ile Ser Ser Glu Gly Asp Ala Asp Pro Asp Gly  
               
               
                      50                  55                  60  
               
               
                   
               
               
                 Gly Leu Asp Leu Glu Glu Phe Ser Arg Tyr Leu Gln Glu Arg Glu Gln  
               
               
                  65                  70                  75                  80  
               
               
                   
               
               
                 Arg Leu Leu Leu Met Phe His Ser Leu Asp Arg Asn Gln Asp Gly His  
               
               
                                  85                  90                  95  
               
               
                   
               
               
                 Ile Asp Val Ser Glu Ile Gln Gln Ser Phe Arg Ala Leu Gly Ile Ser  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ile Ser Leu Glu Gln Ala Glu Lys Ile Leu His Ser Met Asp Arg Asp  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Gly Thr Met Thr Ile Asp Trp Gln Glu Trp Arg Asp His Phe Leu Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 His Ser Leu Glu Asn Val Glu Asp Val Leu Tyr Phe Trp Lys His Ser  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Thr Val Leu Asp Ile Gly Glu Cys Leu Thr Val Pro Asp Glu Phe Ser  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Gln Glu Lys Leu Thr Gly Met Trp Trp Lys Gln Leu Val Ala Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ala Val Ala Gly Ala Val Ser Arg Thr Gly Thr Ala Pro Leu Asp Arg  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Lys Val Phe Ile Gln Val His Ala Ser Lys Thr Asn Arg Leu Asn  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ile Leu Gly Gly Leu Arg Ser Met Val Leu Glu Gly Gly Ile Arg Cys  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Trp Arg Gly Asn Gly Ile Asn Val Leu Lys Ile Ala Pro Glu Ser  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Ile Lys Phe Met Ala Tyr Glu Gln Val Arg Arg Ala Ile Leu Gly  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Gln Glu Thr Leu His Val Gln Glu Arg Phe Val Ala Gly Ser Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ala Gly Ala Thr Ala Gln Thr Ile Ile Tyr Pro Met Glu Val Leu Lys  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Thr Arg Leu Thr Leu Arg Arg Thr Gly Gln Tyr Lys Gly Leu Leu Asp  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Cys Ala Arg Arg Ile Leu Glu Arg Glu Gly Pro Arg Ala Phe Tyr Arg  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Gly Tyr Leu Pro Asn Val Leu Gly Ile Ile Pro Tyr Ala Gly Ile Asp  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Leu Ala Val Tyr Glu Val Leu Lys Asn Trp Trp Leu Gln Gln Tyr Ser  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 His Asp Ser Ala Asp Pro Gly Ile Leu Val Leu Leu Ala Cys Gly Thr  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Ile Ser Ser Thr Cys Gly Gln Ile Ala Ser Tyr Pro Leu Ala Leu Val  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Arg Thr Arg Met Gln Ala Gln Ala Ser Ile Glu Gly Gly Pro Gln Leu  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Ser Met Leu Gly Leu Leu Arg His Ile Leu Ser Gln Glu Gly Met Arg  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Gly Leu Tyr Arg Gly Ile Ala Pro Asn Phe Met Lys Val Ile Pro Ala  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Val Ser Ile Ser Tyr Val Val Tyr Glu Asn Met Lys Gln Ala Leu Gly  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Val Thr Ser Arg  
               
               
                 465  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 55  
               
               
                 &lt;211&gt; LENGTH: 953  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (50)..(853)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 55  
               
               
                   
               
               
                 cagaggcagc atgagctgag agggtgatag gaaggcggcg ctagacagc atg gag gac     58  
               
               
                                                                       Met Glu Asp  
               
               
                                                                       1  
               
               
                   
               
               
                 ttt ctg ctc tcc aat ggg tac cag ctg ggc aag acc att ggg gaa ggg      106  
               
               
                 Phe Leu Leu Ser Asn Gly Tyr Gln Leu Gly Lys Thr Ile Gly Glu Gly  
               
               
                     5                   10                  15  
               
               
                   
               
               
                 acc tac tca aaa gtc aaa gaa gca ttt tcc aaa aaa cac caa aga aaa      154  
               
               
                 Thr Tyr Ser Lys Val Lys Glu Ala Phe Ser Lys Lys His Gln Arg Lys  
               
               
                 20                  25                  30                  35  
               
               
                   
               
               
                 gtg gca att aaa gtt ata gac aag atg gga act tcc tca gag ttt atc      202  
               
               
                 Val Ala Ile Lys Val Ile Asp Lys Met Gly Thr Ser Ser Glu Phe Ile  
               
               
                                 40                  45                  50  
               
               
                   
               
               
                 cag aga ttc ctc cct cgg gag ctc caa atc gtc cgt acc ctg gac cac      250  
               
               
                 Gln Arg Phe Leu Pro Arg Glu Leu Gln Ile Val Arg Thr Leu Asp His  
               
               
                             55                  60                  65  
               
               
                   
               
               
                 aag aac atc atc cag gtg tat gag atg ctg gag tct gcc gac ggg aaa      298  
               
               
                 Lys Asn Ile Ile Gln Val Tyr Glu Met Leu Glu Ser Ala Asp Gly Lys  
               
               
                         70                  75                  80  
               
               
                   
               
               
                 atc tgc ctg gtg atg gag ctc gct gag gga ggg gat gtc ttt gac tgc      346  
               
               
                 Ile Cys Leu Val Met Glu Leu Ala Glu Gly Gly Asp Val Phe Asp Cys  
               
               
                     85                  90                  95  
               
               
                   
               
               
                 gtg ctg aat ggg ggg cca ctg cct gaa agc cgg gcc aag gcc ctc ttc      394  
               
               
                 Val Leu Asn Gly Gly Pro Leu Pro Glu Ser Arg Ala Lys Ala Leu Phe  
               
               
                 100                 105                 110                 115  
               
               
                   
               
               
                 cgt cag atg gtt gag gcc atc cgc tac tgc cat ggc tgt ggt gtg gcc      442  
               
               
                 Arg Gln Met Val Glu Ala Ile Arg Tyr Cys His Gly Cys Gly Val Ala  
               
               
                                 120                 125                 130  
               
               
                   
               
               
                 cac cgg gac ctc aaa tgt gag aac gcc ttg ttg cag ggc ttc aac ctg      490  
               
               
                 His Arg Asp Leu Lys Cys Glu Asn Ala Leu Leu Gln Gly Phe Asn Leu  
               
               
                             135                 140                 145  
               
               
                   
               
               
                 aag ctg act gac ttt ggc ttt gcc aag gtg ttg ccc aag tca cac cgg      538  
               
               
                 Lys Leu Thr Asp Phe Gly Phe Ala Lys Val Leu Pro Lys Ser His Arg  
               
               
                         150                 155                 160  
               
               
                   
               
               
                 gag ctg agc cag acc ttc tgc ggc agt aca gcc tat gct gcc ccc gag      586  
               
               
                 Glu Leu Ser Gln Thr Phe Cys Gly Ser Thr Ala Tyr Ala Ala Pro Glu  
               
               
                     165                 170                 175  
               
               
                   
               
               
                 gtg ctg cag ggc att ccc cac gat agc aaa aaa ggt gat gtc tgg agc      634  
               
               
                 Val Leu Gln Gly Ile Pro His Asp Ser Lys Lys Gly Asp Val Trp Ser  
               
               
                 180                 185                 190                 195  
               
               
                   
               
               
                 atg ggt gtg gtc ctg tat gtc atg ctc tgt gcc agc cta cct ttt gac      682  
               
               
                 Met Gly Val Val Leu Tyr Val Met Leu Cys Ala Ser Leu Pro Phe Asp  
               
               
                                 200                 205                 210  
               
               
                   
               
               
                 gac aca gac atc ccc aag atg ctg tgg cag cag cag aag ggg gtg tcc      730  
               
               
                 Asp Thr Asp Ile Pro Lys Met Leu Trp Gln Gln Gln Lys Gly Val Ser  
               
               
                             215                 220                 225  
               
               
                   
               
               
                 ttc ccc act cat ctg agc atc tcg gcc gat tgc cag gac ctg ctc aag      778  
               
               
                 Phe Pro Thr His Leu Ser Ile Ser Ala Asp Cys Gln Asp Leu Leu Lys  
               
               
                         230                 235                 240  
               
               
                   
               
               
                 agg ctc ctg gaa ccc gat atg atc ctc cgg cct tca att gaa gaa gtt      826  
               
               
                 Arg Leu Leu Glu Pro Asp Met Ile Leu Arg Pro Ser Ile Glu Glu Val  
               
               
                     245                 250                 255  
               
               
                   
               
               
                 agt tgg cat cca tgg cta gca agc act tgataaaagc aatggcaagt            873  
               
               
                 Ser Trp His Pro Trp Leu Ala Ser Thr  
               
               
                 260                 265  
               
               
                   
               
               
                 gctctccaat aaagtagggg gagaaagcaa acccaaaaac ccgcttctaa aatggtgata    933  
               
               
                   
               
               
                 tatattttac gctttaagtt                                                953  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 56  
               
               
                 &lt;211&gt; LENGTH: 268  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 56  
               
               
                   
               
               
                 Met Glu Asp Phe Leu Leu Ser Asn Gly Tyr Gln Leu Gly Lys Thr Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gly Glu Gly Thr Tyr Ser Lys Val Lys Glu Ala Phe Ser Lys Lys His  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Gln Arg Lys Val Ala Ile Lys Val Ile Asp Lys Met Gly Thr Ser Ser  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Glu Phe Ile Gln Arg Phe Leu Pro Arg Glu Leu Gln Ile Val Arg Thr  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Asp His Lys Asn Ile Ile Gln Val Tyr Glu Met Leu Glu Ser Ala  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Asp Gly Lys Ile Cys Leu Val Met Glu Leu Ala Glu Gly Gly Asp Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Phe Asp Cys Val Leu Asn Gly Gly Pro Leu Pro Glu Ser Arg Ala Lys  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ala Leu Phe Arg Gln Met Val Glu Ala Ile Arg Tyr Cys His Gly Cys  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Gly Val Ala His Arg Asp Leu Lys Cys Glu Asn Ala Leu Leu Gln Gly  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Phe Asn Leu Lys Leu Thr Asp Phe Gly Phe Ala Lys Val Leu Pro Lys  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ser His Arg Glu Leu Ser Gln Thr Phe Cys Gly Ser Thr Ala Tyr Ala  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Ala Pro Glu Val Leu Gln Gly Ile Pro His Asp Ser Lys Lys Gly Asp  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Val Trp Ser Met Gly Val Val Leu Tyr Val Met Leu Cys Ala Ser Leu  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Pro Phe Asp Asp Thr Asp Ile Pro Lys Met Leu Trp Gln Gln Gln Lys  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Gly Val Ser Phe Pro Thr His Leu Ser Ile Ser Ala Asp Cys Gln Asp  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Leu Lys Arg Leu Leu Glu Pro Asp Met Ile Leu Arg Pro Ser Ile  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Glu Glu Val Ser Trp His Pro Trp Leu Ala Ser Thr  
               
               
                             260                 265  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 57  
               
               
                 &lt;211&gt; LENGTH: 2490  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (40)..(2457)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 57  
               
               
                   
               
               
                 cgcgcgctgc ctgaggacgc cgcggccccc gcccccgcc atg ggc gcc cct gcc        54  
               
               
                                                            Met Gly Ala Pro Ala  
               
               
                                                            1               5  
               
               
                   
               
               
                 tgc gcc ctc gcg ctc tgc gtg gcc gtg gcc atc gtg gcc ggc gcc tcc      102  
               
               
                 Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile Val Ala Gly Ala Ser  
               
               
                                 10                  15                  20  
               
               
                   
               
               
                 tcg gag tcc ttg ggg acg gag cag cgc gtc gtg ggg cga gcg gca gaa      150  
               
               
                 Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val Gly Arg Ala Ala Glu  
               
               
                             25                  30                  35  
               
               
                   
               
               
                 gtc ccg ggc cca gag ccc ggc cag cag gag cag ttg gtc ttc ggc agc      198  
               
               
                 Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln Leu Val Phe Gly Ser  
               
               
                         40                  45                  50  
               
               
                   
               
               
                 ggg gat gct gtg gag ctg agc tgt ccc ccg ccc ggg ggt ggt ccc atg      246  
               
               
                 Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro Gly Gly Gly Pro Met  
               
               
                     55                  60                  65  
               
               
                   
               
               
                 ggg ccc act gtc tgg gtc aag gat ggc aca ggg ctg gtg ccc tcg gag      294  
               
               
                 Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly Leu Val Pro Ser Glu  
               
               
                 70                  75                  80                  85  
               
               
                   
               
               
                 cgt gtc ctg gtg ggg ccc cag cgg ctg cag gtg ctg aat gcc tcc cac      342  
               
               
                 Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val Leu Asn Ala Ser His  
               
               
                                 90                   95                 100  
               
               
                   
               
               
                 gag gac tcc ggg gcc tac agc tgc cgg cag cgg ctc acg cag cgc gta      390  
               
               
                 Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg Leu Thr Gln Arg Val  
               
               
                             105                 110                 115  
               
               
                   
               
               
                 ctg tgc cac ttc agt gtg cgg gtg aca gac gct cca tcc tcg gga gat      438  
               
               
                 Leu Cys His Phe Ser Val Arg Val Thr Asp Ala Pro Ser Ser Gly Asp  
               
               
                         120                 125                 130  
               
               
                   
               
               
                 gac gaa gac ggg gag gac gag gct gag gac aca ggt gtg gac aca ggg      486  
               
               
                 Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr Gly Val Asp Thr Gly  
               
               
                     135                 140                 145  
               
               
                   
               
               
                 gcc cct tac tgg aca cgg ccc gag cgg atg gac aag aag ctg ctg gcc      534  
               
               
                 Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp Lys Lys Leu Leu Ala  
               
               
                 150                 155                 160                 165  
               
               
                   
               
               
                 gtg ccg gcc gcc aac acc gtc cgc ttc cgc tgc cca gcc gct ggc aac      582  
               
               
                 Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys Pro Ala Ala Gly Asn  
               
               
                                 170                 175                 180  
               
               
                   
               
               
                 ccc act ccc tcc atc tcc tgg ctg aag aac ggc agg gag ttc cgc ggc      630  
               
               
                 Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly Arg Glu Phe Arg Gly  
               
               
                             185                 190                 195  
               
               
                   
               
               
                 gag cac cgc att gga ggc atc aag ctg cgg cat cag cag tgg agc ctg      678  
               
               
                 Glu His Arg Ile Gly Gly Ile Lys Leu Arg His Gln Gln Trp Ser Leu  
               
               
                         200                 205                 210  
               
               
                   
               
               
                 gtc atg gaa agc gtg gtg ccc tcg gac cgc ggc aac tac acc tgc gtc      726  
               
               
                 Val Met Glu Ser Val Val Pro Ser Asp Arg Gly Asn Tyr Thr Cys Val  
               
               
                     215                 220                 225  
               
               
                   
               
               
                 gtg gag aac aag ttt ggc agc atc cgg cag acg tac acg ctg gac gtg      774  
               
               
                 Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr Tyr Thr Leu Asp Val  
               
               
                 230                 235                 240                 245  
               
               
                   
               
               
                 ctg gag cgc tcc ccg cac cgg ccc atc ctg cag gcg ggg ctg ccg gcc      822  
               
               
                 Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln Ala Gly Leu Pro Ala  
               
               
                                 250                 255                 260  
               
               
                   
               
               
                 aac cag acg gcg gtg ctg ggc agc gac gtg gag ttc cac tgc aag gtg      870  
               
               
                 Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu Phe His Cys Lys Val  
               
               
                             265                 270                 275  
               
               
                   
               
               
                 tac agt gac gca cag ccc cac atc cag tgg ctc aag cac gtg gag gtg      918  
               
               
                 Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu Lys His Val Glu Val  
               
               
                         280                 285                 290  
               
               
                   
               
               
                 aac ggc agc aag gtg ggc ccg gac ggc aca ccc tac gtt acc gtg ctc      966  
               
               
                 Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro Tyr Val Thr Val Leu  
               
               
                     295                 300                 305  
               
               
                   
               
               
                 aag acg gcg ggc gct aac acc acc gac aag gag cta gag gtt ctc tcc     1014  
               
               
                 Lys Thr Ala Gly Ala Asn Thr Thr Asp Lys Glu Leu Glu Val Leu Ser  
               
               
                 310                 315                 320                 325  
               
               
                   
               
               
                 ttg cac aac gtc acc ttt gag gac gcc ggg gag tac acc tgc ctg gcg     1062  
               
               
                 Leu His Asn Val Thr Phe Glu Asp Ala Gly Glu Tyr Thr Cys Leu Ala  
               
               
                                 330                 335                 340  
               
               
                   
               
               
                 ggc aat tct att ggg ttt tct cat cac tct gcg tgg ctg gtg gtg ctg     1110  
               
               
                 Gly Asn Ser Ile Gly Phe Ser His His Ser Ala Trp Leu Val Val Leu  
               
               
                             345                 350                 355  
               
               
                   
               
               
                 cca gcc gag gag gag ctg gtg gag gct gac gag gcg ggc agt gtg tat     1158  
               
               
                 Pro Ala Glu Glu Glu Leu Val Glu Ala Asp Glu Ala Gly Ser Val Tyr  
               
               
                         360                 365                 370  
               
               
                   
               
               
                 gca ggc atc ctc agc tac ggg gtg ggc ttc ttc ctg ttc atc ctg gtg     1206  
               
               
                 Ala Gly Ile Leu Ser Tyr Gly Val Gly Phe Phe Leu Phe Ile Leu Val  
               
               
                     375                 380                 385  
               
               
                   
               
               
                 gtg gcg gct gtg acg ctc tgc cgc ctg cgc agc ccc ccc aag aaa ggc     1254  
               
               
                 Val Ala Ala Val Thr Leu Cys Arg Leu Arg Ser Pro Pro Lys Lys Gly  
               
               
                 390                 395                 400                 405  
               
               
                   
               
               
                 ctg ggc tcc ccc acc gtg cac aag atc tcc cgc ttc ccg ctc aag cga     1302  
               
               
                 Leu Gly Ser Pro Thr Val His Lys Ile Ser Arg Phe Pro Leu Lys Arg  
               
               
                                 410                 415                 420  
               
               
                   
               
               
                 cag gtg tcc ctg gag tcc aac gcg tcc atg agc tcc aac aca cca ctg     1350  
               
               
                 Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser Ser Asn Thr Pro Leu  
               
               
                             425                 430                 435  
               
               
                   
               
               
                 gtg cgc atc gca agg ctg tcc tca ggg gag ggc ccc acg ctg gcc aat     1398  
               
               
                 Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly Pro Thr Leu Ala Asn  
               
               
                         440                 445                 450  
               
               
                   
               
               
                 gtc tcc gag ctc gag ctg cct gcc gac ccc aaa tgg gag ctg tct cgg     1446  
               
               
                 Val Ser Glu Leu Glu Leu Pro Ala Asp Pro Lys Trp Glu Leu Ser Arg  
               
               
                     455                 460                 465  
               
               
                   
               
               
                 gcc cgg ctg acc ctg ggc aag ccc ctt ggg gag ggc tgc ttc ggc cag     1494  
               
               
                 Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu Gly Cys Phe Gly Gln  
               
               
                 470                 475                 480                 485  
               
               
                   
               
               
                 gtg gtc atg gcg gag gcc atc ggc att gac aag gac cgg gcc gcc aag     1542  
               
               
                 Val Val Met Ala Glu Ala Ile Gly Ile Asp Lys Asp Arg Ala Ala Lys  
               
               
                                 490                 495                 500  
               
               
                   
               
               
                 cct gtc acc gta gcc gtg aag atg ctg aaa gac gat gcc act gac aag     1590  
               
               
                 Pro Val Thr Val Ala Val Lys Met Leu Lys Asp Asp Ala Thr Asp Lys  
               
               
                             505                 510                 515  
               
               
                   
               
               
                 gac ctg tcg gac ctg gtg tct gag atg gag atg atg aag atg atc ggg     1638  
               
               
                 Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met Met Lys Met Ile Gly  
               
               
                         520                 525                 530  
               
               
                   
               
               
                 aaa cac aaa aac atc atc aac ctg ctg ggc gcc tgc acg cag ggc ggg     1686  
               
               
                 Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala Cys Thr Gln Gly Gly  
               
               
                     535                 540                 545  
               
               
                   
               
               
                 ccc ctg tac gtg ctg gtg gag tac gcg gcc aag ggt aac ctg cgg gag     1734  
               
               
                 Pro Leu Tyr Val Leu Val Glu Tyr Ala Ala Lys Gly Asn Leu Arg Glu  
               
               
                 550                 555                 560                 565  
               
               
                   
               
               
                 ttt ctg cgg gcg cgg cgg ccc ccg ggc ctg gac tac tcc ttc gac acc     1782  
               
               
                 Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp Tyr Ser Phe Asp Thr  
               
               
                                 570                 575                 580  
               
               
                   
               
               
                 tgc aag ccg ccc gag gag cag ctc acc ttc aag gac ctg gtg tcc tgt     1830  
               
               
                 Cys Lys Pro Pro Glu Glu Gln Leu Thr Phe Lys Asp Leu Val Ser Cys  
               
               
                             585                 590                 595  
               
               
                   
               
               
                 gcc tac cag gtg gcc cgg ggc atg gag tac ttg gcc tcc cag aag tgc     1878  
               
               
                 Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu Ala Ser Gln Lys Cys  
               
               
                         600                 605                 610  
               
               
                   
               
               
                 atc cac agg gac ctg gct gcc cgc aat gtg ctg gtg acc gag gac aac     1926  
               
               
                 Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu Val Thr Glu Asp Asn  
               
               
                     615                 620                 625  
               
               
                   
               
               
                 gtg atg aag atc gca gac ttc ggg ctg gcc cgg gac gtg cac aac ctc     1974  
               
               
                 Val Met Lys Ile Ala Asp Phe Gly Leu Ala Arg Asp Val His Asn Leu  
               
               
                 630                 635                 640                 645  
               
               
                   
               
               
                 gac tac tac aag aag aca acc aac ggc cgg ctg ccc gtg aag tgg atg     2022  
               
               
                 Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu Pro Val Lys Trp Met  
               
               
                                 650                 655                 660  
               
               
                   
               
               
                 gcg cct gag gcc ttg ttt gac cga gtc tac act cac cag agt gac gtc     2070  
               
               
                 Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr His Gln Ser Asp Val  
               
               
                             665                 670                 675  
               
               
                   
               
               
                 tgg tcc ttt ggg gtc ctg ctc tgg gag atc ttc acg ctg ggg ggc tcc     2118  
               
               
                 Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe Thr Leu Gly Gly Ser  
               
               
                         680                 685                 690  
               
               
                   
               
               
                 ccg tac ccc ggc atc cct gtg gag gag ctc ttc aag ctg ctg aag gag     2166  
               
               
                 Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe Lys Leu Leu Lys Glu  
               
               
                     695                 700                 705  
               
               
                   
               
               
                 ggc cac cgc atg gac aag ccc gcc aac tgc aca cac gac ctg tac atg     2214  
               
               
                 Gly His Arg Met Asp Lys Pro Ala Asn Cys Thr His Asp Leu Tyr Met  
               
               
                 710                 715                 720                 725  
               
               
                   
               
               
                 atc atg cgg gag tgc tgg cat gcc gcg ccc tcc cag agg ccc acc ttc     2262  
               
               
                 Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser Gln Arg Pro Thr Phe  
               
               
                                 730                 735                 740  
               
               
                   
               
               
                 aag cag ctg gtg gag gac ctg gac cgt gtc ctt acc gtg acg tcc acc     2310  
               
               
                 Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu Thr Val Thr Ser Thr  
               
               
                             745                 750                 755  
               
               
                   
               
               
                 gac gag tac ctg gac ctg tcg gcg cct ttc gag cag tac tcc ccg ggt     2358  
               
               
                 Asp Glu Tyr Leu Asp Leu Ser Ala Pro Phe Glu Gln Tyr Ser Pro Gly  
               
               
                         760                 765                 770  
               
               
                   
               
               
                 ggc cag gac acc ccc agc tcc agc tcc tca ggg gac gac tcc gtg ttt     2406  
               
               
                 Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly Asp Asp Ser Val Phe  
               
               
                     775                 780                 785  
               
               
                   
               
               
                 gcc cac gac ctg ctg ccc ccg gcc cca ccc agc agt ggg ggc tcg cgg     2454  
               
               
                 Ala His Asp Leu Leu Pro Pro Ala Pro Pro Ser Ser Gly Gly Ser Arg  
               
               
                 790                 795                 800                 805  
               
               
                   
               
               
                 acg tgaagggcca ctggtcccca acaatgtgag ggg                            2490  
               
               
                 Thr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 58  
               
               
                 &lt;211&gt; LENGTH: 806  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 58  
               
               
                   
               
               
                 Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly Ile Lys Leu Arg His  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Asn Tyr Thr Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Phe His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Val Thr Val Leu Lys Thr Ala Gly Ala Asn Thr Thr Asp Lys Glu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Leu Glu Val Leu Ser Leu His Asn Val Thr Phe Glu Asp Ala Gly Glu  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Tyr Thr Cys Leu Ala Gly Asn Ser Ile Gly Phe Ser His His Ser Ala  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Trp Leu Val Val Leu Pro Ala Glu Glu Glu Leu Val Glu Ala Asp Glu  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly Phe Phe  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Leu Phe Ile Leu Val Val Ala Ala Val Thr Leu Cys Arg Leu Arg Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile Ser Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser Met Ser  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly Glu Gly  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro Ala Asp Pro Lys  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu Gly Glu  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile Asp Lys  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys Met Leu Lys Asp  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met Glu Met  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu Gly Ala  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Val Glu Tyr Ala Ala Lys  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Gly Asn Leu Arg Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly Leu Asp  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu Glu Gln Leu Thr Phe Lys  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu Tyr Leu  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn Val Leu  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe Gly Leu Ala Arg  
               
               
                 625                 630                 635                 640  
               
               
                   
               
               
                 Asp Val His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly Arg Leu  
               
               
                                 645                 650                 655  
               
               
                   
               
               
                 Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val Tyr Thr  
               
               
                             660                 665                 670  
               
               
                   
               
               
                 His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu Ile Phe  
               
               
                         675                 680                 685  
               
               
                   
               
               
                 Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu Leu Phe  
               
               
                     690                 695                 700  
               
               
                   
               
               
                 Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro Ala Asn Cys Thr  
               
               
                 705                 710                 715                 720  
               
               
                   
               
               
                 His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala Pro Ser  
               
               
                                 725                 730                 735  
               
               
                   
               
               
                 Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg Val Leu  
               
               
                             740                 745                 750  
               
               
                   
               
               
                 Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser Ala Pro Phe Glu  
               
               
                         755                 760                 765  
               
               
                   
               
               
                 Gln Tyr Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser Ser Gly  
               
               
                     770                 775                 780  
               
               
                   
               
               
                 Asp Asp Ser Val Phe Ala His Asp Leu Leu Pro Pro Ala Pro Pro Ser  
               
               
                 785                 790                 795                 800  
               
               
                   
               
               
                 Ser Gly Gly Ser Arg Thr  
               
               
                                 805  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 59  
               
               
                 &lt;211&gt; LENGTH: 2427  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(2424)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 59  
               
               
                   
               
               
                 atg ggc gcc cct gcc tgc gcc ctc gcg ctc tgc gtg gcc gtg gcc atc       48  
               
               
                 Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 gtg gcc ggc gcc tcc tcg gag tcc ttg ggg acg gag cag cgc gtc gtg       96  
               
               
                 Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val  
               
               
                              20                  25                  30  
               
               
                   
               
               
                 ggg cga gcg gca gaa gtc ccg ggc cca gag ccc ggc cag cag gag cag      144  
               
               
                 Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 ttg gtc ttc ggc agc ggg gat gct gtg gag ctg agc tgt ccc ccg ccc      192  
               
               
                 Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 ggg ggt ggt ccc atg ggg ccc act gtc tgg gtc aag gat ggc aca ggg      240  
               
               
                 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 ctg gtg ccc tcg gag cgt gtc ctg gtg ggg ccc cag cgg ctg cag gtg      288  
               
               
                 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 ctg aat gcc tcc cac gag gac tcc ggg gcc tac agc tgc cgg cag cgg      336  
               
               
                 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 ctc acg cag cgc gta ctg tgc cac ttc agt gtg cgg gtg aca gac gct      384  
               
               
                 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 cca tcc tcg gga gat gac gaa gac ggg gag gac gag gct gag gac aca      432  
               
               
                 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 ggt gtg gac aca ggg gcc cct tac tgg aca cgg ccc gag cgg atg gac      480  
               
               
                 Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 aag aag ctg ctg gcc gtg ccg gcc gcc aac acc gtc cgc ttc cgc tgc      528  
               
               
                 Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 cca gcc gct ggc aac ccc act ccc tcc atc tcc tgg ctg aag aac ggc      576  
               
               
                 Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 agg gag ttc cgc ggc gag cac cgc att gga ggc atc aag ctg cgg cat      624  
               
               
                 Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly Ile Lys Leu Arg His  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 cag cag tgg agc ctg gtc atg gaa agc gtg gtg ccc tcg gac cgc ggc      672  
               
               
                 Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 aac tac acc tgc gtc gtg gag aac aag ttt ggc agc atc cgg cag acg      720  
               
               
                 Asn Tyr Thr Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 tac acg ctg gac gtg ctg gag cgc tcc ccg cac cgg ccc atc ctg cag      768  
               
               
                 Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gcg ggg ctg ccg gcc aac cag acg gcg gtg ctg ggc agc gac gtg gag      816  
               
               
                 Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 ttc cac tgc aag gtg tac agt gac gca cag ccc cac atc cag tgg ctc      864  
               
               
                 Phe His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 aag cac gtg gag gtg aac ggc agc aag gtg ggc ccg gac ggc aca ccc      912  
               
               
                 Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 tac gtt acc gtg ctc aag tcc tgg atc agt gag agt gtg gag gcc gac      960  
               
               
                 Tyr Val Thr Val Leu Lys Ser Trp Ile Ser Glu Ser Val Glu Ala Asp  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gtg cgc ctc cgc ctg gcc aat gtg tcg gag cgg gac ggg ggc gag tac     1008  
               
               
                 Val Arg Leu Arg Leu Ala Asn Val Ser Glu Arg Asp Gly Gly Glu Tyr  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 ctc tgt cga gcc acc aat ttc ata ggc gtg gcc gag aag gcc ttt tgg     1056  
               
               
                 Leu Cys Arg Ala Thr Asn Phe Ile Gly Val Ala Glu Lys Ala Phe Trp  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 ctg agc gtt cac ggg ccc cga gca gcc gag gag gag ctg gtg gag gct     1104  
               
               
                 Leu Ser Val His Gly Pro Arg Ala Ala Glu Glu Glu Leu Val Glu Ala  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 gac gag gcg ggc agt gtg tat gca ggc atc ctc agc tac ggg gtg ggc     1152  
               
               
                 Asp Glu Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 ttc ttc ctg ttc atc ctg gtg gtg gcg gct gtg acg ctc tgc cgc ctg     1200  
               
               
                 Phe Phe Leu Phe Ile Leu Val Val Ala Ala Val Thr Leu Cys Arg Leu  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 cgc agc ccc ccc aag aaa ggc ctg ggc tcc ccc acc gtg cac aag atc     1248  
               
               
                 Arg Ser Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 tcc cgc ttc ccg ctc aag cga cag gtg tcc ctg gag tcc aac gcg tcc     1296  
               
               
                 Ser Arg Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 atg agc tcc aac aca cca ctg gtg cgc atc gca agg ctg tcc tca ggg     1344  
               
               
                 Met Ser Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 gag ggc ccc acg ctg gcc aat gtc tcc gag ctc gag ctg cct gcc gac     1392  
               
               
                 Glu Gly Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro Ala Asp  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 ccc aaa tgg gag ctg tct cgg gcc cgg ctg acc ctg ggc aag ccc ctt     1440  
               
               
                 Pro Lys Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 ggg gag ggc tgc ttc ggc cag gtg gtc atg gcg gag gcc atc ggc att     1488  
               
               
                 Gly Glu Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 gac aag gac cgg gcc gcc aag cct gtc acc gta gcc gtg aag atg ctg     1536  
               
               
                 Asp Lys Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys Met Leu  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 aaa gac gat gcc act gac aag gac ctg tcg gac ctg gtg tct gag atg     1584  
               
               
                 Lys Asp Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 gag atg atg aag atg atc ggg aaa cac aaa aac atc atc aac ctg ctg     1632  
               
               
                 Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 ggc gcc tgc acg cag ggc ggg ccc ctg tac gtg ctg gtg gag tac gcg     1680  
               
               
                 Gly Ala Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Val Glu Tyr Ala  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 gcc aag ggt aac ctg cgg gag ttt ctg cgg gcg cgg cgg ccc ccg ggc     1728  
               
               
                 Ala Lys Gly Asn Leu Arg Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 ctg gac tac tcc ttc gac acc tgc aag ccg ccc gag gag cag ctc acc     1776  
               
               
                 Leu Asp Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu Glu Gln Leu Thr  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 ttc aag gac ctg gtg tcc tgt gcc tac cag gtg gcc cgg ggc atg gag     1824  
               
               
                 Phe Lys Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 tac ttg gcc tcc cag aag tgc atc cac agg gac ctg gct gcc cgc aat     1872  
               
               
                 Tyr Leu Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 gtg ctg gtg acc gag gac aac gtg atg aag atc gca gac ttc ggg ctg     1920  
               
               
                 Val Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe Gly Leu  
               
               
                 625                 630                 635                 640  
               
               
                   
               
               
                 gcc cgg gac gtg cac aac ctc gac tac tac aag aag aca acc aac ggc     1968  
               
               
                 Ala Arg Asp Val His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly  
               
               
                                 645                 650                 655  
               
               
                   
               
               
                 cgg ctg ccc gtg aag tgg atg gcg cct gag gcc ttg ttt gac cga gtc     2016  
               
               
                 Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val  
               
               
                             660                 665                 670  
               
               
                   
               
               
                 tac act cac cag agt gac gtc tgg tcc ttt ggg gtc ctg ctc tgg gag     2064  
               
               
                 Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu  
               
               
                         675                 680                 685  
               
               
                   
               
               
                 atc ttc acg ctg ggg ggc tcc ccg tac ccc ggc atc cct gtg gag gag     2112  
               
               
                 Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu  
               
               
                     690                 695                 700  
               
               
                   
               
               
                 ctc ttc aag ctg ctg aag gag ggc cac cgc atg gac aag ccc gcc aac     2160  
               
               
                 Leu Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro Ala Asn  
               
               
                 705                 710                 715                 720  
               
               
                   
               
               
                 tgc aca cac gac ctg tac atg atc atg cgg gag tgc tgg cat gcc gcg     2208  
               
               
                 Cys Thr His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala  
               
               
                                 725                 730                 735  
               
               
                   
               
               
                 ccc tcc cag agg ccc acc ttc aag cag ctg gtg gag gac ctg gac cgt     2256  
               
               
                 Pro Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg  
               
               
                             740                 745                 750  
               
               
                   
               
               
                 gtc ctt acc gtg acg tcc acc gac gag tac ctg gac ctg tcg gcg cct     2304  
               
               
                 Val Leu Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser Ala Pro  
               
               
                         755                 760                 765  
               
               
                   
               
               
                 ttc gag cag tac tcc ccg ggt ggc cag gac acc ccc agc tcc agc tcc     2352  
               
               
                 Phe Glu Gln Tyr Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser  
               
               
                     770                 775                 780  
               
               
                   
               
               
                 tca ggg gac gac tcc gtg ttt gcc cac gac ctg ctg ccc ccg gcc cca     2400  
               
               
                 Ser Gly Asp Asp Ser Val Phe Ala His Asp Leu Leu Pro Pro Ala Pro  
               
               
                 785                 790                 795                 800  
               
               
                   
               
               
                 ccc agc agt ggg ggc tcg cgg acg tga                                 2427  
               
               
                 Pro Ser Ser Gly Gly Ser Arg Thr  
               
               
                                 805  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 60  
               
               
                 &lt;211&gt; LENGTH: 808  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 60  
               
               
                   
               
               
                 Met Gly Ala Pro Ala Cys Ala Leu Ala Leu Cys Val Ala Val Ala Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Val Ala Gly Ala Ser Ser Glu Ser Leu Gly Thr Glu Gln Arg Val Val  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Gly Arg Ala Ala Glu Val Pro Gly Pro Glu Pro Gly Gln Gln Glu Gln  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Leu Val Phe Gly Ser Gly Asp Ala Val Glu Leu Ser Cys Pro Pro Pro  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Gly Gly Gly Pro Met Gly Pro Thr Val Trp Val Lys Asp Gly Thr Gly  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Leu Val Pro Ser Glu Arg Val Leu Val Gly Pro Gln Arg Leu Gln Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Leu Asn Ala Ser His Glu Asp Ser Gly Ala Tyr Ser Cys Arg Gln Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Thr Gln Arg Val Leu Cys His Phe Ser Val Arg Val Thr Asp Ala  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Pro Ser Ser Gly Asp Asp Glu Asp Gly Glu Asp Glu Ala Glu Asp Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Gly Val Asp Thr Gly Ala Pro Tyr Trp Thr Arg Pro Glu Arg Met Asp  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Lys Leu Leu Ala Val Pro Ala Ala Asn Thr Val Arg Phe Arg Cys  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Pro Ala Ala Gly Asn Pro Thr Pro Ser Ile Ser Trp Leu Lys Asn Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Arg Glu Phe Arg Gly Glu His Arg Ile Gly Gly Ile Lys Leu Arg His  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Gln Gln Trp Ser Leu Val Met Glu Ser Val Val Pro Ser Asp Arg Gly  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Asn Tyr Thr Cys Val Val Glu Asn Lys Phe Gly Ser Ile Arg Gln Thr  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Tyr Thr Leu Asp Val Leu Glu Arg Ser Pro His Arg Pro Ile Leu Gln  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Gly Leu Pro Ala Asn Gln Thr Ala Val Leu Gly Ser Asp Val Glu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Phe His Cys Lys Val Tyr Ser Asp Ala Gln Pro His Ile Gln Trp Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Lys His Val Glu Val Asn Gly Ser Lys Val Gly Pro Asp Gly Thr Pro  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Val Thr Val Leu Lys Ser Trp Ile Ser Glu Ser Val Glu Ala Asp  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Val Arg Leu Arg Leu Ala Asn Val Ser Glu Arg Asp Gly Gly Glu Tyr  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Leu Cys Arg Ala Thr Asn Phe Ile Gly Val Ala Glu Lys Ala Phe Trp  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Leu Ser Val His Gly Pro Arg Ala Ala Glu Glu Glu Leu Val Glu Ala  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Asp Glu Ala Gly Ser Val Tyr Ala Gly Ile Leu Ser Tyr Gly Val Gly  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Phe Phe Leu Phe Ile Leu Val Val Ala Ala Val Thr Leu Cys Arg Leu  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Arg Ser Pro Pro Lys Lys Gly Leu Gly Ser Pro Thr Val His Lys Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Ser Arg Phe Pro Leu Lys Arg Gln Val Ser Leu Glu Ser Asn Ala Ser  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Met Ser Ser Asn Thr Pro Leu Val Arg Ile Ala Arg Leu Ser Ser Gly  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Glu Gly Pro Thr Leu Ala Asn Val Ser Glu Leu Glu Leu Pro Ala Asp  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Pro Lys Trp Glu Leu Ser Arg Ala Arg Leu Thr Leu Gly Lys Pro Leu  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Gly Glu Gly Cys Phe Gly Gln Val Val Met Ala Glu Ala Ile Gly Ile  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Asp Lys Asp Arg Ala Ala Lys Pro Val Thr Val Ala Val Lys Met Leu  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Lys Asp Asp Ala Thr Asp Lys Asp Leu Ser Asp Leu Val Ser Glu Met  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Glu Met Met Lys Met Ile Gly Lys His Lys Asn Ile Ile Asn Leu Leu  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Gly Ala Cys Thr Gln Gly Gly Pro Leu Tyr Val Leu Val Glu Tyr Ala  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Ala Lys Gly Asn Leu Arg Glu Phe Leu Arg Ala Arg Arg Pro Pro Gly  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Leu Asp Tyr Ser Phe Asp Thr Cys Lys Pro Pro Glu Glu Gln Leu Thr  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Phe Lys Asp Leu Val Ser Cys Ala Tyr Gln Val Ala Arg Gly Met Glu  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Tyr Leu Ala Ser Gln Lys Cys Ile His Arg Asp Leu Ala Ala Arg Asn  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 Val Leu Val Thr Glu Asp Asn Val Met Lys Ile Ala Asp Phe Gly Leu  
               
               
                 625                 630                 635                 640  
               
               
                   
               
               
                 Ala Arg Asp Val His Asn Leu Asp Tyr Tyr Lys Lys Thr Thr Asn Gly  
               
               
                                 645                 650                 655  
               
               
                   
               
               
                 Arg Leu Pro Val Lys Trp Met Ala Pro Glu Ala Leu Phe Asp Arg Val  
               
               
                             660                 665                 670  
               
               
                   
               
               
                 Tyr Thr His Gln Ser Asp Val Trp Ser Phe Gly Val Leu Leu Trp Glu  
               
               
                         675                 680                 685  
               
               
                   
               
               
                 Ile Phe Thr Leu Gly Gly Ser Pro Tyr Pro Gly Ile Pro Val Glu Glu  
               
               
                     690                 695                 700  
               
               
                   
               
               
                 Leu Phe Lys Leu Leu Lys Glu Gly His Arg Met Asp Lys Pro Ala Asn  
               
               
                 705                 710                 715                 720  
               
               
                   
               
               
                 Cys Thr His Asp Leu Tyr Met Ile Met Arg Glu Cys Trp His Ala Ala  
               
               
                                 725                 730                 735  
               
               
                   
               
               
                 Pro Ser Gln Arg Pro Thr Phe Lys Gln Leu Val Glu Asp Leu Asp Arg  
               
               
                             740                 745                 750  
               
               
                   
               
               
                 Val Leu Thr Val Thr Ser Thr Asp Glu Tyr Leu Asp Leu Ser Ala Pro  
               
               
                         755                 760                 765  
               
               
                   
               
               
                 Phe Glu Gln Tyr Ser Pro Gly Gly Gln Asp Thr Pro Ser Ser Ser Ser  
               
               
                     770                 775                 780  
               
               
                   
               
               
                 Ser Gly Asp Asp Ser Val Phe Ala His Asp Leu Leu Pro Pro Ala Pro  
               
               
                 785                 790                 795                 800  
               
               
                   
               
               
                 Pro Ser Ser Gly Gly Ser Arg Thr  
               
               
                                 805  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 61  
               
               
                 &lt;211&gt; LENGTH: 2077  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(1977)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 61  
               
               
                   
               
               
                 atg gag cgg tgg cgc gac cgg ctg gcg ctg gtg acg ggg gcc tcg ggg       48  
               
               
                 Met Glu Arg Trp Arg Asp Arg Leu Ala Leu Val Thr Gly Ala Ser Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 ggc atc ggc gcg gcc gtg gcc cgg gcc ctg gtc cag cag gga ctg aag       96  
               
               
                 Gly Ile Gly Ala Ala Val Ala Arg Ala Leu Val Gln Gln Gly Leu Lys  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 gtg gtg ggc tgc gcc cgc act gtg ggc aac atc gag gag ctg gct gct      144  
               
               
                 Val Val Gly Cys Ala Arg Thr Val Gly Asn Ile Glu Glu Leu Ala Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 gaa tgt aag agt gca ggc tac ccc ggg act ttg atc ccc tac aga tgt      192  
               
               
                 Glu Cys Lys Ser Ala Gly Tyr Pro Gly Thr Leu Ile Pro Tyr Arg Cys  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 gac cta tca aat gaa gag gac atc ctc tcc atg ttc tca gct atc cgt      240  
               
               
                 Asp Leu Ser Asn Glu Glu Asp Ile Leu Ser Met Phe Ser Ala Ile Arg  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 tct cag cac agc ggt gta gac atc tgc atc aac aat gct ggc ttg gcc      288  
               
               
                 Ser Gln His Ser Gly Val Asp Ile Cys Ile Asn Asn Ala Gly Leu Ala  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 cgg cct gac acc ctg ctc tca ggc agc acc agt ggt tgg aag gac atg      336  
               
               
                 Arg Pro Asp Thr Leu Leu Ser Gly Ser Thr Ser Gly Trp Lys Asp Met  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 ttc aat gtg aac gtg ctg gcc ctc agc atc tgc aca cgg gaa gcc tac      384  
               
               
                 Phe Asn Val Asn Val Leu Ala Leu Ser Ile Cys Thr Arg Glu Ala Tyr  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 cag tcc atg aag gag cgg aat gtg gac gat ggg cac atc att aac atc      432  
               
               
                 Gln Ser Met Lys Glu Arg Asn Val Asp Asp Gly His Ile Ile Asn Ile  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 aat agc atg tct ggc cac cga gtg tta ccc ctg tct gtg acc cac ttc      480  
               
               
                 Asn Ser Met Ser Gly His Arg Val Leu Pro Leu Ser Val Thr His Phe  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 tat agt gcc acc aag tat gcc gtc act gcg ctg aca gag gga ctg agg      528  
               
               
                 Tyr Ser Ala Thr Lys Tyr Ala Val Thr Ala Leu Thr Glu Gly Leu Arg  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 caa gag ctt cgg gag gcc cag acc cac atc cga gcc acg tgg cag ctt      576  
               
               
                 Gln Glu Leu Arg Glu Ala Gln Thr His Ile Arg Ala Thr Trp Gln Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 cgg agg gag gag gcc gct gcc gga tat cag gca gcc atc act gtg aag      624  
               
               
                 Arg Arg Glu Glu Ala Ala Ala Gly Tyr Gln Ala Ala Ile Thr Val Lys  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 ctg ggg ttc tgt ggc ctc cat cct ctc ccc tcg acc tcc cca aga cct      672  
               
               
                 Leu Gly Phe Cys Gly Leu His Pro Leu Pro Ser Thr Ser Pro Arg Pro  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 ggc aaa gct cag ccc ctg aga agg ccc tct ctg ttg gcc cag tgc atc      720  
               
               
                 Gly Lys Ala Gln Pro Leu Arg Arg Pro Ser Leu Leu Ala Gln Cys Ile  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 tct cca ggt gtg gtg gag aca caa ttc gcc ttc aaa ctc cac gac aag      768  
               
               
                 Ser Pro Gly Val Val Glu Thr Gln Phe Ala Phe Lys Leu His Asp Lys  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gac cct gag aag gca gct gcc acc tat gag caa atg aag tgt ctc aaa      816  
               
               
                 Asp Pro Glu Lys Ala Ala Ala Thr Tyr Glu Gln Met Lys Cys Leu Lys  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 ccc gag gat gtg gcc gag gct gtt atc tac gtc ctc agc acc ccc gca      864  
               
               
                 Pro Glu Asp Val Ala Glu Ala Val Ile Tyr Val Leu Ser Thr Pro Ala  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 cac atc cag att gga gac atc cag atg agg ccc acg gag cag aga gct      912  
               
               
                 His Ile Gln Ile Gly Asp Ile Gln Met Arg Pro Thr Glu Gln Arg Ala  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 cgg cgg aga cgg ctg tcg agt acc ctt cac ctc ggt gtt ggg agc ctg      960  
               
               
                 Arg Arg Arg Arg Leu Ser Ser Thr Leu His Leu Gly Val Gly Ser Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gga gcg aac tgc ggc gcg ggt tac cgc tcc cgg gga cgc agc aag ggg     1008  
               
               
                 Gly Ala Asn Cys Gly Ala Gly Tyr Arg Ser Arg Gly Arg Ser Lys Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 cat cga gtc cct ggc ggg agc tgc gcc atg gca ttg ctc tcg acc gtc     1056  
               
               
                 His Arg Val Pro Gly Gly Ser Cys Ala Met Ala Leu Leu Ser Thr Val  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 cgg ggc gcg acc tgg ggt cgc ctc gtc acc cgt cat ttc tcc cat gca     1104  
               
               
                 Arg Gly Ala Thr Trp Gly Arg Leu Val Thr Arg His Phe Ser His Ala  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 gcg cgg cat ggg gag cgg cct ggt ggg gag gag cta agc cgc ttg ctg     1152  
               
               
                 Ala Arg His Gly Glu Arg Pro Gly Gly Glu Glu Leu Ser Arg Leu Leu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 ctg gat gac ctg gtg ccg acc tct cgg ctg gag ctt ctg ttt ggc atg     1200  
               
               
                 Leu Asp Asp Leu Val Pro Thr Ser Arg Leu Glu Leu Leu Phe Gly Met  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 acc ccg tgt ctc ctg gct ctg cag gcc gcc cgc cgc tct gtg gcc cgg     1248  
               
               
                 Thr Pro Cys Leu Leu Ala Leu Gln Ala Ala Arg Arg Ser Val Ala Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 ctc ctg ctc cag gcg ggt aaa gct ggg ctg cag ggg aag cgg gcc gag     1296  
               
               
                 Leu Leu Leu Gln Ala Gly Lys Ala Gly Leu Gln Gly Lys Arg Ala Glu  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 ctg ctc cgg atg gcc gag gcg cgg gac att cca gtt ctg cgg ccc aga     1344  
               
               
                 Leu Leu Arg Met Ala Glu Ala Arg Asp Ile Pro Val Leu Arg Pro Arg  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 cgg cag aaa ctg gac aca atg tgc cgc tac cag gtc cac cag ggt gtc     1392  
               
               
                 Arg Gln Lys Leu Asp Thr Met Cys Arg Tyr Gln Val His Gln Gly Val  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 tgc atg gag gtg agc ccg ctg cgg ccc cgg cct tgg aga gag gcc ggg     1440  
               
               
                 Cys Met Glu Val Ser Pro Leu Arg Pro Arg Pro Trp Arg Glu Ala Gly  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 gag gcg agc cca ggc gac gac ccc cag cag ttg tgg ctc gtc ctc gat     1488  
               
               
                 Glu Ala Ser Pro Gly Asp Asp Pro Gln Gln Leu Trp Leu Val Leu Asp  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 ggg atc cag gat ccc cgg aat ttt ggg gct gtg ctg cgt tcc gca cac     1536  
               
               
                 Gly Ile Gln Asp Pro Arg Asn Phe Gly Ala Val Leu Arg Ser Ala His  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 ttc ctc gga gtg gat aag acc aaa gcc cag cag ggc tgg ctc gtg gcc     1584  
               
               
                 Phe Leu Gly Val Asp Lys Thr Lys Ala Gln Gln Gly Trp Leu Val Ala  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 ggc acg gtg ggc tgc cca agc aca gag gat ccc cag tcc tcc gag atc     1632  
               
               
                 Gly Thr Val Gly Cys Pro Ser Thr Glu Asp Pro Gln Ser Ser Glu Ile  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 ccc atc atg agt tgc ttg gag ttc ctc tgg gaa cgg cct act ctc ctt     1680  
               
               
                 Pro Ile Met Ser Cys Leu Glu Phe Leu Trp Glu Arg Pro Thr Leu Leu  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 gtg ctg ggg aat gag ggc tca ggt cta tcc cag gag gtg cag gcc tcc     1728  
               
               
                 Val Leu Gly Asn Glu Gly Ser Gly Leu Ser Gln Glu Val Gln Ala Ser  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 tgc cag ctt ctc ctc acc atc ctg ccc cgg cgc cag ctg cct cct gga     1776  
               
               
                 Cys Gln Leu Leu Leu Thr Ile Leu Pro Arg Arg Gln Leu Pro Pro Gly  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 ctt gag tcc ttg aac gtc tct gtg gct gca gga att ctt ctt cac tcc     1824  
               
               
                 Leu Glu Ser Leu Asn Val Ser Val Ala Ala Gly Ile Leu Leu His Ser  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 att tgc agc cag agg aag ggt ttc ccc aca gag ggg gag aga agg cag     1872  
               
               
                 Ile Cys Ser Gln Arg Lys Gly Phe Pro Thr Glu Gly Glu Arg Arg Gln  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 ctt ctc caa gac ccc caa gaa ccc tca gcc agg tct gaa ggg ctc agc     1920  
               
               
                 Leu Leu Gln Asp Pro Gln Glu Pro Ser Ala Arg Ser Glu Gly Leu Ser  
               
               
                 625                 630                 635                 640  
               
               
                   
               
               
                 atg gct cag cac cca ggg ctg tct tca ggc cca gag aaa gag agg caa     1968  
               
               
                 Met Ala Gln His Pro Gly Leu Ser Ser Gly Pro Glu Lys Glu Arg Gln  
               
               
                                 645                 650                 655  
               
               
                   
               
               
                 aat gag ggc tgacgtggac tgtccacagt gttcatgtgc tggagtcagg             2017  
               
               
                 Asn Glu Gly  
               
               
                   
               
               
                 gacggccgca cctgcctccg ccggctccag tgtgcgggga gcctctgcct gagtgtgcac   2077  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 62  
               
               
                 &lt;211&gt; LENGTH: 659  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 62  
               
               
                   
               
               
                 Met Glu Arg Trp Arg Asp Arg Leu Ala Leu Val Thr Gly Ala Ser Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gly Ile Gly Ala Ala Val Ala Arg Ala Leu Val Gln Gln Gly Leu Lys  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Val Val Gly Cys Ala Arg Thr Val Gly Asn Ile Glu Glu Leu Ala Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Glu Cys Lys Ser Ala Gly Tyr Pro Gly Thr Leu Ile Pro Tyr Arg Cys  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asp Leu Ser Asn Glu Glu Asp Ile Leu Ser Met Phe Ser Ala Ile Arg  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ser Gln His Ser Gly Val Asp Ile Cys Ile Asn Asn Ala Gly Leu Ala  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Arg Pro Asp Thr Leu Leu Ser Gly Ser Thr Ser Gly Trp Lys Asp Met  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Phe Asn Val Asn Val Leu Ala Leu Ser Ile Cys Thr Arg Glu Ala Tyr  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Gln Ser Met Lys Glu Arg Asn Val Asp Asp Gly His Ile Ile Asn Ile  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Asn Ser Met Ser Gly His Arg Val Leu Pro Leu Ser Val Thr His Phe  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Tyr Ser Ala Thr Lys Tyr Ala Val Thr Ala Leu Thr Glu Gly Leu Arg  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Gln Glu Leu Arg Glu Ala Gln Thr His Ile Arg Ala Thr Trp Gln Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Arg Arg Glu Glu Ala Ala Ala Gly Tyr Gln Ala Ala Ile Thr Val Lys  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Gly Phe Cys Gly Leu His Pro Leu Pro Ser Thr Ser Pro Arg Pro  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Gly Lys Ala Gln Pro Leu Arg Arg Pro Ser Leu Leu Ala Gln Cys Ile  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Ser Pro Gly Val Val Glu Thr Gln Phe Ala Phe Lys Leu His Asp Lys  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Asp Pro Glu Lys Ala Ala Ala Thr Tyr Glu Gln Met Lys Cys Leu Lys  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Pro Glu Asp Val Ala Glu Ala Val Ile Tyr Val Leu Ser Thr Pro Ala  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 His Ile Gln Ile Gly Asp Ile Gln Met Arg Pro Thr Glu Gln Arg Ala  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Arg Arg Arg Arg Leu Ser Ser Thr Leu His Leu Gly Val Gly Ser Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Gly Ala Asn Cys Gly Ala Gly Tyr Arg Ser Arg Gly Arg Ser Lys Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 His Arg Val Pro Gly Gly Ser Cys Ala Met Ala Leu Leu Ser Thr Val  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Arg Gly Ala Thr Trp Gly Arg Leu Val Thr Arg His Phe Ser His Ala  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ala Arg His Gly Glu Arg Pro Gly Gly Glu Glu Leu Ser Arg Leu Leu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Leu Asp Asp Leu Val Pro Thr Ser Arg Leu Glu Leu Leu Phe Gly Met  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Thr Pro Cys Leu Leu Ala Leu Gln Ala Ala Arg Arg Ser Val Ala Arg  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Leu Leu Leu Gln Ala Gly Lys Ala Gly Leu Gln Gly Lys Arg Ala Glu  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Leu Leu Arg Met Ala Glu Ala Arg Asp Ile Pro Val Leu Arg Pro Arg  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Arg Gln Lys Leu Asp Thr Met Cys Arg Tyr Gln Val His Gln Gly Val  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Cys Met Glu Val Ser Pro Leu Arg Pro Arg Pro Trp Arg Glu Ala Gly  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Glu Ala Ser Pro Gly Asp Asp Pro Gln Gln Leu Trp Leu Val Leu Asp  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Gly Ile Gln Asp Pro Arg Asn Phe Gly Ala Val Leu Arg Ser Ala His  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Phe Leu Gly Val Asp Lys Thr Lys Ala Gln Gln Gly Trp Leu Val Ala  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Gly Thr Val Gly Cys Pro Ser Thr Glu Asp Pro Gln Ser Ser Glu Ile  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Pro Ile Met Ser Cys Leu Glu Phe Leu Trp Glu Arg Pro Thr Leu Leu  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Val Leu Gly Asn Glu Gly Ser Gly Leu Ser Gln Glu Val Gln Ala Ser  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Cys Gln Leu Leu Leu Thr Ile Leu Pro Arg Arg Gln Leu Pro Pro Gly  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Leu Glu Ser Leu Asn Val Ser Val Ala Ala Gly Ile Leu Leu His Ser  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Ile Cys Ser Gln Arg Lys Gly Phe Pro Thr Glu Gly Glu Arg Arg Gln  
               
               
                     610                 615                 620  
               
               
                   
               
               
                 Leu Leu Gln Asp Pro Gln Glu Pro Ser Ala Arg Ser Glu Gly Leu Ser  
               
               
                 625                 630                 635                 640  
               
               
                   
               
               
                 Met Ala Gln His Pro Gly Leu Ser Ser Gly Pro Glu Lys Glu Arg Gln  
               
               
                                 645                 650                 655  
               
               
                   
               
               
                 Asn Glu Gly  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 63  
               
               
                 &lt;211&gt; LENGTH: 736  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (13)..(696)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 63  
               
               
                   
               
               
                 aaagcacccg ag atg acc ccg gct cct cca cca gga gcg cgg ccg ggc gcg     51  
               
               
                               Met Thr Pro Ala Pro Pro Pro Gly Ala Arg Pro Gly Ala  
               
               
                               1                5                  10  
               
               
                   
               
               
                 gcg tcc cta gcg ggc ttc gcc ggg gtg gcg tct ctg ggg cct ggg gac       99  
               
               
                 Ala Ser Leu Ala Gly Phe Ala Gly Val Ala Ser Leu Gly Pro Gly Asp  
               
               
                     15                  20                  25  
               
               
                   
               
               
                 ccc cgc cgc gcc gct gac ccg cgc cct ctg ccc cca gcg ctg tgc ttc      147  
               
               
                 Pro Arg Arg Ala Ala Asp Pro Arg Pro Leu Pro Pro Ala Leu Cys Phe  
               
               
                 30                  35                  40                  45  
               
               
                   
               
               
                 gcc gtg agc cgc tcg ctg ctg ctg acg tgc ctg gtg ccg gcc gcg ctg      195  
               
               
                 Ala Val Ser Arg Ser Leu Leu Leu Thr Cys Leu Val Pro Ala Ala Leu  
               
               
                                 50                  55                  60  
               
               
                   
               
               
                 ctg ggc ctg cgc tac tac tac agc cgc aag gtg atc cgc gcc tac ctg      243  
               
               
                 Leu Gly Leu Arg Tyr Tyr Tyr Ser Arg Lys Val Ile Arg Ala Tyr Leu  
               
               
                             65                  70                  75  
               
               
                   
               
               
                 gag tgc gcg ctg cac acg gac atg gcg gac atc gag cag tac tac atg      291  
               
               
                 Glu Cys Ala Leu His Thr Asp Met Ala Asp Ile Glu Gln Tyr Tyr Met  
               
               
                         80                  85                  90  
               
               
                   
               
               
                 aag ccg ccc ggt gtg tcc ctg acc gcc cta tcc cct gca ggc tcc tgc      339  
               
               
                 Lys Pro Pro Gly Val Ser Leu Thr Ala Leu Ser Pro Ala Gly Ser Cys  
               
               
                     95                  100                 105  
               
               
                   
               
               
                 ttc tgg gtg gcc gtg ctg gat ggc aac gtg gtg ggc att gtg gct gca      387  
               
               
                 Phe Trp Val Ala Val Leu Asp Gly Asn Val Val Gly Ile Val Ala Ala  
               
               
                 110                 115                 120                 125  
               
               
                   
               
               
                 cgg gcc cac gag gag gac aac acg gtg gag ctg ctg cgg atg tct gtg      435  
               
               
                 Arg Ala His Glu Glu Asp Asn Thr Val Glu Leu Leu Arg Met Ser Val  
               
               
                                 130                 135                 140  
               
               
                   
               
               
                 gac tca cgt ttc cga ggc aag ggc atc gcc aag gcg ctg ggc cgg aag      483  
               
               
                 Asp Ser Arg Phe Arg Gly Lys Gly Ile Ala Lys Ala Leu Gly Arg Lys  
               
               
                             145                 150                 155  
               
               
                   
               
               
                 gtg ctg gag ttc gcc gtg gtg cac aac tac tcc gcg gtg gtg ctg ggc      531  
               
               
                 Val Leu Glu Phe Ala Val Val His Asn Tyr Ser Ala Val Val Leu Gly  
               
               
                         160                 165                 170  
               
               
                   
               
               
                 acg acg gcc gtc aag gtg gcc gcc cac aag ctc tac gag tcg ctg ggc      579  
               
               
                 Thr Thr Ala Val Lys Val Ala Ala His Lys Leu Tyr Glu Ser Leu Gly  
               
               
                     175                 180                 185  
               
               
                   
               
               
                 ttc aga cac atg ggc gcc agt gac cac tac gtg ctg ccg ggc atg acc      627  
               
               
                 Phe Arg His Met Gly Ala Ser Asp His Tyr Val Leu Pro Gly Met Thr  
               
               
                 190                 195                 200                 205  
               
               
                   
               
               
                 ctc tcg ctg gct gag cgc ctc ttc ttc cag gtc cgc tac cac cgc tac      675  
               
               
                 Leu Ser Leu Ala Glu Arg Leu Phe Phe Gln Val Arg Tyr His Arg Tyr  
               
               
                                 210                 215                 220  
               
               
                   
               
               
                 cgc ctg cag ctg cgc gag gag tgaccgccgc cgctcgcccg cccgcccccc         726  
               
               
                 Arg Leu Gln Leu Arg Glu Glu  
               
               
                             225  
               
               
                   
               
               
                 cggccgccct                                                           736  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 64  
               
               
                 &lt;211&gt; LENGTH: 228  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 64  
               
               
                   
               
               
                 Met Thr Pro Ala Pro Pro Pro Gly Ala Arg Pro Gly Ala Ala Ser Leu  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Ala Gly Phe Ala Gly Val Ala Ser Leu Gly Pro Gly Asp Pro Arg Arg  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Ala Asp Pro Arg Pro Leu Pro Pro Ala Leu Cys Phe Ala Val Ser  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Arg Ser Leu Leu Leu Thr Cys Leu Val Pro Ala Ala Leu Leu Gly Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Arg Tyr Tyr Tyr Ser Arg Lys Val Ile Arg Ala Tyr Leu Glu Cys Ala  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Leu His Thr Asp Met Ala Asp Ile Glu Gln Tyr Tyr Met Lys Pro Pro  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Gly Val Ser Leu Thr Ala Leu Ser Pro Ala Gly Ser Cys Phe Trp Val  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ala Val Leu Asp Gly Asn Val Val Gly Ile Val Ala Ala Arg Ala His  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Glu Glu Asp Asn Thr Val Glu Leu Leu Arg Met Ser Val Asp Ser Arg  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Phe Arg Gly Lys Gly Ile Ala Lys Ala Leu Gly Arg Lys Val Leu Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Phe Ala Val Val His Asn Tyr Ser Ala Val Val Leu Gly Thr Thr Ala  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Val Lys Val Ala Ala His Lys Leu Tyr Glu Ser Leu Gly Phe Arg His  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Met Gly Ala Ser Asp His Tyr Val Leu Pro Gly Met Thr Leu Ser Leu  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ala Glu Arg Leu Phe Phe Gln Val Arg Tyr His Arg Tyr Arg Leu Gln  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Leu Arg Glu Glu  
               
               
                 225  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 65  
               
               
                 &lt;211&gt; LENGTH: 1748  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (98)..(1648)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 65  
               
               
                   
               
               
                 gttcacccca agactaagtt ctttcccaag ttagagaaga agagagaaag caaaaagaag     60  
               
               
                   
               
               
                 agaggaaagt tctcccttcc cctcctccgt gcctgtc atg tcc tct aag cca gag     115  
               
               
                                                          Met Ser Ser Lys Pro Glu  
               
               
                                                          1               5  
               
               
                   
               
               
                 ccg aag gac gtc cac caa ctg aac ggg act ggc cct tct gcc tct ccc      163  
               
               
                 Pro Lys Asp Val His Gln Leu Asn Gly Thr Gly Pro Ser Ala Ser Pro  
               
               
                             10                  15                  20  
               
               
                   
               
               
                 tgc tct tca gat ggc cca ggg aga gag ccc ttg gct ggg acc tca gag      211  
               
               
                 Cys Ser Ser Asp Gly Pro Gly Arg Glu Pro Leu Ala Gly Thr Ser Glu  
               
               
                         25                  30                  35  
               
               
                   
               
               
                 ttc ctg ggg cct gat ggg gct ggg gta gag gtg gtg att gag tct cgg      259  
               
               
                 Phe Leu Gly Pro Asp Gly Ala Gly Val Glu Val Val Ile Glu Ser Arg  
               
               
                     40                  45                  50  
               
               
                   
               
               
                 gcc aac gcc aag ggg gtt cgg gag gag gac gcc ctg ctg gag aac ggg      307  
               
               
                 Ala Asn Ala Lys Gly Val Arg Glu Glu Asp Ala Leu Leu Glu Asn Gly  
               
               
                 55                  60                  65                  70  
               
               
                   
               
               
                 agc cag agc aac gaa agt gac gac gtc agc aca gac cgt ggc cct gcg      355  
               
               
                 Ser Gln Ser Asn Glu Ser Asp Asp Val Ser Thr Asp Arg Gly Pro Ala  
               
               
                                 75                  80                  85  
               
               
                   
               
               
                 cca cct tcc ccg ctc aag gag acc tcc ttt tcc atc ggg ctg caa gta      403  
               
               
                 Pro Pro Ser Pro Leu Lys Glu Thr Ser Phe Ser Ile Gly Leu Gln Val  
               
               
                             90                  95                  100  
               
               
                   
               
               
                 ctg ttt cca ttc ctc ctg gca ggc ttt ggg acc gtg gct gct ggc atg      451  
               
               
                 Leu Phe Pro Phe Leu Leu Ala Gly Phe Gly Thr Val Ala Ala Gly Met  
               
               
                         105                 110                 115  
               
               
                   
               
               
                 gtg ttg gac atc gtg cag cac tgg gaa gtc ttc cag aag gtg aca gag      499  
               
               
                 Val Leu Asp Ile Val Gln His Trp Glu Val Phe Gln Lys Val Thr Glu  
               
               
                     120                 125                 130  
               
               
                   
               
               
                 gtc ttc atc cta gtg cct gcg ctg ctg ggg ctc aaa ggg aac ctg gaa      547  
               
               
                 Val Phe Ile Leu Val Pro Ala Leu Leu Gly Leu Lys Gly Asn Leu Glu  
               
               
                 135                 140                 145                 150  
               
               
                   
               
               
                 atg acc ctg gca tca agg ctt tcc act gca gcg agt atc aac att gga      595  
               
               
                 Met Thr Leu Ala Ser Arg Leu Ser Thr Ala Ala Ser Ile Asn Ile Gly  
               
               
                                 155                 160                 165  
               
               
                   
               
               
                 cac atg gac aca ccc aag gag ctc tgg cgg atg atc act ggg aac atg      643  
               
               
                 His Met Asp Thr Pro Lys Glu Leu Trp Arg Met Ile Thr Gly Asn Met  
               
               
                             170                 175                 180  
               
               
                   
               
               
                 gcc ctc atc cag gtg cag gcc acg gtg gtg ggc ttc ctg gcg tcc atc      691  
               
               
                 Ala Leu Ile Gln Val Gln Ala Thr Val Val Gly Phe Leu Ala Ser Ile  
               
               
                         185                 190                 195  
               
               
                   
               
               
                 gca gcc gtc gtc ttt ggc tgg atc cct gat ggc cac ttc agt att ccg      739  
               
               
                 Ala Ala Val Val Phe Gly Trp Ile Pro Asp Gly His Phe Ser Ile Pro  
               
               
                     200                 205                 210  
               
               
                   
               
               
                 cac gcc ttc ctg ctc tgt gct agc agc gtg gcc aca gcc ttc att gcc      787  
               
               
                 His Ala Phe Leu Leu Cys Ala Ser Ser Val Ala Thr Ala Phe Ile Ala  
               
               
                 215                 220                 225                 230  
               
               
                   
               
               
                 tcc ctg gta ctg ggt atg atc atg att gga gtc atc att ggc tct cgc      835  
               
               
                 Ser Leu Val Leu Gly Met Ile Met Ile Gly Val Ile Ile Gly Ser Arg  
               
               
                                 235                 240                 245  
               
               
                   
               
               
                 aag att ggg atc aac cca gac aat gtg gcc aca ccc att gct gcc agc      883  
               
               
                 Lys Ile Gly Ile Asn Pro Asp Asn Val Ala Thr Pro Ile Ala Ala Ser  
               
               
                             250                 255                 260  
               
               
                   
               
               
                 ctg ggc gac ctc atc acc ttg gcg ctg ctc tca ggc atc agc tgg gga      931  
               
               
                 Leu Gly Asp Leu Ile Thr Leu Ala Leu Leu Ser Gly Ile Ser Trp Gly  
               
               
                         265                 270                 275  
               
               
                   
               
               
                 ctc ctg acc tct gcc ctc tca gat cac tgg cga tac atc tac cca ctg      979  
               
               
                 Leu Leu Thr Ser Ala Leu Ser Asp His Trp Arg Tyr Ile Tyr Pro Leu  
               
               
                     280                 285                 290  
               
               
                   
               
               
                 gtg tgt gct ttc ttt gtg gcc ctg ctg cct gtc tgg gtg gtg ctg gcc     1027  
               
               
                 Val Cys Ala Phe Phe Val Ala Leu Leu Pro Val Trp Val Val Leu Ala  
               
               
                 295                 300                 305                 310  
               
               
                   
               
               
                 cga cga agt cca gcc aca agg gag gtg ttg tac tcg ggc tgg gag cct     1075  
               
               
                 Arg Arg Ser Pro Ala Thr Arg Glu Val Leu Tyr Ser Gly Trp Glu Pro  
               
               
                                 315                 320                 325  
               
               
                   
               
               
                 gtt atc att gcc atg gcc atc agc agt gtg gga ggc ctc atc ttg gac     1123  
               
               
                 Val Ile Ile Ala Met Ala Ile Ser Ser Val Gly Gly Leu Ile Leu Asp  
               
               
                             330                 335                 340  
               
               
                   
               
               
                 aag act gtc tca gac ccc aac ttt gct ggg atg gct gtc ttc acg cct     1171  
               
               
                 Lys Thr Val Ser Asp Pro Asn Phe Ala Gly Met Ala Val Phe Thr Pro  
               
               
                         345                 350                 355  
               
               
                   
               
               
                 gtg att aat ggt gtt ggg ggc aat ctg gtg gca gtg cag gcc agc cgc     1219  
               
               
                 Val Ile Asn Gly Val Gly Gly Asn Leu Val Ala Val Gln Ala Ser Arg  
               
               
                     360                 365                 370  
               
               
                   
               
               
                 atc tcc acc ttc ctg cac atg aat gga atg ccc gga gag aac tct gag     1267  
               
               
                 Ile Ser Thr Phe Leu His Met Asn Gly Met Pro Gly Glu Asn Ser Glu  
               
               
                 375                 380                 385                 390  
               
               
                   
               
               
                 caa gct cct cgc cgc tgt ccc agt cct tgt acc acc ttc ttc agc cct     1315  
               
               
                 Gln Ala Pro Arg Arg Cys Pro Ser Pro Cys Thr Thr Phe Phe Ser Pro  
               
               
                                 395                 400                 405  
               
               
                   
               
               
                 ggt gtg aat tct cgc tca gcc cgg gtc ctc ttc ctc ctc gtg gtc cca     1363  
               
               
                 Gly Val Asn Ser Arg Ser Ala Arg Val Leu Phe Leu Leu Val Val Pro  
               
               
                             410                 415                 420  
               
               
                   
               
               
                 gga cac ctg gtg ttc ctc tac acc atc agc tgt atg cag ggc ggg cac     1411  
               
               
                 Gly His Leu Val Phe Leu Tyr Thr Ile Ser Cys Met Gln Gly Gly His  
               
               
                         425                 430                 435  
               
               
                   
               
               
                 acc acc ctc aca ctc atc ttc atc atc ttc tat atg aca gct gca ctg     1459  
               
               
                 Thr Thr Leu Thr Leu Ile Phe Ile Ile Phe Tyr Met Thr Ala Ala Leu  
               
               
                     440                 445                 450  
               
               
                   
               
               
                 ctc cag gtg ctg att ctc ctg tac atc gca gac tgg atg gtg cac tgg     1507  
               
               
                 Leu Gln Val Leu Ile Leu Leu Tyr Ile Ala Asp Trp Met Val His Trp  
               
               
                 455                 460                 465                 470  
               
               
                   
               
               
                 atg tgg ggc cgg ggc ctg gac ccg gac aac ttc tcc atc cca tac ttg     1555  
               
               
                 Met Trp Gly Arg Gly Leu Asp Pro Asp Asn Phe Ser Ile Pro Tyr Leu  
               
               
                                 475                 480                 485  
               
               
                   
               
               
                 act gct ctg ggg gac ctg ctt ggc act ggg ctc cta gca ctc agc ttc     1603  
               
               
                 Thr Ala Leu Gly Asp Leu Leu Gly Thr Gly Leu Leu Ala Leu Ser Phe  
               
               
                             490                 495                 500  
               
               
                   
               
               
                 cat gtt ctc tgg ctc ata ggg gac cga gac acg gat gtc ggg gac         1648  
               
               
                 His Val Leu Trp Leu Ile Gly Asp Arg Asp Thr Asp Val Gly Asp  
               
               
                         505                 510                 515  
               
               
                   
               
               
                 tagcttggtc actcaacatt ttccccatcc ctctgcactt tctatttgaa atttttcttt   1708  
               
               
                   
               
               
                 tgttcccctg tccctcctcc accccacact cccacctctt                         1748  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 66  
               
               
                 &lt;211&gt; LENGTH: 517  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 66  
               
               
                   
               
               
                 Met Ser Ser Lys Pro Glu Pro Lys Asp Val His Gln Leu Asn Gly Thr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gly Pro Ser Ala Ser Pro Cys Ser Ser Asp Gly Pro Gly Arg Glu Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Leu Ala Gly Thr Ser Glu Phe Leu Gly Pro Asp Gly Ala Gly Val Glu  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Val Val Ile Glu Ser Arg Ala Asn Ala Lys Gly Val Arg Glu Glu Asp  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ala Leu Leu Glu Asn Gly Ser Gln Ser Asn Glu Ser Asp Asp Val Ser  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Thr Asp Arg Gly Pro Ala Pro Pro Ser Pro Leu Lys Glu Thr Ser Phe  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ser Ile Gly Leu Gln Val Leu Phe Pro Phe Leu Leu Ala Gly Phe Gly  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Thr Val Ala Ala Gly Met Val Leu Asp Ile Val Gln His Trp Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Phe Gln Lys Val Thr Glu Val Phe Ile Leu Val Pro Ala Leu Leu Gly  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Leu Lys Gly Asn Leu Glu Met Thr Leu Ala Ser Arg Leu Ser Thr Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Ser Ile Asn Ile Gly His Met Asp Thr Pro Lys Glu Leu Trp Arg  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Met Ile Thr Gly Asn Met Ala Leu Ile Gln Val Gln Ala Thr Val Val  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gly Phe Leu Ala Ser Ile Ala Ala Val Val Phe Gly Trp Ile Pro Asp  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Gly His Phe Ser Ile Pro His Ala Phe Leu Leu Cys Ala Ser Ser Val  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ala Thr Ala Phe Ile Ala Ser Leu Val Leu Gly Met Ile Met Ile Gly  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Val Ile Ile Gly Ser Arg Lys Ile Gly Ile Asn Pro Asp Asn Val Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Thr Pro Ile Ala Ala Ser Leu Gly Asp Leu Ile Thr Leu Ala Leu Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Ser Gly Ile Ser Trp Gly Leu Leu Thr Ser Ala Leu Ser Asp His Trp  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Arg Tyr Ile Tyr Pro Leu Val Cys Ala Phe Phe Val Ala Leu Leu Pro  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Val Trp Val Val Leu Ala Arg Arg Ser Pro Ala Thr Arg Glu Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Tyr Ser Gly Trp Glu Pro Val Ile Ile Ala Met Ala Ile Ser Ser Val  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Gly Gly Leu Ile Leu Asp Lys Thr Val Ser Asp Pro Asn Phe Ala Gly  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Met Ala Val Phe Thr Pro Val Ile Asn Gly Val Gly Gly Asn Leu Val  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ala Val Gln Ala Ser Arg Ile Ser Thr Phe Leu His Met Asn Gly Met  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Pro Gly Glu Asn Ser Glu Gln Ala Pro Arg Arg Cys Pro Ser Pro Cys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Thr Thr Phe Phe Ser Pro Gly Val Asn Ser Arg Ser Ala Arg Val Leu  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Phe Leu Leu Val Val Pro Gly His Leu Val Phe Leu Tyr Thr Ile Ser  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Cys Met Gln Gly Gly His Thr Thr Leu Thr Leu Ile Phe Ile Ile Phe  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Tyr Met Thr Ala Ala Leu Leu Gln Val Leu Ile Leu Leu Tyr Ile Ala  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Asp Trp Met Val His Trp Met Trp Gly Arg Gly Leu Asp Pro Asp Asn  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Phe Ser Ile Pro Tyr Leu Thr Ala Leu Gly Asp Leu Leu Gly Thr Gly  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Leu Leu Ala Leu Ser Phe His Val Leu Trp Leu Ile Gly Asp Arg Asp  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Thr Asp Val Gly Asp  
               
               
                         515  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 67  
               
               
                 &lt;211&gt; LENGTH: 1899  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (31)..(1878)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 67  
               
               
                   
               
               
                 cgtctcgccc gccagtctcc ctcccgcgcg atg gcc tcg gcg ctg agc tat gtc      54  
               
               
                                                  Met Ala Ser Ala Leu Ser Tyr Val  
               
               
                                                  1               5  
               
               
                   
               
               
                 tcc aag ttc aag tcc ttc gtg atc ttg ttc gtc acc ccg ctc ctg ctg      102  
               
               
                 Ser Lys Phe Lys Ser Phe Val Ile Leu Phe Val Thr Pro Leu Leu Leu  
               
               
                     10                  15                  20  
               
               
                   
               
               
                 ctg cca ctc gtc att ctg atg ccc gcc aag gtc agt tgc tgt gcc tac      150  
               
               
                 Leu Pro Leu Val Ile Leu Met Pro Ala Lys Val Ser Cys Cys Ala Tyr  
               
               
                 25                  30                  35                  40  
               
               
                   
               
               
                 gtc atc atc ctc atg gcc att tac tgg tgc aca gaa gtc atc cct ctg      198  
               
               
                 Val Ile Ile Leu Met Ala Ile Tyr Trp Cys Thr Glu Val Ile Pro Leu  
               
               
                                 45                  50                  55  
               
               
                   
               
               
                 gct gtc acc tct ctc atg cct gtc ttg ctt ttc cca ctc ttc cag att      246  
               
               
                 Ala Val Thr Ser Leu Met Pro Val Leu Leu Phe Pro Leu Phe Gln Ile  
               
               
                             60                  65                  70  
               
               
                   
               
               
                 ctg gac tcc agg cag gtg tgt gtc cag tac atg aag gac acc aac atg      294  
               
               
                 Leu Asp Ser Arg Gln Val Cys Val Gln Tyr Met Lys Asp Thr Asn Met  
               
               
                         75                  80                  85  
               
               
                   
               
               
                 ctg ttc ctg ggc ggc ctc atc gtg gcc gtg gct gtg gag cgc tgg aac      342  
               
               
                 Leu Phe Leu Gly Gly Leu Ile Val Ala Val Ala Val Glu Arg Trp Asn  
               
               
                     90                  95                  100  
               
               
                   
               
               
                 ctg cac aag agg atc gcc ctg cgc acg ctc ctc tgg gtg ggg gcc aag      390  
               
               
                 Leu His Lys Arg Ile Ala Leu Arg Thr Leu Leu Trp Val Gly Ala Lys  
               
               
                 105                 110                 115                 120  
               
               
                   
               
               
                 cct gca cgg ctg atg ctg ggc ttc atg ggc gtc aca gcc ctc ctg tcc      438  
               
               
                 Pro Ala Arg Leu Met Leu Gly Phe Met Gly Val Thr Ala Leu Leu Ser  
               
               
                                 125                 130                 135  
               
               
                   
               
               
                 atg tgg atc agt aac acg gca acc acg gcc atg atg gtg ccc atc gtg      486  
               
               
                 Met Trp Ile Ser Asn Thr Ala Thr Thr Ala Met Met Val Pro Ile Val  
               
               
                             140                 145                 150  
               
               
                   
               
               
                 gag gcc ata ttg cag cag atg gaa gcc aca agc gca gcc acc gag gcc      534  
               
               
                 Glu Ala Ile Leu Gln Gln Met Glu Ala Thr Ser Ala Ala Thr Glu Ala  
               
               
                         155                 160                 165  
               
               
                   
               
               
                 ggc ctg gag gga caa ggt acc aca ata aac aac ctg aat gca ctg gag      582  
               
               
                 Gly Leu Glu Gly Gln Gly Thr Thr Ile Asn Asn Leu Asn Ala Leu Glu  
               
               
                     170                 175                 180  
               
               
                   
               
               
                 gat gat aca gtg aaa gca gta cta gga gga aag tgt gta gct ata ata      630  
               
               
                 Asp Asp Thr Val Lys Ala Val Leu Gly Gly Lys Cys Val Ala Ile Ile  
               
               
                 185                 190                 195                 200  
               
               
                   
               
               
                 agc act tac gtc aaa aaa gta gaa aaa ctt caa ata aac aat cta atg      678  
               
               
                 Ser Thr Tyr Val Lys Lys Val Glu Lys Leu Gln Ile Asn Asn Leu Met  
               
               
                                 205                 210                 215  
               
               
                   
               
               
                 aca cct ctt aaa aaa cta gaa aag caa gag caa cag gac cta ggg cct      726  
               
               
                 Thr Pro Leu Lys Lys Leu Glu Lys Gln Glu Gln Gln Asp Leu Gly Pro  
               
               
                             220                 225                 230  
               
               
                   
               
               
                 ggc atc agg cct cag gac tct gcc cag tgc cag gaa gac caa gag cgg      774  
               
               
                 Gly Ile Arg Pro Gln Asp Ser Ala Gln Cys Gln Glu Asp Gln Glu Arg  
               
               
                         235                 240                 245  
               
               
                   
               
               
                 aag agg ttg tgt aag gcc atg acc ctg tgc atc tgc tac gcg gcc agc      822  
               
               
                 Lys Arg Leu Cys Lys Ala Met Thr Leu Cys Ile Cys Tyr Ala Ala Ser  
               
               
                     250                 255                 260  
               
               
                   
               
               
                 atc ggg ggc acc gcc acc ctg acc ggg acg gga ccc aac gtg gtg ctc      870  
               
               
                 Ile Gly Gly Thr Ala Thr Leu Thr Gly Thr Gly Pro Asn Val Val Leu  
               
               
                 265                 270                 275                 280  
               
               
                   
               
               
                 ctg ggc cag atg aac gag ttg ttt cct gac agc aag gac ctc gtg aac      918  
               
               
                 Leu Gly Gln Met Asn Glu Leu Phe Pro Asp Ser Lys Asp Leu Val Asn  
               
               
                                 285                 290                 295  
               
               
                   
               
               
                 ttt gct tcc tgg ttt gca ttt gcc ttt ccc aac atg ctg gtg atg ctg      966  
               
               
                 Phe Ala Ser Trp Phe Ala Phe Ala Phe Pro Asn Met Leu Val Met Leu  
               
               
                             300                 305                 310  
               
               
                   
               
               
                 ctg ttc gcc tgg ctg tgg ctc cag ttt gtt tac atg ttc tcc agt ttt     1014  
               
               
                 Leu Phe Ala Trp Leu Trp Leu Gln Phe Val Tyr Met Phe Ser Ser Phe  
               
               
                         315                 320                 325  
               
               
                   
               
               
                 aaa aag tcc tgg ggc tgc ggg cta gag agc aag aaa aac gag aag gct     1062  
               
               
                 Lys Lys Ser Trp Gly Cys Gly Leu Glu Ser Lys Lys Asn Glu Lys Ala  
               
               
                     330                 335                 340  
               
               
                   
               
               
                 gcc ctc aag gtg ctg cag gag gag tac cgg aag ctg ggg ccc ttg tcc     1110  
               
               
                 Ala Leu Lys Val Leu Gln Glu Glu Tyr Arg Lys Leu Gly Pro Leu Ser  
               
               
                 345                 350                 355                 360  
               
               
                   
               
               
                 ttc gcg gag atc aac gtg ctg atc tgc ttc ttc ctg ctg gtc atc ctg     1158  
               
               
                 Phe Ala Glu Ile Asn Val Leu Ile Cys Phe Phe Leu Leu Val Ile Leu  
               
               
                                 365                 370                 375  
               
               
                   
               
               
                 tgg ttc tcc cga gac ccc ggc ttc atg ccc ggc tgg ctg act gtt gcc     1206  
               
               
                 Trp Phe Ser Arg Asp Pro Gly Phe Met Pro Gly Trp Leu Thr Val Ala  
               
               
                             380                 385                 390  
               
               
                   
               
               
                 tgg gtg gag ggt gag aca aag tca gtc tcc gat gcc act gtg gcc atc     1254  
               
               
                 Trp Val Glu Gly Glu Thr Lys Ser Val Ser Asp Ala Thr Val Ala Ile  
               
               
                         395                 400                 405  
               
               
                   
               
               
                 ttt gtg gcc acc ctg cta ttc att gtg cct tca cag aag ccc aag ttt     1302  
               
               
                 Phe Val Ala Thr Leu Leu Phe Ile Val Pro Ser Gln Lys Pro Lys Phe  
               
               
                     410                 415                 420  
               
               
                   
               
               
                 aac ttc cgc agc cag act gag gaa ggt aag tct cct gtt ctg atc gcc     1350  
               
               
                 Asn Phe Arg Ser Gln Thr Glu Glu Gly Lys Ser Pro Val Leu Ile Ala  
               
               
                 425                 430                 435                 440  
               
               
                   
               
               
                 ccc cct ccc ctg ctg gat tgg aag gta acc cag gag aaa gtg ccc tgg     1398  
               
               
                 Pro Pro Pro Leu Leu Asp Trp Lys Val Thr Gln Glu Lys Val Pro Trp  
               
               
                                 445                 450                 455  
               
               
                   
               
               
                 ggc atc gtg ctg cta cta ggg ggc gga ttt gct ctg gct aaa gga tcc     1446  
               
               
                 Gly Ile Val Leu Leu Leu Gly Gly Gly Phe Ala Leu Ala Lys Gly Ser  
               
               
                             460                 465                 470  
               
               
                   
               
               
                 gag gcc tcg ggg ctg tcc gtg tgg atg ggg aag cag atg gag ccc ttg     1494  
               
               
                 Glu Ala Ser Gly Leu Ser Val Trp Met Gly Lys Gln Met Glu Pro Leu  
               
               
                         475                 480                 485  
               
               
                   
               
               
                 cac gca gtg ccc ccg gca gcc atc acc ttg atc ttg tcc ttg ctc gtt     1542  
               
               
                 His Ala Val Pro Pro Ala Ala Ile Thr Leu Ile Leu Ser Leu Leu Val  
               
               
                     490                 495                 500  
               
               
                   
               
               
                 gcc gtg ttc act gag tgc aca agc aac gtg gcc acc acc acc ttg ttc     1590  
               
               
                 Ala Val Phe Thr Glu Cys Thr Ser Asn Val Ala Thr Thr Thr Leu Phe  
               
               
                 505                 510                 515                 520  
               
               
                   
               
               
                 ctg ccc atc ttt gcc tcc atg tct cgc tcc atc ggc ctc aat ccg ctg     1638  
               
               
                 Leu Pro Ile Phe Ala Ser Met Ser Arg Ser Ile Gly Leu Asn Pro Leu  
               
               
                                 525                 530                 535  
               
               
                   
               
               
                 tac atc atg ctg ccc tgt acc ctg agt gcc tcc ttt gcc ttc atg ttg     1686  
               
               
                 Tyr Ile Met Leu Pro Cys Thr Leu Ser Ala Ser Phe Ala Phe Met Leu  
               
               
                             540                 545                 550  
               
               
                   
               
               
                 cct gtg gcc acc cct cca aat gcc atc gtg ttc acc tat ggg cac ctc     1734  
               
               
                 Pro Val Ala Thr Pro Pro Asn Ala Ile Val Phe Thr Tyr Gly His Leu  
               
               
                         555                 560                 565  
               
               
                   
               
               
                 aag gtt gct gac atg gta aaa aca gga gtc ata atg aac ata att gga     1782  
               
               
                 Lys Val Ala Asp Met Val Lys Thr Gly Val Ile Met Asn Ile Ile Gly  
               
               
                     570                 575                 580  
               
               
                   
               
               
                 gtc ttc tgt gtg ttt ttg gct gtc aac acc tgg gga cgg gcc ata ttt     1830  
               
               
                 Val Phe Cys Val Phe Leu Ala Val Asn Thr Trp Gly Arg Ala Ile Phe  
               
               
                 585                 590                 595                 600  
               
               
                   
               
               
                 gac ttg gat cat ttc cct gac tgg gct aat gtg aca cat att gag act     1878  
               
               
                 Asp Leu Asp His Phe Pro Asp Trp Ala Asn Val Thr His Ile Glu Thr  
               
               
                                 605                 610                 615  
               
               
                   
               
               
                 taggaagagc cacaagacca c                                             1899  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 68  
               
               
                 &lt;211&gt; LENGTH: 616  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 68  
               
               
                   
               
               
                 Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Lys Val Ser Cys Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Gly Gln Gly Thr Thr  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Ile Asn Asn Leu Asn Ala Leu Glu Asp Asp Thr Val Lys Ala Val Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gly Gly Lys Cys Val Ala Ile Ile Ser Thr Tyr Val Lys Lys Val Glu  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Leu Gln Ile Asn Asn Leu Met Thr Pro Leu Lys Lys Leu Glu Lys  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Gln Glu Gln Gln Asp Leu Gly Pro Gly Ile Arg Pro Gln Asp Ser Ala  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Gln Cys Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met Thr  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu Thr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu Phe  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe Ala  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu Gln  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Phe Val Tyr Met Phe Ser Ser Phe Lys Lys Ser Trp Gly Cys Gly Leu  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu Glu  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu Ile  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly Phe  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys Ser  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe Ile  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu Glu  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Gly Lys Ser Pro Val Leu Ile Ala Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Ser  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Arg Ser Ile Gly Leu Asn Pro Leu Tyr Ile Met Leu Pro Cys Thr Leu  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Ser Ala Ser Phe Ala Phe Met Leu Pro Val Ala Thr Pro Pro Asn Ala  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Ile Val Phe Thr Tyr Gly His Leu Lys Val Ala Asp Met Val Lys Thr  
               
               
                                 565                 570                 575  
               
               
                   
               
               
                 Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val Phe Leu Ala Val  
               
               
                             580                 585                 590  
               
               
                   
               
               
                 Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His Phe Pro Asp Trp  
               
               
                         595                 600                 605  
               
               
                   
               
               
                 Ala Asn Val Thr His Ile Glu Thr  
               
               
                     610                 615  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 69  
               
               
                 &lt;211&gt; LENGTH: 1790  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (16)..(1719)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 69  
               
               
                   
               
               
                 tctccctccc gcgcg atg gcc tcg gcg ctg agc tat gtc tcc aag ttc aag      51  
               
               
                                  Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys  
               
               
                                  1               5                   10  
               
               
                   
               
               
                 tcc ttc gtg atc ttg ttc gtc acc ccg ctc ctg ctg ctg cca ctc gtc       99  
               
               
                 Ser Phe Val Ile Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val  
               
               
                         15                  20                  25  
               
               
                   
               
               
                 att ctg atg ccc gcc aag gtc agt tgt gcc tac gtc atc atc ctc atg      147  
               
               
                 Ile Leu Met Pro Ala Lys Val Ser Cys Ala Tyr Val Ile Ile Leu Met  
               
               
                     30                  35                  40  
               
               
                   
               
               
                 gcc att tac tgg tgc aca gaa gtc atc cct ctg gct gtc acc tct ctc      195  
               
               
                 Ala Ile Tyr Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu  
               
               
                 45                  50                  55                  60  
               
               
                   
               
               
                 atg cct gtc ttg ctt ttc cca ctc ttc cag att ctg gac tcc agg cag      243  
               
               
                 Met Pro Val Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln  
               
               
                                 65                  70                  75  
               
               
                   
               
               
                 gtg tgt gtc cag tac atg aag gac acc aac atg ctg ttc ctg ggc ggc      291  
               
               
                 Val Cys Val Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly  
               
               
                             80                  85                  90  
               
               
                   
               
               
                 ctc atc gtg gcc gtg gct gtg gag cgc tgg aac ctg cac aag agg atc      339  
               
               
                 Leu Ile Val Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile  
               
               
                         95                  100                 105  
               
               
                   
               
               
                 gcc ctg cgc acg ctc ctc tgg gtg ggg gcc aag cct gca cgg ctg atg      387  
               
               
                 Ala Leu Arg Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met  
               
               
                     110                 115                 120  
               
               
                   
               
               
                 ctg ggc ttc atg ggc gtc aca gcc ctc ctg tcc atg tgg atc agt aac      435  
               
               
                 Leu Gly Phe Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn  
               
               
                 125                 130                 135                 140  
               
               
                   
               
               
                 acg gca acc acg gcc atg atg gtg ccc atc gtg gag gcc ata ttg cag      483  
               
               
                 Thr Ala Thr Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln  
               
               
                                 145                 150                 155  
               
               
                   
               
               
                 cag atg gaa gcc aca agc gca gcc acc gag gcc ggc ctg gag ctg gtg      531  
               
               
                 Gln Met Glu Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val  
               
               
                             160                 165                 170  
               
               
                   
               
               
                 gac aag ggc aag gcc aag gag ctg cca ggg agt caa gtg att ttt gaa      579  
               
               
                 Asp Lys Gly Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu  
               
               
                         175                 180                 185  
               
               
                   
               
               
                 ggc ccc act ctg ggg cag cag gaa gac caa gag cgg aag agg ttg tgt      627  
               
               
                 Gly Pro Thr Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys  
               
               
                     190                 195                 200  
               
               
                   
               
               
                 aag gcc atg acc ctg tgc atc tgc tac gcg gcc agc atc ggg ggc acc      675  
               
               
                 Lys Ala Met Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr  
               
               
                 205                 210                 215                 220  
               
               
                   
               
               
                 gcc acc ctg acc ggg acg gga ccc aac gtg gtg ctc ctg ggc cag atg      723  
               
               
                 Ala Thr Leu Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met  
               
               
                                 225                 230                 235  
               
               
                   
               
               
                 aac gag ttg ttt cct gac agc aag gac ctc gtg aac ttt gct tcc tgg      771  
               
               
                 Asn Glu Leu Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp  
               
               
                             240                 245                 250  
               
               
                   
               
               
                 ttt gca ttt gcc ttt ccc aac atg ctg gtg atg ctg ctg ttc gcc tgg      819  
               
               
                 Phe Ala Phe Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp  
               
               
                         255                 260                 265  
               
               
                   
               
               
                 ctg tgg ctc cag ttt gtt tac atg ttc tcc agt ttt aaa aag tcc tgg      867  
               
               
                 Leu Trp Leu Gln Phe Val Tyr Met Phe Ser Ser Phe Lys Lys Ser Trp  
               
               
                     270                 275                 280  
               
               
                   
               
               
                 ggc tgc ggg cta gag agc aag aaa aac gag aag gct gcc ctc aag gtg      915  
               
               
                 Gly Cys Gly Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val  
               
               
                 285                 290                 295                 300  
               
               
                   
               
               
                 ctg cag gag gag tac cgg aag ctg ggg ccc ttg tcc ttc gcg gag atc      963  
               
               
                 Leu Gln Glu Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile  
               
               
                                 305                 310                 315  
               
               
                   
               
               
                 aac gtg ctg atc tgc ttc ttc ctg ctg gtc atc ctg tgg ttc tcc cga     1011  
               
               
                 Asn Val Leu Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg  
               
               
                             320                 325                 330  
               
               
                   
               
               
                 gac ccc ggc ttc atg ccc ggc tgg ctg act gtt gcc tgg gtg gag ggt     1059  
               
               
                 Asp Pro Gly Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly  
               
               
                         335                 340                 345  
               
               
                   
               
               
                 gag aca aag tat gtc tcc gat gcc act gtg gcc atc ttt gtg gcc acc     1107  
               
               
                 Glu Thr Lys Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr  
               
               
                     350                 355                 360  
               
               
                   
               
               
                 ctg cta ttc att gtg cct tca cag aag ccc aag ttt aac ttc cgc agc     1155  
               
               
                 Leu Leu Phe Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser  
               
               
                 365                 370                 375                 380  
               
               
                   
               
               
                 cag act gag gaa ggt aag tct cct gtt ctg atc gcc ccc cct ccc ctg     1203  
               
               
                 Gln Thr Glu Glu Gly Lys Ser Pro Val Leu Ile Ala Pro Pro Pro Leu  
               
               
                                 385                 390                 395  
               
               
                   
               
               
                 ctg gat tgg aag gta acc cag gag aaa gtg ccc tgg ggc atc gtg ctg     1251  
               
               
                 Leu Asp Trp Lys Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu  
               
               
                             400                 405                 410  
               
               
                   
               
               
                 cta cta ggg ggc gga ttt gct ctg gct aaa gga tcc gag gcc tcg ggg     1299  
               
               
                 Leu Leu Gly Gly Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly  
               
               
                         415                 420                 425  
               
               
                   
               
               
                 ctg tcc gtg tgg atg ggg aag cag atg gag ccc ttg cac gca gtg ccc     1347  
               
               
                 Leu Ser Val Trp Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro  
               
               
                     430                 435                 440  
               
               
                   
               
               
                 ccg gca gcc atc acc ttg atc ttg tcc ttg ctc gtt gcc gtg ttc act     1395  
               
               
                 Pro Ala Ala Ile Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr  
               
               
                 445                 450                 455                 460  
               
               
                   
               
               
                 gag tgc aca agc aac gtg gcc acc acc acc ttg ttc ctg ccc atc ttt     1443  
               
               
                 Glu Cys Thr Ser Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe  
               
               
                                 465                 470                 475  
               
               
                   
               
               
                 gcc tcc atg tct cgc tcc atc ggc ctc aat ccg ctg tac atc atg ctg     1491  
               
               
                 Ala Ser Met Ser Arg Ser Ile Gly Leu Asn Pro Leu Tyr Ile Met Leu  
               
               
                             480                 485                 490  
               
               
                   
               
               
                 ccc tgt acc ctg agt gcc tcc ttt gcc ttc atg ttg cct gtg gcc acc     1539  
               
               
                 Pro Cys Thr Leu Ser Ala Ser Phe Ala Phe Met Leu Pro Val Ala Thr  
               
               
                         495                 500                 505  
               
               
                   
               
               
                 cct cca aat gcc atc gtg ttc acc tat ggg cac ctc aag gtt gct gac     1587  
               
               
                 Pro Pro Asn Ala Ile Val Phe Thr Tyr Gly His Leu Lys Val Ala Asp  
               
               
                     510                 515                 520  
               
               
                   
               
               
                 atg gtg aaa aca gga gtc ata atg aac ata att gga gtc ttc tgt gtg     1635  
               
               
                 Met Val Lys Thr Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val  
               
               
                 525                 530                 535                 540  
               
               
                   
               
               
                 ttt ttg gct gtc aac acc tgg gga cgg gcc ata ttt gac ttg gat cat     1683  
               
               
                 Phe Leu Ala Val Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His  
               
               
                                 545                 550                 555  
               
               
                   
               
               
                 ttc cct gac tgg gct aat gtg aca cat att gag act taggaagagc          1729  
               
               
                 Phe Pro Asp Trp Ala Asn Val Thr His Ile Glu Thr  
               
               
                             560                 565  
               
               
                   
               
               
                 cacaagacca cacacacagc ccttaccctc ctcaggacta ccgaaccttc tggcacacct   1789  
               
               
                   
               
               
                 t                                                                   1790  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 70  
               
               
                 &lt;211&gt; LENGTH: 568  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 70  
               
               
                   
               
               
                 Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Lys Val Ser Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr Trp  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val Gln  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val Ala  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg Thr  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe Met  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly Lys  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr Leu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met Thr  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu Thr  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu Phe  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu Gln  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Phe Val Tyr Met Phe Ser Ser Phe Lys Lys Ser Trp Gly Cys Gly Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu Ile  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly Phe  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys Tyr  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe Ile  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Gly Lys Ser Pro Val Leu Ile Ala Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Ser  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Arg Ser Ile Gly Leu Asn Pro Leu Tyr Ile Met Leu Pro Cys Thr Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ser Ala Ser Phe Ala Phe Met Leu Pro Val Ala Thr Pro Pro Asn Ala  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Ile Val Phe Thr Tyr Gly His Leu Lys Val Ala Asp Met Val Lys Thr  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val Phe Leu Ala Val  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His Phe Pro Asp Trp  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Ala Asn Val Thr His Ile Glu Thr  
               
               
                                 565  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 71  
               
               
                 &lt;211&gt; LENGTH: 3147  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (2)..(1705)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 71  
               
               
                   
               
               
                 g atg gcc tcg gcg ctg agc tat gtc tcc aag ttc aag tcc ttc gtg atc     49  
               
               
                   Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                   1               5                   10                  15  
               
               
                   
               
               
                 ttg ttc gtc acc ccg ctc ctg ctg ctg cca ctc gtc att ctg atg ccc       97  
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 gcc aag ttt gtc agg tgt gcc tac gtc atc atc ctc atg gcc att tac      145  
               
               
                 Ala Lys Phe Val Arg Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 tgg tgc aca gaa gtc atc cct ctg gct gtc acc tct ctc atg cct gtc      193  
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 ttg ctt ttc cca ctc ttc cag att ctg gac tcc agg cag gtg tgt gtc      241  
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 cag tac atg aag gac acc aac atg ctg ttc ctg ggc ggc ctc atc gtg      289  
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 gcc gtg gct gtg gag cgc tgg aac ctg cac aag agg atc gcc ctg cgc      337  
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 acg ctc ctc tgg gtg ggg gcc aag cct gca cgg ctg atg ctg ggc ttc      385  
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 atg ggc gtc aca gcc ctc ctg tcc atg tgg atc agt aac acg gca acc      433  
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 acg gcc atg atg gtg ccc atc gtg gag gcc ata ttg cag cag atg gaa      481  
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 gcc aca agc gca gcc acc gag gcc ggc ctg gag ctg gtg gac aag ggc      529  
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 aag gcc aag gag ctg cca ggg agt caa gtg att ttt gaa ggc ccc act      577  
               
               
                 Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 ctg ggg cag cag gaa gac caa gag cgg aag agg ttg tgt aag gcc atg      625  
               
               
                 Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 acc ctg tgc atc tgc tac gcg gcc agc atc ggg ggc acc gcc acc ctg      673  
               
               
                 Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 acc ggg acg gga ccc aac gtg gtg ctc ctg ggc cag atg aac gag ttg      721  
               
               
                 Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ttt cct gac agc aag gac ctc gtg aac ttt gct tcc tgg ttt gca ttt      769  
               
               
                 Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gcc ttt ccc aac atg ctg gtg atg ctg ctg ttc gcc tgg ctg tgg ctc      817  
               
               
                 Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 cag ttt gtt tac atg aga ttc aat ttt aaa aag tcc tgg ggc tgc ggg      865  
               
               
                 Gln Phe Val Tyr Met Arg Phe Asn Phe Lys Lys Ser Trp Gly Cys Gly  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 cta gag agc aag aaa aac gag aag gct gcc ctc aag gtg ctg cag gag      913  
               
               
                 Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 gag tac cgg aag ttg ggg ccc ttg tcc ttc gcg gag atc aac gtg ctg      961  
               
               
                 Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 atc tgc ttc ttc ctg ctg gtc atc ctg tgg ttc tcc cga gac ccc ggc     1009  
               
               
                 Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 ttc atg ccc ggc tgg ctg act gtt gcc tgg gtg gag ggt gag aca aag     1057  
               
               
                 Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 tat gtc tcc gat gcc act gtg gcc atc ttt gtg gcc acc ctg cta ttc     1105  
               
               
                 Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 att gtg cct tca cag aag ccc aag ttt aac ttc cgc agc cag act gag     1153  
               
               
                 Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 gaa gaa agg aaa act cca ttt tat ccc cct ccc ctg ctg gat tgg aag     1201  
               
               
                 Glu Glu Arg Lys Thr Pro Phe Tyr Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 gta acc cag gag aaa gtg ccc tgg ggc atc gtg ctg cta cta ggg ggc     1249  
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 gga ttt gct ctg gct aaa gga tcc gag gcc tcg ggg ctg tcc gtg tgg     1297  
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 atg ggg aag cag atg gag ccc ttg cac gca gtg ccc ccg gca gcc atc     1345  
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 acc ttg atc ttg tcc ttg ctc gtt gcc gtg ttc act gag tgc aca agc     1393  
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 aac gtg gcc acc acc acc ttg ttc ctg ccc atc ttt gcc tcc atg tct     1441  
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Ser  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 cgc tcc atc ggc ctc aat ccg ctg tac atc atg ctg ccc tgt acc ctg     1489  
               
               
                 Arg Ser Ile Gly Leu Asn Pro Leu Tyr Ile Met Leu Pro Cys Thr Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 agt gcc tcc ttt gcc ttc atg ttg cct gtg gcc acc cct cca aat gcc     1537  
               
               
                 Ser Ala Ser Phe Ala Phe Met Leu Pro Val Ala Thr Pro Pro Asn Ala  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 atc gtg ttc acc tat ggg cac ctc aag gtt gct gac atg gtg aaa aca     1585  
               
               
                 Ile Val Phe Thr Tyr Gly His Leu Lys Val Ala Asp Met Val Lys Thr  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 gga gtc ata atg aac ata att gga gtc ttc tgt gtg ttt ttg gct gtc     1633  
               
               
                 Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val Phe Leu Ala Val  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 aac acc tgg gga cgg gcc ata ttt gac ttg gat cat ttc cct gac tgg     1681  
               
               
                 Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His Phe Pro Asp Trp  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 gct aat gtg aca cat att gag act taggaagagc cacaagacca cacacacagc    1735  
               
               
                 Ala Asn Val Thr His Ile Glu Thr  
               
               
                                 565  
               
               
                   
               
               
                 ccttaccctc ctcaggacta ccgaaccttc tggcacacct tgtacagagt tttggggttc   1795  
               
               
                   
               
               
                 acaccccaaa atgacccaac gatgtccaca caccaccaaa acccagccaa tgggccacct   1855  
               
               
                   
               
               
                 cttcctccaa gcccagatgc agagatggtc atgggcagct ggagggtagg ctcagaaatg   1915  
               
               
                   
               
               
                 aagggaaccc ctcagtgggc tgctggaccc atctttccca agccttgcca ttatctctgt   1975  
               
               
                   
               
               
                 gagggaggcc aggtagccga gggatcagga tgcaggctgc tgtacccgct ctgcctcaag   2035  
               
               
                   
               
               
                 catcccccac acagggctct ggttttcact cgcttcgtcc tagatagttt aaatgggaat   2095  
               
               
                   
               
               
                 cggatcccct ggttgagagc taagacaacc acctaccagt gcccatgtcc cttccagctc   2155  
               
               
                   
               
               
                 accttgagca gcctcagatc atctctgtca ctctggaagg gacaccccag ccagggacgg   2215  
               
               
                   
               
               
                 aatgcctggt cttgagcaac ctcccactgc tggagtgcga gtgggaatca gagcctcctg   2275  
               
               
                   
               
               
                 aagcctctgg gaactcctcc tgtggccacc accaaaggat gaggaatctg agttgccaac   2335  
               
               
                   
               
               
                 ttcaggacga cacctggctt gccacccaca gtgcaccaca ggccaaccta cgcccttcat   2395  
               
               
                   
               
               
                 cacttggttc tgttttaatc gactggcccc ctgtcccacc tctccagtga gcctccttca   2455  
               
               
                   
               
               
                 actccttggt cccctgttgt ctgggtcaac atttgccgag acgccttggc tggcaccctc   2515  
               
               
                   
               
               
                 tggggtcccc cttttctccc aggcaggtca tcttttctgg gagatgcttc ccctgccatc   2575  
               
               
                   
               
               
                 cccaaatagc taggatcaca ctccaagtat gggcagtgat ggcgctctgg gggccacagt   2635  
               
               
                   
               
               
                 gggctatcta ggccctccct cacctgaggc ccagagtgga cacagctgtt aatttccact   2695  
               
               
                   
               
               
                 ggctatgcca cttcagagtc tttcatgcca gcgtttgagc tcctctgggt aaaatcttcc   2755  
               
               
                   
               
               
                 ctttgttgac tggccttcac agccatggct ggtgacaaca gaggatcgtt gagattgagc   2815  
               
               
                   
               
               
                 agcgcttggt gatctctcag caaacaaccc ctgcccgtgg gccaatctac ttgaagttac   2875  
               
               
                   
               
               
                 tcggacaaag accccaaagt ggggcaacaa ctccagagag gctgtgggaa tcttcagaag   2935  
               
               
                   
               
               
                 cccccctgta agagacagac atgagagaca agcatcttct ttcccccgca agtccatttt   2995  
               
               
                   
               
               
                 atttccttct tgtgctgctc tggaagagag gcagtagcaa agagatgagc tcctggatgg   3055  
               
               
                   
               
               
                 cattttccag ggcaggagaa agtatgagag cctcaggaaa ccccatcaag gaccgagtat   3115  
               
               
                   
               
               
                 gtgtctggtt cctttggtgg ttggcttctg gc                                 3147  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 72  
               
               
                 &lt;211&gt; LENGTH: 568  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 72  
               
               
                   
               
               
                 Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Lys Phe Val Arg Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Phe Val Tyr Met Arg Phe Asn Phe Lys Lys Ser Trp Gly Cys Gly  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Glu Glu Arg Lys Thr Pro Phe Tyr Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Ser  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Arg Ser Ile Gly Leu Asn Pro Leu Tyr Ile Met Leu Pro Cys Thr Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ser Ala Ser Phe Ala Phe Met Leu Pro Val Ala Thr Pro Pro Asn Ala  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Ile Val Phe Thr Tyr Gly His Leu Lys Val Ala Asp Met Val Lys Thr  
               
               
                         515                 520                 525  
               
               
                   
               
               
                 Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val Phe Leu Ala Val  
               
               
                     530                 535                 540  
               
               
                   
               
               
                 Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His Phe Pro Asp Trp  
               
               
                 545                 550                 555                 560  
               
               
                   
               
               
                 Ala Asn Val Thr His Ile Glu Thr  
               
               
                                 565  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 73  
               
               
                 &lt;211&gt; LENGTH: 1606  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (2)..(1567)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 73  
               
               
                   
               
               
                 g atg gcc tcg gcg ctg agc tat gtc tcc aag ttc aag tcc ttc gtg atc     49  
               
               
                   Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                   1               5                   10                  15  
               
               
                   
               
               
                 ttg ttc gtc acc ccg ctc ctg ctg ctg cca ctc gtc att ctg atg ccc       97  
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 gcc aag ttt gtc agg tgt gcc tac gtc atc atc ctc atg gcc att tac      145  
               
               
                 Ala Lys Phe Val Arg Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 tgg tgc aca gaa gtc atc cct ctg gct gtc acc tct ctc atg cct gtc      193  
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 ttg ctt ttc cca ctc ttc cag att ctg gac tcc agg cag gtg tgt gtc      241  
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 cag tac atg aag gac acc aac atg ctg ttc ctg ggc ggc ctc atc gtg      289  
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 gcc gtg gct gtg gag cgc tgg aac ctg cac aag agg atc gcc ctg cgc      337  
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 acg ctc ctc tgg gtg ggg gcc aag cct gca cgg ctg atg ctg ggc ttc      385  
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 atg ggc gtc aca gcc ctc ctg tcc atg tgg atc agt aac acg gca acc      433  
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 acg gcc atg atg gtg ccc atc gtg gag gcc ata ttg cag cag atg gaa      481  
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 gcc aca agc gca gcc acc gag gcc ggc ctg gag ctg gtg gac aag ggc      529  
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 aag gcc aag gag ctg cca ggg agt caa gtg att ttt gaa ggc ccc act      577  
               
               
                 Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 ctg ggg cag cag gaa gac caa gag cgg aag agg ttg tgt aag gcc atg      625  
               
               
                 Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 acc ctg tgc atc tgc tac gcg gcc agc atc ggg ggc acc gcc acc ctg      673  
               
               
                 Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 acc ggg acg gga ccc aac gtg gtg ctc ctg ggc cag atg aac gag ttg      721  
               
               
                 Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ttt cct gac agc aag gac ctc gtg aac ttt gct tcc tgg ttt gca ttt      769  
               
               
                 Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gcc ttt ccc aac atg ctg gtg atg ctg ctg ttc gcc tgg ctg tgg ctc      817  
               
               
                 Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 cag ttt gtt tac atg aga ttc aat ttt aaa aag tcc tgg ggc tgc ggg      865  
               
               
                 Gln Phe Val Tyr Met Arg Phe Asn Phe Lys Lys Ser Trp Gly Cys Gly  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 cta gag agc aag aaa aac gag aag gct gcc ctc aag gtg ctg cag gag      913  
               
               
                 Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 gag tac cgg aag ttg ggg ccc ttg tcc ttc gcg gag atc aac gtg ctg      961  
               
               
                 Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 atc tgc ttc ttc ctg ctg gtc atc ctg tgg ttc tcc cga gac ccc ggc     1009  
               
               
                 Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 ttc atg ccc ggc tgg ctg act gtt gcc tgg gtg gag ggt gag aca aag     1057  
               
               
                 Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 tat gtc tcc gat gcc act gtg gcc atc ttt gtg gcc acc ctg cta ttc     1105  
               
               
                 Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 att gtg cct tca cag aag ccc aag ttt aac ttc cgc agc cag act gag     1153  
               
               
                 Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 gaa gaa agg aaa act cca ttt tat ccc cct ccc ctg ctg gat tgg aag     1201  
               
               
                 Glu Glu Arg Lys Thr Pro Phe Tyr Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 gta acc cag gag aaa gtg ccc tgg ggc atc gtg ctg cta cta ggg ggc     1249  
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 gga ttt gct ctg gct aaa gga tcc gag gcc tcg ggg ctg tcc gtg tgg     1297  
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 atg ggg aag cag atg gag ccc ttg cac gca gtg ccc ccg gca gcc atc     1345  
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 acc ttg atc ttg tcc ttg ctc gtt gcc gtg ttc act gag tgc aca agc     1393  
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 aac gtg gcc acc acc acc ttg ttc ctg ccc atc ttt gcc tcc atg gtg     1441  
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Val  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 aaa aca gga gtc ata atg aac ata att gga gtc ttc tgt gtg ttt ttg     1489  
               
               
                 Lys Thr Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val Phe Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 gct gtc aac acc tgg gga cgg gcc ata ttt gac ttg gat cat ttc cct     1537  
               
               
                 Ala Val Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His Phe Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 gac tgg gct aat gtg aca cat att gag act taggaagagc cacaagacca       1587  
               
               
                 Asp Trp Ala Asn Val Thr His Ile Glu Thr  
               
               
                         515                 520  
               
               
                   
               
               
                 cacacatagc ccttaccct                                                1606  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 74  
               
               
                 &lt;211&gt; LENGTH: 522  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 74  
               
               
                   
               
               
                 Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Lys Phe Val Arg Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Phe Val Tyr Met Arg Phe Asn Phe Lys Lys Ser Trp Gly Cys Gly  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Glu Glu Arg Lys Thr Pro Phe Tyr Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Val  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Lys Thr Gly Val Ile Met Asn Ile Ile Gly Val Phe Cys Val Phe Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ala Val Asn Thr Trp Gly Arg Ala Ile Phe Asp Leu Asp His Phe Pro  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Asp Trp Ala Asn Val Thr His Ile Glu Thr  
               
               
                         515                 520  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 75  
               
               
                 &lt;211&gt; LENGTH: 1781  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (2)..(1549)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 75  
               
               
                   
               
               
                 g atg gcc tcg gcg ctg agc tat gtc tcc aag ttc aag tcc ttc gtg atc     49  
               
               
                   Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                   1               5                   10                  15  
               
               
                   
               
               
                 ttg ttc gtc acc ccg ctc ctg ctg ctg cca ctc gtc att ctg atg ccc       97  
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 gcc aag ttt gtc agg tgt gcc tac gtc atc atc ctc atg gcc att tac      145  
               
               
                 Ala Lys Phe Val Arg Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 tgg tgc aca gaa gtc atc cct ctg gct gtc acc tct ctc atg cct gtc      193  
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 ttg ctt ttc cca ctc ttc cag att ctg gac tcc agg cag gtg tgt gtc      241  
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 cag tac atg aag gac acc aac atg ctg ttc ctg ggc ggc ctc atc gtg      289  
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 gcc gtg gct gtg gag cgc tgg aac ctg cac aag agg atc gcc ctg cgc      337  
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 acg ctc ctc tgg gtg ggg gcc aag cct gca cgg ctg atg ctg ggc ttc      385  
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 atg ggc gtc aca gcc ctc ctg tcc atg tgg atc agt aac acg gca acc      433  
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 acg gcc atg atg gtg ccc atc gtg gag gcc ata ttg cag cag atg gaa      481  
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 gcc aca agc gca gcc acc gag gcc ggc ctg gag ctg gtg gac aag ggc      529  
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 aag gcc aag gag ctg cca ggg agt caa gtg att ttt gaa ggc ccc act      577  
               
               
                 Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 ctg ggg cag cag gaa gac caa gag cgg aag agg ttg tgt aag gcc atg      625  
               
               
                 Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 acc ctg tgc atc tgc tac gcg gcc agc atc ggg ggc acc gcc acc ctg      673  
               
               
                 Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 acc ggg acg gga ccc aac gtg gtg ctc ctg ggc cag atg aac gag ttg      721  
               
               
                 Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ttt cct gac agc aag gac ctc gtg aac ttt gct tcc tgg ttt gca ttt      769  
               
               
                 Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 gcc ttt ccc aac atg ctg gtg atg ctg ctg ttc gcc tgg ctg tgg ctc      817  
               
               
                 Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 cag ttt gtt tac atg aga ttc aat ttt aaa aag tcc tgg ggc tgc ggg      865  
               
               
                 Gln Phe Val Tyr Met Arg Phe Asn Phe Lys Lys Ser Trp Gly Cys Gly  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 cta gag agc aag aaa aac gag aag gct gcc ctc aag gtg ctg cag gag      913  
               
               
                 Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 gag tac cgg aag ttg ggg ccc ttg tcc ttc gcg gag atc aac gtg ctg      961  
               
               
                 Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 atc tgc ttc ttc ctg ctg gtc atc ctg tgg ttc tcc cga gac ccc ggc     1009  
               
               
                 Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 ttc atg ccc ggc tgg ctg act gtt gcc tgg gtg gag ggt gag aca aag     1057  
               
               
                 Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 tat gtc tcc gat gcc act gtg gcc atc ttt gtg gcc acc ctg cta ttc     1105  
               
               
                 Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 att gtg cct tca cag aag ccc aag ttt aac ttc cgc agc cag act gag     1153  
               
               
                 Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 gaa gaa agg aaa act cca ttt tat ccc cct ccc ctg ctg gat tgg aag     1201  
               
               
                 Glu Glu Arg Lys Thr Pro Phe Tyr Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 gta acc cag gag aaa gtg ccc tgg ggc atc gtg ctg cta cta ggg ggc     1249  
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 gga ttt gct ctg gct aaa gga tcc gag gcc tcg ggg ctg tcc gtg tgg     1297  
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 atg ggg aag cag atg gag ccc ttg cac gca gtg ccc ccg gca gcc atc     1345  
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 acc ttg atc ttg tcc ttg ctc gtt gcc gtg ttc act gag tgc aca agc     1393  
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 aac gtg gcc acc acc acc ttg ttc ctg ccc atc ttt gcc tcc atg aat     1441  
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Asn  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 cac gtc ccc aag agc ttc tgt gtt ctg tac ggt gat gtt gca gtg ctg     1489  
               
               
                 His Val Pro Lys Ser Phe Cys Val Leu Tyr Gly Asp Val Ala Val Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 tct ttc cgc agt ctc gct cca tcg gcc tca atc cgc tgt aca tca tgc     1537  
               
               
                 Ser Phe Arg Ser Leu Ala Pro Ser Ala Ser Ile Arg Cys Thr Ser Cys  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 tgc cct gta ccc tgagtgcctc ctttgccttc atgttgcctg tggccacccc         1589  
               
               
                 Cys Pro Val Pro  
               
               
                         515  
               
               
                   
               
               
                 tccaaatgcc atcgtgttca cctatgggca cctcaaggtt gctgacatgg tgaaaacagg   1649  
               
               
                   
               
               
                 agtcataatg aacataattg gagtcttctg tgtgtttttg gctgtcaaca cctggggacg   1709  
               
               
                   
               
               
                 ggccatattt gacttggatc atttccctga ctgggctaat gtgacacata ttgagactta   1769  
               
               
                   
               
               
                 ggaagagcca ca                                                       1781  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 76  
               
               
                 &lt;211&gt; LENGTH: 516  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 76  
               
               
                   
               
               
                 Met Ala Ser Ala Leu Ser Tyr Val Ser Lys Phe Lys Ser Phe Val Ile  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Leu Phe Val Thr Pro Leu Leu Leu Leu Pro Leu Val Ile Leu Met Pro  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Ala Lys Phe Val Arg Cys Ala Tyr Val Ile Ile Leu Met Ala Ile Tyr  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Trp Cys Thr Glu Val Ile Pro Leu Ala Val Thr Ser Leu Met Pro Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Leu Phe Pro Leu Phe Gln Ile Leu Asp Ser Arg Gln Val Cys Val  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Gln Tyr Met Lys Asp Thr Asn Met Leu Phe Leu Gly Gly Leu Ile Val  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ala Val Ala Val Glu Arg Trp Asn Leu His Lys Arg Ile Ala Leu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Thr Leu Leu Trp Val Gly Ala Lys Pro Ala Arg Leu Met Leu Gly Phe  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Met Gly Val Thr Ala Leu Leu Ser Met Trp Ile Ser Asn Thr Ala Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Thr Ala Met Met Val Pro Ile Val Glu Ala Ile Leu Gln Gln Met Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Thr Ser Ala Ala Thr Glu Ala Gly Leu Glu Leu Val Asp Lys Gly  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Ala Lys Glu Leu Pro Gly Ser Gln Val Ile Phe Glu Gly Pro Thr  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Leu Gly Gln Gln Glu Asp Gln Glu Arg Lys Arg Leu Cys Lys Ala Met  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Thr Leu Cys Ile Cys Tyr Ala Ala Ser Ile Gly Gly Thr Ala Thr Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Thr Gly Thr Gly Pro Asn Val Val Leu Leu Gly Gln Met Asn Glu Leu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Phe Pro Asp Ser Lys Asp Leu Val Asn Phe Ala Ser Trp Phe Ala Phe  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Ala Phe Pro Asn Met Leu Val Met Leu Leu Phe Ala Trp Leu Trp Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Phe Val Tyr Met Arg Phe Asn Phe Lys Lys Ser Trp Gly Cys Gly  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Leu Glu Ser Lys Lys Asn Glu Lys Ala Ala Leu Lys Val Leu Gln Glu  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Glu Tyr Arg Lys Leu Gly Pro Leu Ser Phe Ala Glu Ile Asn Val Leu  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Ile Cys Phe Phe Leu Leu Val Ile Leu Trp Phe Ser Arg Asp Pro Gly  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Phe Met Pro Gly Trp Leu Thr Val Ala Trp Val Glu Gly Glu Thr Lys  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Tyr Val Ser Asp Ala Thr Val Ala Ile Phe Val Ala Thr Leu Leu Phe  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ile Val Pro Ser Gln Lys Pro Lys Phe Asn Phe Arg Ser Gln Thr Glu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Glu Glu Arg Lys Thr Pro Phe Tyr Pro Pro Pro Leu Leu Asp Trp Lys  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Val Thr Gln Glu Lys Val Pro Trp Gly Ile Val Leu Leu Leu Gly Gly  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Gly Phe Ala Leu Ala Lys Gly Ser Glu Ala Ser Gly Leu Ser Val Trp  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Met Gly Lys Gln Met Glu Pro Leu His Ala Val Pro Pro Ala Ala Ile  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Thr Leu Ile Leu Ser Leu Leu Val Ala Val Phe Thr Glu Cys Thr Ser  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Asn Val Ala Thr Thr Thr Leu Phe Leu Pro Ile Phe Ala Ser Met Asn  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 His Val Pro Lys Ser Phe Cys Val Leu Tyr Gly Asp Val Ala Val Leu  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ser Phe Arg Ser Leu Ala Pro Ser Ala Ser Ile Arg Cys Thr Ser Cys  
               
               
                             500                 505                 510  
               
               
                   
               
               
                 Cys Pro Val Pro  
               
               
                         515  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 77  
               
               
                 &lt;211&gt; LENGTH: 972  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(969)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 77  
               
               
                   
               
               
                 atg gat tcg aaa tat cag tgt gtg aag ctg aat gat ggt cac ttc atg       48  
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 cct gtc ctg gga ttt ggc acc tat gcg cct gca gag gtt cct aaa agt       96  
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 aaa gct tta gag gcc acc aaa ttg gca att gaa gct ggc ttc cgc cat      144  
               
               
                 Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 att gat tct gct cat tta tac aat aat gag gag cag gtt gga ctg gcc      192  
               
               
                 Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 atc cga agc aag att gca gat ggc agt gtg aag aga gaa gac ata ttc      240  
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 tac act tca aag ctt tgg tgc aat tcc cat cga cca gag ttg gtc cga      288  
               
               
                 Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 cca gcc ttg gaa agg tca ctg aaa aat ctt caa ttg gat tat gtt gac      336  
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 ctc tac ctt att cat ttt cca gtg tct gta aag cca ggt gag gaa gtg      384  
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 atc cca aaa gat gaa aat gga aaa ata cta ttt gac aca gtg gat ctc      432  
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 tgt gcc acg tgg gag gcc gtg gag aag tgt aaa gat gca gga ttg gcc      480  
               
               
                 Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 aag tcc atc ggg gtg tcc aac ttc aac cgc agg cag ctg gag atg atc      528  
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 ctc aac aag cca ggg ctc aag tac aag cct gtc tgc aac cag gtg gaa      576  
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 tgt cat cct tac ttc aac cag aga aaa ctg ctg gat ttc tgc aag tca      624  
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 aaa gac att gtt ctg gtt gcc tat agt gct ctg gga tcc cac cga gaa      672  
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 gaa cca tgg gtg gac ccg aac tcc ccg gtg ctc ttg gag gac cca gtc      720  
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ctt tgt gcc ttg gca aaa aag cac aag cga acc cca gcc ctg att gcc      768  
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 ctg cgc tac cag cta cag cgt ggg gtt gtg gtc ctg gcc aag agc tac      816  
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 aat gag cag cgc atc aga cag aac gtg cag gtg ttt gaa ttc cag ttg      864  
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 act tca gag gag atg aaa gcc ata gat ggc cta aac aga aat gtg cga      912  
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 tat ttg acc ctt gat att ttt gct ggc ccc cct aat tat cca ttt tct      960  
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gat gaa tat taa                                                      972  
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 78  
               
               
                 &lt;211&gt; LENGTH: 323  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 78  
               
               
                   
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 79  
               
               
                 &lt;211&gt; LENGTH: 983  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (30)..(980)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 79  
               
               
                   
               
               
                 atggattcga tatcagtgtg tgaagctga atg atg gtc act tcg tgc ctg tcc       53  
               
               
                                                 Met Met Val Thr Ser Cys Leu Ser  
               
               
                                                 1               5  
               
               
                   
               
               
                 tgg gat ttg gca cct atg cgc ctg cag agg tta ctc ccc cag gtt cct      101  
               
               
                 Trp Asp Leu Ala Pro Met Arg Leu Gln Arg Leu Leu Pro Gln Val Pro  
               
               
                     10                  15                  20  
               
               
                   
               
               
                 aaa agt aaa gct tta gag gcc acc aaa ttg gca att gaa gct ggc ttc      149  
               
               
                 Lys Ser Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe  
               
               
                 25                  30                  35                  40  
               
               
                   
               
               
                 cgc cat att gat tct gct cat tta tac aat aat gag gag cag gtt gga      197  
               
               
                 Arg His Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly  
               
               
                                 45                  50                  55  
               
               
                   
               
               
                 ctg gcc atc cga agc aag att gca gat ggc agt gtg aag aga gaa gac      245  
               
               
                 Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp  
               
               
                             60                  65                  70  
               
               
                   
               
               
                 ata ttc tac act tca aag ctt tgg tgc aat tcc cat cga cca gag ttg      293  
               
               
                 Ile Phe Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu  
               
               
                         75                  80                  85  
               
               
                   
               
               
                 gtc cga cca gcc ttg gaa agg tca ctg aaa aat ctt caa ttg gat tat      341  
               
               
                 Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr  
               
               
                     90                  95                  100  
               
               
                   
               
               
                 gtt gac ctc tac ctt att cat ttt cca gtg tct gta aag cca ggt gag      389  
               
               
                 Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu  
               
               
                 105                 110                 115                 120  
               
               
                   
               
               
                 gaa gtg atc cca aaa gat gaa agt gga aaa ata cta ttt gac aca gtg      437  
               
               
                 Glu Val Ile Pro Lys Asp Glu Ser Gly Lys Ile Leu Phe Asp Thr Val  
               
               
                                 125                 130                 135  
               
               
                   
               
               
                 gat ctc tgt gcc acg tgg gag gcc gtg gag aag tgt aaa gat gca gga      485  
               
               
                 Asp Leu Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly  
               
               
                             140                 145                 150  
               
               
                   
               
               
                 ttg gcc aag tcc atc ggg gtg tcc aac ttc aac cgc agg cag ctg gag      533  
               
               
                 Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu  
               
               
                         155                 160                 165  
               
               
                   
               
               
                 atg atc ctc aac aag cca ggg ctc aag tac aag cct gtc tgc aac cag      581  
               
               
                 Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln  
               
               
                     170                 175                 180  
               
               
                   
               
               
                 gtg gaa tgt cat cct tac ttc aac cag aga aaa ctg ctg gat ttc tgc      629  
               
               
                 Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys  
               
               
                 185                 190                 195                 200  
               
               
                   
               
               
                 aag tca aaa gac att gtt ctg gtt gcc tat agt gct ctg gga tcc cac      677  
               
               
                 Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His  
               
               
                                 205                 210                 215  
               
               
                   
               
               
                 cga gaa gaa cca tgg gtg gac ccg aac tcc ccg gtg ctc ttg gag gac      725  
               
               
                 Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp  
               
               
                             220                 225                 230  
               
               
                   
               
               
                 cca gtc ctt tgt gcc ttg gca aaa aag cac aag cga acc cca gcc ctg      773  
               
               
                 Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu  
               
               
                         235                 240                 245  
               
               
                   
               
               
                 gtt gcc ctg cgc tac cag cta cag cgt ggg gtt gtg gtc ctg gcc aag      821  
               
               
                 Val Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys  
               
               
                     250                 255                 260  
               
               
                   
               
               
                 agc tac aat gag cag cgc atc aga cag aac gtg cag gtg ttt gaa ttc      869  
               
               
                 Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe  
               
               
                 265                 270                 275                 280  
               
               
                   
               
               
                 cag ttg act tca gag gag atg aaa gcc ata gat ggc cta aac aga aat      917  
               
               
                 Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn  
               
               
                                 285                 290                 295  
               
               
                   
               
               
                 gtg cga tat ttg acc ctt gat att ttt gct ggc ccc cct aat tat cca      965  
               
               
                 Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro  
               
               
                             300                 305                 310  
               
               
                   
               
               
                 ttt tct gat gaa tat taa                                              983  
               
               
                 Phe Ser Asp Glu Tyr  
               
               
                         315  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 80  
               
               
                 &lt;211&gt; LENGTH: 317  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 80  
               
               
                   
               
               
                 Met Met Val Thr Ser Cys Leu Ser Trp Asp Leu Ala Pro Met Arg Leu  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gln Arg Leu Leu Pro Gln Val Pro Lys Ser Lys Ala Leu Glu Ala Thr  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Leu Ala Ile Glu Ala Gly Phe Arg His Ile Asp Ser Ala His Leu  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala Ile Arg Ser Lys Ile Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Asp Gly Ser Val Lys Arg Glu Asp Ile Phe Tyr Thr Ser Lys Leu Trp  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Cys Asn Ser His Arg Pro Glu Leu Val Arg Pro Ala Leu Glu Arg Ser  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp Leu Tyr Leu Ile His Phe  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Pro Val Ser Val Lys Pro Gly Glu Glu Val Ile Pro Lys Asp Glu Ser  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Gly Lys Ile Leu Phe Asp Thr Val Asp Leu Cys Ala Thr Trp Glu Ala  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Val Glu Lys Cys Lys Asp Ala Gly Leu Ala Lys Ser Ile Gly Val Ser  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Asn Phe Asn Arg Arg Gln Leu Glu Met Ile Leu Asn Lys Pro Gly Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Lys Tyr Lys Pro Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe Asn  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser Lys Asp Ile Val Leu Val  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Ala Tyr Ser Ala Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp Pro  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Asn Ser Pro Val Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala Lys  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Lys His Lys Arg Thr Pro Ala Leu Val Ala Leu Arg Tyr Gln Leu Gln  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Arg Gly Val Val Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg Ile Arg  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Asn Val Gln Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met Lys  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Ala Ile Asp Gly Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp Ile  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser Asp Glu Tyr  
               
               
                 305                 310                 315  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 81  
               
               
                 &lt;211&gt; LENGTH: 972  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(969)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 81  
               
               
                   
               
               
                 atg gat tcg aaa tat cag tgt gtg aag ctg aat gat ggt cac ttc atg       48  
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 cct gtc ctg gga ttt ggc acc tat gcg cct gca gag gtt cct aaa agt       96  
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 aaa gct tta gag gcc acc aaa ttg gca att gaa gct ggc ttc cgc cat      144  
               
               
                 Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 att gat tct gct cat tta tac aat aat gag gag cag gtt gga ctg gcc      192  
               
               
                 Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 atc cga agc aag att gca gat ggc agt gtg aag aga gaa gac ata ttc      240  
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 tac act tca aag ctt tgg tgc aat tcc cat cga cca gag ttg gtc cga      288  
               
               
                 Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 cca gcc ttg gaa agg tca ctg aaa aat ctt caa ttg gat tat gtt gac      336  
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 ctc tac ctt att cat ttt cca gtg tct gta aag cca ggt gag gaa gtg      384  
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 atc cca aaa gat gaa aat gga aaa ata cta ttt gac aca gtg gat ctc      432  
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 tgt gcc acg tgg gag gcc gtg gag aag tgt aaa gat gca gga ttg gcc      480  
               
               
                 Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 aag tcc atc ggg gtg tcc aac ttc aac cgc agg cag ctg gag atg atc      528  
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 ctc aac aag cca ggg ctc aag tac aag cct gtc tgc aac cag gtg gaa      576  
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 tgt cat cct tac ttc aac cag aga aaa ctg ctg gat ttc tgc aag tca      624  
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 aaa gac att gtt ctg gtt gcc tat agt gct ctg gga tcc cac cga gaa      672  
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 gaa cca tgg gtg gac ccg aac tcc ccg gtg ctc ttg gag gac cca gtc      720  
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ctt tgt gcc ttg gca aaa aag cac aag cga acc cca gcc ctg att gcc      768  
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 ctg cgc tac cag cta cag cgt ggg gtt gtg gtc ctg gcc aag aga tac      816  
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Arg Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 aat gag cag cgc atc aga cag aac gtg cag gtg ttt gaa ttc cag ttg      864  
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 act tca gag gag atg aaa gcc ata gat ggc cta aac aga aat gtg cga      912  
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 tat ttg acc ctt gat att ttt gct ggc ccc cct aat tat cca ttt tct      960  
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 gat gaa tat taa                                                      972  
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 82  
               
               
                 &lt;211&gt; LENGTH: 323  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 82  
               
               
                   
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Arg Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 83  
               
               
                 &lt;211&gt; LENGTH: 994  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (16)..(978)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 83  
               
               
                   
               
               
                 gccagatctc ccacc atg gat tcg aaa tat cag tgt gtg aag ctg aat gat      51  
               
               
                                  Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp  
               
               
                                  1               5                   10  
               
               
                   
               
               
                 ggt cac ttc atg cct gtc ctg gga ttt ggc acc tat gcg cct gca gag       99  
               
               
                 Gly His Phe Met Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu  
               
               
                         15                  20                  25  
               
               
                   
               
               
                 gtt cct aaa agt aaa gct tta gag gcc acc aaa ttg gca att gaa gct      147  
               
               
                 Val Pro Lys Ser Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala  
               
               
                     30                  35                  40  
               
               
                   
               
               
                 ggc ttc cgc cat att gat tct gct cat tta tac aat aat gag gag cag      195  
               
               
                 Gly Phe Arg His Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln  
               
               
                 45                  50                  55                  60  
               
               
                   
               
               
                 gtt gga ctg gcc atc cga agc aag att gca gat ggc agt gtg aag aga      243  
               
               
                 Val Gly Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg  
               
               
                                 65                  70                  75  
               
               
                   
               
               
                 gaa gac ata ttc tac act tca aag ctt tgg tgc aat tcc cat cga cca      291  
               
               
                 Glu Asp Ile Phe Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro  
               
               
                             80                  85                  90  
               
               
                   
               
               
                 gag ttg gtc cga cca gcc ttg gaa agg tca ctg aaa aat ctt caa ttg      339  
               
               
                 Glu Leu Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu  
               
               
                         95                  100                 105  
               
               
                   
               
               
                 gat tat gtt gac ctc tac ctt att cat ttt cca gtg tct gta aag cca      387  
               
               
                 Asp Tyr Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro  
               
               
                     110                 115                 120  
               
               
                   
               
               
                 ggt gag gaa gtg atc cca aaa gat gaa aat gga aaa ata cta ttt gac      435  
               
               
                 Gly Glu Glu Val Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp  
               
               
                 125                 130                 135                 140  
               
               
                   
               
               
                 aca gtg gat ctc tgt gcc acg tgg gag gcc gtg gag aag tgt aaa gat      483  
               
               
                 Thr Val Asp Leu Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp  
               
               
                                 145                 150                 155  
               
               
                   
               
               
                 gca gga ttg gcc aag tcc atc ggg gtg tcc aac ttc aac cgc agg cag      531  
               
               
                 Ala Gly Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln  
               
               
                             160                 165                 170  
               
               
                   
               
               
                 ctg gag atg atc ctc aac aag cca ggg ctc aag tac aag cct gtc tgc      579  
               
               
                 Leu Glu Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys  
               
               
                         175                 180                 185  
               
               
                   
               
               
                 aac cag gtg gaa tgt cat cct tac ttc aac cag aga aaa ctg ctg gat      627  
               
               
                 Asn Gln Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp  
               
               
                     190                 195                 200  
               
               
                   
               
               
                 ttc tgc aag tca aaa gac att gtt ctg gtt gcc tat agt gct ctg gga      675  
               
               
                 Phe Cys Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly  
               
               
                 205                 210                 215                 220  
               
               
                   
               
               
                 tcc cac cga gaa gaa cca tgg gtg gac ccg aac tcc ccg gtg ctc ttg      723  
               
               
                 Ser His Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu  
               
               
                                 225                 230                 235  
               
               
                   
               
               
                 gag gac cca gtc ctt tgt gcc ttg gca aaa aag cac aag cga acc cca      771  
               
               
                 Glu Asp Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro  
               
               
                             240                 245                 250  
               
               
                   
               
               
                 gcc ctg att gcc ctg cgc tac cag cta cag cgt ggg gtt gtg gtc ctg      819  
               
               
                 Ala Leu Ile Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu  
               
               
                         255                 260                 265  
               
               
                   
               
               
                 gcc aag agc tac aat gag cag cgc atc aga cag aac gtg cag gtg ttt      867  
               
               
                 Ala Lys Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe  
               
               
                     270                 275                 280  
               
               
                   
               
               
                 gaa ttc cag ttg act tca gag gag atg aaa gcc ata gat ggc cta aac      915  
               
               
                 Glu Phe Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn  
               
               
                 285                 290                 295                 300  
               
               
                   
               
               
                 aga aat gtg cga tat ttg acc ctt gat att ttt gct ggc ccc cct aat      963  
               
               
                 Arg Asn Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn  
               
               
                                 305                 310                 315  
               
               
                   
               
               
                 tat cca ttt tct gat gaatatctcg agggtg                                994  
               
               
                 Tyr Pro Phe Ser Asp  
               
               
                             320  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 84  
               
               
                 &lt;211&gt; LENGTH: 321  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 84  
               
               
                   
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Asp  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 85  
               
               
                 &lt;211&gt; LENGTH: 1219  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (24)..(992)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 85  
               
               
                   
               
               
                 tgctaaccag gccagtgaca gaa atg gat tcg aaa tac cag tgt gtg aag ctg     53  
               
               
                                           Met Asp Ser Lys Tyr Gln Cys Val Lys Leu  
               
               
                                           1                5                  10  
               
               
                   
               
               
                 aat gat ggt cac ttc atg cct gtc ctg gga ttt ggc acc tat gcg cct      101  
               
               
                 Asn Asp Gly His Phe Met Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro  
               
               
                                 15                  20                  25  
               
               
                   
               
               
                 gca gag gtt cct aaa agt aaa gct cta gag gcc gtc aaa ttg gca ata      149  
               
               
                 Ala Glu Val Pro Lys Ser Lys Ala Leu Glu Ala Val Lys Leu Ala Ile  
               
               
                             30                  35                  40  
               
               
                   
               
               
                 gaa gcc ggg ttc cac cat att gat tct gca cat gtt tac aat aat gag      197  
               
               
                 Glu Ala Gly Phe His His Ile Asp Ser Ala His Val Tyr Asn Asn Glu  
               
               
                         45                  50                  55  
               
               
                   
               
               
                 gag cag gtt gga ctg gcc atc cga agc aag att gca gat ggc agt gtg      245  
               
               
                 Glu Gln Val Gly Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val  
               
               
                     60                  65                  70  
               
               
                   
               
               
                 aag aga gaa gac ata ttc tac act tca aag ctt tgg agc aat tcc cat      293  
               
               
                 Lys Arg Glu Asp Ile Phe Tyr Thr Ser Lys Leu Trp Ser Asn Ser His  
               
               
                 75                  80                  85                  90  
               
               
                   
               
               
                 cga cca gag ttg gtc cga cca gcc ttg gaa agg tca ctg aaa aat ctt      341  
               
               
                 Arg Pro Glu Leu Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu  
               
               
                                 95                  100                 105  
               
               
                   
               
               
                 caa ttg gac tat gtt gac ctc tat ctt att cat ttt cca gtg tct gta      389  
               
               
                 Gln Leu Asp Tyr Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val  
               
               
                             110                 115                 120  
               
               
                   
               
               
                 aag cca ggt gag gaa gtg atc cca aaa gat gaa aat gga aaa ata cta      437  
               
               
                 Lys Pro Gly Glu Glu Val Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu  
               
               
                         125                 130                 135  
               
               
                   
               
               
                 ttt gac aca gtg gat ctc tgt gcc acg tgg gag gcc atg gag aag tgt      485  
               
               
                 Phe Asp Thr Val Asp Leu Cys Ala Thr Trp Glu Ala Met Glu Lys Cys  
               
               
                     140                 145                 150  
               
               
                   
               
               
                 aaa gat gca gga ttg gcc aag tcc atc ggg gtg tcc aac ttc aac cac      533  
               
               
                 Lys Asp Ala Gly Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn His  
               
               
                 155                 160                 165                 170  
               
               
                   
               
               
                 agg ctg ctg gag atg atc ctc aac aag cca ggg ctc aag tac aag cct      581  
               
               
                 Arg Leu Leu Glu Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro  
               
               
                                 175                 180                 185  
               
               
                   
               
               
                 gtc tgc aac cag gtg gaa tgt cat cct tac ttc aac cag aga aaa ctg      629  
               
               
                 Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu  
               
               
                             190                 195                 200  
               
               
                   
               
               
                 ctg gat ttc tgc aag tca aaa gac att gtt ctg gtt gcc tat agt gct      677  
               
               
                 Leu Asp Phe Cys Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala  
               
               
                         205                 210                 215  
               
               
                   
               
               
                 ctg gga tcc cat cga gaa gaa cca tgg gtg gac ccg aac tcc ccg gtg      725  
               
               
                 Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val  
               
               
                     220                 225                 230  
               
               
                   
               
               
                 ctc ttg gag gac cca gtc ctt tgt gcc ttg gca aaa aag cac aag cga      773  
               
               
                 Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg  
               
               
                 235                 240                 245                 250  
               
               
                   
               
               
                 acc cca gcc ctg att gcc ctg cgc tac cag ctg cag cgt ggg gtt gtg      821  
               
               
                 Thr Pro Ala Leu Ile Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val  
               
               
                                 255                 260                 265  
               
               
                   
               
               
                 gtc ctg gcc aag agc tac aat gag cag cgc atc aga cag aac gtg cag      869  
               
               
                 Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln  
               
               
                             270                 275                 280  
               
               
                   
               
               
                 gtg ttt gaa ttc cag ttg act tca gag gag atg aaa gcc ata gat ggc      917  
               
               
                 Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly  
               
               
                         285                 290                 295  
               
               
                   
               
               
                 cta aac aga aat gtg cga tat ttg acc ctt gat att ttt gct ggc ccc      965  
               
               
                 Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro  
               
               
                     300                 305                 310  
               
               
                   
               
               
                 cct aat tat cca ttt tct gat gaa tat taacatggag ggcattgcat           1012  
               
               
                 Pro Asn Tyr Pro Phe Ser Asp Glu Tyr  
               
               
                 315                 320  
               
               
                   
               
               
                 gaggtctgcc agaaggccct gcgtgtggat ggtgacacag aggatggctc tatgctggtg   1072  
               
               
                   
               
               
                 actggacaca tcgcctctgg ttaaatctct cctgcttggc gacttcagta agctacagct   1132  
               
               
                   
               
               
                 aagcccatcg gccggaaaag aaagacaata attttgtttt ttcattttga aaaaattaaa   1192  
               
               
                   
               
               
                 tgctctctcc taaagattct tcaccta                                       1219  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 86  
               
               
                 &lt;211&gt; LENGTH: 323  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 86  
               
               
                   
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Ala Leu Glu Ala Val Lys Leu Ala Ile Glu Ala Gly Phe His His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asp Ser Ala His Val Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Thr Ser Lys Leu Trp Ser Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Cys Ala Thr Trp Glu Ala Met Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn His Arg Leu Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 87  
               
               
                 &lt;211&gt; LENGTH: 1001  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (11)..(982)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 87  
               
               
                   
               
               
                 catctaggcc acc atg gcc atg gat tcg aaa tat cag tgt gtg aag ctg        49  
               
               
                            Thr Met Ala Met Asp Ser Lys Tyr Gln Cys Val Lys Leu  
               
               
                            1               5                   10  
               
               
                   
               
               
                 aat gat ggt cac ttc atg cct gtc ctg gga ttt ggc acc tat gcg cct       97  
               
               
                 Asn Asp Gly His Phe Met Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro  
               
               
                     15                  20                  25  
               
               
                   
               
               
                 gca gag gtt cct aaa agt aaa gct tta gag gcc acc aaa ttg gca att      145  
               
               
                 Ala Glu Val Pro Lys Ser Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile  
               
               
                 30                  35                  40                  45  
               
               
                   
               
               
                 gaa gct ggc ttc cgc cat att gat tct gct cat tta tac aat aat gag      193  
               
               
                 Glu Ala Gly Phe Arg His Ile Asp Ser Ala His Leu Tyr Asn Asn Glu  
               
               
                                 50                  55                  60  
               
               
                   
               
               
                 gag cag gtt gga ctg gcc atc cga agc aag att gca gat ggc agt gtg      241  
               
               
                 Glu Gln Val Gly Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val  
               
               
                             65                  70                  75  
               
               
                   
               
               
                 aag aga gaa gac ata ttc tac act tca aag ctt tgg tgc aat tcc cat      289  
               
               
                 Lys Arg Glu Asp Ile Phe Tyr Thr Ser Lys Leu Trp Cys Asn Ser His  
               
               
                         80                  85                  90  
               
               
                   
               
               
                 cga cca gag ttg gtc cga cca gcc ttg gaa agg tca ctg aaa aat ctt      337  
               
               
                 Arg Pro Glu Leu Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu  
               
               
                     95                  100                 105  
               
               
                   
               
               
                 caa ttg gat tat gtt gac ctc tac ctt att cat ttt cca gtg tct gta      385  
               
               
                 Gln Leu Asp Tyr Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val  
               
               
                 110                 115                 120                 125  
               
               
                   
               
               
                 aag cca ggt gag gaa gtg atc cca aaa gat gaa aat gga aaa ata cta      433  
               
               
                 Lys Pro Gly Glu Glu Val Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu  
               
               
                                 130                 135                 140  
               
               
                   
               
               
                 ttt gac aca gtg gat ctc tgt gcc acg tgg gag gcc gtg gag aag tgt      481  
               
               
                 Phe Asp Thr Val Asp Leu Cys Ala Thr Trp Glu Ala Val Glu Lys Cys  
               
               
                             145                 150                 155  
               
               
                   
               
               
                 aaa gat gca gga ttg gcc aag tcc atc ggg gtg tcc aac ttc aac cgc      529  
               
               
                 Lys Asp Ala Gly Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn Arg  
               
               
                         160                 165                 170  
               
               
                   
               
               
                 agg cag ctg gag atg atc ctc aac aag cca ggg ctc aag tac aag cct      577  
               
               
                 Arg Gln Leu Glu Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro  
               
               
                     175                 180                 185  
               
               
                   
               
               
                 gtc tgc aac cag gtg gaa tgt cat cct tac ttc aac cag aga aaa ctg      625  
               
               
                 Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu  
               
               
                 190                 195                 200                 205  
               
               
                   
               
               
                 ctg gat ttc tgc aag tca aaa gac att gtt ctg gtt gcc tat agt gct      673  
               
               
                 Leu Asp Phe Cys Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala  
               
               
                                 210                 215                 220  
               
               
                   
               
               
                 ctg gga tcc cac cga gaa gaa cca tgg gtg gac ccg aac tcc ccg gtg      721  
               
               
                 Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val  
               
               
                             225                 230                 235  
               
               
                   
               
               
                 ctc ttg gag gac cca gtc ctt tgt gcc ttg gca aaa aag cac aag cga      769  
               
               
                 Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg  
               
               
                         240                 245                 250  
               
               
                   
               
               
                 acc cca gcc ctg att gcc ctg cgc tac cag cta cag cgt ggg gtt gtg      817  
               
               
                 Thr Pro Ala Leu Ile Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val  
               
               
                     255                 260                 265  
               
               
                   
               
               
                 gtc ctg gcc aag agc tac aat gag cag cgc atc aga cag aac gtg cag      865  
               
               
                 Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln  
               
               
                 270                 275                 280                 285  
               
               
                   
               
               
                 gtg ttt gaa ttc cag ttg act tca gag gag atg aaa gcc ata gat ggc      913  
               
               
                 Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly  
               
               
                                 290                 295                 300  
               
               
                   
               
               
                 cta aac aga aat gtg cga tat ttg acc ctt gat att ttt gct ggc ccc      961  
               
               
                 Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro  
               
               
                             305                 310                 315  
               
               
                   
               
               
                 cct aat tat cca ttt tct gat gaatattaaa cgcgtgatc                    1001  
               
               
                 Pro Asn Tyr Pro Phe Ser Asp  
               
               
                         320  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 88  
               
               
                 &lt;211&gt; LENGTH: 324  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 88  
               
               
                   
               
               
                 Thr Met Ala Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 His Phe Met Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Pro Lys Ser Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Phe Arg His Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Gly Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Asp Ile Phe Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Leu Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Tyr Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Glu Glu Val Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Val Asp Leu Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Gly Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Glu Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Gln Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Cys Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 His Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Asp Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Ile Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Lys Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Phe Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Asn Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Pro Phe Ser Asp  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 89  
               
               
                 &lt;211&gt; LENGTH: 1012  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (1)..(1011)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 89  
               
               
                   
               
               
                 gcc ggt acc acc atg ggc cac cat cac cac cat cac gat tcg aaa tat       48  
               
               
                 Ala Gly Thr Thr Met Gly His His His His His His Asp Ser Lys Tyr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 cag tgt gtg aag ctg aat gat ggt cac ttc atg cct gtc ctg gga ttt       96  
               
               
                 Gln Cys Val Lys Leu Asn Asp Gly His Phe Met Pro Val Leu Gly Phe  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 ggc acc tat gcg cct gca gag gtt cct aaa agt aaa gct tta gag gcc      144  
               
               
                 Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser Lys Ala Leu Glu Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 acc aaa ttg gca att gaa gct ggc ttc cgc cat att gat tct gct cat      192  
               
               
                 Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His Ile Asp Ser Ala His  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 tta tac aat aat gag gag cag gtt gga ctg gcc atc cga agc aag att      240  
               
               
                 Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala Ile Arg Ser Lys Ile  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 gca gat ggc agt gtg aag aga gaa gac ata ttc tac act tca aag ctt      288  
               
               
                 Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe Tyr Thr Ser Lys Leu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 tgg tgc aat tcc cat cga cca gag ttg gtc cga cca gcc ttg gaa agg      336  
               
               
                 Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg Pro Ala Leu Glu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 tca ctg aaa aat ctt caa ttg gat tat gtt gac ctc tac ctt att cat      384  
               
               
                 Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp Leu Tyr Leu Ile His  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 ttt cca gtg tct gta aag cca ggt gag gaa gtg atc cca aaa gat gaa      432  
               
               
                 Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val Ile Pro Lys Asp Glu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 aat gga aaa ata cta ttt gac aca gtg gat ctc tgt gcc acg tgg gag      480  
               
               
                 Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu Cys Ala Thr Trp Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 gcc gtg gag aag tgt aaa gat gca gga ttg gcc aag tcc atc ggg gtg      528  
               
               
                 Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala Lys Ser Ile Gly Val  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 tcc aac ttc aac cgc agg cag ctg gag atg atc ctc aac aag cca ggg      576  
               
               
                 Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile Leu Asn Lys Pro Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 ctc aag tac aag cct gtc tgc aac cag gtg gaa tgt cat cct tac ttc      624  
               
               
                 Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 aac cag aga aaa ctg ctg gat ttc tgc aag tca aaa gac att gtt ctg      672  
               
               
                 Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser Lys Asp Ile Val Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 gtt gcc tat agt gct ctg gga tcc cac cga gaa gaa cca tgg gtg gac      720  
               
               
                 Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 ccg aac tcc ccg gtg ctc ttg gag gac cca gtc ctt tgt gcc ttg gca      768  
               
               
                 Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 aaa aag cac aag cga acc cca gcc ctg att gcc ctg cgc tac cag cta      816  
               
               
                 Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala Leu Arg Tyr Gln Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 cag cgt ggg gtt gtg gtc ctg gcc aag agc tac aat gag cag cgc atc      864  
               
               
                 Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg Ile  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 aga cag aac gtg cag gtg ttt gaa ttc cag ttg act tca gag gag atg      912  
               
               
                 Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 aaa gcc ata gat ggc cta aac aga aat gtg cga tat ttg acc ctt gat      960  
               
               
                 Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 att ttt gct ggc ccc cct aat tat cca ttt tct gat gaa tat ctc gag     1008  
               
               
                 Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser Asp Glu Tyr Leu Glu  
               
               
                                 325                 330                 335  
               
               
                 ggt g                                                               1012  
               
               
                 Gly  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 90  
               
               
                 &lt;211&gt; LENGTH: 337  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 90  
               
               
                   
               
               
                 Ala Gly Thr Thr Met Gly His His His His His His Asp Ser Lys Tyr  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Gln Cys Val Lys Leu Asn Asp Gly His Phe Met Pro Val Leu Gly Phe  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser Lys Ala Leu Glu Ala  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His Ile Asp Ser Ala His  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala Ile Arg Ser Lys Ile  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe Tyr Thr Ser Lys Leu  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg Pro Ala Leu Glu Arg  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp Leu Tyr Leu Ile His  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val Ile Pro Lys Asp Glu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu Cys Ala Thr Trp Glu  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala Lys Ser Ile Gly Val  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile Leu Asn Lys Pro Gly  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser Lys Asp Ile Val Leu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala Leu Arg Tyr Gln Leu  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg Ile  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser Asp Glu Tyr Leu Glu  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Gly  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 91  
               
               
                 &lt;211&gt; LENGTH: 1225  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (24)..(992)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 91  
               
               
                   
               
               
                 tgctaaccag gccagtgaca gaa atg gat tcg aaa tac cag tgt gtg aag ctg     53  
               
               
                                           Met Asp Ser Lys Tyr Gln Cys Val Lys Leu  
               
               
                                           1                5                  10  
               
               
                   
               
               
                 aat gat ggt cac ttc atg cct gtc ctg gga ttt ggc acc tat gcg cct      101  
               
               
                 Asn Asp Gly His Phe Met Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro  
               
               
                                 15                  20                  25  
               
               
                   
               
               
                 gca gag gtt cct aaa agt aaa gct cta gag gcc gtc aaa ttg gca ata      149  
               
               
                 Ala Glu Val Pro Lys Ser Lys Ala Leu Glu Ala Val Lys Leu Ala Ile  
               
               
                             30                  35                  40  
               
               
                   
               
               
                 gaa gcc ggg ttc cac cat att gat tct gca cat gtt tac aat aat gag      197  
               
               
                 Glu Ala Gly Phe His His Ile Asp Ser Ala His Val Tyr Asn Asn Glu  
               
               
                         45                  50                  55  
               
               
                   
               
               
                 gag cag gtt gga ctg gcc atc cga agc aag att gca gat ggc agt gtg      245  
               
               
                 Glu Gln Val Gly Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val  
               
               
                     60                  65                  70  
               
               
                   
               
               
                 aag aga gaa gac ata ttc tac act tca aag ctt tgg agc aat tcc cat      293  
               
               
                 Lys Arg Glu Asp Ile Phe Tyr Thr Ser Lys Leu Trp Ser Asn Ser His  
               
               
                 75                  80                  85                  90  
               
               
                   
               
               
                 cga cca gag ttg gtc cga cca gcc ttg gaa agg tca ctg aaa aat ctt      341  
               
               
                 Arg Pro Glu Leu Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu  
               
               
                                 95                  100                 105  
               
               
                   
               
               
                 caa ttg gac tat gtt gac ctc tat ctt att cat ttt cca gtg tct gta      389  
               
               
                 Gln Leu Asp Tyr Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val  
               
               
                             110                 115                 120  
               
               
                   
               
               
                 aag cca ggt gag gaa gtg atc cca aaa gat gaa aat gga aaa ata cta      437  
               
               
                 Lys Pro Gly Glu Glu Val Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu  
               
               
                         125                 130                 135  
               
               
                   
               
               
                 ttt gac aca gtg gat ctc tgt gcc acg tgg gag gcc atg gag aag tgt      485  
               
               
                 Phe Asp Thr Val Asp Leu Cys Ala Thr Trp Glu Ala Met Glu Lys Cys  
               
               
                     140                 145                 150  
               
               
                   
               
               
                 aaa gat gca gga ttg gcc aag tcc atc ggg gtg tcc aac ttc aac cac      533  
               
               
                 Lys Asp Ala Gly Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn His  
               
               
                 155                 160                 165                 170  
               
               
                   
               
               
                 agg ctg ctg gag atg atc ctc aac aag cca ggg ctc aag tac aag cct      581  
               
               
                 Arg Leu Leu Glu Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro  
               
               
                                 175                 180                 185  
               
               
                   
               
               
                 gtc tgc aac cag gtg gaa tgt cat cct tac ttc aac cag aga aaa ctg      629  
               
               
                 Val Cys Asn Gln Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu  
               
               
                             190                 195                 200  
               
               
                   
               
               
                 ctg gat ttc tgc aag tca aaa gac att gtt ctg gtt gcc tat agt gct      677  
               
               
                 Leu Asp Phe Cys Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala  
               
               
                         205                 210                 215  
               
               
                   
               
               
                 ctg gga tcc cat cga gaa gaa cca tgg gtg gac ccg aac tcc ccg gtg      725  
               
               
                 Leu Gly Ser His Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val  
               
               
                     220                 225                 230  
               
               
                   
               
               
                 ctc ttg gag gac cca gtc ctt tgt gcc ttg gca aaa aag cac aag cga      773  
               
               
                 Leu Leu Glu Asp Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg  
               
               
                 235                 240                 245                 250  
               
               
                   
               
               
                 acc cca gcc ctg att gcc ctg cgc tac cag ctg cag cgt ggg gtt gtg      821  
               
               
                 Thr Pro Ala Leu Ile Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val  
               
               
                                 255                 260                 265  
               
               
                   
               
               
                 gtc ctg gcc aag agc tac aat gag cag cgc atc aga cag aac gtg cag      869  
               
               
                 Val Leu Ala Lys Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln  
               
               
                             270                 275                 280  
               
               
                   
               
               
                 gtg ttt gaa ttc cag ttg act tca gag gag atg aaa gcc ata gat ggc      917  
               
               
                 Val Phe Glu Phe Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly  
               
               
                         285                 290                 295  
               
               
                   
               
               
                 cta aac aga aat gtg cga tat ttg acc ctt gat att ttt gct ggc ccc      965  
               
               
                 Leu Asn Arg Asn Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro  
               
               
                     300                 305                 310  
               
               
                   
               
               
                 cct aat tat cca ttt tct gat gaa tat taacatggag ggcattgcat           1012  
               
               
                 Pro Asn Tyr Pro Phe Ser Asp Glu Tyr  
               
               
                 315                 320  
               
               
                   
               
               
                 gaggtctgcc agaaggccct gcgtgtggat ggtgacacag aggatggctc tatgctggtg   1072  
               
               
                   
               
               
                 actggacaca tcgcctctgg ttaaatctct cctgcttggc gacttcagta agctacagct   1132  
               
               
                   
               
               
                 aagcccatcg gccggaaaag aaagacaata attttgtttt ttcattttga aaaaattaaa   1192  
               
               
                   
               
               
                 tgctctctcc taaagattct tcacctaaaa aaa                                1225  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 92  
               
               
                 &lt;211&gt; LENGTH: 323  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 92  
               
               
                   
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Ala Leu Glu Ala Val Lys Leu Ala Ile Glu Ala Gly Phe His His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asp Ser Ala His Val Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Thr Ser Lys Leu Trp Ser Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Cys Ala Thr Trp Glu Ala Met Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn His Arg Leu Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 93  
               
               
                 &lt;211&gt; LENGTH: 996  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (16)..(984)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 93  
               
               
                   
               
               
                 caccgcggcc gcacc atg gat tcg aaa tat cag tgt gtg aag ctg aat gat      51  
               
               
                                  Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp  
               
               
                                  1               5                   10  
               
               
                   
               
               
                 ggt cac ttc atg cct gtc ctg gga ttt ggc acc tat gcg cct gca gag       99  
               
               
                 Gly His Phe Met Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu  
               
               
                         15                  20                  25  
               
               
                   
               
               
                 gtt cct aaa agt aaa gct tta gag gcc acc aaa ttg gca att gaa gct      147  
               
               
                 Val Pro Lys Ser Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala  
               
               
                     30                  35                  40  
               
               
                   
               
               
                 ggc ttc cgc cat att gat tct gct cat tta tac aat aat gag gag cag      195  
               
               
                 Gly Phe Arg His Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln  
               
               
                 45                  50                  55                  60  
               
               
                   
               
               
                 gtt gga ctg gcc atc cga agc aag att gca gat ggc agt gtg aag aga      243  
               
               
                 Val Gly Leu Ala Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg  
               
               
                                 65                  70                  75  
               
               
                   
               
               
                 gaa gac ata ttc tac act tca aag ctt tgg tgc aat tcc cat cga cca      291  
               
               
                 Glu Asp Ile Phe Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro  
               
               
                             80                  85                  90  
               
               
                   
               
               
                 gag ttg gtc cga cca gcc ttg gaa agg tca ctg aaa aat ctt caa ttg      339  
               
               
                 Glu Leu Val Arg Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu  
               
               
                         95                  100                 105  
               
               
                   
               
               
                 gat tat gtt gac ctc tac ctt att cat ttt cca gtg tct gta aag cca      387  
               
               
                 Asp Tyr Val Asp Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro  
               
               
                     110                 115                 120  
               
               
                   
               
               
                 ggt gag gaa gtg atc cca aaa gat gaa aat gga aaa ata cta ttt gac      435  
               
               
                 Gly Glu Glu Val Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp  
               
               
                 125                 130                 135                 140  
               
               
                   
               
               
                 aca gtg gat ctc tgt gcc acg tgg gag gcc gtg gag aag tgt aaa gat      483  
               
               
                 Thr Val Asp Leu Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp  
               
               
                                 145                 150                 155  
               
               
                   
               
               
                 gca gga ttg gcc aag tcc atc ggg gtg tcc aac ttc aac cgc agg cag      531  
               
               
                 Ala Gly Leu Ala Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln  
               
               
                             160                 165                 170  
               
               
                   
               
               
                 ctg gag atg atc ctc aac aag cca ggg ctc aag tac aag cct gtc tgc      579  
               
               
                 Leu Glu Met Ile Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys  
               
               
                         175                 180                 185  
               
               
                   
               
               
                 aac cag gtg gaa tgt cat cct tac ttc aac cag aga aaa ctg ctg gat      627  
               
               
                 Asn Gln Val Glu Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp  
               
               
                     190                 195                 200  
               
               
                   
               
               
                 ttc tgc aag tca aaa gac att gtt ctg gtt gcc tat agt gct ctg gga      675  
               
               
                 Phe Cys Lys Ser Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly  
               
               
                 205                 210                 215                 220  
               
               
                   
               
               
                 tcc cac cga gaa gaa cca tgg gtg gac ccg aac tcc ccg gtg ctc ttg      723  
               
               
                 Ser His Arg Glu Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu  
               
               
                                 225                 230                 235  
               
               
                   
               
               
                 gag gac cca gtc ctt tgt gcc ttg gca aaa aag cac aag cga acc cca      771  
               
               
                 Glu Asp Pro Val Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro  
               
               
                             240                 245                 250  
               
               
                   
               
               
                 gcc ctg att gcc ctg cgc tac cag cta cag cgt ggg gtt gtg gtc ctg      819  
               
               
                 Ala Leu Ile Ala Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu  
               
               
                         255                 260                 265  
               
               
                   
               
               
                 gcc aag agc tac aat gag cag cgc atc aga cag aac gtg cag gtg ttt      867  
               
               
                 Ala Lys Ser Tyr Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe  
               
               
                     270                 275                 280  
               
               
                   
               
               
                 gaa ttc cag ttg act tca gag gag atg aaa gcc ata gat ggc cta aac      915  
               
               
                 Glu Phe Gln Leu Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn  
               
               
                 285                 290                 295                 300  
               
               
                   
               
               
                 aga aat gtg cga tat ttg acc ctt gat att ttt gct ggc ccc cct aat      963  
               
               
                 Arg Asn Val Arg Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn  
               
               
                                 305                 310                 315  
               
               
                   
               
               
                 tat cca ttt tct gat gaa tat taggtcgacg gc                            996  
               
               
                 Tyr Pro Phe Ser Asp Glu Tyr  
               
               
                             320  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 94  
               
               
                 &lt;211&gt; LENGTH: 323  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 94  
               
               
                   
               
               
                 Met Asp Ser Lys Tyr Gln Cys Val Lys Leu Asn Asp Gly His Phe Met  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Pro Val Leu Gly Phe Gly Thr Tyr Ala Pro Ala Glu Val Pro Lys Ser  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Lys Ala Leu Glu Ala Thr Lys Leu Ala Ile Glu Ala Gly Phe Arg His  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Ile Asp Ser Ala His Leu Tyr Asn Asn Glu Glu Gln Val Gly Leu Ala  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ile Arg Ser Lys Ile Ala Asp Gly Ser Val Lys Arg Glu Asp Ile Phe  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Tyr Thr Ser Lys Leu Trp Cys Asn Ser His Arg Pro Glu Leu Val Arg  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Pro Ala Leu Glu Arg Ser Leu Lys Asn Leu Gln Leu Asp Tyr Val Asp  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Leu Tyr Leu Ile His Phe Pro Val Ser Val Lys Pro Gly Glu Glu Val  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Ile Pro Lys Asp Glu Asn Gly Lys Ile Leu Phe Asp Thr Val Asp Leu  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Cys Ala Thr Trp Glu Ala Val Glu Lys Cys Lys Asp Ala Gly Leu Ala  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Lys Ser Ile Gly Val Ser Asn Phe Asn Arg Arg Gln Leu Glu Met Ile  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Asn Lys Pro Gly Leu Lys Tyr Lys Pro Val Cys Asn Gln Val Glu  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Cys His Pro Tyr Phe Asn Gln Arg Lys Leu Leu Asp Phe Cys Lys Ser  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Lys Asp Ile Val Leu Val Ala Tyr Ser Ala Leu Gly Ser His Arg Glu  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Glu Pro Trp Val Asp Pro Asn Ser Pro Val Leu Leu Glu Asp Pro Val  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Leu Cys Ala Leu Ala Lys Lys His Lys Arg Thr Pro Ala Leu Ile Ala  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Leu Arg Tyr Gln Leu Gln Arg Gly Val Val Val Leu Ala Lys Ser Tyr  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Asn Glu Gln Arg Ile Arg Gln Asn Val Gln Val Phe Glu Phe Gln Leu  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Thr Ser Glu Glu Met Lys Ala Ile Asp Gly Leu Asn Arg Asn Val Arg  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Tyr Leu Thr Leu Asp Ile Phe Ala Gly Pro Pro Asn Tyr Pro Phe Ser  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Asp Glu Tyr  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 95  
               
               
                 &lt;211&gt; LENGTH: 3815  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;221&gt; NAME/KEY: CDS  
               
               
                 &lt;222&gt; LOCATION: (263)..(1789)  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 95  
               
               
                   
               
               
                 cggccgcgat ccccaccaca ccaccagccc ggccgcacgg ggcactgagc cgggtgctga     60  
               
               
                   
               
               
                 gcaccggagg ccccgccgag gccgggactc agatgttgaa agttaatttg tgtaaagact    120  
               
               
                   
               
               
                 tatgcacgtg gtgacatgag ttctgcccag tgctctgaaa tcaaagtgaa gaaataaatc    180  
               
               
                   
               
               
                 catggaagcc caggcaaatg atgggtgtag ctatgactct ctgaaggacc tgcagagaaa    240  
               
               
                   
               
               
                 cgcctcctga ttttgtctta ca atg gaa ctt aaa aag tcg cct gac ggt gga     292  
               
               
                                          Met Glu Leu Lys Lys Ser Pro Asp Gly Gly  
               
               
                                          1                5                  10  
               
               
                   
               
               
                 tgg ggc tgg gtg att gtg ttt gtc tcc ttc ctt act cag ttt ttg tgt      340  
               
               
                 Trp Gly Trp Val Ile Val Phe Val Ser Phe Leu Thr Gln Phe Leu Cys  
               
               
                                 15                  20                  25  
               
               
                   
               
               
                 tac gga tcc cca cta gct gtt gga gtc ctg tac ata gaa tgg ctg gat      388  
               
               
                 Tyr Gly Ser Pro Leu Ala Val Gly Val Leu Tyr Ile Glu Trp Leu Asp  
               
               
                             30                  35                  40  
               
               
                   
               
               
                 gcc ttt ggt gaa gga aaa gga aaa aca gcc tgg gtt gga tcc ctg gca      436  
               
               
                 Ala Phe Gly Glu Gly Lys Gly Lys Thr Ala Trp Val Gly Ser Leu Ala  
               
               
                         45                  50                  55  
               
               
                   
               
               
                 agt gga gtt ggc ttg ctt gca agt cct gtc tgc agt ctc tgt gtc tca      484  
               
               
                 Ser Gly Val Gly Leu Leu Ala Ser Pro Val Cys Ser Leu Cys Val Ser  
               
               
                     60                  65                  70  
               
               
                   
               
               
                 tct ttt gga gca aga cct gtc aca atc ttc agt ggc ttc atg gtg gct      532  
               
               
                 Ser Phe Gly Ala Arg Pro Val Thr Ile Phe Ser Gly Phe Met Val Ala  
               
               
                 75                  80                  85                  90  
               
               
                   
               
               
                 gga ggc ctg atg ttg agc agt ttt gct ccc aat atc tac ttt ctg ttt      580  
               
               
                 Gly Gly Leu Met Leu Ser Ser Phe Ala Pro Asn Ile Tyr Phe Leu Phe  
               
               
                                 95                  100                 105  
               
               
                   
               
               
                 ttt tcc tat ggc att gtt gta ggt ctt gga tgt ggt tta tta tac act      628  
               
               
                 Phe Ser Tyr Gly Ile Val Val Gly Leu Gly Cys Gly Leu Leu Tyr Thr  
               
               
                             110                 115                 120  
               
               
                   
               
               
                 gca aca gtg acc att acg tgc cag tat ttt gac gat cgc cga ggc cta      676  
               
               
                 Ala Thr Val Thr Ile Thr Cys Gln Tyr Phe Asp Asp Arg Arg Gly Leu  
               
               
                         125                 130                 135  
               
               
                   
               
               
                 gcg ctt ggc ctg att tca aca ggt tca agc gtt ggc ctt ttc ata tat      724  
               
               
                 Ala Leu Gly Leu Ile Ser Thr Gly Ser Ser Val Gly Leu Phe Ile Tyr  
               
               
                     140                 145                 150  
               
               
                   
               
               
                 gct gct ctg cag agg atg ctg gtt gag ttc tat gga ctg gat gga tgc      772  
               
               
                 Ala Ala Leu Gln Arg Met Leu Val Glu Phe Tyr Gly Leu Asp Gly Cys  
               
               
                 155                 160                 165                 170  
               
               
                   
               
               
                 ttg ctg att gtg ggt gct tta gct tta aat ata tta gcc tgt ggc agt      820  
               
               
                 Leu Leu Ile Val Gly Ala Leu Ala Leu Asn Ile Leu Ala Cys Gly Ser  
               
               
                                 175                 180                 185  
               
               
                   
               
               
                 ctg atg aga ccc ctc caa tct tct gat tgt cct ttg cct aaa aaa ata      868  
               
               
                 Leu Met Arg Pro Leu Gln Ser Ser Asp Cys Pro Leu Pro Lys Lys Ile  
               
               
                             190                 195                 200  
               
               
                   
               
               
                 gct cca gaa gat cta cca gat aaa tac tcc att tac aat gaa aaa gga      916  
               
               
                 Ala Pro Glu Asp Leu Pro Asp Lys Tyr Ser Ile Tyr Asn Glu Lys Gly  
               
               
                         205                 210                 215  
               
               
                   
               
               
                 aag aat ctg gaa gaa aac ata aac att ctt gac aag agc tac agt agt      964  
               
               
                 Lys Asn Leu Glu Glu Asn Ile Asn Ile Leu Asp Lys Ser Tyr Ser Ser  
               
               
                     220                 225                 230  
               
               
                   
               
               
                 gag gaa aaa tgc agg atc acg tta gcc aat ggt gac tgg aaa caa gac     1012  
               
               
                 Glu Glu Lys Cys Arg Ile Thr Leu Ala Asn Gly Asp Trp Lys Gln Asp  
               
               
                 235                 240                 245                 250  
               
               
                   
               
               
                 agc cta ctt cat aaa aac ccc aca gtg aca cac aca aaa gag cct gaa     1060  
               
               
                 Ser Leu Leu His Lys Asn Pro Thr Val Thr His Thr Lys Glu Pro Glu  
               
               
                                 255                 260                 265  
               
               
                   
               
               
                 acg tac aaa aag aaa gtt gca gaa cag aca tat ttt tgc aaa cag ctt     1108  
               
               
                 Thr Tyr Lys Lys Lys Val Ala Glu Gln Thr Tyr Phe Cys Lys Gln Leu  
               
               
                             270                 275                 280  
               
               
                   
               
               
                 gcc aag agg aag tgg cag tta tat aaa aac tac tgt ggt gaa act gtg     1156  
               
               
                 Ala Lys Arg Lys Trp Gln Leu Tyr Lys Asn Tyr Cys Gly Glu Thr Val  
               
               
                         285                 290                 295  
               
               
                   
               
               
                 gct ctt ttt aaa aac aaa gta ttt tca gcc ctt ttc att gct atc tta     1204  
               
               
                 Ala Leu Phe Lys Asn Lys Val Phe Ser Ala Leu Phe Ile Ala Ile Leu  
               
               
                     300                 305                 310  
               
               
                   
               
               
                 ctc ttt gac atc gga ggg ttt cca cct tca tta ctt atg gaa gat gta     1252  
               
               
                 Leu Phe Asp Ile Gly Gly Phe Pro Pro Ser Leu Leu Met Glu Asp Val  
               
               
                 315                 320                 325                 330  
               
               
                   
               
               
                 gca aga agt tca aac gtg aaa gaa gaa gag ttt att atg cca ctt att     1300  
               
               
                 Ala Arg Ser Ser Asn Val Lys Glu Glu Glu Phe Ile Met Pro Leu Ile  
               
               
                                 335                 340                 345  
               
               
                   
               
               
                 tcc att ata ggc att atg aca gca gtt ggt aaa ctg ctt tta ggg ata     1348  
               
               
                 Ser Ile Ile Gly Ile Met Thr Ala Val Gly Lys Leu Leu Leu Gly Ile  
               
               
                             350                 355                 360  
               
               
                   
               
               
                 ctg gct gac ttc aag tgg att aat acc ttg tat ctt tat gtt gct acc     1396  
               
               
                 Leu Ala Asp Phe Lys Trp Ile Asn Thr Leu Tyr Leu Tyr Val Ala Thr  
               
               
                         365                 370                 375  
               
               
                   
               
               
                 tta atc atc atg ggc cta gcc ttg tgt gca att cca ttt gcc aaa agc     1444  
               
               
                 Leu Ile Ile Met Gly Leu Ala Leu Cys Ala Ile Pro Phe Ala Lys Ser  
               
               
                     380                 385                 390  
               
               
                   
               
               
                 tat gtc aca ttg gcg ttg ctt tct ggg atc cta ggg ttt ctt act ggt     1492  
               
               
                 Tyr Val Thr Leu Ala Leu Leu Ser Gly Ile Leu Gly Phe Leu Thr Gly  
               
               
                 395                 400                 405                 410  
               
               
                   
               
               
                 aat tgg tcc atc ttt cca tat gtg acc acg aag act gtg gga att gaa     1540  
               
               
                 Asn Trp Ser Ile Phe Pro Tyr Val Thr Thr Lys Thr Val Gly Ile Glu  
               
               
                                 415                 420                 425  
               
               
                   
               
               
                 aaa tta gcc cat gcc tat ggg ata tta atg ttc ttt gct gga ctt gga     1588  
               
               
                 Lys Leu Ala His Ala Tyr Gly Ile Leu Met Phe Phe Ala Gly Leu Gly  
               
               
                             430                 435                 440  
               
               
                   
               
               
                 aat agc cta gga cca cca tcg ttg ggt tgg ttt tat gac tgg acc cag     1636  
               
               
                 Asn Ser Leu Gly Pro Pro Ser Leu Gly Trp Phe Tyr Asp Trp Thr Gln  
               
               
                         445                 450                 455  
               
               
                   
               
               
                 acc tat gat att gca ttt tat ttt agt ggc ttc tgc gtc ctg ctg gga     1684  
               
               
                 Thr Tyr Asp Ile Ala Phe Tyr Phe Ser Gly Phe Cys Val Leu Leu Gly  
               
               
                     460                 465                 470  
               
               
                   
               
               
                 ggt ttt att ctg ctg ctg gca gcc ttg ccc tct tgg gat aca tgc aac     1732  
               
               
                 Gly Phe Ile Leu Leu Leu Ala Ala Leu Pro Ser Trp Asp Thr Cys Asn  
               
               
                 475                 480                 485                 490  
               
               
                   
               
               
                 aag caa ctc ccc aag cca gct cca aca act ttc ttg tac aaa gtt gcc     1780  
               
               
                 Lys Gln Leu Pro Lys Pro Ala Pro Thr Thr Phe Leu Tyr Lys Val Ala  
               
               
                                 495                 500                 505  
               
               
                   
               
               
                 tct aat gtt tagaagaata ttggaagaca ctatttttgc tattttatac             1829  
               
               
                 Ser Asn Val  
               
               
                   
               
               
                 catatagcaa cgatatttta acagattctc aagcaaattt tctagagtca agactatttt   1889  
               
               
                   
               
               
                 ctcatagcaa aatttcacaa tgactgactc tgaatgaatt attttttttt atatatccta   1949  
               
               
                   
               
               
                 ttttttatgt agtgtatgcg tagcctctat ctcgtatttt tttctatttc tcctccccac   2009  
               
               
                   
               
               
                 accatcaatg ggactattct gttttgctgt tattcactag ttcttaacat tgtaaaaagt   2069  
               
               
                   
               
               
                 ttgaccagcc tcagaaggct ttctctgtgt aaagaagtat aatttctctg ctgactccat   2129  
               
               
                   
               
               
                 ttaatccact gcaaggcacc tagagagact gctcctattt taaaagtgat gcaagcatca   2189  
               
               
                   
               
               
                 tgataagata tgtgtgaagc ccactaggaa ataaatcatt ctcttctcta tgtttgactt   2249  
               
               
                   
               
               
                 gctagtaaac agaagacttc aagccagcca ggaaattaaa gtggcgacta aaacagcctt   2309  
               
               
                   
               
               
                 aagaattgca gtggagcaaa ttggtcattt tttaaaaaaa tatattttaa cctacagtca   2369  
               
               
                   
               
               
                 ccagttttca ttattctatt tacctcactg aagtactcgc atgttgtttg gtacccactg   2429  
               
               
                   
               
               
                 agcaactgtt tcagttccta aggtatttgc tgagatgtgg gtgaactcca aatggagaag   2489  
               
               
                   
               
               
                 tagtcactgt agactttctt catggttgac cactccaacc ttgctcactt ttgcttcttg   2549  
               
               
                   
               
               
                 gccatccact cagctgatgt ttcctggaag tgctaatttt acctgtttcc aaattggaaa   2609  
               
               
                   
               
               
                 cacatttctc aatcattccg ttctggcaaa tgggaaacat ccatttgctt tgggcacagt   2669  
               
               
                   
               
               
                 ggggatgggc tgcaagttct tgcatatcct cccagtgaag catttatttg ctactatcag   2729  
               
               
                   
               
               
                 attttaccac tatcaaatat aattcaaggg cagaattaaa cgtgagtgtg tgtgtgtgtg   2789  
               
               
                   
               
               
                 tgtgtgtgtg tgctatgcat gctctaagtc tgcatgggat atgggaatgg aaaagggcaa   2849  
               
               
                   
               
               
                 taagaaatta atacccttat gcagttgcat ttaaccttaa gaaaaatgtc cttgggataa   2909  
               
               
                   
               
               
                 actccaatgt ttaatacatt gatttttttt ctaaagaaat gggttttaaa ctttggtatg   2969  
               
               
                   
               
               
                 catcagaatt ccctatagat ctttttgaaa atataggtac ctgggtatca cacatagaac   3029  
               
               
                   
               
               
                 ttttaattct gctggtgtag gctgttgccc aaacatctat aattttactg agctcttcaa   3089  
               
               
                   
               
               
                 gtgattctga taacacagcc tggattgaga atttttataa gattggcaat ggaaaaacat   3149  
               
               
                   
               
               
                 ttattctttt aaataataat ttttttaaaa cccaagaggt caggggattt tataaaccaa   3209  
               
               
                   
               
               
                 tagccaagtg ttctttaaat aggaggcacc cttcccattg tgccaaaatc atcttttcat   3269  
               
               
                   
               
               
                 ttattttgaa atttgtatga ttattttata cttgtatgtt gcctttcttc gaaggcgcct   3329  
               
               
                   
               
               
                 gaagcacttt ataaacacaa atcctcacaa tacctctgtg aggtaggtaa atagtacttt   3389  
               
               
                   
               
               
                 tctatgtagt aaacctggaa tatggagaat ttcataacag ttcattctac ttaataatgc   3449  
               
               
                   
               
               
                 aataatggag ctccaagttg tcttggactt ctacaccaca ctcagacttc tggaaagttt   3509  
               
               
                   
               
               
                 tctgtacctc attctttagt ccctgtcaag gttagtaaat aaaataagtg acataaaaaa   3569  
               
               
                   
               
               
                 aaaaaaaaaa ctaaactact tgttgtgttg aaagttcctt tttgccagtt atgttcagga   3629  
               
               
                   
               
               
                 aacccaataa cctgaaaaag tttgactttg atgtgacatc ttcatattca tcaatgctga   3689  
               
               
                   
               
               
                 taattgtcca aaggcatctt cactatgtct gctaaataac atccaatgtg ggcgttatct   3749  
               
               
                   
               
               
                 gttgtctagg ggatgaattt taagttacaa taaaatattt ttctttgttt tgcatcaaaa   3809  
               
               
                   
               
               
                 aaaaaa                                                              3815  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 96  
               
               
                 &lt;211&gt; LENGTH: 509  
               
               
                 &lt;212&gt; TYPE: PRT  
               
               
                 &lt;213&gt; ORGANISM: Homo sapiens  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 96  
               
               
                   
               
               
                 Met Glu Leu Lys Lys Ser Pro Asp Gly Gly Trp Gly Trp Val Ile Val  
               
               
                 1               5                   10                  15  
               
               
                   
               
               
                 Phe Val Ser Phe Leu Thr Gln Phe Leu Cys Tyr Gly Ser Pro Leu Ala  
               
               
                             20                  25                  30  
               
               
                   
               
               
                 Val Gly Val Leu Tyr Ile Glu Trp Leu Asp Ala Phe Gly Glu Gly Lys  
               
               
                         35                  40                  45  
               
               
                   
               
               
                 Gly Lys Thr Ala Trp Val Gly Ser Leu Ala Ser Gly Val Gly Leu Leu  
               
               
                     50                  55                  60  
               
               
                   
               
               
                 Ala Ser Pro Val Cys Ser Leu Cys Val Ser Ser Phe Gly Ala Arg Pro  
               
               
                 65                  70                  75                  80  
               
               
                   
               
               
                 Val Thr Ile Phe Ser Gly Phe Met Val Ala Gly Gly Leu Met Leu Ser  
               
               
                                 85                  90                  95  
               
               
                   
               
               
                 Ser Phe Ala Pro Asn Ile Tyr Phe Leu Phe Phe Ser Tyr Gly Ile Val  
               
               
                             100                 105                 110  
               
               
                   
               
               
                 Val Gly Leu Gly Cys Gly Leu Leu Tyr Thr Ala Thr Val Thr Ile Thr  
               
               
                         115                 120                 125  
               
               
                   
               
               
                 Cys Gln Tyr Phe Asp Asp Arg Arg Gly Leu Ala Leu Gly Leu Ile Ser  
               
               
                     130                 135                 140  
               
               
                   
               
               
                 Thr Gly Ser Ser Val Gly Leu Phe Ile Tyr Ala Ala Leu Gln Arg Met  
               
               
                 145                 150                 155                 160  
               
               
                   
               
               
                 Leu Val Glu Phe Tyr Gly Leu Asp Gly Cys Leu Leu Ile Val Gly Ala  
               
               
                                 165                 170                 175  
               
               
                   
               
               
                 Leu Ala Leu Asn Ile Leu Ala Cys Gly Ser Leu Met Arg Pro Leu Gln  
               
               
                             180                 185                 190  
               
               
                   
               
               
                 Ser Ser Asp Cys Pro Leu Pro Lys Lys Ile Ala Pro Glu Asp Leu Pro  
               
               
                         195                 200                 205  
               
               
                   
               
               
                 Asp Lys Tyr Ser Ile Tyr Asn Glu Lys Gly Lys Asn Leu Glu Glu Asn  
               
               
                     210                 215                 220  
               
               
                   
               
               
                 Ile Asn Ile Leu Asp Lys Ser Tyr Ser Ser Glu Glu Lys Cys Arg Ile  
               
               
                 225                 230                 235                 240  
               
               
                   
               
               
                 Thr Leu Ala Asn Gly Asp Trp Lys Gln Asp Ser Leu Leu His Lys Asn  
               
               
                                 245                 250                 255  
               
               
                   
               
               
                 Pro Thr Val Thr His Thr Lys Glu Pro Glu Thr Tyr Lys Lys Lys Val  
               
               
                             260                 265                 270  
               
               
                   
               
               
                 Ala Glu Gln Thr Tyr Phe Cys Lys Gln Leu Ala Lys Arg Lys Trp Gln  
               
               
                         275                 280                 285  
               
               
                   
               
               
                 Leu Tyr Lys Asn Tyr Cys Gly Glu Thr Val Ala Leu Phe Lys Asn Lys  
               
               
                     290                 295                 300  
               
               
                   
               
               
                 Val Phe Ser Ala Leu Phe Ile Ala Ile Leu Leu Phe Asp Ile Gly Gly  
               
               
                 305                 310                 315                 320  
               
               
                   
               
               
                 Phe Pro Pro Ser Leu Leu Met Glu Asp Val Ala Arg Ser Ser Asn Val  
               
               
                                 325                 330                 335  
               
               
                   
               
               
                 Lys Glu Glu Glu Phe Ile Met Pro Leu Ile Ser Ile Ile Gly Ile Met  
               
               
                             340                 345                 350  
               
               
                   
               
               
                 Thr Ala Val Gly Lys Leu Leu Leu Gly Ile Leu Ala Asp Phe Lys Trp  
               
               
                         355                 360                 365  
               
               
                   
               
               
                 Ile Asn Thr Leu Tyr Leu Tyr Val Ala Thr Leu Ile Ile Met Gly Leu  
               
               
                     370                 375                 380  
               
               
                   
               
               
                 Ala Leu Cys Ala Ile Pro Phe Ala Lys Ser Tyr Val Thr Leu Ala Leu  
               
               
                 385                 390                 395                 400  
               
               
                   
               
               
                 Leu Ser Gly Ile Leu Gly Phe Leu Thr Gly Asn Trp Ser Ile Phe Pro  
               
               
                                 405                 410                 415  
               
               
                   
               
               
                 Tyr Val Thr Thr Lys Thr Val Gly Ile Glu Lys Leu Ala His Ala Tyr  
               
               
                             420                 425                 430  
               
               
                   
               
               
                 Gly Ile Leu Met Phe Phe Ala Gly Leu Gly Asn Ser Leu Gly Pro Pro  
               
               
                         435                 440                 445  
               
               
                   
               
               
                 Ser Leu Gly Trp Phe Tyr Asp Trp Thr Gln Thr Tyr Asp Ile Ala Phe  
               
               
                     450                 455                 460  
               
               
                   
               
               
                 Tyr Phe Ser Gly Phe Cys Val Leu Leu Gly Gly Phe Ile Leu Leu Leu  
               
               
                 465                 470                 475                 480  
               
               
                   
               
               
                 Ala Ala Leu Pro Ser Trp Asp Thr Cys Asn Lys Gln Leu Pro Lys Pro  
               
               
                                 485                 490                 495  
               
               
                   
               
               
                 Ala Pro Thr Thr Phe Leu Tyr Lys Val Ala Ser Asn Val  
               
               
                             500                 505  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 97  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 97  
               
               
                   
               
               
                 000  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 98  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 98  
               
               
                   
               
               
                 aattctcatc gctttcatga ag                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 99  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 99  
               
               
                   
               
               
                 taagtcgttc agacccatcc tcctct                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 100  
               
               
                 &lt;211&gt; LENGTH: 25  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 100  
               
               
                   
               
               
                 ataggagtta ttggcaatct tctga                                           25  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 101  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 101  
               
               
                   
               
               
                 tgagcaaacg catggacatc                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 102  
               
               
                 &lt;211&gt; LENGTH: 28  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 102  
               
               
                   
               
               
                 tccatccaag tcacagaaag catcgcac                                        28  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 103  
               
               
                 &lt;211&gt; LENGTH: 19  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 103  
               
               
                   
               
               
                 tgggttgagg cagctgtga                                                  19  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 104  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 104  
               
               
                   
               
               
                 gaggctctct ccagtaacat ca                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 105  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 105  
               
               
                   
               
               
                 tactctcctt gtcctctgag gcgctc                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 106  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 106  
               
               
                   
               
               
                 gcagtttggt tgtttggttt ac                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 107  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 107  
               
               
                   
               
               
                 gggaaatggg ttgtccatat at                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 108  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 108  
               
               
                   
               
               
                 ttcctgcagc cttataagaa gtccac                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 109  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 109  
               
               
                   
               
               
                 atctgaaatg gccagattta gc                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 110  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 110  
               
               
                   
               
               
                 ccagtgccag taccagaata tc                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 111  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 111  
               
               
                   
               
               
                 taaccagaca ctctcagctg caggca                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 112  
               
               
                 &lt;211&gt; LENGTH: 19  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 112  
               
               
                   
               
               
                 ctctctggcc tctcagcaa                                                  19  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 113  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 113  
               
               
                   
               
               
                 gtctgcgtga agatcaatca tt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 114  
               
               
                 &lt;211&gt; LENGTH: 25  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 114  
               
               
                   
               
               
                 taggacacgg actacgacca cgaca                                           25  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 115  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 115  
               
               
                   
               
               
                 cggaccgtac ggagtagata ct                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 116  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 116  
               
               
                   
               
               
                 ctactactgg tggctgcgaa t                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 117  
               
               
                 &lt;211&gt; LENGTH: 25  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 117  
               
               
                   
               
               
                 tcagatcatg acccacttgc ctgga                                           25  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 118  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 118  
               
               
                   
               
               
                 actcttcagc ggatgtagat ca                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 119  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 119  
               
               
                   
               
               
                 ggacttctgt ggaccttatg tg                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 120  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 120  
               
               
                   
               
               
                 tttttcctct ttgctggagt gctcct                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 121  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 121  
               
               
                   
               
               
                 ttcctttggt ttctggaact tt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 122  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 122  
               
               
                   
               
               
                 tcagaaggga atcatgatat cg                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 123  
               
               
                 &lt;211&gt; LENGTH: 27  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 123  
               
               
                   
               
               
                 tccttgataa aactccaggc tcctttg                                         27  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 124  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 124  
               
               
                   
               
               
                 tttggaaggt aggcatattg g                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 125  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 125  
               
               
                   
               
               
                 gtcagcttct cttgctttga ga                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 126  
               
               
                 &lt;211&gt; LENGTH: 23  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 126  
               
               
                   
               
               
                 tcactgtcag gcactcgcca atg                                             23  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 127  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 127  
               
               
                   
               
               
                 ctgtatttct ggaagcattc ca                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 128  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 128  
               
               
                   
               
               
                 ttgatgtctc tgagatccaa ca                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 129  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 129  
               
               
                   
               
               
                 tagtttccga gctctgggca tttcca                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 130  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 130  
               
               
                   
               
               
                 catgctgtgc aaaattttct c                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 131  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 131  
               
               
                   
               
               
                 aaaaggtgat gtctggagca t                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 132  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 132  
               
               
                   
               
               
                 ttgtatgtca tgctctgtgc cagcct                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 133  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 133  
               
               
                   
               
               
                 gatgtctgtg tcgtcaaaag g                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 134  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 134  
               
               
                   
               
               
                 aaaaggtgat gtctggagca t                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 135  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 135  
               
               
                   
               
               
                 ttgtatgtca tgctctgtgc cagcct                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 136  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 136  
               
               
                   
               
               
                 gatgtctgtg tcgtcaaaag g                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 137  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 137  
               
               
                   
               
               
                 aaaaggtgat gtctggagca t                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 138  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 138  
               
               
                   
               
               
                 ttgtatgtca tgctctgtgc cagcct                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 139  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 139  
               
               
                   
               
               
                 gatgtctgtg tcgtcaaaag g                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 140  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 140  
               
               
                   
               
               
                 cctacgttac cgtgctcaag                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 141  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 141  
               
               
                   
               
               
                 tcgctaacac caccgacaag gagcta                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 142  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 142  
               
               
                   
               
               
                 gacgttgtgc aaggagagaa c                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 143  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 143  
               
               
                   
               
               
                 cctacgttac cgtgctcaag                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 144  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 144  
               
               
                   
               
               
                 tcgctaacac caccgacaag gagcta                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 145  
               
               
                 &lt;211&gt; LENGTH: 21  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 145  
               
               
                   
               
               
                 gacgttgtgc aaggagagaa c                                               21  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 146  
               
               
                 &lt;211&gt; LENGTH: 19  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 146  
               
               
                   
               
               
                 tcaccgtagc cgtgaagat                                                  19  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 147  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 147  
               
               
                   
               
               
                 taaagacgat gccactgaca aggacc                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 148  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 148  
               
               
                   
               
               
                 ttcatcatct ccatctcaga ca                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 149  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 149  
               
               
                   
               
               
                 ggactttgat cccctacaga tg                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 150  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 150  
               
               
                   
               
               
                 ttcaaatgaa gaggacatcc tctcca                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 151  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 151  
               
               
                   
               
               
                 ctgagaacgg atagctgaga ac                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 152  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 152  
               
               
                   
               
               
                 cgctactact acagccgcaa                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 153  
               
               
                 &lt;211&gt; LENGTH: 23  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 153  
               
               
                   
               
               
                 tgtgatccgc gcctacctgg agt                                             23  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 154  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 154  
               
               
                   
               
               
                 gggcggcttc atgtagtact                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 155  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 155  
               
               
                   
               
               
                 cgctactact acagccgcaa                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 156  
               
               
                 &lt;211&gt; LENGTH: 23  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 156  
               
               
                   
               
               
                 tgtgatccgc gcctacctgg agt                                             23  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 157  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 157  
               
               
                   
               
               
                 gggcggcttc atgtagtact                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 158  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 158  
               
               
                   
               
               
                 tctacaccat cagctgtatg ca                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 159  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 159  
               
               
                   
               
               
                 tcaccaccct cacactcatc ttcatc                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 160  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 160  
               
               
                   
               
               
                 gcagtgcagc tgtcatatag aa                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 161  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 161  
               
               
                   
               
               
                 ccatttactg gtgcacagaa gt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 162  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 162  
               
               
                   
               
               
                 tatccctctg gctgtcacct ctctca                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 163  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 163  
               
               
                   
               
               
                 ggagtccaga atctggaaga gt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 164  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 164  
               
               
                   
               
               
                 ccatttactg gtgcacagaa gt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 165  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 165  
               
               
                   
               
               
                 tatccctctg gctgtcacct ctctca                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 166  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 166  
               
               
                   
               
               
                 ggagtccaga atctggaaga gt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 167  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 167  
               
               
                   
               
               
                 000  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 168  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 168  
               
               
                   
               
               
                 ctggccaaga gctacaatga                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 169  
               
               
                 &lt;211&gt; LENGTH: 26  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 169  
               
               
                   
               
               
                 tcatcagaca gaacgtgcag gtgttt                                          26  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 170  
               
               
                 &lt;211&gt; LENGTH: 20  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 170  
               
               
                   
               
               
                 aggccatcta tggctttcat                                                 20  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 171  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 171  
               
               
                   
               
               
                 ttcctatggc attgttgtag gt                                              22  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 172  
               
               
                 &lt;211&gt; LENGTH: 29  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 172  
               
               
                   
               
               
                 ttggtttatt atacactgca acagtgacc                                       29  
               
               
                   
               
               
                   
               
               
                 &lt;210&gt; SEQ ID NO 173  
               
               
                 &lt;211&gt; LENGTH: 22  
               
               
                 &lt;212&gt; TYPE: DNA  
               
               
                 &lt;213&gt; ORGANISM: Artificial Sequence  
               
               
                 &lt;220&gt; FEATURE:  
               
               
                 &lt;223&gt; OTHER INFORMATION: Description of Artifical Sequence:  
               
               
                       Primer/Probe  
               
               
                   
               
               
                 &lt;400&gt; SEQUENCE: 173  
               
               
                   
               
               
                 atcgtcaaaa tactggcacg ta                                              22